0001193125-24-047942.txt : 20240227 0001193125-24-047942.hdr.sgml : 20240227 20240227161635 ACCESSION NUMBER: 0001193125-24-047942 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SLR HC BDC LLC CENTRAL INDEX KEY: 0001832148 ORGANIZATION NAME: IRS NUMBER: 851801692 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56247 FILM NUMBER: 24686967 BUSINESS ADDRESS: STREET 1: 500 PARK AVENUE STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 993-1670 MAIL ADDRESS: STREET 1: 500 PARK AVENUE STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 10-K 1 d774279d10k.htm 10-K 10-K
falseFY0001832148NYP5YP4Ytwo yearsCommencement of operationsIndicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2023, on a fair value basis, non-qualifying assets in the portfolio represented 20.8% of the total assets of the Company.Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.Not annualized for periods less than one year.Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year.Floating rate debt investments typically bear interest at a rate determined by reference to either the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) has provided the current interest rate in effect as of December 31, 2023.Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively.BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor.Non-income producing security.Aggregate net unrealized depreciation for U.S. federal income tax purposes is $71; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $318 and $389, respectively, based on a tax cost of $43,968. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load.Aggregate net unrealized depreciation for U.S. federal income tax purposes is $241; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $600 and $841, respectively, based on a tax cost of $63,516. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.Includes PIK capitalization and accretion of discountIncludes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.Denotes a Level 1 investment. 0001832148 2022-01-01 2022-12-31 0001832148 2023-01-01 2023-12-31 0001832148 2021-01-05 2021-12-31 0001832148 2022-12-31 0001832148 2021-12-31 0001832148 2023-12-31 0001832148 2024-02-23 0001832148 2021-12-31 2021-12-31 0001832148 2023-06-30 0001832148 2021-01-01 2021-12-31 0001832148 2021-01-04 0001832148 cik0001832148:SpvFacilityMember 2022-12-31 0001832148 cik0001832148:SubscriptionFacilityMember 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Apeel Technology Inc. | Biotechnology | S+625 | 1.00% | 8.75% | 6/29/2022 | 6/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ivy Fertility Services LLC | Health Care Providers & Services | L+625 | 1.00% | 10.39% | 12/22/2021 | 2/25/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Oral Surgery Partners Holdings LLC | Health Care Providers & Services | S+625| 1.00% | 10.92% | 11/29/2022 | 5/10/2024 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Pediatric Home Respiratory Services LLC | Health Care Providers & Services | S+625 | 1.00% | 10.67% | 8/19/2022 |12/4/2024 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Spectrum Pharmaceuticals Inc. | Biotechnology | S+570 | 2.30% | 9.88% | 9/21/2022 | 9/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2022-12-31 0001832148 cik0001832148:UvpManagementLlcMember 2022-12-31 0001832148 cik0001832148:UrologyManagementHoldingsInc.Member 2022-12-31 0001832148 cik0001832148:RetinaMidcoInc.Member 2022-12-31 0001832148 cik0001832148:CvausaManagementLlcMember 2022-12-31 0001832148 cik0001832148:AahTopcoLlcMember 2022-12-31 0001832148 cik0001832148:OisManagementServicesLlcMember 2022-12-31 0001832148 cik0001832148:MedrinaLlcMember 2022-12-31 0001832148 cik0001832148:VertosMedicalInc.Member 2022-12-31 0001832148 cik0001832148:UnitedDigestiveMsoParentLlcMember 2022-12-31 0001832148 cik0001832148:ArcutisBiotherapeticsInc.Member 2022-12-31 0001832148 cik0001832148:PlasticsManagementLlcMember 2022-12-31 0001832148 cik0001832148:GlookoInc.Member 2022-12-31 0001832148 cik0001832148:SunmedGroupHoldingsLlcMember 2022-12-31 0001832148 cik0001832148:IvyFertilityServicesLlcMember 2022-12-31 0001832148 cik0001832148:BaymarkHealthServicesInc.Member 2022-12-31 0001832148 cik0001832148:ArdelyxInc.Member 2022-12-31 0001832148 cik0001832148:SouthernOrthodonicPartnersManagementLlcMember 2022-12-31 0001832148 cik0001832148:CerapedicsIncMember 2022-12-31 0001832148 cik0001832148:OrthopedicCarePartnersManagementLlcMember 2022-12-31 0001832148 cik0001832148:MeditrinaIncMember 2022-12-31 0001832148 cik0001832148:OralSurgeryPartnersHoldingsLlcMember 2022-12-31 0001832148 cik0001832148:SpectrumPharmaceuticalsIncMember 2022-12-31 0001832148 cik0001832148:PediatricHomeRespiratoryServicesLlcMember 2022-12-31 0001832148 cik0001832148:OutsetMedicalIncMember 2022-12-31 0001832148 cik0001832148:ScpEyeCareLlcMember 2022-12-31 0001832148 cik0001832148:ExactcareParentInc.Member 2022-12-31 0001832148 cik0001832148:WcibxcPurchaserLlcMember 2022-12-31 0001832148 cik0001832148:ApeelTechnologyInc.Member 2022-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2022-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueFebruaryTwoThousandAndTwentySevenTheSpvFacilityMember 2022-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueMarchTwoThousandAndTwentyFourTheSubscriptionFacilityMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/30/2022 | 2/23/2023 2022-12-31 0001832148 Warrants | Vapotherm Inc. | Health Care Equipment & Supplies | 2/18/2022 2022-12-31 0001832148 Warrants | Spectrum Pharmaceuticals Inc. | Biotechnology | 9/21/2022 2022-12-31 0001832148 Warrants | Meditrina Inc. | Health Care Equipment & Supplies | 12/20/2022 2022-12-31 0001832148 Total Investments 2022-12-31 0001832148 Total Warrant 2022-12-31 0001832148 Bank Debt/Senior Secured Loans 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember srt:WeightedAverageMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember srt:MaximumMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember srt:MinimumMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:WeightedAverageMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 cik0001832148:BridgebioPharmaIncMember 2022-12-31 0001832148 cik0001832148:VapothermInc.Member 2022-12-31 0001832148 cik0001832148:BiotechnologyMember 2022-12-31 0001832148 cik0001832148:PharmaceuticalsMember 2022-12-31 0001832148 cik0001832148:HealthCareTechnologyMember 2022-12-31 0001832148 cik0001832148:LifeSciencesToolsServicesMember 2022-12-31 0001832148 cik0001832148:HealthCareEquipmentSuppliesMember 2022-12-31 0001832148 cik0001832148:HealthCareProvidersServicesMember 2022-12-31 0001832148 cik0001832148:SpvFacilityMember 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Retina Midco, Inc | Health Care Providers & Services | S+ 575 |1.00% | 11.38% | 12/18/2023 | 1/31/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | UVP Management LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.79% | 9/18/2023 | 9/15/2025 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Urology Management Holdings Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.93% | 2/7/2023 | 6/15/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | United Digestive MSO Parent LLC | Health Care Providers & Services | S+ 675 |1.00% | 12.29% | 3/30/2023 | 3/30/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | WCI-BXC Purchaser, LLC | Distributors | S+ 625 |1.00% | 11.64% | 11/6/2023 | 11/6/2030 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vertos Medical Inc | Health Care Equipment & Supplies | S+515 | 4.75% | 10.48% | 6/14/2023 | 7/1/2028 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco LLC | Health Care Providers & Services | S+ 650 | 1.00% | 11.63% | 1/4/2023|1/3/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Exactcare Parent, Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.89% | 11/3/2023 | 11/5/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | CVAUSA Management LLC | Health Care Providers & Services | S+ 550 | 1.00% | 11.74% | 5/22/2023 | 5/22/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | ONS MSO LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.62%| 2/10/2023 | 7/8/2025 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | OIS Management Services, LLC | Health Care Providers & Services | S+ 575 |1.00% | 11.20% | 12/29/2023 | 11/16/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Medrina, LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.67% | 10/20/2023 | 10/20/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Maxor Acquisition Inc | Health Care Providers & Services | S+ 675 |1.00% | 12.48%| 3/1/2023 | 3/1/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2023-12-31 0001832148 cik0001832148:CvausaManagementLlcMember 2023-12-31 0001832148 cik0001832148:UvpManagementLlcMember 2023-12-31 0001832148 cik0001832148:UrologyManagementHoldingsInc.Member 2023-12-31 0001832148 cik0001832148:ExactcareParentInc.Member 2023-12-31 0001832148 cik0001832148:RetinaMidcoInc.Member 2023-12-31 0001832148 cik0001832148:OisManagementServicesLlcMember 2023-12-31 0001832148 cik0001832148:MedrinaLlcMember 2023-12-31 0001832148 cik0001832148:VertosMedicalInc.Member 2023-12-31 0001832148 cik0001832148:UnitedDigestiveMsoParentLlcMember 2023-12-31 0001832148 cik0001832148:PlasticsManagementLlcMember 2023-12-31 0001832148 cik0001832148:ArcutisBiotherapeticsInc.Member 2023-12-31 0001832148 cik0001832148:GlookoInc.Member 2023-12-31 0001832148 cik0001832148:SunmedGroupHoldingsLlcMember 2023-12-31 0001832148 cik0001832148:BaymarkHealthServicesInc.Member 2023-12-31 0001832148 cik0001832148:IvyFertilityServicesLlcMember 2023-12-31 0001832148 cik0001832148:ArdelyxInc.Member 2023-12-31 0001832148 cik0001832148:SouthernOrthodonicPartnersManagementLlcMember 2023-12-31 0001832148 cik0001832148:OrthopedicCarePartnersManagementLlcMember 2023-12-31 0001832148 cik0001832148:MeditrinaIncMember 2023-12-31 0001832148 cik0001832148:SpectrumPharmaceuticalsIncMember 2023-12-31 0001832148 cik0001832148:PediatricHomeRespiratoryServicesLlcMember 2023-12-31 0001832148 cik0001832148:CerapedicsIncMember 2023-12-31 0001832148 cik0001832148:AahTopcoLlcMember 2023-12-31 0001832148 cik0001832148:OutsetMedicalIncMember 2023-12-31 0001832148 cik0001832148:ScpEyeCareLlcMember 2023-12-31 0001832148 cik0001832148:OralSurgeryPartnersHoldingsLlcMember 2023-12-31 0001832148 cik0001832148:WcibxcPurchaserLlcMember 2023-12-31 0001832148 cik0001832148:ApeelTechnologyInc.Member 2023-12-31 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member 2023-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2023-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueMarchTwoThousandAndTwentyFourTheSubscriptionFacilityMember 2023-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueFebruaryTwoThousandAndTwentySevenTheSpvFacilityMember 2023-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 cik0001832148:InitialUnitholderMember 2023-12-31 0001832148 srt:MinimumMember 2023-12-31 0001832148 srt:MaximumMember 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2023-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/29/2023 | 2/27/2024 2023-12-31 0001832148 Warrants | Vertos Medical, Inc. | Health Care Equipment & Supplies | 6/14/2023 2023-12-31 0001832148 Warrants | Vapotherm Inc. | Health Care Equipment & Supplies | 2/18/2022 2023-12-31 0001832148 Warrants | Meditrina Inc. | Health Care Equipment & Supplies | 12/20/2022 2023-12-31 0001832148 Common Equity/Warrants | Assertio Holdings Inc Common Stock | Pharmaceuticals | 7/31/2023 2023-12-31 0001832148 Bank Debt/Senior Secured Loans 2023-12-31 0001832148 Total Warrant 2023-12-31 0001832148 Total Investments 2023-12-31 0001832148 cik0001832148:FirstLienLifeScienceLoansMember srt:MinimumMember 2023-12-31 0001832148 cik0001832148:FirstLienLifeScienceLoansMember srt:MaximumMember 2023-12-31 0001832148 cik0001832148:FirstLienHealthCareCashFlowLoansMember srt:MaximumMember 2023-12-31 0001832148 cik0001832148:FirstLienHealthCareCashFlowLoansMember srt:MinimumMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember srt:MinimumMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember srt:WeightedAverageMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember srt:MaximumMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:WeightedAverageMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 cik0001832148:VapothermInc.Member 2023-12-31 0001832148 cik0001832148:BridgebioPharmaIncMember 2023-12-31 0001832148 cik0001832148:HealthCareProvidersServicesMember 2023-12-31 0001832148 cik0001832148:PharmaceuticalsMember 2023-12-31 0001832148 cik0001832148:BiotechnologyMember 2023-12-31 0001832148 cik0001832148:HealthCareTechnologyMember 2023-12-31 0001832148 cik0001832148:LifeSciencesToolsServicesMember 2023-12-31 0001832148 cik0001832148:HealthCareEquipmentSuppliesMember 2023-12-31 0001832148 cik0001832148:DistributorsMember 2023-12-31 0001832148 cik0001832148:InvestmentModificationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:CompetitionPotentialForInsufficientInvestmentOpportunitiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RecourseToTheCompanysAssetsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LeveragedCompaniesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PortfolioTurnoverMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToTheRussianInvasionOfUkraineMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AssetsBelievedToBeUndervaluedOrIncorrectlyValuedMember 2023-01-01 2023-12-31 0001832148 cik0001832148:NoAssuranceOfCashDistributionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AdverseConsequencesOfDefaultMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DistributionsInKindMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ThirdpartyInvolvementMember 2023-01-01 2023-12-31 0001832148 cik0001832148:U.s.DollarDenominationOfUnitsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ForwardLookingStatementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ReferralRelationshipsWithFinancialSponsorsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulationsOfHealthcareIndustryMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LitigationAndRelatedRisksAssociatedWithOriginationAndServicingMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AbilityToOriginateLoansOnAdvantageousTermsCompetitionAndSupplyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DefaultsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ConcentrationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SectorRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsInHealthcareCompaniesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:HealthcareAndLifeScienceIndustriesRelatedRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubordinatedLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ReportingCompanyFilingRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LicensingRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:OtherRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:WarrantsAndRightsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatingToReferenceRatesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ManagementRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:HighYieldDebtAndUnratedSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:EquityrelatedSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksAssociatedWithBankruptcyAndInsolvencyCasesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:CollateralRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatingToBankLoansAndCorporateLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MezzanineSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UnsecuredLoansOrDebtMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PrepaymentRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksInherentInHealthcarerelatedAssetsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FinancialFraudMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InterestRateRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LiquidityRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InflationdeflationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:HedgingTransactionsAndRelatedRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ForwardsAndDerivativesTransactionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MarketRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToTheU.s.DebtCeilingMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ConvertibleSecuritiesRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DocumentationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToEconomicRecessionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PreferredSecuritiesRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulatoryRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToPortfolioInvestmentMonitoringAndInvolvementMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MoneyMarketAndOtherLiquidInstrumentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ZerocouponBondsDeferredInterestRateBondsAndPaymentinkindSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:GeneralEconomicAndMarketRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ManagementRiskAndRelianceOnManagementMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsInSmallerAndMiddleMarketCompaniesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:GeneralLeverageRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:NoMarketForUnitsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PublicHealthCrisesRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DueDiligenceRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:OfacFcpaAndRelatedConsiderationsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatingToWaiversOrDeferralsOfCovenantsAndCovenantliteLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:GeneralCreditRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RiskOfLossMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InsufficientCapitalForFollowonInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PortfolioInvestmentRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FraudulentConveyanceAndPreferenceConsiderationsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RestrictedSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToDispositionOfInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LenderLiabilityConsiderationsAndEquitableSubordinationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PooledInvestmentVehiclesAndPassthroughEntitiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:U.s.GovernmentAndAgencySecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LackOfControlOverInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ControlPositionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToElectronicCommunicationscybersecurityRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ProjectionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ConcentrationOfPortfolioInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulatoryInvestigationsOrThirdpartyLitigationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:BroadIndemnificationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ModelRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ValuationOfIlliquidAssetsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UnspecifiedUseOfProceedsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:IdentificationOfPotentialInvestmentOpportunitiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FinancialServicesIndustryRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MachineLearningTechnologyRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:CorporateSocialResponsibilityRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FailureToQualifyAsARicMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ClimateChangeRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RecognizingIncomeBeforeOrWithoutReceivingCashMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TaxConsiderationsRegardingDividendsForPrivateBdcsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TechnologicalInnovationRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ChangesInTaxLawMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InkindDividendConsiderationsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PotentialDividendDeferralsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ChangesToDerivativesRegulationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UncertaintyOfTheU.s.PoliticalClimateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:U.s.DoddfrankWallStreetReformAndConsumerProtectionActMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FinancialServicesAndGovernmentInterventionMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToChangesInRegulatoryPolicyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulatoryRisksRelatingToTheCompanyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DistributionAndAssetCoverageRatioRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PermissibleIncurredLeverageMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ChangesToAccountingStandardsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ExemptiveReliefMember 2023-01-01 2023-12-31 0001832148 cik0001832148:QualifyingAssetRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UnrealizedDepreciationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DocumentationOfInternalControlsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsAndCashEquivalentsMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember srt:MaximumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TypeOfAgreementFirstMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TypeOfAgreementSecondMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:TypeOfAgreementSecondMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:TypeOfAgreementFourthMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:TypeOfAgreementFourthMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PreExchangeListingIncentiveFeeMember cik0001832148:TypeOfAgreementFourthMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:TypeOfAgreementSecondMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PreExchangeListingIncentiveFeeMember cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AnnuallyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:QuarterlyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AdviserMember 2023-01-01 2023-12-31 0001832148 cik0001832148:EbitdaConcentrationRiskMember cik0001832148:FirstLienHealthCareCashFlowLoansMember srt:MaximumMember 2023-01-01 2023-12-31 0001832148 cik0001832148:EbitdaConcentrationRiskMember cik0001832148:FirstLienHealthCareCashFlowLoansMember srt:MinimumMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienLifeScienceLoansMember 2023-01-01 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-01-01 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienLifeScienceLoansMember srt:MaximumMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienHealthCareCashFlowLoansMember srt:MaximumMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienHealthCareCashFlowLoansMember srt:MinimumMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienLifeScienceLoansMember srt:MinimumMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | United Digestive MSO Parent LLC | Health Care Providers & Services | S+ 675 |1.00% | 12.29% | 3/30/2023 | 3/30/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | WCI-BXC Purchaser, LLC | Distributors | S+ 625 |1.00% | 11.64% | 11/6/2023 | 11/6/2030 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | CVAUSA Management LLC | Health Care Providers & Services | S+ 550 | 1.00% | 11.74% | 5/22/2023 | 5/22/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Exactcare Parent, Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.89% | 11/3/2023 | 11/5/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco LLC | Health Care Providers & Services | S+ 650 | 1.00% | 11.63% | 1/4/2023|1/3/2029 2023-01-01 2023-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/29/2023 | 2/27/2024 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vertos Medical Inc | Health Care Equipment & Supplies | S+515 | 4.75% | 10.48% | 6/14/2023 | 7/1/2028 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | UVP Management LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.79% | 9/18/2023 | 9/15/2025 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Urology Management Holdings Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.93% | 2/7/2023 | 6/15/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Maxor Acquisition Inc | Health Care Providers & Services | S+ 675 |1.00% | 12.48%| 3/1/2023 | 3/1/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Medrina, LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.67% | 10/20/2023 | 10/20/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | OIS Management Services, LLC | Health Care Providers & Services | S+ 575 |1.00% | 11.20% | 12/29/2023 | 11/16/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | ONS MSO LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.62%| 2/10/2023 | 7/8/2025 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Retina Midco, Inc | Health Care Providers & Services | S+ 575 |1.00% | 11.38% | 12/18/2023 | 1/31/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsAndCashEquivalentsMember 2021-01-05 2021-12-31 0001832148 us-gaap:InvestmentsMember 2021-01-05 2021-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2021-01-05 2021-12-31 0001832148 cik0001832148:InvestmentsAndCashEquivalentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember 2022-01-01 2022-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-01-01 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Apeel Technology Inc. | Biotechnology | S+625 | 1.00% | 8.75% | 6/29/2022 | 6/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Oral Surgery Partners Holdings LLC | Health Care Providers & Services | S+625| 1.00% | 10.92% | 11/29/2022 | 5/10/2024 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Pediatric Home Respiratory Services LLC | Health Care Providers & Services | S+625 | 1.00% | 10.67% | 8/19/2022 |12/4/2024 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ivy Fertility Services LLC | Health Care Providers & Services | L+625 | 1.00% | 10.39% | 12/22/2021 | 2/25/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2022-01-01 2022-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/30/2022 | 2/23/2023 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Spectrum Pharmaceuticals Inc. | Biotechnology | S+570 | 2.30% | 9.88% | 9/21/2022 | 9/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2022-01-01 2022-12-31 0001832148 cik0001832148:InitialUnitholderMember 2021-01-05 2021-01-05 0001832148 cik0001832148:InitialUnitholderMember 2021-01-05 0001832148 cik0001832148:InitialUnitholderMember 2021-03-08 2021-03-08 0001832148 cik0001832148:InitialUnitholderMember 2021-03-08 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember 2021-03-19 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member srt:MaximumMember 2022-02-18 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member srt:MinimumMember 2022-02-18 0001832148 cik0001832148:SpvFacilityMember srt:MaximumMember us-gaap:SubsequentEventMember 2024-01-23 0001832148 cik0001832148:SpvFacilityMember srt:MinimumMember us-gaap:SubsequentEventMember 2024-01-23 0001832148 us-gaap:InvestmentsMember 2022-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:InvestmentsMember 2023-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:InvestmentsMember 2021-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2021-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2021-12-31 iso4217:USD xbrli:pure xbrli:shares utr:Year iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-K
 
 
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NUMBER:
000-56247
 
 
SLR HC BDC LLC
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
85-1801692
(State of formation)
 
(I.R.S. Employer
Identification No.)
 
500 Park Avenue
New York,
NY
 
10022
(Address of principal executive offices)
 
(Zip Code)
(212)
993-1670
(Registrant’s telephone number, including area code)
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
 
Title of Each Class
 
Trading Symbol
 
Name of Each Exchange on Which Registered
N/A
 
N/A
 
N/A
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
Unit
(Title of Class)
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐ No 
If securities are registered pursuant to Section 12(b) of the Exchange Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. 
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act). Yes ☐ No 
As of June 30, 2023, there was no established public market for the registrant’s units. The issuer had 1,069,642 units outstanding as of February 23, 2024.
 
Auditor Firm Id: 185   Auditor Name: KPMG LLP   Auditor Location: New York, NY
 
 
 

SLR HC BDC LLC
FORM
10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
TABLE OF CONTENTS
 
    
PAGE
 
  
PART I.
  
     2  
     30  
     65  
     65  
     66  
     67  
     67  
PART II.
  
     68  
     69  
     70  
     80  
     81  
     110  
     110  
     110  
     110  
PART III.
  
     111  
     114  
     115  
     115  
     124  
PART IV.
  
     125  
     126  
     127  
 

PART I
Item 1. Business
SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on July 7, 2020 as a
closed-end,
externally managed investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a BDC and a RIC, we are required to comply with certain regulatory requirements. The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below. SLR Capital Partners, LLC (the “Adviser” or “SLR”) serves as the Company’s investment adviser pursuant to an investment management agreement between the Company and the Adviser (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”).
The Company pursues a corporate lending strategy focused on direct sourcing, underwriting and managing a diverse portfolio of private loans to U.S. healthcare companies. The Company’s principal focus is to invest in two differentiated strategies: first lien healthcare cash flow loans and first lien life science loans. First lien healthcare cash flow loans are expected to be made to private equity-owned upper middle market healthcare companies with EBITDA between approximately $25 million and $100 million. These loan tranches are expected to range in size from $100 million to $300 million. Healthcare cash flow loans are generally expected to have a five to six year final maturity and are often repaid within three years. First lien life science loans are expected to be made to venture capital owned
pre-commercialization
or early revenue drug and device development companies. These loan tranches are expected to range in size from $25 million to $150 million. Loans to life science companies are generally expected to have an initial interest-only period and then straight-line amortization with a four to five year final maturity. These loans are often repaid within two to three years. The Company expects to primarily invest in
non-investment
grade debt instruments. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments. The Company expects to
co-invest
with other vehicles managed by SLR (the “SLR Funds”). The Company and the SLR Funds are under common control with SLR. There can be no assurance that the Company will be able to
co-invest
with such other funds, including as a result of legal restrictions and contractual restrictions and, as a result, the Company may not be able to meet its investment objective. The Company believes the potential scale resulting from
co-investments
with vehicles managed by SLR will provide the Company a significant advantage to source loans over other lenders that do not have the capital base to provide significant debt financing. The Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”.
The Adviser believes the broad experience of the Adviser’s senior investment team enables it to successfully identify, assess and structure customized senior secured loans, and to manage potential risk and return at all stages of the economic cycle. As an unlisted BDC, the Company is not subject to many of the regulatory limitations that govern traditional lending institutions such as banks. This lack of regulation allows the Adviser to be more flexible than regulated lending institutions in selecting and structuring investments, adjusting investment criteria, transaction structures and, in some cases, the types of securities in which the Company is expected to invest. The Adviser believes financial sponsors, management teams and investment banks see this flexibility as a benefit, making it an attractive financing partner. The Adviser believes that this approach enables it to procure attractive investment opportunities throughout the economic cycle so that it can make investments consistent with its stated investment objective even during turbulent periods in the capital markets.
Moreover, the Company may opportunistically seek to acquire investments in the secondary market at attractive and/or discounted prices, especially during periods of significant market volatility. In analyzing such investments, the Company will employ a substantially similar analytical process as it uses for its primary investments as well as any prior knowledge of the target company.
The Adviser seeks to create a diverse, predominantly floating rate investment portfolio for the Company. There is no guarantee that the Company will achieve its goals or that even if achieved, an investment in the Company will result in gains to an investor. For the avoidance of doubt, any investment guidelines discussed in this annual report apply to a fully
ramped-up
portfolio of investments, (i.e., after the Company has invested substantially all of the capital available to the Company in accordance with the Company’s investment strategy) and are based on total available capital including unfunded equity commitments from the holders (“Unitholders”) of the Company’s units (“Units”) and total expected leverage, as reasonably determined by the Adviser. The Company will not be required to take any action (including unwinding or liquidating any position) in the event that such guideline is exceeded subsequent to the investment date, whether as a result of changes in the market value of the Company’s portfolio or otherwise.
 
2

The Adviser — SLR Capital Partners, LLC
SLR serves as the Company’s investment adviser pursuant to an investment management agreement with the Company (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”). Subject to the overall supervision of the Company’s Board of Directors (the “Board”), the Adviser is responsible for managing the Company’s business and activities, including sourcing investment opportunities, conducting research, performing diligence on potential investments, structuring our investments, and monitoring the Company’s portfolio companies on an ongoing basis through a team of investment professionals. The managing members of the Adviser are Michael Gross and Bruce Spohler. The Adviser has established an investment committee that is dedicated to the Company (the “Investment Committee”), which is currently comprised of Michael Gross, Bruce Spohler, Philip Guerin, Julie Reyes, Anthony Storino and Krishna Thiyagarajan.
The Board of Directors
Overall responsibility for the Company’s operations rests with the Board. The Board is responsible for overseeing the Adviser and other service providers in our operations in accordance with the provisions of the 1940 Act, applicable provisions of state and other laws, and the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”). The Board currently consists of five members, three of whom are not “interested persons” of the Company as defined in Section 2(a)(19) of the 1940 Act. The Company refers to these individuals as our independent directors. The Board elects officers, who serve at the discretion of the Board. The responsibilities of each director include, among other things, the oversight of investment activities, the quarterly valuation of assets, and oversight of financing arrangements. The Board has established an audit committee and a nominating and corporate governance committee and may establish additional committees in the future.
Investment Management Agreement
Subject to the overall supervision of the Board, the Adviser manages the investments of, and provide certain services to, the Company pursuant to the Investment Management Agreement, including:
 
  (i)
providing overall investment management services to the Company in accordance with the LLC Agreement and in accordance with the 1940 Act, including without limitation, sourcing, structuring, negotiating, underwriting, performing diligence, originating and disposing of investments of the Company;
 
  (ii)
making investment decisions for the Company;
 
  (iii)
servicing investments including, without limitation, monitoring the investments and the creditworthiness of all issuers, developing and executing work out strategies where applicable;
 
  (iv)
overseeing the placement of purchase and sale orders on behalf of the Company;
 
  (v)
undertaking certain compliance-related activities in respect of the Company in accordance with the investment objective;
 
  (vi)
providing good faith valuations of investments for which market quotes are not readily available pursuant to the LLC Agreement;
 
  (vii)
voting proxies, exercise rights, options, warrants, conversion privileges, and redemption privileges, and tender securities pursuant to a tender offer;
 
  (viii)
enter into agreements and execute any documents (e.g., any loan or credit facility agreements), including without limitation, any market and/or industry standard documentation and standard representations contained therein; and
 
  (ix)
providing periodic and special reports to the Company as requested.
 
3

The Company and its special-purpose vehicles (such as special-purpose vehicles used for credit facilities or tax blockers) engage or otherwise transact with, one or more Service Providers (defined herein) in connection with their investment process, including in respect of Portfolio Investments. “Service Providers” include consultants (including in connection with the acquisition, management and disposition of Portfolio Investments), advisors, transaction finders or sources, operating partners, loan and other servicers, loan and other originators, property and other asset managers, investment bankers, valuation agents, pricing service providers, legal counsel, appraisers, industry or sector experts, joint venture partners and development partners, contract employees, outside legal counsel and/or temporary employees (as well as employees of any of the foregoing), whether working onsite or offsite. Any fees, costs, expenses and liabilities incurred in connection with services provided by Service Providers will be borne (directly or indirectly) by the Company, subject to the cap on operating expenses, and will not offset Management Fees (defined herein), and such amounts may be substantial.
Investment Management Agreement Term
Unless terminated earlier as described below, the Investment Management Agreement will remain in effect from
year-to-year
if approved annually by a majority of the Board or by the holders of a majority of our outstanding voting securities and, in each case, a majority of the independent directors, in accordance with the requirements of the 1940 Act.
The Investment Management Agreement will automatically terminate in the event of its “assignment” within the meaning of the 1940 Act and related Securities and Exchange Commission (“SEC”) guidance and interpretations. In accordance with the 1940 Act, without payment of any penalty, we may terminate the Investment Management Agreement with the Adviser upon 60 days’ written notice. In addition, without payment of any penalty, the Adviser may generally terminate the Investment Management Agreement upon 60 days’ written notice.
Notwithstanding the foregoing, at any time during the term of the Investment Management Agreement, the Adviser may assign the full and exclusive authority and responsibility granted to it under the Investment Management Agreement to an investment adviser under common control with the Adviser, subject to applicable law. The Adviser may take any actions that are necessary or incidental to any such assignment, including assigning the Investment Management Agreement or causing the Company to enter into a new Investment Management Agreement. It is expected that (x) any new investment adviser would be a registered investment adviser under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), (y) the management fee and incentive fee payable by the Company to such entities would be identical to that payable to the Adviser and (z) certain of the investment professionals would continue to be responsible for managing the Company’s assets.
Compensation of Adviser
Pursuant to the Investment Management Agreement we have entered into with the Adviser, we pay the Adviser certain management and incentive fees prior to and following an Exchange Listing. Prior to an Exchange Listing, we pay the Adviser, in its capacity as Administrative Coordinator, an administration fee for administrative and coordination services, each as defined and described further below. Following an Exchange Listing, we intend to enter into a separate administration agreement with an affiliate pursuant to which administrative services would be provided to the Company, as described further below. The cost of the base management fee, the incentive fee and the administration fee will ultimately be borne by our Unitholders.
Management Fees and Administration Fees
The Company pays the Adviser a management fee prior to an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the
“Pre-Exchange
Listing Management Fee”) and a management fee following an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the “Post-Exchange Listing Management Fee” and, together with the
Pre-Exchange
Listing Management Fee, the “Management Fee”). The Management Fee will be payable quarterly in arrears, as follows:
 
   
Pre-Exchange
Listing
. Prior to an Exchange Listing, the
Pre-Exchange
Listing Management Fee will be calculated as of the close of business on the last day of each calendar quarter in an amount equal to 1.50%
per annum
of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company used to make Portfolio Investments and (ii) the total amount of credit drawn on subscription or similarly structured credit facilities).
 
4

   
Post-Exchange Listing
. Following an Exchange Listing, the Post-Exchange Listing Management Fee will be an amount equal to 1.50% per annum of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters; provided, however, the Post-Exchange Listing Management Fee will be calculated at an annual rate of 1.00% of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters that exceeds the product of (i) 200% and (ii) the value of the Company’s total net assets at the end of the immediately preceding calendar quarter.
The Management Fee will be appropriately adjusted for any stub period. The Adviser may arrange for the Company to direct to a placement agent any portion of the Management Fee that the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent.
The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, the Management Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such Management Fee may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the Management Fee.
Incentive Fee
Distributions
. Prior to an Exchange Listing, the Company makes distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, prepayment fees and exit fees, other than Disposition Proceeds, less Company expenses. The Adviser apportions each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds.
Pre-Exchange
Listing Incentive Fee
.
 
Prior to an Exchange Listing, and subject to availability, the Company will cause distributable cash to be distributed to Unitholders and to be paid to the Adviser as an incentive fee (the
“Pre-Exchange
Listing Incentive Fee”). Amounts of Investment Proceeds apportioned to Unitholders are divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority:
(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a
Pre-Exchange
Listing Incentive Fee, on the other hand, in the following amounts and order of priority:
(A) First, Return of Capital Contributions: 100% to such Unitholder until such Unitholders has received cumulative distributions of Investment Proceeds pursuant to this clause (A) equal to such Unitholder’s total capital contributions to the Company (including amounts contributed to pay
Pre-Exchange
Listing Management Fees,
Pre-Exchange
Listing Administration Fees, Organizational Expenses (as defined below) and other Company expenses);
(B) Second, Unitholder Preferred Return: 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and clause (ii)(A) and (ii)(C) below equal to 6% per annum, compounded annually, on Unitholders’ capital contributions to the Company (including amounts contributed to pay
Pre-Exchange
Listing Management Fees,
Pre-Exchange
Listing Administration Fees, Organizational Expenses and other Company expenses), determined on the basis of all capital contributions made by such Unitholder and considering all distributions (including the subject distribution) under this
“—Pre-Exchange
Listing Incentive Fee” made to such Unitholder (computed from the dates that such capital contributions were due (or, if actually made later, the date on which such capital contributions were actually made) until the date that the Company, in its sole discretion, designates distributable cash as available for distribution or, if no such designation is made, the occurrence of an Event of Dissolution, as defined in the LLC Agreement) (the “Preferred Return”);
(C) Third, Adviser Catch Up: 100% of all remaining Disposition Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee, until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) below equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (B) above and this clause (C) and clause (ii)(A) and (ii)(B) below; and
(D) Fourth, 90%/10%: 90% of all remaining Disposition Proceeds to Unitholders and 10% of all remaining Disposition Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee.
 
5

In no event will the Adviser receive amounts of
Pre-Exchange
Listing Incentive Fees under clause (i)(C) and (i)(D) above in excess of the percentage of the Disposition Proceeds actually distributed to Unitholders pursuant to clause (i)(B), (i)(C) and (i)(D) above.
In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation.
(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a
Pre-Exchange
Listing Incentive Fee, on the other hand, in the following amounts and order of priority:
(A) First, Unitholder Preferred Return: 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) above equal to the Preferred Return;
(B) Second, Adviser Catch Up: Second, 100% of all remaining Current Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) above equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (A) above and this clause (B) and pursuant to clause (i)(B) and clause (i)(C) above; and
(C) Third, 90%/10%: Thereafter, 90% of all remaining Current Proceeds to Unitholders and 10% of all remaining Current Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee.
In no event will the Adviser receive amounts of
Pre-Exchange
Listing Incentive Fees under clause (ii)(B) and (ii)(C) above in excess of the percentage of the Current Proceeds actually distributed to Unitholders pursuant to clause (ii)(A), (ii)(B) and (ii)(C) above.
Post-Exchange Listing Incentive Fee
. Following an Exchange Listing, the Company will pay an incentive fee to the Adviser consisting of two parts, as follows (the “Post-Exchange Listing Incentive Fee”):
 
  (i)
Pre-Incentive
Fee Net Investment Income. One part will be calculated and payable quarterly in arrears based on the net investment income for the immediately preceding calendar quarter.
 
  a.
For this purpose,
Pre-Incentive
Fee Net Investment Income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies) accrued by the Company during the calendar quarter, minus the Company’s operating expenses for the quarter (including the Post-Exchange Listing Management Fees, expenses payable under an administration agreement, and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the Post-Exchange Listing Incentive Fee).
 
  b.
Pre-Incentive
Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation.
Pre-Incentive
Fee Net Investment Income, expressed as a rate of return on the value of the Company’s net assets at the end of the immediately preceding calendar quarter, will be compared to a “hurdle rate” of 1.50% per quarter (6.00% annualized). The Company’s
Pre-Incentive
Fee Net Investment Income used to calculate this part of the Post-Exchange Listing Incentive Fee is also included in the amount of its gross assets used to calculate the 1.50% Post-Exchange Listing Management Fees.
 
  c.
The Company will pay the Adviser a Post-Exchange Listing Incentive Fee with respect to the Company’s
Pre-Incentive
Fee Net Investment Income in each calendar quarter as follows:
 
  i.
no Post-Exchange Listing Incentive Fee in any calendar quarter in which the Company’s
Pre-Incentive
Fee Net Investment Income does not exceed the quarterly hurdle rate of 1.50%;
 
6

  ii.
100% of the Company’s
Pre-Incentive
Fee Net Investment Income with respect to that portion of such
Pre-Incentive
Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 1.875% in any calendar quarter (7.5% annualized); this portion of the
Pre-Incentive
Fee Net Investment Income (which exceeds the hurdle but is less than 1.875%) is referred to herein as the
“catch-up.”
The
“catch-up”
is meant to provide the Adviser with 20% of the Company’s
Pre-Incentive
Fee Net Investment Income as if a hurdle did not apply if this
Pre-Incentive
Fee Net Investment Income exceeds 1.875% in any calendar quarter; and
 
  iii.
20% of the amount of the Company’s
Pre-Incentive
Fee Net Investment Income, if any, that exceeds 1.875% in any calendar quarter (7.5% annualized) payable to the Adviser (once the hurdle is reached and the
catch-up
is achieved, 20% of all
Pre-Incentive
Fee Net investment income thereafter is allocated to the Adviser).
These calculations will be
appropriately pro-rated for
any period of less than three months.
Capital Gains Fee
. The second part of the Post-Exchange Listing Incentive Fee, the “Capital Gains Fee”, will be determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement as set forth below), commencing as of the end of the first fiscal year following an Exchange Listing, and will equal 20.0% of the Company’s realized capital gains, if any, on a cumulative basis through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation as of each fiscal year end, less the amount of any previously paid capital gain Post-Exchange Listing Incentive Fees, with respect to the Company; provided that the Post-Exchange Listing Incentive Fee determined as of the end of the fiscal year in which an Exchange Listing is completed will be calculated for a period of shorter than twelve calendar months to take into account any realized capital gains computed net of all realized capital losses and unrealized capital depreciation. In the event that the Investment Management Agreement will terminate as of a date that is not a calendar year end, the termination date will be treated as though it were a calendar year end for purposes of calculating and paying a Capital Gains Fee.
Incentive Fee Waiver and Recoupment
.
The Adviser will have the right to waive or reduce, in its sole discretion, as well as recoup in a subsequent period, all or any portion of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee that would otherwise be earned in any particular calendar quarter, and may cause any or all amounts subsequently available for distribution to the Unitholders to be distributed to the Adviser until it has received the same aggregate amount of
Pre-Exchange
Listing Incentive Fees or Post-Exchange Listing Incentive Fees had it not previously waived receipt of such
Pre-Exchange
Listing Incentive Fees or Post-Exchange Listing Incentive Fees. Any such
Pre-Exchange
Listing Incentive Fees or Post-Exchange Listing Incentive Fees may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee.
The Adviser will be entitled to withhold from any distributions, in its discretion, any required tax withholdings. Amounts of taxes paid or withheld from amounts otherwise distributable to a Unitholder will be deemed distributed for purposes of the calculations above.
The Adviser may arrange for the Company to direct to a placement agent any portion of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent.
Administration Fees and Expenses
Pre-Exchange
Listing Administration Fees
. The Company will pay SLR, in its capacity as the Administrative Coordinator, a fee (the
“Pre-Exchange
Listing Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as, as of any date, the aggregate accreted and amortized cost of all Portfolio Investments, including (i) any amounts reinvested in Portfolio Investments and (ii) the cost of Portfolio Investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The
Pre-Exchange
Listing Administration Fee will not offset any fees paid to the Adviser. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain
on-going,
routine,
non-investment-related
administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company and (iii) certain Unitholder servicing functions.
 
7

The
Pre-Exchange
Listing Administration Fee will be appropriately adjusted for any stub period.
The Administrative Coordinator will have the right, in its sole discretion, to waive, as well as recoup in a subsequent period, the
Pre-Exchange
Listing Administration Fee to which it is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such
Pre-Exchange
Listing Administration Fee may be recouped by the Administrative Coordinator in a future calendar quarter within three years of the date of the applicable waiver of the
Pre-Exchange
Listing Administration Fee.
Post-Exchange Listing Administration Expenses
. In connection with an Exchange Listing, and subject to Board approval, the Company intends to enter into an administration agreement with SLR Capital Management, LLC (“SCM”) pursuant to which SCM will provide administrative services to the Company. For providing these services, facilities and personnel, the Company will reimburse SCM for the Company’s allocable portion of overhead and other expenses incurred by SCM in performing its obligations under the administration agreement (together with the
Pre-Exchange
Listing Administration Fee, the “Administration Expenses”).
Limitation of Liability and Indemnification
The Investment Management Agreement provides that the Adviser (which includes, for all purposes of this paragraph, its members, principals, officers, managers, investors, employees and other representatives and agents and entities controlling, controlled by or under common control with the Adviser) will not be liable to the Company or to the Unitholders for any loss suffered by the Company or the Unitholders which arises out of any action or inaction of the Adviser taken or made by the Adviser in good faith and in the belief that such action or inaction is in or is not contrary to the best interests of the Company, except for any loss resulting from fraud, willful misfeasance, gross negligence or reckless disregard of the duties of the Adviser in the conduct of the Adviser’s office, and except as otherwise required by applicable law. In addition, the Company will indemnify and hold harmless the Adviser, to the fullest extent permitted by applicable law, against any loss resulting from claims or threatened claims with respect to the Adviser’s performance or
non-performance
of its obligations pursuant to the Investment Management Agreement, except for any such loss resulting from fraud, willful misfeasance, gross negligence or reckless disregard of duties of the Adviser in the conduct of the Adviser’s office.
Adviser Clawback
Prior to an Exchange Listing, and in connection with the liquidation of the Company, the Adviser will be required to restore funds to the Company for distribution to the Unitholders if and to the extent that the Adviser has received cumulative
Pre-Exchange
Listing Incentive Fees in excess of the
Pre-Exchange
Listing Incentive Fees that would have been payable to the Adviser if the formulas set forth under “
– Compensation of Adviser – Incentive Fee
” above were applied on an aggregate basis covering all transactions of the Company; provided, however, that in no event will the Adviser be required to contribute an aggregate amount in excess of 100% of the net amount distributed to the Adviser (net of taxes) on account of its
Pre-Exchange
Listing Incentive Fees. In addition, the Adviser will apply an interim
Pre-Exchange
Listing Incentive Fee adjustment at the end of each fiscal year so that, in the event of any over-distribution of
Pre-Exchange
Listing Incentive Fee to the Adviser (measured with respect to each Unitholder at the end of the applicable fiscal year as if the Company were to liquidate on such date), future distributions that would, absent such interim incentive fee adjustment, otherwise be distributed to the Adviser as a
Pre-Exchange
Listing Incentive Fee, shall be distributed to such Unitholder until such over-distribution (net of taxes payable by the Adviser with respect to such
Pre-Exchange
Listing Incentive Fee) has been eliminated.
Administration Services
Pre-Exchange
Listing
. Prior to an Exchange Listing, pursuant to the Investment Management Agreement, the Adviser was appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Administrative Coordinator supervises or provides the Company’s administrative services, including operational trade support, net asset value (“NAV”) calculations, financial reporting, fund accounting, registrar and transfer agent services. The Administrative Coordinator provides assistance to the Adviser in connection with communicating with investors and other persons with respect to the Company. The Administrative Coordinator will not provide any investment advisory or investment management services to the Company. In the event that the Administrative Coordinator is terminated or resigns as the administrative coordinator to the Company, the Company reserves the ability to appoint one or more different or replacement administrative coordinators in its sole discretion at any time without notice to the Unitholders. Pursuant to the Investment Management Agreement, the Company pays the Administrative Coordinator the
Pre-Exchange
Listing Administration Fee for its services. See “—
Administration Fees and Expenses
.”
 
8

The Investment Management Agreement contains limitations on liability and indemnifications in favor of the Administrative Coordinator, provided that the Administrative Coordinator’s actions do not constitute fraud, bad faith, gross negligence or willful misconduct (collectively, “Wrongful Conduct”). The Administrative Coordinator’s liability to the Company is subject to an overall cap (except where the Administrative Coordinator has engaged in Wrongful Conduct). In the event that the Administrative Coordinator is terminated or resigns as the administrative coordinator to the Company, the Board reserves the ability to appoint one or more different or replacement administrative coordinators in its sole discretion at any time without notice to the Unitholders, or to assume the Administrative Coordinator’s role on the same or similar terms in providing administration services to the Company.
Concurrent with the review and approval of the Investment Management Agreement, our Board will review and approve the engagement of the Administrative Coordinator on an annual basis. In connection with such approval, the Board, including a majority of independent directors, reviews the engagement of the Administrative Coordinator to determine that the relevant provisions of the Investment Management Agreement are carried out satisfactorily and to determine, among other things, whether the fees payable to the Administrative Coordinator are reasonable in light of the services provided. The Board also considers the possibility of obtaining such services from a different third party and whether any other third party service provider would be capable of providing all such services at comparable cost, quality and timeliness.
Post-Exchange Listing
. As described above, in connection with an Exchange Listing, and subject to Board approval, the Company intends to enter into an administration agreement with SCM pursuant to which SCM will provide administrative services to the Company. For providing these services, facilities and personnel, the Company will reimburse SCM for the Company’s allocable portion of overhead and other expenses incurred by SCM in performing its obligations under the administration agreement.
Payment of Our Expenses under the Investment Management Agreement
The Company (directly or indirectly) bears:
 
  (i)
all of its fees, costs, expenses and liabilities, all of its investment-related fees, costs, expenses and liabilities (including with respect to amounts incurred prior to the Company’s initial closing) and all of its other operating fees, costs, expenses and liabilities, including all fees, due diligence costs and other fees, costs, expenses and liabilities related to the identification, sourcing, evaluation, pursuit, acquisition, holding, appraisals, asset management, restructuring and disposing of investments, including all reasonable travel-related fees, costs, expenses and liabilities, including lodging and meals, all fees, costs, expenses and liabilities of legal counsel and financial and other advisers incurred in connection therewith, all fees, costs, expenses and liabilities of information technology services relating to the ongoing management of investments, and all other investment-related fees, costs, expenses and liabilities (to the extent not reimbursed by the relevant portfolio company);
 
  (ii)
all fees, costs, expenses and liabilities related to any audits or agreed upon procedures, tax forms and return preparations and filings, custodian fees and expenses, fund accounting, administrator services, financial statement preparation and reporting, web services for the benefit of Unitholders, delivery costs and expenses in connection with reporting obligations and communications and compliance services;
 
  (iii)
all fees, costs, expenses and liabilities relating to insurance policies (including director and officer liability insurance) maintained by or for the Company, including in respect of Portfolio Investments and/or personnel of the Adviser, the Administrative Coordinator and their affiliates;
 
  (iv)
other administrative fees, costs, and liabilities;
 
  (v)
all fees, costs, expenses and liabilities of brokers, transaction finders and other intermediaries, including brokerage commissions and spreads, and all other transaction-related fees, costs, expenses and liabilities, including reverse
break-up
fees;
 
  (vi)
all fees, costs, expenses and liabilities relating to derivatives and hedging transactions;
 
  (vii)
all principal amounts of, and interest expense on, borrowings and guarantees, and all other fees, costs, expenses and liabilities arising out of borrowings and guarantees, including the arranging and maintenance thereof, whether incurred by the Company or incurred or facilitated by a special purpose vehicle that makes Portfolio Investments;
 
  (viii)
Management Fees and Incentive Fees;
 
9

  (ix)
Administration Expenses;
 
  (x)
all fees, costs, expenses and liabilities incurred through the use or engagement of Service Providers;
 
  (xi)
all taxes, fees, penalties and other governmental charges levied against the Company (see “
Certain U.S. Federal Income Tax Considerations
” below) and all fees, costs, expenses, penalties and liabilities related to tax compliance;
 
  (xii)
all fees, costs, expenses and liabilities of the Company’s legal counsel related to extraordinary matters, including expenses for any dispute resolution (including litigation and regulatory-related legal expenses);
 
  (xiii)
all fees, costs, expenses and liabilities relating to legal, governance and regulatory compliance and filings, including securities law filings relating to Portfolio Investments;
 
  (xiv)
all fees, costs, expenses and liabilities related to the Company’s indemnification or contribution obligations;
 
  (xv)
all fees, costs, expenses and liabilities for subscription services (to the extent such subscription is required by a placement agent);
 
  (xvi)
any required regulatory filings and related legal fees;
 
  (xvii)
all fees, costs, expenses and liabilities of liquidating the Company;
 
  (xviii)
transfer agent services;
 
  (xix)
any other fees, costs, expenses and liabilities not specifically assumed by the Adviser or the Administrative Coordinator;
 
  (xx)
all fees, costs, expenses and liabilities of the independent directors, including resources retained by the independent directors, or on their behalf, while representing and/or acting on behalf of all Unitholders; and
 
  (xxi)
all fees, costs, expenses and liabilities related to an Exchange Listing (including any transactions effectuated in connection therewith) or other business combination.
In addition, prior to an Exchange Listing, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company set forth in clauses (ii)-(iv) and the operating expenses included in
sub-clauses
(xiii) and (xvi) related to U.S. regulatory bodies above borne by the Company (directly or indirectly) will not exceed the following limits in any fiscal year: (A) if the Company has less than or equal to $400 million in Commitments, an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1.25 million, or (B) if the Company has greater than $400 million in Commitments, $2.25 million (such figure, the “Operating Expense Cap”). Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. Solely by way of example, if Commitments equal $350 million, the Operating Expense Cap will be equal to $2.125 million. For the avoidance of doubt, (i) the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder or in connection with (xxi) above, (ii) the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the Company’s portfolio investments at each quarter end and (iii) the Operating Expense Cap will no longer apply upon the effectuation of an Exchange Listing.
The Adviser or Administrative Coordinator and/or their affiliates may advance to the Company organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (the “Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) will be reimbursed by the Company for such advanced expenses in an amount not to exceed $500,000. The Company will be responsible for and pay (or reimburse) the Organizational Expenses subject to the cap described in the preceding sentence. Accordingly, in 2021, $0.2 million of offering expenses were charged to capital and $0.2 million of organizational costs were expensed.
 
10
Placement Agreement
The Company has retained certain third parties to find potential investors (i.e., a “placement agent”). If an investor purchases Units through a placement agent, the Adviser may be subject to finder-related fees, the arrangements of which are set forth in detail in our Private Placement Memorandum.
Use of Name
Pursuant to the LLC Agreement, SLR has granted us a
non-exclusive
license to use the name “SLR HC BDC LLC” as the name of the Company and in connection with the marketing and operation of the Company. We have a right to use the “SLR HC BDC LLC” name for so long as the Adviser or one of its affiliates remains our investment adviser. Other than with respect to this limited license, we have no legal right to the “SLR HC BDC LLC” name or logo.
Market Opportunity
The Company focuses on providing private corporate loans to middle market companies within the healthcare industry. We believe that the Company is well-positioned to provide a superior risk-adjusted return relative to publicly-traded corporate bonds and loans for the following reasons:
Resilient and defensive industry:
 
   
The healthcare sector has historically been insulated from business cycle fluctuations and may act as a hedge against an extended economic slowdown.
Ripe for consolidation and innovation:
 
   
Digitization of healthcare services provides opportunities for private solutions to reduce costs through revenue cycle management, care coordination and drug discovery, which presents opportunities for investors to support healthcare IT and medical technology companies.
Favorable long-term supply-demand dynamics in U.S. middle market lending which benefit lenders
 
   
Robust demand for debt capital to fund private equity transactions
 
   
Middle market debt capital raised in the last few years is not expected to meet demand
Premium pricing in private corporate loans over public high yield and syndicated leveraged loans and healthcare outperformance
 
   
Capturing illiquidity premiums:
The illiquid nature of private corporate loans results in lenders earning an “illiquidity premium” over public high yield and syndicated leveraged loans.
 
   
Capturing size and risk premium:
Middle market lenders also typically receive a premium relative to larger company loan investors to compensate them for investing in smaller companies and in niche industries. Middle market companies tend to be less followed by investors and research analysts and typically have lower ratings from ratings agencies due to their size. As a result, we expect that there will be a smaller investor base while demand will remain robust, resulting in premium pricing for middle market borrowers.
 
   
Capitalizing on market inefficiencies:
We believe that the market inefficiencies are greater in the private middle market, which allows lenders to capture higher risk-adjusted returns. We believe that, among others, the drivers of middle market inefficiencies include the following: information asymmetry, the analytical complexity in evaluating private middle market companies, the need for long-dated capital that typically requires higher return expectation, fewer and more sophisticated lenders, and the requirement to underwrite to maturity as opposed to a trade.
 
   
Healthcare outperformance:
Healthcare credit investments have historically outperformed broader averages.
 
11

Stronger underwriting process in private corporate loans versus public syndicated leveraged loans
 
   
Deeper due diligence
: Private corporate lenders are typically able to conduct detailed due diligence on a company, often alongside the financial sponsor acquiring the company, which provides the lender significantly more time to form a more comprehensive understanding of the company, including its competitive position and risks. In contrast, public high yield and syndicated leveraged loan investors are typically provided a single syndication meeting and minimal access to diligence materials before placing their order.
 
   
Inclusion of covenants
: Covenants are contractual restrictions that lenders place on companies to limit the corporate actions a company can pursue that are negative to the lender and act as warning signals for lenders. The loans in which the Company is expected to invest are expected to have comprehensive covenants including covenants that are tested on a recurring basis to ensure ongoing compliance (i.e., “maintenance covenants”). Although syndicated leveraged loans have covenants, many are “covenant-lite,” which means they do not have a complete set of financial covenants, thus providing borrower companies more freedom to negatively impact lenders. High yield bonds provide even weaker protection for lenders because they typically have incurrence-based covenants, which are only tested if the company issues more debt.
 
   
Ability to exert greater influence over the negotiation of lending terms
: Private corporate loan terms are negotiated directly by the lender(s) and the company, therefore removing the underwriting bank that negotiates the terms for public high yield or syndicated leveraged loans. This allows the private corporate lender to customize the terms to mitigate risks and address the unique needs of the company.
 
   
Lower default rates and higher recovery rates
: The more comprehensive underwriting process for private corporate loans has resulted in historically lower default rates and higher recovery rates than syndicated loans.
Investment Guidelines
The Company has a broad, flexible investment mandate, and the Company is not subject to any investment guidelines, limitations or restrictions other than as set forth below. Interpretation of the application of the guidelines described below will be made by the Adviser in its sole discretion, and any guideline generally will be measured, if applicable, at the time such investment is made based upon good faith estimates using data known to the Adviser at such time. The Company will not be required to take any action (including unwinding or liquidating any position) in the event that such guideline is exceeded subsequent to the investment date, whether as a result of changes in the market value of the Company’s portfolio or otherwise.
The Company uses reasonable best efforts to achieve the guidelines set forth herein. For purposes of such guidelines, (i) the Company’s “total portfolio” will equal the total amount of Commitments plus the Company’s total expected leverage, as reasonably determined by the Adviser and (ii) the Adviser will take into account the underlying portfolio of any company the Company may acquire. In addition, the Adviser may consider the impact of hedging transactions, and of cash and cash equivalents in the portfolio, in applying the below guidelines:
 
   
at least 90% of the Company’s total portfolio will be comprised of secured loans;
 
   
at least 85% of the Company’s total portfolio will be comprised of floating rate loans;
 
   
no more than 15% of the Company’s total portfolio will consist of loans to lower middle market
(i.e.
, EBITDA below $15 million) corporate borrowers (
provided
,
however
, that such guideline will not apply to Life Sciences borrowers);
 
   
the Company will take no more than four (4) positions greater than 7.5% of the Company’s total portfolio, and the balance of the Company’s positions will each comprise 5%, directly or indirectly, or less of the Company’s total portfolio;
 
   
the Company’s 10 largest positions will comprise no more than 60% of the Company’s total portfolio;
 
   
the Company’s portfolio will be comprised of investments in the United States and Canada, provided that up to 7.5% of the total portfolio may be outside of the United States and Canada; and
 
   
the target percentage of the Company’s Life Sciences lending investments will be 15% to 20% of the Company’s total portfolio.
 
12

Notwithstanding anything to the contrary herein, the guidelines will in no way restrict or otherwise limit the Company’s ability to acquire an investment in an issuer that is sufficiently large (as determined by the Adviser in its discretion) to enable the Company to influence or control any restructuring,
work-out
and/or bankruptcy process in accordance with the Company’s investment program.
For the avoidance of doubt, these investment guidelines are not deemed to be the type of policies referenced in Section 8(b) of the 1940 Act. The foregoing guidelines will no longer be applicable upon the occurrence of an Exchange Listing.
Leverage
The Company is required to comply with the asset coverage requirements of the 1940 Act. The Company employs leverage and otherwise incurs indebtedness with respect to the portfolio both on a recourse and
non-recourse
basis (including and potentially through guarantees, derivatives, forward commitments and reverse repurchase agreements), but will not exceed the maximum amount permitted by the 1940 Act. The Company is generally permitted, under specified conditions, to issue senior securities in amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after such issuance. In connection with the organization of the Company, the Adviser, as the initial Unitholder, has authorized the Company to adopt the 150% asset coverage ratio. In connection with their subscriptions for Units, our Unitholders are required to acknowledge the Company’s ability to operate with an asset coverage ratio that may be as low as 150%. The Company will be exposed to the risks of leverage, which may be considered a speculative investment technique. The use of leverage magnifies the potential for gain and loss on amounts invested and therefore increases the risks associated with investing in our securities. In addition, the costs associated with our borrowings, including any increase in the management fee payable to the Adviser, will be borne by our Unitholders.
Investment Process Overview
We are committed to our value-oriented investment philosophy, with a focus on the preservation of capital and a commitment to managing downside exposure.
Proprietary Sourcing and Origination
We believe that SLR’s senior investment professionals’ longstanding relationships with financial sponsors, corporate management teams, commercial and investment banks and other financial intermediaries provide us with a strong pipeline of proprietary origination opportunities. We believe the broad experience of our senior investment team and their ability to draw upon their average of over 30 years of experience enables us to identify, assess and structure investments successfully.
We expect that the Company will benefit from SLR’s extensive experience investing in middle market companies in the healthcare industry. With the benefit of billions of dollars of debt investments made to hundreds of companies, SLR has developed an extensive database of information on middle market issuers and industries. The Adviser’s investment team is expected to include a number of SLR’s specialists in healthcare cash flow lending to sponsor backed companies as well as life science lending. We believe that the
in-depth
experience of SLR’s investment team in investing throughout various stages of the economic cycle provides us with access to ongoing market insights in addition to a powerful asset for investment sourcing.
Our senior investment team’s strong relationship network is enhanced by the collaborative role SLR plays in the private equity industry. SLR is an independent credit platform that does not pursue traditional private equity strategies, so the Company is not expected to be seen as a competitive threat to financial sponsors seeking to acquire a company. Our ability to offer tailored solutions, certainty of capital and scale is expected to provide us with greater deal flow. We also expect that our reputation as a constructive partner and a flexible “solutions provider” with a proven ability to evaluate highly complex situations is likely to result in the ability to source a significant number of investment opportunities for the Company. Additionally, SLR is well-known for its deep experience in healthcare transactions and ability to provide quick and constructive feedback to financial sponsors. Furthermore, SLR’s investment team has a well-developed network of relationships that includes industry executives, consultants, traders, brokers, advisors, lawyers, accountants, investment bankers and other industry sources, which can result in early notification of developing investment opportunities.
Corporate Cash Flow Lending — Sponsor Coverage
Our cash flow origination strategy is driven by a rigorous analysis of the healthcare
sub-sectors
that we believe benefit from strong macroeconomic tail winds by reducing costs to the overall healthcare system by investing in healthcare companies that provide services, products and technologies that improve the efficiency and reduce the cost of existing products and services. We seek to find businesses that reward value based care and have significant customer and location diversity. We specifically
 
13

avoid subsectors that are subject to consumer discretion or are subject to government policy “stroke of the pen” risk (
i.e.,
the risk that a change in the rules governing the
sub-sector
in which the portfolio company operates could impair the portfolio company’s financial performance). SLR’s underwriters provide clear guidelines to our origination team on the target subsectors that form our areas of focus. Origination efforts are aligned to work with sponsors and management teams who have deep healthcare expertise and longstanding successful track records in the healthcare industry. These sponsors tend to have a deeper understanding of the complexities involved with healthcare companies, given their involvement with multiple portfolio companies in the healthcare space, and can leverage industry relationships with payors and management teams. Our origination efforts represent a highly targeted, proactive approach to finding investments in segments consistent with our underwriting philosophy.
SLR’s investment team works in concert with sponsors to proactively manage investment opportunities by acting as a partner throughout the investment process. We actively focus on the middle-market financial sponsor community, with a particular focus on the
upper-end
of the middle-market (i.e., sponsors with equity funds of $500 million to $5 billion). We favor such sponsors because they typically:
 
   
Buy larger companies with strong business franchises;
 
   
Invest significant amounts of equity in their portfolio companies;
 
   
Value flexibility and creativity in structuring their transactions;
 
   
Possess longer track records over multiple investment funds;
 
   
Have a deeper management bench by investing in healthcare companies that provide services, products and technologies that improve the efficiency and reduce the cost of existing products and services
 
   
Have a better ability to withstand downturns; and
 
   
Possess the ability to support portfolio companies with additional capital.
We divide our coverage of these sponsors among our more senior investment professionals, who are responsible for
day-to-day
interaction with financial sponsors. Our coverage approach aims to act proactively, provide quick feedback, deliver on commitments, and are constructive throughout the life cycle of an investment.
On average, over 100 healthcare cash flow transaction opportunities are screened each year with less than 5% of all opportunities sourced, closed and funded.
Life Science Lending
SLR employs a direct origination strategy for life science investment opportunities that leverages its deep-rooted relationships and reputation established over its history. The team directly generates deal flow through targeted company management contact and through venture capital and private equity sponsor coverage. Frequently, these equity investors will connect SLR to portfolio companies with
non-dilutive
debt financing investment needs. We maintain strong relationships and frequent contact with other like-minded bank and
non-bank
lenders that leads to a large number of refinancing and new deal opportunities. In addition, market intermediaries may connect SLR’s team to many healthcare companies who have chosen to outsource the debt financing procurement process.
On average, approximately 100 life science investment opportunities are screened per year through SLR team’s multiple origination channels with expectations (based on SLR’s historical data) of approximately 10% of all opportunities sourced to be closed and funded. Prior to joining SLR in 2014, the life science team originated approximately $2.1 billion of life science investments while at GE Capital.
Due Diligence
Our “private equity” approach to credit investing typically incorporates extensive
in-depth
due diligence often alongside the financial sponsor. In conducting due diligence, we use publicly available information as well as information from the investment team’s extensive relationships with former and current management teams, consultants, competitors and investment bankers. We also leverage proprietary insights from SLR’s healthcare ABL platform. Managed by senior leadership with an average of over 30 years of credit experience, SLR’s healthcare ABL platform has unique insights into a wide array of
 
14

healthcare
sub-specialties,
industry developments and reimbursement trends. We believe our due diligence methodology allows us to screen a high volume of potential investment opportunities on a consistent and thorough basis. Furthermore, we believe that the combination of our extensive industry knowledge and relationships provide the Company a significant advantage in identifying potential risks.
Our due diligence typically includes:
 
   
review of historical and prospective financial information, including the quality and collectability of receivables;
 
   
review and valuation of assets, including appraisals;
 
   
research relating to the company’s management, industry, markets, products and services and competitors;
 
   
review of the reimbursement environment and trends, including the diversity of reimbursement codes;
 
   
review of the payor mix;
 
   
on-site
visits;
 
   
discussions with management, employees, customers or vendors of the potential portfolio company;
 
   
review of material legal documents and legal issues;
 
   
review of third party due diligence report including quality of earnings, field exams, industry reports; and
 
   
background investigations on management and the company.
We also expect to evaluate the financial sponsor making the investment. Given the nuances involved in healthcare investing, a sponsor with deep industry knowledge and experience is incredibly important. Further, due to SLR’s considerable repeat business with sponsors, the Adviser’s investment team has direct experience with the management teams of many sponsors. A financial sponsor is typically the controlling shareholder upon completion of an investment and as such is considered critical to the success of the investment. The financial sponsor is evaluated using several key criteria, including:
 
   
healthcare investment track record;
 
   
industry experience;
 
   
capacity and willingness to provide additional financial support to the company through additional capital contributions, if necessary; and
 
   
reference checks.
Throughout the due diligence process, a deal team is in frequent dialogue with the management team and sponsor of the company in which we are considering investing to ensure that any concerns are addressed as early as possible through the process, which we believe increases the likelihood that unsuitable investments are filtered out before considerable time has been invested.
Upon the completion of due diligence and a decision to proceed with an investment in a company, the investment professionals leading the investment present the investment opportunity to the Investment Committee, which then determines the amount of the initial investment. Additional due diligence with respect to any investment may be conducted on our behalf by attorneys and independent accountants prior to the closing of the investment, as well as other outside advisers, as appropriate.
Portfolio Company Characteristics
We have identified several criteria that we believe are important in identifying and investing in prospective portfolio companies. These criteria provide general guidelines for investment decisions; however, not all of these criteria will be met by each prospective portfolio company in which we choose to invest.
 
15

Upper Middle Market Corporate Cash Flow Healthcare Lending
In our cash flow segment, we seek to make investments in sponsor-backed upper middle-market healthcare companies generating stable and recurring cash flows which are positioned for growth. The businesses we target are those capitalizing on the evolution of the healthcare sector by delivering innovative products and services or who are reducing overall costs to the system through greater scale and improved operational efficiency. We favor investments in businesses that emphasize quality over quantity of care, have low reimbursement risk and significant diversity of revenue streams and payors. Often, the sponsor’s investment thesis includes acquisitive growth which allows us to increase the size of our investment in a given business as
add-on
acquisitions are executed.
We believe that businesses with these characteristics may help facilitate internally generated cash flow, leading to the payment of our interest and the repayment of our principal, represents a key means by which we will be able to exit from our investments over time. In addition, we also seek to invest in companies whose business models and expected future cash flows offer attractive exit possibilities. Upper middle-market companies in particular are attractive candidates for strategic acquisition by other industry participants and more likely to repay our investments through an initial public offering of common stock or another capital market transaction than smaller businesses. We underwrite our investments on a
held-to-maturity
basis, but expensive capital is often repaid prior to stated maturity. Historically, SLR’s investments have averaged three-year hold periods.
 
   
Well Positioned to Benefit from Macro Tailwinds in the Healthcare Sector
: We believe that companies that help to reduce overall costs in the healthcare sector are well positioned for long term growth. That includes businesses that emphasize quality of care over the quantity of procedures and increase efficiencies in the healthcare setting. We seek to avoid companies that have concentration in locations or reimbursement codes.
 
   
Stable Earnings and Strong Free Cash Flow
: We seek to invest in companies that have demonstrated strong credit fundamentals with stable earnings through economic cycles. We target companies that we believe can
de-lever
through consistent generation of cash flows rather than relying solely on growth to service and repay our loans. We also believe that a key tenet of sustainable earnings in the healthcare sector is a stable reimbursement profile and we generally avoid investments for which the reimbursement profile is subject to “stroke of pen” risks (i.e., particularly sensitive to regulatory changes).
 
   
Favorable Reimbursement Profile
: Our target borrowers benefit from a diversity of reimbursement codes and payors. A key risk inherent in the healthcare sector is a company’s ability to collect on revenue billed to a patient’s insurance. Through SLR’s healthcare ABL platform we have unique insight on reimbursement trends across the healthcare services landscape. We plan to only invest in businesses whose revenue is diversified across a variety of reimbursement codes and we avoid lending to companies whose revenue is concentrated in codes we expect to suffer from fee compression. Further, we also avoid situations where borrowers generate a disproportionate amount of revenue from a single payor.
 
   
Strong Competitive Position in Industry
: We seek to invest in target companies that have developed leading market positions within their respective markets and are well positioned to capitalize on growth opportunities. We seek to invest in companies that demonstrate significant competitive advantages versus their competitors, which we believe may help to protect their market position and profitability.
 
   
Experienced and Committed Management
: We generally require that portfolio companies have an experienced management team. We also require portfolio companies have in place proper incentives to induce management to succeed and to act in concert with our interests as investors, including having significant equity interests.
 
   
Strong Sponsorship
: We generally aim to invest alongside other sophisticated investors. We typically seek to partner with successful financial sponsors who have historically generated high returns with minimal losses and have demonstrated a strong healthcare track record. Healthcare investments in particular require a financial sponsor who has deep experience and knowledge of the healthcare
sub-sectors
as well as deep relationships within the industry to leverage both during due diligence and after investment. We believe that investing in these sponsors’ portfolio companies enables us to benefit from their direct involvement and due diligence.
 
   
Exit Strategy
: We seek to invest predominantly in companies that provide multiple alternatives for an eventual exit such as an initial public offering (“IPO”), sale of company, refinancing of the capital structure, etc.
 
16

Life Science Lending
 
   
Focused Healthcare Investment Strategy
: We seek investments in private or publicly-traded
small-cap
drug and medical device companies with substantial equity invested to date who are in later stages of drug or product development and/or in transition to commercialization. Borrowers typically are led by strong management teams and board of directors with proven track records. Venture capital sponsors typically have continuing involvement and influence. In our experience, borrowers have typically successfully demonstrated access to the private and/or public equity markets and seek debt financing to broaden their funding sources and project stability.
 
   
Value Orientation
: We focus on later stage development and commercial bio pharma and device companies with multi-product pipelines (post
pre-clinical
stage), platforms and/or disruptive technologies. Borrowers typically have had significant equity invested to date and have had support from venture capital firms and strategic investors.
 
   
Senior secured, collateral-based underwriting
: Loans typically are made at
conservative 20%-to-30%
loan-to-value
and are collateralized by all assets, including cash on the balance sheet from most recent equity round, and have a negative or full pledge on the intellectual property. The loans are structured to amortize on a straight-line basis after a period of interest only payments, resulting in significant
de-risking
of the investment and shorter weighted average holding periods.
 
   
Sophisticated Knowledge Base and Industry Expertise
: Highly specialized, experienced and cohesive investment team which previously founded and managed GE Capital’s life science loan business where they established a strong and consistent track record over
a 13-year
period. Team has extensive network of relationships with venture capital sponsors, management teams and strategic investors.
 
   
Exit Strategy
: Exits typically
occur 24-36 months
after initial deal closing through refinancings, an IPO or sale of the company to a strategic buyer.
Investment Structure
We invest in portfolio companies typically in the form of first lien senior secured loans. We obtain security interests in the assets of our portfolio companies that serve as collateral in support of the repayment of these loans. We expect that this collateral will take the form of first priority liens on all of the assets of a portfolio company.
Upper Middle Market Corporate Healthcare Cash Flow Lending
Typically, we expect that the Company’s senior secured loans to upper middle market healthcare companies will have a first priority lien on all of the assets of the issuer, will be floating rate with Secured Overnight Financing Rate (“SOFR”) floors, will include upfront fees and may include meaningful prepayment penalties. Covenants are typically included. The loans generally are expected to have a five to six year final maturity and are often repaid within three years.
Life Science Lending
Typically, we expect that the Company’s loans to life science companies will have a first priority lien, will be floating rate with SOFR floors, and will include meaningful prepayment penalties, exit fees and success fees or warrants. Warrants will generally have an exercise price based on the last private equity round valuation or average public trading price and, thus, as a portfolio company appreciates in value, the Company will be well-positioned to achieve additional investment returns from this equity interest. The loans generally are expected to have an initial interest-only period and then straight-line amortization with a four to five year final maturity. These loans are often repaid within two to three years.
Ongoing Relationships with Portfolio Companies
We will monitor our portfolio companies on an ongoing basis. We will monitor the financial trends of each portfolio company to determine if it is meeting its business plan and to assess the appropriate course of action for each company.
We have several methods of evaluating and monitoring the performance and fair value of our investments, which include the following:
 
   
Assessment of success in adhering to each portfolio company’s business plan and compliance with covenants;
 
17

   
Periodic and regular contact with portfolio company management and, if appropriate, the financial or strategic sponsor, to discuss financial position, requirements and accomplishments;
 
   
Comparisons to portfolio companies of other SLR clients in the industry, if any;
 
   
Review of any material changes to the industry, regulatory framework or reimbursement profile that could impact future performance;
 
   
Attendance at and participation in board meetings (as an observer) or lender meetings; and
 
   
Review of monthly and/or quarterly financial statements and financial projections for portfolio companies.
Beyond monitoring financial and operating trends, SLR’s healthcare expertise positions us to act as a value-added partner to private equity and venture capital sponsors throughout the course of an investment. In particular, we work collaboratively with sponsors and management teams to periodically
re-assess
the optimal capital structure of a portfolio company. Our ability to evaluate a business on the basis of cash flow, life science, and ABL capital solutions enables SLR to bring a differentiated, and highly valued, perspective to a given situation. Further, we regularly engage SLR’s healthcare ABL platform to review a borrower’s exposure to reimbursement codes and payors, and to advise on a portfolio company’s future plans for adding additional services or engaging new payors. By working collaboratively with sponsors and management teams, we can help drive better outcomes for all investors.
In addition to various risk management and monitoring tools, the Adviser also uses an investment rating system to characterize and monitor our expected level of returns on each investment in our portfolio.
We use an investment rating scale of 1 to 4. The following is a description of the conditions associated with each investment rating:
 
Investment
Rating
  
Summary
1
   Involves the least amount of risk in our portfolio, the portfolio company is performing above expectations, and the trends and risk factors are generally favorable (including a potential exit).
2
   Risk that is similar to the risk at the time of origination, the portfolio company is performing as expected, and the risk factors are neutral to favorable; all new investments are initially assessed a grade of 2.
3
   The portfolio company is performing below expectations, may be out of compliance with debt covenants, and requires procedures for closer monitoring.
4
   The investment is performing well below expectations and is not anticipated to be repaid in full.
We monitor and, when appropriate, change the investment ratings assigned to each investment in our portfolio.
Competition
Our primary competitors provide financing to middle-market companies and include other BDCs, commercial and investment banks, commercial financing companies and, to the extent they provide an alternative form of financing, private equity and venture capital funds. Additionally, alternative investment vehicles, such as hedge funds, frequently invest in middle-market companies. As a result, competition for investment opportunities at middle-market companies can be intense. While many middle market companies were previously able to raise senior debt financing through traditional large financial institutions, we believe this approach to financing will become more difficult as implementation of U.S. and international financial reforms limits the capacity of large financial institutions to hold
non-investment
grade leveraged loans on their balance sheets. We believe that many of these financial institutions have
de-emphasized
their service and product offerings to middle market companies in particular. That said, many of our competitors are substantially larger and have considerably greater financial, technical and marketing resources than we do. For example, some competitors may have a lower cost of funds and access to funding sources that are not available to us. In addition, some of our competitors may have higher risk tolerances or different risk assessments, which could allow them to consider a wider variety of investments and establish more relationships than us. Furthermore, many of our competitors are not subject to the regulatory restrictions that the 1940 Act imposes on us as a BDC. We use the industry information available to Michael S. Gross and Bruce Spohler and the other investment professionals of SLR to assess investment risks and determine appropriate pricing for our investments in portfolio companies. In addition, we believe that the relationships of Michael S. Gross and Bruce Spohler and the other investment professionals of our investment adviser enable us to learn about, and compete effectively for, financing opportunities with attractive leveraged companies in the industries in which we seek to invest. See
“Item 1A. Risk Factors — Risk Relating to Our Business and Structure —
Competition; Potential for Insufficient Investment Opportunities.”
 
18

The Private Offering
The Company is organized for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). Certain other investors may also invest directly in the Company. For those investors who invest through the Access Fund, we expect the Access Fund will issue a pro rata interest to each investor in the Access Fund (the “Access Fund LPs”) that, with respect to each Access Fund LP’s investment in the Access Fund, corresponds to such Access Fund LP’s pro rata share of the Units issued by the Company to the Access Fund. To purchase an interest in the Access Fund, each Access Fund LP will be required to represent that it is an “accredited investor” within the meaning of Rule 501(a) of Regulation D (an “Accredited Investor”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). To purchase Units, investors must be Accredited Investors and “qualified purchasers” for purposes of Section 3(c)(7) of the 1940 Act, or “knowledgeable employees” or companies owned exclusively by “knowledgeable employees” for purposes of the rules promulgated under the 1940 Act. Any sale of Units outside of the United States will be conducted in accordance with Regulation S under the Securities Act. We expect the Access Fund will pass its voting rights in respect of any Units of the Company held by the Access Fund through to the Access Fund LPs.
Closing
The Company was permitted to hold closings at any time during the offering period (the “Offering Period”), which ended on December 31, 2022. At each closing, investors made capital commitments to the Company (each, a “Commitment”) pursuant to a subscription agreement entered into with the Company (a “Subscription Agreement”). Unitholders are required to make capital contributions, in an aggregate amount that does not exceed each Unitholder’s remaining commitment, each time the Adviser delivers a capital call notice. Commitments will be drawn pro rata from Unitholders based on the relative unfunded commitment of each Unitholder on the date the capital call notice is issued.
Investment Period
Commitments may be drawn down from time to time until the date that is the earlier of (x) an Exchange Listing (as defined below) or (y) four (4) years after the Company’s final closing with the Access Fund, which was held on February 11, 2021 (such period, the “Investment Period”). After the end of the Investment Period, Commitments may be called only to (i) make investments which were in process (
e.g.
, investments for which the Company has submitted a binding or
non-binding
bid or indication of interest) but were not yet consummated as of the end of the Investment Period, the Board having been notified of such Portfolio Investments, (ii) cover accrued and/or anticipated expenses, liabilities and obligations of the Company, including amounts owing or which may become due under any borrowings or other extensions of credit, (iii) make
“follow-on”
investments as may be advisable in the Adviser’s sole discretion in order to enhance, preserve or protect one or more of the Company’s existing Portfolio Investments (subject to a maximum amount of 20% of aggregate Commitments), and (iv) adjust any hedging positions as the Adviser may deem advisable.
Term
The term of the Company will be seven (7) years from the end of the Offering Period (unless the Company is terminated earlier or effectuates an Exchange Listing as set forth in the LLC Agreement), but may be extended by the Board for up to two (2) consecutive
one-year
periods upon approval of the Company’s independent directors and the approval of Unitholders, which approval will be obtained through a
non-1940
Act vote. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. Unitholders generally will not be permitted to voluntarily withdraw or redeem their Units prior to the termination of the Company.
Exchange Listing
At any time prior to the end of the Term, subject to any requirements of the 1940 Act and applicable law, the Board may, without the approval of Unitholders, cause the Units (or securities into which the Units are converted or exchanged) to be listed for trading on a national securities exchange (an “Exchange Listing”). In connection with any such Exchange Listing, subject to any requirements of the 1940 Act and applicable law, the Board may, without the approval of Unitholders, cause the Company to complete (i) an initial public offering, (ii) a merger with another entity, including an affiliated company, subject to any limitations under the 1940 Act, (iii) the sale, exchange or disposition of all or a portion of the assets of the Company, or (iv) a conversion of the Company into a corporation incorporated in a state determined by the Board, either through a conversion in accordance with applicable law, a merger with or into an existing corporation, or otherwise, in which all Units will be converted into or exchanged for shares of common stock of the resulting corporation.
 
19

If the Company is unable to effectuate an Exchange Listing prior to the end of the Term, the Company will use commercially reasonable efforts to wind down or liquidate pursuant to the procedures set forth in the LLC Agreement.
The Units are not currently listed on an exchange and given that we have no current intention of pursuing an Exchange Listing in the near term, it is unlikely that a secondary trading market will develop for the Units. In addition, given that there is no guarantee on if or when the Company will be able to consummate an Exchange Listing and the fact that the Company will not seek to wind down and/or liquidate and dissolve until the end of the Term, an investment in the Units is not suitable for investors that may need access to the money they invest in the foreseeable future.
Lock-Up
Period
Prior to an Exchange Listing, and except as provided in the LLC Agreement, a Unitholder may not withdraw its capital contribution or sell, assign or transfer its Units without the prior written consent of the Adviser, which the Adviser may grant or withhold in its sole and absolute discretion. Following an Exchange Listing, during the
Lock-Up
Period (as defined below), a Unitholder will be restricted from: (1) offering, pledging, selling, contracting to sell, sell any option or contract to purchase, purchasing any option or contract to sell, granting any option, right or warrant to purchase or otherwise transferring or disposing of, directly or indirectly, any Units, securities into which the Units are converted, or securities convertible into or exchangeable or exercisable for any Units, or publicly disclosing the intention to make any offer, sale, pledge or disposition, (2) entering into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of Units or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of Units or such other securities, in cash or otherwise), or (3) if applicable, making any demand for or exercise any right with respect to the registration of any Units or any security convertible into or exercisable or exchangeable for Units. The
“Lock-Up
Period” is (i) 180 days after the date of an Exchange Listing for all Units held by a Unitholder, (ii) 270 days after the date of an Exchange Listing for
two-thirds
of the Units held by a Unitholder, and (iii) 365 days after the date of an Exchange Listing for
one-third
of the Units held by a Unitholder. The
lock-up
will apply to all Units acquired prior to an Exchange Listing, but will not apply to any securities of the Company acquired after the date of an Exchange Listing.
Emerging Growth Company
We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and we are eligible to take advantage of certain specified reduced disclosure and other requirements that are otherwise generally applicable to public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). We expect to remain an emerging growth company for up to five years following the completion of any Exchange Listing or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues equals or exceeds $1.07 billion, (ii) December 31 of the fiscal year that we become a “large accelerated filer” as defined in Rule
12b-2
under the Securities Exchange Act of 1934, as amended (the “1934 Act”) which would occur if the market value of our Units that is held by
non-affiliates
exceeds $700 million as of the last business day of our most recently completed second fiscal quarter and we have been publicly reporting for at least 12 months or (iii) the date on which we have issued more than $1 billion in
non-convertible
debt securities during the preceding three-year period. In addition, we will take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards.
Staffing
We do not currently have any employees. Mr. Gross, our
Co-Chief
Executive Officer, President and a board member, and Mr. Spohler, our
Co-Chief
Executive Officer, Chief Operating Officer and a board member, are managing members and senior investment professionals of, and have financial and controlling interests in, SLR. In addition, Shiraz Kajee, our Chief Financial Officer and Treasurer serves as the Chief Financial Officer for SLR. Guy Talarico, our Chief Compliance Officer and Secretary serves as the Chief Compliance Officer and General Counsel for SLR.
Pursuant to the Investment Management Agreement, the Company has delegated full and exclusive authority and responsibility to the Adviser to invest, reinvest and dispose of the assets of the Company, and (together with the Administrative Coordinator) to manage the
day-to-day
operations of the Company, subject to the overall supervision of the Board. The Adviser is authorized to delegate all, or any such part as it deems appropriate, of its discretionary management and investment advisory authority and responsibility to any of its members or their respective affiliates.
 
20

Key Person Event
Prior to the earlier of (i) an Exchange Listing and (ii) the end of the Investment Period, if any two of Michael Gross, Bruce Spohler, Anthony Storino or Julie Reyes (the “Principals”) die, become permanently incapacitated or cease to be actively involved in the management of the Company, the Investment Period will terminate and the Company will be wound down in accordance with the terms of the LLC Agreement. For the avoidance of doubt, if only one of the Principals dies, becomes permanently incapacitated, or ceases to be actively involved in the management of the Company, the preceding sentence will not be triggered.
Prior to an Exchange Listing, if any two of the Principals voluntarily ceases to be actively involved in the management of the Company, the Company will suspend the Investment Period. If acceptable replacements for each Principal are not identified and approved by (i) the independent directors of the Company and (ii) a majority of the Unitholders, subject to any requirements of the 1940 Act, within 90 days following the suspension of the Investment Period, the Investment Period will terminate and all new investment activity will cease.
For the avoidance of doubt, the provisions described in this “
Key Person Event
” will not apply upon the effectuation of an Exchange Listing.
Regulation as a Business Development Company
A BDC is regulated by the 1940 Act. A BDC must be organized in the U.S. for the purpose of investing in or lending to primarily private companies and making significant managerial assistance available to those investments that constitute qualifying assets (discussed below). A BDC may use capital provided by public unitholders and from other sources to make long-term, private investments in businesses.
The Company may not change the nature of its business so as to cease to be, or withdraw our election as, a BDC unless authorized by vote of a majority of outstanding voting securities, as required by the 1940 Act. A majority of the outstanding voting securities of a company is defined under the 1940 Act as the lesser of: (a) 67% or more of such company’s voting securities present at a meeting if more than 50% of the outstanding voting securities of such company are present or represented by proxy, or (b) more than 50% of the outstanding voting securities of such company. However, by signing a Subscription Agreement with the Company, each Unitholder is providing the approval required by the 1940 Act to effectuate the withdrawal of the Company’s election to be regulated as a BDC (i) concurrently with the liquidation or dissolution of the Company, or (ii) in connection with an Exchange Listing (including any transaction effectuated in connection therewith), provided that the exchange-listed successor entity has elected to be regulated as a BDC. The Company does not anticipate any substantial change in the nature of our business.
As with other companies regulated by the 1940 Act, a BDC must adhere to certain substantive regulatory requirements. A majority of the Company’s directors must be persons who are not interested persons, as that term is defined in the 1940 Act. Additionally, the Company is required to provide and maintain a bond issued by a reputable fidelity insurance company to protect the BDC. Furthermore, as a BDC, the Company is prohibited from protecting any director or officer against any liability to the Company or its Unitholders arising from willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such person’s office.
As a BDC, the Company is required to meet an asset coverage ratio, reflecting the value of our total assets to our total senior securities, which include all of our borrowings and any preferred units we may issue in the future, of at least 150%. The Company may also be prohibited under the 1940 Act from knowingly participating in certain transactions with our affiliates without the prior approval of directors who are not interested persons and, in some cases, prior approval by the SEC.
On June 13, 2017, SLR received an exemptive order that permits the Company to participate in negotiated
co-investment
transactions with certain affiliates, in a manner consistent with the Company’s investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors, and pursuant to various conditions (the “Order”). If the Company is unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although the Adviser’s investment professionals will endeavor to allocate investment opportunities in a fair and equitable manner, the Company and its Unitholders could be adversely affected to the extent investment opportunities are allocated among us and other investment vehicles managed or sponsored by, or affiliated with, our executive officers, directors and members of the Adviser.
 
21

The Company is generally not able to issue and sell Units at a price below NAV per Unit without Unitholder approval. The Company may, however, in accordance with the conditions set forth in Section 63(2) of the 1940 Act, sell Units, or warrants, options or rights to acquire our Units, at a price below the then-current NAV of the Units if the Board determines that such sale is in the best interests of the Company and the Unitholders, and the Unitholders approve such sale.
The Company may be periodically examined by the SEC for compliance with the federal securities laws, including the 1940 Act.
Qualifying Assets
Under the 1940 Act, a BDC may not acquire any asset other than assets of the type listed in Section 55(a) of the 1940 Act, which are referred to as qualifying assets, unless, at the time the acquisition is made, qualifying assets represent at least 70% of the BDC’s total assets. The principal categories of qualifying assets relevant to our business are the following:
 
  (1)
Securities purchased in transactions not involving any public offering from the issuer of such securities, which issuer (subject to certain limited exceptions) is an eligible portfolio company, or from any person who is, or has been during the preceding 13 months, an affiliated person of an eligible portfolio company, or from any other person, subject to such rules as may be prescribed by the SEC. An eligible portfolio company is defined in the 1940 Act as any issuer which:
 
  (a)
is organized under the laws of, and has its principal place of business in, the U.S.;
 
  (b)
is not an investment company (other than a small business investment company wholly owned by the BDC); and
 
  (c)
satisfies any of the following:
 
  i.
does not have any class of securities that is traded on a national securities exchange;
 
  ii.
has a class of securities listed on a national securities exchange, but has an aggregate market value of outstanding voting and
non-voting
common equity of less than $250 million;
 
  iii.
is controlled by a BDC or a group of companies including a BDC and the BDC has an affiliated person who is a director of the eligible portfolio company; or
 
  iv.
is a small and solvent company having total assets of not more than $4.0 million and capital and surplus of not less than $2.0 million.
 
  (2)
Securities of any eligible portfolio company which the Company controls, which, as defined by the 1940 Act, is presumed to exist where a BDC beneficially owns more than 25% of the outstanding voting securities of the portfolio company.
 
  (3)
Securities purchased in a private transaction from a U.S. issuer that is not an investment company or from an affiliated person of the issuer, or in transactions incident thereto, if the issuer is in bankruptcy and subject to reorganization or if the issuer, immediately prior to the purchase of its securities, was unable to meet its obligations as they came due without material assistance other than conventional lending or financing arrangements.
 
  (4)
Securities of an eligible portfolio company purchased from any person in a private transaction if there is no ready market for such securities and the Company already owns 60% of the outstanding equity of the eligible portfolio company.
 
  (5)
Securities received in exchange for or distributed on or with respect to securities described in (1) through (4) above, or pursuant to the exercise of warrants or rights relating to such securities.
 
22

  (6)
Cash, cash equivalents, U.S. government securities or high-quality debt securities maturing in one year or less from the time of investment.
 
  (7)
Office furniture and equipment, interests in real estate and leasehold improvements and facilities maintained to conduct the business operations of the BDC, deferred organization and operating expenses, and other noninvestment assets necessary and appropriate to its operations as a BDC, including notes of indebtedness of directors, officers, employees, and general partners held by a BDC as payment for securities of such company issued in connection with an executive compensation plan described in Section 57(j) of the 1940 Act.
Under Section 55(b) of the 1940 Act, the value of a BDC’s assets shall be determined as of the date of the most recent financial statements filed by such company with the SEC pursuant to Section 13 of the 1934 Act, and shall be determined no less frequently than annually.
Significant Managerial Assistance to Portfolio Companies
As a BDC, the Company offers, and must provide upon request, significant managerial assistance to its portfolio companies that constitute qualifying assets. This assistance could involve, among other things, monitoring the operations of portfolio companies, participating in board and management meetings, consulting with and advising officers of portfolio companies and providing other organizational and financial guidance. The Company may also receive fees for these services. The Administrative Coordinator provides such managerial assistance, if any, on the Company’s behalf to portfolio companies that request this assistance.
Temporary Investments
Pending investment in other types of “qualifying assets,” as described above, the Company’s investments may consist of cash, cash equivalents, U.S. government securities or high-quality investment grade debt securities maturing in one year or less from the time of investment, which we refer to, collectively, as temporary investments, so that 70% of the Company’s assets are qualifying assets. Typically, we will invest in U.S. Treasury bills or other short-term, U.S. government securities, including agencies, or in repurchase agreements, provided that such repurchase agreements are fully collateralized by cash or securities issued by the U.S. government or its agencies. A repurchase agreement involves the purchase by an investor, such as the Company, of a specified security and the simultaneous agreement by the seller to repurchase it at an agreed-upon future date and at a price that is greater than the purchase price by an amount that reflects an agreed-upon interest rate. There is no percentage restriction on the proportion of the Company’s assets that may be invested in such repurchase agreements. However, if more than 25% of the Company’s total assets constitute repurchase agreements from a single counterparty, the Company would not meet the diversification tests in order to qualify as a RIC for U.S. federal income tax purposes. Thus, the Company does not intend to enter into repurchase agreements with a single counterparty in excess of this limit. The Adviser will monitor the creditworthiness of the counterparties with which we enter into repurchase agreement transactions.
Senior Securities
The Company is permitted, under specified conditions, to issue multiple classes of indebtedness and one class of units senior to Units if asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after each such issuance. In addition, while certain senior securities remain outstanding, the Company must make provisions to prohibit any distribution to Unitholders or the repurchase of such securities or units unless the Company meets the applicable asset coverage ratios at the time of the distribution or repurchase. The Company may also borrow amounts up to 5% of the value of the Company’s total assets for temporary purposes, which borrowings would not be considered senior securities. The Company’s borrowings, whether for temporary purposes or otherwise, are subject to the asset coverage requirements of section 61(a)(1) of the 1940 Act. The Company may borrow money, which would magnify the potential for gain or loss on amounts invested and may increase the risk of investing in the Company.
Code of Ethics
The Company and the Adviser have each adopted a code of ethics pursuant to Rule
17j-1
under the 1940 Act and Rule
204A-1
under the Advisers Act, respectively, which establish procedures for personal investments and restricts certain transactions by personnel. The codes of ethics generally does not permit investments by employees in securities that may be purchased or held by the Company. Each code of ethics is available on the EDGAR database on the SEC’s Internet site at
http://www.sec.gov
. You may also obtain copies of the code of ethics, after paying a duplicating fee, by electronic request at the following email address:
publicinfo@sec.gov
.
 
23

Proxy Voting Policies and Procedures
We have delegated our proxy voting responsibility to the Adviser. A summary of the Proxy Voting Policies and Procedures of the Adviser are set forth below. The guidelines are reviewed periodically by the Adviser and our independent directors, and, accordingly, are subject to change.
As an investment adviser registered under the Advisers Act, the Adviser has a fiduciary duty to act solely in the best interests of its clients. As part of this duty, it recognizes that it must vote securities held by its clients in a timely manner free of conflicts of interest. These policies and procedures for voting proxies for investment advisory clients are intended to comply with Section 206 of, and Rule
206(4)-6
under, the Advisers Act.
The Adviser votes proxies relating to our portfolio securities in the best interest of Unitholders. The Adviser reviews on a
case-by-case
basis each proposal submitted for a proxy vote to determine its impact on our investments. Although it generally votes against proposals that may have a negative impact on our investments, it may vote for such a proposal if there exists compelling long-term reasons to do so. The proxy voting decisions of the Adviser are made by the senior investment professionals who are responsible for monitoring each of our investments. To ensure that our vote is not the product of a conflict of interest, it requires that: (i) anyone involved in the decision making process disclose to a managing member of the Adviser any potential conflict that he or she is aware of and any contact that he or she has had with any interested party regarding a proxy vote; and (ii) employees involved in the decision making process or vote administration are prohibited from revealing how we intend to vote on a proposal in order to reduce any attempted influence from interested parties.
You may obtain information about how we voted proxies by making a written request for proxy voting information to: SLR Capital Partners LLC, 500 Park Avenue, New York, NY 10022.
Privacy Policy
We endeavor to maintain the privacy of our recordholders and to safeguard their
non-public
personal information. The following information is provided to help you understand what personal information we collect, how we protect that information and why, in certain cases, we may share information with select other parties.
Generally, we will not receive any
non-public
personal information about recordholders of the units of the Company, although certain of our recordholders’
non-public
information may become available to us. The
non-public
personal information that we may receive falls into the following categories:
 
   
Information we receive from recordholders, whether we receive it orally, in writing or electronically. This includes recordholders’ communications to us concerning their investment;
 
   
Information about recordholders’ transactions and history with us; and
 
   
Other general information that we may obtain about recordholders, such as demographic and contact information such as address.
We disclose
non-public
personal information about recordholders:
 
   
to our affiliates (such as SLR) and their employees for everyday business purposes;
 
   
to our service providers (such as our accountants, attorneys, custodians, transfer agent, underwriter and proxy solicitors) and their employees as is necessary to service recordholder accounts or otherwise provide the applicable service;
 
   
to comply with court orders, subpoenas, lawful discovery requests, or other legal or regulatory requirements; or
 
   
as allowed or required by applicable law or regulation.
 
24

When the Company shares
non-public
recordholder personal information referred to above, the information is made available for limited business purposes and under controlled circumstances designed to protect our recordholders’ privacy. The Company does not permit use of recordholder information for any
non-business
or marketing purpose, nor does the Company permit third parties to rent, sell, trade or otherwise release or disclose information to any other party.
The Company’s service providers, such as SLR and its transfer agent, are required to maintain physical, electronic, and procedural safeguards to protect recordholder
non-public
personal information; to prevent unauthorized access or use; and to dispose of such information when it is no longer required.
Personnel of affiliates may access recordholder information only for business purposes. The degree of access is based on the sensitivity of the information and on personnel need for the information to service a recordholder’s account or comply with legal requirements.
If a recordholder ceases to be a recordholder, we will adhere to the privacy policies and practices as described above. We may choose to modify our privacy policies at any time. Before we do so, we will notify recordholders and provide a description of our privacy policy.
In the event of a corporate change in control resulting from, for example, a sale to, or merger with, another entity, or in the event of a sale of assets, we reserve the right to transfer your
non-public
personal information to the new party in control or the party acquiring assets.
Reporting Obligations
We furnish our Unitholders with annual reports containing audited financial statements, quarterly reports, and such other periodic reports as we determine to be appropriate or as may be required by law. We are required to comply with all periodic reporting, proxy solicitation and other applicable requirements under the 1934 Act.
The SEC maintains an Internet site that contains reports, proxy and information statements and other information filed electronically by us with the SEC, which are available on the SEC’s website at
http://www.sec.gov
. Copies of these reports, proxy and information statements and other information may be obtained, after paying a duplicating fee, by electronic request at the following
e-mail
address:
publicinfo@sec.gov.
Certain U.S. Federal Income Tax Considerations
The following discussion is a general summary of certain U.S. federal income tax considerations applicable to the Company and to an investment in Units. This discussion is based on the provisions of the Code and the regulations of the U.S. Department of Treasury promulgated thereunder, or “Treasury regulations,” each as in effect as of the date of this report.
These provisions are subject to differing interpretations and change by legislative or administrative action, and any change may be retroactive. This discussion does not constitute a detailed explanation of all U.S. federal income tax aspects affecting the Company and its Unitholders and does not purport to deal with the U.S. federal income tax consequences that may be important to particular Unitholders in light of their individual investment circumstances or to some types of Unitholders subject to special tax rules, such as financial institutions, broker dealers, insurance companies,
tax-exempt
organizations, persons holding Units in connection with a hedging, straddle, conversion or other integrated transaction, investors who are subject to the special tax accounting rules under Section 451(b) of the Code,
Non-U.S.
Unitholders (as defined below) engaged in a trade or business in the U.S., persons who have ceased to be U.S. citizens or to be taxed as resident aliens or individual
Non-U.S.
Unitholders present in the U.S. for 183 days or more during a taxable year. This discussion also does not address any aspects of U.S. estate or gift tax or foreign, state or local tax. This discussion assumes that Unitholders hold their Units as capital assets for U.S. federal income tax purposes (generally, assets held for investment). The Company has not requested a ruling from the Internal Revenue Service, or “IRS,” or opinion of counsel regarding any matter discussed herein.
For purposes of this discussion, a “U.S. Unitholder” is a beneficial owner of Units that is for U.S. federal income tax purposes:
 
   
an individual who is a citizen or resident of the U.S.;
 
   
a corporation created or organized in or under the laws of the U.S., any state therein or the District of Columbia;
 
   
an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
 
   
a trust if a court within the U.S. is able to exercise primary jurisdiction over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust.
 
25

For purposes of this discussion, a
“Non-U.S.
Unitholder” means a beneficial owner of Units that is for U.S. federal income tax purposes that is not a U.S. Unitholder or a partnership (or other entity classified as a partnership for U.S. federal income tax purposes).
If a partnership (or other entity classified as a partnership, for U.S. federal income tax purposes) holds Units, the treatment of the partnership and each partner for U.S. federal income tax purposes generally will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. An investor considering an investment in a partnership that will invest in Units should consult the disclosure documents provided to such investor from such partnership in conjunction with this discussion to determine the applicability of this discussion to an indirect investment in Units through such partnership. In addition, such investor should consult its own tax advisers regarding the U.S. federal income tax consequences of the acquisition, ownership and disposition of interests in a partnership and of Units by such partnership in light of such partner’s particular circumstances.
Taxation of the Company
The Company elected to be treated, and intends to qualify annually as a RIC for U.S. federal income tax purposes under Subchapter M of the Code, commencing with taxable year ended December 31, 2021. As a RIC, the Company generally will not pay corporate-level U.S. federal income taxes on any ordinary income or capital gains that it timely distributes to Unitholders as dividends.
To qualify as a RIC, the Company must, among other things:
 
   
derive in each taxable year at least 90% of its gross income from dividends, interest, payments with respect to certain securities loans, gains from the sale or other taxable disposition of stock, securities or foreign currencies, other income derived with respect to the business of investing in stock, securities or currencies, or net income derived from an interest in a “qualified publicly traded partnership,” or “QPTP,” hereinafter the “90% Gross Income Test;” and
 
   
diversify its holdings so that, at the end of each quarter of each taxable year:
 
   
at least 50% of the value of its total assets is represented by cash and cash items, U.S. Government securities, the securities of other RICs and other securities, with other securities limited, in respect of any one issuer, to an amount not greater than 5% of the value of total assets and not more than 10% of the outstanding voting securities of such issuer; and
 
   
not more than 25% of the value of its total assets is invested in the securities of any issuer (other than U.S. Government securities and the securities of other RICs), the securities of any two or more issuers that the Company controls and that are determined to be engaged in the same business or similar or related trades or businesses, or the securities of one or more QPTPs, or the “Diversification Tests.”
As a RIC, the Company (but not its Unitholders) is generally not subject to U.S. federal income tax on investment company taxable income and net capital gains that it timely distributes to Unitholders in any taxable year with respect to which it distributes an amount equal to at least 90% of the sum of its (i) investment company taxable income (which includes, among other items, dividends, interest and the excess of any net realized short-term capital gains over net realized long-term capital losses and other taxable income (other than any net capital gain), reduced by deductible expenses) determined without regard to the deduction for dividends and distributions paid and (ii) net
tax-exempt
interest income (which is the excess of gross
tax-exempt
interest income over certain disallowed deductions), or the “Annual Distribution Requirement.” The Company intends to distribute annually all or substantially all of such income. Generally, if the Company fails to meet this Annual Distribution Requirement for any taxable year, it will fail to qualify as a RIC for such taxable year. To the extent the Company meets the Annual Distribution Requirement for a taxable year, but retains net capital gains for investment or any investment company taxable income, it is subject to U.S. federal income tax on such retained capital gains and investment company taxable income. The Company may choose to retain net capital gains for investment or any investment company taxable income, and pay the associated corporate-level U.S. federal income tax, including the 4% U.S. federal excise tax described below.
The Company is subject to a nondeductible 4% U.S. federal excise tax on certain of its undistributed income, unless it timely distributes (or is deemed to have timely distributed) each calendar year an amount equal to the sum of:
 
   
at least 98% of net ordinary income (not taking into account any capital gains or losses) for the calendar year;
 
26

   
at least 98.2% of the amount by which capital gains exceed capital losses (adjusted for certain ordinary losses) for a
one-year
period ending on October 31 of the calendar year; and
 
   
100% of any ordinary income and net capital gain income recognized in preceding years, but were not distributed during such years, and on which the Company paid no corporate-level U.S. federal income tax.
While the Company currently expects to distribute any income and capital gains in order to avoid the imposition of this 4% U.S. federal excise tax, it may not be successful in avoiding entirely the imposition of this tax. In that case, the Company will be liable for the tax only on the amount by which it does not meet the foregoing distribution requirement.
The Company is authorized to borrow funds and to sell assets in order to satisfy distribution requirements. However, under the 1940 Act, it is not permitted to make distributions to Unitholders while any senior securities are outstanding unless it meets the applicable asset coverage ratios. Moreover, the Company’s ability to dispose of assets or otherwise distribute amounts necessary to meet distribution requirements may be limited by (1) the illiquid nature of its portfolio, (2) other requirements relating to status as a RIC, including the Diversification Tests and/or (3) the limitations under one or more of our credit facilities. If the Company disposes of assets in order to meet the Annual Distribution Requirement or to avoid the 4% U.S. federal excise tax, it may make such dispositions at times that, from an investment standpoint, are not advantageous.
A RIC is limited in its ability to deduct expenses in excess of its “investment company taxable income” (which is, generally, ordinary income plus the excess of net short-term capital gains over net long-term capital losses). If the Company’s expenses in a given year exceed investment company taxable income, it would experience a net operating loss for that year. However, a RIC is not permitted to carry forward net operating losses to subsequent years. In addition, expenses can be used only to offset investment company taxable income, not net capital gain. Due to these limits on the deductibility of expenses, the Company may, for tax purposes, have aggregate taxable income for several years that it is required to distribute and that is taxable to Unitholders even if such income is greater than the aggregate net income the Company actually earned during those years. Such required distributions may be made from cash assets or by liquidation of investments, if necessary. The Company may realize gains or losses from such liquidations. In the event the Company realizes net capital gains from such transactions, Unitholders may receive a larger capital gain distribution than they would have received in the absence of such transactions.
Check-the-Box
Election and Failure to be Taxed as a RIC
In connection with the intention to be taxed as a RIC, the Company filed a
check-the-box
election to be classified as a corporation for U.S. federal income tax purposes. In addition, while the Company has elected and expects to qualify to be treated as a RIC annually, no assurance can be provided that it will qualify as a RIC for any taxable year. For example, the Company anticipates that it may have difficulty satisfying the Diversification Tests as it deploys initial capital and builds a portfolio. If the Company is subsequently unable to qualify for treatment as a RIC, and certain amelioration provisions are not applicable, it would be subject to U.S. federal income tax on all taxable income (including net capital gains) at regular corporate rates. The Company would not be able to deduct distributions to Unitholders, nor would distributions be required. Distributions, including distributions of net long-term capital gain, would generally be taxable to Unitholders as ordinary dividend income to the extent of current and accumulated earnings and profits. Subject to certain limitations under the Code, corporate Unitholders would be eligible to claim a dividend received deduction with respect to such dividend;
non-corporate
Unitholders would generally be able to treat such dividends as “qualified dividend income,” which is subject to reduced rates of U.S. federal income tax. Distributions in excess of current and accumulated earnings and profits would be treated first as a return of capital to the extent of the Unitholder’s tax basis, and any remaining distributions would be treated as a capital gain. If the Company subsequently fails to qualify as a RIC, in order to requalify as a RIC, in addition to the other requirements discussed above, the Company would be required to distribute all previously undistributed earnings attributable to the period it failed to qualify as a RIC by the end of the first year that it intends to requalify as a RIC. If the Company fails to requalify as a RIC for a period greater than two taxable years, it may be subject to regular corporate-level U.S. federal income tax on any net
built-in
gains with respect to certain assets (
i.e.
, the excess of the aggregate gains, including items of income, over aggregate losses that would have been realized with respect to such assets if the Company had been liquidated) that it elects to recognize on requalification or when recognized over the next five years.
The remainder of this discussion assumes that the Company qualifies as a RIC for each taxable year.
Company Investments
Certain investment practices are subject to special and complex U.S. federal income tax provisions that may, among other things, (i) disallow, suspend or otherwise limit the allowance of certain losses or deductions, including the dividends received deduction, (ii) convert lower taxed long-term capital gains and qualified dividend income into higher taxed short-term capital
 
27

gains or ordinary income, (iii) convert ordinary loss or a deduction into capital loss (the deductibility of which is more limited), (iv) cause the Company to recognize income or gain without a corresponding receipt of cash, (v) adversely affect the time as to when a purchase or sale of stock or securities is deemed to occur, (vi) adversely alter the characterization of certain complex financial transactions, or (vii) produce income that will not qualify as good income for purposes of the 90% Gross Income Test. The Company monitors transactions and may make certain tax elections and may be required to borrow money or dispose of securities to mitigate the effect of these rules and to prevent disqualification as a RIC but there can be no assurance of success in this regard.
Taxable Subsidiaries
. Some of the income and fees that the Company may recognize will not satisfy the 90% Gross Income Test. In order to ensure that such income and fees do not disqualify the Company from RIC tax treatment as a result of a failure to satisfy the 90% Gross Income Test, the Company may hold assets that generate such income and provide services that generate such fees indirectly through one or more entities treated as corporations for U.S. federal income tax purposes. Such corporations will be required to pay U.S. federal corporate income tax on their earnings, which ultimately will reduce the Company’s return on such income and fees.
Passive Foreign Investment Companies
. If the Company purchases shares in a “passive foreign investment company,” or PFIC, it may be subject to U.S. federal income tax on a portion of any “excess distribution” or gain from the disposition of such shares even if such income is distributed as a taxable dividend by the Company to Unitholders. Certain elections are available under certain circumstances that may allow the Company to ameliorate the impact of this tax. Such elections may require the Company to recognize in a year income in excess of the current cash distributions (if any) from the applicable PFICs and the proceeds from dispositions of PFIC stock during that year, and such income will nevertheless be subject to the Annual Distribution Requirement and will be taken into account for purposes of the 4% U.S. federal excise tax.
Debt Instruments
.
In certain circumstances, the Company may be required to recognize taxable income prior to its receipt of the related cash. For example, if the Company holds debt instruments that are treated under applicable tax rules as having OID (such as debt instruments with an
end-of-term
payment and/or PIK income payment or, in certain cases, increasing interest rates or issued with warrants), it must include in taxable income each year a portion of the OID that accrues over the life of the obligation, regardless of whether cash representing such income is received in the same taxable year. Because any OID accrued will be included in investment company taxable income for the year of accrual, the Company may be required to make a distribution to Unitholders in order to satisfy the Annual Distribution Requirement and to avoid the 4% U.S. federal excise tax, even though it will not have received any corresponding cash amount.
Warrants
.
Gain or loss realized from the sale or exchange of warrants acquired as well as any loss attributable to the lapse of such warrants generally are treated as capital gain or loss. The treatment of such gain or loss as long-term or short-term generally depends on how long the Company has held a particular warrant and on the nature of the disposition transaction.
Foreign Currency Transactions
.
Under the Code, gains or losses attributable to fluctuations in exchange rates which occur between the time the Company accrues income or other receivables or accrues expenses or other liabilities denominated in a foreign currency and the time the Company actually collects such receivables or pays such liabilities generally are treated as ordinary income or loss. Similarly, on disposition of debt instruments and certain other instruments denominated in a foreign currency, gains or losses attributable to fluctuations in the value of the foreign currency between the date of acquisition of the instrument and the date of disposition also are treated as ordinary gain or loss.
General Tax Cooperation
The Company will provide Unitholders with certain information regarding the amount of each distribution by us characterized as a “return of capital distribution,” “interest-related dividend distribution,” “ordinary dividend distribution,” “short term capital gain distribution” or “long term capital gain distribution” for U.S. federal income tax purposes on an estimated basis in connection with such distribution. The Company will use reasonable best efforts to provide such information on a final basis by March 1
st
of the taxable year following the distribution, but in no event later than March 15th of the taxable year following the distribution (subject to the filing of an extension for the filing of Forms
1042-S).
The Company and the Adviser shall use commercially reasonable efforts to provide Unitholders annually with any other tax information that the Company and the Adviser possess, or can reasonably obtain, reasonably requested by Unitholders in writing, concerning distributions by the Company or redemption of Units by the Company. The Company and the Adviser shall use commercially reasonable efforts to cooperate with Unitholders by providing any additional tax information and/or assisting in the filing of additional tax forms relating to the Company, as reasonably requested by Unitholders.
 
28

Importance of Obtaining Professional Advice
The foregoing analysis is not intended as a substitute for careful tax planning. Accordingly, prospective investors in the Company are strongly urged to consult their tax advisors with specific reference to their own situations regarding the possible tax consequences of an investment in the Company.
Summary Risk Factors
General Risks Related to Investment Strategy
 
   
The Company intends to make investments in the healthcare and life science industries, which involve substantial risks.
 
   
The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally.
 
   
Various segments of the life sciences industry are (or may become) (i) highly regulated, (ii) subject to frequent regulatory change and (iii) dependent upon various government or private insurance reimbursement programs.
 
   
The Company could be subject to the risks associated with investments in senior secured loans, subordinated loans, Mezzanine Securities (as defined below) and unsecured loans.
 
   
The Company’s loans may permit borrowers to prepay, which could affect the yield of the Company’s investments.
 
   
Terms and conditions of the Company’s loan agreements may be amended, modified or waived only by the agreement of the lenders.
 
   
The Company may make investments in loans, or securities backed by loans, that are or
may be non-performing loans.
 
   
The Company’s success will depend, in part, on originating loans on advantageous terms.
 
   
Bank loans and corporate loans may not be readily marketable and may be subject to restrictions on resale.
 
   
The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally.
 
   
Periods of market volatility have occurred and could continue to occur in response to pandemics or other events.
 
   
The Adviser will rely on information provided by internal sources and third parties when conducting due diligence.
 
   
Fixed and floating rate debt instruments are subject to the risks associated with change in interest rates.
 
   
The Company could be subject to the risks associated with investments in smaller and middle market companies.
 
   
Most of the Company’s Portfolio Investments at any given time are expected to be illiquid.
 
   
The Company is subject to risks related to inflation and deflation.
 
   
Economic sanction laws may prohibit investments in certain countries and with certain individuals and companies.
 
   
The Company may choose to waive or defer enforcement of covenants in the debt securities held in its portfolio, which may cause the Company to lose all or part of its investment in these companies.
General Risks Related to the Company
 
   
There can be no guarantee of returns and Unitholders may lose all of their money by investing in the Company.
 
   
Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed.
 
   
The Company is subject to management risk because the Adviser actively manages its investment portfolio.
 
   
If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio.
 
   
The Company’s assets are available to satisfy all liabilities and other obligations of the Company.
 
   
There is no assurance that the Adviser’s analysis of potential investments will take into consideration all appropriate factors.
 
   
The Company could be substantially adversely affected by the unfavorable performance of any single investment.
 
   
The Company will include in its income certain amounts that the Company has not yet received in cash.
 
   
It is expected that the majority of the Company’s investments will not have market quotations available.
 
29

   
Securities that the Adviser believes are not valued correctly may not ultimately be valued as projected.
 
   
The Adviser may employ financial/analytical models that may not reflect actual results.
 
   
The Company and the Adviser may be subject to the risks and costs of regulatory investigations or becoming involved in litigation with third parties.
 
   
A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment.
 
   
The Company and/or the Adviser may enter into various indemnification agreements or arrangements with third parties.
 
   
The Company could be subject to the risks related to the Russian invasion of Ukraine.
 
   
Unitholders could be subject to cybersecurity risks associated with electronic databases and communications.
 
   
Adverse developments affecting the financial services industry could have a material adverse effect on the Company, the Adviser and the Portfolio Investments.
 
   
The Company is subject to technological risks, including those associated with artificial intelligence and machine learning technology.
 
   
The Company is subject to risks associated with ESG (as defined below) initiatives and climate change.
 
   
The Company is subject to risks associated with U.S. government shutdowns, uncertainty over the U.S. debt ceiling and any related downgrades in the U.S.’s credit ratings.
Risks Related to RICs and BDCs
 
   
The Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain.
 
   
No assurance can be given that the Company will be able to maintain qualification as a RIC.
 
   
Unitholders will experience the increased risks pertaining to the Company’s use of leverage to partially finance its investments.
 
   
A BDC must carry investments at market value or at fair value, as determined in good faith by the Board.
 
   
At least 70% of a BDC’s assets must consist of “qualifying assets”.
Regulatory Risks Relating to the Company
 
   
The Company and its affiliates are substantially limited in their
ability to co-invest in
privately negotiated transactions.
 
   
The Company could be precluded from conducting Rule 506 Offerings (as defined below) due to “Bad Actor” restrictions.
 
   
The Company could be subject to the risks associated with complying with the Sarbanes-Oxley Act (as defined below).
Other Risks Related to Portfolio Investments
 
   
The Company could be subject to the risks associated with investments in high yield securities, corporate debt securities, convertible securities, preferred stock, reverse repurchase agreements, and distressed companies.
 
   
The Company could be subject to the risks associated with the use of warrants and rights.
 
   
The Company could be subject to the risks associated with the elimination of LIBOR and use of SOFR.
 
   
The Company could be subject to the risks associated with the effect of an economic slowdown on Portfolio Investments.
 
   
The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings.
 
   
The Company could be subject to the risks associated
with investments in zero-coupon bonds, deferred
interest rate bonds and PIKs.
 
   
The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, initial public offerings, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized.
Item 1A. Risk Factors.
The purchase of Units involves a number of significant risks and other important factors relating to investments in BDCs generally, and relating to the strategy and investment objective of the Company in particular. An investment in the Company is a potentially suitable investment only for a sophisticated investor for whom such an investment does not represent a complete investment program and who, in consultation with its investment and tax advisors, fully understands and is capable of assuming the risks of an investment in the Company.
 
30

The Company holds certain investments and conducts certain activities through investing in wholly-owned SPVs. All references to investments by the Company in this annual report
on Form 10-K refer,
as the context requires, to investments by either the Company or those SPVs.
There can be no assurance that the Company will achieve its investment objective, that the Company will not lose capital, that the Adviser’s judgment will result in profitable investments by the Company or that the Adviser will successfully be able to implement the Company’s investment strategy. An investment in the Company involves investment considerations and risk factors that prospective investors should consider before subscribing. No guarantee or representation is made that the Company’s investments will succeed.
Certain of the characteristics and risks of the portfolio instruments and investment, hedging, financing and disposition techniques that the Adviser may utilize in managing the Company are set forth below. This is not intended to be a complete description or enumeration of portfolio instruments, investment, hedging, financing or disposition techniques or risks.
The Company’s ability to achieve its investment objective may be affected by, among other things, the factors described below. The Company may also invest in instruments or engage in investment, hedging, financing or disposition techniques other than those described below, including instruments or investment, hedging, financing or disposition techniques that are not in existence as of the date of this annual report
on Form 10-K. Consistent
with its investment strategy, the Company may invest in instruments and engage in investment, hedging, financing or disposition techniques of any and all types, which exist now or are hereafter created.
The discussion below, to the extent it relates to bankruptcy law or proceedings or to debtors’ and creditors’ rights, is based upon principles of U.S. federal and state laws. Insofar as the Portfolio Investments,
include obligations of non-U.S. issuers, or
bankruptcy, reorganization or similar proceedings in a country other than the U.S., the laws of such other countries, and the rights and obligations of debtors and creditors in such other countries, under factual circumstances similar to those described below, may or may not be analogous to those described below.
General Risks Related to Investment Strategy
Healthcare and Life Science Industries’ Related Risks
. The Company intends to make investments in the healthcare and life science industries, although the Company may also opportunistically invest in other sectors in order to accomplish its investment objective. Investing in healthcare companies involves substantial risks. Such risks include, but are not limited to, the following: changes in government policies, including policies regarding reimbursement of medical expenses; certain companies in which the Company may invest may have limited or no operating histories/ or may have limited products, markets and financial resources; rapidly changing technologies may cause products to quickly become obsolete; unanticipated problems often arise in connection with the development of new products, and many such efforts are ultimately unsuccessful; scarcity of management and marketing personnel with appropriate technological or medical training may slow or impede companies’ growth; the possibility of lawsuits related to technological and medical patents could cause delays and expense in product development and implementation; regulatory changes and/or government actions may prevent a company from marketing its products; changing investors’ sentiments and preferences with regard to investments in healthcare companies (which may be perceived as risky) may have an adverse effect on the price of underlying securities; volatility in the U.S. stock markets affecting the prices of securities of healthcare and life sciences companies may cause the Company to experience substantial volatility; and certain healthcare and life sciences companies may be subject to extensive government regulation and affected by government reimbursement policy changes. In addition, many healthcare and life sciences companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or even under normal market conditions or such capital may be obtained on terms that are not favorable.
Also, obtaining government approval for new products from governmental agencies can be lengthy, expensive and uncertain, and withdrawal or curtailment of government support could have an adverse impact on the profitability or market price of healthcare and life sciences companies. Furthermore, delays in generating products (as well as more general ongoing capital requirements) may result in the need for companies to seek additional capital, potentially diluting the interest of existing investors, such as the Company (and indirectly, the Unitholders).
Investments in Healthcare Companies
. The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally. The Company’s investment strategy is subject to numerous and significant risks and uncertainties, some of which are highlighted generally below. The following is general information and does not purport to describe all risks associated with investing in the healthcare industry.
 
31

Sector Risk.
Sector risk is the risk associated with a Company holding a significant amount of investments in similar businesses, which would be similarly affected by particular economic or market events, which may, in certain circumstances, cause the value of the equity and debt securities of companies in a particular sector of the market to change. To the extent a Company has substantial holdings within a particular sector, the risks to a Company associated with that sector increase.
Concentration Risk.
The Company’s principal focus is to invest in the healthcare and life sciences industry. The focus of the Company’s portfolio on a specific industry may present more risks than if its portfolio were broadly diversified over numerous industries and sectors of the economy. A downturn in this industry would have a larger impact on the Company than on an investment company that does not concentrate in such industry. At times, the performance of securities of companies in the healthcare industry will lag the performance of other industries or the broader market as a whole.
While investment in multiple opportunities may provide some diversification of investment risk, no assurance can be given that such diversification will occur, or if it does, that it will not reduce, rather than increase, potential net profits.
Risks Inherent in Healthcare-Related Assets.
Substantially all of the Company’s investments will be in the healthcare industry. Concentration in one industry involves significant risks greater than those generally associated with diversified acquisition funds, including significant fluctuations in returns. The healthcare industry is challenged by factors such as government regulations; changes in government policies, including policies regarding reimbursement of medical expenses and policies that impact company’s abilities to market products; changes in technology, including changes that may cause products to quickly become obsolete; medical innovations and accompanied unanticipated problems; changes in healthcare practices or delivery systems; scarcity of management and marketing personnel with appropriate technological or medical training; possibilities of lawsuits related to technological and medical patents, and resulting delays and expenses in product development and implementation; changing macroeconomic conditions in the U.S. and globally, intense competition, susceptibility to natural disasters, large capital requirements and the introduction of new, competing healthcare facilities, properties or other leisure activities.
Companies in the healthcare sector are subject to extensive government regulation and their profitability can be significantly affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure (including price discounting), limited product lines and an increased emphasis on the delivery of healthcare through outpatient services. Companies in the healthcare sector are heavily dependent on obtaining and defending patents, which may be time consuming and costly, and the expiration of patents may also adversely affect the profitability of these companies. Healthcare companies are also subject to extensive litigation based on product liability and similar claims. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the healthcare sector require significant research and development and may be subject to regulatory approvals, all of which may be time consuming and costly with no guarantee that any product will come to market.
The Company’s assets will compete in a relatively uncertain political, economic, and regulatory environment, and instability or an overall decline within the healthcare sector will not be balanced by investments in industries not so affected.
In addition, many healthcare companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or such capital may be obtained on terms that are not favorable to existing investors.
Regulations of Healthcare Industry.
The regulatory environment surrounding the healthcare industry has intensified both in the amount and type of regulations and in the efforts to enforce those regulations. The extensive federal, state, and local, laws and regulations affecting the healthcare industry include, but are not limited to, laws and regulations relating to licensure, certification as a Medicare and Medicaid provider, conduct of operations, ownership of facilities, addition of facilities and equipment, allowable costs, services, prices for services, quality of care, patient rights, patient abuse and neglect, fraudulent reimbursement practices, and financial and other arrangements which may be entered into by healthcare providers.
Federal and state governments have intensified enforcement policies, resulting in a significant increase in the number of inspections, citations of regulatory deficiencies and other regulatory sanctions, including terminations from the Medicare and Medicaid programs, bans on Medicare and Medicaid payments for new admissions, civil monetary penalties and even criminal penalties. The Company’s investments could be forced to expend considerable resources on responding to an investigation or other enforcement action under applicable laws or regulations, The Company is unable to predict the future course of federal, state and local regulation or legislation, including the Medicare and Medicaid statutes and regulations. Changes in regulatory framework could have a material adverse effect on the Company’s Portfolio Investments and the Company.
 
 
32

Senior Secured Loans
. With respect to the Company’s investments in senior secured loans (including first lien loans), the Company will generally have a security interest in assets of the company, which should mitigate the risk that the Company will not be repaid. However, the collateral securing the Company’s loans may decrease in value over time, may be difficult to sell in a timely manner, may be difficult to appraise, and may fluctuate in value based upon the success of the business and market conditions, including as a result of the inability of the company to raise additional capital. In some circumstances, the Company’s lien could be subordinated to claims of other creditors. In addition, deterioration in a company’s financial condition and prospects, including its inability to raise additional capital, may be accompanied by deterioration in the value of the collateral for the loan. Consequently, the fact that a loan is secured does not guarantee that the Company will receive principal and interest payments according to the loan’s terms, or at all, or that the Company will be able to collect on the loan should it be forced to enforce its remedies. Furthermore, if a secured loan is foreclosed, the Company could own the underlying collateral (
e.g.
, real estate), and would be subject to the risks, costs and liabilities associated with owning and disposing of the collateral.
Subordinated Loans
. The Company may invest in subordinated loans. In the event of a loss of value of the underlying assets that collateralize the loans, the subordinate portions of the loans may suffer a loss prior to the more senior portions suffering a loss. If a borrower defaults and lacks sufficient assets to satisfy the Company’s loan, the Company may suffer a loss of principal or interest. If a borrower declares bankruptcy, the Company may not have full recourse to the assets of the borrower, or the assets of the borrower may not be sufficient to satisfy the loan. In addition, certain of the Company’s loans may be subordinate to other debt of the borrower. As a result, if a borrower defaults on the Company’s loan or on debt senior to the Company’s loan, or in the event of the bankruptcy of a borrower, the Company’s loan will be satisfied only after all senior debt is paid in full. The Company’s ability to amend the terms of the Company’s loans, assign the Company’s loans, accept prepayments, exercise the Company’s remedies (through “standstill periods”) and control decisions made in bankruptcy proceedings relating to borrowers may be limited by intercreditor arrangements if debt senior to the Company’s loans exists. In addition, the Company will be subject to the potential risks of foreclosure and ownership of underlying collateral described in “
—Senior Secured Loans
” above.
Mezzanine Securities
. The Company may invest in unsecured securities that are senior to common stock or other equity securities (“Mezzanine Securities”). Mezzanine Securities are subordinated to substantial amounts of senior debt, all or a portion of which may be secured. As a result, holders of Mezzanine Securities are generally not entitled to receive any payments in bankruptcy or liquidation until senior creditors are paid in full. In addition, the legal remedies available to holders of Mezzanine Securities are normally limited by restrictions benefiting senior creditors. In the event a company in which the Company holds Mezzanine Securities cannot generate adequate cash flow to meet senior debt service, the Company may suffer a partial or total loss of capital invested. Because issuers of Mezzanine Securities are often highly leveraged,
their relatively high debt-to-equity ratios create
increased risks that their operations will not be able to generate adequate cash flow to meet senior debt service.
Unsecured Loans or Debt
. The Company may invest in unsecured loans which are not secured by collateral. In the event of default on an unsecured loan, the first priority lien holder has first claim to the underlying collateral of the loan. It is possible that no collateral value would remain for an unsecured holder and therefore result in a loss of investment to the Company. Because unsecured loans are lower in priority of payment to secured loans, they are subject to the additional risk that the cash flow of the borrower may be insufficient to meet scheduled payments after giving effect to the secured obligations of the borrower. Unsecured loans generally have greater price volatility than secured loans and may be less liquid.
Prepayment Risk
. The terms of loans in which the Company invests may permit borrowers to voluntarily prepay loans at any time,
either
with no or a nominal prepayment premium. This prepayment right could result in the borrower repaying the principal on an obligation held by the Company earlier than expected. This may happen when there is a decline in interest rates or when the borrower’s improved credit or operating or financial performance allows the refinancing of certain classes of debt with lower cost debt. The yield of the Company’s investment assets may be affected by the rate of prepayments differing from the Adviser’s expectations.
Investment Modification Risk
. The terms and conditions of loan agreements and related assignments may be amended, modified or waived only by the agreement of the lenders. Generally, any such agreement must include a majority or a super majority (measured by outstanding loans or commitments) or, in certain circumstances, a unanimous vote of the lenders. Consequently, the terms and conditions of the payment obligation arising from Portfolio Investments could be modified, amended or waived in a manner contrary to the preferences of the Company if a sufficient number of the other lenders concurred with such modification, amendment or waiver. There can be no assurance that any obligations arising from a Portfolio Investment will maintain the terms and conditions to which the Company originally agreed.
 
 
33

Collateral Risk
. The collateral and security arrangements in relation to such secured obligations as the Company may invest in will be subject to such security or collateral having been correctly created and perfected and any applicable legal or regulatory requirements which may restrict the giving of collateral or security by an obligor, such as, for example, thin capitalization, over-indebtedness, financial assistance and corporate benefit requirements. If one or more Portfolio Investments do not benefit from the expected collateral or security arrangements, this may adversely affect the value of or, in the event of default, the recovery of principal or interest from such Portfolio Investments made by the Company. Accordingly, any such failure to properly create or perfect collateral and security interests attaching to the Portfolio Investments could have a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units. A component of the Adviser’s analysis of the desirability of making a given investment relates to the estimated residual or recovery value of such Portfolio Investments in the event of the insolvency of the obligor. This residual or recovery value will be driven primarily by the value of the anticipated future cash flows of the obligor’s business and by the value of any underlying assets constituting the collateral for such Portfolio Investment. The anticipated future cash flows of the obligor’s business and the value of collateral can, however, be extremely difficult to predict as in certain circumstances market quotations and third-party pricing information may not be available. If the recovery value of the collateral associated with the Portfolio Investments in which the Company invests decreases or is materially worse than expected by the Company, such a decrease or deficiency may affect the value of the Portfolio Investments made by the Company. Accordingly, there may be a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units.
Defaults
. The Company may make investments in loans, or securities backed by loans, that may be at the time of their acquisition, or may become
after acquisition, non-performing loans.
In the event of any default under a loan directly held by the Company or a loan underlying a security held by the Company, the Company will bear a risk of loss of principal to the extent of any deficiency between the value of the collateral and the principal and accrued interest of the loan, which could have a material adverse effect on the Company’s cash flow
from operations. Other non-performing loans may
require workout negotiations and/or restructuring, which may entail, among other things, a substantial reduction in the interest rate and/or a substantial write-down of the original principal amount of such loans. Further, even if a restructuring were successfully accomplished, unless the restructuring provided for full amortization on or prior to maturity and the borrower strictly complied with that restructuring, a risk exists that upon maturity of such loans, replacement financing will not be available and such loans may not be repaid. In the event of the bankruptcy of a borrower, the loan to that borrower will be deemed to be secured only to the extent of the value of the underlying collateral at the time of bankruptcy (as determined by the bankruptcy court), the lien securing the loan will be subject to the avoidance powers of the
bankruptcy trustee or debtor-in-possession to the
extent the lien is unenforceable under state law, and realizing any value under such circumstances can be an expensive and lengthy process that could have a substantial negative effect on the anticipated return on the loan and on the security backed by such loan. Other risks attendant to a bankruptcy filing are described below. The foregoing statement does not apply in the context of a borrower insolvency case commenced under chapter 13 of the U.S. Bankruptcy Code where the underlying collateral is used as the principal residence of the borrower, but in such instances, the lender will nonetheless be stayed from the collection of its claim, taking possession of the collateral, and enforcing its lien unless and until the lender obtains relief from the automatic stay under the U.S. Bankruptcy Code.
Litigation and Related Risks Associated with Origination and Servicing
. Loan origination and servicing companies are routinely involved in legal proceedings concerning matters that arise in the ordinary course of their business. These legal proceedings range from actions involving a single plaintiff to class action lawsuits with potentially tens of thousands of class members. In addition, a number of participants in the loan origination and servicing industry (including control persons of industry participants) have been the subject of regulatory actions by state regulators, including state Attorneys General, and by the federal government. Governmental investigations, examinations or regulatory actions, or private lawsuits, including purported class action lawsuits, may adversely affect such companies’ financial results. To the extent the Company seeks to engage in origination and/or servicing directly, or has a financial interest in, or is otherwise affiliated with, an origination or servicing company, the Company will be subject to enhanced risks of litigation, regulatory actions and other proceedings. As a result, the Company may be required to pay legal fees, settlement costs, damages, penalties or other charges, any or all of which could materially adversely affect the Company and its investments.
Ability to Originate Loans on Advantageous Terms; Competition and Supply
. The Company’s success depends, in part, on the ability of the Company or its affiliates to originate loans on advantageous terms. In originating and purchasing loans, the Company or its affiliates will compete with a broad spectrum of lenders. Increased competition for, or a diminishment in the available supply of, qualifying loans could result in lower yields on such loans, which could reduce returns (if any) to investors. The Company intends to originate certain investments and later offer to syndicate all or a portion of one or more investments to certain other funds or accounts managed by the Adviser and its affiliates, in each case subject to their own investment-review
process, and to co-investors and/or third
parties. Prior to such syndication, or if such syndication is not successful, the Company’s exposure to the originated investment may exceed the exposure that the Company intends to have over the long-term or would have had if it had purchased such investment in the secondary market rather than originating it. Where
 
34

syndication is not successful, the Company may elect to sell all or a portion of an originated investment at a loss in order to rebalance the Company’s portfolio. The level of analytical sophistication, both financial and legal, necessary for successful financing to companies, particularly companies experiencing significant business and financial difficulties is unusually high. There is no assurance that the Adviser will correctly evaluate the value of the assets collateralizing the Company loans, the prospects for successful repayment or a successful reorganization or similar action.
Risks Relating to Bank Loans and Corporate Loans
. Bank loans and corporate loans (which the Company will originate, invest in or otherwise gain exposure to) may not be readily marketable and may be subject to restrictions on resale. In some cases, negotiations involved in disposing of indebtedness may require weeks to complete. Consequently, some indebtedness may be difficult or impossible to dispose of readily at what the Adviser believes to be a fair price. In addition, bank loans and corporate loans are often less liquid than other types of debt securities, particularly in times of significant market dislocation. Loans to small and middle market entities (“SMEs”) may involve certain heightened risks. See “—
Investments in Smaller and Middle Market Companies
” below.
Holders of bank loans, corporate loans and other forms of direct indebtedness depend primarily upon the creditworthiness of the corporate or other borrower for payment of principal and interest. If the Company does not receive scheduled interest or principal payments on such indebtedness, the value of the Company’s investments could be adversely affected. The Company may invest in secured and unsecured bank loans and corporate loans. Bank loans and corporate loans that are fully secured may offer the Company more protection than an unsecured loan in
the event of non-payment of scheduled
interest or principal. However, there is no assurance that the liquidation of any collateral from a secured bank loan or corporate loan would satisfy the borrower’s obligation, or that such collateral could be liquidated. In the event of the bankruptcy of a borrower, the Company could experience delays or limitations in its ability to realize the benefits of any collateral securing a loan and could be compelled to accept new instruments or interests in respect of its claims under the bank loan in a plan of reorganization. These new instruments or interests may be on terms different from prevailing market terms for similar instruments and interests.
Bank loans usually require, in addition to scheduled payments of interest and principal, the prepayment of the bank loan from free cash flow. The degree to which borrowers prepay bank loans, whether as a contractual requirement or at their election, may be affected by general business conditions, the financial condition of the borrower and competitive conditions among lenders, among others. As such, prepayments cannot be predicted with accuracy. Upon a prepayment, either in part or in full, the actual outstanding debt on which the Company derives interest income will be reduced. The effect of prepayments on the Company’s performance may or may not be mitigated by the receipt of prepayment fees and/or the Company’s reinvestment of prepayments in other bank loans that have similar or identical yields.
The Company may purchase “assignments” of bank loans from lenders. The purchaser of an assignment typically succeeds to all the rights and obligations under the loan agreement with the same rights and obligations as the assigning lender. Assignments may, however, be arranged through private negotiations between potential assignees and potential assignors, and the rights and obligations acquired by the purchaser of an assignment may differ from, and be more limited than, those held by the assigning lender.
The Company may also invest in “participations” in bank loans. Participations by the Company in a lender’s portion of a bank loan typically will result in the Company having a contractual relationship only with such lender, not with the borrower. As a result, the Company may have the right to receive payments of principal, interest and any fees to which it is entitled only from the lender selling the participation and only upon receipt by
such lender of such payments from the borrower. In connection with purchasing participations, the Company generally will have no right to enforce compliance by the borrower with the terms of the loan agreement, nor any rights with respect to any funds acquired by
other lenders through set-off against the
borrower, and the Company may not directly benefit from any collateral supporting the bank loan in which it has purchased the participation. As a result, the Company assumes the credit risk of both the borrower and the lender selling the participation.
In many cases bank loans and loan participations would not be deemed to be securities for purposes of U.S. federal and/or state securities laws. As a result, an investment in bank loans would not be afforded the same protections as an investment in securities, such as the extensive disclosure requirements under U.S. federal and/or state securities laws, which may adversely impact the Company’s ability to seek recourse in respect of such investments. Similarly, the documentation evidencing bank loans and loan participations will not necessarily be maintained with the Company’s custodian.
 
 
35

General Economic and Market Risk
. The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally, such as real or perceived adverse economic conditions, supply and demand for particular instruments, changes in the general outlook for certain markets or corporate earnings, interest rates, announcements of political information or adverse investor sentiment generally. The market values of the Company’s investments may decline for a number of reasons, including increases in defaults resulting from changes in overall economic conditions and widening of credit spreads. Unfavorable market conditions may also increase funding costs, limit access to the capital markets or result in credit terms changing or credit becoming unavailable. These events could have an adverse effect on the Company’s investments and the Company’s overall performance.
Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may also contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide. Such events, including rising trade tensions between the United States and China, other uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies with other countries, the large-scale invasion of Ukraine by Russia that began in February 2022 and resulting sanctions or other restrictive actions that the United States and other countries have imposed against
Russia, the COVID-19 pandemic,
certain regional bank failures, an inflationary environment and the ongoing war in the Middle East, could adversely affect the Company’s business, financial condition or results of operations. These market and economic disruptions could negatively impact the operating results of the Company’s Portfolio Investments.
Additionally, the Federal Reserve raised the Federal Funds Rate in 2022 and in 2023. Although the Federal Reserve left its benchmark rates steady in the fourth quarter of 2023, it has indicated that additional rate increases in the future may be necessary to mitigate inflationary pressures and there can be no assurance that the Federal Reserve will not make upward adjustments to the federal funds rate in 2024. However, there are reports that the Federal Reserve may begin to cut the benchmark rates. These developments, along with the United States government’s credit and deficit concerns, global economic uncertainties and market volatility and the
impacts of COVID-19, could
cause interest rates to be volatile, which may negatively impact the Company’s ability to access the debt markets and capital markets on favorable terms.
Continuing market uncertainty may have a significant impact on the business of the Company. Among other things, the level of investment opportunities may decline from the Adviser’s current expectations. One possible consequence is that the Company may take a longer than anticipated period to invest capital and/or the Company may be relatively concentrated in a limited number of investments. Consequently, during this period, the returns (if any) realized by Unitholders may be substantially adversely affected by the unfavorable performance of a small number of these investments. Furthermore, market conditions may unfavorably impact the Company’s ability to secure leverage on terms as favorable as more established borrowers in the market, or to obtain any leverage on commercially favorable terms. To the extent the Company is able to secure financing for investments, increases in interest rates or in the risk spread demanded by financing sources would make the use of leverage more expensive and could limit the Company’s ability to structure and consummate its investments. Although the Adviser believes that recent market dislocations will result in attractive investment opportunities, the Company may not be able to time the acquisition or disposition of its investments correctly, which could result in further depreciation in values.
Public Health Crises Risk
. Periods of market volatility have occurred and could continue to occur in response to pandemics or other events outside of the Company’s control. These types of events have adversely affected and could continue to adversely affect operating results for the Company and for its Portfolio Investments. For
example, the COVID-19 pandemic
has adversely impacted global commercial activity and contributed to significant volatility in the equity and debt markets. The
COVID-19
pandemic and restrictive measures taken to contain or mitigate its spread have caused, and are continuing to cause, business shutdowns, or
the re-introduction
of business shutdowns, cancellations of events and restrictions on travel, significant reductions in demand for certain goods and services, reductions in business activity and financial transactions, supply chain interruptions, labor shortages, increased inflationary pressure and overall economic and financial market instability both globally and in the United States. Many states, including those in which the Company and Portfolio Investments may operate, have issued orders requiring the closure of, or certain restrictions on the operation of, certain businesses. Such actions and effects remain ongoing and the ultimate duration and severity of
the COVID-19
pandemic,
including COVID-19
variants, remain uncertain.
Despite actions of the U.S. federal government and foreign governments, the uncertainty surrounding
the COVID-19
pandemic, including uncertainty regarding existing or future variants and other factors, has contributed to significant volatility in the global public equity markets and global debt capital markets.
General Credit Risk
. The Company is subject to significant credit risk (
i.e.
, the risk that an issuer or borrower will default in the payment of principal and/or interest on an instrument) in light of its investment strategy. Credit risk also includes the risk that a counterparty to a derivatives transaction (
e.g.
, a swap counterparty) will be unwilling or unable to meet its obligations. Financial strength and solvency of an issuer or borrower are the primary factors influencing credit risk. In addition, degree of
 
36

subordination, lack or inadequacy of collateral or credit enhancement for a debt instrument may affect its credit risk. The degree of credit risk associated with any particular Portfolio Investment or any collateral relating thereto may be difficult or impossible for the Adviser to determine within reasonable standards of predictability. The Adviser utilizes various third parties that hold Company assets (such as the Custodian and prime brokers) in implementing the Company’s investment strategy, and the Company will therefore also be subject to credit risk with respect to such entities.
Although most of the Company’s investments will not be rated by any credit rating agency, in some cases, the credit risk of some of the Company’s Portfolio Investments may be broadly gauged by the credit ratings of such Portfolio Investments. However, ratings are only the opinions of the agencies issuing them, may change less quickly than relevant circumstances, are not absolute guarantees of the quality of the rated securities and are subject to downgrade. Credit ratings and ratings agencies have recently been criticized for ratings which did not fully reflect the risks of certain securities or which did not reflect such risks in a timely manner. For most investments, however, the Adviser will rely on its own independent analysis of the credit quality and risks associated with individual securities considered for the Company, rather than relying on ratings agencies or third-party research. Therefore, the Adviser’s capabilities in analyzing credit quality and associated risks will be particularly important (especially since it is currently anticipated that most of the Company’s assets will not be rated by a ratings agency or will be rated below investment grade), and there can be no assurance that the Adviser will be successful in this regard. See also “—
High Yield Debt and Unrated Securities
” below.
General Leverage Risks
. The Company employs leverage and otherwise incurs indebtedness with respect to the portfolio both on
a recourse or non-recourse basis (including
through guarantees, derivatives, forward commitments and reverse repurchase agreements). The Company is not required to take any action (including unwinding or liquidating any position) in the event that such guideline is exceeded subsequent to the borrowing date, whether in the event of changes in the market value of the Company’s portfolio or otherwise. Prospective investors in the Company should expect that the effective leverage utilized by the Company may exceed such guideline, which only applies to direct borrowings; for instance, economic leverage inherent in the Company’s derivatives transactions and other investments will not be counted for purposes of such guideline, notwithstanding that such investments will be subject to many of the leverage-related risks described herein. In addition, determinations relating to leverage are inherently subjective and will involve the exercise of discretion by the Adviser (for instance, the Adviser may deem the amount of the Company’s direct borrowings to be reduced by cash and cash equivalents held by the Company or by a counterparty). See “—
Leveraged Companies
” below.
The use of leverage has the potential to magnify the gains or the losses on investments and to make the Company’s returns more volatile. Moreover, if the Company is
required to de-lever as
a result of changing market conditions or otherwise, it may be forced to sell Portfolio Investments at inopportune times or at disadvantageous prices. On the other hand, while the Company will have the flexibility to use leverage, there can be no guarantee that leverage can be obtained, or obtained on terms and pricing the Adviser finds attractive, especially in the current market environment. As a result, prospective investors in the Company should recognize that Portfolio Investments may not be leveraged, or may be leveraged at an amount below any leverage level otherwise expected by the Adviser. Moreover, even if leverage can be arranged, the Company is not obligated to utilize such leverage and may do so at the sole discretion of the Adviser. Should leverage not be obtained or utilized by the Company, the returns for the Company may be lower than they would have been had such leverage been obtained and utilized.
In connection with any leverage utilized by the Company, the Company may secure its obligations with respect thereto with any and all of its assets, including its right to receive capital contributions from the Unitholders, pursuant to a pledge or other security agreement on terms that the Company determines are fair and reasonable to the Company. If the Company were to default on its obligations under such transactions, the counterparty could foreclose on the collateral and take possession of the Company’s assets and/or call capital from the Unitholders for purposes of repaying debt.
The terms of any leverage utilized by the Company are likely to impose significant restrictions on the Company’s operations and investment program, including as to the Company’s ability to pay distributions, incur additional leverage and engage in certain transactions.
Investments in Smaller and Middle Market Companies
. The Company generally invests in smaller and middle market companies. While smaller and middle market companies generally have potential for rapid growth, they often involve higher risks because they may lack the management experience, financial resources, product diversification, competitive strength and access to capital of larger companies. In addition, in many instances, the frequency and volume of the trading of securities for such companies may be substantially less than is typical of larger companies. As a result, the securities of smaller and middle market companies may be subject to wider price fluctuations. When liquidating positions in smaller and middle market companies, the Company may have to sell portfolio holdings at discounts from quoted prices or may have to make a series of small transactions over an extended period of time. Investments in such companies may also be particularly difficult to analyze due to (among other factors) limited attention from analysts and large institutional investors, limited access to liquidity sources and, in certain cases, limited publicly available financial information. With respect to the Company’s investments in SMEs and similar loans, the Company may receive less borrower information, receive less collateral and be subject to heightened default risk as compared to loans made to other types of entities.
 
37

Hedging Transactions and Related Risks
. The Company may, but is not required to, engage in hedging transactions. In particular, as many of the Company’s Portfolio Investments are expected to consist of relatively illiquid securities whose price behavior is not particularly correlated to general fixed income or equity index returns, such Portfolio Investments are expected to be difficult or expensive to hedge, and as such the Company may not employ any hedging strategy in respect of such Portfolio Investments (including with respect to their credit risk). To the extent the Adviser employs a hedging strategy for the Company, the success of any such hedging strategy will depend, in part, upon the Adviser’s ability to correctly assess the degree of correlation between the performance of the instruments used in the hedging strategy and the performance of the investments being hedged. Since the characteristics of many securities change as markets change or time passes, the success of the Company’s hedging strategy will also be subject to the Adviser’s ability to continually recalculate, readjust and execute hedges in an efficient and timely manner. While the Company may enter into hedging transactions to seek to reduce risk, such transactions may result in a poorer overall performance for the Company than if it had not engaged in such hedging transactions. For a variety of reasons, the Adviser may not seek to establish a precise correlation between the hedging instruments utilized and the portfolio holdings being hedged. Such an imprecise correlation may prevent the Company from achieving the intended hedge or expose the Company to risk of loss. Additionally, the Adviser may not hedge against a particular risk because it does not regard the probability of the risk occurring to be sufficiently high as to justify the cost of the hedge, or because it does not foresee the occurrence of the risk. Moreover, there is no guarantee that the Company’s intended hedging strategy will be successful in hedging out the subject risks.
Due Diligence Risk
. When conducting due diligence and making an assessment regarding a Portfolio Investment, the Adviser relies on the resources available to it, including internal sources of information as well as information provided by third parties. The due diligence process may at times be required to rely on limited or incomplete information. The Adviser selects Portfolio Investments in part on the basis of information and data filed with various government regulators and publicly available or made directly available by prospective portfolio companies or third parties. The Adviser expects that it will not be in a position to confirm the completeness, genuineness or accuracy of such information and data, and will therefore be dependent upon the integrity of the management of the entities filing such information and of such portfolio companies and third parties providing such information. In addition, there can be no assurance that any consultants or experts engaged by the Adviser will accurately evaluate such Portfolio Investments. Investment analyses and decisions by the Adviser may be undertaken on an expedited basis to enable the Company to take advantage of investment opportunities with accelerated timelines. In such cases, the available information at the time of an investment decision may be limited, inaccurate and/or incomplete. Accordingly, the Adviser cannot guarantee that its due diligence investigations will reveal or highlight all relevant facts that may be necessary or helpful in evaluating investment opportunities. Furthermore, the Company bears its proportionate share of all due diligence-related fees, costs, expenses and liabilities (including in respect of investments that are not ultimately consummated); such fees, costs, expenses and liabilities may be significant and could reduce Company returns.
Interest Rate Risk
. Interest rate risk refers to the risks associated with market changes in interest rates. In general, rising interest rates, such as the recent economic period, will negatively impact the price of fixed rate debt instruments and falling interest rates will have a positive effect on the price of such debt instruments. Many of the Company’s investments are expected to be variable rate loans with interest that adjusts with market rates. These loans will generally also react to interest rate changes in a similar manner although generally to a lesser degree (depending, however, on the characteristics of the reset terms, including the index chosen, frequency of reset and reset caps or floors, among other factors). The Company’s other investments and transactions may also be affected by changes in interest rates. Declines in market value, if not offset by any corresponding gains on hedging instruments, may ultimately reduce earnings or result in losses to the Company.
The prices of long-term debt obligations generally fluctuate more than prices of short-term debt obligations as interest rates change. To the extent the Company invests in longer-term Portfolio Investments, it will be impacted to a greater degree by changes in market interest rates than if the Company invested primarily in short-term debt securities.
To the extent the Company borrows money or issues preferred Units to make investments, its net investment income will depend, in part, upon the difference between the rate at which it borrows funds or pays distributions on preferred Units and the rate at which the Company invests those funds. As a result, the Company can offer no assurance that a significant change in market interest rates will not have a material adverse effect on its net investment income in the event the Company uses debt to finance investments. In periods of rising interest rates, such as the recent economic period, the Company’s cost of funds will increase because the interest rates on the amounts borrowed under the Company’s credit facilities or certain other financing arrangements will typically be floating, which could reduce the Company’s net investment income to the extent any Portfolio Investments have fixed interest rates, and the interest rate on Portfolio Investments with an interest rate floor (such as a SOFR (as defined below) floor) above then-current levels will not increase until interest rates exceed the applicable minimum interest rate floor. Rising interest rates may also increase the cost of debt for the Portfolio Investments, which could adversely impact the Portfolio Investment’s financial performance and ability to meet ongoing obligations to the Company.
 
 
38

The Company expects that its long-term fixed-rate investments will be financed primarily with equity and long-term debt. The Company may use interest rate risk management techniques in an effort to limit its exposure to interest rate fluctuations. Such techniques may include various interest rate hedging activities to the extent permitted by the 1940 Act. These activities could limit the Company’s ability to participate in the benefits of lower interest rates with respect to the hedged borrowings. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on the Company’s business, financial condition and results of operations.
Also, an increase in interest rates available to investors could make an investment in the Company’s Units less attractive if the Company is not able to increase its distribution rate, which could reduce the value of the Company’s Units.
Liquidity Risk
. Most of the Company’s Portfolio Investments at any given time are expected to be illiquid, such that either no market exists for them or they are restricted as to their transferability under federal, state or foreign securities laws. Similarly, the Adviser may from time to
time possess material, non-public information about
an issuer, which could limit the ability of the Company to buy and sell Portfolio Investments. The illiquid nature of the Company’s positions may make it difficult, if not impossible, for the Company to (i) close out unprofitable positions and redeploy capital, except when a viable exit strategy can be developed (which may require a much longer commitment than the Adviser had anticipated), and (ii) meet margin calls or similar requirements of Company transaction counterparties to furnish additional liquid collateral. In addition, the sale of the Company’s investments may be made at substantial discounts and/or otherwise disadvantageous terms.
Inflation/Deflation Risk
. Inflation risk results from the variation in the value of cash flows from a security due to inflation, as measured in terms of purchasing power. The Company is exposed to inflation risk with respect to any fixed rate investments that it makes, if any, because the interest rate the issuer has to pay the Company is fixed for the life of the security. To the extent that interest rates reflect the expected inflation rate, floating rate loans have a lower level of inflation risk.
Any disruptions in the capital markets, as a result of inflation and a rising interest environment or otherwise, may increase the spread between the yields realized on risk-free and higher risk securities and can result in illiquidity in parts of the capital markets, significant write-offs in the financial sector
and re-pricing of
credit risk in the broadly syndicated market. These and any other unfavorable economic conditions could increase the Company’s funding costs, limit the Company’s access to the capital markets or result in a decision by lenders not to extend credit to the Company. In addition, market conditions (including inflation, supply chain issues and decreased consumer demand) could impact the operations of certain of the Company’s Portfolio Investments. If the financial results of middle-market companies, like those in which the Company intends to invest, experience deterioration, it could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults, and further deterioration in market conditions will further depress the outlook for those companies. Further, adverse economic conditions may decrease the value of collateral securing some of the Company’s loans and the value of the Company’s equity investments. Such may require the Company to modify the payment terms of its investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of the Company’s Portfolio Investments may be negatively impacted by these economic or other conditions, which can result in the Company’s receipt of reduced interest income from its Portfolio Investments and/or realized and unrealized losses related to its Portfolio Investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations.
Financial Fraud
. Instances of fraud and other deceptive practices committed by management, employees or Service Providers of the Company’s Portfolio Investments or by other financial institutions may undermine the Adviser’s due diligence efforts with respect to, and/or negatively affect the valuation of, the Company’s Portfolio Investments. In addition, financial fraud may contribute to overall market volatility, which can negatively impact the Company’s investment program.
OFAC, FCPA and Related Considerations
. Economic sanction laws in the U.S. and other jurisdictions may prohibit the Adviser, its personnel and the Company from transacting with or in certain countries and with certain individuals and companies. In the U.S., the U.S. Department of the Treasury’s Office of Foreign Assets Control administers and enforces laws, Executive Orders and regulations establishing U.S. economic and trade sanctions. Such sanctions prohibit, among other things, transactions with, and the provision of services to, certain foreign countries, territories, entities and individuals. These types of sanctions may restrict the Company’s investment activities.
In some countries, there is a greater acceptance than in the U.S. of government involvement in commercial activities, and of corruption. The Company may be adversely affected because of its unwillingness to participate in transactions that violate such laws or regulations. Such laws and regulations may make it difficult in certain circumstances for the Company to act successfully on investment opportunities and for Portfolio Investments to obtain or retain business.
 
 
39

In recent years, the U.S. Department of Justice and the SEC have devoted greater resources to enforcement of the U.S. Foreign Corrupt Practices Act (the “FCPA”). In addition, the United Kingdom has recently significantly expanded the reach of its anti-bribery laws. Violations of the FCPA or other applicable anti-corruption laws or anti-bribery laws could result in, among other things, civil and criminal penalties, material fines, profit disgorgement, injunctions on future conduct, securities litigation and a general loss of investor confidence, any one of which could adversely affect the Company’s ability to achieve its investment objective and/or conduct its operations.
Risks Relating to Waivers or Deferrals of Covenants and Covenant-Lite Loans
. The Company structures the debt in its Portfolio Investments to include business and financial covenants placing affirmative and negative obligations on the operation of the company’s business and its financial condition. However, from time to time the Company may elect to waive breaches of these covenants, including its right to payment, or waive or defer enforcement of remedies, such as acceleration of obligations or foreclosure on collateral, depending upon the financial condition and prospects of the particular Portfolio Investment. These actions may reduce the likelihood of the Company receiving the full amount of future payments of interest or principal and be accompanied by a deterioration in the value of the underlying collateral as many of these companies may have limited financial resources, may be unable to meet future obligations and may go bankrupt. This could negatively impact the Company’s ability to pay distributions, could adversely affect its results of operation and financial condition and cause the loss of all or part of your investment.
In addition, some of the loans in which the Company may invest may be “covenant-lite” loans. The Company uses the term “covenant-lite” loans to refer generally to loans that do not have a complete set of financial maintenance covenants. Generally, “covenant-lite” loans provide borrower companies more freedom to negatively impact lenders because their covenants are incurrence-based, which means they are only tested and can only be breached following an affirmative action of the borrower, rather than by a deterioration in the borrower’s financial condition. Accordingly, to the extent the Company invests in “covenant-lite” loans, the Company may have fewer rights against a borrower and may have a greater risk of loss on such investments as compared to investments in or exposure to loans with financial maintenance covenants.
General Risks Related to the Company
Risk of Loss
. An investment in the Company is highly risky. There can be no assurance that the Company will achieve its investment objective or any particular level of returns. An investor may lose all of its money by investing in the Company. Among other things, the Company may invest in assets that are underperforming or non performing and/or in securities of issuers who are under financial stress. By their nature, such investments are considered speculative and entail substantial risks that are generally higher than the risks of investments in performing assets and securities of issuers that are not under financial stress. Any losses in the Company will be borne solely by investors in the Company and not by the Adviser or any of its respective affiliates (except to the extent they invest capital in the Company, in which case they, with respect to such capital invested, will bear their pro rata portion of such loss).
No Market for Units
. Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed. A Unitholder is not expected to be able to sell, assign or transfer its Units. In addition, transfers of Units may be affected by restrictions on resales imposed by federal and state securities laws. The Units are not registered under the Securities Act or any state securities laws and may not be transferred unless registered under applicable federal and state securities laws or unless an exemption from such laws is available. The Company has no plans, and is under no obligation, to register the Units under the Securities Act or any state securities laws. No market exists for the Units, and none is expected to develop. Therefore, an investment in the Company must be considered illiquid and must only be made by
persons
that are able to bear the risk of their investment in the Company for an indefinite period of time.
Management Risk and Reliance on Management
. The Company is subject to management risk because the Adviser actively manages its investment portfolio. The Adviser will apply investment and disposition techniques and risk analyses in making investment and disposition decisions for the Company, but there can be no guarantee that these will produce the desired results. In addition, as Unitholders may not participate in the management of the Company, only investors who are willing to entrust all aspects of the management of the Company to the Adviser should subscribe for Units.
The success of the Company is highly dependent upon the financial and managerial experience of the Adviser and any consultants or other Service Providers retained by the Company. The success of the Adviser is highly dependent on the financial and managerial experience of the investment professionals, who may not continue to be employed by or associated with the Adviser during the entire term of the Company. In
addition
, a number of members of the professional staff of the Adviser are
 
40

investors in other investment vehicles advised by SLR and are actively involved in managing the investment decisions of these investment vehicles, as well as investment decisions of other clients of SLR. Accordingly, the members of the professional staff of the Adviser have demands on their time for the investment, monitoring and other functions of other funds and other clients advised by SLR. In addition, competition in the financial services, private equity and alternative asset management industries for qualified investment professionals is intense. The Adviser’s continued ability to effectively manage the Company’s investments depends on its ability to attract new investment professionals and to retain and motivate its existing investment professionals.
Notwithstanding the foregoing, at any time during the Company’s term, the Adviser may assign the full and exclusive authority and responsibility granted to it under the Investment Management Agreement to an investment adviser under common control with the Adviser, subject to applicable law. The Adviser may take any actions that are necessary or incidental to any such assignment, including assigning the Investment Management Agreement or causing the Company to enter into a new Investment Management Agreement. Although it is expected that (x) any new investment adviser would be a registered investment adviser under the Advisers Act, (y) the management fee and incentive fee payable by the Company to such entities would be identical to that payable to the Adviser and (z) certain investment professionals would continue to be responsible for managing the Company’s assets, there is no guarantee that any or all of such characteristics will apply to any such new investment adviser.
The Investment
Committee may delegate non-investment decisions (including
decisions relating to cash management
and similar non-material transactions
(which shall not be considered “investments” for these purposes), diligence decisions, decisions relating to
transactions involving material non-public information and
decisions relating to the engagement of consultants, law firms and other Service Providers) to other investment professionals in their sole discretion. Any decisions made by such subset or other investment professionals may be materially different and/or less optimal than decisions that would have been made by the Investment Committee.
Referral Relationships with Financial Sponsors
. The Adviser expects that the professional staff of the Adviser will maintain and develop their relationships with financial sponsors, including venture capital sponsors, and the Company will rely to a significant extent upon these relationships to provide the Company with potential investment opportunities. If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio. In addition, individuals with whom the professional staff of the Adviser have relationships are not obligated to provide the Company with investment opportunities, and, therefore, there is no assurance that such relationships will generate investment opportunities for the Company. If the Adviser is unable to source investment opportunities, the Company may hold a greater percentage of its assets in cash and cash equivalents than anticipated, which could impact potential returns on the Company’s portfolio.
Recourse to the Company’s Assets
. The Company’s assets, including any Portfolio Investments made by the Company and any capital held by the Company, are available to satisfy all liabilities and other obligations of the Company. In addition, the Company may pledge its right to call capital from Unitholders. If the Company becomes subject to a liability, parties seeking to have the liability satisfied may have recourse to the Company’s assets generally and may not be limited to any particular asset, such as the Portfolio Investment giving rise to the liability. To the extent the Company chooses to use special-purpose entities for individual transactions to reduce recourse risk (and it may, but will be under no obligation to do so), the
 bona fides
 of such entities may be subject to later challenge based on a number of theories, including veil piercing or substantive consolidation.
Unspecified Use of Proceeds
. The proceeds from the issuance of the Units are intended to be invested in Portfolio Investments. Unitholders will not have an opportunity to evaluate for themselves the relevant economic, financial and other information regarding the investments in which the proceeds from the issuance of the Units will be invested and, accordingly, are dependent upon the judgment and ability of the Adviser in investing and managing the capital of the Company.
Identification of Potential Investment Opportunities
. There is no assurance that the Adviser’s analysis in this regard, as implemented, will take into consideration all appropriate factors or appropriately weigh the factors that are considered in its analysis, especially given the heightened difficulty of the analysis required to evaluate certain Portfolio Investments. In particular, catalysts and/or exit strategies that initially appear to be viable may be precluded over time due to economic, legal, political or other factors. In addition, because the successful implementation of the Company’s investment strategy depends, in part, on its ability to successfully predict and take advantage of changing market conditions, to the extent it is unable to do so, returns may be adversely affected. These considerations are particularly relevant in light of the current uncertain economic and regulatory environment. See “—
Regulatory Risks Relating to the Company
” below.
 
 
41

Competition; Potential for Insufficient Investment Opportunities
. The business of identifying and effecting investments of the types contemplated by the Adviser is competitive and there can be no assurance that the Adviser will be able to identify and obtain a sufficient number of investment opportunities to invest the full amount of capital that may be committed to the Company. Increased competition for, or a diminishment in the available supply of, potential Portfolio Investments could result in lower returns on such Portfolio Investments. The Company may engage in auction or similar bidding processes with respect to certain Portfolio Investments, which processes are often highly competitive and may involve numerous other bidders about which the Company possesses limited or no information; as a result, the foregoing considerations will be applicable with respect to any such processes.
Insufficient Capital for
Follow-On
 Investments
. Following its initial investment in a Portfolio Investment, the Company may have the opportunity to increase its investment in such Portfolio Investment. There is no assurance that the
Company will make follow-on investments or
that the Company will have sufficient resources to, or be permitted to, make such investments. Any decision
not to make follow-on investments or the
Company’s inability to make them may have a substantial negative impact on the company in need of such an investment, may result in missed opportunities for the Company or may result in dilution of the Company’s investment.
Concentration of Portfolio Investments
. The Company may participate in a limited number of Portfolio Investments and, as a consequence, the aggregate return of the Company may be substantially adversely affected by the unfavorable performance of any single investment. The Company has a broad and flexible investment mandate, and, beyond the asset diversification requirements associated with the Company’s intention to comply with the requirements to qualify as a RIC for U.S. tax purposes, and except as noted above, the Company is not subject to any limits or proportions with respect to the mix of permitted Portfolio Investments. As a result, the Company’s Portfolio Investments could potentially be concentrated in relatively few strategies, issuers, industries, markets, geographies or
investment types. Such non-diversification would make the
Company more susceptible to risks associated with a single economic, political or regulatory occurrence than a more diversified portfolio might be. The Company could be subject to significant losses if it holds a relatively large position in a single strategy, issuer, industry, market, geographic region or a particular type of Portfolio Investment that declines in value, and the losses could increase even further if the Portfolio Investments cannot be liquidated without adverse market reaction or are otherwise adversely affected by changes in market conditions or circumstances.
Third-Party Involvement
. The Company may hold a portion of its investments through partnerships, joint ventures, securitization vehicles or other entities with third-party investors (collectively, “joint ventures”). Joint venture investments involve various risks, including the risk that the Company will not be able to implement investment decisions or exit strategies because of limitations on the Company’s control under applicable agreements with joint venture partners, the risk that a joint venture partner may become bankrupt or may at any time have economic or business interests or goals that are inconsistent with those of the Company, the risk that a joint venture partner may be in a position to take action contrary to the Company’s objectives, the risk of liability based upon the actions of a joint venture partner and the risk of disputes or litigation with such partner and the inability to enforce fully all rights (or the incurrence of additional risk in connection with enforcement of rights) one partner may have against the other, including in connection with foreclosure on partner loans, because of risks arising under state law. In addition, the Company may be liable for actions of its joint venture partners.
Leveraged Companies
. The Company will invest in Portfolio Investments whose capital structures have significant leverage. Such Portfolio Investments are inherently more sensitive to declines in revenues and asset values and to increases in expenses and interest rates. The leveraged capital structure of such Portfolio Investments will increase the exposure of the Portfolio Investments to adverse economic factors such as downturns in the economy or deterioration in the condition of the Portfolio Investment, its underlying assets or its industry. Additionally, the securities acquired by the Company may be the most junior securities in what may be a complex capital structure, and thus subject to the greatest risk of loss.
Portfolio Turnover
. The Company will not place any limit on the rate of portfolio turnover, and Portfolio Investments may be sold or otherwise disposed of without regard to the time they have been held when, in the judgment of the Adviser, investment considerations warrant such action. A high rate of portfolio turnover involves correspondingly greater expenses than a lower rate, may act to reduce the Company’s investment gains or create a loss for investors and may result in significant tax costs for investors
depending
on the tax provisions applicable to such investors.
No Assurance of Cash Distributions
. Subject to the Board’s discretion and applicable legal restrictions, the Company expects to declare and pay distributions quarterly. The Company expects to pay these distributions out of assets legally available for distribution. However, there are no assurances that the Company will achieve investment results that will allow a targeted level
 
of
cash distributions or year-to-year increases in cash
distributions. All distributions that are made will be at the discretion of the Board and will depend on earnings, financial condition, maintenance of RIC status and other factors as the Board may deem to be relevant. The Company’s ability to pay distributions might be adversely affected by the impact of one or more of the risk
 
42

factors described in this annual report on Form
10-K.
If the Company violates certain covenants under its existing or future credit facilities or other leverage, the Company may be limited in its ability to make distributions. To the extent the Company makes distributions to Unitholders that include a return of capital, such portion of the distribution essentially constitutes a return of the Unitholder’s investment. In addition, the inability to satisfy the asset coverage test applicable to a BDC may limit the Company’s ability to pay distributions. There can be no assurances that the Company will pay distributions to Unitholders in the future.
In certain cases, the Company may recognize income before or without receiving the accompanying cash. Depending on the amount of noncash income, this could result in difficulty satisfying the annual distribution requirement applicable to RICs. Accordingly, the Company may have to sell some Portfolio Investments at times it would not consider advantageous, raise additional debt or equity capital or reduce new investments to meet these distribution
requirements
.
U.S.
 Dollar Denomination of Units
. Units are denominated in U.S. Dollars. Investors subscribing for Units in any country in which U.S. Dollars are not the local currency should note that changes in the rate of exchange between U.S. Dollars and such currency may have an adverse effect on the value, price or income of the investment to such investor. There may be foreign exchange regulations applicable
to investments in non-U.S. currencies in certain
jurisdictions. Each prospective investor should consult with its own counsel and advisors as to all legal, tax, financial and related matters concerning an investment in the Units.
Forward-Looking Statements
. This
annual
report on Form
10-K
contains forward-looking statements, including observations about market and industry and regulatory trends as of the original date of this annual report
on Form 10-K. Those forward-looking
statements reflect the Adviser’s current view in respect of future events. Actual events could differ materially from those in the forward-looking statements as a result of factors beyond the Adviser’s or the Company’s control. Investors are cautioned not to place undue reliance on such statements. No party has an obligation to update any of the forward-looking statements in this annual report
on Form 10-K.
Projections
. The Company may rely upon projections, forecasts or estimates developed by the Adviser, the Company or an issuer in which the Company is invested concerning the issuer’s future performance and cash flow. Projections, forecasts and estimates are forward-looking statements, are inherently uncertain and are based upon certain assumptions. Actual events are difficult to predict and beyond the Company’s control. Actual events may differ from those assumed. Some important factors which could cause actual results to differ materially from those in any forward-looking statements include changes in interest rates; domestic and foreign business, market, financial or legal conditions; leverage amounts and costs; and the degree to which the Portfolio Investments are hedged and the effectiveness of such hedges. Accordingly, there can be no assurance that estimated returns or projections can be realized or that actual returns or results will not be materially lower than those estimated therein.
Valuation of Illiquid Assets
. It is expected that the majority of the Company’s investments will be in securities or other financial instruments for which market quotations are not available. The process of valuing securities for which reliable market quotations are not available is based on inherent uncertainties, and the resulting values may differ from values that would have been determined had a ready market existed for such securities, from values placed on such securities by other investors and from prices at which such securities may ultimately be sold. In addition, third-party pricing information may at times not be available regarding certain of the Company’s assets or, if available, may not be considered reliable. In particular, recent disruptions in the credit markets have resulted in a severe lack of liquidity for many securities, making them more difficult to value and, in many cases, putting significant downward pressure on prices. Subject to approval by the Board, the Adviser will determine the fair value of securities, loans or other instruments for which market quotes are not readily available (or if extraordinary events occur after the last readily available quotation). The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by
Rule 2a-5 under
the 1940 Act; and (6) maintain recordkeeping requirements under
Rule 2a-5.
There can be no assurance that such valuations will be reliable, accurate or reflective of the prices at which such investments are ultimately realized. In addition, certain of the securities or other assets that the Company seeks to sell or acquire via cross trade may be illiquid and difficult to value, therefore there can be no assurance that such valuation will be accurate.
Assets Believed to Be Undervalued or Incorrectly Valued
. Securities that the Adviser believes are fundamentally undervalued or incorrectly valued may not ultimately be valued in the capital markets at prices and/or within the timeframe the Adviser anticipates. As a result, the Company may lose all or substantially all of its investment in any particular instance.
 
 
43

Model Risks
. The Adviser may employ financial/analytical models to aid in the selection of the Portfolio Investments, to allocate investments across various strategies and risks and to determine the risk profile of the Company. If any such models are employed, the success of the Company’s investment activities will depend, in large part, upon the viability of these models. There can be no assurance that the models are currently viable, or will remain viable during the term of the Company, due to various factors, including the quality of the data input into the models and the assumptions underlying such models, which to varying degrees involve the exercise of judgment, as well as the possibility of errors in constructing or of using the model. Even if the models function as anticipated, they cannot account for all factors that may influence the returns on the Portfolio Investments. Also, there can be no assurance that the investment professionals utilizing the models will be able to (i) determine that any model is or will become not viable or not completely viable or (ii) notice, predict or adequately react to any change in the viability of a model. The use of a model that is not viable or not materially viable could, at any time, have a material adverse effect on the performance of the Company.
Regulatory Investigations or Third-Party Litigation
. The Company as well as the Adviser and its affiliates participate in a highly regulated industry and are each subject to regulatory examinations in the ordinary course of business. There can be no assurance that the Company and the Adviser and/or any of its affiliates will avoid regulatory investigation and possible enforcement actions stemming therefrom. The Adviser is a registered investment adviser and, as such, is subject to the provisions of the Advisers Act. The Company and the Adviser are each, from time to time, subject to formal and informal examinations, investigations, inquiries, audits and reviews from numerous regulatory authorities both in response to issues and questions raised in such examinations or investigations and in connection with the changing priorities of the applicable regulatory authorities across the market in general.
The Company’s investment activities may subject it to the risks and costs of becoming involved in litigation with third parties due to, among other reasons, the fact that different investor groups may have qualitatively different, and frequently conflicting, interests with respect to certain Portfolio Investments. The risk of litigation with third parties will be elevated in situations where an issuer is stressed or distressed. See “—
Litigation and Related Risks Associated with Origination and Servicing
” above. The expense of defending against claims by third parties and
paying
any amounts pursuant to settlements or judgments, or bringing claims against third parties, would generally be borne by the Company and would reduce net assets. In addition, the Company’s investment activities may subject it to certain risks inherent in restructuring, bankruptcy and similar proceedings. See “—
Risks Associated with Bankruptcy and Insolvency Cases
” below.
Broad Indemnification
. The Company and/or the Adviser on behalf of the Company may enter into various agreements or arrangements which limit the liability of its Service Providers, including the Adviser and its affiliates, the Administrative Coordinator, the Custodian, and their affiliates, employees, officers and directors, and require the Company to indemnify and/or provide broad representations, warranties and covenants in favor of such persons. U.S. federal and state securities laws impose liabilities under certain circumstances on persons that cannot be waived by contract, other agreements or documents. Therefore, nothing in those agreements should be deemed or construed in a manner that purports to waive or limit any right to the extent prohibited by law.
The Company is required to indemnify the Adviser and its respective affiliates, each of the former, current and future shareholders, partners, members, other equity holders, officers, directors, employees, managers, trustees, agents and other representatives of the Adviser and its respective affiliates, and other persons set forth in the LLC Agreement as an “Indemnitee” for Claims (as defined in the LLC Agreement) that may accrue to or be incurred by an Indemnitee, in connection with any claim, demand, investigation, suit, proceeding or action in which an Indemnitee may become involved, as a party or otherwise, or with which an Indemnitee may be threatened, relating to or arising out of the investments or other activities of the Company, activities undertaken in connection with the Company, or otherwise relating to or arising out of the LLC Agreement or the Subscription Agreement, and otherwise as provided in the LLC Agreement or the Subscription Agreement. Such Claims may be material and have an adverse effect on the returns to the Unitholders. The Company may also provide broad indemnities, representations, warranties and covenants in connection with the acquisition, management and disposition of Portfolio Investments or otherwise in connection with the Company’s investment program.
Any indemnification obligations of the Company would be payable from the assets of the Company, including the unfunded Commitments of the Unitholders, and would adversely affect the Company’s returns.
Adverse Consequences of Default
. A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment. When a Unitholder defaults, the Board, in its discretion, may cause the defaulting Unitholder to forfeit a portion of the distributions to which the defaulting Unitholder may otherwise have been entitled. The Board may also require a forced sale of the defaulting Unitholder’s Interest. In addition, the Board may pursue any available legal or equitable remedies, with the expenses of collection of the unpaid amount, including attorneys’ fees, to be paid by the defaulting Unitholder.
 
44

Upon the default of a Unitholder, the Company may deliver an amended funding notice to the
non-defaulting
Unitholders increasing their capital contributions by up to an aggregate amount equal to the capital contribution that the defaulting Unitholder failed to make, not in excess of a Unitholder’s unfunded Commitment.
The Board may require a defaulting Unitholder to contribute the entirety of its remaining Commitment to the Company. For any such Unitholder, the return on its Company investment may be materially lower than returns to Unitholders
who do not pre-fund their Commitments.
Distributions in Kind
. If distributions are made of assets held by the Company in lieu of cash, the amount of any such distribution will be accounted for at the fair market value of such assets as determined in accordance with procedures set forth in the LLC Agreement. An independent appraisal generally will not be required and is not expected to be obtained. Assets distributed in kind may not be readily marketable or disposable, and Unitholders therefore must be prepared to bear the risks of owning such assets for an indefinite period of time (and to incur costs and expenses in connection with any disposition thereof). In addition, there can be no
assurance
that the value of such assets as determined in accordance with procedures set forth in the LLC Agreement will ultimately be realized.
Risks Related to the Russian Invasion of Ukraine
. On February 24, 2022, the Russian military commenced a full-scale invasion of
Russia’s pre-positioned forces
into Ukraine, which could have a negative impact on the economy and business activity globally (including in the countries in which the Company invests), and therefore could adversely affect the performance of the Company’s Portfolio Investments. Following such invasion, the United States and several European nations announced sanctions against Russia. Furthermore, the conflict between the two nations and the varying involvement of the United States and other NATO countries could preclude prediction as to their ultimate adverse impact on global economic and market conditions, and, as a result, presents material uncertainty and risk with respect to the Company and the performance of its investments or operations, and the ability of the Company to achieve its investment objectives. Additionally, to the extent that third parties, investors, or related customer bases have material operations or assets in Russia or Ukraine, they may have adverse consequences related to the ongoing conflict.
Risks Related to Electronic Communications/Cybersecurity Risk
. The Company provides to Unitholders statements, reports and other communications relating to the Company and/or the Unitholder’s Interest in electronic form, such
as e-mail or
via a password protected website (“Electronic Communications”). There are certain costs and possible risks associated with the use of Electronic Communications. Electronic Communications may be modified, corrupted, or contain viruses or malicious code, and may not be compatible with a Unitholder’s electronic system. The Company cannot provide any assurance that Electronic Communications are secure and will not be responsible for any computer viruses, problems or malfunctions resulting from the use of Electronic Communications. In addition, reliance on Electronic Communications involves the risk of inaccessibility, power outages or slowdowns for a variety of reasons. These periods of inaccessibility may delay or prevent receipt of reports or other information by the Unitholders.
The Company relies on the Adviser’s enterprise-wide cybersecurity program, to protect its information, including due oversight of the cybersecurity programs of the Company’s key Service Providers and processes for the assessment, identification, and management of material risks from cybersecurity threats, including those associated with the use of third-party Service Providers. While the Adviser employs various measures to address cybersecurity-related issues, the Adviser, the Administrative Coordinator, the Company and their respective Service Providers may nevertheless be subject to operational and information security risks resulting from cybersecurity incidents. A cybersecurity incident refers to both intentional and unintentional events that may cause the Adviser, the Company or their respective Service Providers to lose or compromise confidential information, suffer data corruption or lose operational capacity. Cybersecurity incidents include stealing or corrupting data maintained online or digitally, denial of service attacks on websites, the unauthorized release of confidential information or various other operational disruptions. If unauthorized parties gain access to such information and technology systems, they may be able to steal, publish, delete or modify private and sensitive information, including nonpublic personal information related to Unitholders (and their beneficial owners) and material nonpublic information. The systems the Adviser has implemented to manage risks relating to these types of events could prove to be inadequate and, if compromised, could become inoperable for extended periods of time, cease to function properly or fail to adequately secure private information. Breaches such as those involving covertly introduced malware, impersonation of authorized users and industrial or other espionage may not be identified even with sophisticated prevention and detection systems, potentially resulting in further harm and preventing them from being addressed appropriately. The failure of these systems or of disaster recovery plans for any reason could cause significant interruptions in the Company’s and the Adviser’s operations and result in a failure to maintain the security, confidentiality or privacy of sensitive data, including personal information relating to Unitholders, material nonpublic information and other sensitive information in the Adviser’s possession.
 
 
45
A disaster or a disruption in the infrastructure that supports the Adviser’s business, including a disruption involving Electronic Communications or other services used by the Adviser or third parties with whom the Adviser conducts business, or directly affecting the Adviser’s headquarters, could have a material adverse impact on the Adviser’s ability to continue to operate its business without interruption and to protect the Company, insofar as is practicable, from the hazards of cybersecurity threats and vulnerabilities in accordance with applicable legal requirements and guidance. The Adviser’s disaster recovery programs may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse the Adviser for its losses, if at all.
Although the Company is not currently aware of any cyber-attacks or other incidents that, individually or in the aggregate, have materially affected, or would reasonably be expected to materially affect, its operations or financial condition, there has been an increase in the frequency and sophistication of the cyber and security threats faced in the marketplace. Cyber-attacks and other security threats could originate from a wide variety of sources, including cyber criminals, nation state hackers, hacktivists and other outside or inside parties. The Company may be a target for attacks because, as a specialty finance company, it holds confidential and other sensitive information, including price information, about existing and potential investments. Further, the Company is dependent on third-party vendors for hosting hardware, software and data processing systems that it does not control. The Company also relies on third-party Service Providers for certain aspects of its business, including for certain information systems, technology and administration of its Portfolio Investments and compliance matters. While the Company relies on the cybersecurity strategy and policies implemented by the Adviser, its reliance on the Adviser and third-party Service Providers removes certain cybersecurity functions from outside of the Company’s immediate control, and cyber-attacks on the Adviser, on the Company or on third-party Service Providers could adversely affect the Company, its business, and its reputation. The costs related to cyber-attacks or other security threats or disruptions may not be fully insured or indemnified by others, including by the
Company’s
third-party providers.
As the Company’s reliance on computer hardware and software systems, data processing systems, and other technology has increased, so have the risks posed to such systems, both those the Adviser controls and those provided by third-party vendors. Cyber-attacks may originate from a wide variety of sources, and while the Adviser has implemented processes, procedures, and internal controls designed to mitigate cybersecurity risks and cyber-attacks, these measures do not guarantee that a cyber-attack will not occur or that the Company’s financial results, operations, or confidential information, personal, or other sensitive information will not be negatively impacted by such an incident, especially because the techniques of threat actors change frequently and are often not recognized until launched. The Adviser relies on industry accepted security measures and technology to securely maintain confidential and proprietary information maintained on its information systems, as well as on policies and procedures to protect against the unauthorized or unlawful disclosure of confidential, personal, or other sensitive information. Although the Adviser takes protective measures and endeavors to strengthen its computer systems, software, technology assets, and networks to prevent and address potential cyber-attacks, there can be no assurance that any of these measures prove effective. The Adviser expects to be required to devote increasing levels of funding and resources, which may in part be allocated to the Company, to comply with evolving cybersecurity and privacy laws and regulations and to continually monitor and enhance its cybersecurity procedures and controls. In addition, the Company, the Adviser, the Administrative Coordinator, or their employees, if any, may also be the target of fraudulent emails or other targeted attempts to gain unauthorized access to confidential, personal, or other sensitive information. The result of any cyber-attack or other security incidents may include disrupted operations, misstated or unreliable financial data, fraudulent transfers or requests for transfers of money, liability for stolen information (including personal information), investigations, misappropriation of assets, increased cybersecurity protection and insurance costs, litigation and damage to the Company’s business relationships, regulatory fines or penalties, or other adverse effects on its business, financial condition or results of operations. The Adviser may be required to expend significant additional resources to modify its protective measures and to investigate and remediate vulnerabilities or other exposures arising from operational and security risks related to cyber-attacks. The rapid evolution and increasing prevalence of artificial intelligence technologies may also increase cybersecurity risks.
In addition, cybersecurity has become a top priority for global lawmakers and regulators around the world, and some jurisdictions have proposed or enacted laws requiring companies to notify regulators and individuals of data security breaches involving certain types of personal data. In particular, state and federal laws and regulations related to cybersecurity compliance continue to evolve and change, which may require substantial investments in new technology, software and personnel, which could affect the Company’s profitability. These changes may also result in enhanced and unforeseen consequences for cyber- related breaches and incidents, which may further adversely affect the Company’s profitability. If the Adviser fails to comply with the relevant and increasing laws and regulations, the Adviser could suffer financial losses, a disruption of its businesses, liability to investors, regulatory intervention or reputational damage.
 
46

Policies of remote working, whether by the Adviser, the Administrative Coordinator, the Company or by their respective Service Providers, could strain technology resources, introduce operational risks and otherwise heighten the risks described above. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts.
Cybersecurity risks are exacerbated by the rapidly increasing volume of highly sensitive data, including the Company’s proprietary business information, personal information of the Adviser’s employees, the Company’s investors and others, and other sensitive information that the Adviser collects, processes, and stores in its data centers and on its networks or those of third-party Service Providers. The secure processing, maintenance, and transmission of this information are critical to the Company’s operations. There is a risk that encryption and other protective measures against cyber-attacks may be circumvented, particularly to the extent that new computing technologies increase the speed and computing power available. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and, in fact, may not be detected. A significant actual or potential theft, loss, corruption, exposure, fraudulent use or misuse of investor or other personal information, proprietary business data or other sensitive information, whether by third parties or as a result of malfeasance by the Adviser’s employees or otherwise,
non-compliance
with applicable contractual or other legal obligations regarding such data or intellectual property or a violation of applicable privacy and security policies with respect to such data could result in significant investigation, remediation and other costs, fines, penalties, litigation or regulatory actions against the Company and significant reputational harm, any of which could harm the Company’s business and results of operations. Cybersecurity risks require continuous and increasing attention and other resources from the Adviser to, among other actions, identify and quantify these risks and upgrade and expand its technologies, systems and processes to adequately address such risks. Such attention diverts time and other resources from other activities and there is no assurance that the Adviser’s efforts will be effective.
Cybersecurity incidents may adversely impact the Company and its Unitholders. There is no guarantee that the Company, the Adviser, and/or their respective Service Providers will be successful in protecting against cybersecurity incidents.
Financial Services Industry Risks
. Cash not held in custody accounts and held by the Company, the Adviser and the Portfolio Investments in
non-interest-bearing
and interest-bearing operating accounts could, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, the Company, the Adviser, or the Portfolio Investments could lose all or a portion of those amounts held in excess of such insurance limits. In addition, actual events involving limited liquidity, defaults,
non-performance
or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect the Company, the Adviser’s and the Portfolio Investments’ business, financial condition, results of operations, or prospects.
Although the Company and the Adviser assess its and the Portfolio Investments’ banking and financing relationships as the Company believes necessary or appropriate, the Company and the Portfolio Investments’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which the Company, the Adviser or the Portfolio Investments have arrangements directly or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company, the Adviser or the Portfolio Investments have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.
In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for the Company, the Adviser, or the Portfolio Investments to acquire financing on acceptable terms or at all.
Technological Innovation Risks
. Technological innovations have disrupted traditional approaches in multiple industries and can permit younger companies to achieve success and in the process disrupt markets and market practices. The Company can provide no assurance that new businesses and approaches will not be created that would compete with the Company and/or its Portfolio Investments or alter the market practices in which the Adviser and its affiliates and the Company have been designed to function within and on which the Company depends on for its investment return. New approaches could damage the Company’s investments, disrupt the market in which it operates and subject it to increased competition, which could materially and adversely affect the Company’s business, financial condition and results of investments.
 
 
47

Machine Learning Technology Risks
. Recent technological advances in artificial intelligence and machine learning technology (“Machine Learning Technology”) pose risks to the Company and its Portfolio Investments. The Company and its Portfolio Investments could be exposed to the risks of Machine Learning Technology if third-party service providers or any counterparties use Machine Learning Technology in their business activities. The Company and the Adviser are not in a position to control the use of Machine Learning Technology in third-party products or services. Use of Machine Learning Technology could include the input of confidential information in contravention of applicable policies, contractual or other obligations or restrictions, resulting in such confidential information becoming part accessible by other third-party Machine Learning Technology applications and users. Machine Learning Technology and its applications continue to develop rapidly, and the Company cannot predict the risks that may arise from such developments.
Machine Learning Technology is generally highly reliant on the collection and analysis of large amounts of data, and it is not possible or practicable to incorporate all relevant data into the model that Machine Learning Technology utilizes to operate. Certain data in such models will inevitably contain a degree of inaccuracy and error and could otherwise be inadequate or flawed, which would be likely to degrade the effectiveness of Machine Learning Technology. To the extent the Company or its Portfolio Investments are exposed to the risks of Machine Learning Technology use, any such inaccuracies or errors could adversely impact the Company or its Portfolio Investments.
Corporate Social Responsibility Risks
. The Company’s business (including that of its Portfolio Investments) faces increasing public scrutiny related to environmental, social and governance (“ESG”) activities, which are increasingly considered to contribute to reducing a company’s operational risk, market risk and reputational risk, which may in turn impact the long-term sustainability of a company’s performance. A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG ratings and measures to their investment decisions.
The Company risks damage to its brand and reputation if it fails to act responsibly in a number of areas, including, but not limited to, diversity, equity and inclusion, human rights, climate change, environmental stewardship, support for local communities, corporate governance, transparency and consideration of ESG factors in the Company’s investment processes. Adverse incidents with respect to ESG activities could impact the value of the Company’s brand, its relationship with existing and future Portfolio Investments, the cost of the Company’s operations and relationships with investors, all of which could adversely affect its business and results of operations.
However, regional and investor specific sentiment may differ in what constitutes a material positive or negative ESG corporate practice. There is no guarantee that the Company’s ESG and sustainability practices will uniformly fit every investor’s definition of best practices for all environmental, social and governance considerations across geographies and investor types. If we do not successfully manage expectations across varied stakeholder interests, it could erode stakeholder trust, impact our reputation and constrain our investment opportunities.
There is also a growing regulatory interest across jurisdictions in improving transparency regarding the definition, measurement and disclosure of ESG factors in order to allow investors to validate and better understand sustainability claims. For example, the SEC has proposed, or has announced that it is working on proposals for, rules that, among other matters, would establish a framework for reporting of climate-related risks, corporate and fund carbon emissions, broad diversity and capital management. At this time, there is uncertainty regarding the scope of such proposals or when they would become effective (if at all). In 2021, the SEC established an enforcement task force to look into ESG practices and disclosures by public companies and investment managers and has started to bring enforcement actions based on ESG disclosures not matching actual investment processes. Further, in 2022 the SEC issued a proposed rule regarding the enhancement and standardization of mandatory climate-related disclosures for investors that would mandate extensive disclosure of climate-related data, risks and opportunities for certain public companies.
The Company and its Portfolio Investments are subject to the risk that similar measures might be introduced in other jurisdictions in the future. Additionally, compliance with any new laws or regulations increases the Company’s regulatory burden and could make compliance more difficult and expensive, affect the manner in which the Company or its Portfolio Investments conduct its businesses and adversely affect the Company’s profitability.
Climate Change Risks
. There may be evidence of global climate change. Climate change creates physical and financial risk and some of the Company’s Portfolio Investments may be adversely affected by climate change. For example, the needs of customers of energy companies vary with weather conditions, primarily temperature and humidity. To the extent weather conditions are affected by climate change, energy use could increase or decrease depending on the duration and magnitude of
 
48

any changes. Increases in the cost of energy could adversely affect the cost of operations of the Company’s Portfolio Investments if the use of energy products or services is material to their business. A decrease in energy use due to weather changes may affect some of the Company’s Portfolio Investments’ financial condition, through decreased revenues. Extreme weather conditions in general require more system backup, adding to costs, and can contribute to increased system stresses, including service interruptions. Energy companies could also be affected by the potential for lawsuits against or taxes or other regulatory costs imposed on greenhouse gas emitters, based on links drawn between greenhouse gas emissions and climate change.
In December 2015 the United Nations, of which the U.S. is a member, adopted a climate accord with the long-term goal of limiting global warming and the short-term goal of significantly reducing greenhouse gas emissions. As a result, some of the Company’s Portfolio Investments may become subject to new or strengthened regulations or legislation, which could increase their operating costs and/or decrease their revenues.
Risks Related to RICs and BDCs
Failure to Qualify as a RIC
. Although the Company has obtained qualification as a RIC, no assurance can be given that it will be able to maintain qualification as a RIC. To maintain qualification as a RIC, the Company must meet
source-of-income, asset
diversification, and distribution requirements on an ongoing basis.
The income source requirement will be satisfied if the Company obtains at least 90% of gross income for each year from dividends, interest, foreign currency, payments with respect to loans of certain securities, gains from the sale of Units or other securities, net income from certain “qualifiedpublicly traded partnerships,” or similar sources.
The asset diversification requirement will be satisfied if the Company meets certain asset diversification requirements at the end of each quarter of the taxable year. Failure to meet those requirements may result in the Company having to dispose of certain investments quickly in order to prevent the loss of qualification as a RIC. Because most of the Company’s investments will be relatively illiquid, any such dispositions could be made at disadvantageous prices and could result in substantial losses.
The annual distribution requirement will be satisfied if the Company distributes to its Unitholders on an annual basis at least 90% of net ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any. Because the Company may use debt financing, it is subject to certain asset coverage ratio requirements under the 1940 Act and financial covenants under loan and credit agreements that could, under certain circumstances, restrict the Company from making distributions necessary to satisfy the distribution requirement. If the Company is unable to obtain cash from other sources, it could fail to qualify as a RIC.
If the Company fails to qualify as a RIC for any reason and therefore becomes subject to corporate income tax, the resulting corporate taxes could substantially reduce net assets, the amount of income available for distribution and the amount of distributions.
Recognizing Income Before or Without Receiving Cash
. For U.S. federal income tax purposes, the Company will include in income certain amounts that the Company has not yet received in cash, such as the accrual of original issue discount (“OID”). This may arise if the Company receives warrants in connection with the making of a loan and in other circumstances, or
through contracted payment-in-kind (“PIK”) interest,
which represents contractual interest added to the loan balance and due at the end of the loan term. Such OID, which could be significant relative to the Company’s overall investment activities, and increases in loan balances as a result of contracted PIK arrangements will be included in income before the Company receives any corresponding cash payments. The Company also may be required to include in income certain other amounts that the Company will not currently receive in cash.
Since in certain cases the Company may recognize income before or without receiving cash representing such income, the Company may have difficulty meeting the requirement to timely distribute at least 90% of its net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any, to maintain its qualification as a RIC. In such a case, the Company may have to sell some of its Portfolio Investments at times the Company would not consider advantageous or raise additional debt or equity capital or reduce new investment originations to meet these distribution requirements. If the Company is not able to obtain cash from other sources and is otherwise unable to satisfy such distribution requirement, the Company may fail to maintain its qualification as a RIC and become subject to corporate-level U.S. federal income tax.
 
 
49

Tax Considerations Regarding Dividends for Private BDCs
. The Company does not currently qualify as a “publicly offered regulated investment company,” as defined in the Code. Accordingly, U.S. individual and other noncorporate Unitholders will be taxed as though they received a distribution of some of the Company’s expenses. A “publicly offered regulated investment company” is a RIC whose Units are either (i) continuously offered pursuant to a public offering, (ii) regularly traded on an established securities market, or (iii) held by at least 500 persons at all times during the taxable year. The Company anticipates that it will not qualify as a publicly offered RIC for the 2023 tax year, and cannot determine when it will qualify as a publicly offered RIC. Since the Company is not a publicly offered RIC,
a non-corporate Unitholder’s
allocable portion of the Company’s affected expenses, including a portion of its management fees, will be treated as an additional distribution to the Unitholders.
A non-corporate Unitholder’s
allocable portion of these expenses are treated as miscellaneous itemized deductions that are not currently deductible by such Unitholder (and beginning in 2026, will be deductible by such Unitholder for regular U.S. federal income tax purposes but not for alternative minimum tax purposes only to the extent they exceed 2% of such Unitholder’s adjusted gross income).
Potential Dividend Deferrals
. In order to maintain its tax status as a RIC, the Company must distribute to Unitholders for each taxable year at least 90% of its investment company taxable income (i.e., net ordinary income plus realized net short-term capital gains in excess of realized net long-term capital losses). If the Company qualifies for taxation as a RIC, it generally will not be subject to corporate-level U.S. federal income tax on its investment company taxable income and net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) that it timely distributes to Unitholders. The Company will be subject to a 4% U.S. federal excise tax on undistributed earnings of a RIC unless it distributes each calendar year at least the sum of (i) 98.0% of its ordinary income for the calendar year, (ii) 98.2% of its capital gains in excess of capital losses for
the one-year period
ending on October 31 of the calendar year, and (iii) any ordinary income and net capital gains for preceding years that were not distributed during such years and on which it paid no U.S. federal income tax.
Under the Code, the Company may pay certain RIC dividends after the end of the current year. In particular, if the Company pays a distribution in January of the following year that was declared in October, November, or December of the current year and is payable to Unitholders of record in the current year, the dividend will be treated for all U.S. federal income tax purposes as if it were paid on December 31 of the current year. In addition, under the Code, the Company may pay dividends, referred to as “spillover dividends,” that are paid during the following taxable year that will allow the Company to maintain its qualification for taxation as a RIC and eliminate its liability for corporate-level U.S. federal income tax. Under these spillover dividend procedures, the Company may defer distributions of income earned during the current year until December of the following year. For example, the Company may defer distributions of income earned during 2024 until as late as December 31, 2025. If the Company chooses to pay a spillover dividend, it will incur the 4% U.S. federal excise tax on some or all of the distribution.
Due to events such as
the COVID-19 pandemic,
certain regional bank failures, the Russian invasion of Ukraine, the ongoing war in the Middle East or other disruptions in the economy, such as the recent inflationary environment, the Company may take certain actions with respect to the timing and amounts of its distributions in order to preserve cash and maintain flexibility. For example, the Company may reduce and/or defer dividends to the following year as discussed above. To further preserve cash, the Company may combine these deferrals of dividends with one or more distributions that are payable partially in Units as discussed below under “
In-Kind
 Dividend Considerations
.”
In-Kind
 Dividend Considerations
. The Company may distribute taxable dividends that are payable in part in Units. In accordance with certain applicable U.S. Treasury regulations and published IRS guidance, a RIC may treat a distribution of its own shares as fulfilling the RIC distribution requirements if each Unitholder may elect to receive the entire distribution in either cash or shares of the RIC. The IRS has published a revenue procedure indicating that, in the case of publicly offered RICs, this rule will apply where the total amount of cash to be distributed is not less than 20% of the total distribution. Under this revenue procedure, if too many Unitholders elect to receive cash, the cash available for distribution must be allocated among the Unitholders electing to receive cash (with the balance of the distribution paid in Units). Because the Company is not currently a publicly offered RIC, its ability to rely on the revenue procedure and other guidance is uncertain. If the Company elects to pay a distribution in its own Units consistent with the revenue procedure and other guidance, for U.S. federal income tax purposes, the amount of the dividend paid in Units will be equal to the amount of cash that could have been received instead of Units. Taxable Unitholders receiving such dividends will be required to include the amount of the dividends as ordinary income (or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of the Company’s current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a Unitholder may be required to pay tax with respect to such dividends in excess of any cash received, and, the Company may be required to withhold U.S. tax with respect to dividends payable in Units
to non-U.S. Unitholders.
Changes in Tax Law
. Legislative or other actions relating to taxes could have a negative effect on the Company. The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. New legislation and any other tax law developments including new or revised U.S. Treasury regulations, administrative interpretations or court decisions, could negatively and perhaps retroactively affect the U.S. federal income tax consequences to the Company and its Unitholders, or could have other adverse consequences. Investors are urged to consult with their tax advisor regarding tax legislative, regulatory, or administrative developments and proposals and their potential effect on an investment in the Company.
 
50

Permissible Incurred Leverage
. Leverage magnifies the potential for loss on investments and on invested equity capital. As the Company uses leverage to partially finance its investments, Unitholders will experience increased risks of investing in the Company’s securities. If the value of the Company’s assets increases, then leveraging would cause the NAV attributable to the Company’s Units to increase more sharply than it would have had the Company not leveraged. Conversely, if the value of the Company’s assets decreases, leveraging would cause NAV to decline more sharply than it otherwise would have had the Company not leveraged its business. Similarly, any increase in the Company’s income in excess of interest payable on the borrowed funds would cause net investment income to increase more than it would without the leverage, while any decrease in the Company’s income would cause net investment income to decline more sharply than it would have had the Company not borrowed. Such a decline could negatively affect the Company’s ability to pay dividends on Units, scheduled debt payments or other payments related to securities. Leverage is generally considered a speculative investment technique.
Distribution and Asset Coverage Ratio Requirements
. In order to satisfy the requirements applicable to RICs and to avoid payment of excise taxes, the Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain net income except for certain net capital gains, which it intends to retain and to elect to treat as deemed distributions to Unitholders. The Company may issue debt securities, other evidences of indebtedness or preferred Units, and may borrow money from banks or other financial institutions, which are referred to collectively herein as “senior securities,” up to the maximum amount permitted by the 1940 Act. The 1940 Act permits the Company to issue senior securities in
amounts
such that its asset coverage, as defined in the 1940 Act, equals at least 150% after each issuance of senior securities. The Company’s ability to pay dividends or issue additional senior securities would be restricted if the asset coverage ratio were not at least 150%. If the value of the Company’s assets declines, the Company may be unable to satisfy this test. If that happens, the Company may be required to liquidate a portion of its investments and repay a portion of its indebtedness at a time when such sales or repayment may be disadvantageous. As a result of issuing senior securities, the Company will also be exposed to typical risks associated with leverage, including an increased risk of loss. If the Company issues preferred Units, such preferred Units will rank “senior” to common Units in the Company’s capital structure, preferred Unitholders will have separate voting rights for certain purposes and may have rights, preferences or privileges more favorable than those of the Company’s common Units and the issuance of preferred Units could have the effect of delaying, deferring or preventing a transaction or a change of control that might involve a premium price for Unitholders or otherwise be in the best interest of Unitholders.
To the extent the Company is constrained in its ability to issue debt or other senior securities, it will depend on issuances of capital interests to finance operations. As a BDC, the Company is generally not able to issue Units at a price below NAV without first obtaining required approvals of Unitholders and independent directors in accordance with the conditions set forth in Section 63(2) of the 1940 Act. If the Company raises additional funds by issuing more common Units or senior securities convertible into, or exchangeable for, common Units, the percentage ownership of Unitholders at that time would decrease and Unitholders may experience dilution. In addition to issuing securities to raise capital as described above, the Company could, in the future, securitize loans to generate cash for funding new investments. An inability to successfully securitize its loan portfolio could limit the Company’s ability to grow its business, fully execute its business strategy and improve profitability.
Unrealized Depreciation
. As a BDC, the Company is required to carry investments at market value or, if no market value is ascertainable, at fair value as determined in good faith by the Board. Decreases in the market values or fair values of investments will be recorded as unrealized depreciation. Any unrealized depreciation in the Company’s loan portfolio could be an indication of a Portfolio Investment’s inability to meet its repayment obligations with respect to the loans whose market values or fair values decreased. This could result in realized losses in the future and ultimately in reductions of income available for distribution in future periods.
Qualifying Asset Requirements
. As a BDC, the Company may not acquire any assets other than “qualifying assets” unless, at the time of such acquisition, at least 70% of its total assets are qualifying assets. Therefore, the Company may be precluded from investing in what it believes are attractive investments if such investments are not qualifying assets. Similarly, these rules could prevent the Company from making additional investments in existing Portfolio Investments, which could result in the dilution of its position, or could require disposal of investments at an inopportune time to comply with the 1940 Act. If the Company were forced to
sell non-qualifying investments
for compliance purposes, the proceeds from such sale could be significantly less than the current value of such investments. Conversely, if the Company failed to invest a sufficient portion of assets in qualifying assets, it could lose status as a BDC, which would subject the Company to substantially more regulatory restrictions and significantly decrease operating flexibility.
 
51

Regulatory Risks Relating to the Company
Exemptive Relief
. The Company and the other BDCs for which SLR is the investment adviser (SLR Investment Corp. (Nasdaq: SLRC) (“SLRC”), SCP Private Credit Income BDC LLC (“PCI BDC”) and SLR Private Credit BDC II LLC (“PC BDC,” and, together with SLRC and PCI BDC, the “SLR BDCs”) are substantially limited in their
ability to co-invest in privately
negotiated transactions with affiliated funds other than as permitted by the Order. While the Order permits the Company to participate
in negotiated co-investment transactions with
the SLR BDCs and other affiliated funds, such participation is subject to numerous conditions. If the Company and the SLR BDCs are unable to comply with these conditions or are otherwise unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although SLR will endeavor to allocate investment opportunities in a fair and equitable manner, the Company could be adversely affected to the extent investment opportunities are allocated among the Company and other investment vehicles managed or sponsored by, or affiliated with SLR and its affiliates, including the SLR BDCs, pursuant to the conditions of the Order.
Regulatory Risks Relating to the Company
. Legal and regulatory changes could occur during the term of the Company that may adversely affect the Company. The Company may be subject to, and adversely affected by, new federal, state or non-U.S. laws or new regulation by the SEC, the Commodity Futures Trading Commission (the “CFTC”), the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the FDIC, the European Commission and other federal, state and
non-U.S.
securities or banking regulators, and other governmental regulatory authorities or self-regulatory organizations that supervise the financial markets. The Company may also be adversely affected by changes in the enforcement or interpretation of existing statutes and rules by courts and/or these governmental regulatory authorities or self-regulatory organizations. For example, a recent court decision casts doubt on whether federal or state usury laws apply with respect to loans originated by national banks and then sold to
non-bank
investors such as the Company; this decision could significantly disrupt the bank loan secondary market and adversely impact the Company’s investment program. In addition, the approach taken by a federal court in the “Sun Capital” decision may significantly expand the scope of potential joint and several liability for pension obligations of portfolio companies commonly held by affiliated funds; this decision could create significant uncertainty with respect to such investments and adversely impact the Company. Moreover, legal and regulatory changes may adversely affect the Company’s ability to obtain financing by (among other things) reducing the availability of financing and/or adversely impacting financing costs and other terms.
The financial services industry is subject to extensive regulation. Banking regulators have broad and largely discretionary powers, which include prohibiting “unsafe or unsound” practices; requiring affirmative actions to correct any violation or practice; issuing administrative orders that can be judicially enforced; directing increases in capital; directing the sale of subsidiaries or other assets; limiting dividends and distributions; restricting growth; assessing civil monetary penalties; removing officers and directors; and terminating deposit insurance. These actions and other regulatory requirements could have a material adverse effect on an investment in the Company. The financial institutions in which the Company will invest and with which the Company will transact are subject to laws, regulations, administrative actions and policies in each location in which they operate. The regulatory environment for private investment funds is evolving, and changes in the regulation or taxation of private investment funds may adversely affect the value of the investments held by the Company and the ability of the Company to execute its investment strategy.
In addition, the securities and futures markets are subject to comprehensive statutes, regulations and margin requirements. The SEC and
other U.S. and non-U.S. regulators, self-regulatory organizations
and exchanges are authorized to take extraordinary actions in the event of market emergencies. The regulation of derivatives transactions and funds that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action. The effect of any future regulatory change on the Company could be substantial and adverse.
Risks Related to Changes in Regulatory Policy
. The U.S. government has recently called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new and
difficult-to-quantify
macroeconomic and political risks with potentially
far-reaching
implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas.
 
52

Financial Services and Government Intervention
. From time to time, certain governments and regulatory authorities, such as the U.S. federal government, the U.S. Federal Reserve and the governments and regulatory authorities of certain member countries of the EU, have taken actions to provide or arrange credit support to financial institutions whose operations have been compromised by credit market dislocations and to restore liquidity and stability to the financial system in such jurisdictions. The implementation of any current or future governmental interventions (which may be significantly altered or terminated prior to implementation or during their terms), and their impact on both the credit markets generally and the Company’s investment program in particular, are uncertain.
U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act
. In response to the recent disruption in the credit markets and the global economic downturn, various agencies and regulatory bodies of the U.S. federal government have taken or are considering taking various actions. These actions include, but are not limited to, the enactment of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), which was signed into law on July 21, 2010, and which imposes a new regulatory framework over the U.S.
financial services industry, non-U.S. financial entities
that are regulated by or affiliated with entities regulated by U.S. financial regulators, and the consumer credit markets in general, and proposed and final regulations adopted thereunder, as well as proposed and final regulations to implement the Basel III regulatory capital accords. Given the broad scope and sweeping nature of these changes and the fact that certain final implementing rules and regulations have not yet been adopted or implemented, the potential impact of these actions on the Adviser and the Company is unknown, and no assurance can be made that the impact of such changes would not have a material adverse effect on the Adviser or the Company. For example, the U.S. Financial Stability Oversight Council (“FSOC”) created by the Dodd-Frank Act has the authority to designate asset management firms as a “systemically important financial institution” (“SIFI”). If the Adviser, or one of its affiliates, were designated as a SIFI, it would be subject to a variety of regulations, including capital requirements and limitations on leverage, which could have a material adverse effect on the ability of the Company to pursue its investment strategy. In addition, the Dodd-Frank Act created a new regulator for the credit industry in the U.S. known as the U.S. Consumer Financial Protection Bureau (“CFPB”). The CFPB may, among other things, regulate interest rates and other charges, require certain disclosures and regulate foreclosure practices. Future regulatory actions authorized by the Dodd-Frank Act (including any regulatory actions or other measures taken by the FSOC and/or the CFPB) may significantly reduce the profitability of the Company and its Portfolio Investments.
Changes to Derivatives Regulation
. Through comprehensive new global regulatory regimes impacting derivatives (
e.g.
, the Dodd-Frank Act, European Market Infrastructure Regulation (“EMIR”), Markets in Financial Investments Regulation (“MIFIR”)/Markets in Financial Instruments Directive
(“MIFID II”)), certain over-the-counter derivatives transactions
in which the Company may engage are either now or will soon be subject to various requirements, such as mandatory central clearing of transactions which include additional margin requirements and in certain cases trading on electronic platforms,
pre-and
post-trade transparency reporting
requirements and mandatory bi-lateral exchange of
initial margin for non-cleared swaps.
The Dodd-Frank Act also created new categories of regulated market participants, such as “swap dealers,” “security-based swap dealers,” “major swap participants,” and “major security-based swap participants” who are subject to significant new capital, registration, recordkeeping, reporting, disclosure, business conduct and other regulatory requirements. The EU and some other jurisdictions are implementing similar requirements. Because these requirements are new and evolving (and some of the rules are not yet final), their ultimate impact remains unclear. However, even if the Company itself is not located in a particular jurisdiction or directly subject to the jurisdiction’s derivatives regulations, the Company may still be impacted to the extent the Company enters into a derivatives transaction with a regulated market participant or counterparty that is organized in that jurisdiction or otherwise subject to that jurisdiction’s derivatives regulations.
Based on information available as of the date of this annual report
on Form 10-K, the
effect of such requirements will be likely to (directly or indirectly) increase the Company’s overall costs of entering into derivatives transactions. In particular, new margin requirements, position limits and significantly higher capital charges resulting from new global capital regulations, even if not directly applicable to the Company, may cause an increase in the pricing of derivatives transactions entered into by market participants to whom such requirements apply or affect the overall ability of the Company to enter into derivatives transactions with certain counterparties. Such new global capital regulations and the need to satisfy the various requirements by counterparties are resulting in increased funding costs and increased overall transaction costs and are significantly affecting balance sheets, thereby resulting in changes to financing terms and potentially impacting the Company’s ability to obtain financing. Administrative costs, due to new requirements such as registration, recordkeeping, reporting, and compliance, even if not directly applicable to the Company, may also be reflected in the Company’s derivatives transactions. New requirements to trade certain derivatives transactions on electronic trading platforms and trade reporting requirements may lead to (among other things) fragmentation of the markets, higher transaction costs or reduced availability of derivatives, and/or a reduced ability to hedge, all of which could adversely affect the performance of certain of the Company’s investing strategies. In addition, changes to derivatives regulations may impact the tax and/or accounting treatment of certain derivatives, which could adversely impact the Company.
 
53

In November 2020, the SEC adopted new rules regarding the ability of a BDC (or a registered investment company) to use derivatives and other transactions that create future payment or delivery obligations. BDCs that use derivatives will be subject to a
value-at-risk
leverage limit, certain other derivatives risk management program and testing requirements and requirements related to board reporting. These new requirements would apply unless the BDC qualified as a “limited derivatives user,” as defined in the adopted rules. A BDC that enters into reverse repurchase agreements or similar financing transactions would need to aggregate the amount of indebtedness associated with the reverse repurchase agreements or similar financing transactions and could either (i) comply with the asset coverage requirements of Section 18 of the 1940 Act when engaging in reverse repurchase agreements or (ii) choose to treat such agreements as derivative transactions under the adopted rules. Under the adopted rules, a BDC may enter into an unfunded commitment agreement that is not a derivatives transaction, such as an agreement to provide financing to a Portfolio Investment, if the BDC has a reasonable belief, at the time it enters into such an agreement, that it will have sufficient cash and cash equivalents to meet its obligations with respect to all of its unfunded commitment agreements, in each case as it becomes due. If the BDC cannot meet this test, it is required to treat unfunded commitments as a derivatives transaction subject to the requirements of the rule. Collectively, these requirements may limit the Company’s ability to use derivatives and/or enter into certain other financial contracts.
Uncertainty of the U.S. Political Climate
. The current administration has called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new
and difficult-to-quantify
macroeconomic and political risks with
potentially far-reaching
implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although the Company cannot predict the impact, if any, of these changes to its business, they could adversely affect the Company’s business, financial condition, operating results and cash flows. Until the Company knows what policy changes are made and how those changes impact its business and the business of the Company’s competitors over the long term, the Company will not know if, overall, it will benefit from them or be negatively affected by them.
Bad Actor” Restrictions for Private Placements Conducted Under Rule 506 of Regulation D
. An issuer is precluded from conducting offerings that rely on the exemption from registration under the Securities Act provided by Rule 506 of Regulation D (“Rule 506 Offerings”) if a “covered person” of the issuer has been the subject of a “disqualifying event” (each as defined below). “Covered persons” include, among others, the issuer, affiliated issuers, any investment manager or solicitor of the issuer, any director, executive officer or other officer participating in the offering of the issuer, any general partner or managing member of the foregoing entities, any promoter of the issuer and any beneficial owner of 20% or more of the issuer’s outstanding voting equity securities, calculated on the basis of voting power. A “disqualifying event” includes, among other things, certain (a) criminal convictions and court injunctions and restraining orders issued in connection with the purchase or sale of a security or false filings with the SEC, (b) final orders from the CFTC, U.S. Federal banking agencies and certain other regulators that bar a person from associating with a regulated entity or engaging in the business of securities, insurance or banking or that are based on certain fraudulent conduct, (c) SEC disciplinary orders relating to investment advisers, brokers, dealers and their associated
persons, (d) SEC cease-and-desist orders relating
to violations of certain anti-fraud provisions and registration requirements of the U.S. federal securities laws, (e) suspensions or expulsions from membership in a self-regulatory organization (“SRO”) or from association with an SRO member, and (f) U.S. Postal Service false representation orders.
A disqualification will occur only in the case of a disqualifying event of a covered person that occurs on or after September 23, 2013, although issuers must disclose to potential investors in a Rule 506 Offering disqualifying events of covered persons that occurred before September 23, 2013. The rule provides an exception from disqualification if the issuer can show that it did not know and, in the exercise of reasonable care could not have known, that the issuer or any other covered person had a disqualifying event, although an issuer will not be able to establish that it has exercised reasonable care unless it has made, in light of the circumstances, factual inquiry into whether any disqualifications exist.
The Adviser has made, and on a periodic basis will continue to make, inquiries into whether any persons that the Adviser has determined to be affiliated issuers have been subject to any disqualifying events; however, in some circumstances the Adviser’s ability to determine whether the Company would be disqualified from relying on Rule 506 may depend on cooperation of third parties over whom the Company may have limited control and influence.
If any of the Adviser’s covered persons, including any affiliated issuer of the Company, is subject to a disqualifying event, the Company could lose the ability to raise capital in a future Rule 506 offering for a significant period of time and the Company’s business, financial condition and results of operations could be materially and adversely affected.
 
54

Changes to Accounting Standards
. The Financial Accounting Standards Board’s Accounting Codification Standards and updates, and additional provisions of U.S. generally accepted accounting principles (“U.S. GAAP”) (or to the extent applicable, International Financial Reporting Standards or other applicable accounting or financial reporting standards), that may be adopted in the future may impose additional, or different, specific requirements as to the valuation of assets and liabilities for purposes of U.S. GAAP-compliant financial reporting.
Licensing Requirements
. Various licensing requirements could apply to the Company or the Adviser with respect to investments in, or the origination, holding, servicing and disposing of, loans and similar assets. The licensing requirements could apply depending on the location of the borrower, the location of the collateral securing the loan, or the location where the Company or the Adviser operates or has offices. Moreover, the Company’s ability to invest in certain properties, participate in the secondary mortgage market, obtain financing for investments, lease properties to tenants and/or engage in lending, advisory, servicing and/or broker activities may be subject to the issuance of permits or licenses. If the Company applies for such licenses, this process may be costly and take several months. There is no assurance that the Company will obtain all of the licenses that it desires or that the Company would not experience significant delays in seeking these licenses. In states and other jurisdictions in which it is licensed, the Company or the Adviser is required to comply with applicable laws and regulations, including possible information requirements and consumer protection and anti-fraud laws, which could impose restrictions on the Company’s or the Adviser’s ability to take certain actions to protect the value of its investments in such assets and impose compliance costs. Failure to comply with such laws and regulations could lead to, among other penalties, a loss of the Company’s or the Adviser’s license, which in turn could restrict the Company’s investment options or require the Company to divest assets located in or secured by real property located in that jurisdiction. These risks also apply to issuers and entities in which the Company invests that hold similar assets, as well as any origination company or servicer in which the Company owns an interest.
Reporting Company Filing Requirements
. As a BDC, the Company is subject to the reporting requirements of the 1934 Act and requirements of the Sarbanes-Oxley Act. These requirements may place a strain on systems and resources. The 1934 Act requires that the Company file annual, quarterly and current reports with respect to business and financial condition. The Sarbanes-Oxley Act requires that the Company maintain effective disclosure controls and procedures and internal controls over financial reporting, which are discussed below. In order to maintain and improve the effectiveness of disclosure controls and procedures and internal controls, significant resources and management oversight are required. The Company has implemented procedures, processes, policies and practices for the purpose of addressing the standards and requirements applicable to reporting companies. These activities may divert management’s attention from other business concerns, which could have a material adverse effect on business, financial condition, results of operations and cash flows. The Company incurs significant additional annual expenses related to these steps and, among other things, directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, additional administrative expenses payable to the Administrative Coordinator to compensate them for hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses.
The systems and resources necessary to comply with public company reporting requirements will increase further once the Company ceases to be an “emerging growth company” under the JOBS Act. As long as the Company remains an emerging growth company, it intends to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. The Company will remain an emerging growth company for up to five years following any future IPO (however, the Company does not anticipate engaging in an IPO of its Units), although if the market value of the Units that are held by
non-affiliates
exceeds $700 million as of any June 30 before that time, the Company would cease to be an emerging growth company as of the following December 31.
Additionally, because the Units are registered under the 1934 Act, ownership information for any person who beneficially owns 5% or more of the Units will have to be disclosed in a Schedule 13G or other filings with the SEC. Beneficial ownership for these purposes is determined in accordance with the rules of the SEC, and includes having voting or investment power over the securities. In some circumstances, Unitholders who choose to reinvest their dividends may see their percentage stake in the Company increased to more than 5%, thus triggering this filing requirement. Each Unitholder is responsible for determining their filing obligations and preparing the filings. In addition, Unitholders who hold more than 10% of a class of Units may be subject to Section 16(b) of the 1934 Act, which recaptures for the benefit of the Company profits from the purchase and sale of registered
Units within a six-month period.
Documentation of Internal Controls
. The Company is obligated to maintain proper and effective internal control over financial reporting, including the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act (“Section 404”). The Company is not required to comply with all of the requirements under Section 404 until the date it is no longer an emerging growth company under the JOBS Act. Accordingly, the Company’s internal controls over financial
 
55

reporting do not currently meet all of the standards contemplated by Section 404 that they will eventually be required to meet. Specifically, the Company is required to conduct annual management assessments of the effectiveness of its internal controls over financial reporting. However, the Company’s independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial reporting until the date it is no longer an emerging growth company under the JOBS Act.
The Company’s internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If the Company fails to maintain the adequacy of its internal controls, including any failure to implement required new or improved controls, or if the Company experiences difficulties in their implementation, the Company’s business and operating results could be harmed and it could fail to meet its financial reporting obligations.
Other Risks Related to Portfolio Investments
High Yield Debt and Unrated Securities
. High yield securities are typically junior to the obligations of companies to senior creditors, trade creditors and employees. High yield securities and unrated securities (which are not rated by a rating agency) may be more susceptible to real or perceived adverse economic and competitive industry conditions than investment-grade securities. A projection of an economic downturn or of a period of rising interest rates, such as the recent economic period, for example, could cause a decline in the prices of high yield securities and unrated securities, because the advent of a recession could lessen the ability of an issuer to make principal and interest payments on its debt obligations. In addition, such securities have historically experienced greater default rates than investment grade securities. The ability of holders of high yield debt to influence a company’s affairs will be substantially less than that of senior creditors, especially during periods of financial distress or following insolvency.
As with other Portfolio Investments, there may not be a liquid market for certain high yield debt which is held by the Company, which could result in the Company being unable to sell such securities for an extended period of time, if at all. In addition, as with other types of Portfolio Investments, the market for high yield debt has historically been subject to disruptions that have caused substantial volatility in the prices of such securities. Consolidation in the financial services industry has resulted in there being fewer market makers for high yield debt, which may result in further risk of illiquidity and volatility with respect to high yield debt held by the Company, and this trend may continue in the future. Furthermore, high yield debt which is held by the Company may not be registered under the Securities Act, and, unless so registered, the Company is not able to sell such high yield debt except pursuant to an exemption from registration under the Securities Act. Unrated securities may be less liquid than comparable rated securities and may also involve the risk that the Adviser may not accurately evaluate the security’s comparative credit rating.
Analysis of creditworthiness of issuers of high yield and unrated securities may be more complex than for issuers of higher-quality fixed income securities. Since it is expected that most of the Company’s assets will not be rated by any rating agency or will be rated below investment grade, the Company is more dependent on the Adviser’s creditworthiness analysis than if the Company invested exclusively in higher-quality and rated securities. Securities rated below investment grade are often referred to as “leveraged loans,” “high yield” or “junk” securities, and may be considered “high risk” compared to debt instruments that are rated investment grade. See “—
General Credit Risk
” above.
Equity-Related Securities
. As with other Portfolio Investments, the value of equity or equity-related securities held by the Company may be adversely affected by actual or perceived negative events relating to the issuer of such securities, the industry or geographic areas in which such issuer operates or the financial markets generally. However, equity securities may be even more susceptible to such events given their subordinate position in the issuer’s capital structure. As such, equity securities generally have greater price volatility than fixed income securities, and the market price of equity securities owned by the Company is more susceptible to moving up or down in a rapid or unpredictable manner. In addition, equity securities
often
lose a significant amount of their value and may become worthless as a result of a bankruptcy proceeding or reorganization.
Convertible Securities Risk
. Convertible securities generally offer lower interest or dividend yields than
non-convertible
debt securities of similar quality. The market values of convertible securities tend to decline as interest rates increase and, conversely, to increase as interest rates decline. However, a convertible security’s market value tends to reflect the market price of the common stock of the issuing company when that stock price approaches or is greater than the convertible security’s “conversion price.” The conversion price is defined as the predetermined price at which the convertible security could be exchanged for the associated stock. As the market price of the underlying common stock declines, the price of the convertible security tends to be influenced more by the yield of the convertible security. Thus, it may not decline in price to the same extent as the underlying common stock. Generally, in the event of a liquidation of the issuing company, holders of
 
56

convertible securities would be paid before the company’s common stockholders but after holders of any senior debt obligations of the company. Consequently, the issuer’s convertible securities generally entail less risk than its common stock but more risk than its debt obligations. There is also a risk that, under certain circumstances, a bankruptcy court may order that convertible securities are treated as equity.
The Company may invest in synthetic convertible securities, which are created through a combination of separate securities that possess the two principal characteristics of a traditional convertible security,
i.e.
, an income-producing security (“income-producing component”) and the right to acquire an equity security (“convertible component”). The income-producing component is achieved by investing in
non-convertible,
income-producing securities such as bonds, preferred stocks and money market instruments. The convertible component is achieved by purchasing warrants or options to buy common stock at a certain exercise price, or options on a stock index. The values of synthetic convertible securities will respond differently to market fluctuations than a traditional convertible security because a synthetic convertible is composed of two or more separate securities or instruments, each with its own market value. Synthetic convertible securities are also subject to the risks associated with derivatives. In addition, if the value of the underlying common stock or the level of the index involved in the convertible element falls below the strike price of the warrant or option, the warrant or option may lose all value.
Preferred Securities Risk
. In addition to credit risk, investment in preferred stocks involves certain other risks. Certain preferred stocks contain provisions that allow an issuer under certain conditions to skip or defer distributions. If the Company owns preferred stock that is deferring its distribution, the Company may be required to report income for U.S. federal income tax purposes despite the fact that it is not receiving current income on this position. Preferred stock often is subject to legal provisions that allow for redemption in the event of certain tax or legal changes or at the issuer’s call. In the event of redemption, the Company may not be able to reinvest the proceeds at comparable rates of return. Preferred stock is subordinated to bonds and other debt securities in an issuer’s capital structure in terms of priority for corporate income and liquidation payments and, therefore, will be subject to greater credit risk than those debt securities. Preferred stock may trade less frequently and in a more limited volume and may be subject to more abrupt or erratic price movements than many other securities, such as common stocks, corporate debt securities and U.S. government securities.
Forwards and Derivatives Transactions
. The Company may engage in a variety of derivatives transactions. A
derivative
is a financial contract the value of which depends upon, or is derived from, the value of underlying assets, reference rates or indices. Derivatives may relate to securities, interest rates, currencies or currency exchange rates, inflation rates, commodities and related indices, and include foreign currency contracts, swap contracts, options, forward and futures contracts (including options thereon), repurchase or reverse repurchase
agreements or other over-the-counter contracts. The
Company may use derivatives for many purposes, including as a substitute for direct investment, as a way to adjust its exposure to various securities, markets and currencies without actually having to sell existing investments and/or make new investments, and as a means to hedge other investments and to manage liquidity and excess cash. The Company’s use of derivatives may result in losses, reduce the Company’s return, and/or increase the volatility of the Company (particularly since many derivatives are inherently leveraged), especially in unusual or extreme
market
conditions
.
All derivatives transactions involve risks different from, and potentially greater than, the risks associated with investing directly in securities and other more traditional assets, including:
Market Risk
. This is the general risk that the value of a particular investment or transaction will change in a way detrimental to the Company’s interests.
Management Risk
. Derivatives contracts are specialized contracts that require investment techniques and risk analyses with additional levels of complexity associated with the underlying investments. In addition to risks associated with the underlying instruments, counterparty and unsecured risk (among others) need to be computed and tracked in relation to the Company’s overall risk profile.
Documentation Risk
. Many derivatives transactions also have documentation risk. Because contracts for
over-the-counter
derivatives transactions are individually negotiated with specific counterparties, there exists the risk that the parties may interpret contractual terms (
e.g.
, the definition of default) differently than the Company. If that occurs, the cost and unpredictability of the legal proceedings required for the Company to enforce its contractual rights may lead the Company to decide not to pursue its claims against the counterparty. The Company, therefore, assumes the risk that it may be unable to obtain payments the Adviser believes are owed to it under derivatives transactions, or those payments may be delayed or made only after the Company has incurred the costs of litigation. Also, payment amounts calculated in connection with standard industry conventions for resolving contractual issues (
e.g.
, ISDA Protocols and auction processes) may be different than would be realized if a counterparty were required to comply with the literal terms of the derivatives transaction (
e.g.
, physical delivery). There is little case law interpreting the terms of most derivatives or characterizing their tax treatment.
 
57

Regulatory Risk
. The derivatives market is subject to various risks related to existing as well as new and evolving regulation both within and outside the U.S. Additional regulation of the derivatives markets may make derivatives more costly, may limit the availability of derivatives, or may otherwise adversely affect the value or performance of derivatives. Any such adverse future developments could impair the effectiveness of a Company’s derivatives transactions and cause the Company to lose value. They may also render certain strategies in which the Company might otherwise engage impossible or so costly that they will no longer be economical to implement. See “—
Changes to Derivatives Regulation
” above.
Other Risks
. Derivatives also involve the risk that changes in their value may not correlate perfectly with the assets, rates or indices they are designed to track. Suitable derivatives may not be available in all circumstances. Under the terms of certain contracts governing derivatives transactions, the occurrence of certain events with respect to the Company (such as a decline in the Company’s NAV) may cause the Company’s derivatives transactions to be terminated early, including at an inopportune time or at an unfavorable price.
Warrants and Rights
. The Company may purchase or otherwise receive warrants or rights. Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a stated price. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of options. Unlike most options, however, warrants and rights are issued in specific amounts, and warrants generally have longer terms than options. Warrants and rights are not likely to be as liquid as exchange-traded options backed by a recognized clearing agency. In addition, the terms of warrants or rights may limit the Company’s ability to exercise the warrants or rights at such time, or in such quantities, as the Company would otherwise wish.
Risks
 Relating to Reference Rates
. The London Interbank Offered Rate (“LIBOR”) is an index rate that historically was widely used in lending transactions and was a common reference rate for setting the floating interest rate on private loans. LIBOR was typically the reference rate used in floating-rate loans extended to the Company’s Portfolio Investments.
The ICE Benchmark Administration (“IBA”) (the entity that is responsible for calculating LIBOR) ceased providing overnight, one, three, six and twelve months USD LIBOR tenors on June 30, 2023. In addition, the United Kingdom’s Financial Conduct Authority (“FCA”), which oversees the IBA, now prohibits entities supervised by the FCA from using LIBORs, including USD LIBOR, except in very limited circumstances.
In the United States, SOFR is the preferred alternative rate for LIBOR. SOFR is a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. SOFR is published by the Federal Reserve Bank of New York each U.S. Government Securities Business Day, for transactions made on the immediately preceding U.S. Government Securities Business Day. Alternative reference rates that may replace LIBOR, including SOFR for USD transactions, may not yield the same or similar economic results as LIBOR over the lives of such transactions.
As of the filing date of this annual report on Form
10-K,
many of the Company’s loans that referenced LIBOR have been amended to reference the forward-looking term rate published by CME Group Benchmark Administration Limited based on SOFR (“CME Term SOFR”) or CME Term SOFR plus a fixed spread adjustment. CME Term SOFR rates are forward-looking rates that are derived by compounding projected overnight SOFR rates over one, three, and six months taking into account the values of multiple consecutive, executed,
one-month
and three-month CME Group traded SOFR futures contracts and, in some cases,
over-the-counter
SOFR Overnight Indexed Swaps as an indicator of CME Term SOFR reference rate values. CME Term SOFR and the inputs on which it is based are derived from SOFR. Since CME Term SOFR is a relatively new market rate, there will likely be no established trading market for credit agreements or other financial instruments when they are issued, and an established market may never develop or may not be liquid. Market terms for instruments referencing CME Term SOFR rates may be lower than those of later-issued CME Term SOFR indexed instruments. Similarly, if CME Term SOFR does not prove to be widely used, the trading price of instruments referencing CME Term SOFR may be lower than those of instruments indexed to indices that are more widely used. Further, the composition and characteristics of SOFR and CME Term SOFR are not the same as those of LIBOR. Even with the application of a fixed spread adjustment, LIBOR and CME Term SOFR will not have the same composition and characteristics, and there can be no assurance that the replacement rate, as so adjusted, will be a direct substitute for LIBOR.
There can be no guarantee that SOFR will not be discontinued or fundamentally altered in a manner that is materially adverse to the interests of investors in loans referencing SOFR. If the manner in which SOFR or CME Term SOFR is calculated is changed, that change may result in a reduction of the amount of interest payable on such loans and the trading prices of the SOFR Loans. In addition, there can be no guarantee that loans referencing SOFR or CME Term SOFR will continue to reference those rates until maturity or that, in the future, the Company’s loans will reference benchmark rates other than CME Term SOFR. Should any of these events occur, the Company’s loans, and the yield generated thereby, could be affected. Specifically, the anticipated yield on the Company’s loans may not be fully realized and the Company’s loans may be subject to increased pricing volatility and market risk.
 
58

Risks Related to Economic Recessions
. The recent macroeconomic environment is characterized by record-high inflation, supply chain challenges, labor shortages, high interest rates, foreign currency exchange volatility, volatility in global capital markets and growing recession risk. The risks associated with the Company’s and the Portfolio Investments’ businesses are more severe during periods of economic slowdown or recession.
Many of the Company’s Portfolio Investments may be susceptible to economic slowdowns or recessions and may be unable to repay its loans during these periods. The global outbreak
of COVID-19
has disrupted economic markets, and the prolonged economic impact is uncertain. Many manufacturers of goods have seen a downturn in production due to the suspension of business and temporary closure of factories globally in an attempt to curb the continued spread of the virus. As a result of these disruptions, the
Company’s non-performing
assets may increase and the value of its portfolio may decrease during these periods as the Company is required to record the values of its investments. Adverse economic conditions also may decrease the value of collateral securing some of the Company’s loans and the value of its equity investments at fair value. Economic slowdowns or recessions could lead to financial losses in the Company’s portfolio and a decrease in revenues, net income and assets. Unfavorable economic conditions also could increase the Company’s funding costs, limit its access to the capital markets or result in a decision by lenders not to extend credit to the Company. These events could prevent the Company from increasing investments and result in its receipt of a reduced level of interest income from the Company’s Portfolio Investments and/or losses or charge offs related to its investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations.
A Portfolio Investment’s failure to satisfy financial or operating covenants imposed by the Company or other lenders could lead to defaults and, potentially, acceleration of the time when the loans are due and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize the Portfolio Investment’s ability to meet its obligations under the debt that the Company holds. The Company may incur additional expenses to the extent necessary to seek recovery upon default or to negotiate new terms with a defaulting Portfolio Investment. In addition, if one of the Company’s Portfolio Investments were to go bankrupt, depending on the facts and circumstances, including the extent to which the Company actually provided significant managerial assistance to that Portfolio Investment, a bankruptcy court
might re-characterize
its debt holdings and subordinate all or a portion of the Company’s claim to that of other creditors.
These Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive research and development, manufacturing, marketing and service capabilities and greater number of qualified and experienced managerial and technical personnel. They may need additional financing that they are unable to secure and that the Company is unable or unwilling to provide, or they may be subject to adverse developments unrelated to the technologies they acquire.
The Company’s business is directly influenced by the economic cycle and could be negatively impacted by a downturn in economic activity in the U.S. as well as globally. Fiscal and monetary actions taken by U.S.
and non-U.S.
government and regulatory authorities could have a material adverse impact on the Company’s business. To the extent uncertainty regarding the U.S. or global economy, including as a result of
the COVID-19
pandemic, certain regional bank failures, the Russian invasion of Ukraine and the ongoing war in the Middle East, negatively impacts consumer confidence and consumer credit factors, the Company’s business, financial condition and results of operations could be adversely affected. Moreover, Federal Reserve policy, including with respect to certain interest rates and the decision to end its quantitative easing policy, along with the general policies of the current Presidential administration, may also adversely affect the value, volatility and liquidity of dividend- and interest-paying securities. Market volatility, periods of rising interest rates, such as the recent economic period, and/or a return to unfavorable economic conditions could adversely affect its business.
Risks Related to the U.S.’ Debt Ceiling
. The significant debt in the U.S. is expected to hinder growth in the U.S. for the foreseeable future. In the future, the U.S. government may not be able to meet its debt payments unless the federal debt ceiling is raised. If legislation increasing the debt ceiling is not enacted, as needed, and the debt ceiling is reached, the U.S. federal government may stop or delay making payments on its obligations. Any default by the U.S. government on its obligations or any prolonged U.S. government shutdown could negatively impact the U.S. economy and our Portfolio Investments. In addition, concerns over the United States’ debt ceiling and budget-deficit have driven downgrades by rating agencies to the U.S. government’s credit rating. Downgrades by rating agencies to the U.S. government’s credit rating or concerns about its credit and deficit levels in general could cause interest rates and borrowing costs to rise, which may negatively impact both the perception of credit risk associated with our debt portfolio and our ability to access the debt markets on favorable terms. In addition, a decreased U.S. government credit rating, any default by the U.S. government on its obligations, or any prolonged U.S. government shutdown, could create broader financial turmoil and uncertainty, which may weigh heavily on our financial performance and the value of our common stock. U.S. debt ceiling and budget deficit concerns have
increased
the possibility of additional credit-rating downgrades and economic slowdowns or a recession in the U.S.
 
59

Risks Related to Portfolio Investment Monitoring and Involvement
. The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings. See “—
Control Positions
” below. The Company’s investment program may from time to time enable it to place representatives on the creditors’ or steering committees and/or the boards of directors of certain companies in which it has invested. While such involvement may enable the Adviser to enhance the value of the Company’s Portfolio Investments, it may also prevent the Company from freely disposing of such Portfolio Investments, while also exposing it to legal claims and adverse publicity (including claims of breach of duty of loyalty, securities claims and other management-related claims). In addition, if the Adviser’s representatives are serving as directors of companies which are in the “zone of insolvency,” such persons may have a fiduciary obligation to the creditors of such entity as well as the shareholders of such entity. The interests of such parties may be adverse to the interests of the Company. These fiduciary obligations may conflict with the Adviser’s obligation to the Company, and the Adviser may cause its representatives to resign from such positions in order to reduce such conflicts. Any involvement by the Adviser’s representatives (including through serving on a board of directors, or permanent or ad hoc creditors’ or steering committees) may also entail a substantial time commitment, which may limit such representatives’ ability to participate in other Company matters and investments.
Risks Associated with Bankruptcy and Insolvency Cases
. If any issuers of securities held by the Company or any counterparties to the derivatives transactions and other transactions entered into by the Company, or any custodians of the Company’s assets or any obligors in connection with Portfolio Investments are involved in bankruptcy proceedings, the Company will be subject to certain risks inherent in bankruptcy proceedings, including the duration, administrative costs and impact of a bankruptcy case on the value of assets administered in bankruptcy or on a company’s value (including that a bankruptcy case may damage or diminish a company’s relationship with its employees, customers and/or suppliers). Many of the events within a bankruptcy or insolvency case are adversarial and often beyond the control of the creditors. While creditors generally are afforded an opportunity to object to significant actions, or to demand that certain actions take place, there can be no assurance that a court would not approve actions or inaction which may be contrary to the interests of the Company.
Generally, the duration of a bankruptcy or insolvency case can only be roughly estimated. The reorganization of a company usually involves the design of a business plan, the development and negotiation of a plan of reorganization, plan approval by creditors and confirmation by the court. This process can involve substantial legal, professional and administrative costs to the company and to the Company; is subject to unpredictable and lengthy delays; and during the process the company’s competitive position may erode, key management may depart and the company may not be able to invest adequately. In some cases, the company may not be able to reorganize and may be required to liquidate assets. In addition, the debt of companies in financial reorganization may, in some cases, not pay current interest and other charges, may not even accrue interest and other charges during reorganization, may be
relieved of paying pre-payment premiums and
may be adversely affected by an erosion of the issuer’s fundamental value. Further, a debtor seeking to reorganize under U.S. federal bankruptcy law will frequently obtain a “first day” order from the bankruptcy court limiting trading in claims against, and shares of, the debtor in order to maximize the debtor’s ability to utilize net operating losses following a successful reorganization.
During the pendency of a bankruptcy case, an automatic stay will prevent all creditors from taking action against the debtor to foreclose on collateral or otherwise to collect on amounts owed to such creditors. Unless a creditor’s claim in such case is secured by assets having a value in excess of such claim, or the bankruptcy estate is determined to be solvent, no interest will be permitted to accrue and, therefore, a creditor’s return on investment can be adversely affected by the passage of time during which the plan of reorganization of the debtor is being negotiated, approved by the creditors and confirmed by the bankruptcy court.
The priority of perfected liens held by secured creditors as of the commencement of the bankruptcy case is typically recognized in a bankruptcy case, unless avoided. Occasionally, however, a court will
allow a debtor-in-possession financing to
receive
liens that prime pre-existing, valid liens.
The administrative costs in connection with a bankruptcy case are frequently high and will generally be paid out of the debtor’s estate prior to any return to creditors (other than out of assets or proceeds thereof which are subject to valid and enforceable liens and other security interests) and equity holders. In addition, certain unsecured claims that have priority by law over the claims of certain creditors (for example, claims arising post-petition and certain claims for taxes) may be quite high.
U.S. bankruptcy law permits the classification of “substantially similar” claims in determining the classification of claims in a reorganization for the purpose of voting on a plan of reorganization. Because the standard for classification is vague, there exists a significant risk that the Company’s influence with respect to a class of securities can be lost by the inflation of the number and the amount of claims in, or other gerrymandering of, the class.
 
60

Although a creditor is not typically compelled to release direct claims it may have against
non-debtor
third parties, in certain circumstances a court may compel such release in the context of a plan of reorganization.
Claims in bankruptcy cases are often paid at less than par and, depending on the debtor’s assets and liabilities, there may be no recovery at all for some classes of creditors. The claims of even over-secured secured creditors are often paid out over time, and may receive debt securities that will trade below par. Initially, only the debtor may file a proposed plan of reorganization. While the U.S. Bankruptcy
Code permits other parties-in-interest to file
proposed plans of reorganization after the debtors’ “exclusive period” to do so ends, bankruptcy courts often extend the debtor’s exclusive period, which effectively permits only the debtor to file a proposed reorganization plan. While creditors can vote on the plan of reorganization, the unanimous consent of all creditor classes is not necessarily required for the bankruptcy court to confirm the plan. Therefore, a plan can, subject to the provisions of the U.S. Bankruptcy Code, be “crammed down” on dissenting classes of creditors. Moreover, minority members of a class may be deemed to be members of an accepting class if the requisite majority vote is acquired.
Even if a class of claims is entitled to a recovery in a reorganization or liquidation proceeding, such recovery could be in the form of instruments or interests different from the form of instrument or interest which formed the basis for the claim, including debt securities, equity securities, convertible securities, warrants, options, cash, interests in litigation claims or trusts formed to pursue such litigation claims, interests in liquidation trusts, or other property or interests, any of which could be illiquid and/or difficult to value. Furthermore, the terms of instruments or interests distributed in a bankruptcy or insolvency proceeding may differ from prevailing market terms for similar instruments or interests, and may have a market value of less than par.
The Company may be presented with the opportunity to make new investments in connection with the reorganization or liquidation of an issuer of Portfolio Investments, including, without limitation, through a rights offering, litigation financing, bridge financing or other exit financing. The Company may make such investments as
part of an in-court or out-of-court restructuring of
an issuer of Portfolio Investments, and any such investment will be subject to the same risks as other Portfolio Investments of the Company.
Contractual subordination provisions are enforceable when a borrower is in bankruptcy, as are most inter-creditor agreement terms. Furthermore, there are instances where creditors and equity holders may lose their ranking and priority when they take over management and functional operating control of a debtor. In those cases where the Company, by virtue of such action, is found to exercise “domination and control” of a debtor, the Company may lose its priority if the debtor or other creditors can demonstrate that the debtor’s business was adversely impacted or other creditors and/or equity holders were harmed by improper or unfair actions of the Company, whether or not the Company is found to be a controlling party of the debtor. In addition, loans extended to a financially distressed borrower by an entity that owns an equity interest in the borrower may be reclassified as having been an equity capital contribution, rather than a debt obligation.
Notwithstanding the corporate structure of various debtor entities, such as special purpose entities created to hold assets and to structure for bankruptcy remoteness, such entities may, in certain cases, be consolidated in bankruptcy proceedings, which can affect the outcome of such proceedings and the amounts ultimately received by creditors. In addition, if a claim can be asserted against only a parent holding entity, such claim may be structurally subordinated to claims against a subsidiary entity that owns assets.
The U.S. Bankruptcy Code and other laws and regulations affecting debtors’ and creditors’ rights are subject to change, including by way of legislative action or judicial interpretation. In addition, governmental actors have recently shown a willingness to intervene in bankruptcy-related matters (for example, the U.S. government’s bailouts of General Motors and Chrysler), which may increase uncertainty regarding the enforcement of creditors’ rights and the bankruptcy process generally. Any such actions could alter the expected outcome or introduce greater uncertainty regarding the expected outcome of an investment situation of the Company, which may adversely affect such investment or the Company’s investment program.
Lack of Control over Investments
. The Company invests in debt securities, but
may hold a non-controlling interest in
one or more Portfolio Investments. Such investments may not give the Company the ability to influence the management of the company or to elect a representative to the Board. In addition, the management of the company or its shareholders may have economic or business interests which are inconsistent with those of the Company, and they may be in a position to take action contrary to the Company’s objectives. A
non-controlling
interest may be especially adverse to the Company in circumstances, such as certain stressed or distressed situations, where an element of control or influence might be beneficial to the subject investment.
 
61

Control Positions
. The Company does not expect to, but may have a controlling interest in a Portfolio Investment (because of its equity ownership, representation on the board of directors and/or contractual rights) either on its own or, in certain cases, with another financial partner or investment fund (
e.g.,
 in accordance with the Company’s receipt of equity in connection with a restructuring). The exercise of control over a company may impose additional risks of liability for environmental damage, product defects, failure to supervise management, pension and other fringe benefits, violation of governmental regulations (including securities laws) or other types of related liability. If these liabilities were to arise, the Company might suffer a significant loss in such investment. In addition, if employees of the Adviser serve as directors of certain of the Portfolio Investments, including public companies, they will have duties to persons other than the Company.
To the extent that the Company owns a controlling stake in or is deemed an affiliate of a particular company, it may also be subject to certain additional bankruptcy or securities laws restrictions that could affect both the liquidity of the Company’s interest and the Company’s ability to liquidate its interest without adversely impacting the price thereof, including insider trading restrictions, the affiliate sale restrictions of Rule 144 of the Securities Act and the disclosure requirements of Sections 13 and 16 of the 1934 Act. Further, to the extent that affiliates of the Company or the Adviser are subject to such restrictions, the Company, by virtue of its affiliation with such entities, may be similarly restricted, regardless of whether the Company stands to benefit from such affiliate’s ownership.
If the Company, alone or as part of a group acting together for certain purposes, becomes the beneficial owner of more than 10% of certain classes of securities of a U.S. public company or places a director on the board of directors of such a company, the Company may be subject to certain additional reporting requirements and to liability for short-swing profits under Section 16 of the 1934 Act. Furthermore, the Company may also be subject to similar reporting requirements and
other limitations in non-U.S. jurisdictions where
it holds significant positions in companies in such jurisdictions.
The exercise of control over a company, depending upon the amount and type of securities owned by the Company, contractual arrangements between the company and the Company, and other relevant factual circumstances, could result in an extension to one year of the
90-day bankruptcy preference
period with respect to payments made to the Company. See “—
Fraudulent Conveyance and Preference Considerations
” below. The exercise of control over a company may also provide grounds for challenges to the priority and enforceability of Portfolio Investments or other claims the Company may have against the company if it is subject to a bankruptcy case or other insolvency proceeding. See “—
Lender Liability Considerations and Equitable Subordination
” below.
Lender Liability Considerations and Equitable Subordination
. In recent years, a number of judicial decisions in the U.S. have upheld the right of borrowers to sue lending institutions on the basis of various evolving legal theories (collectively termed “lender liability”). Generally, lender liability is founded upon the premise that an institutional lender has violated a duty (whether implied or contractual) of good faith and fair dealing owed to the borrower or has assumed a degree of control over the borrower resulting in creation of a fiduciary duty owed to the borrower or its other creditors or shareholders. In addition, courts have in some cases applied the doctrine of equitable subordination to subordinate the claim against a borrower of a creditor, including a lending institution, to claims of other creditors of the borrower when the creditor is found to have engaged in unfair, inequitable or fraudulent conduct. There can be no assurance as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire such claims engaged in any such conduct and, if it did, as to whether the Company would be subject to claims that the Company’s Portfolio Investments should be equitably subordinated based on such conduct. Because of the nature of certain of the Company’s Portfolio Investments, the Company could be subject to allegations of lender liability or to claims that the Company’s Portfolio Investments should be
equitably
subordinated.
Fraudulent Conveyance and Preference Considerations
. Various federal and state laws enacted for the protection of creditors may apply to the purchase of the Company’s Portfolio Investments, or payments or liens related thereto, by virtue of the Company’s role as a creditor with respect to the borrowers under such Portfolio Investments. If a court, in a lawsuit brought by an
unpaid creditor, a debtor-in-possession, a trustee
in bankruptcy, or their respective representatives, were to find that the borrower took any action to intentionally delay or frustrate recoveries by creditors, or did not receive fair consideration or reasonably equivalent value for incurring indebtedness evidenced by an investment and the grant of any security interest or other lien securing such investment, and, after giving effect to such indebtedness and/or grant of any security interest or other lien, the issuer or obligor (i) was insolvent, (ii) was engaged in a business for which the remaining assets of such issuer constituted unreasonably small capital or (iii) intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature, such court could, under certain circumstances, invalidate, in whole or in part, such indebtedness and such security interest or other lien as fraudulent conveyances, could subordinate such indebtedness to existing or future creditors of the borrower and could allow the borrower to recover amounts previously paid by the borrower to the creditor (including to the Company) in satisfaction of such indebtedness or proceeds of such security interest or other lien previously applied in satisfaction of such indebtedness.
 
62

The measure of insolvency for purposes of the foregoing will vary. Generally, an issuer or obligor would be considered insolvent at a particular time if the sum of its debts were then greater than all of its property at a fair valuation, or if the present fair saleable value of its assets were less than the amount that would be required to pay its probable liabilities on its existing debts as they became absolute and matured. There can be no assurance as to what standard a court would apply in order to determine whether the issuer or obligor was “insolvent” after giving effect to the incurrence of the indebtedness and/or the granting of any security interest or other lien or that, regardless of the method of valuation, a court would not determine that the issuer was “insolvent” upon giving effect to such incurrence of indebtedness and/or grant of security interests or other lien.
The Company may invest in bank debt or other indebtedness issued by a borrower which is guaranteed by other entities within the borrower’s corporate family. In such circumstances, the borrower often has little or no assets other than the stock of its subsidiaries and, as a result, any recovery is often available only, if at all, from the entities that guaranteed the indebtedness. There is a risk, however, that the obligations of such guarantors and any security interests or other liens issued by the guarantors to secure such obligations may be avoided as fraudulent conveyances in the event that a court were to determine that such guarantors did not receive reasonably equivalent value in exchange for the issuance of the guarantees and for the security interests or other liens. A court could determine that the guarantors did not receive reasonably equivalent value or fair consideration in incurring the obligations and granting the security interests or other liens despite the existence of “indirect” benefits to the guarantors, such as the strengthening of the corporate enterprise in the transaction. Additionally, provisions in guarantees and other similar documents governing similar obligations by which fraudulent conveyance exposure is sought to be reduced or
eliminated, such as so-called “savings clauses,”
may not be enforceable. As a result, the Company’s Portfolio Investment in corporate bank debt or other indebtedness could be subject to avoidance as a fraudulent conveyance.
If a transaction is found to have been a fraudulent conveyance, the transferee may be compelled to return the value of the assets transferred as of the time of the transfer, even if the then current value is substantially less. In addition, unless the transferee is deemed to be a “good faith” transferee, the return of the asset may not even provide for the compensation back to the transferee of the value paid to the transferor.
In addition, in the event of the insolvency (as determined by a court based on the law of the jurisdiction which is being applied) of an issuer of a Portfolio Investment, payments made on the Company’s Portfolio Investment, or new liens granted, could be subject to avoidance as a “preference” if made within a certain period of time (which may be as long as one year) before insolvency, depending on a number of factors.
In general, if payments on a Company’s Portfolio Investment are avoidable, whether as a fraudulent conveyance or preference, such payments can be recaptured either from the initial recipient (such as the Company) or from subsequent transferees of such payments, including Unitholders. Additionally, if the grant of a security interest or other lien is avoidable, whether as a fraudulent conveyance or preference, the value of the security interest or other lien can be recovered from the initial transferee or the entity for whose benefit such transfer was made (such as the Company), and such recovery could include the diminution in value of the property which was subject to the security interest or other lien from the date of transfer.
There can be no assurance that a successful cause of action for fraudulent conveyance or preference will not occur, or as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire a Portfolio Investment engaged in any conduct to give rise to such causes of action, and if it did, as to whether such causes of action could be asserted against the Company and/or the Unitholders.
Portfolio Investment Risk
. The Company’s Portfolio Investments may involve a high degree of business and financial risk. Portfolio Investments may be in early stages of development, may have operating losses or significant variations in operating results and may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence. Portfolio Investments will also include companies that are experiencing or are expected to experience financial difficulties, which may never be overcome. In addition, many of them will have weak financial conditions and may require substantial additional capital to support their operations, to finance expansion or to maintain their competitive positions. Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive development, manufacturing, marketing, and other capabilities and a larger number of qualified managerial and technical personnel. In addition, Portfolio Investments in which the Company invests may be required to comply with
numerous U.S. and non-U.S. statutory and
regulatory standards. A Portfolio Investment could be materially and adversely affected as a result of statutory or regulatory changes or changes in judicial or administrative interpretations of existing laws and regulations that impose more comprehensive or stringent requirements on such Portfolio Investment, the markets in which such Portfolio Investment operates or such Portfolio Investment’s industry generally.
 
63

There can be no assurance that a Portfolio Investment’s management team will be able to operate such Portfolio Investment successfully. In addition, instances of fraud or other illegal practices committed by the management team of a Portfolio Investment may undermine the Company’s investment in such Portfolio Investment and the Company may suffer losses. Additionally, Portfolio Investments need to attract, retain and develop executives and members of their management teams. There can be no assurance that a Portfolio Investment will be able to attract and develop suitable
members
of its management team, which may adversely affect the Company.
Zero-Coupon Bonds, Deferred Interest Rate Bonds and
 Payment-In-Kind
 Securities
. Zero-coupon bonds pay interest only at maturity rather than at intervals during the life of the security. Deferred interest rate bonds generally provide for a period of delay before the regular payment of interest begins. PIK securities are debt obligations that pay “interest” in the form of other debt obligations, instead of in cash. Each of these instruments is normally issued and traded at a deep discount from face value. Zero-coupon bonds, deferred interest rate bonds and PIKs allow an issuer to avoid or delay the need to generate cash to meet current interest payments and, as a result, may involve greater credit risk than bonds that pay interest currently or in cash. In addition, such investments experience greater volatility in market value due to changes in interest rates than debt obligations that provide for regular payments of interest.
To the extent the Company invests in OID instruments, including PIK, zero coupon bonds, and debt securities with attached warrants, investors will be exposed to the risks associated with the inclusion of
such non-cash income
in taxable and accounting income prior to receipt of cash, including the following:
 
   
The interest payments deferred on a PIK loan are subject to the risk that the borrower may default when the deferred payments are due in cash at the maturity of the loan;
 
   
The interest rates on PIK loans are higher to reflect the time-value of money on deferred interest payments and the higher credit risk of borrowers who may need to defer interest payments;
 
   
PIK instruments may have unreliable valuations because the accruals require judgments about ultimate collectability of the deferred payments and the value of the associated collateral;
 
   
An election to defer PIK income payments by adding them to principal increases the Company’s gross assets and, thus, increases future base fees to the Adviser and, because income payments will then be payable on a larger principal amount, the PIK election also increases the Adviser’s future income incentive fees at a compounding rate;
 
   
Market prices of OID instruments are more volatile because they are affected to a greater extent by interest rate changes than instruments that pay interest periodically in cash;
 
   
The deferral of interest on a PIK loan
increases its loan-to-value ratio,
which is a measure of the riskiness of a loan; and
 
   
OID creates the
risk of non-refundable cash
payments to the Adviser
based on non-cash accruals
that may never be realized.
Money Market and Other Liquid Instruments
. The Company may invest its assets in such liquid securities as the Adviser may deem to be advisable, including fixed income securities, money market instruments, money market mutual funds, and debt securities issued or guaranteed by the U.S., certain U.S. government agencies or instrumentalities. Money market instruments are short-term fixed income obligations, which generally have remaining maturities of one year or less, and may include commercial paper, certificates of deposit, and bankers’ acceptances issued by domestic branches of U.S. banks that are members of the FDIC. The Company may be prevented from achieving its investment objective during any period in which its assets are not substantially invested in accordance with its investment strategy. Notwithstanding their general high-quality nature, money market funds and liquid securities are subject to the risk of loss.
Among other liquid investments, the Company may invest cash, pending investment, reinvestment or distribution thereof or in connection with the maintenance of reserves, in money fund products offered from time to time by its Custodian, including the use of bank “sweep” short-term offerings.
Pooled Investment Vehicles and Pass-through Entities
. The Company may invest or take short positions in pooled investment vehicle and pass-through entities, including affiliated or third-party unregistered investment vehicles, investment companies registered under the 1940 Act (including
exchange-traded funds and closed-end companies) and
master limited partnerships (“Pooled Investment Vehicles”). To the extent the Company invests directly in Pooled Investment Vehicles and other “pass-through” entities which are treated as partnerships for U.S. federal income taxation purposes, the Company must rely on such vehicles to deliver to it certain tax information that is necessary to complete the Company’s own tax returns. If this information is not delivered to the Company in a timely fashion, the Company will be delayed in providing tax information to the investors.
 
64

U.S. Government and Agency Securities
. The Company may invest in debt securities issued or guaranteed by certain U.S. government agencies, instrumentalities and sponsored enterprises. Some U.S. government securities, such as Treasury bills, notes and bonds and MBS guaranteed by Ginnie Mae, are supported by the full faith and credit of the U.S.; others are supported by the right of the issuer to borrow from the U.S. Treasury; others are supported by the discretionary authority of the U.S. government to purchase the agency’s obligations; and still others are supported only by the credit of the instrumentality. Although U.S. government-sponsored enterprises, such as Fannie Mae and Freddie Mac, may be chartered or sponsored by Congress, they are not funded by Congressional appropriations, and their securities are not issued by the U.S. Treasury or supported by the full faith and credit of the U.S. government and involve increased credit risks. In addition, certain governmental entities have been subject to regulatory scrutiny regarding their accounting policies and practices and other concerns that may result in legislation, changes in regulatory oversight and/or other consequences that could adversely affect the credit quality, availability or investment character of securities issued by these entities.
Restricted Securities
. It is expected that a significant portion of the Company’s Portfolio Investments will
b
e securities (“restricted securities”) that have not been registered for sale to the public under the Securities Act pursuant to an exemption from registration (including Section 4(a)(2) of, or Rule 144A under, the Securities Act). Restricted securities are generally only sold to institutional investors in private sales from the issuer or from an affiliate of the issuer. These securities may be less liquid than securities registered for sale to the general public. The liquidity of a restricted security may be affected by a number of factors, including: (i) the credit quality of the issuer; (ii) the frequency of trades and quotes for the security; (iii) the number of dealers willing to purchase or sell the security and the number of other potential purchasers; (iv) dealer undertakings to make a market in the security; and (v) the nature of the security and the nature of marketplace trades. Also, restricted securities may be difficult to value because market quotations may not be readily available.
In addition, a debtor in a reorganization case may be granted a trading restriction order by a bankruptcy court in order to protect such debtor’s net operating losses (a “NOL Order”). Such an order may prohibit or severely restrict the ability of some creditors to sell their claims and interests in the debtor. The Company’s ability to transfer its interests in such a debtor may be impaired, delayed or prohibited as a consequence of a NOL Order. The Company may also incur added expenses if it attempts to challenge or limit the scope of a NOL Order, and such an attempt may not be successful. Similarly, issuers with net operating losses sometimes adopt Unitholder rights plans or similar arrangements in order to preserve the ability to utilize such net operating losses in the future; any such actions could also limit or otherwise adversely impact the Company’s ability to transfer or dispose of its interests in any such issuer.
Risks Related to Disposition of Investments
. The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, IPOs, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized. See, for example, “—
Risks Relating to Bank Loans and Corporate Loans
” above. In particular, certain disposition techniques and structures may expose the Company to liability for (among other things) securities laws violations, breaches of representations and warranties, and repurchase or “putback” obligations with respect to securitizations or similar structures.
Item 1B. Unresolved Staff Comments
None.
Item 1C. Cybersecurity
Risk Management and Strategy
We recognize the importance of assessing, identifying, and managing material risks from cybersecurity threats, as such term is defined in Item 106(a) of Regulation
S-K.
These risks include, among other things, operational risks, financial loss, intellectual property theft, fraud, extortion, loss of sensitive data, harm to individuals including stockholders, violation of privacy or security laws, increased costs associated with mitigation of damages and remediation, and other legal and reputational risks. We have implemented several cybersecurity processes and controls to aid in our efforts to assess, identify, and manage such material risks.
 
65

We rely on the Adviser’s enterprise-wide cybersecurity program to protect our information, including due oversight of the cybersecurity programs of our key service providers and processes for the assessment, identification, and management of material risks from cybersecurity threats, including those associated with the use of third-party service providers. The Adviser considers such cybersecurity threats as part of its broader risk management framework, and its cybersecurity program is designed to, among other things, protect us, insofar as is practicable, from the hazards of cybersecurity threats and vulnerabilities in accordance with applicable legal requirements and guidance. The Adviser collaborates with third-party subject-matter experts, as necessary, to identify and assess material cybersecurity threat risks and evaluate and test its cybersecurity protections, including through continuous network and endpoint monitoring, employee anti-phishing training, vulnerability assessments, and penetration testing to inform the Adviser’s risk identification and assessment. The Adviser also performs due diligence reviews on third-parties that have access to our systems, data, or facilities that house such systems or data and continually monitors cybersecurity threat risks identified through such diligence.
Together with management, the Board has designated an Information Security Group (“ISG”) to monitor issues relating to cybersecurity and work with the Adviser’s third-party Information Technology (“IT”) service provider to evaluate potential cyber risk vulnerabilities. While its composition may change over time, the ISG currently consists of our Chief Financial Officer and Chief Compliance Officer. The ISG, together with the Adviser’s third-party IT service provider, annually reviews the cyber risks applicable to our business and the measures established by the Adviser and other service providers to protect against those risks and recommends changes or enhancements, as necessary. The Adviser’s management and the third-party IT service provider also monitor the Adviser’s network to identify internal and external cybersecurity threats and vulnerabilities in order to determine any steps that should be taken to protect information stored on the Adviser’s network and promptly inform the ISG of any identified cybersecurity threats or vulnerabilities. The ISG also makes inquiries of the Adviser’s management and the third-party IT service provider regarding such efforts.
Material Impact of Cybersecurity Risks
The potential impact of risks from cybersecurity threats on us are assessed on an ongoing basis, and how such risks could materially affect our business strategy, operational results, or financial condition are regularly evaluated. During the reporting period, we did not identify any risks from cybersecurity threats, including as a result of previous cybersecurity incidents, that we believe have materially affected, or are reasonably likely to materially affect, our business strategy, operational results, or financial condition. We further describe cybersecurity risks that we face in “The failure in cyber security systems, as well as the occurrence of events unanticipated in our disaster recovery systems and management continuity planning could impair our ability to conduct business effectively” and “We, our Adviser and our portfolio companies are subject to risks associated with cyber-attacks” under “Item 1A. Risk Factors” of this annual report on Form
10-K.
Governance
The Board has overall responsibility for risk oversight, including risks related to cybersecurity threats. The Board is aware of the critical nature of managing these risks and has sought to establish oversight mechanisms to ensure effective governance in managing risks associated with cybersecurity and appropriate review of the protections provided to us by the Adviser.
In conducting its duties, the ISG relies on the experience and expertise of the Adviser’s third-party IT service provider, which includes, among other things, over two decades of managing network security for companies, a track record of collaborating with management teams on incident response and threat mitigation, and, through various partnerships, vetting and implementing cutting-edge cybersecurity technologies. The ISG will provide a report, at least annually, to the entire Board regarding our cybersecurity threat risk management and strategy processes, covering topics such as data security posture, results from third-party assessments, progress towards
pre-determined
risk mitigation-related goals, the Adviser’s incident response plan, and cybersecurity threat risks or incidents and developments, as well as the steps the Adviser’s management has taken to respond to and mitigate such risks. The Adviser’s incident response plan provides guidelines for responding to cyber incidents and facilitates coordination across multiple operational functions of the Adviser. The incident response plan includes notification to the ISG and, depending on its nature, escalation to the Board, if appropriate. The Board is also encouraged to engage with the ISG on cybersecurity topics at other times, and material cybersecurity threats and risks are also considered by the Board in relation to other important matters that come before it.
Item 2. Properties
Our executive offices are located at 500 Park Avenue, New York, New York 10022, and are provided by SLR in accordance with the terms of the Investment Management Agreement. We believe that our office facilities are suitable and adequate for our business as it is presently conducted.
 
66

Item 3. Legal Proceedings
Neither we nor our subsidiaries are currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us or our subsidiaries. From time to time, we or our subsidiaries may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. Our business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of these legal or regulatory proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.
Item 4. Mine Safety Disclosures
Not applicable.
 
67

PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Units will only be sold (i) in the U.S. only to U.S. persons who are “accredited investors” within the meaning of Regulation D under the Securities Act and (ii) outside the U.S. in accordance with Regulation S under the Securities Act. There is no public market for our Units, and none is expected to develop. For this reason, the Company is not providing the performance graph required by Item 201(e) of Regulation
S-K.
Because Units are being acquired by investors in one or more transactions “not involving a public offering,” they are “restricted securities” and may be required to be held indefinitely. Our Units may not be sold, transferred, assigned, pledged or otherwise disposed of unless (i) our written consent is granted, and (ii) the Units are registered under applicable securities laws or specifically exempted from registration (in which case the unitholder may, at our option, be required to provide us with a legal opinion, in form and substance satisfactory to us, that registration is not required). We do not anticipate consenting to sales, transfers or assignments of Units. Accordingly, an investor must be willing to bear the economic risk of investment in the Units until we are liquidated. No sale, transfer, assignment, pledge or other disposition, whether voluntary or involuntary, of the Units may be made without our written consent.
Holders
As of February 23, 2024, there were 3 holders of record of our Units.
Recent Sales of Unregistered Securities
None, other than those already disclosed in certain Form
8-Ks
filed with the SEC.
Issuer Repurchases of Equity Securities
None.
Distributions
Tax characteristics of all distributions will be reported to Unitholders on Form 1099 after the end of the calendar year. Future quarterly distributions, if any, will be determined by our Board. We expect that our distributions to Unitholders will generally be from accumulated net investment income, from net realized capital gains or
non-taxable
return of capital, if any, as applicable.
We have elected to be taxed as a RIC under Subchapter M of the Code. To maintain our RIC tax treatment, we must distribute at least 90% of our ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any, out of the assets legally available for distribution. In addition, although we currently intend to distribute realized net capital gains (
i.e.
, net long-term capital gains in excess of short-term capital losses), if any, at least annually, out of the assets legally available for such distributions, we may in the future decide to retain such capital gains for investment.
We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, due to the asset coverage test applicable to us as a business development company, we may in the future be limited in our ability to make distributions. Also, our revolving credit facility may limit our ability to declare distributions if we default under certain provisions. If we do not distribute a certain percentage of our income annually, we will suffer adverse tax consequences, including possible loss of the tax benefits available to us as a regulated investment company. In addition, in accordance with GAAP and tax regulations, we include in income certain amounts that we have not yet received in cash, such as contractual
payment-in-kind
income, which represents contractual income added to the loan balance that becomes due at the end of the loan term, or the accrual of original issue or market discount. Since we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the requirement to distribute at least 90% of our investment company taxable income to obtain tax benefits as a regulated investment company.
 
68

With respect to the distributions to Unitholders, income from origination, structuring, closing and certain other upfront fees associated with investments in portfolio companies are treated as taxable income and accordingly, distributed to Unitholders.
We cannot assure Unitholders that they will receive any distributions at a particular level.
Item 6. Reserved
 
69

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
This Annual Report on Form
10-K
contains forward-looking statements that involve substantial risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors and undue reliance should not be placed thereon. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about the Company, our current and prospective portfolio investments, our industry, our beliefs and opinions, and our assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “will,” “may,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “should,” “targets,” “projects,” “outlook,” “potential,” “predicts” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:
 
   
our future operating results, including our ability to achieve objectives;
 
   
our business prospects and the prospects of our portfolio companies;
 
   
the impact of investments that we expect to make;
 
   
our contractual arrangements and relationships with third parties;
 
   
the dependence of our future success on the general economy and its impact on the industries in which we invest;
 
   
the impact of any protracted decline in the liquidity of credit markets on our business;
 
   
the ability of our portfolio companies to achieve their objectives;
 
   
the valuation of our investments in portfolio companies, particularly those having no liquid trading market;
 
   
market conditions and our ability to access different debt markets and additional debt and equity capital;
 
   
our expected financings and investments;
 
   
the adequacy of our cash resources and working capital;
 
   
the timing of cash flows, if any, from the operations of our portfolio companies;
 
   
the ability of the Adviser to locate suitable investments for us and to monitor and administer our investments;
 
   
the ability of the Adviser to attract and retain highly talented professionals;
 
   
the ability of the Adviser to adequately allocate investment opportunities among the Company and its other advisory clients;
 
   
any conflicts of interest posed by the structure of the management fee and incentive fee to be paid to the Adviser;
 
   
changes in political, economic or industry conditions, relations between the United States, Russia, Ukraine and other nations, the interest rate environment, certain regional bank failures or conditions affecting the financial and capital markets;
 
   
the escalating conflict in the Middle East;
 
   
changes in the general economy, slowing economy, rising inflation, risk of recession and risks in respect of a failure to increase the U.S. debt ceiling; and
 
   
our ability to anticipate and identify evolving market expectations with respect to environmental, social and governance matters, including the environmental impacts of our portfolio companies’ supply chains and operations.
These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:
 
   
an economic downturn could impair our portfolio companies’ ability to continue to operate, which could lead to the loss of some or all of our investments in such portfolio companies;
 
   
a contraction of available credit and/or an inability to access the equity markets could impair our lending and investment activities;
 
   
interest rate volatility could adversely affect our results, particularly because we use leverage as part of our investment strategy;
 
   
currency fluctuations could adversely affect the results of our investments in foreign companies, particularly to the extent that we receive payments denominated in foreign currency rather than U.S. dollars; and
 
   
the risks, uncertainties and other factors we identify in Item 1A. — Risk Factors contained in this Annual Report on Form
10-K
and in our other filings with the SEC.
 
70

Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans and objectives will be achieved. These risks and uncertainties include those described or identified in the section entitled “Item 1A. Risk Factors” and elsewhere in this report. These forward-looking statements apply only as of the date of this report. Moreover, we assume no duty and do not undertake to update the forward-looking statements.
The following analysis of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto contained elsewhere in this Annual Report on Form
10-K.
Overview
The Company (the “Company”, “we”, “us” our “our”) was formed as a limited liability company under the laws of the State of Delaware on July 7, 2020 as a
closed-end,
externally managed investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”), and have elected to be treated as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue code of 1986, as amended (the “Code”). As a BDC and a RIC, we are required to comply with certain regulatory requirements. As such, we are required to comply with various regulatory requirements, such as the requirement to invest at least 70% of our assets in “qualifying assets,” source of income limitations, RIC asset diversification requirements, and the requirement to distribute annually at least 90% of our taxable income
and tax-exempt interest.
SLR Capital Partners, LLC (the “Adviser” or “SLR”) serves as the Company’s investment adviser pursuant to an investment management agreement between the Company and the Adviser (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”). Subject to the overall supervision of the Company’s Board of Directors (the “Board”), the Adviser is responsible for managing the Company’s business and activities, including sourcing investment opportunities, conducting research, performing diligence on potential investments, structuring our investments, and monitoring the Company’s portfolio companies on an ongoing basis through a team of investment professionals.
Prior to the Company’s units being listed for trading on a national securities exchange (an “Exchange Listing”), the Adviser has also been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Administrative Coordinator supervises or provides the Company’s administrative services, including operational trade support, net asset value calculations, financial reporting, fund accounting, registrar and transfer agent services. The Administrative Coordinator also provides assistance to the Adviser in connection with communicating with investors and other persons with respect to the Company.
The Company is organized for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). Certain other investors may also invest directly in the Company. For those investors who invest through the Access Fund, we expect the Access Fund will issue a pro rata interest to each investor in the Access Fund (the “Access Fund LPs”) that, with respect to each Access Fund LP’s investment in the Access Fund, corresponds to such Access Fund LP’s pro rata share of the Units issued by the Company to the Access Fund. To purchase an interest in the Access Fund, each Access Fund LP will be required to represent that it is an “accredited investor” within the meaning of Rule 501(a) of Regulation D (an “Accredited Investor”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). To purchase Units, investors must be Accredited Investors and “qualified purchasers” for purposes of Section 3(c)(7) of the 1940 Act, or “knowledgeable employees” or companies owned exclusively by “knowledgeable employees” for purposes of the rules promulgated under the 1940 Act. Any sale of Units outside of the United States will be conducted in accordance with Regulation S under the Securities Act. We expect the Access Fund will pass its voting rights in respect of any Units of the Company held by the Access Fund through to the Access Fund LPs.
The Company’s principal focus is to invest in two differentiated strategies, first lien healthcare cash flow loans and first lien life science loans. First lien healthcare cash flow loans are expected to be made to private equity-owned upper middle market healthcare companies with EBITDA between approximately $25 million and $100 million. These loan tranches are expected to range in size from $100 million to $300 million. Healthcare cash flow loans are generally expected to have a five to six year final maturity and are often repaid within three years. First lien life science loans are expected to be made to venture capital owned
pre-commercialization
or early revenue drug and device development companies. These loan tranches are expected to range in size from $25 million to $150 million. Loans to life science companies are generally expected to have an initial interest-only period and then straight-line amortization with a four to five year final maturity. These loans are often repaid within two to three years. The Company expects to primarily invest in
non-investment
grade debt instruments. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments. The Company
 
71

expects to
co-invest
with other vehicles managed by SLR (the “SLR Funds”). The Company and the SLR Funds are under common control with SLR. There can be no assurance that the Company will be able to
co-invest
with such other funds, including as a result of legal restrictions and contractual restrictions and, as a result, the Company may not be able to meet its investment objective. The Company believes the potential scale resulting from
co-investments
with vehicles managed by SLR will provide the Company a significant advantage to source loans over other lenders that do not have the capital base to provide significant debt financing. The Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”.
The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and the Company may from time to time take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act.
Recent Developments
On January 23, 2024, the Company, through its wholly-owned subsidiary, SLR HC BDC SPV LLC (the “SPV”), reduced the size of its $75 million revolving credit facility due February 2027 (the “SPV Facility”) to $35 million.
Revenues
The Company generates revenue primarily in the form of interest income from the securities it holds and capital gains, if any, on investment securities that it may sell. Our debt investments typically bear interest at a floating rate usually determined on the basis of a benchmark Secured Overnight Financing Rate (“SOFR”), commercial paper rate, or the prime rate. Interest on our debt investments is generally payable monthly or quarterly. We may also generate revenue in the form of commitment, origination, structuring fees, and fees for providing managerial assistance.
The Company’s principal focus is to invest in first lien secured loans typically to upper middle market private equity-owned companies in the healthcare sector, with EBITDA between approximately $25 million and $100 million, generating significant free cash flow, and operating in the
non-cyclical
healthcare
sub-sectors
in which we have direct experience. These loan tranches are generally $100 million to $300 million. In addition, the Company intends to invest a portion of its assets in loans to late stage drug and medical device development companies. The Company seeks to leverage the significant capital base of the SLR platform to
co-invest
alongside other SLR managed investment vehicles enabling the Company to participate in larger, more attractive upper middle-market financings and have more control over structuring through greater ownership of a financing tranche.
Expenses
The Company (directly or indirectly) bears:
 
  (i)
all of its fees, costs, expenses and liabilities, all of its investment-related fees, costs, expenses and liabilities (including with respect to amounts incurred prior to the Company’s initial closing) and all of its other operating fees, costs, expenses and liabilities, including all fees, due diligence costs and other fees, costs, expenses and liabilities related to the identification, sourcing, evaluation, pursuit, acquisition, holding, appraisals, asset management, restructuring and disposing of investments, including all reasonable travel-related fees, costs, expenses and liabilities, including lodging and meals, all fees, costs, expenses and liabilities of legal counsel and financial and other advisers incurred in connection therewith, all fees, costs, expenses and liabilities of information technology services relating to the ongoing management of investments, and all other investment-related fees, costs, expenses and liabilities (to the extent not reimbursed by the relevant portfolio company);
 
  (ii)
all fees, costs, expenses and liabilities related to any audits or agreed upon procedures, tax forms and return preparations and filings, custodian fees and expenses, fund accounting, administrator services, financial statement preparation and reporting, web services for the benefit of Unitholders, delivery costs and expenses in connection with reporting obligations and communications and compliance services;
 
  (iii)
all fees, costs, expenses and liabilities relating to insurance policies (including director and officer liability insurance) maintained by or for the Company, including in respect of Portfolio Investments and/or personnel of the Adviser, the Adviser in its capacity as Administrative Coordinator and their affiliates;
 
  (iv)
other administrative fees, costs, and liabilities;
 
72

  (v)
all fees, costs, expenses and liabilities of brokers, transaction finders and other intermediaries, including brokerage commissions and spreads, and all other transaction-related fees, costs, expenses and liabilities, including reverse
break-up
fees;
 
  (vi)
all fees, costs, expenses and liabilities relating to derivatives and hedging transactions;
 
  (vii)
all principal amounts of, and interest expense on, borrowings and guarantees, and all other fees, costs, expenses and liabilities arising out of borrowings and guarantees, including the arranging and maintenance thereof, whether incurred by the Company or incurred or facilitated by a special purpose vehicle that makes Portfolio Investments;
 
  (viii)
management fees and incentive fees;
 
  (ix)
administration expenses;
 
  (x)
all fees, costs, expenses and liabilities incurred through the use or engagement of Service Providers;
 
  (xi)
all taxes, fees, penalties and other governmental charges levied against the Company and all fees, costs, expenses, penalties and liabilities related to tax compliance;
 
  (xii)
all fees, costs, expenses and liabilities of the Company’s legal counsel related to extraordinary matters, including expenses for any dispute resolution (including litigation and regulatory-related legal expenses);
 
  (xiii)
all fees, costs, expenses and liabilities relating to legal, governance and regulatory compliance and filings, including securities law filings relating to Portfolio Investments;
 
  (xiv)
all fees, costs, expenses and liabilities related to the Company’s indemnification or contribution obligations;
 
  (xv)
all fees, costs, expenses and liabilities for subscription services (to the extent such subscription is required by a placement agent);
 
  (xvi)
any required regulatory filings and related legal fees;
 
  (xvii)
all fees, costs, expenses and liabilities of liquidating the Company;
 
  (xviii)
transfer agent services;
 
  (xix)
any other fees, costs, expenses and liabilities not specifically assumed by the Adviser or the Administrative Coordinator;
 
  (xx)
all fees, costs, expenses and liabilities of the independent directors, including resources retained by the independent directors, or on their behalf, while representing and/or acting on behalf of all Unitholders; and
 
  (xxi)
all fees, costs, expenses and liabilities related to an exchange listing (including any transactions effectuated in connection therewith) or other business combination.
In addition, prior to an Exchange Listing, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company set forth in clauses (ii)-(iv) and the operating expenses included in
sub-clauses
(xiii) and (xvi) related to U.S. regulatory bodies above borne by the Company (directly or indirectly) will not exceed the following limits in any fiscal year: (A) if the Company has less than or equal to $400 million in Commitments, an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1.25 million, or (B) if the Company has greater than $400 million in Commitments, $2.25 million (such figure, the “Operating Expense Cap”). Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. Solely by way of example, if Commitments equal $350 million, the Operating Expense Cap will be equal to $2.125 million. For the avoidance of doubt, (i) the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder or in connection with (xxi) above, (ii) the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the Company’s portfolio investments at each quarter end and (iii) the Operating Expense Cap will no longer apply upon the effectuation of an Exchange Listing.
 
73

The Adviser or Administrative Coordinator and/or their affiliates may advance to the Company organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (the “Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) will be reimbursed by the Company for such advanced expenses in an amount not to exceed $500,000. The Company will be responsible for and pay (or reimburse) the Organizational Expenses subject to the cap described in the preceding sentence. Accordingly, $0.2 million of offering expenses were charged to capital and $0.2 million of organizational costs were expensed in 2021.
Macroeconomic Environment
Credit markets showed resilience in 2023 in the face of persistent but declining inflationary pressures and higher interest rates. The U.S. economy grew during the year and central banks have postured toward lower interest rates. The year ended with uncertainties around the economy and geopolitical issues.
Portfolio and Investment Activity
During the year ended December 31, 2023, we invested approximately $25.5 million across 23 portfolio companies. This compares to investing approximately $28.4 million across 21 portfolio companies for the year ended December 31, 2022. Investments sold or prepaid during the year ended December 31, 2023 totaled approximately $7.3 million versus approximately $12.5 million for the year ended December 31, 2022.
At December 31, 2023, our portfolio consisted of 29 portfolio companies and was invested greater than 99.9% in senior secured loans and less than 0.1% in common equity/equity interests/warrants, in each case, measured at fair value versus 20 portfolio companies invested greater than 99.9% in senior secured loans and less than 0.1% in common equity/equity interests/warrants, in each case, measured at fair value, at December 31, 2022.
At December 31, 2023, 94.0% of our income producing investment portfolio was floating rate and 6.0% was fixed rate, measured at fair value. At December 31, 2022, 91.6% of our income producing investment portfolio was floating rate and 8.4% was fixed rate, measured at fair value.
Critical Accounting Policies
The preparation of the consolidated financial statements in accordance with U.S. GAAP will require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses for the periods covered by such consolidated financial statements. Actual results could materially differ from those estimates, which the Company will evaluate on an ongoing basis. The Company has identified the following items as critical accounting policies. The Company will disclose these and any other critical accounting policies in the notes to its future consolidated financial statements.
Valuation of Portfolio Investments
In December 2020, the SEC adopted Rule
2a-5
under the 1940 Act addressing fair valuation of fund investments. The rule sets forth requirements for good faith determinations of fair value, as well as for the performance of fair value determinations, including related oversight and reporting obligations. The rule also defines “readily available market quotations” for purposes of the definition of “value” under the 1940 Act, and the SEC noted that this definition will apply in all contexts under the 1940 Act. The Company complies with Rule
2a-5’s
valuation requirements.
The Company conducts the valuation of its assets, pursuant to which the Company’s net asset value is determined, at all times consistent with GAAP, and the 1940 Act. The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as a
p
plicable; (5) oversee the reporting required by Rule
2a-5
under the 1940 Act; and (6) maintain recordkeeping requirements under Rule
2a-5.
 
74

It is anticipated that in respect of many of the Company’s assets, readily available market quotations will not be obtainable and that such assets will be valued at fair value. A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation.
For purposes of calculating the NAV, the Company’s assets will generally be valued as described in Note 2(b) to the Company’s Consolidated Financial Statements.
Hedging
We may, but are not required to, enter into interest rate, foreign exchange or other derivative agreements to hedge interest rate, currency, credit or other risks, but we do not generally intend to enter into any such derivative agreements for speculative purposes. Any derivative agreements entered into for speculative purposes are not expected to be material to the Company’s business or results of operations. These hedging activities, which will be in compliance with applicable legal and regulatory requirements, may include the use of futures, options and forward contracts. We will bear the costs incurred in connection with entering into, administering and settling any such derivative contracts. There can be no assurance any hedging strategy we employ will be successful.
Leverage
The Company is required to comply with the asset coverage requirements of the 1940 Act. The Company expects to employ leverage and otherwise incur indebtedness with respect to the portfolio both on a recourse and
non-recourse
basis (including and potentially through guarantees, derivatives, forward commitments and reverse repurchase agreements), but will not exceed the maximum amount permitted by the 1940 Act. The Company is generally permitted, under specified conditions, to issue senior securities in amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after such issuance. In connection with the organization of the Company, the Adviser, as the initial Unitholder, has authorized the Company to adopt the 150% asset coverage ratio. In connection with their subscriptions for Units, our Unitholders are required to acknowledge the Company’s ability to operate with an asset coverage ratio that may be as low as 150%. The Company will be exposed to the risks of leverage, which may be considered a speculative investment technique. The use of leverage magnifies the potential for gain and loss on amounts invested and therefore increases the risks associated with investing in our securities. In addition, the costs associated with our borrowings, including any increase in the management fee payable to the Adviser, will be borne by our Unitholders. As of December 31, 2023, the Company held $41.8 million of senior securities, for an asset coverage ratio of 155.0%.
Taxation as a Regulated Investment Company (“RIC”)
The Company elected to be treated as a RIC under Subchapter M of the Code and intends to qualify for taxation as a RIC annually. As a RIC, the Company generally will not pay corporate-level U.S. federal income taxes on any ordinary income or capital gains that it timely distributes to Unitholders as dividends. In order to qualify for taxation as a RIC, the Company is required, among other things, to be diversified at each quarter end and to timely distribute to its Unitholders at least 90% of investment company taxable income, as defined by the Code, for each year. There is no guarantee the Company will be able to maintain its status as a RIC. Depending on the level of taxable income earned in a given tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and pay a nondeductible 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company will accrue an estimated excise tax, if any, on estimated excess taxable income.
Recent Accounting Pronouncements
None.
 
75

Results of Operations
Results are shown for the fiscal years ended December 31, 2023 and December 31, 2022. Results for the fiscal period January 5, 2021 (commencement of operations) to December 31, 2021 can be found in Item 7 of the Company’s report on Form
10-K
filed on February 28, 2023, which is incorporated by reference herein.
Investment Income
For the fiscal years ended December 31, 2023 and 2022, gross investment income totaled $6.8 million and $3.7 million, respectively. The comparative increase in gross investment income is due to a substantial increase in the size of the income-producing portfolio along with higher SOFR.
Expenses
Expenses totaled $5.4 million and $3.0 million, respectively, for the fiscal years ended December 31, 2023 and 2022, of which $0.6 million and $0.4 million, respectively, were management fees and administration fees and $4.1 million and $1.9 million, respectively were interest and other credit facility expenses. Other general and administrative expenses totaled $0.7 million and $0.6 million, respectively, for the fiscal years ended December 31, 2023 and 2022. Expenses generally consist of management fees, administration fees, performance-based incentive fees, if any, administrative services expenses, insurance, legal expenses, directors’ fees and expenses, audit and tax expenses and other general and administrative expenses. Interest and other credit facility expenses generally consist of interest, unused fees, agency fees and financing costs, if any, among others. The comparative increase in expenses is due to higher interest expense from increased borrowings to support a larger portfolio, along with an increase in SOFR.
Net Investment Income
The Company’s net investment income totaled $1.4 million and $0.8 million or $1.33 and $1.07 per average unit, respectively, for the fiscal years ended December 31, 2023 and 2022.
Net Realized Loss
The Company had investment sales and prepayments totaling approximately $7.3 million and $12.5 million, respectively, for the fiscal years ended December 31, 2023 and 2022. Net realized losses over the same periods were $19 thousand and $16 thousand, respectively. Net realized losses for both comparative periods were primarily related to the sale of select assets.
Net Change in Unrealized Gain
For the fiscal years ended December 31, 2023 and 2022, net change in unrealized gain on the Company’s investments totaled $0.2 million and $0.2 million, respectively. Net unrealized gain for the fiscal year ended December 31, 2023 is primarily due to appreciation on our investments in SCP Eye Care, LLC, ONS MSO, LLC and CVAUSA Management, LLC, among others. Net unrealized gain for the fiscal year ended December 31, 2022 is primarily due to appreciation on our investments in Ivy Fertility Services, LLC and Arcutis Biotherapeutics, Inc., among others.
Net Increase in Unitholders’ Capital Resulting From Operations
For the fiscal years ended December 31, 2023 and 2022, the Company had a net increase in unitholders’ capital resulting from operations of $1.6 million and $0.9 million, respectively. For the same periods, income per average unit was $1.54 and $1.30, respectively.
Financial Condition, Liquidity and Capital Resources
Our primary uses of cash are for (i) investments in portfolio companies and other investments to comply with certain portfolio RIC diversification requirements, (ii) the cost of operations (including paying the Adviser), (iii) debt service of any borrowings, and (iv) cash distributions to our Unitholders.
 
76

Equity
During the period January 5, 2021 (commencement of operations) to December 31, 2023, on a net basis, the Company sold and issued 1,069,642 Units at an average price of $22.44 per Unit, for net proceeds of $24.0 million. All of our outstanding Units were issued and sold in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. Unfunded equity capital commitments totaled $59.9 million at December 31, 2023. The Offering Period of the Company ended on December 31, 2022.
Debt
SPV Facility
—On February 18, 2022, the Company, through its wholly-owned subsidiary, SLR HC BDC SPV LLC (the “SPV”), entered into the $50 million SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. On May 30, 2023, the SPV Facility was amended, increasing commitments to $75 million. The stated interest rate on the SPV Facility is Term SOFR plus 3.07% with no SOFR floor requirement and the final maturity date is February 18, 2027. The fee on undrawn commitments is currently 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $24.2 million of borrowings outstanding under the SPV Facility.
Subscription Facility
—On March 19, 2021, the Company established the $25 million Subscription Facility with ING Capital LLC. The stated interest rate on the Subscription Facility is SOFR plus
2.75-3.00%
and the current stated maturity date is March 15, 2024. On December 14, 2021, the Subscription Facility was amended, allowing for increased borrowing base availability, among other changes. On June 14, 2023, the Subscription Facility entered into a second amendment, which replaced the benchmark rate of LIBOR with SOFR. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $17.6 million of borrowings outstanding under the Subscription Facility.
Cash Equivalents
We deem certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities as cash equivalents. The Company makes purchases that are consistent with its purpose of making investments in securities described in paragraphs 1 through 3 of Section 55(a) of the 1940 Act. From time to time, including at or near the end of each fiscal quarter, we consider using various temporary investment strategies for our business. One strategy includes taking proactive steps by utilizing cash equivalents as temporary assets with the objective of enhancing our investment flexibility pursuant to Section 55 of the 1940 Act. More specifically, from
time-to-time
we may purchase U.S. Treasury bills or other high-quality, short-term debt securities at or near the end of the quarter and typically close out the position on a net cash basis subsequent to quarter end. We may also utilize repurchase agreements or other balance sheet transactions, including drawing down on our credit facilities, as deemed appropriate. The amount of these transactions or such drawn cash for this purpose is excluded from total assets for purposes of computing the asset base upon which the management fee is determined. We held approximately $10 million par amount in cash equivalents as of December 31, 2023.
Contractual Obligations
We have entered into certain contracts under which we have material future commitments. We have entered into the Investment Management Agreement with the Adviser in accordance with the 1940 Act. Pursuant to the Investment Management Agreement we have entered into with the Adviser, we pay the Adviser certain management and incentive fees prior to and following an Exchange Listing. Prior to an Exchange Listing, we pay the Adviser, in its capacity as Administrative Coordinator, an administration fee for administrative and coordination services, each as defined and described further below. Following an Exchange Listing, the Company intends to enter into a separate administration agreement with an affiliate pursuant to which administrative services would be provided to the Company, as described further below. The
Pre-Exchange
Listing Administration Fee will not offset any fees paid to the Adviser. Under the Investment Management Agreement, prior to an Exchange Listing, the Administrative Coordinator may engage or delegate certain administrative functions to third parties or affiliates on behalf of the Company. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain
on-going,
routine,
non-investment-related
administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company, and (iii) certain Unitholder servicing functions.
 
77

    
Payments due by Period as of December 31, 2023
(dollars in millions)
 
    
Total
    
Less than
1 year
    
1-3 years
    
3-5 years
    
More than
5 years
 
Credit facilities (1)
   $ 41.8      $ 17.6    $ —       $ 24.2    $ — 
 
(1)
At December 31, 2023, we had a total of $58.2 million of unused borrowing capacity under our credit facilities, subject to borrowing base limits.
If any of the contractual obligations discussed above are terminated, our costs under any new agreements that we enter into may increase. In addition, we would likely incur significant time and expense in locating alternative parties to provide the services we expect to receive under the Investment Management Agreement. Any new investment advisory agreement would also be subject to approval by our Unitholders.
Off-Balance
Sheet Arrangements
From
time-to-time
and in the normal course of business, the Company may make unfunded capital commitments to current or prospective portfolio companies. Typically, the Company may agree to provide delayed-draw term loans or, to a lesser extent, revolving loan or equity commitments. These unfunded capital commitments always take into account the Company’s liquidity and cash available for investment, portfolio and issuer diversification, and other considerations. Accordingly, the Company had the following unfunded capital commitments at December 31, 2023 and December 31, 2022, respectively:
 
78

    
December 31,
2023
    
December 31,
2022
 
(in millions)
     
AAH Topco, LLC
   $ 2.3      $ —   
OIS Management Services, LLC
     1.7        —   
Southern Orthodontic Partners Management, LLC
     1.3        0.7  
Ardelyx, Inc.
     1.3        0.7  
CVAUSA Management, LLC
     1.1        —   
Retina Midco, Inc.
     1.0        —   
Orthopedic Care Partners Management, LLC
     0.9        0.5  
United Digestive MSO Parent, LLC
     0.4        —   
SCP Eye Care, LLC
     0.3        1.0  
Vertos Medical, Inc.
     0.3        —   
Medrina, LLC
     0.2        —   
UVP Management, LLC
     0.2        —   
Urology Management Holdings, Inc.
     0.2        —   
SunMed Group Holdings, LLC
     0.1        0.1  
Exactcare Parent, Inc.
     0.1        —   
WCI-BXC
Purchaser, LLC
     0.1        —   
Outset Medical, Inc.
     —         3.1  
Apeel Technology, Inc.
     —         2.9  
Glooko, Inc.
     —         1.6  
Arcutis Biotherapeutics, Inc.
     —         0.8  
Oral Surgery Partners Holdings, LLC
     —         0.8  
Plastics Management, LLC
     —         0.8  
Spectrum Pharmaceuticals, Inc.
     —         0.8  
Cerapedics, Inc.
     —         0.6  
Pediatric Home Respiratory Services, LLC
     —         0.6  
Meditrina, Inc.
     —         0.3  
Ivy Fertility Services, LLC
     —         0.1  
BayMark Health Services, Inc.
     —         0.1  
  
 
 
    
 
 
 
Total Commitments
   $ 11.5      $ 15.5  
  
 
 
    
 
 
 
The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of December 31, 2023 and December 31, 2022, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.
Distributions
Tax characteristics of all distributions will be reported to Unitholders on Form 1099 after the end of the calendar year. Future quarterly distributions, if any, will be determined by our Board. We expect that our distributions to Unitholders will generally be from accumulated net investment income, from net realized capital gains or
non-taxable
return of capital, if any, as applicable.
We have elected to be taxed as a RIC under Subchapter M of the Code. To maintain our RIC tax treatment, we must distribute at least 90% of our ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any, out of the assets legally available for distribution. In addition, although we currently intend to distribute realized net capital gains (
i.e.
, net long-term capital gains in excess of short-term capital losses), if any, at least annually, out of the assets legally available for such distributions, we may in the future decide to retain such capital gains for investment.
We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, due to the asset coverage test applicable to us as a business development company, we may in the future be limited in our ability to make distributions. Also, our revolving credit facility may limit our ability to declare distributions if we default under certain provisions. If we do not distribute a certain percentage of our income annually, we will suffer adverse tax consequences, including possible loss of the tax benefits available to us as
 
79

a RIC. In addition, in accordance with GAAP and tax regulations, we include in income certain amounts that we have not yet received in cash, such as contractual
payment-in-kind
income, which represents contractual income added to the loan balance that becomes due at the end of the loan term, or the accrual of original issue or market discount. Since we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the requirement to distribute at least 90% of our investment company taxable income to obtain tax benefits as a RIC.
With respect to the distributions to Unitholders, income from origination, structuring, closing and certain other upfront fees associated with investments in portfolio companies are treated as taxable income and accordingly, distributed to Unitholders.
Related Parties
We have entered into the Investment Management Agreement with the Adviser pursuant to which we pay management fees, administrative coordinator fees and incentive fees to the Adviser.
Mr. Gross, our Chairman,
Co-Chief
Executive Officer and President and Mr. Spohler, our
Co-Chief
Executive Officer, Chief Operating Officer and board member, are managing members and senior investment professionals of, and have financial and controlling interests in, the Adviser. In addition, Mr. Kajee, our Chief Financial Officer and Treasurer serves as the Chief Financial Officer for the Adviser and Mr. Talarico, our Chief Compliance Officer and Secretary, serves as Partner, General Counsel and Chief Compliance Officer for the Adviser. The Adviser may also manage other funds in the future that may have investment mandates that are similar, in whole and in part, with ours. For example, the Adviser presently serves as investment adviser to SLR Investment Corp., a publicly traded BDC, which focuses on investing in senior secured loans, including financing leases and to a lesser extent, unsecured loans and equity securities, SCP Private Credit Income BDC LLC, an unlisted BDC that focuses on investing primarily in senior secured loans, including
non-traditional
asset-based loans and first lien loans, and SLR Private Credit BDC II LLC, an unlisted BDC focused on first lien senior secured floating rate loans. In addition, Mr. Gross, our Chairman,
Co-Chief
Executive Officer and President, Mr. Spohler, our
Co-Chief
Executive Officer and Chief Operating Officer, Mr. Kajee, our Chief Financial Officer, and Mr. Talarico, our Chief Compliance Officer and Secretary, serve in similar capacities for SLR Investment Corp., SCP Private Credit Income BDC LLC and SLR Private Credit BDC II LLC. The Adviser and certain investment advisory affiliates may determine that an investment is appropriate for us and for one or more of those other funds. In such event, depending on the availability of such investment and other appropriate factors, the Adviser or its affiliates may determine that we should invest
side-by-side
with one or more other funds. Any such investments will be made only to the extent permitted by applicable law and interpretive positions of the SEC and its staff, and consistent with the Adviser’s allocation procedures. On June 13, 2017, the Adviser received an exemptive order that permits the Company to participate in
negotiated co-investment transactions
with certain affiliates, in a manner consistent with the Company’s investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors, and pursuant to various conditions (the “Order”). If the Company is unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although the Adviser’s investment professionals will endeavor to allocate investment opportunities in a fair and equitable manner, the Company and its Unitholders could be adversely affected to the extent investment opportunities are allocated among us and other investment vehicles managed or sponsored by, or affiliated with, our executive officers, directors and members of the Adviser. In addition, we have adopted a formal code of ethics that governs the conduct of our officers and directors. Our officers and directors also remain subject to the duties imposed by both the 1940 Act and the Delaware Limited Liability Company Act.
Item 7A. Quantitative and Qualitative Disclosures about Market Risk
We are subject to financial market risks, including changes in interest rates. Uncertainty with respect to interest rates, inflationary pressures, risks in respect of a failure to increase the U.S. debt ceiling or a downgrade in the U.S. credit rating, the war between Ukraine and Russia, certain regional bank failures, an inflationary environment, the ongoing war in the Middle East and health epidemics and pandemics introduced significant volatility in the financial markets, and the effects of this volatility have materially impacted and could continue to materially impact our market risks. Because we fund a portion of our investments with borrowings, our net investment income is affected by the difference between the rate at which we invest and the rate at which we borrow. As a result, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In a low interest rate environment, including a reduction of SOFR to zero, the difference between the total interest income earned on interest earning assets and the total interest expense incurred on interest bearing liabilities may be compressed, reducing our net interest income and potentially adversely affecting our
 
80

operating results. Conversely, in a rising interest rate environment, such as the recent economic environment, such difference could potentially increase thereby increasing our net investment income. During the fiscal year ended December 31, 2023, certain investments in our investment portfolio had floating interest rates. These floating rate investments were primarily based on floating SOFR and typically have durations of one to three months after which they reset to current market interest rates. Additionally, some of these investments have floors. The Company also has revolving credit facilities that are generally based on floating SOFR. Assuming no changes to our balance sheet as of December 31, 2023 and no new defaults by portfolio companies, a hypothetical one percent decrease in SOFR on our comprehensive floating rate assets and liabilities would decrease our net investment income by approximately fifteen cents per average unit over the next twelve months. Assuming no changes to our balance sheet as of December 31, 2023 and no new defaults by portfolio companies, a hypothetical one percent increase in SOFR on our comprehensive floating rate assets and liabilities would increase our net investment income by approximately fifteen cents per average unit over the next twelve months. However, we may hedge against interest rate fluctuations from
time-to-time
by using standard hedging instruments such as futures, options, swaps and forward contracts subject to the requirements of the 1940 Act. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in any benefits of certain changes in interest rates with respect to our portfolio of investments. At December 31, 2023, we have no interest rate hedging instruments outstanding on our balance sheet.
 
Increase (Decrease) in SOFR
     (1.00 %)      1.00
  
 
 
   
 
 
 
Increase (Decrease) in Net Investment Income Per Unit Per Year
   $ (0.15   $ 0.15  
  
 
 
   
 
 
 
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 
    
Page
 
     82  
     83  
     84  
     85  
     86  
     87  
     93  
 
81

Report of Independent Registered Public Accounting Firm
To the Unitholders’ and Board of Directors
SLR HC BDC LLC:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated statements of assets and liabilities, including the
consolidated
schedules of investments, of SLR HC BDC LLC (the Company) (and subsidiary) as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in unitholders’ capital, and cash flows for the years ended December 31, 2023 and 2022 and for the period January 5, 2021 (commencement of operations) to December 31, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years ended December 31, 2023 and 2022 and for the period January 5, 2021 to December 31, 2021, in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our procedures included confirmation of securities owned as of December 31, 2023 and 2022, by correspondence with the custodian, portfolio companies or agents. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
/s/ KPMG LLP
We have served as the Company’s auditor since 2020.
New York, New York
February 27, 2024
 
82

SLR HC BDC LLC
Consolidated Statements of Assets and Liabilities
(in thousands, except unit amounts)
 
    
December 31, 2023
   
December 31, 2022
 
Assets
    
Investments at fair value:
    
Non-controlled/non-affiliated
investments (cost: $62,743 and $43,602, respectively)
   $ 63,275     $ 43,897  
Cash
     1,871       3,986  
Cash equivalents (cost: $9,919 and $29,828, respectively)
     9,919       29,828  
Interest receivable
     503       271  
Prepaid expenses
     14       15  
  
 
 
   
 
 
 
Total assets
   $ 75,582     $ 77,997  
  
 
 
   
 
 
 
Liabilities
    
Revolving credit facility due February 2027 (the “SPV Facility”) ($24,210 and $14,675 face amounts, respectively, reported net of unamortized debt issuance costs of $709 and $624, respectively. See note 5)
   $ 23,501     $ 14,051  
Revolving credit facility due March 2024 (the “Subscription Facility”) ($17,550 and $13,800 face amounts, respectively, reported net of unamortized debt issuance costs of $28 and $49, respectively. See note 5)
     17,522       13,751  
Payable for cash equivalents purchased
     9,919       29,828  
Management fee payable (see note 3)
     524       325  
Administration fee payable (see note 3)
     12       8  
Interest payable (see note 5)
     904       493  
Other liabilities and accrued expenses
     231       193  
  
 
 
   
 
 
 
Total liabilities
   $ 52,613     $ 58,649  
  
 
 
   
 
 
 
Commitments and contingencies (see note 6)
    
Unitholders’ Capital
    
Common Unitholders’ capital (1,069,642 and 888,565 units, respectively, issued and outstanding, see note 2f)
     23,393       19,461  
Accumulated distributable net loss (see note 2f)
     (424     (113
  
 
 
   
 
 
 
Total unitholders’ capital
   $ 22,969     $ 19,348  
  
 
 
   
 
 
 
Total liabilities and unitholders’ capital
   $ 75,582     $ 77,997  
  
 
 
   
 
 
 
Net asset value per unit
   $ 21.47     $ 21.77  
  
 
 
   
 
 
 
See notes to consolidated financial statements.
 
83
SLR HC BDC LLC
Consolidated Statements of Operations
(in thousands, except unit amounts)
 
    
Year ended
December 31, 2023
    
Year ended
December 31, 2022
    
For the period
January 5, 2021* to
December 31, 2021
 
Investment Income:
        
Interest income from
non-controlled/non-affiliated
investments
   $ 6,696      $ 3,732      $ 1,018  
Other income from
non-controlled/non-affiliated
investments
     71        16        1  
  
 
 
    
 
 
    
 
 
 
Total investment income
     6,767        3,748        1,019  
  
 
 
    
 
 
    
 
 
 
Expenses:
        
Management fees (see note 3)
   $ 565      $ 419      $ 224  
Administration fees (see note 3)
     42        27        9  
Interest and other credit facility expenses (see note 5)
     4,058        1,939        398  
Services fee
                   250  
Organizational expenses
                   229  
Other general and administrative expenses
     737        592        732  
  
 
 
    
 
 
    
 
 
 
Total expenses
     5,402        2,977        1,842  
  
 
 
    
 
 
    
 
 
 
Net investment income (loss)
   $ 1,365      $ 771      $ (823
  
 
 
    
 
 
    
 
 
 
Realized and unrealized gain (loss) on investments and cash equivalents:
        
Net realized loss on
non-controlled/non-affiliated
investments and cash equivalents
   $ (19)      $ (16)      $ (5)  
Net change in unrealized gain on
non-controlled/non-affiliated
investments and cash equivalents
     237        178        117  
  
 
 
    
 
 
    
 
 
 
Net realized and unrealized gain on
non-controlled/non-affiliated
investments and cash equivalents
     218        162        112  
  
 
 
    
 
 
    
 
 
 
Net Increase (Decrease) in Unitholders’ Capital Resulting From Operations
  
$
1,583
 
  
$
933
 
  
$
(711
  
 
 
    
 
 
    
 
 
 
Net Income (Loss) Per Unit
   $ 1.54      $ 1.30      $ (2.57
  
 
 
    
 
 
    
 
 
 
 
*
Commencement of operations
See notes to consolidated financial statements.
 
84

SLR HC BDC LLC
Consolidated Statements of Changes in Unitholders’ Capital
(in thousands, except unit amounts)
 
    
Year ended
December 31, 2023
   
Year ended
December 31, 2022
   
For the
period
January 5,
2021* to
December 31,
2021
 
Increase (decrease) in unitholders’ capital resulting from operations:
      
Net investment income (loss)
   $ 1,365     $ 771     $ (823
Net realized loss
     (19     (16     (5
Net change in unrealized gain
     237       178       117  
  
 
 
   
 
 
   
 
 
 
Net increase (decrease) in unitholders’ capital resulting from operations
     1,583       933       (711
  
 
 
   
 
 
   
 
 
 
Distributions to unitholders (see note 9a):
      
From distributable earnings
     (1,870     (697      
From return of capital
     (92            
  
 
 
   
 
 
   
 
 
 
Net distributions to Unitholders
     (1,962     (697      
  
 
 
   
 
 
   
 
 
 
Increase (decrease) in unitholders’ capital resulting from capital activity (see note 7):
      
Contributions
     4,000       4,500       15,501  
Less offering costs
                 (177
Cancellation
                 (1
  
 
 
   
 
 
   
 
 
 
Net increase in unitholders’ capital resulting from capital activity
     4,000       4,500       15,323  
  
 
 
   
 
 
   
 
 
 
Total increase in unitholders’ capital
     3,621       4,736       14,612  
Unitholders’ capital, beginning of period
     19,348       14,612        
  
 
 
   
 
 
   
 
 
 
Unitholders’ capital, end of period
   $ 22,969     $ 19,348     $ 14,612  
  
 
 
   
 
 
   
 
 
 
Capital unit activity (see note 7):
      
Units issued
     181,077       206,138       682,467  
Units canceled
                 (40
  
 
 
   
 
 
   
 
 
 
Net increase from capital unit activity
     181,077       206,138       682,427  
  
 
 
   
 
 
   
 
 
 
 
*
Commencement of operations
See notes to consolidated financial statements.
 
85

SLR HC BDC LLC
Consolidated Statements of Cash Flows
(in thousands)
 
    
Year ended
December 31, 2023
   
Year ended
December 31, 2022
   
For the period
January 5, 2021* to
December 31, 2021
 
Cash Flows from Operating Activities:
      
Net increase (decrease) in unitholders’ capital resulting from
operations
   $ 1,583     $ 933     $ (711
Adjustments to reconcile net increase (decrease) in unitholders’ capital resulting from operations to net cash used in operating activities:
      
Net realized loss on investments and cash equivalents
     19       16       5  
Net change in unrealized gain on investments
     (237     (178     (117
Deferred financing costs
     336       345       133  
(Increase) decrease in operating assets:
      
Purchase of investments
     (25,482     (28,404     (33,983
Proceeds from disposition of investments
     7,164       12,289       6,870  
Net accretion of discount on investments
     (469     (234     (61
Capitalization of
payment-in-kind
income
     (373     (100      
Interest receivable
     (232     (100     (171
Prepaid expenses
     1       (1     (14
Increase (decrease) in operating liabilities:
      
Payable for cash equivalents purchased
     (19,909     9,828       20,000  
Management fee payable
     199       262       63  
Administration fee payable
     4       4       4  
Interest payable
     411       454       39  
Other liabilities and accrued expenses
     38       (221     414  
  
 
 
   
 
 
   
 
 
 
Net Cash Used in Operating Activities
     (36,947     (5,107     (7,529
  
 
 
   
 
 
   
 
 
 
Cash Flows from Financing Activities:
      
Contributions from unitholders
     4,000       4,500       15,501  
Cancellation of units
                 (1
Cash distributions paid
     (1,962     (697      
Offering costs
                 (177
Proceeds from borrowings
     30,635       42,401       24,723  
Repayments of borrowings
     (17,750     (27,750     (12,050
  
 
 
   
 
 
   
 
 
 
Net Cash Provided by Financing Activities
     14,923       18,454       27,996  
  
 
 
   
 
 
   
 
 
 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
     (22,024     13,347       20,467  
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
     33,814       20,467        
  
 
 
   
 
 
   
 
 
 
CASH AND CASH EQUIVALENTS AT END OF PERIOD
   $ 11,790     $ 33,814       20,467  
  
 
 
   
 
 
   
 
 
 
Supplemental disclosure of cash flow information:
      
Cash paid for interest
   $ 3,647     $ 1,485     $ 359  
  
 
 
   
 
 
   
 
 
 
*
Commencement of operations
See notes to consolidated financial statements.
 
86
SLR HC BDC LLC
Consolidated Schedule of Investments
December 31, 2023
(in thousands, except share/unit amounts)
 
Description
 
  
Industry
  
Spread above
Index
(2)
    
Floor
 
   
Interest Rate 
(1)
   
Acquisition
Date
    
Maturity Date
    
Par Amount
    
Cost
    
Fair
Value
 
Bank Debt/Senior Secured Loans — 275.4%
 
Arcutis Biotherapeutics, Inc.
(3)(4)
   Pharmaceuticals      S+745        0.10     12.90     12/22/2021        1/1/2027      $ 6,288      $ 6,422      $ 6,414  
Ardelyx, Inc.
(3)(4)
   Pharmaceuticals      S+795        1.00     13.32     2/23/2022        3/1/2027        1,548        1,559        1,596  
BayMark Health Services, Inc.
(4)
   Health Care
Providers &
Services
     S+500        1.00     10.61     6/29/2021        6/11/2027        4,026        4,000        4,026  
BridgeBio Pharma, Inc.
(3)(4)
   Biotechnology      —         —        9.00 %
(6)
 
    11/17/2021        11/17/2026        3,767        3,765        3,777  
Cerapedics Inc.
(4)
   Biotechnology      S+620        2.75     11.55     12/27/2022        1/1/2028        3,348        3,357        3,348  
CVAUSA Management, LLC
(4)
   Health Care
Providers &
Services
     S+650        1.00     11.74     5/22/2023        5/22/2029        1,691        1,643        1,691  
Exactcare Parent, Inc.
4)
   Health Care
Providers &
Services
     S+650        1.00     11.89     11/3/2023        11/5/2029        934        909        908  
Fertility (ITC) Investment Holdco, LLC
(4)
   Health Care
Providers &
Services
     S+650        1.00     11.97     1/4/2023        1/3/2029        2,643        2,574        2,643  
Glooko, Inc.
(4)
   Health Care
Technology
     S+790        0.10     13.35     9/30/2021        10/1/2026        907        919        948  
Maxor Acquisition, Inc.
(4)
   Health Care
Providers &
Services
     S+675        1.00     12.48     3/1/2023        3/1/2029        1,761        1,714        1,761  
Meditrina, Inc.
(4)
   Health Care
Equipment &
Supplies
     S+550        3.45     10.85     12/20/2022        12/1/2027        312        313        315  
Medrina, LLC
(4)
   Health Care
Providers &
Services
     S+625        1.00     11.67     10/20/2023        10/20/2029        697        680        680  
OIS Management Services, LLC
(4)
   Health Care
Providers &
Services
     S+575        0.75     11.20     12/29/2023        11/16/2028        875        868        858  
ONS MSO, LLC
(4)
   Health Care
Providers &
Services
     S+625        1.00     11.62     2/10/2023        7/8/2026        2,527        2,469        2,527  
Orth
op
edic Care Partners Management, LLC
(4)
   Health Care
Providers &
Services
     S+650        1.00     12.11     8/17/2022        5/16/2024        1,673        1,669        1,673  
Outset Medical, Inc.
(3)(4)
   Health Care
Equipment &
Supplies
     S+515        2.75     10.50     11/3/2022        11/1/2027        3,909        3,918        3,918  
Plastics Management, LLC
(4)
   Health Care
Providers &
Services
     S+500        1.00     10.45     8/26/2021        8/18/2027        3,861        3,824        3,861  
Retina Midco, Inc.
(4)
   Health Care
Providers &
Services
     S+575        1.00     11.38     12/18/2023        1/31/2026        2,897        2,840        2,839  
RQM+ Corp.
(4)
   Life Sciences
Tools &
Services
     S+575        1.00     11.36     8/20/2021        8/12/2026        3,992        3,957        3,992  
SCP Eye Care, LLC
(4)
   Health Care
Providers &
Services
     S+575        1.00     11.19     10/6/2022        10/5/2029        3,499        3,399        3,499  
Southern Orthodontic Partners Management, LLC
(4)
   Health Care
Providers &
Services
     S+625        1.00     11.72     6/3/2022        1/27/2026        2,075        2,050        2,075  
SunMed Group Holdings, LLC
(4)
   Health Care
Equipment &
Supplies
     S+550        0.75     10.96     6/16/2021        6/16/2028        1,950        1,926        1,950  
United Digestive MSO Parent, LLC
(4)
   Health Care
Providers &
Services
     S+675        1.00     12.25     3/30/2023        3/30/2029        982        955        982  
Urology Management Holdings, Inc.
(4)
   Health Care
Providers &
Services
     S+650        1.00     11.93     2/7/2023        6/15/2026        920        897        913  
UVP Management, LLC
(4)
   Health Care
Providers &
Services
     S+625        1.00     11.75     9/18/2023        9/15/2025        1,285        1,257        1,253  
Vapotherm, Inc.
(4)
   Health Care
Equipment &
Supplies
     S+930        1.00     14.75 %
(7)
 
    2/18/2022        2/1/2027        3,384        3,437        3,435  
Vertos Medical, Inc.
(4)
   Health Care
Equipment &
Supplies
     S+515        4.75     10.50     6/14/2023        7/1/2028        567        563        567  
WCI-BXC
Purchaser, LLC
   Distributors      S+625        1.00     11.64     11/6/2023        11/6/2030        840        820        819  
                     
 
 
    
 
 
 
Total Bank Debt/Senior Secured Loans
 
  
$
62,704
 
  
$
63,268
 
     
 
 
    
 
 
 
                    
Shares/Warrants
       
Common Equity/Warrants—0.1%
                        
Assertio Holdings, Inc. Common Stock
(8)
*
  
Pharmaceuticals
               7/31/2023        1,088      $ 4      $ 1  
Meditrina, Inc. Warrants
*
   Health Care
Equipment &
Supplies
               12/20/2022        2,719        2        2  
Vapotherm, Inc. Warrants
*
   Health Care
Equipment &
Supplies
               2/18/2022        7,029        29        —   
Vertos Medical, Inc. Warrants
*
   Health Care
Equipment &
Supplies
               6/14/2023        13,779        4        4  
     
 
 
    
 
 
 
Total Common Equity/Warrants
 
  
$
39
 
  
$
7
 
     
 
 
    
 
 
 
Total Investments
(5)
 
275.5%
 
     
$
62,743
 
  
$
63,275
 
     
 
 
    
 
 
 
Cash Equivalents — 43.2%
 
        
U.S. Treasury Bill
   Government             12/29/2023        2/27/2024      $ 10,000      $ 9,919      $ 9,919  
     
 
 
    
 
 
 
Total Investments & Cash Equivalents
 
318.7%
 
  
$
72,662
 
  
$
73,194
 
Liabilities in Excess of Other Assets — (218.7%)
 
        (50,225
        
 
 
 
Net Assets — 100.0%
 
     
 
$ 22,969
 
                        
 
 
 
 
(1)
Floating rate debt investments typically bear interest at a rate determined by reference to either the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) has provided the current interest rate in effect as of December 31, 2023.
(2)
Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor.
(3)
Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making
follow-on
investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2023, on a fair value basis,
non-qualifying
assets in the portfolio represented 20.8% of the total assets of the Company.
(4)
Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
See notes to consolidated financial statements.
 
87

SLR HC BDC LLC
Consolidated Schedule of Investments (continued)
December 31, 2023
(in thousands)
 
(5)
Aggregate net unrealized depreciation for U.S. federal income tax purposes is $241; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $600 and $841, respectively, based on a tax cost of $63,516. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
(6)
BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
(7)
Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.
(8)
Denotes a Level 1 investment.
*
Non-income
producing security.
 
Industry Classification
  
Percentage of Total
Investments (at
fair value) as of
December 31, 2023
 
Health Care Providers & Services
     50.9
Health Care Equipment & Supplies
     16.1
Pharmaceuticals
     12.7
Biotechnology
     11.3
Life Science Tools & Services
     6.3
Health Care Technology
     1.5
Distributors
     1.2
  
 
 
 
Total Investments
     100.0
  
 
 
 
See notes to consolidated financial statements.
 
88

SLR HC BDC LLC
Consolidated Schedule of Investments
December 31, 2022
(in thousands, except share/unit amounts)
 
Description
 
  
Industry
    
Spread above
Index
(2)
    
Floor
 
   
Interest Rate 
(1)
   
Acquisition
Date
    
Maturity Date
    
Par Amount
    
Cost
    
Fair
Value
 
Bank Debt/Senior Secured Loans — 226.8%
 
     
Apeel Technology, Inc.
(4)
     Biotechnology        S+625        1.00     8.75     6/29/2022        6/1/2027      $ 317      $ 315      $ 317  
Arcutis Biotherapeutics, Inc.
(3)(4)
     Pharmaceuticals        L+745        0.10     11.62     12/22/2021        1/1/2027        6,288        6,322        6,367  
Ardelyx, Inc.
(3)(4)
     Pharmaceuticals        L+795        0.10     12.12     2/23/2022        3/1/2027        851        854        853  
BayMark Health Services, Inc.
(4)
    
 
Health Care
Providers &
Services
 
 
 
     L+500        1.00     9.73     6/29/2021        6/11/2027        4,068        4,034        4,068  
BridgeBio Pharma, Inc.
(3)(4)
     Biotechnology                     9.00 %
(6)
 
    11/17/2021        11/17/2026        3,683        3,656        3,683  
Cerapedics Inc.
(4)
     Biotechnology        S+620        2.75     10.52     12/27/2022        1/1/2028        2,494        2,488        2,488  
Glooko, Inc.
(4)
     Health Care
Technology
 
 
     L+790        0.10     12.07     9/30/2021        10/1/2026        1,452        1,456        1,455  
Ivy Fertility Services, LLC
(4)
    
 
Health Care
Providers &
Services
 
 
 
     L+625        1.00     10.39     12/22/2021        2/25/2026        2,697        2,659        2,724  
Meditrina, Inc.
(4)
    
 
Health Care
Equipment &
Supplies
 
 
 
     S+550        3.45     9.82     12/20/2022        12/1/2027        312        309        311  
Oral Surgery Partners Holdings, LLC
    
 
Health Care
Providers &
Services
 
 
 
     S+625        1.00     10.92     11/29/2022        5/10/2024        567        557        556  
Orthopedic Care Partners Management, LLC
(4)
    
 
Health Care
Providers &
Services
 
 
 
     S+650        1.00     10.91     8/17/2022        5/16/2024        1,087        1,080        1,087  
Outset Medical, Inc.
(3)(4)
    
 
Health Care
Equipment &
Supplies
 
 
 
     S+515        2.75     9.33     11/3/2022        11/1/2027        3,052        3,034        3,029  
Pediatric Home Respiratory Services, LLC
(4)
    
 
Health Care
Providers &
Services
 
 
 
     S+625        1.00     10.67     8/19/2022        12/4/2024        463        457        459  
Plastics Management, LLC
(4)
    
 
Health Care
Providers &
Services
 
 
 
     S+500        1.00     9.89     8/26/2021        8/18/2027        3,107        3,069        3,107  
RQM+ Corp.
(4)
    
 
Life Sciences
Tools &
Services
 
 
 
     S+575        1.00     10.59     8/20/2021        8/12/2026        4,033        3,986        4,033  
SCP Eye Care, LLC
(4)
    
 
Health Care
Providers &
Services
 
 
 
     S+575        1.00     9.46     10/6/2022        10/5/2029        2,905        2,813        2,810  
Southern Orthodontic Partners Management, LLC
(4)
    
 
Health Care
Providers &
Services
 
 
 
     S+600        1.00     10.77     6/3/2022        1/27/2026        489        485        489  
Spectrum Pharmaceuticals, Inc.
(4)
     Biotechnology        S+570        2.30     9.88     9/21/2022        9/1/2027        915        905        906  
SunMed Group Holdings, LLC
(4)
    
 
Health Care
Equipment &
Supplies
 
 
 
     L+575        0.75     10.48     6/16/2021        6/16/2028        2,033        2,004        2,033  
Vapotherm, Inc.
    
 
Health Care
Equipment &
Supplies
 
 
 
     S+830        1.00     12.58 %
(7)
 
    2/18/2022        2/1/2027        3,095        3,094        3,111  
                     
 
 
    
 
 
 
Total Bank Debt/Senior Secured Loans
 
     
$
 43,577
 
  
$
 43,886
 
     
 
 
    
 
 
 
Warrants —0.1%
                    
Warrants
       
Meditrina, Inc.*
    
 
Health Care
Equipment &
Supplies
 
 
 
               12/20/2022        2,719      $ 2      $ 2  
Spectrum Pharmaceuticals, Inc.*
     Biotechnology                  9/21/2022        13,871        4        1  
Vapotherm, Inc.*
    
 
Health Care
Equipment &
Supplies
 
 
 
               2/18/2022        3,324        19        8  
     
 
 
    
 
 
 
Total Warrants
 
            
$
25
 
  
$
11
 
     
 
 
    
 
 
 
Total Investments
(5)
 
226.9%.
 
     
$
43,602
 
  
$
43,897
 
     
 
 
    
 
 
 
Cash Equivalents — 154.1%
 
        
U.S. Treasury Bill
     Government               12/30/2022        2/23/2023      $ 30,000      $ 29,828      $ 29,828  
     
 
 
    
 
 
 
Total Investments & Cash Equivalents
 
381.0%
 
        
$
73,430
 
  
$
73,725
 
Liabilities in Excess of Other Assets
(281.0%)
 
                (54,377
                        
 
 
 
Net Assets — 100.0%
 
             
$
19,348
 
                        
 
 
 
(1)
Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) has provided the current interest rate in effect as of December 31, 2022.
(2)
Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.
(3)
Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (“1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making
follow-on
investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2022, on a fair value basis,
non-qualifying
assets in the portfolio represented 17.9% of the total assets of the Company.
(4)
Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
(5)
Aggregate net unrealized depreciation for U.S. federal income tax purposes is $71; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $318 and $389, respectively, based on a tax cost of $43,968. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
(6)
BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
(7)
Vapotherm, Inc. may elect to defer up to 8.00% of the coupon as PIK.
*
Non-income
producing security.
See notes to consolidated financial statements.
 
89

SLR HC BDC LLC
Consolidated Schedule of Investments (continued)
December 31, 2022
(in thousands)
 
Industry Classification
  
Percentage of Total
Investments (at
fair value) as of
December 31, 2022
 
Health Care Providers & Services
     34.9
Health Care Equipment & Supplies
     19.3
Biotechnology
     16.8
Pharmaceuticals
     16.5
Life Science Tools & Services
     9.2
Health Care Technology
     3.3
  
 
 
 
Total Investments
     100.0
  
 
 
 
See notes to consolidated financial statements.
 
90

SLR HC BDC LLC
Notes to Consolidated Financial Statements
December 31, 2023
(in thousands, except unit amounts)
Note 1. Organization
SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on July 7, 2020 as a
closed-end,
externally managed investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a BDC and a RIC, we are required to comply with certain regulatory requirements. The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below. SLR Capital Partners, LLC (the “Adviser” or “SLR”) serves as the Company’s investment adviser pursuant to an investment management agreement with the Company (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”).
In connection with the Company’s formation, the Company issued and sold 40 units to the Adviser (the “Initial Unitholder”), which were acquired for an initial capital contribution of $1 on January 5, 2021 in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. The Company’s capital commitments total $83,850. The Company’s initial drawdown occurred on March 8, 2021 with the sale and issuance of units at an aggregate purchase price of $3,500 or $29.30 per unit. Prior to the issuance of units on March 8, 2021, the Initial Unitholder’s initial seed capital was withdrawn from the Company and its Units were canceled. As of December 31, 2023, $24,000 of capital commitments were drawn and $59,850 were unfunded.
The Company pursues a corporate lending strategy focused on direct sourcing, underwriting and managing a diverse portfolio of private loans to U.S. healthcare companies. The Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”. The Company’s principal focus is to invest in two differentiated strategies: first lien healthcare cash flow loans and first lien life science loans. First lien healthcare cash flow loans are expected to be made to private equity-owned upper middle market healthcare companies with EBITDA between approximately $25,000 and $100,000. These aggregate loan tranches are expected to range in size from $100,000 to $300,000. Healthcare cash flow loans are generally expected to have a
five
to six year
final maturity and are often repaid within three years. First lien life science loans are expected to be made to venture capital owned
pre-commercialization
or early revenue drug and device development companies. These aggregate loan tranches are expected to range in size from $25,000 to $150,000. Loans to life science companies are generally expected to have an initial interest-only period and then straight-line amortization with a
four
to five year
final maturity. These loans are often repaid within
two
to three years
. The Company expects to primarily invest in
non-investment
grade debt instruments. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments.
The Company is organized for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). The Company was permitted to hold closings at any time during the offering period (the “Offering Period”), which ended on December 31, 2022. The term of the Company is expected to be seven years from the Company’s final closing with the Access Fund, which was held on February 11, 2021, unless the Company is terminated earlier or causes the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange (an “Exchange Listing”) as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a
non-1940
Act vote as described in Item 11 of the Company’s Form 10. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31.
 
91

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
At any time prior to the end of the term, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange. In connection with any such Exchange Listing, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the Company to complete (i) an initial public offering, (ii) a merger with another entity, including an affiliated company, subject to any limitations under the 1940 Act, (iii) the sale, exchange or disposition of all or a portion of the assets of the Company, or (iv) a conversion of the Company into a corporation incorporated in a state determined by the board of directors, either through a conversion in accordance with applicable law, a merger with or into an existing corporation, or otherwise, in which all units will be converted into or exchanged for shares of common stock of the resulting corporation. If the Company is unable to effectuate an Exchange Listing prior to the end of the term, the Company will use commercially reasonable efforts to wind down or liquidate pursuant to the procedures set forth in the LLC Agreement.
Note 2. Summary of Significant Accounting Policies
The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”), and include the accounts of the Company and certain wholly-owned subsidiaries, if any. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform to current period presentation.
The preparation of consolidated financial statements in conformity with GAAP and pursuant to the requirements for reporting on Form
10-K
and Regulation
S-X,
as appropriate, also requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reported periods. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially.
In the opinion of management, all adjustments which are of a normal recurring nature and considered necessary for the fair presentation of financial statements, have been included.
The significant accounting policies consistently followed by the Company are:
 
  (a)
Investment transactions are accounted for on the trade date.
 
  (b)
In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows:
 
  (i)
securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation;
 
  (ii)
exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes;
 
  (iii)
short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and
 
92

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
  (iv)
securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below:
 
  a.
the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment;
 
  b.
preliminary valuation conclusions are then documented and discussed with senior management of the Adviser;
 
  c.
the audit committee of the Board of Directors (the “Board”) reviews the preliminary valuations of the Adviser and third-party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and
 
  d.
the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third-party valuation specialist, if any, which may from time to time be engaged by the Board.
The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion.
The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule
2a-5
under the 1940 Act; and (6) maintain recordkeeping requirements under Rule
2a-5.
When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.
Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC
820-10,
certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the fiscal year ended December 31, 2023, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process.
ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy:
Level
 1
: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date.
 
93

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
Level
 2
: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices.
Level
 3
: Unobservable inputs for the asset or liability.
In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience.
 
  (c)
Gains or losses on investments are calculated by using the specific identification method.
 
  (d)
The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other
non-recurring
fee income as well as management fee and other fee income for services rendered, if any, are recorded as other income when earned.
 
  (e)
The Company intends to comply with the applicable provisions of the Code pertaining to RICs to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate.
 
  (f)
Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP; accordingly at December 31, 2023, $23 was reclassified on our balance sheet between accumulated distributable net loss and common Unitholders’ capital. Total earnings and net asset value are not affected.
 
  (g)
Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually.
 
  (h)
In accordance with Regulation
S-X
and ASC Topic 810—
Consolidation
, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company.
 
  (i)
The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company.
 
  (j)
In accordance with ASC
835-30,
the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method.
 
94

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
  (k)
The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC
946-20-25.
 
  (l)
Investments that are expected to pay regularly scheduled interest in cash are generally placed on
non-accrual
status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such
non-accrual
investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment.
 
  (m)
The Company records expenses directly related to its organization as incurred.
 
  (n)
The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents.
Note 3. Agreements and Related Party Transactions
Pursuant to the Investment Management Agreement we have entered into with the Adviser, we will pay the Adviser certain management and incentive fees prior to and following an Exchange Listing. Prior to an Exchange Listing, the Adviser has been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay an administration fee to the Administrative Coordinator for such administrative and coordination services, each as defined and described further below. Following an Exchange Listing, we intend to enter into a separate administration agreement with an affiliate pursuant to which administrative services would be provided to the Company, as described further below. The cost of the base management fee, the incentive fee and the administration fee will ultimately be borne by our Unitholders.
Management Fees
The Company pays the Adviser a management fee prior to an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the
“Pre-Exchange
Listing Management Fee”) and will pay a management fee following an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the “Post-Exchange Listing Management Fee” and, together with the
Pre-Exchange
Listing Management Fee, the “Management Fee”). The Management Fee will be payable quarterly in arrears, as
follows:
 
95

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
   
Pre-Exchange
Listing
. Prior to an Exchange Listing, the
Pre-Exchange
Listing Management Fee will be calculated as of the close of business on the last day of each calendar quarter in an amount equal to 1.50%
per annum
of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company used to make Portfolio Investments and (ii) the total amount of credit drawn on subscription or similarly structured credit facilities).
 
   
Post-Exchange Listing
. Following an Exchange Listing, the Post-Exchange Listing Management Fee will be an amount equal to 1.50% per annum of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters; provided, however, the Post-Exchange Listing Management Fee will be calculated at an annual rate of 1.00% of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters that exceeds the product of (i) 200% and (ii) the value of the Company’s total net assets at the end of the immediately preceding calendar quarter.
The Management Fee will be appropriately adjusted for any stub period. The Adviser may arrange for the Company to direct to a placement agent any portion of the Management Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent.
The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, the Management Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such Management Fee may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the Management Fee. No Management Fees have been waived as of December 31, 2023.
Incentive Fee
Distributions
. Prior to an Exchange Listing, the Company makes distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, prepayment fees and exit fees, other than Disposition Proceeds, less Company expenses. The Adviser apportions each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds.
Pre-Exchange
Listing Incentive Fee
.
 
Prior to an Exchange Listing, and subject to availability, the Company will cause distributable cash to be distributed to Unitholders and to be paid to the Adviser as an incentive fee (the
“Pre-Exchange
Listing Incentive Fee”). Amounts of Investment Proceeds apportioned to Unitholders are divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority:
(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a
Pre-Exchange
Listing Incentive Fee, on the other hand, in the following amounts and order of priority:
(A) First, Return of Capital Contributions: 100% to such Unitholder until such Unitholders has received cumulative distributions of Investment Proceeds pursuant to this clause (A) equal to such Unitholder’s total capital contributions to the Company (including amounts contributed to pay
Pre-Exchange
Listing Management Fees,
Pre-Exchange
Listing Administration Fees (defined below), Organizational Expenses (defined below) and other Company
expenses);
 
96

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
(B) Second, Unitholder Preferred Return: 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and clause (ii)(A) and (ii)(C) below equal to 6% per annum, compounded annually, on Unitholders’ capital contributions to the Company (including amounts contributed to pay
Pre-Exchange
Listing Management Fees,
Pre-Exchange
Listing Administration Fees, Organizational Expenses and other Company expenses), determined on the basis of all capital contributions made by such Unitholder and considering all distributions (including the subject distribution) under this
“—Pre-Exchange
Listing Incentive Fee” made to such Unitholder (computed from the dates that such capital contributions were due (or, if actually made later, the date on which such capital contributions were actually made) until the date that the Company, in its sole discretion, designates distributable cash as available for distribution or, if no such designation is made, the occurrence of an Event of Dissolution, as defined in the LLC Agreement) (the “Preferred Return”);
(C) Third, Adviser Catch Up: 100% of all remaining Disposition Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee, until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) below equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (B) above and this clause (C) and clause (ii)(A) and (ii)(B) below; and
(D) Fourth, 90%/10%: 90% of all remaining Disposition Proceeds to Unitholders and 10% of all remaining Disposition Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee.
In no event will the Adviser receive amounts of
Pre-Exchange
Listing Incentive Fees under clause (i)(C) and (i)(D) above in excess of the percentage of the Disposition Proceeds actually distributed to Unitholders pursuant to clause (i)(B), (i)(C) and (i)(D) above.
In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation.
(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a
Pre-Exchange
Listing Incentive Fee, on the other hand, in the following amounts and order of priority:
(A) First, Unitholder Preferred Return: 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) above equal to the Preferred Return;
(B) Second, Adviser Catch Up: Second, 100% of all remaining Current Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) above equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (A) above and this clause (B) and pursuant to clause (i)(B) and clause (i)(C) above; and
(C) Third, 90%/10%: Thereafter, 90% of all remaining Current Proceeds to Unitholders and 10% of all remaining Current Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee.
 
97

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
In no event will the Adviser receive amounts of
Pre-Exchange
Listing Incentive Fees under clause (ii)(B) and (ii)(C) above in excess of the percentage of the Current Proceeds actually distributed to Unitholders pursuant to clause (ii)(A), (ii)(B) and (ii)(C) above.
Post-Exchange Listing Incentive Fee
. Following an Exchange Listing, the Company will pay an incentive fee to the Adviser consisting of two parts, as follows (the “Post-Exchange Listing Incentive Fee”):
 
  (i)
Pre-Incentive
Fee Net Investment Income. One part will be calculated and payable quarterly in arrears based on the net investment income for the immediately preceding calendar quarter.
 
  a.
For this purpose,
Pre-Incentive
Fee Net Investment Income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies) accrued by the Company during the calendar quarter, minus the Company’s operating expenses for the quarter (including the Post-Exchange Listing Management Fees, expenses payable under an administration agreement, and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the Post-Exchange Listing Incentive Fee).
 
  b.
Pre-Incentive
Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation.
Pre-Incentive
Fee Net Investment Income, expressed as a rate of return on the value of the Company’s net assets at the end of the immediately preceding calendar quarter, will be compared to a “hurdle rate” of 1.50% per quarter (6.00% annualized). The Company’s
Pre-Incentive
Fee Net Investment Income used to calculate this part of the Post-Exchange Listing Incentive Fee is also included in the amount of its gross assets used to calculate the 1.50% Post-Exchange Listing Management Fees.
 
  c.
The Company will pay the Adviser a Post-Exchange Listing Incentive Fee with respect to the Company’s
Pre-Incentive
Fee Net Investment Income in each calendar quarter as follows:
 
  i.
no Post-Exchange Listing Incentive Fee in any calendar quarter in which the Company’s
Pre-Incentive
Fee Net Investment Income does not exceed the quarterly hurdle rate of 1.50%;
 
98

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
  ii.
100% of the Company’s
Pre-Incentive
Fee Net Investment Income with respect to that portion of such
Pre-Incentive
Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 1.875% in any calendar quarter (7.5% annualized); this portion of the
Pre-Incentive
Fee Net Investment Income (which exceeds the hurdle but is less than 1.875%) is referred to herein as the
“catch-up.”
The
“catch-up”
is meant to provide the Adviser with 20% of the Company’s
Pre-Incentive
Fee Net Investment Income as if a hurdle did not apply if this
Pre-Incentive
Fee Net Investment Income exceeds 1.875% in any calendar quarter; and
 
  iii.
20% of the amount of the Company’s
Pre-Incentive
Fee Net Investment Income, if any, that exceeds 1.875% in any calendar quarter (7.5% annualized) payable to the Adviser (once the hurdle is reached and the
catch-up
is achieved, 20% of all
Pre-Incentive
Fee Net Investment Income thereafter is allocated to the Adviser).
These calculations will be
appropriately pro-rated for
any period of less than three months.
Capital Gains Fee
. The second part of the Post-Exchange Listing Incentive Fee, the “Capital Gains Fee”, will be determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement as set forth below), commencing as of the end of the first fiscal year following an Exchange Listing, and will equal 20.0% of the Company’s realized capital gains, if any, on a cumulative basis through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation as of each fiscal year end, less the amount of any previously paid capital gain Post-Exchange Listing Incentive Fees, with respect to the Company; provided that the Post-Exchange Listing Incentive Fee determined as of the end of the fiscal year in which an Exchange Listing is completed will be calculated for a period of shorter than twelve calendar months to take into account any realized capital gains computed net of all realized capital losses and unrealized capital depreciation. In the event that the Investment Management Agreement will terminate as of a date that is not a calendar year end, the termination date will be treated as though it were a calendar year end for purposes of calculating and paying a Capital Gains Fee.
The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, all or any portion of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such
Pre-Exchange
Listing Incentive Fees or Post-Exchange Listing Incentive Fees may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee.
The Adviser may arrange for the Company to direct to a placement agent any portion of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent.
Administration Fees and Expenses
Pre-Exchange
Listing Administration Fees
. The Company will pay SLR, in its capacity as the Administrative Coordinator, a fee (the
“Pre-Exchange
Listing Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as, as of any date, the aggregate accreted and amortized cost of all Portfolio Investments, including (i) any amounts reinvested in Portfolio Investments and (ii) the cost of Portfolio Investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The
Pre-Exchange
Listing Administration Fee will not offset any fees paid to the Adviser. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain
on-going,
routine,
non-investment-related
administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company and (iii) certain Unitholder servicing functions.
The
Pre-Exchange
Listing Administration Fee will be appropriately adjusted for any stub period.
 
99

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
The Administrative Coordinator will have the right, in its sole discretion, to waive, as well as recoup in a subsequent period, the
Pre-Exchange
Listing Administration Fee to which it is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such
Pre-Exchange
Listing Administration Fee may be recouped by the Administrative Coordinator in a future calendar quarter within three years of the date of the applicable waiver of the
Pre-Exchange
Listing Administration Fee.
Post-Exchange Listing Administration Expenses
. In connection with an Exchange Listing, and subject to Board approval, the Company intends to enter into an administration agreement with SLR Capital Management, LLC (“SCM”) pursuant to which SCM will provide administrative services to the Company. For providing these services, facilities and personnel, the Company will reimburse SCM for the Company’s allocable portion of overhead and other expenses incurred by SCM in performing its obligations under the administration agreement (together with the
Pre-Exchange
Listing Administration Fee, the “Administration Expenses”).
For the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021, the Company incurred $565, $419 and $224, respectively, in Management Fees, $42, $27 and $9, respectively, in Administration Fees and $0, $0 and $0, respectively in Incentive Fees.
In addition, prior to an Exchange Listing, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company will not exceed the following limits in any fiscal year: (A) if the Company has less than or equal to $400,000 in Commitments, an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in Commitments, $2,250 (such figure, the “Operating Expense Cap”). Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, (i) the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder, (ii) the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the Company’s portfolio investments at each quarter end and (iii) the Operating Expense Cap will no longer apply upon the effectuation of an Exchange Listing.
The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (the “Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) will be reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. The Company will be responsible for and pay (or reimburse) the Organizational Expenses subject to the cap described in the preceding sentence. Accordingly, in 2021, $177 of offering expenses were charged to capital and $229 of organizational costs were expensed.
 
100

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
Note 4. Fair Value
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows:
Level
 1.
 Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access.
Level
 2.
 Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:
 
  a)
Quoted prices for similar assets or liabilities in active markets;
 
  b)
Quoted prices for identical or similar assets or liabilities in
non-active
markets;
 
  c)
Pricing models whose inputs are observable for substantially the full term of the asset or liability; and
 
  d)
Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability.
Level
 3.
Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use in pricing the asset or liability.
When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3).
Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).
A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1.
 
101

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
The following tables present the balances of assets measured at fair value on a recurring basis, as of December 31, 2023 and December 31, 2022:
Fair Value Measurements
As of December 31, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $    $    $ 63,268      $ 63,268  
Warrants
     1               6        7  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 1      $      $ 63,274      $ 63,275  
  
 
 
    
 
 
    
 
 
    
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2023, the fair value of the SPV Facility and the Subscription Facility would be $24,210 and $17,550, respectively.
Fair Value Measurements
As of December 31, 2022
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $    $    $ 43,886      $ 43,886  
Warrants
                   11        11  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $      $      $ 43,897      $ 43,897  
  
 
 
    
 
 
    
 
 
    
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2022, the fair value of the SPV Facility and the Subscription Facility would be $14,675 and $13,800, respectively.
 
102
SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
 
The following tables provides a summary of the changes in fair value of Level 3 assets for the years ended December 31, 2023 and 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2023 and 2022:
 
    
Bank Debt/Senior
Secured Loans
    
Warrants
    
Total
 
Fair value, December 31, 2022
   $ 43,886      $ 11      $ 43,897  
Total gains or losses included in earnings:
        
Net realized gain
                    
Net change in unrealized gain (loss)
     254        (15      239  
Purchase of investment securities*
     26,306        15        26,321  
Proceeds from dispositions of investment securities
     (7,178      (5      (7,183
Transfers into Level 3
                    
Transfers out of Level 3
                    
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2023
   $ 63,268      $ 6      $ 63,274  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 259      $ (18    $ 241  
  
 
 
    
 
 
    
 
 
 
 
    
Bank Debt/Senior
Secured Loans
    
Warrants
    
Total
 
Fair value, December 31, 2021
   $ 27,286      $      $ 27,286  
Total gains or losses included in earnings:
        
Net realized gain
                    
Net change in unrealized gain (loss)
     192        (14      178  
Purchase of investment securities*
     28,713        25        28,738  
Proceeds from dispositions of investment securities
     (12,305             (12,305
Transfers into Level 3
                    
Transfers out of Level 3
                    
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2022
   $ 43,886      $ 11      $ 43,897  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 243      $ (14    $ 229  
  
 
 
    
 
 
    
 
 
 
 
*
Includes PIK capitalization and accretion of discount
 
103

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued) 
December 31, 2023
(in thousands, except unit amounts)
Quantitative Information about Level 3 Fair Value Measurements
The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company.
Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2023 is summarized in the table below:
 
    
Asset or
Liability
    
Fair Value at
December 31,
2023
    
Principal Valuation

Technique/Methodology
    
Unobservable Input
    
Range (Weighted
Average)
 
Bank Debt / Senior Secured Loans
     Asset      $ 63,268        Income Approach        Market Yield        10.6% – 17.6%
(13.0%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Warrants
     Asset      $ 6        Market Approach        Volatility        18.9% – 18.9%
(18.9%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below:
 
    
Asset or
Liability
    
Fair Value at
December 31,
2022
    
Principal Valuation

Technique/Methodology
    
Unobservable Input
    
Range (Weighted
Average)
 
Bank Debt / Senior Secured Loans
     Asset      $ 43,886        Income Approach        Market Yield        9.8% – 18.2%
(12.5%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Warrants
     Asset      $ 11        Market Approach        Volatility        26.0% – 26.0%
(26.0%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
 
104

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued) 
December 31, 2023
(in thousands, except unit amounts)
Note 5. Debt
SPV Facility
—On February 18, 2022, the Company, through its wholly-owned subsidiary, SLR HC BDC SPV LLC (the “SPV”), entered into the $50,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. On May 30, 2023, the SPV Facility was amended, increasing commitments to $75,000. The stated interest rate on the SPV Facility is Term SOFR plus 3.07% with no SOFR floor requirement and the final maturity date is February 18, 2027. The fee on undrawn commitments is currently 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $24,210 of borrowings outstanding under the SPV Facility.
Subscription Facility
—On March 19, 2021, the Company established the $25,000 Subscription Facility with ING Capital LLC. The stated interest rate on the Subscription Facility is SOFR plus
2.75-3.00%
and the current stated maturity date is March 15, 2024. On December 14, 2021, the Subscription Facility was amended, allowing for increased borrowing base availability, among other changes. On June 14, 2023, the Subscription Facility entered into a second amendment, which replaced the benchmark rate of LIBOR with SOFR. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $17,550 of borrowings outstanding under the Subscription Facility.
The average annualized interest cost for borrowings for the years ended December 31, 2023 and 2022 was 8.11% and 4.88%, respectively. These costs are exclusive of other credit facility expenses such as unused fees. The maximum amount borrowed on the credit facilities during the years ended December 31, 2023 and 2022 was $44,010 and $32,775, respectively.
 
105

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
Note 6. Commitments and Contingencies
The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of December 31, 2023 and December 31, 2022 is $11,545 and $15,513, respectively, comprised of the following:
 
    
December 31,
2023
    
December 31,
2022
 
AAH Topco, LLC
   $ 2,262      $  
OIS Management Services, LLC
     1,710         
Southern Orthodontic Partners Management, LLC
     1,347        670  
Ardelyx, Inc.
     1,345        696  
CVAUSA Management, LLC
     1,059         
Retina Midco, Inc.
     966         
Orthopedic Care Partners Management, LLC
     901        566  
United Digestive MSO Parent, LLC
     391         
SCP Eye Care, LLC
     343        968  
Vertos Medical, Inc.
     283         
Medrina, LLC
     239         
UVP Management, LLC
     218         
Urology Management Holdings, Inc.
     151         
SunMed Group Holdings, LLC
     132        69  
Exactcare Parent, Inc.
     102         
WCI-BXC
Purchaser, LLC
     96         
Outset Medical, Inc.
            3,052  
Apeel Technology, Inc.
            2,852  
Glooko, Inc.
            1,633  
Arcutis Biotherapeutics, Inc.
            786  
Oral Surgery Partners Holdings, LLC
            843  
Plastics Management, LLC
            794  
Spectrum Pharmaceuticals, Inc.
            763  
Cerapedics, Inc.
            623  
Pediatric Home Respiratory Services, LLC
            630  
Meditrina, Inc.
            312  
Ivy Fertility Services, LLC
            128  
BayMark Health Services, Inc.
            128  
  
 
 
    
 
 
 
Total Commitments
   $ 11,545      $  15,513  
  
 
 
    
 
 
 
The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of December 31, 2023, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.
In the normal course of our business, we invest or trade in various financial instruments and may enter into various investment activities with
off-balance
sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of
off-balance
sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Statement of Assets and Liabilities.
 
106

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
Note 7. Unitholders’ Capital
Transactions in Unitholders’ capital were as follows:
 
    
Year ended
December 31,
2023
    
Year ended
December 31,
2022
 
Units at beginning of period
     888,565        682,427  
Units issued
     181,077        206,138  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     1,069,642        888,565  
  
 
 
    
 
 
 
 
107

SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
Note 8. Financial Highlights
The following is a schedule of financial highlights for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021:
 
    
Year ended
December 31,
2023
   
Year ended
December 31,
2022
   
For the period
January 5, 2021*
to December 31,
2021
 
Per Unit Data: (a)
      
Net asset value per unit, beginning of period
   $ 21.77     $ 21.41     $  
  
 
 
   
 
 
   
 
 
 
Net investment income (loss)
     1.33       1.07       (2.97
Net realized and unrealized gain
     0.28 **      0.26       0.40  
  
 
 
   
 
 
   
 
 
 
Net increase (decrease) in Unitholders’ capital resulting from operations
     1.61       1.33       (2.57
Issuance of initial units
                 24.62 ** 
Offering costs
                 (0.64
Distributions to Unitholders:
      
From distributable earnings
     (1.85     (0.97      
From return of capital
     (0.06            
  
 
 
   
 
 
   
 
 
 
Net asset value per unit, end of period
   $ 21.47     $ 21.77     $ 21.41  
  
 
 
   
 
 
   
 
 
 
Total Return(b)(c)
     7.40     6.21     (26.93 )% 
Unitholders’ capital, end of period
   $ 22,969     $ 19,348     $ 14,612  
Units outstanding, end of period
     1,069,642       888,565       682,427  
Ratios to average net assets of Unitholders’ Capital (c):
      
Net investment income (loss)
     6.08     4.91     (16.59 )% 
  
 
 
   
 
 
   
 
 
 
Operating expenses
     5.99     6.61     29.12
Interest and other credit facility expenses
     18.08     12.33     8.02
  
 
 
   
 
 
   
 
 
 
Total expenses
     24.07     18.94     37.14
  
 
 
   
 
 
   
 
 
 
Average debt outstanding
   $ 31,744     $ 20,453     $ 7,352  
Portfolio turnover ratio
     13.9     36.5     59.7
 
(a)
Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively.
(b)
Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load.
(c)
Not annualized for periods less than one year.
*
Commencement of operations
**
Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.
 
108
SLR HC BDC LLC
Notes to Consolidated Financial Statements (continued)
December 31, 2023
(in thousands, except unit amounts)
Note 9(a). Income Tax Information and Distributions to Unitholders
The tax character of distributions for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 were as follows(1):
 
    
2023
   
2022
   
2021
 
Ordinary income
   $ 1,817        92.6   $ 603        86.5   $        0.0
Capital gains
     53        2.7     94        13.5            0.0
Return of capital
     92        4.7            0.0            0.0
  
 
 
    
 
 
   
 
 
    
 
 
   
 
 
    
 
 
 
Total distributions
   $ 1,962        100.0   $ 697        100.0   $        0.0
  
 
 
    
 
 
   
 
 
    
 
 
   
 
 
    
 
 
 
As of December 31, 2023, 2022 and 2021 the total accumulated earnings (loss) on a tax basis were as follows(1):
 
    
2023
    
2022
    
2021
 
Undistributed ordinary income
   $      $ 155      $  
Undistributed long-term net capital gains
                    
  
 
 
    
 
 
    
 
 
 
Total undistributed net earnings
            155         
Post-October capital losses
                    
Capital loss carryforward
                    
Other book/tax temporary differences
     (183      (197      (213
Net unrealized depreciation
     (241      (71      (136
  
 
 
    
 
 
    
 
 
 
Total tax accumulated loss
   $ (424    $ (113    $ (349
  
 
 
    
 
 
    
 
 
 
 
(1)
Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year.
The Company recognizes in its consolidated financial statements the tax effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. To the best of our knowledge, we did not have any uncertain tax positions that met the recognition or measurement criteria of ASC
740-10-25
nor did we have any unrecognized tax benefits as of the periods presented herein. Although we file federal and state tax returns, our major tax jurisdiction is federal. Our tax returns for federal tax years since 2021 remain subject to examination by the Internal Revenue Service and the state department of revenue.
Note 9(b). Other Tax Information (unaudited)
For the fiscal years ended December 31, 2023 and December 31, 2022, none of the ordinary distributions paid during the year were eligible for qualified dividend income treatment or the dividends received deduction for corporate stockholders. For the fiscal years ended December 31, 2023 and December 31, 2022, 98.16% and 99.58%, respectively, of each of the ordinary distributions paid during the year represent interest-related dividends. For the fiscal years ended December 31, 2023 and December 31, 2022, 0.90% and 0%, respectively, of the distributions represent short-term capital gains dividends. There were no distributions during the period January 5, 2021 (commencement of operations) to December 31, 2021.
Note 10. Subsequent Events
The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the financial statements were issued.
On January 23, 2024, the Company, through the SPV, reduced the size of its $75,000 SPV Facility to $35,000.
 
109

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures
As of December 31, 2023 (the end of the period covered by this report), our management, including our
Co-Chief
Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule
13a-15(e)
of the 1934 Act). Based on that evaluation, our management, including the
Co-Chief
Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed in our periodic SEC filings is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our
Co-Chief
Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. However, in evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of such possible controls and procedures.
(b) Report of Management on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, and for performing an assessment of the effectiveness of internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. The Company’s internal control over financial reporting includes those policies and procedures that (i) pertain to assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.
Management performed an assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023 based upon the criteria in the 2013 Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on management’s assessment, management determined that the Company’s internal control over financial reporting was effective as of December 31, 2023.
Due to the Company’s status as an “emerging growth company” under the JOBS Act, the Company was not required to obtain an attestation report from the Company’s independent registered public accounting firm on the Company’s internal control over financial reporting as of December 31, 2023.
(c) Changes in Internal Controls Over Financial Reporting
Management has not identified any change in the Company’s internal control over financial reporting that occurred during the fourth quarter of 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
Item 9B. Other Information
Rule
10b5-1
Trading Plans
During the fiscal year ended December 31, 2023, none of our directors or officers (as defined in Rule
16a-1(f)
under the 1934 Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule
10b5-1(c)
under the 1934 Act or any
no
n-Rule
10b5-1
trading arrangement” as defined in Item 408(c) of Regulation
S-K.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not Applicable.
 
110

PART III
Item 10. Directors, Executive Officers and Corporate Governance
Certain information with respect to the Company’s directors is set forth below, including their names, ages, a brief description of their recent business experience, including present occupations and employment, certain directorships that each person holds, the year in which each person became a director of the Company, and a discussion of their particular experience, qualifications, attributes or skills that lead the Company to conclude that such individual should serve as a director of the Company, in light of the Company’s business and structure. There were no legal proceedings of the type described in Item 401(f) of Regulation
S-K
in the past 10 years against any of the directors, director nominees, officers, or promoters of the Company and none are currently pending. There is no arrangement or understanding between any of the Company’s directors or officers pursuant to which they were selected as directors or officers and the Company or any other person or entity.
Mr. Gross is an “interested person” of the Company as defined in the 1940 Act due to his position as
Co-Chief
Executive Officer and President of the Company and a managing member of the Adviser. Mr. Spohler is an “interested person” of the Company as defined in the 1940 Act due to his position as
Co-Chief
Executive Officer and Chief Operating Officer of the Company and a managing member of the Adviser. Each of Mr. Wachter, Mr. Hochberg and Mr. Potter is not an “interested person” of the Company as defined in the 1940 Act. Information regarding the Board is as follows:
 
Name
  
Age
  
Position
  
Director Since
Interested Directors
Michael S. Gross    62   
Co-Chief
Executive Officer, President and Director
   2020
Bruce Spohler    63   
Co-Chief
Executive Officer, Chief Operating Officer and Director
   2020
Independent Directors
Steve Hochberg    62    Director    2020
David S. Wachter    60    Director    2020
Leonard A. Potter    62    Director    2020
The address for each of our directors is c/o SLR HC BDC LLC, 500 Park Avenue, New York, NY 10022.
Executive Officers Who Are Not Directors
 
Name
  
Age
  
Position
Shiraz Y. Kajee    44    Chief Financial Officer and Treasurer
Guy Talarico    68    Chief Compliance Officer and Secretary
Biographical Information
Interested Directors
Michael S. Gross
 has been the chairman of the board of directors, President, and
Co-Chief
Executive Officer of the Company since September 2020. Mr. Gross has been the chairman of the board of directors of SLR Investment Corp. since December 2007, president of SLR Investment Corp. since November 2007, sole chief executive officer of SLR Investment Corp. from November 2007 to June 2019 and
co-chief
executive officer of SLR Investment Corp. since June 2019. Mr. Gross has been the chairman of the board of directors SCP Private Credit Income BDC LLC since May 2018, president of SCP Private Credit Income BDC LLC since June 2018, sole chief executive officer of SCP Private Credit Income BDC LLC from June 2018 to June 2019 and
co-chief
executive officer of SCP Private Credit Income BDC LLC since June 2019. Mr. Gross has been the chairman of the board of directors,
co-chief
executive officer and president of SLR Private Credit BDC II LLC since April 2022. Mr. Gross also currently serves as a managing member of SLR. Mr. Gross was previously the chairman of the board of directors and president of SLR Senior Investment Corp. from December 2010 to April 2022, sole chief executive officer of SLR Senior Investment Corp. from December 2010 to June 2019 and
co-chief
executive officer of SLR Senior Investment Corp. from June 2019 to April 2022. Mr. Gross also serves as the chairman of the board of directors of Global Ship Lease Inc.
 
111

Mr. Gross holds a B.B.A. in accounting from the University of Michigan and an M.M. from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Gross’ intimate knowledge of the business and operations of SLR Capital Partners, extensive familiarity with the financial industry and the investment management process in particular, and experience as a director of other public and private companies not only gives the Board valuable insight but also positions him well to continue to serve as the Chairman of our Board.
Bruce Spohler
 has been a director, Chief Operating Officer and
Co-Chief
Executive Officer of the Company since September 2020. Mr. Spohler has been a director of SLR Investment Corp. since September 2009, chief operating officer of SLR Investment Corp. since December 2007, and
co-chief
executive officer of SLR Investment Corp. since June 2019. Mr. Spohler has been a director of SCP Private Credit Income BDC LLC since May 2018, chief operating officer of SCP Private Credit Income BDC LLC since June 2018 and the
co-chief
executive officer of SCP Private Credit Income BDC LLC since June 2019. Mr. Spohler has been the
co-chief
executive officer, chief operating officer and a director of SLR Private Credit BDC II LLC since April 2022. Mr. Spohler also currently serves as a managing member of SLR. Mr. Spohler was previously the chief operating officer and a director of SLR Senior Investment Corp. from December 2010 to April 2022 and the
co-chief
executive officer of SLR Senior Investment Corp. from June 2019 to April 2022.
Mr. Spohler earned a B.S. from Syracuse University and an M.M. from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Spohler’s depth of experience in managerial positions in investment management, leveraged finance and financial services, as well as his intimate knowledge of SLR Capital’s business and operations, gives the Board valuable industry-specific knowledge and experience on these and other matters.
Independent Directors
Steven Hochberg
 has been a director of the Company since September 2020. Further, he has been a director of SLR Investment Corp. since November 2007, a director of SCP Private Credit Income BDC LLC since May 2018 and a director of SLR Private Credit BDC II LLC since April 2022. Mr. Hochberg previously served as the director of SLR Senior Investment Corp. from January 2011 until April 2022. Mr. Hochberg is the
co-founder
and
co-general
partner of Triatomic Capital G.P. LLC, a technology focused venture capital firm, since 2022. Mr. Hochberg has been an operating partner of Deerfield Management, a healthcare investing firm, since 2022 and served as a partner of Deerfield Management from 2013 to 2021. Mr. Hochberg is
the co-founder and
manager of Ascent Biomedical Ventures, a venture capital firm focused on early stage investment development and of biomedical companies, since 2004. Since 2011, Mr. Hochberg had been the chairman of the board of directors Continuum Health Partners, one of the
largest non-profit hospital
systems in New York City, until its merger with Mount Sinai in 2013, where he is a vice chairman of Mount Sinai Health System,
a non-profit healthcare
integrated delivery system in New York City. Mr. Hochberg serves on the board of directors of a number of private healthcare companies, and as a director of the Cardiovascular Research Foundation, an organization focused on advancing new technologies and education in the field of cardiovascular medicine. Mr. Hochberg holds a B.B.A. from the University of Michigan and an M.B.A. from Harvard Business School. Mr. Hochberg’s varied experience in investing in medical technology companies provides the Board with particular knowledge of this field, and his role as chairman of other companies’ board of directors brings the perspective of a knowledgeable corporate leader.
Leonard A. Potter
 has been a director of the Company since September 2020. Further, he has been a director of SLR Investment Corp. since September 2009, a director of SCP Private Credit Income BDC LLC since May 2018 and a director of SLR Private Credit BDC II LLC since April 2022. Mr. Potter previously served as a director of SLR Senior Investment Corp. from January 2011 to April 2022. Mr. Potter is currently the president and chief investment officer of Wildcat Capital Management, LLC since 2011. Mr. Potter has served as senior managing director of Vida Ventures I and II, each a biotech venture fund, since 2017. From 2002 to 2009, Mr. Potter was a managing director — Soros Private Equity at Soros Fund Management LLC where, from May 2005 through July 2009, Mr. Potter served
as co-head of
the Private Equity group and a member of the Private Equity Investment Committee. Mr. Potter is currently a member of the board of directors of Hilton Grand Vacations Inc. since 2017 and a director (currently lead independent director) of SuRo Capital Corp. since 2011, and several private companies. Mr. Potter has a B.A. from Brandeis University and a J.D. from the Fordham University School of Law. Mr. Potter’s experience practicing as a corporate lawyer provides valuable insight to the Board on regulatory and risk management issues. In addition, his tenure in private equity investments and service as a director of both public and private companies provide industry-specific knowledge and experience to the Board.
David S. Wachter
 has been a director of the Company since September 2020. Further, he has been a director of SLR Investment Corp. since November 2007, a director of SCP Private Credit Income BDC LLC since May 2018 and a director of SLR Private Credit BDC II LLC since April 2022. Mr. Wachter previously served as a director of SLR Senior Investment Corp. from January 2011 to April 2022. Mr. Wachter is a founding partner and managing partner of W Capital Partners, a private equity fund manager, since 2001. Mr. Wachter has a B.S. in Engineering, with a major in Computer Science and Applied Mathematics, from Tufts University and an M.B.A. from New York University Graduate School of Business. Mr. Wachter’s extensive knowledge of private equity and investment banking provides the Board with the valuable insight of an experienced financial manager.
 
112

Executive Officers Who Are Not Directors
Shiraz Y. Kajee
 has been the Chief Financial Officer and Treasurer of the Company since April 2023. He has been the chief financial officer and treasurer of SLR Investment Corp. since April 2023, the chief financial officer and treasurer of SCP Private Credit Income BDC LLC since April 2023 and the chief financial officer and treasurer of SLR Private Credit BDC II LLC since April 2023. From December 2015 through March 2023, Mr. Kajee served as a Managing Director at New Mountain Capital, L.L.C., which included serving as Chief Financial Officer and Treasurer of the following business development companies: New Mountain Finance Corporation since 2015, NMF SLF I, Inc. since 2019, New Mountain Guardian III BDC, L.L.C. since 2019 and New Mountain Guardian IV BDC, L.L.C. since 2022. Mr. Kajee received both his Master of Science in Accounting and a Bachelor of Business Administration in Finance from Baruch College—City University of New York. He is a New York State Certified Public Accountant and a Chartered Global Management Accountant.
Guy Talarico
 has been the Chief Compliance Officer of the Company since September 2020 and Secretary since November 2023. He has been the chief compliance officer of SLR Investment Corp. since July 2008 and Secretary since November 2023, the chief compliance officer of SCP Private Credit Income BDC LLC since June 2018 and Secretary since November 2023 and the chief compliance officer of SLR Private Credit BDC II LLC since April 2022 and Secretary since November 2023. Mr. Talarico currently serves as General Counsel and Chief Compliance Officer for SLR Capital Partners, LLC since May 2023. In addition, Mr. Talarico previously served as the chief compliance officer of SLR Senior Investment Corp. from December 2010 until April 2022. Mr. Talarico previously served as managing director of ACA Group, LLC (successor to Foreside Consulting Services LLC, and ultimate successor to Alaric Compliance Services, LLC, which he founded in December 2005). Mr. Talarico holds a B.S. ChE from Lehigh University, an M.B.A. from Fairleigh Dickinson University and a J.D. from New York Law School.
Audit Committee
The Audit Committee operates pursuant to a charter approved by our Board. The charter sets forth the responsibilities of the Audit Committee. The Audit Committee’s responsibilities include selecting the independent registered public accounting firm for the Company, reviewing with such independent registered public accounting firm the planning, scope and results of their audit of the Company’s financial
statements, pre-approving the
fees for services performed, reviewing with the independent registered public accounting firm the adequacy of internal control systems, reviewing the Company’s annual financial statements and periodic filings and receiving the Company’s audit reports and financial statements. The Audit Committee has also established guidelines and make recommendations to our Board regarding the valuation of our investments. The Audit Committee is responsible for aiding our Board in determining the fair value of debt and equity securities that are not publicly traded or for which current market values are not readily available. The Board and the Audit Committee may utilize the services of nationally recognized third-party valuation firms to help determine the fair value of material assets. The Audit Committee is composed of Steve Hochberg, David S. Wachter and Leonard A. Potter. Mr. Hochberg serves as Chairman of the Audit Committee. Our Board has determined that Mr. Hochberg is an “audit committee financial expert” as that term is defined under Item 407
of Regulation S-K, as
promulgated under the 1934 Act. Mr. Hochberg meets the current independence and experience requirements
of Rule 10A-3 of
the 1934 Act.
Code of Ethics
The Company has adopted a code of ethics that applies to, among others, its senior officers, including its
Co-Chief
Executive Officers and its Chief Financial Officer, as well as every officer, director and employee of the Company. The Company’s code of ethics is filed herewith and the Company intends to disclose amendments to or waivers from a required provision of the code of ethics on
Form 8-K.
Nomination of Directors
There have been no material changes to the procedures by which Unitholders may recommend nominees to our Board of Directors implemented since the filing of our annual report on Form
10-K
for the fiscal year ended December 31, 2022. The Nominating and Corporate Governance Committee of the Company currently does not consider nominees recommended by our Unitholders.
 
113

Item 11. Executive Compensation
Compensation of Executive Officers
None of our affiliated officers receives direct compensation from the Company. Mr. Gross, our
Co-Chief
Executive Officer and President, and Mr. Spohler, our
Co-Chief
Executive Officer and Chief Operating Officer, through their ownership interest in the Adviser, are entitled to a portion of any profits earned by the Company, which includes any fees payable by us to the Company under the terms of the Investment Management Agreement, less expenses incurred by Adviser in performing its services under the Investment Management Agreement. Mr. Gross and Mr. Spohler do not receive any additional compensation from Adviser in connection with the management of our portfolio.
Mr. Kajee, our Chief Financial Officer and Treasurer and Mr. Talarico, our Chief Compliance Officer and Secretary are paid by the Adviser or its affiliates, and such costs or payments are not subject to reimbursement by the Company.
Compensation of Directors
The following table sets forth the compensation of the Company’s directors for the year ended December 31, 2023.
 
Name
  
Fees Earned or Paid
in Cash(1)
    
Stock
Awards(2)
    
All Other
Compensation
    
Total
 
Interested Directors
           
Michael S. Gross
     —         —         —         —   
Bruce Spohler
     —         —         —         —   
Independent Directors
           
Steven Hochberg
   $ 25,000        —         —       $ 25,000  
David S. Wachter
   $ 25,000        —         —       $ 25,000  
Leonard A. Potter
   $ 25,000        —         —       $ 25,000  
 
(1)
No compensation is paid to our directors who are “interested persons,” as such term is defined in Section 2(a) (19) of the 1940 Act. We pay each independent director $25,000 per year for serving as a director. We are also authorized to pay the reasonable
out-of-pocket
expenses of each independent director incurred by such director in connection with the fulfillment of his or her duties as an independent director.
(2)
We do not maintain a stock or option
plan, non-equity incentive
plan or pension plan for our directors.
Compensation Committee
The Company currently does not have a Compensation Committee.
Compensation Committee Interlocks and Insider Participation
During fiscal year 2023 none of the Company’s executive officers served on the board of directors (or a compensation committee thereof or other board committee performing equivalent functions) of any entities that had one or more executive officers serve on the Compensation Committee of the Company or on the Board of Directors of the Company. No member of the Compensation Committee had any relationship requiring disclosure under any paragraph of Item 404 of Regulation
S-K.
Compensation Committee Report
Currently, none of our executive officers are compensated by the Company, and as such the Company is not required to produce a report on executive officer compensation for inclusion in our annual report on Form
10-K.
 
114

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Unitholder Matters
The following table sets forth, as of February 23, 2024, the beneficial ownership of each director and executive officer of the Company, and the executive officers and directors as a group.
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Unless otherwise indicated, the Company believes that each beneficial owner set forth in the table has sole voting and investment power and has the same address as the Company. Our address is 500 Park Avenue, New York, New York 10022.
 
Name and Address of Beneficial Owner
  
Number of Units
Owned Beneficially
(1)
    
Percentage
of Class(2)
 
Interested Directors
     
Michael S. Gross
     —         —   
Bruce Spohler
     —         —   
Independent Directors
     
Steven Hochberg
     —         —   
Leonard A. Potter
     —         —   
David S. Wachter
     —         —   
Executive Officers
     
Shiraz Y. Kajee
     —         —   
Guy Talarico
     —         —   
All executive officers and directors as a group (7 persons)
     —         —   
 
(1)
Beneficial ownership has been determined in accordance with Rule
13d-3
under the 1934 Act.
(2)
Based on a total of 1,069,642 Company’s Units issued and outstanding on February 23, 2024.
Set forth below is the dollar range of equity securities beneficially owned by each of our directors as of February 23, 2024. We are not part of a “family of investment companies,” as that term is defined in the 1940 Act.
 
Name of Director
  
Dollar Range of Equity Securities Beneficially
Owned
(1)(2)
 
Interested Directors
     —   
Michael S. Gross
     —   
Bruce Spohler
     —   
Independent Directors
  
Steven Hochberg
     —   
Leonard A. Potter
     —   
David S. Wachter
     —   
 
(1)
The dollar ranges are:
None, $1-$10,000, $10,001-$50,000, $50,001-$100,000, or
Over $100,000.
(2)
Beneficial ownership has been determined in accordance with Rule
16a-1(a)(2)
of the 1934 Act.
Item 13. Certain Relationships and Related Transactions, and Director Independence
Transactions with Related Persons, Promoters and Certain Control Persons
Investment Management Agreement
We have entered into the Investment Management Agreement with the Adviser pursuant to which we pay management fees, administrative coordinator fees and incentive fees to the Adviser. The Board held a meeting on October 25, 2023 to approve the Investment Management Agreement. In reliance on certain exemptive relief provided by the SEC, the Board ratified the approval of the Investment Management Agreement at its next
in-person
meeting held on November 6, 2023. Subject to certain restrictions, the Investment Management Agreement will remain in effect from year to year if approved annually by a majority of the Board, including a majority of independent directors, or by the holders of a majority of our outstanding voting securities until terminated by the Company, or by the Adviser, upon 60 days’ prior written notice.
 
115

Administration Services
Pre-Exchange
Listing
. Prior to an Exchange Listing, pursuant to the Investment Management Agreement, the Adviser has also been appointed as the Administrative Coordinator. The Administrative Coordinator will supervise or provide the Company’s administrative services, including operational trade support, NAV calculations, financial reporting, fund accounting, registrar and transfer agent services. The Administrative Coordinator provides assistance to the Adviser in connection with communicating with investors and other persons with respect to the Company. The Administrative Coordinator, when acting in its administrative capacity, does not provide any investment advisory or investment management services to the Company. Pursuant to the Investment Management Agreement, the Company pays the Administrative Coordinator the
Pre-Exchange
Listing Administration Fee for its services.
The Investment Management Agreement contains limitations on liability and indemnifications in favor of the Administrative Coordinator, provided that the Administrative Coordinator’s actions do not constitute fraud, bad faith, gross negligence or willful misconduct (collectively, “Wrongful Conduct”). The Administrative Coordinator’s liability to the Company is subject to an overall cap (except where the Administrative Coordinator has engaged in Wrongful Conduct). In the event that the Administrative Coordinator is terminated or resigns as the administrative coordinator to the Company, the Board reserves the ability to appoint one or more different or replacement administrative coordinators in its sole discretion at any time without notice to the Unitholders, or to assume the Administrative Coordinator’s role on the same or similar terms in providing administration services to the Company.
Our Board will approve the engagement of the Administrative Coordinator on an annual basis prior to an Exchange Listing. In connection with such approval, the Board, including a majority of independent directors, reviews the engagement of the Administrative Coordinator to determine that the relevant provisions of the Investment Management Agreement are carried out satisfactorily and to determine, among other things, whether the fees payable to the Administrative Coordinator are reasonable in light of the services provided. The Board also considers the possibility of obtaining such services from a different third party and whether any other third party service provider would be capable of providing all such services at comparable cost, quality and timeliness.
Post-Exchange Listing
. As described above, in connection with an Exchange Listing, and subject to Board approval, the Company intends to enter into an administration agreement with SCM pursuant to which SCM will provide administrative services to the Company. For providing these services, facilities and personnel, the Company will reimburse SCM for the Company’s allocable portion of overhead and other expenses incurred by SCM in performing its obligations under the administration agreement.
Use of Name
Pursuant to the LLC Agreement, SLR has granted us
a non-exclusive license
to use the name “SLR HC BDC LLC” as the name of the Company and in connection with the marketing and operation of the Company. We have a right to use the “SLR HC BDC LLC” name for so long as the Adviser or one of its affiliates remains our investment adviser. Other than with respect to this limited license, we have no legal right to the “SLR HC BDC LLC” name or logo.
Relationship with the Adviser and Potential Conflicts of Interest
Conflicts of Interest; Other Activities of the Adviser
. Various potential and actual conflicts of interest are expected to arise from the overall investment activities of the Adviser and its affiliates, some of which are noted below. The Adviser and its affiliates serve as an investment adviser to other investment vehicles, funds and clients and expect to make investment decisions for the accounts of others, including other investment vehicles and funds, that are different from those that will be made by the Adviser on behalf of the Company. Such conflicts may arise, for example, when both the Company and/or clients of SLR invest in (i) securities or other instruments issued by a particular issuer and in certain assets owned by such issuer; and (ii) different parts of an issuer’s capital structure, whereby one or more clients own senior debt obligations of an issuer and other clients own junior debt or equity of the same issuer, or one or more clients own public securities and other clients own private securities, as well as circumstances in which clients invest in different tranches of the same investment. In such circumstances, matters such as decisions over the operations or activities of the issuer involved; negotiations over the terms and conditions of the investment; decisions with respect to amendments, consents or waivers; the targeted returns from the investment; the timeframe for, or method of, exiting the investment; or bankruptcy-related matters (including decisions over whether to trigger an event of default or over the terms of any workout) are likely to result in conflicts of interest.
 
116
Similar conflicts of interest are likely to arise to the extent a Portfolio Investment is in competition with investments owned by the Adviser, its clients or affiliates (
e.g.
, investments in similar regions or markets may compete with respect to customers, tenants and/or purchasers). In order to minimize such conflicts, the Company may avoid making certain investments or taking certain actions that would potentially give rise to conflicts of interest, which could have the effect of limiting the Company’s investment opportunities. Alternatively, the Company might resolve the conflict by adopting a particular strategy (including disposing of an investment earlier than it otherwise would have if no conflict existed), which could result in a different investment outcome than might arise if the Company had adopted an otherwise different investment strategy.
All conflicts of interest will be resolved by the Adviser in its sole discretion. When making investment decisions where a conflict of interest may arise, the Adviser will endeavor to act in a fair and equitable manner as between the Company and other clients of SLR; however, there can be no assurance that the Adviser will be able to resolve such conflict of interest in a fair and equitable manner. For example, in certain instances the resolution of the conflict may result in the Adviser acting on behalf of itself, an affiliate or another client of an affiliate of SLR, or any of their respective affiliates (for example, by foreclosing on loans, putting an issuer into default and/or transacting with an issuer) in a manner that is not in the best interests, or is opposed to the interests, of the Company.
Subject to the foregoing and applicable law, (i) the Adviser and its affiliates expect to invest for the accounts of clients in various securities or other instruments or investments that are senior,
pari passu
or junior to, or have interests different from or adverse to, the securities or other instruments or investments that are owned by the Company, (ii) the Adviser and its affiliates may engage in transactions, on an arms-length basis, that arrange for or provide financing or leverage for the Company’s investment program and/or investments, and the Company may pledge or sell assets (including pursuant to reverse repurchase agreements) to the Adviser and its affiliates in connection therewith and (iii) the Adviser and/or its affiliates expects to at certain times be simultaneously seeking to purchase (or sell) investments for the Company and to sell (or purchase) the same investment for accounts, funds or structured products for which it serves as asset manager now or in the future, or for its clients or affiliates, and to enter into cross trades (including similar transactions such as novations of derivatives transactions) in such circumstances, including with respect to securities or other assets that may be illiquid and difficult to value. In addition, the Adviser and its affiliates expect to buy securities and other investments from or sell securities and other investments to the Company, if permitted by and in accordance with applicable law. These other relationships may also result in securities laws restrictions on transactions in these instruments by the Company and otherwise create potential conflicts of interest for the Adviser. In the event that the Adviser enters into a transaction resulting in such simultaneous buying and selling or cross trades, the transaction will be reported to the Board in accordance with the Company’s compliance policies and procedures.
Conflicts of interest may also arise where, for example, the Company holds certain loans of an issuer, and that same issuer has issued other loans or instruments that are owned by other clients of SLR or by an entity, in which other clients of SLR have an interest; in such circumstances, SLR may take actions with respect to the assets held by such client that are adverse to the Company, for example, by foreclosing on loans or by putting an issuer into default. In negotiating the terms and conditions of any such investments, or any subsequent amendments or waivers, the Adviser may find that the interests of the Company and the interests of one or more other clients of SLR could conflict. In these situations, decisions over whether to make an investment, proxy voting, corporate reorganization, how to exit an investment, the servicing of loans or bankruptcy matters are likely to result in conflicts of interest. Similarly, if an issuer in which the Company and one or more other clients of SLR directly or indirectly hold different classes of securities (or other assets, instruments or obligations issued by such issuer or underlying investments of such issuer) encounters financial problems, decisions over the terms of any restructuring or workout are likely to raise conflicts of interest (including, for example, conflicts over proposed waivers and amendments to debt covenants). For example, a debt holder may be better served by a liquidation of the issuer in which it may be paid in full, whereas an equity or junior bond holder might prefer a reorganization that holds the potential to create value for the equity holders. Although in some cases the Adviser may refrain from taking certain actions or making investments on behalf of the Company because of conflicts (potentially disadvantaging the Company as a result of actions not taken or investments not made), in other cases the Adviser will not refrain from taking actions or making investments on behalf of the Company that have the potential to disadvantage other SLR clients.
Except as otherwise expressly set forth in the LLC Agreement, or as required by law, the Adviser or its respective affiliates will not be obligated to refer any actual or potential conflict of interest to Unitholders, or to act in accordance with their advice and counsel. However, if the Company chooses or is required under the LLC Agreement or by law to do so, matters approved by a majority in interest of Unitholders (as applicable) will be final and binding on the Company, the Unitholders, the Access Fund and the Access Fund LPs.
Certain Portfolio Investments may engage in activities or take actions that adversely impact the Company or its other Portfolio Investments; provided that such Portfolio Investment does not engage in such activities or actions at the instruction of the Adviser. With respect to Portfolio Investments for which it does not exercise influence or control, the Adviser will likely have
 
117

limited or no ability to impact such matters. Furthermore, with respect to Portfolio Investments for which it does exercise influence or control, there can be no assurance that the Adviser will be able to impact such matters; for example, directors appointed by the Adviser will have duties to persons other than the Company and/or may recuse themselves from matters presenting actual or potential conflicts of interest.
In addition, the Company may be unable or limited in its ability to acquire Portfolio Investments or take certain actions with respect to Portfolio Investments (including taking “active” positions with respect to such Portfolio Investments) due to the Adviser’s duties to other clients or under applicable law (including the Advisers Act, the 1940 Act and U.S. Employee Retirement Income Security Act of 1974, as amended (“ERISA”)) or by the Adviser’s intention to avoid certain potential conflicts of interest or regulatory issues or obligations, and individual members of the investment team may be subject to similar constraints (or unable to participate in certain Company matters) due to similar considerations. Similarly, the Adviser may be required to take certain actions (including disposing of investments owned by the Company and/or other clients) due to such issues, obligations or potential conflicts. In order for the Adviser to adhere to its applicable fiduciary obligations as well as to address and/or mitigate conflicts of interest, it may not be possible or appropriate to make available resources of the Adviser that might be relevant to particular investment decisions by the investment professionals responsible for the Company’s investment program. Such restrictions could result in such investment professionals making investment or other decisions for the Company that are different from the decisions they would make if there were no such limits or restrictions.
In connection with its investment program, the Company, in the sole discretion of the Adviser may take various forms of action (“Litigation Actions”) with other investors and/or parties, including issuing demand letters, making and defending claims, filing lawsuits and/or taking other dispute resolution-related measures. In connection with such Litigation Actions, the Company may be required to bear certain fees, costs, expenses and liabilities. Other SLR clients that are or were investors in, or otherwise involved with, the subject investments may or may not (depending on the circumstances) be parties to such Litigation Actions, with the result that the Company may participate in Litigation Actions in which not all SLR clients with similar investments may participate, and such
non-participating
clients may benefit from the results of such Litigation Actions without bearing or otherwise being subject to the associated fees, costs, expenses and liabilities. SLR, for example, typically does not pursue legal claims on behalf of its separately managed client accounts.
Although the principals and employees of the Adviser will devote as much time to the Company as the Adviser deems appropriate, the principals and employees may have conflicts in allocating their time and services among the Company and the other accounts now or hereafter advised by the Adviser and/or its affiliates.
The Adviser, the Administrative Coordinator and the Custodian will from time to time act as investment advisers, administrators or custodians in relation to, or otherwise be involved with, other companies established by parties other than the Company. Such companies may have similar objectives to the Company. Should a conflict of interest arise, the Board will endeavor to ensure that it is resolved fairly, to the extent it is in a position to do so.
In implementing its investment program, the Company expects to seek to acquire rights (including rights of first offer, rights of first refusal,
non-competition
rights, exclusivity rights and purchase rights) arising under existing contractual arrangements (including agreements with joint venture partners, servicers, originators and Portfolio Investments) of the Adviser, other clients of the Adviser or other affiliates of the foregoing; conversely, the Company may obtain such rights in connection with its investment program and may seek to transfer such rights to such entities. Any transfer of rights may or may not involve the receipt by the transferor of a purchase price or direct consideration, depending on the circumstances. Such activities are likely to give rise to certain conflicts of interest. In particular, (i) any such rights will likely be illiquid, and if sold will likely be difficult to value; (ii) the Adviser will be conflicted in determining whether to assign a value to any such right, as well as in determining any value assigned thereto; (iii) the Adviser may be incentivized to pursue investment opportunities arising under such arrangements (including due to a desire to maintain a long-term relationship with a transaction counterparty), and may forgo other attractive investment opportunities for the Company as a result; and (iv) to the extent the Company’s rights are dependent on its ownership of a Portfolio Investment, the Adviser may be incentivized to extend such Portfolio Investment’s duration to enable such rights to be transferred to another entity. Conversely, the Company may not (or may be unable to) acquire or dispose of such rights, which could give rise to certain conflicts of interest; for instance, if another client of the Adviser or its affiliates has a right of first offer with respect to transaction types, the Company’s ability to pursue such transactions could be constrained if it does not acquire such right. In addition, the documentation relating to any assignment of such rights could be complex, difficult to enforce and (among other things) potentially expose the Company to the liabilities of another related entity.
The Company expects to make investments through joint ventures, strategic partnerships or similar arrangements with third parties, the terms of which will often provide for the payment of fees, incentive compensation and/or other amounts to such third parties. These amounts will typically be borne (directly or indirectly) by the Company. Such amounts will generally not give rise to a reduction in the Management Fees, Administration Expenses or Incentive Fees payable by the Company, and the Adviser may therefore be incentivized to pursue investment opportunities arising under such arrangements (including to maintain or develop a long-term or strategic relationship with a third party).
 
118

Conflicts Related to Cross-Trades
. The Adviser may, to the extent permitted under applicable law, effect client cross trades where the Adviser causes a transaction to be effected between the Company and another account advised by it or its affiliate. The valuation of loans or other assets that may be transferred from the Company to other funds managed by the Adviser or affiliates involves inherent conflicts of interest for the Adviser, and there is no guarantee that the Adviser will resolve these conflicts in a manner that will not have an adverse effect on the Company.
Conflicts Related to Sale of Loans
. The Company may sell a portion of any loans or certain other assets originated by the Company to other funds managed by the Adviser or affiliates. As a result, the Company’s initial participation in such loans or other assets may be greater, and its available liquid capital less, than it would have been if the Company did not expect to ultimately sell part of such loans or other assets to another fund managed by the Adviser or affiliates. To the extent the Company purchases loans or other assets and subsequently sells a portion thereof to other funds managed by the Adviser or affiliates, the Company will bear the risk of changes in the value of such loans or other assets during the period it holds such loans or other amounts and the amount of capital available to the Company to pursue other investment opportunities may be reduced. Furthermore, it may be difficult to determine the value of the loans or other assets transferred by the Company. As a result, consideration due to the Company from other funds managed by the Adviser or affiliates whenever it may sell the loans or other assets is subject to uncertainty and valuation risks as described elsewhere herein. The valuation of loans or other assets that may be transferred from the Company to other funds managed by the Adviser or affiliates involves inherent conflicts of interest for the Adviser, and there is no guarantee that the Adviser will resolve these conflicts in a manner that will not have an adverse effect on the Company. To help mitigate these conflicts, the Adviser may engage an independent third party valuation agent (whose fees will be borne by the Company) to price loans sold from the Company to other funds managed by the Adviser or affiliates.
Service Providers
. The nature of the relationship with a Service Provider and the amount of time devoted or required to be devoted by a Service Provider are expected to vary considerably. In some cases, a Service Provider may provide sector-, industry- and/or regional-specific insights and feedback on investment themes, assist in transaction due diligence, and/or make introductions to and provide reference checks on management teams. In other cases, Service Providers may take on more extensive roles and serve as executives or directors on the board of directors of Portfolio Investments or portfolio companies or contribute to the origination of new investment opportunities. In certain instances, there may be formal arrangements with Service Providers (which may or may not be terminable upon notice by any party), and in other cases the relationships may be more informal. Service Providers may receive compensation regardless of whether a Portfolio Investment is consummated (including pursuant to retainers and expense reimbursement), and/or may be uncompensated unless and until an engagement with a Portfolio Investment develops. In certain cases, they may have certain attributes of “employees” of the Adviser (
e.g.
, they may have dedicated offices at the Adviser, participate in general meetings and events for the Adviser personnel, work on matters of the Adviser as their primary or sole business activity and/or be compensated on a weekly or monthly basis rather than on a project basis) even though they are not considered employees of the Adviser, affiliates or personnel for purposes of provisions of this report, the LLC Agreement and the Investment Management Agreement relating to Adviser expenses.
Because certain services provided by Service Providers, such as the identification or analysis of investments, might otherwise be provided by employees of the Adviser, the Adviser will have an incentive to retain such Service Providers and have them paid by the Company rather than hiring employees or otherwise paying for these services out of its own resources, particularly since the fees, costs, expenses and liabilities of these parties may be substantial (
e.g.
, fees payable to individual Service Providers may exceed $1 million in any given year). There can be no assurance that any of the Service Providers will continue to serve in such roles for the expected duration of their engagement. Moreover, agreements with Service Providers may provide for the indemnification by the Company of a Service Provider against certain costs and liabilities, which may have the effect of reducing the Adviser’s potential costs and obligations. In addition, if the Company utilizes a Service Provider that the Adviser, its clients and/or its affiliates have an option to acquire, the Adviser may be incentivized to have the Company provide substantial compensation or take other measures with respect to such Service Provider in order to facilitate such acquisition or enable the prospective purchasers to acquire the Service Provider on more favorable terms.
The Company expects to utilize or otherwise engage in transactions with, and to invest in entities that utilize or otherwise engage in transactions with, Service Providers that are owned by, affiliated with or otherwise related to the Company, other clients of the Adviser, the Adviser, or any affiliate or respective personnel thereof. The Company’s involvement with affiliated Service Providers will give rise to conflicts of interest. For example, (i) while the Adviser may have an incentive to cause the Company to utilize affiliated Service Providers, there can be no guarantee that such Service Providers will have a positive impact on the Company or its investments, or that they will produce results better than unaffiliated Service Providers; (ii) the
 
119

Adviser may be less incentivized to pursue remedies and enforce rights against an affiliated Service Provider as compared to an unaffiliated Service Provider; (iii) the Adviser may be incentivized to utilize an affiliated Service Provider in order to support such entity, benefit or reduce amounts owed by the other users of or purchasers from such entity, and/or benefit the Adviser-affiliated owners of such entity (which may not include the Company), including by generating fees or other compensation paid to such entity (which will not offset the Management Fee, Administration Expenses or Incentive Fees paid by the Company); (iv) while the fees and expenses paid to any Service Provider that is an affiliate of the Adviser will be determined in the Board’s commercially reasonable discretion, taking into account the relevant facts and circumstances and consistent with the responsibilities of the Board and the Adviser, the Board may still be incentivized to agree to more favorable compensation terms with an affiliated Service Provider than with an unaffiliated Service Provider, and such terms will not necessarily be confirmed as being comparable to the market rates for such services; (v) to the extent the Company acquires or sells an interest in an affiliated Service Provider via cross trade with another affiliate of the Adviser, such investment will likely be illiquid and difficult to value, and such valuation will result in conflicts of interest; and (vi) to the extent any such Service Provider is owned by or services multiple Adviser-affiliated entities, the allocation of opportunities and expenses among the relevant entities will require the exercise of discretion. In addition, any such Service Provider may have duties to parties other than the Company, and the Company may not be able to control or influence the standards or actions of such Service Provider notwithstanding its affiliation. Any such affiliated Service Provider may also be acquired by one or more third parties or an affiliate of the Adviser, which could reduce or eliminate any benefits the Company previously received by virtue of its prior affiliation.
Potential Conflicts Relating to the Allocation of Investment Opportunities among the Company and Other Investment Vehicles
. Various potential and actual conflicts of interest are expected to arise in connection with the allocation of investment opportunities among the Company and other investment vehicles managed or advised by SLR. Investment opportunities that become known to the Adviser may be appropriate for the Company as well as for the Adviser’s other clients and for the clients of SLR. The Adviser may face conflicts of interest with respect to the allocation of such opportunities.
The Company intends to
co-invest
with other
SEC-regulated
funds and private funds managed by the Adviser or its affiliates in certain circumstances where doing so is consistent with applicable law and SEC staff interpretations. For example, the Company may
co-invest
with such accounts consistent with guidance promulgated by the SEC staff permitting the Company and such other accounts to purchase interests in a single class of privately placed securities so long as certain conditions are met, including that the Adviser, acting on our behalf and on behalf of other clients, negotiates no term other than price. The Company may also
co-invest
with the Adviser’s or its affiliates’ other clients as otherwise permissible under the Order. The Order permits the Company to participate in negotiated
co-investment
transactions with certain affiliates, each of whose investment adviser is SLR or an investment adviser that controls, is controlled by, or is under common control with SLR and is registered under the Advisers Act. Transactions entered pursuant to the Order must be conducted in a manner consistent with the Company’s investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors, and pursuant to the conditions in the Order. The limitations imposed by the Order or the inability to rely upon the Order could limit the ability of the Company to participate in certain investment opportunities.
The Adviser has written policies relating to the allocation of investment opportunities, and the Adviser will allocate investment opportunities that become known to the Adviser and that the Adviser considers appropriate for the Company among the Adviser’s sponsored funds and other clients, in accordance with the Adviser’s allocation policy and procedures. With respect to investment opportunities that are appropriate for other clients of SLR, on the one hand, and the Company, on the other hand, SLR has agreed upon an allocation methodology that it believes will result in the relevant clients each being allocated an appropriate level of such opportunity. Although the Adviser intends to allocate investment opportunities in a fair and equitable manner, decisions as to the allocation of investment opportunities present numerous conflicts of interest, which may not be resolved in a manner that is favorable to the Company’s interests. Moreover, allocation decisions involving
co-investment
opportunities will depend on the ability of the Company and clients of the Adviser and SLR to rely on SEC exemptive relief relating to
co-investments
with business development companies advised by SLR.
The Adviser expects that in certain circumstances it will permit other investment vehicles to
co-invest
with the Company. In that case, allocations will be made in the sole discretion of the Adviser and may result in the investments being made on different terms or in different securities. In addition, these types of
co-investments
may result in conflicts regarding decisions relating to that investment, including with respect to timing of disposition or strategic objectives.
Material
Non-Public
Information
. The Adviser expects to come into possession of material
non-public
information concerning specific issuers. Under applicable securities laws, this may limit the Adviser’s flexibility to buy or sell securities issued by such issuers on behalf of the Company or otherwise use such information for the benefit of the Company (
e.g.
, in situations when the Company is asked to grant consents, waivers or amendments with respect to loans, the Adviser’s ability to assess the desirability of such consents, waivers and amendments may be compromised). The Adviser may decline to pursue certain investment opportunities or exit strategies on behalf of the Company in order to avoid being in possession of material
non-public
 
120

information in respect of an issuer where such possession would limit the Adviser’s ability to trade in other securities of such issuer on behalf of their other clients. Alternatively, the Adviser may decline to receive material
non-public
information in order to avoid trading restrictions, even though access to such information might have been advantageous and other market participants are in possession of such information.
In addition, in circumstances when a Unitholder receives, in connection with its investment in the Company, material
non-public
information concerning specific issuers, such Unitholder’s flexibility to buy or sell securities issued by such issuers or otherwise use such information may similarly be limited or restricted under applicable securities laws.
With respect to transactions involving material
non-public
information (among others), the Investment Committee may delegate investment and/or asset management decisions to other investment professionals of the Adviser in their sole discretion. Any decisions made by such subset or other investment professionals may be materially different and/or less optimal than decisions that would have been made by the Investment Committee.
In the event any material,
non-public
information is disclosed to any person responsible for the affairs of the Company, the Company may be prohibited by applicable securities laws and the Company’s Joint Code of Ethics and Insider Trading Policy from acting upon any such information. Due to these restrictions, the Company may not be able to conclude a transaction that it otherwise might have concluded. In other cases, because of confidential or material
non-public
information acquired by SLR, the Company may also be prohibited from acquiring an investment that it otherwise might have acquired.
Co-Investments
. With respect to a Portfolio Investment for which the Adviser determines
co-investment
capacity is available, the Adviser may, in its sole discretion, offer any portion of a
co-investment
to Unitholders or to third parties (which may be unaffiliated or affiliated with the Adviser or its affiliates, which may include Service Providers), or may cause the Company to retain such amounts. Each
co-investment
may be made by a separate vehicle formed for the purpose of making such
co-investment.
Any Unitholder participating in a
co-investment
may be required to pay fees (including management, incentive and administration fees) in connection with such
co-investment
(and, for the avoidance of doubt, any such fees or amounts shall not be considered Transaction Fees (as defined below). Distributions of income and proceeds related to each
co-investment
will be made separately from, and not aggregated with, distributions of income and proceeds related to the corresponding Portfolio Investment by the Company. “Transaction Fees” means the Company’s portion (as determined by the Company in its reasonable discretion) of any directors’, transaction,
break-up,
consulting, financial and advisory or other fees paid to the Adviser or any of its subsidiaries by any third party in connection with any proposed or existing Portfolio Investment; provided that, in each case, Transaction Fees will not include (i) any amounts paid as reimbursement for
out-of-pocket
expenses incurred in connection with providing services in respect of which such Transaction Fees were paid, (ii) any amounts paid to Service Providers in connection with any Company investment or (iii) any amounts paid by any investor or investment vehicle making a
co-investment
with the Company or investing alongside the Company. In determining the Company’s portion of any Transaction Fees, the Company may take into account its proportionate ownership of a Portfolio Investment’s entire capital structure (including both debt and equity). The Adviser or any of its subsidiaries may take actions to give effect to the above arrangement other than reducing Management Fees (
e.g.
, rebating or waiving Transaction Fees at the Portfolio Investment level), in which case Transaction Fees will not reduce Management Fees as described above. For the avoidance of doubt, any fees and expenses paid to SLR Healthcare ABL (f/k/a Gemino Healthcare Finance LLC), or any existing or future entity which has been acquired by the Adviser or any affiliate of the Adviser, in each case, on an arms-length basis in connection with services provided in relation to any Portfolio Investments are not Transaction Fees and will not offset Management Fees.
The Adviser is under no obligation to provide
co-investment
opportunities to Unitholders, and any such
co-investment
opportunity may be offered to one or more third parties.
Co-investment
opportunities will be allocated as determined by the Adviser in its sole discretion. In determining such allocations, the Adviser may take into account any facts or circumstances it deems appropriate, including the size of the prospective
co-investor’s
investment in the Company and any other vehicles or accounts advised by the Adviser or its affiliates; whether and the extent to which the prospective
co-investor
has expressed an interest in
co-investment
opportunities; the Adviser’s evaluation of the financial resources, sophistication and experience of the potential
co-investor,
with respect to the execution of
co-investment
transactions generally, and with respect to the geographic location or business activities of the applicable Portfolio Investment; perception of past experiences and relationships with each prospective
co-investor;
whether or not such person has
co-invested
previously and the ability of any such
co-investor
to respond promptly and appropriately to potential investment opportunities; perception of the legal, regulatory, reporting, public relations, competitive, confidentiality or other issues that may arise with respect to any prospective
co-investor;
and any strategic value or other benefit to the Adviser or its affiliates resulting from offering such
co-investment
opportunity to a prospective
co-investor.
Nothing in this report constitutes a guarantee, prediction or projection of the availability of
co-investment
opportunities.
 
121

Co-investments
may result in conflicts between the Company and other
co-investors
(for example, over the price and other terms of such investment, exit strategies and related matters, including the exercise of remedies of their respective investments). Furthermore, to the extent that the Company holds interests that are different (or more senior) than those held by such other
co-investors,
the Adviser may be presented with decisions involving circumstances where the interests of such
co-investors
are in conflict with those of the Company. To the extent any affiliate of the Adviser
co-invests
with the Company, such conflicts will be heightened.
The Adviser may grant certain Unitholders a priority right to participate in
co-investment
opportunities, subject to the requirements of the Order and to applicable law. The existence of such priority
co-investment
rights may result in other Unitholders receiving fewer or no
co-investment
opportunities. Because
co-investors
may not be identified and/or may not agree to invest until relatively late in the investment process, or for other reasons,
co-investors
may not bear their proportionate share of investment-related expenses (including “broken deal” expenses). Beneficial owners of more than 25% of the Company’s Units are not permitted to participate in
co-investment
opportunities, and beneficial owners of between 5% and 25% of the Company’s Units are only permitted to participate in
co-investment
opportunities upon approval of the Company’s Board. A
non-binding
indication of interest in
co-investments
does not require the Adviser to notify such interested party of any
co-investment
opportunity.
Certain Potential Conflicts Relating to Expenses
. The appropriate allocation of fees and expenses among the Company and other funds or accounts advised by the Adviser or any of its affiliates often cannot be resolved by reference to a
pre-existing
formula and will require the exercise of discretion. In addition, it is expected that the Company will bear expenses related to investments that it does not consummate (
i.e.,
broken deal expenses). While the Adviser has adopted policies and procedures designed to fairly and equitably allocate expenses, the Adviser and its affiliates will be subject to conflicts of interest in making such determinations, and there can be no assurance that errors will not arise in such allocations, or that any allocations (i) will reflect an entity’s
pro rata
share of such expenses based on the amounts invested (or anticipated to be invested) / market value of the investment held (or anticipated to be held) by each fund or account managed by the Adviser or its affiliates or (ii) will be in proportion to the number of participating funds managed by the Adviser or its affiliates, or the proportion of time spent on each fund managed by the Adviser or its affiliates, or that such allocations will not confer an economic benefit on other entities at the Company’s expense. Similarly, the determination of whether an expense (for instance, the fees and expenses of consultants, contract employees, outside legal counsel and temporary employees (as well as secondees of any of the foregoing) who work on Company -related matters) is appropriately borne by the Company (or a specific group of Company investors) or the Adviser often cannot be resolved by reference to a
pre-existing
formula and will require the exercise of discretion, and the Adviser is subject to conflicts of interest in making such determinations. In particular, the Adviser may be incentivized to (i) classify expenses as borne by the Company as opposed to the Adviser and (ii) decrease the level or quality of third-party services provided to the Company to the extent such services are paid for by the Adviser.
For administrative and other reasons, the Adviser may (i) cause the Company to be invoiced for, advance or otherwise bear on a temporary basis all or a portion of an expense ultimately intended to be borne in whole or in part by another vehicle managed by the Adviser or an affiliate and/or (ii) make corrective allocations of expenses among such vehicles to reflect their appropriate share of such expenses. Such measures generally will not include the imposition of an interest charge or other payments designed to compensate (whether for time value, opportunity cost or otherwise) a particular vehicle for temporarily bearing a disproportionate share of expenses.
The Company and certain other funds managed by the Adviser or an affiliate may, but are not expected to hold certain investments and conduct certain activities through the same SPVs or other structures. The use of such common SPVs or other structures may give rise to various conflicts of interest; for example, the use of any such vehicle may make it more difficult to address specific considerations applicable to the Company than if separate vehicles were used. In addition, a level of discretion will be required with respect to each entity’s relative participation in any such vehicle, including adjustments intended to reflect the entities’ relative capital available for investment as of the conclusion of their respective offering periods.
Incentive Fee; Use of Leverage
. The existence of the Adviser’s Post-Exchange Listing Incentive Fee will create an incentive for the Adviser to make more speculative investments on behalf of the Company than it might otherwise make in the absence of such performance-based compensation. Additionally, the Company has broad authority to utilize leverage; as the use of leverage has the potential to magnify gains, the Adviser may be incentivized to utilize leverage in an effort to enhance the Company’s performance and/or generate Incentive Fees for itself. Additionally, prior to an Exchange Listing, the Adviser may be incentivized to utilize a Commitment-based Company credit facility, since (i) borrowings associated with such facility generally will be included for purposes of the
Pre-Exchange
Listing Management Fee payable to the Adviser and (ii) the utilization of such facility may enable the Adviser not to draw down Commitments and thereby receive
Pre-Exchange
Listing Incentive Fees sooner than it would have in the absence of such facility.
 
122

Valuation
. Subject to approval by the Board, the Adviser will value securities, loans or other instruments for which market quotes are not readily available at fair value (or if extraordinary events occur after the last readily available quotation), and is subject to certain conflicts of interest in doing so. In particular, the Adviser may be incentivized to produce higher valuations in order to enhance Company performance, and/or due to the operation of the guideline.
Diverse Unitholder Group
. It is expected that the Unitholders will have conflicting investment, tax and other interests with respect to their investments in the Company. The conflicting interests of Unitholders may relate to, or arise from, among other things, the acquisition or structuring of Portfolio Investments and the timing and disposition of Portfolio Investments. As a consequence, conflicts of interest may arise in connection with decisions made by the Adviser that may be more beneficial for one investor than for another investor, for example, with respect to Unitholders’ individual tax situations. In addition, the Company may make Portfolio Investments which may have a negative impact on related or unrelated investments made by Unitholders in transactions outside of the Company. In selecting and structuring Portfolio Investments appropriate for the Company, the Adviser will consider the investment and tax objectives of the Company and the Unitholders as a group, not the investment, tax or other objectives of any Unitholder individually.
Changing and Evolving Conflicts and Potential Conflicts
. From time to time, the Adviser, its affiliates and their personnel may enter new lines of business and modify or further develop existing lines of business for itself and for clients. Expertise in a range of disciplines may lead to the Adviser entering new businesses and/or other potential investment opportunities, directly or indirectly (including through joint ventures or other arrangements), which in turn may introduce potential conflicts in the allocation of time, resources and investment opportunities made available to the Company by the Adviser. Similarly, the composition of the Adviser may also change, and these changes may have an impact on the Company’s business lines and the activities it conducts for itself and for clients.
There is no guarantee that the Adviser’s business, and any associated potential conflicts of interest, will not change or become more acute. As a result, it is difficult to predict or foresee the potential conflicts that may arise as the business of the Adviser changes and evolves. Thus, potential investors should view these disclosures as being preliminary only and not exhaustive.
Certain Business Relationships
Certain of our current directors and officers are directors or officers of other funds managed by the Adviser.
Director Independence
Pursuant to Section 56 of the 1940 Act, a majority of a BDC’s board of directors must be comprised of persons who are not “interested persons,” as defined in Section 2(a)(19) of the 1940 Act, of the Company or any of its affiliates.
Consistent with these considerations, after review of all relevant transactions and relationships between each director, or any of his or her family members, and the Company, the Adviser, or of any of their respective affiliates, the Board has determined that Messrs. Hochberg, Potter and Wachter qualify as independent directors. Each director who serves on the Audit Committee is an independent director for purposes of Rule
10A-3
under the 1934 Act.
Promoters and Certain Control Persons
The Adviser may be deemed a promoter of the Company. We have entered into the Investment Management Agreement with the Adviser. The Adviser, for its services to us, is entitled to receive management fees and incentive fees in addition to the reimbursement of certain expenses. In addition, under the Investment Management Agreement, we expect, to the extent permitted by applicable law and in the discretion of our Board, to indemnify the Adviser and certain of its affiliates.
Limitation on Liability of Directors; Indemnification and Advance of Expenses
Under the LLC Agreement, we will fully indemnify any person who was or is involved in any actual or threatened action, suit or proceeding by reason of the fact that such person is or was one of our directors or officers. So long as we are regulated under the 1940 Act, the above indemnification and limitation of liability is limited by the 1940 Act or by any valid rule, regulation or order of the SEC thereunder. The 1940 Act provides, among other things, that a company may not indemnify any director or officer against liability to it or its security holders to which he or she might otherwise be subject by reason of his or her willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his or her office unless a determination is made by final decision of a court, by vote of a majority of a quorum of directors who are disinterested,
non-party
directors or by independent legal counsel that the liability for which indemnification is sought did not arise out of the foregoing conduct. In addition, we have obtained liability insurance for our officers and directors.
 
123

Item 14. Principal Accountant Fees and Services
KPMG LLP has advised us that neither the firm nor any present member or associate of it has any material financial interest, direct or indirect, in the Company or its affiliates.
Table below in thousands
 
    
Fiscal Year

Ended

December 31,

2023
    
Fiscal Year

Ended

December 31,

2022
 
Audit Fees
   $ 135.0      $ 125.2  
Audit-Related Fees
     —         —   
Tax Fees
     17.3        16.5  
All Other Fees
     —         —   
Total Fees:
   $ 152.3      $ 141.7  
Audit Fees
: Audit fees consist of fees for professional services rendered for quarterly reviews and services that are normally provided by KPMG LLP in connection with statutory and regulatory filings.
Audit-Related Fees
: Audit-related services consist of fees for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees.” These services include attest services that are not required by statute or regulation and consultations concerning financial accounting and reporting standards.
Tax Services Fees
:
 Tax services fees consist of fees for professional tax services. These services also include assistance regarding federal, state, and local tax compliance.
All Other Fees
:
 Other fees would include fees for products and services other than the services reported above.
Pre-Approval
Policy
:
The Audit Committee has established
a pre-approval policy
that describes the permitted audit, audit-related, tax and other services to be provided by KPMG LLP, the Company’s independent registered public accounting firm. The policy requires that the Audit
Committee pre-approve the
audit
and non-audit services
performed by the independent auditor in order to assure that the provision of such service does not impair the auditor’s independence.
Any requests for audit, audit-related, tax and other services that have not received
general pre-approval must
be submitted to the Audit Committee for
specific pre-approval, irrespective
of the amount, and cannot commence until such approval has been granted.
Normally, pre-approval is
provided at regularly scheduled meetings of the Audit Committee. However, the Audit Committee may
delegate pre-approval authority
to one or more of its members. The member or members to whom such authority is delegated shall report
any pre-approval decisions
to the Audit Committee at its next scheduled meeting. The Audit Committee does not delegate its responsibilities
to pre-approve services
performed by the independent registered public accounting firm to management. During the fiscal year ended December 31, 2023, the Audit Committee
pre-approved
100% of the services described in this policy.
 
124

PART IV
Item 15. Exhibits and Financial Statement Schedules
(a) Documents Filed as Part of this Report
 
Index
  
Page No.
 
Report of Independent Registered Public Accounting Firm      82  
Consolidated Statements of Assets and Liabilities as of December 31, 2023 and 2022      83  
Consolidated Statements of Operations for the years ended December 31, 2023, December 31, 2022 and the period ended December 31, 2021      84  
Consolidated Statements of Changes in Unitholders’ Capital for the years ended December 31, 2023, December 31, 2022 and the period ended December 31, 2021      85  
Consolidated Statements of Cash Flows for the years ended December 31, 2023, December 31, 2022 and the period ended December 31, 2021      86  
Consolidated Schedules of Investments as of December 31, 2023 and 2022      87  
Notes to Consolidated Financial Statements      93  
(b) Exhibits
The following exhibits are filed as part of this report or are hereby incorporated by reference to exhibits previously filed with the SEC:
 
Exhibit No.
  
Description
  3.1    Certificate of Formation(1)
  3.2    Certificate of Amendment to Certificate of Formation(1)
  3.3    Amended and Restated Limited Liability Company Agreement(1)
  4.1    Form of Subscription Agreement(2)
  4.2    Description of Securities(4)
 10.1    Form of Investment Management Agreement with Solar Capital Partners, LLC(1)
 10.2    Custody Agreement by and between Solar Capital Ltd., Solar Senior Capital Ltd. and Citibank, N.A.(1)
 10.3    Custodial Services Election Agreement by and between the Company and Citibank, N.A(1)
 10.4    Form of Revolving Credit Agreement by and between the Company and ING Capital LLC as Administrative Agent, Sole Lead Arranger and Sole Bookrunner(3)
 10.5    Form of Loan and Security Agreement by and among SLR HC BDC SPV LLC, as borrower; SLR HC BDC LLC as parent and servicer; the Lenders party hereto; the collateral agent, collateral administrator and securities intermediary party hereto and JPMorgan Chase Bank, N.A. as administrative agent, dated as of February 18, 2022(5)
 14.1    Code of Business Conduct(4)
 19.1    Joint Code of Ethics and Insider Trading Policy(6)
 21.1    Subsidiaries of SLR HC BDC LLC*
 31.1    Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
 31.2    Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
 31.3    Certification of Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
 32.1    Certification of Co-Chief Executive Officer pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.*
 32.2    Certification of Co-Chief Executive Officer pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.*
 32.3    Certification of Chief Financial Officer pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.*
101.INS    Inline XBRL Instance Document – the instance document does not appear in the
Interactive
Data File because its XBRL tags are embedded within the Inline XBRL document.*
 
125

101.SCH    Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents*
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104    Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
 
*
Filed herewith
(1)
Previously filed as an exhibit to the Registrant’s Registration Statement on Form 10 (File
No. 000-56247)
filed with the SEC on January 29, 2021.
(2)
Previously filed as an exhibit to Amendment No. 1 to the Registrant’s Registration Statement on Form 10 (File
No. 000-56247)
filed with the SEC on March 22, 2021.
(3)
Previously filed as an exhibit to the Registrant’s quarterly report on Form
10-Q
(File
No. 000-56247)
filed on May 5, 2021.
(4)
Previously filed as an exhibit to the Registrant’s report on Form
10-K
filed on March 1, 2022.
(5)
Previously filed as an exhibit to the Registrant’s quarterly report on Form
10-Q
(File
No. 000-56247)
filed on May 3, 2022.
(6)
Previously filed as an exhibit to the Registrant’s report on Form
10-K
filed on February 28, 2023.
Item 16. Form
10-K
Summary
None.
 
126

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
SLR HC BDC LLC
/
S
/ M
ICHAEL
S. G
ROSS
    /s/ B
RUCE
J. S
POHLER
Michael S. Gross
Co-Chief Executive Officer, President, Chairman of the Board
and Director
Date: February 27, 2024
   
Bruce J. Spohler
Co-Chief Executive Officer, Chief
Operating Officer
and Director
Date: February 27, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacity and on the dates indicated.
 
Date
 
Signature
 
Title
February 27, 2024  
/s/ M
ICHAEL
S. G
ROSS
Michael S. Gross
 
Co-Chief
Executive Officer, President,
Chairman of the Board and Director
(Principal Executive Officer)
February 27, 2024  
/s/ B
RUCE
J. S
POHLER
Bruce J. Spohler
 
Co-Chief
Executive Officer, Chief Operating Officer and Director (Principal Executive Officer)
February 27, 2024  
/s/ S
TEVEN
H
OCHBERG
Steven Hochberg
  Director
February 27, 2024  
/s/ D
AVID
S. W
ACHTER
David S. Wachter
  Director
February 27, 2024  
/s/ L
EONARD
A. P
OTTER
Leonard A. Potter
  Director
February 27, 2024  
/s/ S
HIRAZ
Y. K
AJEE
Shiraz Y. Kajee
  Chief Financial Officer (Principal Financial Officer)
 
127
EX-21.1 2 d774279dex211.htm EX-21.1 EX-21.1

Exhibit 21.1

Subsidiaries of SLR HC BDC LLC

The following list sets forth our consolidated subsidiaries, the state or country under whose laws the subsidiaries are organized, and the percentage of voting securities or membership interests owned by us in each such subsidiary:

SLR HC BDC SPV LLC (Delaware) – 100%

The subsidiaries listed above are consolidated for financial reporting purposes. We may also be deemed to control certain portfolio companies.

EX-31.1 3 d774279dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael S. Gross, certify that:

1. I have reviewed this annual report on Form 10-K of SLR HC BDC LLC;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated this 27th day of February, 2024
/s/ Michael S. Gross
Michael S. Gross
EX-31.2 4 d774279dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bruce J. Spohler, certify that:

1. I have reviewed this annual report on Form 10-K of SLR HC BDC LLC;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated this 27th day of February, 2024
/s/ Bruce J. Spohler
Bruce J. Spohler
EX-31.3 5 d774279dex313.htm EX-31.3 EX-31.3

Exhibit 31.3

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Shiraz Y. Kajee, certify that:

1. I have reviewed this annual report on Form 10-K of SLR HC BDC LLC;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated this 27th day of February, 2024
/s/ Shiraz Y. Kajee
Shiraz Y. Kajee
EX-32.1 6 d774279dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

In connection with the Annual Report on Form 10-K for the year ended December 31, 2023 (the “Report”) of SLR HC BDC LLC (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, MICHAEL S. GROSS, the Co-Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  /s/ Michael S. Gross
Name:   Michael S. Gross
Date:   February 27, 2024
EX-32.2 7 d774279dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

In connection with the Annual Report on Form 10-K for the year ended December 31, 2023 (the “Report”) of SLR HC BDC LLC (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, BRUCE J. SPOHLER, the Co-Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  /s/ Bruce J. Spohler
Name:   Bruce J. Spohler
Date:   February 27, 2024
EX-32.3 8 d774279dex323.htm EX-32.3 EX-32.3

Exhibit 32.3

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

In connection with the Annual Report on Form 10-K for the year ended December 31, 2023 (the “Report”) of SLR HC BDC LLC (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, SHIRAZ Y. KAJEE, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  /s/ Shiraz Y. Kajee
Name:   Shiraz Y. Kajee
Date:   February 27, 2024
EX-101.SCH 9 cik0001832148-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Consolidated Statements of Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Consolidated Statements of Assets and Liabilities (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Consolidated Statements of Changes in Unitholders' Capital link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Consolidated Schedule of Investments link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Consolidated Schedule of Investments Alternate link:presentationLink link:definitionLink link:calculationLink 1009 - Statement - Consolidated Schedule of Investments (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 999001 - Disclosure - Insider Trading Arrangements link:presentationLink link:definitionLink link:calculationLink 999002 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 999003 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 999004 - Disclosure - Agreements and Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 999005 - Disclosure - Fair Value link:presentationLink link:definitionLink link:calculationLink 999006 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 999007 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 999008 - Disclosure - Unitholders' Capital link:presentationLink link:definitionLink link:calculationLink 999009 - Disclosure - Financial Highlights link:presentationLink link:definitionLink link:calculationLink 999010 - Disclosure - Income Tax Information and Distributions to Unitholders link:presentationLink link:definitionLink link:calculationLink 999011 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 999012 - Disclosure - Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 999013 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 999014 - Disclosure - Unitholders' Capital (Tables) link:presentationLink link:definitionLink link:calculationLink 999015 - Disclosure - Financial Highlights (Tables) link:presentationLink link:definitionLink link:calculationLink 999016 - Disclosure - Income Tax Information and Distributions to Unitholders (Tables) link:presentationLink link:definitionLink link:calculationLink 999017 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999018 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999019 - Disclosure - Agreements and Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999020 - Disclosure - Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 999021 - Disclosure - Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 999022 - Disclosure - Fair Value - Summary of Company's Level 3 (Detail) link:presentationLink link:definitionLink link:calculationLink 999023 - Disclosure - Fair Value - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999024 - Disclosure - Debt - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999025 - Disclosure - Commitments and Contingencies - Summary of Unfunded Commitments (Detail) link:presentationLink link:definitionLink link:calculationLink 999026 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999027 - Disclosure - Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) link:presentationLink link:definitionLink link:calculationLink 999028 - Disclosure - Financial Highlights - Summary of Financial Highlights (Detail) link:presentationLink link:definitionLink link:calculationLink 999029 - Disclosure - Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 999030 - Disclosure - Income Tax Information and Distributions to Unitholders - Schedule of Investment Company, Distribution To Shareholders (Detail) link:presentationLink link:definitionLink link:calculationLink 999031 - Disclosure - Income Tax Information and Distributions to Unitholders - Schedule Of Total Accumulated Earnings (Loss) (Detail) link:presentationLink link:definitionLink link:calculationLink 999032 - Disclosure - Income Tax Information and Distributions to Unitholders - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 999033 - Disclosure - Subsequent Events - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 cik0001832148-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 cik0001832148-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 cik0001832148-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 cik0001832148-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page - USD ($)
12 Months Ended
Dec. 31, 2023
Feb. 23, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --12-31    
Entity Registrant Name SLR HC BDC LLC    
Entity Central Index Key 0001832148    
Entity File Number 000-56247    
Entity Current Reporting Status Yes    
Entity Filer Category Non-accelerated Filer    
Entity Interactive Data Current Yes    
Entity Shell Company false    
Entity Small Business false    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Document Annual Report true    
Document Transition Report false    
Entity Tax Identification Number 85-1801692    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 500 Park Avenue    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10022    
City Area Code 212    
Local Phone Number 993-1670    
Entity Common Stock, Shares Outstanding   1,069,642  
Auditor Name KPMG LLP    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 185    
Auditor Location New York, NY    
Entity Public Float     $ 0
ICFR Auditor Attestation Flag false    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Assets and Liabilities - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Investments at fair value:    
Cash $ 1,871 $ 3,986
Cash equivalents (cost: $9,919 and $29,828, respectively) 9,919 29,828
Interest receivable 503 271
Prepaid expenses 14 15
Total assets 75,582 77,997
Liabilities    
Payable for cash equivalents purchased 9,919 29,828
Management fee payable (see note 3) 524 325
Administration fee payable (see note 3) 12 8
Interest payable (see note 5) 904 493
Other liabilities and accrued expenses 231 193
Total liabilities 52,613 58,649
Commitments and contingencies (see note 6)
Unitholders' Capital    
Common Unitholders' capital (1,069,642 and 888,565 units, respectively, issued and outstanding, see note 2f) 23,393 19,461
Accumulated distributable net loss (see note 2f) (424) (113)
Total unitholders' capital [1],[2] 22,969 19,348
Total liabilities and unitholders' capital $ 75,582 $ 77,997
Net asset value per unit [3] $ 21.47 $ 21.77
Non Controlled Non Affiliated Investments [Member]    
Investments at fair value:    
Non-controlled/non-affiliated investments (cost: $62,743 and $43,602, respectively) $ 63,275 $ 43,897
Revolving Credit Facility Due February Two Thousand and Twenty Seven the SPV Facility [Member]    
Liabilities    
Long-Term Line of Credit 23,501 14,051
Revolving Credit Facility Due March Two Thousand and Twenty Four the Subscription Facility [Member]    
Liabilities    
Long-Term Line of Credit $ 17,522 $ 13,751
[1] Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load.
[2] Not annualized for periods less than one year.
[3] Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively.
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Assets and Liabilities (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Investment owned, at Cost $ 72,662 $ 73,430
Cash equivalents, at Cost $ 9,919 $ 29,828
Common unit, Issued 1,069,642 1,069,642
Common unit, Outstanding 888,565 888,565
Revolving Credit Facility Due February Two Thousand and Twenty Seven the SPV Facility [Member]    
Long term debt, Gross $ 24,210 $ 14,675
Debt issuance costs, Line of credit arrangements, Gross 709 624
Revolving Credit Facility Due March Two Thousand and Twenty Four the Subscription Facility [Member]    
Long term debt, Gross 17,550 13,800
Debt issuance costs, Line of credit arrangements, Gross 28 49
Non Controlled Non Affiliated Investments [Member]    
Investment owned, at Cost $ 62,743 $ 43,602
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
[1]
Investment Income:      
Total investment income $ 6,767 $ 3,748 $ 1,019
Expenses:      
Management fees (see note 3) 565 419 224
Administration fees (see note 3) 42 27 9
Interest and other credit facility expenses (see note 5) 4,058 1,939 398
Services fee 0 0 250
Organizational expenses 0 0 229
Other general and administrative expenses 737 592 732
Total expenses 5,402 2,977 1,842
Net investment income (loss) 1,365 771 (823)
Realized and unrealized gain (loss) on investments and cash equivalents:      
Net realized loss on non-controlled/non-affiliated investments and cash equivalents (19) (16) (5)
Net change in unrealized gain on non-controlled/non-affiliated investments and cash equivalents 237 178 117
Net realized and unrealized gain on non-controlled/non-affiliated investments and cash equivalents 218 162 112
Net Increase (Decrease) in Unitholders' Capital Resulting From Operations $ 1,583 $ 933 $ (711)
Net Income (Loss) Per Unit $ 1.54 $ 1.3 $ (2.57)
Investments and cash equivalents [Member]      
Realized and unrealized gain (loss) on investments and cash equivalents:      
Net realized loss on non-controlled/non-affiliated investments and cash equivalents $ (19) $ (16) $ (5)
Net change in unrealized gain on non-controlled/non-affiliated investments and cash equivalents 237 178 117
Non Controlled Non Affiliated Investments [Member]      
Investment Income:      
Interest income from non-controlled/non-affiliated investments 6,696 3,732 1,018
Other income from non-controlled/non-affiliated investments 71 16 1
Realized and unrealized gain (loss) on investments and cash equivalents:      
Net realized loss on non-controlled/non-affiliated investments and cash equivalents $ (19) $ (16) $ (5)
[1] Commencement of operations
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Changes in Unitholders' Capital - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Increase (decrease) in unitholders' capital resulting from operations:      
Net investment income (loss) $ 1,365 $ 771 $ (823) [1]
Net realized loss (19) (16) (5) [1]
Net change in unrealized gain 237 178 117 [1]
Net Increase (Decrease) in Unitholders' Capital Resulting From Operations 1,583 933 (711) [1]
Distributions to unitholders (see note 9a):      
From distributable earnings (1,870) (697) 0 [1]
From return of capital (92) 0 0 [1]
Net distributions to Unitholders (1,962) (697) 0
Increase (decrease) in unitholders' capital resulting from capital activity (see note 7):      
Contributions 4,000 4,500 15,501 [1]
Less offering costs 0 0 (177) [1]
Cancellation 0 0 (1) [1]
Net increase in unitholders' capital resulting from capital activity 4,000 4,500 15,323 [1]
Total increase in unitholders' capital 3,621 4,736 14,612 [1]
Unitholders' capital, beginning of period 19,348 14,612 [1] 0 [1]
Unitholders' capital, end of period $ 22,969 $ 19,348 $ 14,612 [1]
Capital unit activity (see note 7):      
Units issued 181,077 206,138 682,467 [1]
Units canceled 0 0 (40) [1]
Net increase from capital unit activity 181,077 206,138 682,427 [1]
[1] Commencement of operations
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash Flows from Operating Activities:      
Net Increase (Decrease) in Unitholders' Capital Resulting From Operations $ 1,583 $ 933 $ (711) [1]
Adjustments to reconcile net increase (decrease) in unitholders' capital resulting from operations to net cash used in operating activities:      
Net realized loss on investments and cash equivalents 19 16 5 [1]
Deferred financing costs 336 345 133 [1]
(Increase) decrease in operating assets:      
Purchase of investments (25,482) (28,404) (33,983) [1]
Proceeds from disposition of investments 7,164 12,289 6,870 [1]
Net accretion of discount on investments (469) (234) (61) [1]
Capitalization of payment-in-kind income (373) (100) 0 [1]
Interest receivable (232) (100) (171) [1]
Prepaid expenses 1 (1) (14) [1]
Increase (decrease) in operating liabilities:      
Payable for cash equivalents purchased (19,909) 9,828 20,000 [1]
Management fee payable 199 262 63
Administration fee payable 4 4 4 [1]
Interest payable 411 454 39 [1]
Other liabilities and accrued expenses 38 (221) 414 [1]
Net Cash Used in Operating Activities (36,947) (5,107) (7,529) [1]
Cash Flows from Financing Activities:      
Contributions from unitholders 4,000 4,500 15,501 [1]
Cancellation of units 0 0 (1) [1]
Cash distributions paid (1,962) (697) 0 [1]
Offering costs 0 0 (177) [1]
Proceeds from borrowings 30,635 42,401 24,723 [1]
Repayments of borrowings (17,750) (27,750) (12,050) [1]
Net Cash Provided by Financing Activities 14,923 18,454 27,996 [1]
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (22,024) 13,347 20,467 [1]
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 33,814 20,467 [1] 0 [1]
CASH AND CASH EQUIVALENTS AT END OF PERIOD 11,790 33,814 20,467 [1]
Supplemental disclosure of cash flow information:      
Cash paid for interest 3,647 1,485 359 [1]
Investments and cash equivalents [Member]      
Adjustments to reconcile net increase (decrease) in unitholders' capital resulting from operations to net cash used in operating activities:      
Net realized loss on investments and cash equivalents 19 16 5 [1]
Investments [Member]      
Adjustments to reconcile net increase (decrease) in unitholders' capital resulting from operations to net cash used in operating activities:      
Net change in unrealized gain on investments $ (237) $ (178) $ (117) [1]
[1] Commencement of operations
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Schedule of Investments - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Investments [Line Items]    
Cost $ 72,662 $ 73,430
Investments Cash and Cash Equivalents at Fair Value. 73,194 73,725
Liabilities in Excess of Other Assets (50,225) (54,377)
Net Assets $ 22,969 $ 19,348
Percentage of Total Investments 100.00% 100.00%
Health Care Providers Services [Member]    
Schedule of Investments [Line Items]    
Percentage of Total Investments 50.90% 34.90%
Health Care Equipment Supplies [Member]    
Schedule of Investments [Line Items]    
Percentage of Total Investments 16.10% 19.30%
Biotechnology [Member]    
Schedule of Investments [Line Items]    
Percentage of Total Investments 12.70% 16.80%
Pharmaceuticals [Member]    
Schedule of Investments [Line Items]    
Percentage of Total Investments 11.30% 16.50%
Life Sciences Tools Services [Member]    
Schedule of Investments [Line Items]    
Percentage of Total Investments 6.30% 9.20%
Health Care Technology [Member]    
Schedule of Investments [Line Items]    
Percentage of Total Investments 1.50% 3.30%
Distributors [Member]    
Schedule of Investments [Line Items]    
Percentage of Total Investments 1.20%  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans    
Schedule of Investments [Line Items]    
Cost $ 62,704 $ 43,577
Fair Value $ 63,268 $ 43,886
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Apeel Technology Inc. | Biotechnology | S+625 | 1.00% | 8.75% | 6/29/2022 | 6/1/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2]   625.00%
Floor [2]   1.00%
Interest Rate [3]   8.75%
Maturity Date [2]   Jun. 01, 2027
Par Amount [2]   $ 317
Cost [2]   315
Fair Value [2]   $ 317
Acquisition Date [2]   Jun. 29, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2],[4] 745.00% 745.00%
Floor [2],[4] 0.10% 0.10%
Interest Rate [2],[3],[4] 12.90% 11.62%
Maturity Date [2],[4] Jan. 01, 2027 Jan. 01, 2027
Par Amount [2],[4] $ 6,288 $ 6,288
Cost [2],[4] 6,422 6,322
Fair Value [2],[4] $ 6,414 $ 6,367
Acquisition Date [2],[4] Dec. 22, 2021 Dec. 22, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2],[4] 795.00% 795.00%
Floor [2],[4] 1.00% 0.10%
Interest Rate [2],[3],[4] 13.32% 12.12%
Maturity Date [2],[4] Mar. 01, 2027 Mar. 01, 2027
Par Amount [2],[4] $ 1,548 $ 851
Cost [2],[4] 1,559 854
Fair Value [2],[4] $ 1,596 $ 853
Acquisition Date [2],[4] Feb. 23, 2022 Feb. 23, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 500.00% 500.00%
Floor [2] 1.00% 1.00%
Interest Rate [3] 10.61% [2] 9.73%
Maturity Date [2] Jun. 11, 2027 Jun. 11, 2027
Par Amount [2] $ 4,026 $ 4,068
Cost [2] 4,000 4,034
Fair Value [2] $ 4,026 $ 4,068
Acquisition Date [2] Jun. 29, 2021 Jun. 29, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026    
Schedule of Investments [Line Items]    
Spread above Index [1],[2],[4]   0.00%
Floor [2],[4]   0.00%
Interest Rate [2],[3],[4],[5] 9.00% 9.00%
Maturity Date [2],[4] Nov. 17, 2026 Nov. 17, 2026
Par Amount [2],[4] $ 3,767 $ 3,683
Cost [2],[4] 3,765 3,656
Fair Value [2],[4] $ 3,777 $ 3,683
Acquisition Date [2],[4] Nov. 17, 2021 Nov. 17, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | CVAUSA Management LLC | Health Care Providers & Services | S+ 550 | 1.00% | 11.74% | 5/22/2023 | 5/22/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 650.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.74%  
Maturity Date [2] May 22, 2029  
Par Amount [2] $ 1,691  
Cost [2] 1,643  
Fair Value [2] $ 1,691  
Acquisition Date [2] May 22, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 620.00% 620.00%
Floor [2] 2.75% 2.75%
Interest Rate [3] 11.55% [2] 10.52%
Maturity Date [2] Jan. 01, 2028 Jan. 01, 2028
Par Amount [2] $ 3,348 $ 2,494
Cost [2] 3,357 2,488
Fair Value [2] $ 3,348 $ 2,488
Acquisition Date [2] Dec. 27, 2022 Dec. 27, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Exactcare Parent, Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.89% | 11/3/2023 | 11/5/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 650.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.89%  
Maturity Date [2] Nov. 05, 2029  
Par Amount [2] $ 934  
Cost [2] 909  
Fair Value [2] $ 908  
Acquisition Date [2] Nov. 03, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco LLC | Health Care Providers & Services | S+ 650 | 1.00% | 11.63% | 1/4/2023|1/3/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 650.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.97%  
Maturity Date [2] Jan. 03, 2029  
Par Amount [2] $ 2,643  
Cost [2] 2,574  
Fair Value [2] $ 2,643  
Acquisition Date [2] Jan. 04, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 790.00% 790.00%
Floor [2] 0.10% 0.10%
Interest Rate [3] 13.35% [2] 12.07%
Maturity Date [2] Oct. 01, 2026 Oct. 01, 2026
Par Amount [2] $ 907 $ 1,452
Cost [2] 919 1,456
Fair Value [2] $ 948 $ 1,455
Acquisition Date [2] Sep. 30, 2021 Sep. 30, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Ivy Fertility Services LLC | Health Care Providers & Services | L+625 | 1.00% | 10.39% | 12/22/2021 | 2/25/2026    
Schedule of Investments [Line Items]    
Spread above Index [1],[2]   625.00%
Floor [2]   1.00%
Interest Rate [3]   10.39%
Maturity Date [2]   Feb. 25, 2026
Par Amount [2]   $ 2,697
Cost [2]   2,659
Fair Value [2]   $ 2,724
Acquisition Date [2]   Dec. 22, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Maxor Acquisition Inc | Health Care Providers & Services | S+ 675 |1.00% | 12.48%| 3/1/2023 | 3/1/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 675.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 12.48%  
Maturity Date [2] Mar. 01, 2029  
Par Amount [2] $ 1,761  
Cost [2] 1,714  
Fair Value [2] $ 1,761  
Acquisition Date [2] Mar. 01, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 550.00% 550.00%
Floor [2] 3.45% 3.45%
Interest Rate [3] 10.85% [2] 9.82%
Maturity Date [2] Dec. 01, 2027 Dec. 01, 2027
Par Amount [2] $ 312 $ 312
Cost [2] 313 309
Fair Value [2] $ 315 $ 311
Acquisition Date [2] Dec. 20, 2022 Dec. 20, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Medrina, LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.67% | 10/20/2023 | 10/20/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 625.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.67%  
Maturity Date [2] Oct. 20, 2029  
Par Amount [2] $ 697  
Cost [2] 680  
Fair Value [2] $ 680  
Acquisition Date [2] Oct. 20, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | OIS Management Services, LLC | Health Care Providers & Services | S+ 575 |1.00% | 11.20% | 12/29/2023 | 11/16/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 575.00%  
Floor [2] 0.75%  
Interest Rate [2],[3] 11.20%  
Maturity Date [2] Nov. 16, 2028  
Par Amount [2] $ 875  
Cost [2] 868  
Fair Value [2] $ 858  
Acquisition Date [2] Dec. 29, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | ONS MSO LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.62%| 2/10/2023 | 7/8/2025    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 625.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.62%  
Maturity Date [2] Jul. 08, 2026  
Par Amount [2] $ 2,527  
Cost [2] 2,469  
Fair Value [2] $ 2,527  
Acquisition Date [2] Feb. 10, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Oral Surgery Partners Holdings LLC | Health Care Providers & Services | S+625| 1.00% | 10.92% | 11/29/2022 | 5/10/2024    
Schedule of Investments [Line Items]    
Spread above Index [1]   625.00%
Floor   1.00%
Interest Rate [3]   10.92%
Maturity Date   May 10, 2024
Par Amount   $ 567
Cost   557
Fair Value   $ 556
Acquisition Date   Nov. 29, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 650.00% 650.00%
Floor [2] 1.00% 1.00%
Interest Rate [3] 12.11% [2] 10.91%
Maturity Date [2] May 16, 2024 May 16, 2024
Par Amount [2] $ 1,673 $ 1,087
Cost [2] 1,669 1,080
Fair Value [2] $ 1,673 $ 1,087
Acquisition Date [2] Aug. 17, 2022 Aug. 17, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 515.00% 515.00% [4]
Floor [2],[4] 2.75% 2.75%
Interest Rate [3] 10.50% [2],[4] 9.33%
Maturity Date [2],[4] Nov. 01, 2027 Nov. 01, 2027
Par Amount [2],[4] $ 3,909 $ 3,052
Cost [2],[4] 3,918 3,034
Fair Value [2],[4] $ 3,918 $ 3,029
Acquisition Date [2],[4] Nov. 03, 2022 Nov. 03, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Pediatric Home Respiratory Services LLC | Health Care Providers & Services | S+625 | 1.00% | 10.67% | 8/19/2022 |12/4/2024    
Schedule of Investments [Line Items]    
Spread above Index [1],[2]   625.00%
Floor [2]   1.00%
Interest Rate [3]   10.67%
Maturity Date [2]   Dec. 04, 2024
Par Amount [2]   $ 463
Cost [2]   457
Fair Value [2]   $ 459
Acquisition Date [2]   Aug. 19, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 500.00% 500.00%
Floor [2] 1.00% 1.00%
Interest Rate [3] 10.45% [2] 9.89%
Maturity Date [2] Aug. 18, 2027 Aug. 18, 2027
Par Amount [2] $ 3,861 $ 3,107
Cost [2] 3,824 3,069
Fair Value [2] $ 3,861 $ 3,107
Acquisition Date [2] Aug. 26, 2021 Aug. 26, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 575.00% 575.00%
Floor [2] 1.00% 1.00%
Interest Rate [3] 11.36% [2] 10.59%
Maturity Date [2] Aug. 12, 2026 Aug. 12, 2026
Par Amount [2] $ 3,992 $ 4,033
Cost [2] 3,957 3,986
Fair Value [2] $ 3,992 $ 4,033
Acquisition Date [2] Aug. 20, 2021 Aug. 20, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Retina Midco, Inc | Health Care Providers & Services | S+ 575 |1.00% | 11.38% | 12/18/2023 | 1/31/2026    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 575.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.38%  
Maturity Date [2] Jan. 31, 2026  
Par Amount [2] $ 2,897  
Cost [2] 2,840  
Fair Value [2] $ 2,839  
Acquisition Date [2] Dec. 18, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 575.00% 575.00%
Floor [2] 1.00% 1.00%
Interest Rate [3] 11.19% [2] 9.46%
Maturity Date [2] Oct. 05, 2029 Oct. 05, 2029
Par Amount [2] $ 3,499 $ 2,905
Cost [2] 3,399 2,813
Fair Value [2] $ 3,499 $ 2,810
Acquisition Date [2] Oct. 06, 2022 Oct. 06, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 625.00% 600.00%
Floor [2] 1.00% 1.00%
Interest Rate [3] 11.72% [2] 10.77%
Maturity Date [2] Jan. 27, 2026 Jan. 27, 2026
Par Amount [2] $ 2,075 $ 489
Cost [2] 2,050 485
Fair Value [2] $ 2,075 $ 489
Acquisition Date [2] Jun. 03, 2022 Jun. 03, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Spectrum Pharmaceuticals Inc. | Biotechnology | S+570 | 2.30% | 9.88% | 9/21/2022 | 9/1/2027    
Schedule of Investments [Line Items]    
Spread above Index [1],[2]   570.00%
Floor [2]   2.30%
Interest Rate [3]   9.88%
Maturity Date [2]   Sep. 01, 2027
Par Amount [2]   $ 915
Cost [2]   905
Fair Value [2]   $ 906
Acquisition Date [2]   Sep. 21, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 550.00% 575.00%
Floor [2] 0.75% 0.75%
Interest Rate [3] 10.96% [2] 10.48%
Maturity Date [2] Jun. 16, 2028 Jun. 16, 2028
Par Amount [2] $ 1,950 $ 2,033
Cost [2] 1,926 2,004
Fair Value [2] $ 1,950 $ 2,033
Acquisition Date [2] Jun. 16, 2021 Jun. 16, 2021
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | UVP Management LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.79% | 9/18/2023 | 9/15/2025    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 625.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.75%  
Maturity Date [2] Sep. 15, 2025  
Par Amount [2] $ 1,285  
Cost [2] 1,257  
Fair Value [2] $ 1,253  
Acquisition Date [2] Sep. 18, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | United Digestive MSO Parent LLC | Health Care Providers & Services | S+ 675 |1.00% | 12.29% | 3/30/2023 | 3/30/2029    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 675.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 12.25%  
Maturity Date [2] Mar. 30, 2029  
Par Amount [2] $ 982  
Cost [2] 955  
Fair Value [2] $ 982  
Acquisition Date [2] Mar. 30, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Urology Management Holdings Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.93% | 2/7/2023 | 6/15/2026    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 650.00%  
Floor [2] 1.00%  
Interest Rate [2],[3] 11.93%  
Maturity Date [2] Jun. 15, 2026  
Par Amount [2] $ 920  
Cost [2] 897  
Fair Value [2] $ 913  
Acquisition Date [2] Feb. 07, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027    
Schedule of Investments [Line Items]    
Spread above Index [1] 930.00% [2] 830.00%
Floor 1.00% [2] 1.00%
Interest Rate [3],[6] 14.75% [2] 12.58%
Maturity Date Feb. 01, 2027 [2] Feb. 01, 2027
Par Amount $ 3,384 [2] $ 3,095
Cost 3,437 [2] 3,094
Fair Value $ 3,435 [2] $ 3,111
Acquisition Date Feb. 18, 2022 [2] Feb. 18, 2022
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vertos Medical Inc | Health Care Equipment & Supplies | S+515 | 4.75% | 10.48% | 6/14/2023 | 7/1/2028    
Schedule of Investments [Line Items]    
Spread above Index [1],[2] 515.00%  
Floor [2] 4.75%  
Interest Rate [2],[3] 10.50%  
Maturity Date [2] Jul. 01, 2028  
Par Amount [2] $ 567  
Cost [2] 563  
Fair Value [2] $ 567  
Acquisition Date [2] Jun. 14, 2023  
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | WCI-BXC Purchaser, LLC | Distributors | S+ 625 |1.00% | 11.64% | 11/6/2023 | 11/6/2030    
Schedule of Investments [Line Items]    
Spread above Index [1] 625.00%  
Floor 1.00%  
Interest Rate [3] 11.64%  
Maturity Date Nov. 06, 2030  
Par Amount $ 840  
Cost 820  
Fair Value $ 819  
Acquisition Date Nov. 06, 2023  
Investment, Identifier [Axis]: Cash Equivalents | US Treasury Bill | Government | 12/29/2023 | 2/27/2024    
Schedule of Investments [Line Items]    
Maturity Date Feb. 27, 2024  
Par Amount $ 10,000  
Cost 9,919  
Fair Value $ 9,919  
Acquisition Date Dec. 29, 2023  
Investment, Identifier [Axis]: Cash Equivalents | US Treasury Bill | Government | 12/30/2022 | 2/23/2023    
Schedule of Investments [Line Items]    
Maturity Date   Feb. 23, 2023
Par Amount   $ 30,000
Cost   29,828
Fair Value   $ 29,828
Acquisition Date   Dec. 30, 2022
Investment, Identifier [Axis]: Common Equity/Warrants | Assertio Holdings Inc Common Stock | Pharmaceuticals | 7/31/2023    
Schedule of Investments [Line Items]    
Maturity Date [7],[8] Jul. 31, 2023  
Par Amount [7],[8] $ 1,088  
Cost [7],[8] 4  
Fair Value [7],[8] 1  
Investment, Identifier [Axis]: Total Investments    
Schedule of Investments [Line Items]    
Cost 62,743 [9] $ 43,602 [10]
Fair Value 63,275 [9] 43,897 [10]
Investment, Identifier [Axis]: Total Warrant    
Schedule of Investments [Line Items]    
Cost 39 25
Fair Value $ 7 $ 11
Investment, Identifier [Axis]: Warrants | Meditrina Inc. | Health Care Equipment & Supplies | 12/20/2022    
Schedule of Investments [Line Items]    
Maturity Date [8] Dec. 20, 2022 Dec. 20, 2022
Par Amount [8] $ 2,719 $ 2,719
Cost [8] 2 2
Fair Value [8] $ 2 $ 2
Investment, Identifier [Axis]: Warrants | Spectrum Pharmaceuticals Inc. | Biotechnology | 9/21/2022    
Schedule of Investments [Line Items]    
Maturity Date [8]   Sep. 21, 2022
Par Amount [8]   $ 13,871
Cost [8]   4
Fair Value [8]   $ 1
Investment, Identifier [Axis]: Warrants | Vapotherm Inc. | Health Care Equipment & Supplies | 2/18/2022    
Schedule of Investments [Line Items]    
Maturity Date [8] Feb. 18, 2022 Feb. 18, 2022
Par Amount [8] $ 7,029 $ 3,324
Cost [8] $ 29 19
Fair Value [8]   $ 8
Investment, Identifier [Axis]: Warrants | Vertos Medical, Inc. | Health Care Equipment & Supplies | 6/14/2023    
Schedule of Investments [Line Items]    
Maturity Date [8] Jun. 14, 2023  
Par Amount [8] $ 13,779  
Cost [8] 4  
Fair Value [8] $ 4  
[1] Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor.
[2] Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
[3] Floating rate debt investments typically bear interest at a rate determined by reference to either the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) has provided the current interest rate in effect as of December 31, 2023.
[4] Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2023, on a fair value basis, non-qualifying assets in the portfolio represented 20.8% of the total assets of the Company.
[5] BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
[6] Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.
[7] Denotes a Level 1 investment.
[8] Non-income producing security.
[9] Aggregate net unrealized depreciation for U.S. federal income tax purposes is $241; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $600 and $841, respectively, based on a tax cost of $63,516. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
[10] Aggregate net unrealized depreciation for U.S. federal income tax purposes is $71; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $318 and $389, respectively, based on a tax cost of $43,968. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Schedule of Investments (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Schedule of Investments [Line Items]    
Percentage of Non Qualifying Assets in the Portfolio of Total Assets 20.80% 17.90%
Tax Basis of Investments, Unrealized Appreciation (Depreciation), Net [1] $ (241) $ (71)
Tax Basis of Investments, Gross, Unrealized Appreciation 600 318
Tax Basis of Investments, Gross, Unrealized Depreciation 841 389
Tax Basis of Investments, Cost for Income Tax Purposes $ 63,516 $ 43,968
Investment Owned, Net Assets, Percentage 100.00% 100.00%
Percentage Representing Bank Debt Or Senior Secured Loans Owned 275.40% 226.80%
Percentage Representing Shares/Warrants Owned 0.10%  
Percentage Representing Warrants Owned   0.10%
Percentage Representing Total Investments In Investments Owned 275.50% [2] 226.90%
Percentage Representing Cash Equivalents In Investments Owned 43.20% 154.10%
Percentage Representing Total Investments And Cash Equivalents In Investments Owned 318.70% 381.00%
Percentage Representing Liabilities In Excess Of Other Assets In Investments Owned 218.70% 281.00%
BridgeBio Pharma Inc [Member]    
Schedule of Investments [Line Items]    
Rate of coupon as PIK 3.00% 3.00%
Vapotherm, Inc. [Member]    
Schedule of Investments [Line Items]    
Rate of coupon as PIK 9.00% 8.00%
[1] Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year.
[2] Aggregate net unrealized depreciation for U.S. federal income tax purposes is $241; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $600 and $841, respectively, based on a tax cost of $63,516. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure      
Net Income (Loss) $ 1,583 $ 933 $ (711) [1]
[1] Commencement of operations
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
12 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
N-2 - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
[2]
Jan. 04, 2021
[2]
Cover [Abstract]        
Entity Central Index Key 0001832148      
Amendment Flag false      
Securities Act File Number 000-56247      
Document Type 10-K      
Entity Registrant Name SLR HC BDC LLC      
Entity Address, Address Line One 500 Park Avenue      
Entity Address, City or Town New York      
Entity Address, State or Province NY      
Entity Address, Postal Zip Code 10022      
City Area Code 212      
Local Phone Number 993-1670      
Entity Well-known Seasoned Issuer No      
Entity Emerging Growth Company true      
Entity Ex Transition Period false      
General Description of Registrant [Abstract]        
Risk Factors [Table Text Block]
Summary Risk Factors
General Risks Related to Investment Strategy
 
   
The Company intends to make investments in the healthcare and life science industries, which involve substantial risks.
 
   
The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally.
 
   
Various segments of the life sciences industry are (or may become) (i) highly regulated, (ii) subject to frequent regulatory change and (iii) dependent upon various government or private insurance reimbursement programs.
 
   
The Company could be subject to the risks associated with investments in senior secured loans, subordinated loans, Mezzanine Securities (as defined below) and unsecured loans.
 
   
The Company’s loans may permit borrowers to prepay, which could affect the yield of the Company’s investments.
 
   
Terms and conditions of the Company’s loan agreements may be amended, modified or waived only by the agreement of the lenders.
 
   
The Company may make investments in loans, or securities backed by loans, that are or
may be non-performing loans.
 
   
The Company’s success will depend, in part, on originating loans on advantageous terms.
 
   
Bank loans and corporate loans may not be readily marketable and may be subject to restrictions on resale.
 
   
The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally.
 
   
Periods of market volatility have occurred and could continue to occur in response to pandemics or other events.
 
   
The Adviser will rely on information provided by internal sources and third parties when conducting due diligence.
 
   
Fixed and floating rate debt instruments are subject to the risks associated with change in interest rates.
 
   
The Company could be subject to the risks associated with investments in smaller and middle market companies.
 
   
Most of the Company’s Portfolio Investments at any given time are expected to be illiquid.
 
   
The Company is subject to risks related to inflation and deflation.
 
   
Economic sanction laws may prohibit investments in certain countries and with certain individuals and companies.
 
   
The Company may choose to waive or defer enforcement of covenants in the debt securities held in its portfolio, which may cause the Company to lose all or part of its investment in these companies.
General Risks Related to the Company
 
   
There can be no guarantee of returns and Unitholders may lose all of their money by investing in the Company.
 
   
Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed.
 
   
The Company is subject to management risk because the Adviser actively manages its investment portfolio.
 
   
If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio.
 
   
The Company’s assets are available to satisfy all liabilities and other obligations of the Company.
 
   
There is no assurance that the Adviser’s analysis of potential investments will take into consideration all appropriate factors.
 
   
The Company could be substantially adversely affected by the unfavorable performance of any single investment.
 
   
The Company will include in its income certain amounts that the Company has not yet received in cash.
 
   
It is expected that the majority of the Company’s investments will not have market quotations available.
 
   
Securities that the Adviser believes are not valued correctly may not ultimately be valued as projected.
 
   
The Adviser may employ financial/analytical models that may not reflect actual results.
 
   
The Company and the Adviser may be subject to the risks and costs of regulatory investigations or becoming involved in litigation with third parties.
 
   
A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment.
 
   
The Company and/or the Adviser may enter into various indemnification agreements or arrangements with third parties.
 
   
The Company could be subject to the risks related to the Russian invasion of Ukraine.
 
   
Unitholders could be subject to cybersecurity risks associated with electronic databases and communications.
 
   
Adverse developments affecting the financial services industry could have a material adverse effect on the Company, the Adviser and the Portfolio Investments.
 
   
The Company is subject to technological risks, including those associated with artificial intelligence and machine learning technology.
 
   
The Company is subject to risks associated with ESG (as defined below) initiatives and climate change.
 
   
The Company is subject to risks associated with U.S. government shutdowns, uncertainty over the U.S. debt ceiling and any related downgrades in the U.S.’s credit ratings.
Risks Related to RICs and BDCs
 
   
The Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain.
 
   
No assurance can be given that the Company will be able to maintain qualification as a RIC.
 
   
Unitholders will experience the increased risks pertaining to the Company’s use of leverage to partially finance its investments.
 
   
A BDC must carry investments at market value or at fair value, as determined in good faith by the Board.
 
   
At least 70% of a BDC’s assets must consist of “qualifying assets”.
Regulatory Risks Relating to the Company
 
   
The Company and its affiliates are substantially limited in their
ability to co-invest in
privately negotiated transactions.
 
   
The Company could be precluded from conducting Rule 506 Offerings (as defined below) due to “Bad Actor” restrictions.
 
   
The Company could be subject to the risks associated with complying with the Sarbanes-Oxley Act (as defined below).
Other Risks Related to Portfolio Investments
 
   
The Company could be subject to the risks associated with investments in high yield securities, corporate debt securities, convertible securities, preferred stock, reverse repurchase agreements, and distressed companies.
 
   
The Company could be subject to the risks associated with the use of warrants and rights.
 
   
The Company could be subject to the risks associated with the elimination of LIBOR and use of SOFR.
 
   
The Company could be subject to the risks associated with the effect of an economic slowdown on Portfolio Investments.
 
   
The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings.
 
   
The Company could be subject to the risks associated
with investments in zero-coupon bonds, deferred
interest rate bonds and PIKs.
 
   
The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, initial public offerings, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized.
Item 1A. Risk Factors.
The purchase of Units involves a number of significant risks and other important factors relating to investments in BDCs generally, and relating to the strategy and investment objective of the Company in particular. An investment in the Company is a potentially suitable investment only for a sophisticated investor for whom such an investment does not represent a complete investment program and who, in consultation with its investment and tax advisors, fully understands and is capable of assuming the risks of an investment in the Company.
 
The Company holds certain investments and conducts certain activities through investing in wholly-owned SPVs. All references to investments by the Company in this annual report
on Form 10-K refer,
as the context requires, to investments by either the Company or those SPVs.
There can be no assurance that the Company will achieve its investment objective, that the Company will not lose capital, that the Adviser’s judgment will result in profitable investments by the Company or that the Adviser will successfully be able to implement the Company’s investment strategy. An investment in the Company involves investment considerations and risk factors that prospective investors should consider before subscribing. No guarantee or representation is made that the Company’s investments will succeed.
Certain of the characteristics and risks of the portfolio instruments and investment, hedging, financing and disposition techniques that the Adviser may utilize in managing the Company are set forth below. This is not intended to be a complete description or enumeration of portfolio instruments, investment, hedging, financing or disposition techniques or risks.
The Company’s ability to achieve its investment objective may be affected by, among other things, the factors described below. The Company may also invest in instruments or engage in investment, hedging, financing or disposition techniques other than those described below, including instruments or investment, hedging, financing or disposition techniques that are not in existence as of the date of this annual report
on Form 10-K. Consistent
with its investment strategy, the Company may invest in instruments and engage in investment, hedging, financing or disposition techniques of any and all types, which exist now or are hereafter created.
The discussion below, to the extent it relates to bankruptcy law or proceedings or to debtors’ and creditors’ rights, is based upon principles of U.S. federal and state laws. Insofar as the Portfolio Investments,
include obligations of non-U.S. issuers, or
bankruptcy, reorganization or similar proceedings in a country other than the U.S., the laws of such other countries, and the rights and obligations of debtors and creditors in such other countries, under factual circumstances similar to those described below, may or may not be analogous to those described below.
General Risks Related to Investment Strategy
Healthcare and Life Science Industries’ Related Risks
. The Company intends to make investments in the healthcare and life science industries, although the Company may also opportunistically invest in other sectors in order to accomplish its investment objective. Investing in healthcare companies involves substantial risks. Such risks include, but are not limited to, the following: changes in government policies, including policies regarding reimbursement of medical expenses; certain companies in which the Company may invest may have limited or no operating histories/ or may have limited products, markets and financial resources; rapidly changing technologies may cause products to quickly become obsolete; unanticipated problems often arise in connection with the development of new products, and many such efforts are ultimately unsuccessful; scarcity of management and marketing personnel with appropriate technological or medical training may slow or impede companies’ growth; the possibility of lawsuits related to technological and medical patents could cause delays and expense in product development and implementation; regulatory changes and/or government actions may prevent a company from marketing its products; changing investors’ sentiments and preferences with regard to investments in healthcare companies (which may be perceived as risky) may have an adverse effect on the price of underlying securities; volatility in the U.S. stock markets affecting the prices of securities of healthcare and life sciences companies may cause the Company to experience substantial volatility; and certain healthcare and life sciences companies may be subject to extensive government regulation and affected by government reimbursement policy changes. In addition, many healthcare and life sciences companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or even under normal market conditions or such capital may be obtained on terms that are not favorable.
Also, obtaining government approval for new products from governmental agencies can be lengthy, expensive and uncertain, and withdrawal or curtailment of government support could have an adverse impact on the profitability or market price of healthcare and life sciences companies. Furthermore, delays in generating products (as well as more general ongoing capital requirements) may result in the need for companies to seek additional capital, potentially diluting the interest of existing investors, such as the Company (and indirectly, the Unitholders).
Investments in Healthcare Companies
. The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally. The Company’s investment strategy is subject to numerous and significant risks and uncertainties, some of which are highlighted generally below. The following is general information and does not purport to describe all risks associated with investing in the healthcare industry.
 
Sector Risk.
Sector risk is the risk associated with a Company holding a significant amount of investments in similar businesses, which would be similarly affected by particular economic or market events, which may, in certain circumstances, cause the value of the equity and debt securities of companies in a particular sector of the market to change. To the extent a Company has substantial holdings within a particular sector, the risks to a Company associated with that sector increase.
Concentration Risk.
The Company’s principal focus is to invest in the healthcare and life sciences industry. The focus of the Company’s portfolio on a specific industry may present more risks than if its portfolio were broadly diversified over numerous industries and sectors of the economy. A downturn in this industry would have a larger impact on the Company than on an investment company that does not concentrate in such industry. At times, the performance of securities of companies in the healthcare industry will lag the performance of other industries or the broader market as a whole.
While investment in multiple opportunities may provide some diversification of investment risk, no assurance can be given that such diversification will occur, or if it does, that it will not reduce, rather than increase, potential net profits.
Risks Inherent in Healthcare-Related Assets.
Substantially all of the Company’s investments will be in the healthcare industry. Concentration in one industry involves significant risks greater than those generally associated with diversified acquisition funds, including significant fluctuations in returns. The healthcare industry is challenged by factors such as government regulations; changes in government policies, including policies regarding reimbursement of medical expenses and policies that impact company’s abilities to market products; changes in technology, including changes that may cause products to quickly become obsolete; medical innovations and accompanied unanticipated problems; changes in healthcare practices or delivery systems; scarcity of management and marketing personnel with appropriate technological or medical training; possibilities of lawsuits related to technological and medical patents, and resulting delays and expenses in product development and implementation; changing macroeconomic conditions in the U.S. and globally, intense competition, susceptibility to natural disasters, large capital requirements and the introduction of new, competing healthcare facilities, properties or other leisure activities.
Companies in the healthcare sector are subject to extensive government regulation and their profitability can be significantly affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure (including price discounting), limited product lines and an increased emphasis on the delivery of healthcare through outpatient services. Companies in the healthcare sector are heavily dependent on obtaining and defending patents, which may be time consuming and costly, and the expiration of patents may also adversely affect the profitability of these companies. Healthcare companies are also subject to extensive litigation based on product liability and similar claims. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the healthcare sector require significant research and development and may be subject to regulatory approvals, all of which may be time consuming and costly with no guarantee that any product will come to market.
The Company’s assets will compete in a relatively uncertain political, economic, and regulatory environment, and instability or an overall decline within the healthcare sector will not be balanced by investments in industries not so affected.
In addition, many healthcare companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or such capital may be obtained on terms that are not favorable to existing investors.
Regulations of Healthcare Industry.
The regulatory environment surrounding the healthcare industry has intensified both in the amount and type of regulations and in the efforts to enforce those regulations. The extensive federal, state, and local, laws and regulations affecting the healthcare industry include, but are not limited to, laws and regulations relating to licensure, certification as a Medicare and Medicaid provider, conduct of operations, ownership of facilities, addition of facilities and equipment, allowable costs, services, prices for services, quality of care, patient rights, patient abuse and neglect, fraudulent reimbursement practices, and financial and other arrangements which may be entered into by healthcare providers.
Federal and state governments have intensified enforcement policies, resulting in a significant increase in the number of inspections, citations of regulatory deficiencies and other regulatory sanctions, including terminations from the Medicare and Medicaid programs, bans on Medicare and Medicaid payments for new admissions, civil monetary penalties and even criminal penalties. The Company’s investments could be forced to expend considerable resources on responding to an investigation or other enforcement action under applicable laws or regulations, The Company is unable to predict the future course of federal, state and local regulation or legislation, including the Medicare and Medicaid statutes and regulations. Changes in regulatory framework could have a material adverse effect on the Company’s Portfolio Investments and the Company.
 
 
Senior Secured Loans
. With respect to the Company’s investments in senior secured loans (including first lien loans), the Company will generally have a security interest in assets of the company, which should mitigate the risk that the Company will not be repaid. However, the collateral securing the Company’s loans may decrease in value over time, may be difficult to sell in a timely manner, may be difficult to appraise, and may fluctuate in value based upon the success of the business and market conditions, including as a result of the inability of the company to raise additional capital. In some circumstances, the Company’s lien could be subordinated to claims of other creditors. In addition, deterioration in a company’s financial condition and prospects, including its inability to raise additional capital, may be accompanied by deterioration in the value of the collateral for the loan. Consequently, the fact that a loan is secured does not guarantee that the Company will receive principal and interest payments according to the loan’s terms, or at all, or that the Company will be able to collect on the loan should it be forced to enforce its remedies. Furthermore, if a secured loan is foreclosed, the Company could own the underlying collateral (
e.g.
, real estate), and would be subject to the risks, costs and liabilities associated with owning and disposing of the collateral.
Subordinated Loans
. The Company may invest in subordinated loans. In the event of a loss of value of the underlying assets that collateralize the loans, the subordinate portions of the loans may suffer a loss prior to the more senior portions suffering a loss. If a borrower defaults and lacks sufficient assets to satisfy the Company’s loan, the Company may suffer a loss of principal or interest. If a borrower declares bankruptcy, the Company may not have full recourse to the assets of the borrower, or the assets of the borrower may not be sufficient to satisfy the loan. In addition, certain of the Company’s loans may be subordinate to other debt of the borrower. As a result, if a borrower defaults on the Company’s loan or on debt senior to the Company’s loan, or in the event of the bankruptcy of a borrower, the Company’s loan will be satisfied only after all senior debt is paid in full. The Company’s ability to amend the terms of the Company’s loans, assign the Company’s loans, accept prepayments, exercise the Company’s remedies (through “standstill periods”) and control decisions made in bankruptcy proceedings relating to borrowers may be limited by intercreditor arrangements if debt senior to the Company’s loans exists. In addition, the Company will be subject to the potential risks of foreclosure and ownership of underlying collateral described in “
—Senior Secured Loans
” above.
Mezzanine Securities
. The Company may invest in unsecured securities that are senior to common stock or other equity securities (“Mezzanine Securities”). Mezzanine Securities are subordinated to substantial amounts of senior debt, all or a portion of which may be secured. As a result, holders of Mezzanine Securities are generally not entitled to receive any payments in bankruptcy or liquidation until senior creditors are paid in full. In addition, the legal remedies available to holders of Mezzanine Securities are normally limited by restrictions benefiting senior creditors. In the event a company in which the Company holds Mezzanine Securities cannot generate adequate cash flow to meet senior debt service, the Company may suffer a partial or total loss of capital invested. Because issuers of Mezzanine Securities are often highly leveraged,
their relatively high debt-to-equity ratios create
increased risks that their operations will not be able to generate adequate cash flow to meet senior debt service.
Unsecured Loans or Debt
. The Company may invest in unsecured loans which are not secured by collateral. In the event of default on an unsecured loan, the first priority lien holder has first claim to the underlying collateral of the loan. It is possible that no collateral value would remain for an unsecured holder and therefore result in a loss of investment to the Company. Because unsecured loans are lower in priority of payment to secured loans, they are subject to the additional risk that the cash flow of the borrower may be insufficient to meet scheduled payments after giving effect to the secured obligations of the borrower. Unsecured loans generally have greater price volatility than secured loans and may be less liquid.
Prepayment Risk
. The terms of loans in which the Company invests may permit borrowers to voluntarily prepay loans at any time,
either
with no or a nominal prepayment premium. This prepayment right could result in the borrower repaying the principal on an obligation held by the Company earlier than expected. This may happen when there is a decline in interest rates or when the borrower’s improved credit or operating or financial performance allows the refinancing of certain classes of debt with lower cost debt. The yield of the Company’s investment assets may be affected by the rate of prepayments differing from the Adviser’s expectations.
Investment Modification Risk
. The terms and conditions of loan agreements and related assignments may be amended, modified or waived only by the agreement of the lenders. Generally, any such agreement must include a majority or a super majority (measured by outstanding loans or commitments) or, in certain circumstances, a unanimous vote of the lenders. Consequently, the terms and conditions of the payment obligation arising from Portfolio Investments could be modified, amended or waived in a manner contrary to the preferences of the Company if a sufficient number of the other lenders concurred with such modification, amendment or waiver. There can be no assurance that any obligations arising from a Portfolio Investment will maintain the terms and conditions to which the Company originally agreed.
 
Collateral Risk
. The collateral and security arrangements in relation to such secured obligations as the Company may invest in will be subject to such security or collateral having been correctly created and perfected and any applicable legal or regulatory requirements which may restrict the giving of collateral or security by an obligor, such as, for example, thin capitalization, over-indebtedness, financial assistance and corporate benefit requirements. If one or more Portfolio Investments do not benefit from the expected collateral or security arrangements, this may adversely affect the value of or, in the event of default, the recovery of principal or interest from such Portfolio Investments made by the Company. Accordingly, any such failure to properly create or perfect collateral and security interests attaching to the Portfolio Investments could have a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units. A component of the Adviser’s analysis of the desirability of making a given investment relates to the estimated residual or recovery value of such Portfolio Investments in the event of the insolvency of the obligor. This residual or recovery value will be driven primarily by the value of the anticipated future cash flows of the obligor’s business and by the value of any underlying assets constituting the collateral for such Portfolio Investment. The anticipated future cash flows of the obligor’s business and the value of collateral can, however, be extremely difficult to predict as in certain circumstances market quotations and third-party pricing information may not be available. If the recovery value of the collateral associated with the Portfolio Investments in which the Company invests decreases or is materially worse than expected by the Company, such a decrease or deficiency may affect the value of the Portfolio Investments made by the Company. Accordingly, there may be a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units.
Defaults
. The Company may make investments in loans, or securities backed by loans, that may be at the time of their acquisition, or may become
after acquisition, non-performing loans.
In the event of any default under a loan directly held by the Company or a loan underlying a security held by the Company, the Company will bear a risk of loss of principal to the extent of any deficiency between the value of the collateral and the principal and accrued interest of the loan, which could have a material adverse effect on the Company’s cash flow
from operations. Other non-performing loans may
require workout negotiations and/or restructuring, which may entail, among other things, a substantial reduction in the interest rate and/or a substantial write-down of the original principal amount of such loans. Further, even if a restructuring were successfully accomplished, unless the restructuring provided for full amortization on or prior to maturity and the borrower strictly complied with that restructuring, a risk exists that upon maturity of such loans, replacement financing will not be available and such loans may not be repaid. In the event of the bankruptcy of a borrower, the loan to that borrower will be deemed to be secured only to the extent of the value of the underlying collateral at the time of bankruptcy (as determined by the bankruptcy court), the lien securing the loan will be subject to the avoidance powers of the
bankruptcy trustee or debtor-in-possession to the
extent the lien is unenforceable under state law, and realizing any value under such circumstances can be an expensive and lengthy process that could have a substantial negative effect on the anticipated return on the loan and on the security backed by such loan. Other risks attendant to a bankruptcy filing are described below. The foregoing statement does not apply in the context of a borrower insolvency case commenced under chapter 13 of the U.S. Bankruptcy Code where the underlying collateral is used as the principal residence of the borrower, but in such instances, the lender will nonetheless be stayed from the collection of its claim, taking possession of the collateral, and enforcing its lien unless and until the lender obtains relief from the automatic stay under the U.S. Bankruptcy Code.
Litigation and Related Risks Associated with Origination and Servicing
. Loan origination and servicing companies are routinely involved in legal proceedings concerning matters that arise in the ordinary course of their business. These legal proceedings range from actions involving a single plaintiff to class action lawsuits with potentially tens of thousands of class members. In addition, a number of participants in the loan origination and servicing industry (including control persons of industry participants) have been the subject of regulatory actions by state regulators, including state Attorneys General, and by the federal government. Governmental investigations, examinations or regulatory actions, or private lawsuits, including purported class action lawsuits, may adversely affect such companies’ financial results. To the extent the Company seeks to engage in origination and/or servicing directly, or has a financial interest in, or is otherwise affiliated with, an origination or servicing company, the Company will be subject to enhanced risks of litigation, regulatory actions and other proceedings. As a result, the Company may be required to pay legal fees, settlement costs, damages, penalties or other charges, any or all of which could materially adversely affect the Company and its investments.
Ability to Originate Loans on Advantageous Terms; Competition and Supply
. The Company’s success depends, in part, on the ability of the Company or its affiliates to originate loans on advantageous terms. In originating and purchasing loans, the Company or its affiliates will compete with a broad spectrum of lenders. Increased competition for, or a diminishment in the available supply of, qualifying loans could result in lower yields on such loans, which could reduce returns (if any) to investors. The Company intends to originate certain investments and later offer to syndicate all or a portion of one or more investments to certain other funds or accounts managed by the Adviser and its affiliates, in each case subject to their own investment-review
process, and to co-investors and/or third
parties. Prior to such syndication, or if such syndication is not successful, the Company’s exposure to the originated investment may exceed the exposure that the Company intends to have over the long-term or would have had if it had purchased such investment in the secondary market rather than originating it. Where
 
syndication is not successful, the Company may elect to sell all or a portion of an originated investment at a loss in order to rebalance the Company’s portfolio. The level of analytical sophistication, both financial and legal, necessary for successful financing to companies, particularly companies experiencing significant business and financial difficulties is unusually high. There is no assurance that the Adviser will correctly evaluate the value of the assets collateralizing the Company loans, the prospects for successful repayment or a successful reorganization or similar action.
Risks Relating to Bank Loans and Corporate Loans
. Bank loans and corporate loans (which the Company will originate, invest in or otherwise gain exposure to) may not be readily marketable and may be subject to restrictions on resale. In some cases, negotiations involved in disposing of indebtedness may require weeks to complete. Consequently, some indebtedness may be difficult or impossible to dispose of readily at what the Adviser believes to be a fair price. In addition, bank loans and corporate loans are often less liquid than other types of debt securities, particularly in times of significant market dislocation. Loans to small and middle market entities (“SMEs”) may involve certain heightened risks. See “—
Investments in Smaller and Middle Market Companies
” below.
Holders of bank loans, corporate loans and other forms of direct indebtedness depend primarily upon the creditworthiness of the corporate or other borrower for payment of principal and interest. If the Company does not receive scheduled interest or principal payments on such indebtedness, the value of the Company’s investments could be adversely affected. The Company may invest in secured and unsecured bank loans and corporate loans. Bank loans and corporate loans that are fully secured may offer the Company more protection than an unsecured loan in
the event of non-payment of scheduled
interest or principal. However, there is no assurance that the liquidation of any collateral from a secured bank loan or corporate loan would satisfy the borrower’s obligation, or that such collateral could be liquidated. In the event of the bankruptcy of a borrower, the Company could experience delays or limitations in its ability to realize the benefits of any collateral securing a loan and could be compelled to accept new instruments or interests in respect of its claims under the bank loan in a plan of reorganization. These new instruments or interests may be on terms different from prevailing market terms for similar instruments and interests.
Bank loans usually require, in addition to scheduled payments of interest and principal, the prepayment of the bank loan from free cash flow. The degree to which borrowers prepay bank loans, whether as a contractual requirement or at their election, may be affected by general business conditions, the financial condition of the borrower and competitive conditions among lenders, among others. As such, prepayments cannot be predicted with accuracy. Upon a prepayment, either in part or in full, the actual outstanding debt on which the Company derives interest income will be reduced. The effect of prepayments on the Company’s performance may or may not be mitigated by the receipt of prepayment fees and/or the Company’s reinvestment of prepayments in other bank loans that have similar or identical yields.
The Company may purchase “assignments” of bank loans from lenders. The purchaser of an assignment typically succeeds to all the rights and obligations under the loan agreement with the same rights and obligations as the assigning lender. Assignments may, however, be arranged through private negotiations between potential assignees and potential assignors, and the rights and obligations acquired by the purchaser of an assignment may differ from, and be more limited than, those held by the assigning lender.
The Company may also invest in “participations” in bank loans. Participations by the Company in a lender’s portion of a bank loan typically will result in the Company having a contractual relationship only with such lender, not with the borrower. As a result, the Company may have the right to receive payments of principal, interest and any fees to which it is entitled only from the lender selling the participation and only upon receipt by
such lender of such payments from the borrower. In connection with purchasing participations, the Company generally will have no right to enforce compliance by the borrower with the terms of the loan agreement, nor any rights with respect to any funds acquired by
other lenders through set-off against the
borrower, and the Company may not directly benefit from any collateral supporting the bank loan in which it has purchased the participation. As a result, the Company assumes the credit risk of both the borrower and the lender selling the participation.
In many cases bank loans and loan participations would not be deemed to be securities for purposes of U.S. federal and/or state securities laws. As a result, an investment in bank loans would not be afforded the same protections as an investment in securities, such as the extensive disclosure requirements under U.S. federal and/or state securities laws, which may adversely impact the Company’s ability to seek recourse in respect of such investments. Similarly, the documentation evidencing bank loans and loan participations will not necessarily be maintained with the Company’s custodian.
 
 
General Economic and Market Risk
. The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally, such as real or perceived adverse economic conditions, supply and demand for particular instruments, changes in the general outlook for certain markets or corporate earnings, interest rates, announcements of political information or adverse investor sentiment generally. The market values of the Company’s investments may decline for a number of reasons, including increases in defaults resulting from changes in overall economic conditions and widening of credit spreads. Unfavorable market conditions may also increase funding costs, limit access to the capital markets or result in credit terms changing or credit becoming unavailable. These events could have an adverse effect on the Company’s investments and the Company’s overall performance.
Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may also contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide. Such events, including rising trade tensions between the United States and China, other uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies with other countries, the large-scale invasion of Ukraine by Russia that began in February 2022 and resulting sanctions or other restrictive actions that the United States and other countries have imposed against
Russia, the COVID-19 pandemic,
certain regional bank failures, an inflationary environment and the ongoing war in the Middle East, could adversely affect the Company’s business, financial condition or results of operations. These market and economic disruptions could negatively impact the operating results of the Company’s Portfolio Investments.
Additionally, the Federal Reserve raised the Federal Funds Rate in 2022 and in 2023. Although the Federal Reserve left its benchmark rates steady in the fourth quarter of 2023, it has indicated that additional rate increases in the future may be necessary to mitigate inflationary pressures and there can be no assurance that the Federal Reserve will not make upward adjustments to the federal funds rate in 2024. However, there are reports that the Federal Reserve may begin to cut the benchmark rates. These developments, along with the United States government’s credit and deficit concerns, global economic uncertainties and market volatility and the
impacts of COVID-19, could
cause interest rates to be volatile, which may negatively impact the Company’s ability to access the debt markets and capital markets on favorable terms.
Continuing market uncertainty may have a significant impact on the business of the Company. Among other things, the level of investment opportunities may decline from the Adviser’s current expectations. One possible consequence is that the Company may take a longer than anticipated period to invest capital and/or the Company may be relatively concentrated in a limited number of investments. Consequently, during this period, the returns (if any) realized by Unitholders may be substantially adversely affected by the unfavorable performance of a small number of these investments. Furthermore, market conditions may unfavorably impact the Company’s ability to secure leverage on terms as favorable as more established borrowers in the market, or to obtain any leverage on commercially favorable terms. To the extent the Company is able to secure financing for investments, increases in interest rates or in the risk spread demanded by financing sources would make the use of leverage more expensive and could limit the Company’s ability to structure and consummate its investments. Although the Adviser believes that recent market dislocations will result in attractive investment opportunities, the Company may not be able to time the acquisition or disposition of its investments correctly, which could result in further depreciation in values.
Public Health Crises Risk
. Periods of market volatility have occurred and could continue to occur in response to pandemics or other events outside of the Company’s control. These types of events have adversely affected and could continue to adversely affect operating results for the Company and for its Portfolio Investments. For
example, the COVID-19 pandemic
has adversely impacted global commercial activity and contributed to significant volatility in the equity and debt markets. The
COVID-19
pandemic and restrictive measures taken to contain or mitigate its spread have caused, and are continuing to cause, business shutdowns, or
the re-introduction
of business shutdowns, cancellations of events and restrictions on travel, significant reductions in demand for certain goods and services, reductions in business activity and financial transactions, supply chain interruptions, labor shortages, increased inflationary pressure and overall economic and financial market instability both globally and in the United States. Many states, including those in which the Company and Portfolio Investments may operate, have issued orders requiring the closure of, or certain restrictions on the operation of, certain businesses. Such actions and effects remain ongoing and the ultimate duration and severity of
the COVID-19
pandemic,
including COVID-19
variants, remain uncertain.
Despite actions of the U.S. federal government and foreign governments, the uncertainty surrounding
the COVID-19
pandemic, including uncertainty regarding existing or future variants and other factors, has contributed to significant volatility in the global public equity markets and global debt capital markets.
General Credit Risk
. The Company is subject to significant credit risk (
i.e.
, the risk that an issuer or borrower will default in the payment of principal and/or interest on an instrument) in light of its investment strategy. Credit risk also includes the risk that a counterparty to a derivatives transaction (
e.g.
, a swap counterparty) will be unwilling or unable to meet its obligations. Financial strength and solvency of an issuer or borrower are the primary factors influencing credit risk. In addition, degree of
 
subordination, lack or inadequacy of collateral or credit enhancement for a debt instrument may affect its credit risk. The degree of credit risk associated with any particular Portfolio Investment or any collateral relating thereto may be difficult or impossible for the Adviser to determine within reasonable standards of predictability. The Adviser utilizes various third parties that hold Company assets (such as the Custodian and prime brokers) in implementing the Company’s investment strategy, and the Company will therefore also be subject to credit risk with respect to such entities.
Although most of the Company’s investments will not be rated by any credit rating agency, in some cases, the credit risk of some of the Company’s Portfolio Investments may be broadly gauged by the credit ratings of such Portfolio Investments. However, ratings are only the opinions of the agencies issuing them, may change less quickly than relevant circumstances, are not absolute guarantees of the quality of the rated securities and are subject to downgrade. Credit ratings and ratings agencies have recently been criticized for ratings which did not fully reflect the risks of certain securities or which did not reflect such risks in a timely manner. For most investments, however, the Adviser will rely on its own independent analysis of the credit quality and risks associated with individual securities considered for the Company, rather than relying on ratings agencies or third-party research. Therefore, the Adviser’s capabilities in analyzing credit quality and associated risks will be particularly important (especially since it is currently anticipated that most of the Company’s assets will not be rated by a ratings agency or will be rated below investment grade), and there can be no assurance that the Adviser will be successful in this regard. See also “—
High Yield Debt and Unrated Securities
” below.
General Leverage Risks
. The Company employs leverage and otherwise incurs indebtedness with respect to the portfolio both on
a recourse or non-recourse basis (including
through guarantees, derivatives, forward commitments and reverse repurchase agreements). The Company is not required to take any action (including unwinding or liquidating any position) in the event that such guideline is exceeded subsequent to the borrowing date, whether in the event of changes in the market value of the Company’s portfolio or otherwise. Prospective investors in the Company should expect that the effective leverage utilized by the Company may exceed such guideline, which only applies to direct borrowings; for instance, economic leverage inherent in the Company’s derivatives transactions and other investments will not be counted for purposes of such guideline, notwithstanding that such investments will be subject to many of the leverage-related risks described herein. In addition, determinations relating to leverage are inherently subjective and will involve the exercise of discretion by the Adviser (for instance, the Adviser may deem the amount of the Company’s direct borrowings to be reduced by cash and cash equivalents held by the Company or by a counterparty). See “—
Leveraged Companies
” below.
The use of leverage has the potential to magnify the gains or the losses on investments and to make the Company’s returns more volatile. Moreover, if the Company is
required to de-lever as
a result of changing market conditions or otherwise, it may be forced to sell Portfolio Investments at inopportune times or at disadvantageous prices. On the other hand, while the Company will have the flexibility to use leverage, there can be no guarantee that leverage can be obtained, or obtained on terms and pricing the Adviser finds attractive, especially in the current market environment. As a result, prospective investors in the Company should recognize that Portfolio Investments may not be leveraged, or may be leveraged at an amount below any leverage level otherwise expected by the Adviser. Moreover, even if leverage can be arranged, the Company is not obligated to utilize such leverage and may do so at the sole discretion of the Adviser. Should leverage not be obtained or utilized by the Company, the returns for the Company may be lower than they would have been had such leverage been obtained and utilized.
In connection with any leverage utilized by the Company, the Company may secure its obligations with respect thereto with any and all of its assets, including its right to receive capital contributions from the Unitholders, pursuant to a pledge or other security agreement on terms that the Company determines are fair and reasonable to the Company. If the Company were to default on its obligations under such transactions, the counterparty could foreclose on the collateral and take possession of the Company’s assets and/or call capital from the Unitholders for purposes of repaying debt.
The terms of any leverage utilized by the Company are likely to impose significant restrictions on the Company’s operations and investment program, including as to the Company’s ability to pay distributions, incur additional leverage and engage in certain transactions.
Investments in Smaller and Middle Market Companies
. The Company generally invests in smaller and middle market companies. While smaller and middle market companies generally have potential for rapid growth, they often involve higher risks because they may lack the management experience, financial resources, product diversification, competitive strength and access to capital of larger companies. In addition, in many instances, the frequency and volume of the trading of securities for such companies may be substantially less than is typical of larger companies. As a result, the securities of smaller and middle market companies may be subject to wider price fluctuations. When liquidating positions in smaller and middle market companies, the Company may have to sell portfolio holdings at discounts from quoted prices or may have to make a series of small transactions over an extended period of time. Investments in such companies may also be particularly difficult to analyze due to (among other factors) limited attention from analysts and large institutional investors, limited access to liquidity sources and, in certain cases, limited publicly available financial information. With respect to the Company’s investments in SMEs and similar loans, the Company may receive less borrower information, receive less collateral and be subject to heightened default risk as compared to loans made to other types of entities.
 
Hedging Transactions and Related Risks
. The Company may, but is not required to, engage in hedging transactions. In particular, as many of the Company’s Portfolio Investments are expected to consist of relatively illiquid securities whose price behavior is not particularly correlated to general fixed income or equity index returns, such Portfolio Investments are expected to be difficult or expensive to hedge, and as such the Company may not employ any hedging strategy in respect of such Portfolio Investments (including with respect to their credit risk). To the extent the Adviser employs a hedging strategy for the Company, the success of any such hedging strategy will depend, in part, upon the Adviser’s ability to correctly assess the degree of correlation between the performance of the instruments used in the hedging strategy and the performance of the investments being hedged. Since the characteristics of many securities change as markets change or time passes, the success of the Company’s hedging strategy will also be subject to the Adviser’s ability to continually recalculate, readjust and execute hedges in an efficient and timely manner. While the Company may enter into hedging transactions to seek to reduce risk, such transactions may result in a poorer overall performance for the Company than if it had not engaged in such hedging transactions. For a variety of reasons, the Adviser may not seek to establish a precise correlation between the hedging instruments utilized and the portfolio holdings being hedged. Such an imprecise correlation may prevent the Company from achieving the intended hedge or expose the Company to risk of loss. Additionally, the Adviser may not hedge against a particular risk because it does not regard the probability of the risk occurring to be sufficiently high as to justify the cost of the hedge, or because it does not foresee the occurrence of the risk. Moreover, there is no guarantee that the Company’s intended hedging strategy will be successful in hedging out the subject risks.
Due Diligence Risk
. When conducting due diligence and making an assessment regarding a Portfolio Investment, the Adviser relies on the resources available to it, including internal sources of information as well as information provided by third parties. The due diligence process may at times be required to rely on limited or incomplete information. The Adviser selects Portfolio Investments in part on the basis of information and data filed with various government regulators and publicly available or made directly available by prospective portfolio companies or third parties. The Adviser expects that it will not be in a position to confirm the completeness, genuineness or accuracy of such information and data, and will therefore be dependent upon the integrity of the management of the entities filing such information and of such portfolio companies and third parties providing such information. In addition, there can be no assurance that any consultants or experts engaged by the Adviser will accurately evaluate such Portfolio Investments. Investment analyses and decisions by the Adviser may be undertaken on an expedited basis to enable the Company to take advantage of investment opportunities with accelerated timelines. In such cases, the available information at the time of an investment decision may be limited, inaccurate and/or incomplete. Accordingly, the Adviser cannot guarantee that its due diligence investigations will reveal or highlight all relevant facts that may be necessary or helpful in evaluating investment opportunities. Furthermore, the Company bears its proportionate share of all due diligence-related fees, costs, expenses and liabilities (including in respect of investments that are not ultimately consummated); such fees, costs, expenses and liabilities may be significant and could reduce Company returns.
Interest Rate Risk
. Interest rate risk refers to the risks associated with market changes in interest rates. In general, rising interest rates, such as the recent economic period, will negatively impact the price of fixed rate debt instruments and falling interest rates will have a positive effect on the price of such debt instruments. Many of the Company’s investments are expected to be variable rate loans with interest that adjusts with market rates. These loans will generally also react to interest rate changes in a similar manner although generally to a lesser degree (depending, however, on the characteristics of the reset terms, including the index chosen, frequency of reset and reset caps or floors, among other factors). The Company’s other investments and transactions may also be affected by changes in interest rates. Declines in market value, if not offset by any corresponding gains on hedging instruments, may ultimately reduce earnings or result in losses to the Company.
The prices of long-term debt obligations generally fluctuate more than prices of short-term debt obligations as interest rates change. To the extent the Company invests in longer-term Portfolio Investments, it will be impacted to a greater degree by changes in market interest rates than if the Company invested primarily in short-term debt securities.
To the extent the Company borrows money or issues preferred Units to make investments, its net investment income will depend, in part, upon the difference between the rate at which it borrows funds or pays distributions on preferred Units and the rate at which the Company invests those funds. As a result, the Company can offer no assurance that a significant change in market interest rates will not have a material adverse effect on its net investment income in the event the Company uses debt to finance investments. In periods of rising interest rates, such as the recent economic period, the Company’s cost of funds will increase because the interest rates on the amounts borrowed under the Company’s credit facilities or certain other financing arrangements will typically be floating, which could reduce the Company’s net investment income to the extent any Portfolio Investments have fixed interest rates, and the interest rate on Portfolio Investments with an interest rate floor (such as a SOFR (as defined below) floor) above then-current levels will not increase until interest rates exceed the applicable minimum interest rate floor. Rising interest rates may also increase the cost of debt for the Portfolio Investments, which could adversely impact the Portfolio Investment’s financial performance and ability to meet ongoing obligations to the Company.
 
 
The Company expects that its long-term fixed-rate investments will be financed primarily with equity and long-term debt. The Company may use interest rate risk management techniques in an effort to limit its exposure to interest rate fluctuations. Such techniques may include various interest rate hedging activities to the extent permitted by the 1940 Act. These activities could limit the Company’s ability to participate in the benefits of lower interest rates with respect to the hedged borrowings. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on the Company’s business, financial condition and results of operations.
Also, an increase in interest rates available to investors could make an investment in the Company’s Units less attractive if the Company is not able to increase its distribution rate, which could reduce the value of the Company’s Units.
Liquidity Risk
. Most of the Company’s Portfolio Investments at any given time are expected to be illiquid, such that either no market exists for them or they are restricted as to their transferability under federal, state or foreign securities laws. Similarly, the Adviser may from time to
time possess material, non-public information about
an issuer, which could limit the ability of the Company to buy and sell Portfolio Investments. The illiquid nature of the Company’s positions may make it difficult, if not impossible, for the Company to (i) close out unprofitable positions and redeploy capital, except when a viable exit strategy can be developed (which may require a much longer commitment than the Adviser had anticipated), and (ii) meet margin calls or similar requirements of Company transaction counterparties to furnish additional liquid collateral. In addition, the sale of the Company’s investments may be made at substantial discounts and/or otherwise disadvantageous terms.
Inflation/Deflation Risk
. Inflation risk results from the variation in the value of cash flows from a security due to inflation, as measured in terms of purchasing power. The Company is exposed to inflation risk with respect to any fixed rate investments that it makes, if any, because the interest rate the issuer has to pay the Company is fixed for the life of the security. To the extent that interest rates reflect the expected inflation rate, floating rate loans have a lower level of inflation risk.
Any disruptions in the capital markets, as a result of inflation and a rising interest environment or otherwise, may increase the spread between the yields realized on risk-free and higher risk securities and can result in illiquidity in parts of the capital markets, significant write-offs in the financial sector
and re-pricing of
credit risk in the broadly syndicated market. These and any other unfavorable economic conditions could increase the Company’s funding costs, limit the Company’s access to the capital markets or result in a decision by lenders not to extend credit to the Company. In addition, market conditions (including inflation, supply chain issues and decreased consumer demand) could impact the operations of certain of the Company’s Portfolio Investments. If the financial results of middle-market companies, like those in which the Company intends to invest, experience deterioration, it could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults, and further deterioration in market conditions will further depress the outlook for those companies. Further, adverse economic conditions may decrease the value of collateral securing some of the Company’s loans and the value of the Company’s equity investments. Such may require the Company to modify the payment terms of its investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of the Company’s Portfolio Investments may be negatively impacted by these economic or other conditions, which can result in the Company’s receipt of reduced interest income from its Portfolio Investments and/or realized and unrealized losses related to its Portfolio Investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations.
Financial Fraud
. Instances of fraud and other deceptive practices committed by management, employees or Service Providers of the Company’s Portfolio Investments or by other financial institutions may undermine the Adviser’s due diligence efforts with respect to, and/or negatively affect the valuation of, the Company’s Portfolio Investments. In addition, financial fraud may contribute to overall market volatility, which can negatively impact the Company’s investment program.
OFAC, FCPA and Related Considerations
. Economic sanction laws in the U.S. and other jurisdictions may prohibit the Adviser, its personnel and the Company from transacting with or in certain countries and with certain individuals and companies. In the U.S., the U.S. Department of the Treasury’s Office of Foreign Assets Control administers and enforces laws, Executive Orders and regulations establishing U.S. economic and trade sanctions. Such sanctions prohibit, among other things, transactions with, and the provision of services to, certain foreign countries, territories, entities and individuals. These types of sanctions may restrict the Company’s investment activities.
In some countries, there is a greater acceptance than in the U.S. of government involvement in commercial activities, and of corruption. The Company may be adversely affected because of its unwillingness to participate in transactions that violate such laws or regulations. Such laws and regulations may make it difficult in certain circumstances for the Company to act successfully on investment opportunities and for Portfolio Investments to obtain or retain business.
 
In recent years, the U.S. Department of Justice and the SEC have devoted greater resources to enforcement of the U.S. Foreign Corrupt Practices Act (the “FCPA”). In addition, the United Kingdom has recently significantly expanded the reach of its anti-bribery laws. Violations of the FCPA or other applicable anti-corruption laws or anti-bribery laws could result in, among other things, civil and criminal penalties, material fines, profit disgorgement, injunctions on future conduct, securities litigation and a general loss of investor confidence, any one of which could adversely affect the Company’s ability to achieve its investment objective and/or conduct its operations.
Risks Relating to Waivers or Deferrals of Covenants and Covenant-Lite Loans
. The Company structures the debt in its Portfolio Investments to include business and financial covenants placing affirmative and negative obligations on the operation of the company’s business and its financial condition. However, from time to time the Company may elect to waive breaches of these covenants, including its right to payment, or waive or defer enforcement of remedies, such as acceleration of obligations or foreclosure on collateral, depending upon the financial condition and prospects of the particular Portfolio Investment. These actions may reduce the likelihood of the Company receiving the full amount of future payments of interest or principal and be accompanied by a deterioration in the value of the underlying collateral as many of these companies may have limited financial resources, may be unable to meet future obligations and may go bankrupt. This could negatively impact the Company’s ability to pay distributions, could adversely affect its results of operation and financial condition and cause the loss of all or part of your investment.
In addition, some of the loans in which the Company may invest may be “covenant-lite” loans. The Company uses the term “covenant-lite” loans to refer generally to loans that do not have a complete set of financial maintenance covenants. Generally, “covenant-lite” loans provide borrower companies more freedom to negatively impact lenders because their covenants are incurrence-based, which means they are only tested and can only be breached following an affirmative action of the borrower, rather than by a deterioration in the borrower’s financial condition. Accordingly, to the extent the Company invests in “covenant-lite” loans, the Company may have fewer rights against a borrower and may have a greater risk of loss on such investments as compared to investments in or exposure to loans with financial maintenance covenants.
General Risks Related to the Company
Risk of Loss
. An investment in the Company is highly risky. There can be no assurance that the Company will achieve its investment objective or any particular level of returns. An investor may lose all of its money by investing in the Company. Among other things, the Company may invest in assets that are underperforming or non performing and/or in securities of issuers who are under financial stress. By their nature, such investments are considered speculative and entail substantial risks that are generally higher than the risks of investments in performing assets and securities of issuers that are not under financial stress. Any losses in the Company will be borne solely by investors in the Company and not by the Adviser or any of its respective affiliates (except to the extent they invest capital in the Company, in which case they, with respect to such capital invested, will bear their pro rata portion of such loss).
No Market for Units
. Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed. A Unitholder is not expected to be able to sell, assign or transfer its Units. In addition, transfers of Units may be affected by restrictions on resales imposed by federal and state securities laws. The Units are not registered under the Securities Act or any state securities laws and may not be transferred unless registered under applicable federal and state securities laws or unless an exemption from such laws is available. The Company has no plans, and is under no obligation, to register the Units under the Securities Act or any state securities laws. No market exists for the Units, and none is expected to develop. Therefore, an investment in the Company must be considered illiquid and must only be made by
persons
that are able to bear the risk of their investment in the Company for an indefinite period of time.
Management Risk and Reliance on Management
. The Company is subject to management risk because the Adviser actively manages its investment portfolio. The Adviser will apply investment and disposition techniques and risk analyses in making investment and disposition decisions for the Company, but there can be no guarantee that these will produce the desired results. In addition, as Unitholders may not participate in the management of the Company, only investors who are willing to entrust all aspects of the management of the Company to the Adviser should subscribe for Units.
The success of the Company is highly dependent upon the financial and managerial experience of the Adviser and any consultants or other Service Providers retained by the Company. The success of the Adviser is highly dependent on the financial and managerial experience of the investment professionals, who may not continue to be employed by or associated with the Adviser during the entire term of the Company. In
addition
, a number of members of the professional staff of the Adviser are
 
investors in other investment vehicles advised by SLR and are actively involved in managing the investment decisions of these investment vehicles, as well as investment decisions of other clients of SLR. Accordingly, the members of the professional staff of the Adviser have demands on their time for the investment, monitoring and other functions of other funds and other clients advised by SLR. In addition, competition in the financial services, private equity and alternative asset management industries for qualified investment professionals is intense. The Adviser’s continued ability to effectively manage the Company’s investments depends on its ability to attract new investment professionals and to retain and motivate its existing investment professionals.
Notwithstanding the foregoing, at any time during the Company’s term, the Adviser may assign the full and exclusive authority and responsibility granted to it under the Investment Management Agreement to an investment adviser under common control with the Adviser, subject to applicable law. The Adviser may take any actions that are necessary or incidental to any such assignment, including assigning the Investment Management Agreement or causing the Company to enter into a new Investment Management Agreement. Although it is expected that (x) any new investment adviser would be a registered investment adviser under the Advisers Act, (y) the management fee and incentive fee payable by the Company to such entities would be identical to that payable to the Adviser and (z) certain investment professionals would continue to be responsible for managing the Company’s assets, there is no guarantee that any or all of such characteristics will apply to any such new investment adviser.
The Investment
Committee may delegate non-investment decisions (including
decisions relating to cash management
and similar non-material transactions
(which shall not be considered “investments” for these purposes), diligence decisions, decisions relating to
transactions involving material non-public information and
decisions relating to the engagement of consultants, law firms and other Service Providers) to other investment professionals in their sole discretion. Any decisions made by such subset or other investment professionals may be materially different and/or less optimal than decisions that would have been made by the Investment Committee.
Referral Relationships with Financial Sponsors
. The Adviser expects that the professional staff of the Adviser will maintain and develop their relationships with financial sponsors, including venture capital sponsors, and the Company will rely to a significant extent upon these relationships to provide the Company with potential investment opportunities. If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio. In addition, individuals with whom the professional staff of the Adviser have relationships are not obligated to provide the Company with investment opportunities, and, therefore, there is no assurance that such relationships will generate investment opportunities for the Company. If the Adviser is unable to source investment opportunities, the Company may hold a greater percentage of its assets in cash and cash equivalents than anticipated, which could impact potential returns on the Company’s portfolio.
Recourse to the Company’s Assets
. The Company’s assets, including any Portfolio Investments made by the Company and any capital held by the Company, are available to satisfy all liabilities and other obligations of the Company. In addition, the Company may pledge its right to call capital from Unitholders. If the Company becomes subject to a liability, parties seeking to have the liability satisfied may have recourse to the Company’s assets generally and may not be limited to any particular asset, such as the Portfolio Investment giving rise to the liability. To the extent the Company chooses to use special-purpose entities for individual transactions to reduce recourse risk (and it may, but will be under no obligation to do so), the
 bona fides
 of such entities may be subject to later challenge based on a number of theories, including veil piercing or substantive consolidation.
Unspecified Use of Proceeds
. The proceeds from the issuance of the Units are intended to be invested in Portfolio Investments. Unitholders will not have an opportunity to evaluate for themselves the relevant economic, financial and other information regarding the investments in which the proceeds from the issuance of the Units will be invested and, accordingly, are dependent upon the judgment and ability of the Adviser in investing and managing the capital of the Company.
Identification of Potential Investment Opportunities
. There is no assurance that the Adviser’s analysis in this regard, as implemented, will take into consideration all appropriate factors or appropriately weigh the factors that are considered in its analysis, especially given the heightened difficulty of the analysis required to evaluate certain Portfolio Investments. In particular, catalysts and/or exit strategies that initially appear to be viable may be precluded over time due to economic, legal, political or other factors. In addition, because the successful implementation of the Company’s investment strategy depends, in part, on its ability to successfully predict and take advantage of changing market conditions, to the extent it is unable to do so, returns may be adversely affected. These considerations are particularly relevant in light of the current uncertain economic and regulatory environment. See “—
Regulatory Risks Relating to the Company
” below.
 
Competition; Potential for Insufficient Investment Opportunities
. The business of identifying and effecting investments of the types contemplated by the Adviser is competitive and there can be no assurance that the Adviser will be able to identify and obtain a sufficient number of investment opportunities to invest the full amount of capital that may be committed to the Company. Increased competition for, or a diminishment in the available supply of, potential Portfolio Investments could result in lower returns on such Portfolio Investments. The Company may engage in auction or similar bidding processes with respect to certain Portfolio Investments, which processes are often highly competitive and may involve numerous other bidders about which the Company possesses limited or no information; as a result, the foregoing considerations will be applicable with respect to any such processes.
Insufficient Capital for
Follow-On
 Investments
. Following its initial investment in a Portfolio Investment, the Company may have the opportunity to increase its investment in such Portfolio Investment. There is no assurance that the
Company will make follow-on investments or
that the Company will have sufficient resources to, or be permitted to, make such investments. Any decision
not to make follow-on investments or the
Company’s inability to make them may have a substantial negative impact on the company in need of such an investment, may result in missed opportunities for the Company or may result in dilution of the Company’s investment.
Concentration of Portfolio Investments
. The Company may participate in a limited number of Portfolio Investments and, as a consequence, the aggregate return of the Company may be substantially adversely affected by the unfavorable performance of any single investment. The Company has a broad and flexible investment mandate, and, beyond the asset diversification requirements associated with the Company’s intention to comply with the requirements to qualify as a RIC for U.S. tax purposes, and except as noted above, the Company is not subject to any limits or proportions with respect to the mix of permitted Portfolio Investments. As a result, the Company’s Portfolio Investments could potentially be concentrated in relatively few strategies, issuers, industries, markets, geographies or
investment types. Such non-diversification would make the
Company more susceptible to risks associated with a single economic, political or regulatory occurrence than a more diversified portfolio might be. The Company could be subject to significant losses if it holds a relatively large position in a single strategy, issuer, industry, market, geographic region or a particular type of Portfolio Investment that declines in value, and the losses could increase even further if the Portfolio Investments cannot be liquidated without adverse market reaction or are otherwise adversely affected by changes in market conditions or circumstances.
Third-Party Involvement
. The Company may hold a portion of its investments through partnerships, joint ventures, securitization vehicles or other entities with third-party investors (collectively, “joint ventures”). Joint venture investments involve various risks, including the risk that the Company will not be able to implement investment decisions or exit strategies because of limitations on the Company’s control under applicable agreements with joint venture partners, the risk that a joint venture partner may become bankrupt or may at any time have economic or business interests or goals that are inconsistent with those of the Company, the risk that a joint venture partner may be in a position to take action contrary to the Company’s objectives, the risk of liability based upon the actions of a joint venture partner and the risk of disputes or litigation with such partner and the inability to enforce fully all rights (or the incurrence of additional risk in connection with enforcement of rights) one partner may have against the other, including in connection with foreclosure on partner loans, because of risks arising under state law. In addition, the Company may be liable for actions of its joint venture partners.
Leveraged Companies
. The Company will invest in Portfolio Investments whose capital structures have significant leverage. Such Portfolio Investments are inherently more sensitive to declines in revenues and asset values and to increases in expenses and interest rates. The leveraged capital structure of such Portfolio Investments will increase the exposure of the Portfolio Investments to adverse economic factors such as downturns in the economy or deterioration in the condition of the Portfolio Investment, its underlying assets or its industry. Additionally, the securities acquired by the Company may be the most junior securities in what may be a complex capital structure, and thus subject to the greatest risk of loss.
Portfolio Turnover
. The Company will not place any limit on the rate of portfolio turnover, and Portfolio Investments may be sold or otherwise disposed of without regard to the time they have been held when, in the judgment of the Adviser, investment considerations warrant such action. A high rate of portfolio turnover involves correspondingly greater expenses than a lower rate, may act to reduce the Company’s investment gains or create a loss for investors and may result in significant tax costs for investors
depending
on the tax provisions applicable to such investors.
No Assurance of Cash Distributions
. Subject to the Board’s discretion and applicable legal restrictions, the Company expects to declare and pay distributions quarterly. The Company expects to pay these distributions out of assets legally available for distribution. However, there are no assurances that the Company will achieve investment results that will allow a targeted level
 
of
cash distributions or year-to-year increases in cash
distributions. All distributions that are made will be at the discretion of the Board and will depend on earnings, financial condition, maintenance of RIC status and other factors as the Board may deem to be relevant. The Company’s ability to pay distributions might be adversely affected by the impact of one or more of the risk
 
factors described in this annual report on Form
10-K.
If the Company violates certain covenants under its existing or future credit facilities or other leverage, the Company may be limited in its ability to make distributions. To the extent the Company makes distributions to Unitholders that include a return of capital, such portion of the distribution essentially constitutes a return of the Unitholder’s investment. In addition, the inability to satisfy the asset coverage test applicable to a BDC may limit the Company’s ability to pay distributions. There can be no assurances that the Company will pay distributions to Unitholders in the future.
In certain cases, the Company may recognize income before or without receiving the accompanying cash. Depending on the amount of noncash income, this could result in difficulty satisfying the annual distribution requirement applicable to RICs. Accordingly, the Company may have to sell some Portfolio Investments at times it would not consider advantageous, raise additional debt or equity capital or reduce new investments to meet these distribution
requirements
.
U.S.
 Dollar Denomination of Units
. Units are denominated in U.S. Dollars. Investors subscribing for Units in any country in which U.S. Dollars are not the local currency should note that changes in the rate of exchange between U.S. Dollars and such currency may have an adverse effect on the value, price or income of the investment to such investor. There may be foreign exchange regulations applicable
to investments in non-U.S. currencies in certain
jurisdictions. Each prospective investor should consult with its own counsel and advisors as to all legal, tax, financial and related matters concerning an investment in the Units.
Forward-Looking Statements
. This
annual
report on Form
10-K
contains forward-looking statements, including observations about market and industry and regulatory trends as of the original date of this annual report
on Form 10-K. Those forward-looking
statements reflect the Adviser’s current view in respect of future events. Actual events could differ materially from those in the forward-looking statements as a result of factors beyond the Adviser’s or the Company’s control. Investors are cautioned not to place undue reliance on such statements. No party has an obligation to update any of the forward-looking statements in this annual report
on Form 10-K.
Projections
. The Company may rely upon projections, forecasts or estimates developed by the Adviser, the Company or an issuer in which the Company is invested concerning the issuer’s future performance and cash flow. Projections, forecasts and estimates are forward-looking statements, are inherently uncertain and are based upon certain assumptions. Actual events are difficult to predict and beyond the Company’s control. Actual events may differ from those assumed. Some important factors which could cause actual results to differ materially from those in any forward-looking statements include changes in interest rates; domestic and foreign business, market, financial or legal conditions; leverage amounts and costs; and the degree to which the Portfolio Investments are hedged and the effectiveness of such hedges. Accordingly, there can be no assurance that estimated returns or projections can be realized or that actual returns or results will not be materially lower than those estimated therein.
Valuation of Illiquid Assets
. It is expected that the majority of the Company’s investments will be in securities or other financial instruments for which market quotations are not available. The process of valuing securities for which reliable market quotations are not available is based on inherent uncertainties, and the resulting values may differ from values that would have been determined had a ready market existed for such securities, from values placed on such securities by other investors and from prices at which such securities may ultimately be sold. In addition, third-party pricing information may at times not be available regarding certain of the Company’s assets or, if available, may not be considered reliable. In particular, recent disruptions in the credit markets have resulted in a severe lack of liquidity for many securities, making them more difficult to value and, in many cases, putting significant downward pressure on prices. Subject to approval by the Board, the Adviser will determine the fair value of securities, loans or other instruments for which market quotes are not readily available (or if extraordinary events occur after the last readily available quotation). The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by
Rule 2a-5 under
the 1940 Act; and (6) maintain recordkeeping requirements under
Rule 2a-5.
There can be no assurance that such valuations will be reliable, accurate or reflective of the prices at which such investments are ultimately realized. In addition, certain of the securities or other assets that the Company seeks to sell or acquire via cross trade may be illiquid and difficult to value, therefore there can be no assurance that such valuation will be accurate.
Assets Believed to Be Undervalued or Incorrectly Valued
. Securities that the Adviser believes are fundamentally undervalued or incorrectly valued may not ultimately be valued in the capital markets at prices and/or within the timeframe the Adviser anticipates. As a result, the Company may lose all or substantially all of its investment in any particular instance.
 
Model Risks
. The Adviser may employ financial/analytical models to aid in the selection of the Portfolio Investments, to allocate investments across various strategies and risks and to determine the risk profile of the Company. If any such models are employed, the success of the Company’s investment activities will depend, in large part, upon the viability of these models. There can be no assurance that the models are currently viable, or will remain viable during the term of the Company, due to various factors, including the quality of the data input into the models and the assumptions underlying such models, which to varying degrees involve the exercise of judgment, as well as the possibility of errors in constructing or of using the model. Even if the models function as anticipated, they cannot account for all factors that may influence the returns on the Portfolio Investments. Also, there can be no assurance that the investment professionals utilizing the models will be able to (i) determine that any model is or will become not viable or not completely viable or (ii) notice, predict or adequately react to any change in the viability of a model. The use of a model that is not viable or not materially viable could, at any time, have a material adverse effect on the performance of the Company.
Regulatory Investigations or Third-Party Litigation
. The Company as well as the Adviser and its affiliates participate in a highly regulated industry and are each subject to regulatory examinations in the ordinary course of business. There can be no assurance that the Company and the Adviser and/or any of its affiliates will avoid regulatory investigation and possible enforcement actions stemming therefrom. The Adviser is a registered investment adviser and, as such, is subject to the provisions of the Advisers Act. The Company and the Adviser are each, from time to time, subject to formal and informal examinations, investigations, inquiries, audits and reviews from numerous regulatory authorities both in response to issues and questions raised in such examinations or investigations and in connection with the changing priorities of the applicable regulatory authorities across the market in general.
The Company’s investment activities may subject it to the risks and costs of becoming involved in litigation with third parties due to, among other reasons, the fact that different investor groups may have qualitatively different, and frequently conflicting, interests with respect to certain Portfolio Investments. The risk of litigation with third parties will be elevated in situations where an issuer is stressed or distressed. See “—
Litigation and Related Risks Associated with Origination and Servicing
” above. The expense of defending against claims by third parties and
paying
any amounts pursuant to settlements or judgments, or bringing claims against third parties, would generally be borne by the Company and would reduce net assets. In addition, the Company’s investment activities may subject it to certain risks inherent in restructuring, bankruptcy and similar proceedings. See “—
Risks Associated with Bankruptcy and Insolvency Cases
” below.
Broad Indemnification
. The Company and/or the Adviser on behalf of the Company may enter into various agreements or arrangements which limit the liability of its Service Providers, including the Adviser and its affiliates, the Administrative Coordinator, the Custodian, and their affiliates, employees, officers and directors, and require the Company to indemnify and/or provide broad representations, warranties and covenants in favor of such persons. U.S. federal and state securities laws impose liabilities under certain circumstances on persons that cannot be waived by contract, other agreements or documents. Therefore, nothing in those agreements should be deemed or construed in a manner that purports to waive or limit any right to the extent prohibited by law.
The Company is required to indemnify the Adviser and its respective affiliates, each of the former, current and future shareholders, partners, members, other equity holders, officers, directors, employees, managers, trustees, agents and other representatives of the Adviser and its respective affiliates, and other persons set forth in the LLC Agreement as an “Indemnitee” for Claims (as defined in the LLC Agreement) that may accrue to or be incurred by an Indemnitee, in connection with any claim, demand, investigation, suit, proceeding or action in which an Indemnitee may become involved, as a party or otherwise, or with which an Indemnitee may be threatened, relating to or arising out of the investments or other activities of the Company, activities undertaken in connection with the Company, or otherwise relating to or arising out of the LLC Agreement or the Subscription Agreement, and otherwise as provided in the LLC Agreement or the Subscription Agreement. Such Claims may be material and have an adverse effect on the returns to the Unitholders. The Company may also provide broad indemnities, representations, warranties and covenants in connection with the acquisition, management and disposition of Portfolio Investments or otherwise in connection with the Company’s investment program.
Any indemnification obligations of the Company would be payable from the assets of the Company, including the unfunded Commitments of the Unitholders, and would adversely affect the Company’s returns.
Adverse Consequences of Default
. A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment. When a Unitholder defaults, the Board, in its discretion, may cause the defaulting Unitholder to forfeit a portion of the distributions to which the defaulting Unitholder may otherwise have been entitled. The Board may also require a forced sale of the defaulting Unitholder’s Interest. In addition, the Board may pursue any available legal or equitable remedies, with the expenses of collection of the unpaid amount, including attorneys’ fees, to be paid by the defaulting Unitholder.
 
Upon the default of a Unitholder, the Company may deliver an amended funding notice to the
non-defaulting
Unitholders increasing their capital contributions by up to an aggregate amount equal to the capital contribution that the defaulting Unitholder failed to make, not in excess of a Unitholder’s unfunded Commitment.
The Board may require a defaulting Unitholder to contribute the entirety of its remaining Commitment to the Company. For any such Unitholder, the return on its Company investment may be materially lower than returns to Unitholders
who do not pre-fund their Commitments.
Distributions in Kind
. If distributions are made of assets held by the Company in lieu of cash, the amount of any such distribution will be accounted for at the fair market value of such assets as determined in accordance with procedures set forth in the LLC Agreement. An independent appraisal generally will not be required and is not expected to be obtained. Assets distributed in kind may not be readily marketable or disposable, and Unitholders therefore must be prepared to bear the risks of owning such assets for an indefinite period of time (and to incur costs and expenses in connection with any disposition thereof). In addition, there can be no
assurance
that the value of such assets as determined in accordance with procedures set forth in the LLC Agreement will ultimately be realized.
Risks Related to the Russian Invasion of Ukraine
. On February 24, 2022, the Russian military commenced a full-scale invasion of
Russia’s pre-positioned forces
into Ukraine, which could have a negative impact on the economy and business activity globally (including in the countries in which the Company invests), and therefore could adversely affect the performance of the Company’s Portfolio Investments. Following such invasion, the United States and several European nations announced sanctions against Russia. Furthermore, the conflict between the two nations and the varying involvement of the United States and other NATO countries could preclude prediction as to their ultimate adverse impact on global economic and market conditions, and, as a result, presents material uncertainty and risk with respect to the Company and the performance of its investments or operations, and the ability of the Company to achieve its investment objectives. Additionally, to the extent that third parties, investors, or related customer bases have material operations or assets in Russia or Ukraine, they may have adverse consequences related to the ongoing conflict.
Risks Related to Electronic Communications/Cybersecurity Risk
. The Company provides to Unitholders statements, reports and other communications relating to the Company and/or the Unitholder’s Interest in electronic form, such
as e-mail or
via a password protected website (“Electronic Communications”). There are certain costs and possible risks associated with the use of Electronic Communications. Electronic Communications may be modified, corrupted, or contain viruses or malicious code, and may not be compatible with a Unitholder’s electronic system. The Company cannot provide any assurance that Electronic Communications are secure and will not be responsible for any computer viruses, problems or malfunctions resulting from the use of Electronic Communications. In addition, reliance on Electronic Communications involves the risk of inaccessibility, power outages or slowdowns for a variety of reasons. These periods of inaccessibility may delay or prevent receipt of reports or other information by the Unitholders.
The Company relies on the Adviser’s enterprise-wide cybersecurity program, to protect its information, including due oversight of the cybersecurity programs of the Company’s key Service Providers and processes for the assessment, identification, and management of material risks from cybersecurity threats, including those associated with the use of third-party Service Providers. While the Adviser employs various measures to address cybersecurity-related issues, the Adviser, the Administrative Coordinator, the Company and their respective Service Providers may nevertheless be subject to operational and information security risks resulting from cybersecurity incidents. A cybersecurity incident refers to both intentional and unintentional events that may cause the Adviser, the Company or their respective Service Providers to lose or compromise confidential information, suffer data corruption or lose operational capacity. Cybersecurity incidents include stealing or corrupting data maintained online or digitally, denial of service attacks on websites, the unauthorized release of confidential information or various other operational disruptions. If unauthorized parties gain access to such information and technology systems, they may be able to steal, publish, delete or modify private and sensitive information, including nonpublic personal information related to Unitholders (and their beneficial owners) and material nonpublic information. The systems the Adviser has implemented to manage risks relating to these types of events could prove to be inadequate and, if compromised, could become inoperable for extended periods of time, cease to function properly or fail to adequately secure private information. Breaches such as those involving covertly introduced malware, impersonation of authorized users and industrial or other espionage may not be identified even with sophisticated prevention and detection systems, potentially resulting in further harm and preventing them from being addressed appropriately. The failure of these systems or of disaster recovery plans for any reason could cause significant interruptions in the Company’s and the Adviser’s operations and result in a failure to maintain the security, confidentiality or privacy of sensitive data, including personal information relating to Unitholders, material nonpublic information and other sensitive information in the Adviser’s possession.
 
A disaster or a disruption in the infrastructure that supports the Adviser’s business, including a disruption involving Electronic Communications or other services used by the Adviser or third parties with whom the Adviser conducts business, or directly affecting the Adviser’s headquarters, could have a material adverse impact on the Adviser’s ability to continue to operate its business without interruption and to protect the Company, insofar as is practicable, from the hazards of cybersecurity threats and vulnerabilities in accordance with applicable legal requirements and guidance. The Adviser’s disaster recovery programs may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse the Adviser for its losses, if at all.
Although the Company is not currently aware of any cyber-attacks or other incidents that, individually or in the aggregate, have materially affected, or would reasonably be expected to materially affect, its operations or financial condition, there has been an increase in the frequency and sophistication of the cyber and security threats faced in the marketplace. Cyber-attacks and other security threats could originate from a wide variety of sources, including cyber criminals, nation state hackers, hacktivists and other outside or inside parties. The Company may be a target for attacks because, as a specialty finance company, it holds confidential and other sensitive information, including price information, about existing and potential investments. Further, the Company is dependent on third-party vendors for hosting hardware, software and data processing systems that it does not control. The Company also relies on third-party Service Providers for certain aspects of its business, including for certain information systems, technology and administration of its Portfolio Investments and compliance matters. While the Company relies on the cybersecurity strategy and policies implemented by the Adviser, its reliance on the Adviser and third-party Service Providers removes certain cybersecurity functions from outside of the Company’s immediate control, and cyber-attacks on the Adviser, on the Company or on third-party Service Providers could adversely affect the Company, its business, and its reputation. The costs related to cyber-attacks or other security threats or disruptions may not be fully insured or indemnified by others, including by the
Company’s
third-party providers.
As the Company’s reliance on computer hardware and software systems, data processing systems, and other technology has increased, so have the risks posed to such systems, both those the Adviser controls and those provided by third-party vendors. Cyber-attacks may originate from a wide variety of sources, and while the Adviser has implemented processes, procedures, and internal controls designed to mitigate cybersecurity risks and cyber-attacks, these measures do not guarantee that a cyber-attack will not occur or that the Company’s financial results, operations, or confidential information, personal, or other sensitive information will not be negatively impacted by such an incident, especially because the techniques of threat actors change frequently and are often not recognized until launched. The Adviser relies on industry accepted security measures and technology to securely maintain confidential and proprietary information maintained on its information systems, as well as on policies and procedures to protect against the unauthorized or unlawful disclosure of confidential, personal, or other sensitive information. Although the Adviser takes protective measures and endeavors to strengthen its computer systems, software, technology assets, and networks to prevent and address potential cyber-attacks, there can be no assurance that any of these measures prove effective. The Adviser expects to be required to devote increasing levels of funding and resources, which may in part be allocated to the Company, to comply with evolving cybersecurity and privacy laws and regulations and to continually monitor and enhance its cybersecurity procedures and controls. In addition, the Company, the Adviser, the Administrative Coordinator, or their employees, if any, may also be the target of fraudulent emails or other targeted attempts to gain unauthorized access to confidential, personal, or other sensitive information. The result of any cyber-attack or other security incidents may include disrupted operations, misstated or unreliable financial data, fraudulent transfers or requests for transfers of money, liability for stolen information (including personal information), investigations, misappropriation of assets, increased cybersecurity protection and insurance costs, litigation and damage to the Company’s business relationships, regulatory fines or penalties, or other adverse effects on its business, financial condition or results of operations. The Adviser may be required to expend significant additional resources to modify its protective measures and to investigate and remediate vulnerabilities or other exposures arising from operational and security risks related to cyber-attacks. The rapid evolution and increasing prevalence of artificial intelligence technologies may also increase cybersecurity risks.
In addition, cybersecurity has become a top priority for global lawmakers and regulators around the world, and some jurisdictions have proposed or enacted laws requiring companies to notify regulators and individuals of data security breaches involving certain types of personal data. In particular, state and federal laws and regulations related to cybersecurity compliance continue to evolve and change, which may require substantial investments in new technology, software and personnel, which could affect the Company’s profitability. These changes may also result in enhanced and unforeseen consequences for cyber- related breaches and incidents, which may further adversely affect the Company’s profitability. If the Adviser fails to comply with the relevant and increasing laws and regulations, the Adviser could suffer financial losses, a disruption of its businesses, liability to investors, regulatory intervention or reputational damage.
 
Policies of remote working, whether by the Adviser, the Administrative Coordinator, the Company or by their respective Service Providers, could strain technology resources, introduce operational risks and otherwise heighten the risks described above. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts.
Cybersecurity risks are exacerbated by the rapidly increasing volume of highly sensitive data, including the Company’s proprietary business information, personal information of the Adviser’s employees, the Company’s investors and others, and other sensitive information that the Adviser collects, processes, and stores in its data centers and on its networks or those of third-party Service Providers. The secure processing, maintenance, and transmission of this information are critical to the Company’s operations. There is a risk that encryption and other protective measures against cyber-attacks may be circumvented, particularly to the extent that new computing technologies increase the speed and computing power available. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and, in fact, may not be detected. A significant actual or potential theft, loss, corruption, exposure, fraudulent use or misuse of investor or other personal information, proprietary business data or other sensitive information, whether by third parties or as a result of malfeasance by the Adviser’s employees or otherwise,
non-compliance
with applicable contractual or other legal obligations regarding such data or intellectual property or a violation of applicable privacy and security policies with respect to such data could result in significant investigation, remediation and other costs, fines, penalties, litigation or regulatory actions against the Company and significant reputational harm, any of which could harm the Company’s business and results of operations. Cybersecurity risks require continuous and increasing attention and other resources from the Adviser to, among other actions, identify and quantify these risks and upgrade and expand its technologies, systems and processes to adequately address such risks. Such attention diverts time and other resources from other activities and there is no assurance that the Adviser’s efforts will be effective.
Cybersecurity incidents may adversely impact the Company and its Unitholders. There is no guarantee that the Company, the Adviser, and/or their respective Service Providers will be successful in protecting against cybersecurity incidents.
Financial Services Industry Risks
. Cash not held in custody accounts and held by the Company, the Adviser and the Portfolio Investments in
non-interest-bearing
and interest-bearing operating accounts could, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, the Company, the Adviser, or the Portfolio Investments could lose all or a portion of those amounts held in excess of such insurance limits. In addition, actual events involving limited liquidity, defaults,
non-performance
or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect the Company, the Adviser’s and the Portfolio Investments’ business, financial condition, results of operations, or prospects.
Although the Company and the Adviser assess its and the Portfolio Investments’ banking and financing relationships as the Company believes necessary or appropriate, the Company and the Portfolio Investments’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which the Company, the Adviser or the Portfolio Investments have arrangements directly or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company, the Adviser or the Portfolio Investments have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.
In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for the Company, the Adviser, or the Portfolio Investments to acquire financing on acceptable terms or at all.
Technological Innovation Risks
. Technological innovations have disrupted traditional approaches in multiple industries and can permit younger companies to achieve success and in the process disrupt markets and market practices. The Company can provide no assurance that new businesses and approaches will not be created that would compete with the Company and/or its Portfolio Investments or alter the market practices in which the Adviser and its affiliates and the Company have been designed to function within and on which the Company depends on for its investment return. New approaches could damage the Company’s investments, disrupt the market in which it operates and subject it to increased competition, which could materially and adversely affect the Company’s business, financial condition and results of investments.
 
Machine Learning Technology Risks
. Recent technological advances in artificial intelligence and machine learning technology (“Machine Learning Technology”) pose risks to the Company and its Portfolio Investments. The Company and its Portfolio Investments could be exposed to the risks of Machine Learning Technology if third-party service providers or any counterparties use Machine Learning Technology in their business activities. The Company and the Adviser are not in a position to control the use of Machine Learning Technology in third-party products or services. Use of Machine Learning Technology could include the input of confidential information in contravention of applicable policies, contractual or other obligations or restrictions, resulting in such confidential information becoming part accessible by other third-party Machine Learning Technology applications and users. Machine Learning Technology and its applications continue to develop rapidly, and the Company cannot predict the risks that may arise from such developments.
Machine Learning Technology is generally highly reliant on the collection and analysis of large amounts of data, and it is not possible or practicable to incorporate all relevant data into the model that Machine Learning Technology utilizes to operate. Certain data in such models will inevitably contain a degree of inaccuracy and error and could otherwise be inadequate or flawed, which would be likely to degrade the effectiveness of Machine Learning Technology. To the extent the Company or its Portfolio Investments are exposed to the risks of Machine Learning Technology use, any such inaccuracies or errors could adversely impact the Company or its Portfolio Investments.
Corporate Social Responsibility Risks
. The Company’s business (including that of its Portfolio Investments) faces increasing public scrutiny related to environmental, social and governance (“ESG”) activities, which are increasingly considered to contribute to reducing a company’s operational risk, market risk and reputational risk, which may in turn impact the long-term sustainability of a company’s performance. A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG ratings and measures to their investment decisions.
The Company risks damage to its brand and reputation if it fails to act responsibly in a number of areas, including, but not limited to, diversity, equity and inclusion, human rights, climate change, environmental stewardship, support for local communities, corporate governance, transparency and consideration of ESG factors in the Company’s investment processes. Adverse incidents with respect to ESG activities could impact the value of the Company’s brand, its relationship with existing and future Portfolio Investments, the cost of the Company’s operations and relationships with investors, all of which could adversely affect its business and results of operations.
However, regional and investor specific sentiment may differ in what constitutes a material positive or negative ESG corporate practice. There is no guarantee that the Company’s ESG and sustainability practices will uniformly fit every investor’s definition of best practices for all environmental, social and governance considerations across geographies and investor types. If we do not successfully manage expectations across varied stakeholder interests, it could erode stakeholder trust, impact our reputation and constrain our investment opportunities.
There is also a growing regulatory interest across jurisdictions in improving transparency regarding the definition, measurement and disclosure of ESG factors in order to allow investors to validate and better understand sustainability claims. For example, the SEC has proposed, or has announced that it is working on proposals for, rules that, among other matters, would establish a framework for reporting of climate-related risks, corporate and fund carbon emissions, broad diversity and capital management. At this time, there is uncertainty regarding the scope of such proposals or when they would become effective (if at all). In 2021, the SEC established an enforcement task force to look into ESG practices and disclosures by public companies and investment managers and has started to bring enforcement actions based on ESG disclosures not matching actual investment processes. Further, in 2022 the SEC issued a proposed rule regarding the enhancement and standardization of mandatory climate-related disclosures for investors that would mandate extensive disclosure of climate-related data, risks and opportunities for certain public companies.
The Company and its Portfolio Investments are subject to the risk that similar measures might be introduced in other jurisdictions in the future. Additionally, compliance with any new laws or regulations increases the Company’s regulatory burden and could make compliance more difficult and expensive, affect the manner in which the Company or its Portfolio Investments conduct its businesses and adversely affect the Company’s profitability.
Climate Change Risks
. There may be evidence of global climate change. Climate change creates physical and financial risk and some of the Company’s Portfolio Investments may be adversely affected by climate change. For example, the needs of customers of energy companies vary with weather conditions, primarily temperature and humidity. To the extent weather conditions are affected by climate change, energy use could increase or decrease depending on the duration and magnitude of
 
any changes. Increases in the cost of energy could adversely affect the cost of operations of the Company’s Portfolio Investments if the use of energy products or services is material to their business. A decrease in energy use due to weather changes may affect some of the Company’s Portfolio Investments’ financial condition, through decreased revenues. Extreme weather conditions in general require more system backup, adding to costs, and can contribute to increased system stresses, including service interruptions. Energy companies could also be affected by the potential for lawsuits against or taxes or other regulatory costs imposed on greenhouse gas emitters, based on links drawn between greenhouse gas emissions and climate change.
In December 2015 the United Nations, of which the U.S. is a member, adopted a climate accord with the long-term goal of limiting global warming and the short-term goal of significantly reducing greenhouse gas emissions. As a result, some of the Company’s Portfolio Investments may become subject to new or strengthened regulations or legislation, which could increase their operating costs and/or decrease their revenues.
Risks Related to RICs and BDCs
Failure to Qualify as a RIC
. Although the Company has obtained qualification as a RIC, no assurance can be given that it will be able to maintain qualification as a RIC. To maintain qualification as a RIC, the Company must meet
source-of-income, asset
diversification, and distribution requirements on an ongoing basis.
The income source requirement will be satisfied if the Company obtains at least 90% of gross income for each year from dividends, interest, foreign currency, payments with respect to loans of certain securities, gains from the sale of Units or other securities, net income from certain “qualifiedpublicly traded partnerships,” or similar sources.
The asset diversification requirement will be satisfied if the Company meets certain asset diversification requirements at the end of each quarter of the taxable year. Failure to meet those requirements may result in the Company having to dispose of certain investments quickly in order to prevent the loss of qualification as a RIC. Because most of the Company’s investments will be relatively illiquid, any such dispositions could be made at disadvantageous prices and could result in substantial losses.
The annual distribution requirement will be satisfied if the Company distributes to its Unitholders on an annual basis at least 90% of net ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any. Because the Company may use debt financing, it is subject to certain asset coverage ratio requirements under the 1940 Act and financial covenants under loan and credit agreements that could, under certain circumstances, restrict the Company from making distributions necessary to satisfy the distribution requirement. If the Company is unable to obtain cash from other sources, it could fail to qualify as a RIC.
If the Company fails to qualify as a RIC for any reason and therefore becomes subject to corporate income tax, the resulting corporate taxes could substantially reduce net assets, the amount of income available for distribution and the amount of distributions.
Recognizing Income Before or Without Receiving Cash
. For U.S. federal income tax purposes, the Company will include in income certain amounts that the Company has not yet received in cash, such as the accrual of original issue discount (“OID”). This may arise if the Company receives warrants in connection with the making of a loan and in other circumstances, or
through contracted payment-in-kind (“PIK”) interest,
which represents contractual interest added to the loan balance and due at the end of the loan term. Such OID, which could be significant relative to the Company’s overall investment activities, and increases in loan balances as a result of contracted PIK arrangements will be included in income before the Company receives any corresponding cash payments. The Company also may be required to include in income certain other amounts that the Company will not currently receive in cash.
Since in certain cases the Company may recognize income before or without receiving cash representing such income, the Company may have difficulty meeting the requirement to timely distribute at least 90% of its net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any, to maintain its qualification as a RIC. In such a case, the Company may have to sell some of its Portfolio Investments at times the Company would not consider advantageous or raise additional debt or equity capital or reduce new investment originations to meet these distribution requirements. If the Company is not able to obtain cash from other sources and is otherwise unable to satisfy such distribution requirement, the Company may fail to maintain its qualification as a RIC and become subject to corporate-level U.S. federal income tax.
 
 
Tax Considerations Regarding Dividends for Private BDCs
. The Company does not currently qualify as a “publicly offered regulated investment company,” as defined in the Code. Accordingly, U.S. individual and other noncorporate Unitholders will be taxed as though they received a distribution of some of the Company’s expenses. A “publicly offered regulated investment company” is a RIC whose Units are either (i) continuously offered pursuant to a public offering, (ii) regularly traded on an established securities market, or (iii) held by at least 500 persons at all times during the taxable year. The Company anticipates that it will not qualify as a publicly offered RIC for the 2023 tax year, and cannot determine when it will qualify as a publicly offered RIC. Since the Company is not a publicly offered RIC,
a non-corporate Unitholder’s
allocable portion of the Company’s affected expenses, including a portion of its management fees, will be treated as an additional distribution to the Unitholders.
A non-corporate Unitholder’s
allocable portion of these expenses are treated as miscellaneous itemized deductions that are not currently deductible by such Unitholder (and beginning in 2026, will be deductible by such Unitholder for regular U.S. federal income tax purposes but not for alternative minimum tax purposes only to the extent they exceed 2% of such Unitholder’s adjusted gross income).
Potential Dividend Deferrals
. In order to maintain its tax status as a RIC, the Company must distribute to Unitholders for each taxable year at least 90% of its investment company taxable income (i.e., net ordinary income plus realized net short-term capital gains in excess of realized net long-term capital losses). If the Company qualifies for taxation as a RIC, it generally will not be subject to corporate-level U.S. federal income tax on its investment company taxable income and net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) that it timely distributes to Unitholders. The Company will be subject to a 4% U.S. federal excise tax on undistributed earnings of a RIC unless it distributes each calendar year at least the sum of (i) 98.0% of its ordinary income for the calendar year, (ii) 98.2% of its capital gains in excess of capital losses for
the one-year period
ending on October 31 of the calendar year, and (iii) any ordinary income and net capital gains for preceding years that were not distributed during such years and on which it paid no U.S. federal income tax.
Under the Code, the Company may pay certain RIC dividends after the end of the current year. In particular, if the Company pays a distribution in January of the following year that was declared in October, November, or December of the current year and is payable to Unitholders of record in the current year, the dividend will be treated for all U.S. federal income tax purposes as if it were paid on December 31 of the current year. In addition, under the Code, the Company may pay dividends, referred to as “spillover dividends,” that are paid during the following taxable year that will allow the Company to maintain its qualification for taxation as a RIC and eliminate its liability for corporate-level U.S. federal income tax. Under these spillover dividend procedures, the Company may defer distributions of income earned during the current year until December of the following year. For example, the Company may defer distributions of income earned during 2024 until as late as December 31, 2025. If the Company chooses to pay a spillover dividend, it will incur the 4% U.S. federal excise tax on some or all of the distribution.
Due to events such as
the COVID-19 pandemic,
certain regional bank failures, the Russian invasion of Ukraine, the ongoing war in the Middle East or other disruptions in the economy, such as the recent inflationary environment, the Company may take certain actions with respect to the timing and amounts of its distributions in order to preserve cash and maintain flexibility. For example, the Company may reduce and/or defer dividends to the following year as discussed above. To further preserve cash, the Company may combine these deferrals of dividends with one or more distributions that are payable partially in Units as discussed below under “
In-Kind
 Dividend Considerations
.”
In-Kind
 Dividend Considerations
. The Company may distribute taxable dividends that are payable in part in Units. In accordance with certain applicable U.S. Treasury regulations and published IRS guidance, a RIC may treat a distribution of its own shares as fulfilling the RIC distribution requirements if each Unitholder may elect to receive the entire distribution in either cash or shares of the RIC. The IRS has published a revenue procedure indicating that, in the case of publicly offered RICs, this rule will apply where the total amount of cash to be distributed is not less than 20% of the total distribution. Under this revenue procedure, if too many Unitholders elect to receive cash, the cash available for distribution must be allocated among the Unitholders electing to receive cash (with the balance of the distribution paid in Units). Because the Company is not currently a publicly offered RIC, its ability to rely on the revenue procedure and other guidance is uncertain. If the Company elects to pay a distribution in its own Units consistent with the revenue procedure and other guidance, for U.S. federal income tax purposes, the amount of the dividend paid in Units will be equal to the amount of cash that could have been received instead of Units. Taxable Unitholders receiving such dividends will be required to include the amount of the dividends as ordinary income (or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of the Company’s current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a Unitholder may be required to pay tax with respect to such dividends in excess of any cash received, and, the Company may be required to withhold U.S. tax with respect to dividends payable in Units
to non-U.S. Unitholders.
Changes in Tax Law
. Legislative or other actions relating to taxes could have a negative effect on the Company. The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. New legislation and any other tax law developments including new or revised U.S. Treasury regulations, administrative interpretations or court decisions, could negatively and perhaps retroactively affect the U.S. federal income tax consequences to the Company and its Unitholders, or could have other adverse consequences. Investors are urged to consult with their tax advisor regarding tax legislative, regulatory, or administrative developments and proposals and their potential effect on an investment in the Company.
 
Permissible Incurred Leverage
. Leverage magnifies the potential for loss on investments and on invested equity capital. As the Company uses leverage to partially finance its investments, Unitholders will experience increased risks of investing in the Company’s securities. If the value of the Company’s assets increases, then leveraging would cause the NAV attributable to the Company’s Units to increase more sharply than it would have had the Company not leveraged. Conversely, if the value of the Company’s assets decreases, leveraging would cause NAV to decline more sharply than it otherwise would have had the Company not leveraged its business. Similarly, any increase in the Company’s income in excess of interest payable on the borrowed funds would cause net investment income to increase more than it would without the leverage, while any decrease in the Company’s income would cause net investment income to decline more sharply than it would have had the Company not borrowed. Such a decline could negatively affect the Company’s ability to pay dividends on Units, scheduled debt payments or other payments related to securities. Leverage is generally considered a speculative investment technique.
Distribution and Asset Coverage Ratio Requirements
. In order to satisfy the requirements applicable to RICs and to avoid payment of excise taxes, the Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain net income except for certain net capital gains, which it intends to retain and to elect to treat as deemed distributions to Unitholders. The Company may issue debt securities, other evidences of indebtedness or preferred Units, and may borrow money from banks or other financial institutions, which are referred to collectively herein as “senior securities,” up to the maximum amount permitted by the 1940 Act. The 1940 Act permits the Company to issue senior securities in
amounts
such that its asset coverage, as defined in the 1940 Act, equals at least 150% after each issuance of senior securities. The Company’s ability to pay dividends or issue additional senior securities would be restricted if the asset coverage ratio were not at least 150%. If the value of the Company’s assets declines, the Company may be unable to satisfy this test. If that happens, the Company may be required to liquidate a portion of its investments and repay a portion of its indebtedness at a time when such sales or repayment may be disadvantageous. As a result of issuing senior securities, the Company will also be exposed to typical risks associated with leverage, including an increased risk of loss. If the Company issues preferred Units, such preferred Units will rank “senior” to common Units in the Company’s capital structure, preferred Unitholders will have separate voting rights for certain purposes and may have rights, preferences or privileges more favorable than those of the Company’s common Units and the issuance of preferred Units could have the effect of delaying, deferring or preventing a transaction or a change of control that might involve a premium price for Unitholders or otherwise be in the best interest of Unitholders.
To the extent the Company is constrained in its ability to issue debt or other senior securities, it will depend on issuances of capital interests to finance operations. As a BDC, the Company is generally not able to issue Units at a price below NAV without first obtaining required approvals of Unitholders and independent directors in accordance with the conditions set forth in Section 63(2) of the 1940 Act. If the Company raises additional funds by issuing more common Units or senior securities convertible into, or exchangeable for, common Units, the percentage ownership of Unitholders at that time would decrease and Unitholders may experience dilution. In addition to issuing securities to raise capital as described above, the Company could, in the future, securitize loans to generate cash for funding new investments. An inability to successfully securitize its loan portfolio could limit the Company’s ability to grow its business, fully execute its business strategy and improve profitability.
Unrealized Depreciation
. As a BDC, the Company is required to carry investments at market value or, if no market value is ascertainable, at fair value as determined in good faith by the Board. Decreases in the market values or fair values of investments will be recorded as unrealized depreciation. Any unrealized depreciation in the Company’s loan portfolio could be an indication of a Portfolio Investment’s inability to meet its repayment obligations with respect to the loans whose market values or fair values decreased. This could result in realized losses in the future and ultimately in reductions of income available for distribution in future periods.
Qualifying Asset Requirements
. As a BDC, the Company may not acquire any assets other than “qualifying assets” unless, at the time of such acquisition, at least 70% of its total assets are qualifying assets. Therefore, the Company may be precluded from investing in what it believes are attractive investments if such investments are not qualifying assets. Similarly, these rules could prevent the Company from making additional investments in existing Portfolio Investments, which could result in the dilution of its position, or could require disposal of investments at an inopportune time to comply with the 1940 Act. If the Company were forced to
sell non-qualifying investments
for compliance purposes, the proceeds from such sale could be significantly less than the current value of such investments. Conversely, if the Company failed to invest a sufficient portion of assets in qualifying assets, it could lose status as a BDC, which would subject the Company to substantially more regulatory restrictions and significantly decrease operating flexibility.
 
Regulatory Risks Relating to the Company
Exemptive Relief
. The Company and the other BDCs for which SLR is the investment adviser (SLR Investment Corp. (Nasdaq: SLRC) (“SLRC”), SCP Private Credit Income BDC LLC (“PCI BDC”) and SLR Private Credit BDC II LLC (“PC BDC,” and, together with SLRC and PCI BDC, the “SLR BDCs”) are substantially limited in their
ability to co-invest in privately
negotiated transactions with affiliated funds other than as permitted by the Order. While the Order permits the Company to participate
in negotiated co-investment transactions with
the SLR BDCs and other affiliated funds, such participation is subject to numerous conditions. If the Company and the SLR BDCs are unable to comply with these conditions or are otherwise unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although SLR will endeavor to allocate investment opportunities in a fair and equitable manner, the Company could be adversely affected to the extent investment opportunities are allocated among the Company and other investment vehicles managed or sponsored by, or affiliated with SLR and its affiliates, including the SLR BDCs, pursuant to the conditions of the Order.
Regulatory Risks Relating to the Company
. Legal and regulatory changes could occur during the term of the Company that may adversely affect the Company. The Company may be subject to, and adversely affected by, new federal, state or non-U.S. laws or new regulation by the SEC, the Commodity Futures Trading Commission (the “CFTC”), the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the FDIC, the European Commission and other federal, state and
non-U.S.
securities or banking regulators, and other governmental regulatory authorities or self-regulatory organizations that supervise the financial markets. The Company may also be adversely affected by changes in the enforcement or interpretation of existing statutes and rules by courts and/or these governmental regulatory authorities or self-regulatory organizations. For example, a recent court decision casts doubt on whether federal or state usury laws apply with respect to loans originated by national banks and then sold to
non-bank
investors such as the Company; this decision could significantly disrupt the bank loan secondary market and adversely impact the Company’s investment program. In addition, the approach taken by a federal court in the “Sun Capital” decision may significantly expand the scope of potential joint and several liability for pension obligations of portfolio companies commonly held by affiliated funds; this decision could create significant uncertainty with respect to such investments and adversely impact the Company. Moreover, legal and regulatory changes may adversely affect the Company’s ability to obtain financing by (among other things) reducing the availability of financing and/or adversely impacting financing costs and other terms.
The financial services industry is subject to extensive regulation. Banking regulators have broad and largely discretionary powers, which include prohibiting “unsafe or unsound” practices; requiring affirmative actions to correct any violation or practice; issuing administrative orders that can be judicially enforced; directing increases in capital; directing the sale of subsidiaries or other assets; limiting dividends and distributions; restricting growth; assessing civil monetary penalties; removing officers and directors; and terminating deposit insurance. These actions and other regulatory requirements could have a material adverse effect on an investment in the Company. The financial institutions in which the Company will invest and with which the Company will transact are subject to laws, regulations, administrative actions and policies in each location in which they operate. The regulatory environment for private investment funds is evolving, and changes in the regulation or taxation of private investment funds may adversely affect the value of the investments held by the Company and the ability of the Company to execute its investment strategy.
In addition, the securities and futures markets are subject to comprehensive statutes, regulations and margin requirements. The SEC and
other U.S. and non-U.S. regulators, self-regulatory organizations
and exchanges are authorized to take extraordinary actions in the event of market emergencies. The regulation of derivatives transactions and funds that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action. The effect of any future regulatory change on the Company could be substantial and adverse.
Risks Related to Changes in Regulatory Policy
. The U.S. government has recently called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new and
difficult-to-quantify
macroeconomic and political risks with potentially
far-reaching
implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas.
 
Financial Services and Government Intervention
. From time to time, certain governments and regulatory authorities, such as the U.S. federal government, the U.S. Federal Reserve and the governments and regulatory authorities of certain member countries of the EU, have taken actions to provide or arrange credit support to financial institutions whose operations have been compromised by credit market dislocations and to restore liquidity and stability to the financial system in such jurisdictions. The implementation of any current or future governmental interventions (which may be significantly altered or terminated prior to implementation or during their terms), and their impact on both the credit markets generally and the Company’s investment program in particular, are uncertain.
U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act
. In response to the recent disruption in the credit markets and the global economic downturn, various agencies and regulatory bodies of the U.S. federal government have taken or are considering taking various actions. These actions include, but are not limited to, the enactment of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), which was signed into law on July 21, 2010, and which imposes a new regulatory framework over the U.S.
financial services industry, non-U.S. financial entities
that are regulated by or affiliated with entities regulated by U.S. financial regulators, and the consumer credit markets in general, and proposed and final regulations adopted thereunder, as well as proposed and final regulations to implement the Basel III regulatory capital accords. Given the broad scope and sweeping nature of these changes and the fact that certain final implementing rules and regulations have not yet been adopted or implemented, the potential impact of these actions on the Adviser and the Company is unknown, and no assurance can be made that the impact of such changes would not have a material adverse effect on the Adviser or the Company. For example, the U.S. Financial Stability Oversight Council (“FSOC”) created by the Dodd-Frank Act has the authority to designate asset management firms as a “systemically important financial institution” (“SIFI”). If the Adviser, or one of its affiliates, were designated as a SIFI, it would be subject to a variety of regulations, including capital requirements and limitations on leverage, which could have a material adverse effect on the ability of the Company to pursue its investment strategy. In addition, the Dodd-Frank Act created a new regulator for the credit industry in the U.S. known as the U.S. Consumer Financial Protection Bureau (“CFPB”). The CFPB may, among other things, regulate interest rates and other charges, require certain disclosures and regulate foreclosure practices. Future regulatory actions authorized by the Dodd-Frank Act (including any regulatory actions or other measures taken by the FSOC and/or the CFPB) may significantly reduce the profitability of the Company and its Portfolio Investments.
Changes to Derivatives Regulation
. Through comprehensive new global regulatory regimes impacting derivatives (
e.g.
, the Dodd-Frank Act, European Market Infrastructure Regulation (“EMIR”), Markets in Financial Investments Regulation (“MIFIR”)/Markets in Financial Instruments Directive
(“MIFID II”)), certain over-the-counter derivatives transactions
in which the Company may engage are either now or will soon be subject to various requirements, such as mandatory central clearing of transactions which include additional margin requirements and in certain cases trading on electronic platforms,
pre-and
post-trade transparency reporting
requirements and mandatory bi-lateral exchange of
initial margin for non-cleared swaps.
The Dodd-Frank Act also created new categories of regulated market participants, such as “swap dealers,” “security-based swap dealers,” “major swap participants,” and “major security-based swap participants” who are subject to significant new capital, registration, recordkeeping, reporting, disclosure, business conduct and other regulatory requirements. The EU and some other jurisdictions are implementing similar requirements. Because these requirements are new and evolving (and some of the rules are not yet final), their ultimate impact remains unclear. However, even if the Company itself is not located in a particular jurisdiction or directly subject to the jurisdiction’s derivatives regulations, the Company may still be impacted to the extent the Company enters into a derivatives transaction with a regulated market participant or counterparty that is organized in that jurisdiction or otherwise subject to that jurisdiction’s derivatives regulations.
Based on information available as of the date of this annual report
on Form 10-K, the
effect of such requirements will be likely to (directly or indirectly) increase the Company’s overall costs of entering into derivatives transactions. In particular, new margin requirements, position limits and significantly higher capital charges resulting from new global capital regulations, even if not directly applicable to the Company, may cause an increase in the pricing of derivatives transactions entered into by market participants to whom such requirements apply or affect the overall ability of the Company to enter into derivatives transactions with certain counterparties. Such new global capital regulations and the need to satisfy the various requirements by counterparties are resulting in increased funding costs and increased overall transaction costs and are significantly affecting balance sheets, thereby resulting in changes to financing terms and potentially impacting the Company’s ability to obtain financing. Administrative costs, due to new requirements such as registration, recordkeeping, reporting, and compliance, even if not directly applicable to the Company, may also be reflected in the Company’s derivatives transactions. New requirements to trade certain derivatives transactions on electronic trading platforms and trade reporting requirements may lead to (among other things) fragmentation of the markets, higher transaction costs or reduced availability of derivatives, and/or a reduced ability to hedge, all of which could adversely affect the performance of certain of the Company’s investing strategies. In addition, changes to derivatives regulations may impact the tax and/or accounting treatment of certain derivatives, which could adversely impact the Company.
 
In November 2020, the SEC adopted new rules regarding the ability of a BDC (or a registered investment company) to use derivatives and other transactions that create future payment or delivery obligations. BDCs that use derivatives will be subject to a
value-at-risk
leverage limit, certain other derivatives risk management program and testing requirements and requirements related to board reporting. These new requirements would apply unless the BDC qualified as a “limited derivatives user,” as defined in the adopted rules. A BDC that enters into reverse repurchase agreements or similar financing transactions would need to aggregate the amount of indebtedness associated with the reverse repurchase agreements or similar financing transactions and could either (i) comply with the asset coverage requirements of Section 18 of the 1940 Act when engaging in reverse repurchase agreements or (ii) choose to treat such agreements as derivative transactions under the adopted rules. Under the adopted rules, a BDC may enter into an unfunded commitment agreement that is not a derivatives transaction, such as an agreement to provide financing to a Portfolio Investment, if the BDC has a reasonable belief, at the time it enters into such an agreement, that it will have sufficient cash and cash equivalents to meet its obligations with respect to all of its unfunded commitment agreements, in each case as it becomes due. If the BDC cannot meet this test, it is required to treat unfunded commitments as a derivatives transaction subject to the requirements of the rule. Collectively, these requirements may limit the Company’s ability to use derivatives and/or enter into certain other financial contracts.
Uncertainty of the U.S. Political Climate
. The current administration has called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new
and difficult-to-quantify
macroeconomic and political risks with
potentially far-reaching
implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although the Company cannot predict the impact, if any, of these changes to its business, they could adversely affect the Company’s business, financial condition, operating results and cash flows. Until the Company knows what policy changes are made and how those changes impact its business and the business of the Company’s competitors over the long term, the Company will not know if, overall, it will benefit from them or be negatively affected by them.
Bad Actor” Restrictions for Private Placements Conducted Under Rule 506 of Regulation D
. An issuer is precluded from conducting offerings that rely on the exemption from registration under the Securities Act provided by Rule 506 of Regulation D (“Rule 506 Offerings”) if a “covered person” of the issuer has been the subject of a “disqualifying event” (each as defined below). “Covered persons” include, among others, the issuer, affiliated issuers, any investment manager or solicitor of the issuer, any director, executive officer or other officer participating in the offering of the issuer, any general partner or managing member of the foregoing entities, any promoter of the issuer and any beneficial owner of 20% or more of the issuer’s outstanding voting equity securities, calculated on the basis of voting power. A “disqualifying event” includes, among other things, certain (a) criminal convictions and court injunctions and restraining orders issued in connection with the purchase or sale of a security or false filings with the SEC, (b) final orders from the CFTC, U.S. Federal banking agencies and certain other regulators that bar a person from associating with a regulated entity or engaging in the business of securities, insurance or banking or that are based on certain fraudulent conduct, (c) SEC disciplinary orders relating to investment advisers, brokers, dealers and their associated
persons, (d) SEC cease-and-desist orders relating
to violations of certain anti-fraud provisions and registration requirements of the U.S. federal securities laws, (e) suspensions or expulsions from membership in a self-regulatory organization (“SRO”) or from association with an SRO member, and (f) U.S. Postal Service false representation orders.
A disqualification will occur only in the case of a disqualifying event of a covered person that occurs on or after September 23, 2013, although issuers must disclose to potential investors in a Rule 506 Offering disqualifying events of covered persons that occurred before September 23, 2013. The rule provides an exception from disqualification if the issuer can show that it did not know and, in the exercise of reasonable care could not have known, that the issuer or any other covered person had a disqualifying event, although an issuer will not be able to establish that it has exercised reasonable care unless it has made, in light of the circumstances, factual inquiry into whether any disqualifications exist.
The Adviser has made, and on a periodic basis will continue to make, inquiries into whether any persons that the Adviser has determined to be affiliated issuers have been subject to any disqualifying events; however, in some circumstances the Adviser’s ability to determine whether the Company would be disqualified from relying on Rule 506 may depend on cooperation of third parties over whom the Company may have limited control and influence.
If any of the Adviser’s covered persons, including any affiliated issuer of the Company, is subject to a disqualifying event, the Company could lose the ability to raise capital in a future Rule 506 offering for a significant period of time and the Company’s business, financial condition and results of operations could be materially and adversely affected.
 
Changes to Accounting Standards
. The Financial Accounting Standards Board’s Accounting Codification Standards and updates, and additional provisions of U.S. generally accepted accounting principles (“U.S. GAAP”) (or to the extent applicable, International Financial Reporting Standards or other applicable accounting or financial reporting standards), that may be adopted in the future may impose additional, or different, specific requirements as to the valuation of assets and liabilities for purposes of U.S. GAAP-compliant financial reporting.
Licensing Requirements
. Various licensing requirements could apply to the Company or the Adviser with respect to investments in, or the origination, holding, servicing and disposing of, loans and similar assets. The licensing requirements could apply depending on the location of the borrower, the location of the collateral securing the loan, or the location where the Company or the Adviser operates or has offices. Moreover, the Company’s ability to invest in certain properties, participate in the secondary mortgage market, obtain financing for investments, lease properties to tenants and/or engage in lending, advisory, servicing and/or broker activities may be subject to the issuance of permits or licenses. If the Company applies for such licenses, this process may be costly and take several months. There is no assurance that the Company will obtain all of the licenses that it desires or that the Company would not experience significant delays in seeking these licenses. In states and other jurisdictions in which it is licensed, the Company or the Adviser is required to comply with applicable laws and regulations, including possible information requirements and consumer protection and anti-fraud laws, which could impose restrictions on the Company’s or the Adviser’s ability to take certain actions to protect the value of its investments in such assets and impose compliance costs. Failure to comply with such laws and regulations could lead to, among other penalties, a loss of the Company’s or the Adviser’s license, which in turn could restrict the Company’s investment options or require the Company to divest assets located in or secured by real property located in that jurisdiction. These risks also apply to issuers and entities in which the Company invests that hold similar assets, as well as any origination company or servicer in which the Company owns an interest.
Reporting Company Filing Requirements
. As a BDC, the Company is subject to the reporting requirements of the 1934 Act and requirements of the Sarbanes-Oxley Act. These requirements may place a strain on systems and resources. The 1934 Act requires that the Company file annual, quarterly and current reports with respect to business and financial condition. The Sarbanes-Oxley Act requires that the Company maintain effective disclosure controls and procedures and internal controls over financial reporting, which are discussed below. In order to maintain and improve the effectiveness of disclosure controls and procedures and internal controls, significant resources and management oversight are required. The Company has implemented procedures, processes, policies and practices for the purpose of addressing the standards and requirements applicable to reporting companies. These activities may divert management’s attention from other business concerns, which could have a material adverse effect on business, financial condition, results of operations and cash flows. The Company incurs significant additional annual expenses related to these steps and, among other things, directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, additional administrative expenses payable to the Administrative Coordinator to compensate them for hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses.
The systems and resources necessary to comply with public company reporting requirements will increase further once the Company ceases to be an “emerging growth company” under the JOBS Act. As long as the Company remains an emerging growth company, it intends to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. The Company will remain an emerging growth company for up to five years following any future IPO (however, the Company does not anticipate engaging in an IPO of its Units), although if the market value of the Units that are held by
non-affiliates
exceeds $700 million as of any June 30 before that time, the Company would cease to be an emerging growth company as of the following December 31.
Additionally, because the Units are registered under the 1934 Act, ownership information for any person who beneficially owns 5% or more of the Units will have to be disclosed in a Schedule 13G or other filings with the SEC. Beneficial ownership for these purposes is determined in accordance with the rules of the SEC, and includes having voting or investment power over the securities. In some circumstances, Unitholders who choose to reinvest their dividends may see their percentage stake in the Company increased to more than 5%, thus triggering this filing requirement. Each Unitholder is responsible for determining their filing obligations and preparing the filings. In addition, Unitholders who hold more than 10% of a class of Units may be subject to Section 16(b) of the 1934 Act, which recaptures for the benefit of the Company profits from the purchase and sale of registered
Units within a six-month period.
Documentation of Internal Controls
. The Company is obligated to maintain proper and effective internal control over financial reporting, including the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act (“Section 404”). The Company is not required to comply with all of the requirements under Section 404 until the date it is no longer an emerging growth company under the JOBS Act. Accordingly, the Company’s internal controls over financial
 
reporting do not currently meet all of the standards contemplated by Section 404 that they will eventually be required to meet. Specifically, the Company is required to conduct annual management assessments of the effectiveness of its internal controls over financial reporting. However, the Company’s independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial reporting until the date it is no longer an emerging growth company under the JOBS Act.
The Company’s internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If the Company fails to maintain the adequacy of its internal controls, including any failure to implement required new or improved controls, or if the Company experiences difficulties in their implementation, the Company’s business and operating results could be harmed and it could fail to meet its financial reporting obligations.
Other Risks Related to Portfolio Investments
High Yield Debt and Unrated Securities
. High yield securities are typically junior to the obligations of companies to senior creditors, trade creditors and employees. High yield securities and unrated securities (which are not rated by a rating agency) may be more susceptible to real or perceived adverse economic and competitive industry conditions than investment-grade securities. A projection of an economic downturn or of a period of rising interest rates, such as the recent economic period, for example, could cause a decline in the prices of high yield securities and unrated securities, because the advent of a recession could lessen the ability of an issuer to make principal and interest payments on its debt obligations. In addition, such securities have historically experienced greater default rates than investment grade securities. The ability of holders of high yield debt to influence a company’s affairs will be substantially less than that of senior creditors, especially during periods of financial distress or following insolvency.
As with other Portfolio Investments, there may not be a liquid market for certain high yield debt which is held by the Company, which could result in the Company being unable to sell such securities for an extended period of time, if at all. In addition, as with other types of Portfolio Investments, the market for high yield debt has historically been subject to disruptions that have caused substantial volatility in the prices of such securities. Consolidation in the financial services industry has resulted in there being fewer market makers for high yield debt, which may result in further risk of illiquidity and volatility with respect to high yield debt held by the Company, and this trend may continue in the future. Furthermore, high yield debt which is held by the Company may not be registered under the Securities Act, and, unless so registered, the Company is not able to sell such high yield debt except pursuant to an exemption from registration under the Securities Act. Unrated securities may be less liquid than comparable rated securities and may also involve the risk that the Adviser may not accurately evaluate the security’s comparative credit rating.
Analysis of creditworthiness of issuers of high yield and unrated securities may be more complex than for issuers of higher-quality fixed income securities. Since it is expected that most of the Company’s assets will not be rated by any rating agency or will be rated below investment grade, the Company is more dependent on the Adviser’s creditworthiness analysis than if the Company invested exclusively in higher-quality and rated securities. Securities rated below investment grade are often referred to as “leveraged loans,” “high yield” or “junk” securities, and may be considered “high risk” compared to debt instruments that are rated investment grade. See “—
General Credit Risk
” above.
Equity-Related Securities
. As with other Portfolio Investments, the value of equity or equity-related securities held by the Company may be adversely affected by actual or perceived negative events relating to the issuer of such securities, the industry or geographic areas in which such issuer operates or the financial markets generally. However, equity securities may be even more susceptible to such events given their subordinate position in the issuer’s capital structure. As such, equity securities generally have greater price volatility than fixed income securities, and the market price of equity securities owned by the Company is more susceptible to moving up or down in a rapid or unpredictable manner. In addition, equity securities
often
lose a significant amount of their value and may become worthless as a result of a bankruptcy proceeding or reorganization.
Convertible Securities Risk
. Convertible securities generally offer lower interest or dividend yields than
non-convertible
debt securities of similar quality. The market values of convertible securities tend to decline as interest rates increase and, conversely, to increase as interest rates decline. However, a convertible security’s market value tends to reflect the market price of the common stock of the issuing company when that stock price approaches or is greater than the convertible security’s “conversion price.” The conversion price is defined as the predetermined price at which the convertible security could be exchanged for the associated stock. As the market price of the underlying common stock declines, the price of the convertible security tends to be influenced more by the yield of the convertible security. Thus, it may not decline in price to the same extent as the underlying common stock. Generally, in the event of a liquidation of the issuing company, holders of
 
convertible securities would be paid before the company’s common stockholders but after holders of any senior debt obligations of the company. Consequently, the issuer’s convertible securities generally entail less risk than its common stock but more risk than its debt obligations. There is also a risk that, under certain circumstances, a bankruptcy court may order that convertible securities are treated as equity.
The Company may invest in synthetic convertible securities, which are created through a combination of separate securities that possess the two principal characteristics of a traditional convertible security,
i.e.
, an income-producing security (“income-producing component”) and the right to acquire an equity security (“convertible component”). The income-producing component is achieved by investing in
non-convertible,
income-producing securities such as bonds, preferred stocks and money market instruments. The convertible component is achieved by purchasing warrants or options to buy common stock at a certain exercise price, or options on a stock index. The values of synthetic convertible securities will respond differently to market fluctuations than a traditional convertible security because a synthetic convertible is composed of two or more separate securities or instruments, each with its own market value. Synthetic convertible securities are also subject to the risks associated with derivatives. In addition, if the value of the underlying common stock or the level of the index involved in the convertible element falls below the strike price of the warrant or option, the warrant or option may lose all value.
Preferred Securities Risk
. In addition to credit risk, investment in preferred stocks involves certain other risks. Certain preferred stocks contain provisions that allow an issuer under certain conditions to skip or defer distributions. If the Company owns preferred stock that is deferring its distribution, the Company may be required to report income for U.S. federal income tax purposes despite the fact that it is not receiving current income on this position. Preferred stock often is subject to legal provisions that allow for redemption in the event of certain tax or legal changes or at the issuer’s call. In the event of redemption, the Company may not be able to reinvest the proceeds at comparable rates of return. Preferred stock is subordinated to bonds and other debt securities in an issuer’s capital structure in terms of priority for corporate income and liquidation payments and, therefore, will be subject to greater credit risk than those debt securities. Preferred stock may trade less frequently and in a more limited volume and may be subject to more abrupt or erratic price movements than many other securities, such as common stocks, corporate debt securities and U.S. government securities.
Forwards and Derivatives Transactions
. The Company may engage in a variety of derivatives transactions. A
derivative
is a financial contract the value of which depends upon, or is derived from, the value of underlying assets, reference rates or indices. Derivatives may relate to securities, interest rates, currencies or currency exchange rates, inflation rates, commodities and related indices, and include foreign currency contracts, swap contracts, options, forward and futures contracts (including options thereon), repurchase or reverse repurchase
agreements or other over-the-counter contracts. The
Company may use derivatives for many purposes, including as a substitute for direct investment, as a way to adjust its exposure to various securities, markets and currencies without actually having to sell existing investments and/or make new investments, and as a means to hedge other investments and to manage liquidity and excess cash. The Company’s use of derivatives may result in losses, reduce the Company’s return, and/or increase the volatility of the Company (particularly since many derivatives are inherently leveraged), especially in unusual or extreme
market
conditions
.
All derivatives transactions involve risks different from, and potentially greater than, the risks associated with investing directly in securities and other more traditional assets, including:
Market Risk
. This is the general risk that the value of a particular investment or transaction will change in a way detrimental to the Company’s interests.
Management Risk
. Derivatives contracts are specialized contracts that require investment techniques and risk analyses with additional levels of complexity associated with the underlying investments. In addition to risks associated with the underlying instruments, counterparty and unsecured risk (among others) need to be computed and tracked in relation to the Company’s overall risk profile.
Documentation Risk
. Many derivatives transactions also have documentation risk. Because contracts for
over-the-counter
derivatives transactions are individually negotiated with specific counterparties, there exists the risk that the parties may interpret contractual terms (
e.g.
, the definition of default) differently than the Company. If that occurs, the cost and unpredictability of the legal proceedings required for the Company to enforce its contractual rights may lead the Company to decide not to pursue its claims against the counterparty. The Company, therefore, assumes the risk that it may be unable to obtain payments the Adviser believes are owed to it under derivatives transactions, or those payments may be delayed or made only after the Company has incurred the costs of litigation. Also, payment amounts calculated in connection with standard industry conventions for resolving contractual issues (
e.g.
, ISDA Protocols and auction processes) may be different than would be realized if a counterparty were required to comply with the literal terms of the derivatives transaction (
e.g.
, physical delivery). There is little case law interpreting the terms of most derivatives or characterizing their tax treatment.
 
Regulatory Risk
. The derivatives market is subject to various risks related to existing as well as new and evolving regulation both within and outside the U.S. Additional regulation of the derivatives markets may make derivatives more costly, may limit the availability of derivatives, or may otherwise adversely affect the value or performance of derivatives. Any such adverse future developments could impair the effectiveness of a Company’s derivatives transactions and cause the Company to lose value. They may also render certain strategies in which the Company might otherwise engage impossible or so costly that they will no longer be economical to implement. See “—
Changes to Derivatives Regulation
” above.
Other Risks
. Derivatives also involve the risk that changes in their value may not correlate perfectly with the assets, rates or indices they are designed to track. Suitable derivatives may not be available in all circumstances. Under the terms of certain contracts governing derivatives transactions, the occurrence of certain events with respect to the Company (such as a decline in the Company’s NAV) may cause the Company’s derivatives transactions to be terminated early, including at an inopportune time or at an unfavorable price.
Warrants and Rights
. The Company may purchase or otherwise receive warrants or rights. Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a stated price. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of options. Unlike most options, however, warrants and rights are issued in specific amounts, and warrants generally have longer terms than options. Warrants and rights are not likely to be as liquid as exchange-traded options backed by a recognized clearing agency. In addition, the terms of warrants or rights may limit the Company’s ability to exercise the warrants or rights at such time, or in such quantities, as the Company would otherwise wish.
Risks
 Relating to Reference Rates
. The London Interbank Offered Rate (“LIBOR”) is an index rate that historically was widely used in lending transactions and was a common reference rate for setting the floating interest rate on private loans. LIBOR was typically the reference rate used in floating-rate loans extended to the Company’s Portfolio Investments.
The ICE Benchmark Administration (“IBA”) (the entity that is responsible for calculating LIBOR) ceased providing overnight, one, three, six and twelve months USD LIBOR tenors on June 30, 2023. In addition, the United Kingdom’s Financial Conduct Authority (“FCA”), which oversees the IBA, now prohibits entities supervised by the FCA from using LIBORs, including USD LIBOR, except in very limited circumstances.
In the United States, SOFR is the preferred alternative rate for LIBOR. SOFR is a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. SOFR is published by the Federal Reserve Bank of New York each U.S. Government Securities Business Day, for transactions made on the immediately preceding U.S. Government Securities Business Day. Alternative reference rates that may replace LIBOR, including SOFR for USD transactions, may not yield the same or similar economic results as LIBOR over the lives of such transactions.
As of the filing date of this annual report on Form
10-K,
many of the Company’s loans that referenced LIBOR have been amended to reference the forward-looking term rate published by CME Group Benchmark Administration Limited based on SOFR (“CME Term SOFR”) or CME Term SOFR plus a fixed spread adjustment. CME Term SOFR rates are forward-looking rates that are derived by compounding projected overnight SOFR rates over one, three, and six months taking into account the values of multiple consecutive, executed,
one-month
and three-month CME Group traded SOFR futures contracts and, in some cases,
over-the-counter
SOFR Overnight Indexed Swaps as an indicator of CME Term SOFR reference rate values. CME Term SOFR and the inputs on which it is based are derived from SOFR. Since CME Term SOFR is a relatively new market rate, there will likely be no established trading market for credit agreements or other financial instruments when they are issued, and an established market may never develop or may not be liquid. Market terms for instruments referencing CME Term SOFR rates may be lower than those of later-issued CME Term SOFR indexed instruments. Similarly, if CME Term SOFR does not prove to be widely used, the trading price of instruments referencing CME Term SOFR may be lower than those of instruments indexed to indices that are more widely used. Further, the composition and characteristics of SOFR and CME Term SOFR are not the same as those of LIBOR. Even with the application of a fixed spread adjustment, LIBOR and CME Term SOFR will not have the same composition and characteristics, and there can be no assurance that the replacement rate, as so adjusted, will be a direct substitute for LIBOR.
There can be no guarantee that SOFR will not be discontinued or fundamentally altered in a manner that is materially adverse to the interests of investors in loans referencing SOFR. If the manner in which SOFR or CME Term SOFR is calculated is changed, that change may result in a reduction of the amount of interest payable on such loans and the trading prices of the SOFR Loans. In addition, there can be no guarantee that loans referencing SOFR or CME Term SOFR will continue to reference those rates until maturity or that, in the future, the Company’s loans will reference benchmark rates other than CME Term SOFR. Should any of these events occur, the Company’s loans, and the yield generated thereby, could be affected. Specifically, the anticipated yield on the Company’s loans may not be fully realized and the Company’s loans may be subject to increased pricing volatility and market risk.
 
Risks Related to Economic Recessions
. The recent macroeconomic environment is characterized by record-high inflation, supply chain challenges, labor shortages, high interest rates, foreign currency exchange volatility, volatility in global capital markets and growing recession risk. The risks associated with the Company’s and the Portfolio Investments’ businesses are more severe during periods of economic slowdown or recession.
Many of the Company’s Portfolio Investments may be susceptible to economic slowdowns or recessions and may be unable to repay its loans during these periods. The global outbreak
of COVID-19
has disrupted economic markets, and the prolonged economic impact is uncertain. Many manufacturers of goods have seen a downturn in production due to the suspension of business and temporary closure of factories globally in an attempt to curb the continued spread of the virus. As a result of these disruptions, the
Company’s non-performing
assets may increase and the value of its portfolio may decrease during these periods as the Company is required to record the values of its investments. Adverse economic conditions also may decrease the value of collateral securing some of the Company’s loans and the value of its equity investments at fair value. Economic slowdowns or recessions could lead to financial losses in the Company’s portfolio and a decrease in revenues, net income and assets. Unfavorable economic conditions also could increase the Company’s funding costs, limit its access to the capital markets or result in a decision by lenders not to extend credit to the Company. These events could prevent the Company from increasing investments and result in its receipt of a reduced level of interest income from the Company’s Portfolio Investments and/or losses or charge offs related to its investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations.
A Portfolio Investment’s failure to satisfy financial or operating covenants imposed by the Company or other lenders could lead to defaults and, potentially, acceleration of the time when the loans are due and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize the Portfolio Investment’s ability to meet its obligations under the debt that the Company holds. The Company may incur additional expenses to the extent necessary to seek recovery upon default or to negotiate new terms with a defaulting Portfolio Investment. In addition, if one of the Company’s Portfolio Investments were to go bankrupt, depending on the facts and circumstances, including the extent to which the Company actually provided significant managerial assistance to that Portfolio Investment, a bankruptcy court
might re-characterize
its debt holdings and subordinate all or a portion of the Company’s claim to that of other creditors.
These Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive research and development, manufacturing, marketing and service capabilities and greater number of qualified and experienced managerial and technical personnel. They may need additional financing that they are unable to secure and that the Company is unable or unwilling to provide, or they may be subject to adverse developments unrelated to the technologies they acquire.
The Company’s business is directly influenced by the economic cycle and could be negatively impacted by a downturn in economic activity in the U.S. as well as globally. Fiscal and monetary actions taken by U.S.
and non-U.S.
government and regulatory authorities could have a material adverse impact on the Company’s business. To the extent uncertainty regarding the U.S. or global economy, including as a result of
the COVID-19
pandemic, certain regional bank failures, the Russian invasion of Ukraine and the ongoing war in the Middle East, negatively impacts consumer confidence and consumer credit factors, the Company’s business, financial condition and results of operations could be adversely affected. Moreover, Federal Reserve policy, including with respect to certain interest rates and the decision to end its quantitative easing policy, along with the general policies of the current Presidential administration, may also adversely affect the value, volatility and liquidity of dividend- and interest-paying securities. Market volatility, periods of rising interest rates, such as the recent economic period, and/or a return to unfavorable economic conditions could adversely affect its business.
Risks Related to the U.S.’ Debt Ceiling
. The significant debt in the U.S. is expected to hinder growth in the U.S. for the foreseeable future. In the future, the U.S. government may not be able to meet its debt payments unless the federal debt ceiling is raised. If legislation increasing the debt ceiling is not enacted, as needed, and the debt ceiling is reached, the U.S. federal government may stop or delay making payments on its obligations. Any default by the U.S. government on its obligations or any prolonged U.S. government shutdown could negatively impact the U.S. economy and our Portfolio Investments. In addition, concerns over the United States’ debt ceiling and budget-deficit have driven downgrades by rating agencies to the U.S. government’s credit rating. Downgrades by rating agencies to the U.S. government’s credit rating or concerns about its credit and deficit levels in general could cause interest rates and borrowing costs to rise, which may negatively impact both the perception of credit risk associated with our debt portfolio and our ability to access the debt markets on favorable terms. In addition, a decreased U.S. government credit rating, any default by the U.S. government on its obligations, or any prolonged U.S. government shutdown, could create broader financial turmoil and uncertainty, which may weigh heavily on our financial performance and the value of our common stock. U.S. debt ceiling and budget deficit concerns have
increased
the possibility of additional credit-rating downgrades and economic slowdowns or a recession in the U.S.
 
Risks Related to Portfolio Investment Monitoring and Involvement
. The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings. See “—
Control Positions
” below. The Company’s investment program may from time to time enable it to place representatives on the creditors’ or steering committees and/or the boards of directors of certain companies in which it has invested. While such involvement may enable the Adviser to enhance the value of the Company’s Portfolio Investments, it may also prevent the Company from freely disposing of such Portfolio Investments, while also exposing it to legal claims and adverse publicity (including claims of breach of duty of loyalty, securities claims and other management-related claims). In addition, if the Adviser’s representatives are serving as directors of companies which are in the “zone of insolvency,” such persons may have a fiduciary obligation to the creditors of such entity as well as the shareholders of such entity. The interests of such parties may be adverse to the interests of the Company. These fiduciary obligations may conflict with the Adviser’s obligation to the Company, and the Adviser may cause its representatives to resign from such positions in order to reduce such conflicts. Any involvement by the Adviser’s representatives (including through serving on a board of directors, or permanent or ad hoc creditors’ or steering committees) may also entail a substantial time commitment, which may limit such representatives’ ability to participate in other Company matters and investments.
Risks Associated with Bankruptcy and Insolvency Cases
. If any issuers of securities held by the Company or any counterparties to the derivatives transactions and other transactions entered into by the Company, or any custodians of the Company’s assets or any obligors in connection with Portfolio Investments are involved in bankruptcy proceedings, the Company will be subject to certain risks inherent in bankruptcy proceedings, including the duration, administrative costs and impact of a bankruptcy case on the value of assets administered in bankruptcy or on a company’s value (including that a bankruptcy case may damage or diminish a company’s relationship with its employees, customers and/or suppliers). Many of the events within a bankruptcy or insolvency case are adversarial and often beyond the control of the creditors. While creditors generally are afforded an opportunity to object to significant actions, or to demand that certain actions take place, there can be no assurance that a court would not approve actions or inaction which may be contrary to the interests of the Company.
Generally, the duration of a bankruptcy or insolvency case can only be roughly estimated. The reorganization of a company usually involves the design of a business plan, the development and negotiation of a plan of reorganization, plan approval by creditors and confirmation by the court. This process can involve substantial legal, professional and administrative costs to the company and to the Company; is subject to unpredictable and lengthy delays; and during the process the company’s competitive position may erode, key management may depart and the company may not be able to invest adequately. In some cases, the company may not be able to reorganize and may be required to liquidate assets. In addition, the debt of companies in financial reorganization may, in some cases, not pay current interest and other charges, may not even accrue interest and other charges during reorganization, may be
relieved of paying pre-payment premiums and
may be adversely affected by an erosion of the issuer’s fundamental value. Further, a debtor seeking to reorganize under U.S. federal bankruptcy law will frequently obtain a “first day” order from the bankruptcy court limiting trading in claims against, and shares of, the debtor in order to maximize the debtor’s ability to utilize net operating losses following a successful reorganization.
During the pendency of a bankruptcy case, an automatic stay will prevent all creditors from taking action against the debtor to foreclose on collateral or otherwise to collect on amounts owed to such creditors. Unless a creditor’s claim in such case is secured by assets having a value in excess of such claim, or the bankruptcy estate is determined to be solvent, no interest will be permitted to accrue and, therefore, a creditor’s return on investment can be adversely affected by the passage of time during which the plan of reorganization of the debtor is being negotiated, approved by the creditors and confirmed by the bankruptcy court.
The priority of perfected liens held by secured creditors as of the commencement of the bankruptcy case is typically recognized in a bankruptcy case, unless avoided. Occasionally, however, a court will
allow a debtor-in-possession financing to
receive
liens that prime pre-existing, valid liens.
The administrative costs in connection with a bankruptcy case are frequently high and will generally be paid out of the debtor’s estate prior to any return to creditors (other than out of assets or proceeds thereof which are subject to valid and enforceable liens and other security interests) and equity holders. In addition, certain unsecured claims that have priority by law over the claims of certain creditors (for example, claims arising post-petition and certain claims for taxes) may be quite high.
U.S. bankruptcy law permits the classification of “substantially similar” claims in determining the classification of claims in a reorganization for the purpose of voting on a plan of reorganization. Because the standard for classification is vague, there exists a significant risk that the Company’s influence with respect to a class of securities can be lost by the inflation of the number and the amount of claims in, or other gerrymandering of, the class.
 
Although a creditor is not typically compelled to release direct claims it may have against
non-debtor
third parties, in certain circumstances a court may compel such release in the context of a plan of reorganization.
Claims in bankruptcy cases are often paid at less than par and, depending on the debtor’s assets and liabilities, there may be no recovery at all for some classes of creditors. The claims of even over-secured secured creditors are often paid out over time, and may receive debt securities that will trade below par. Initially, only the debtor may file a proposed plan of reorganization. While the U.S. Bankruptcy
Code permits other parties-in-interest to file
proposed plans of reorganization after the debtors’ “exclusive period” to do so ends, bankruptcy courts often extend the debtor’s exclusive period, which effectively permits only the debtor to file a proposed reorganization plan. While creditors can vote on the plan of reorganization, the unanimous consent of all creditor classes is not necessarily required for the bankruptcy court to confirm the plan. Therefore, a plan can, subject to the provisions of the U.S. Bankruptcy Code, be “crammed down” on dissenting classes of creditors. Moreover, minority members of a class may be deemed to be members of an accepting class if the requisite majority vote is acquired.
Even if a class of claims is entitled to a recovery in a reorganization or liquidation proceeding, such recovery could be in the form of instruments or interests different from the form of instrument or interest which formed the basis for the claim, including debt securities, equity securities, convertible securities, warrants, options, cash, interests in litigation claims or trusts formed to pursue such litigation claims, interests in liquidation trusts, or other property or interests, any of which could be illiquid and/or difficult to value. Furthermore, the terms of instruments or interests distributed in a bankruptcy or insolvency proceeding may differ from prevailing market terms for similar instruments or interests, and may have a market value of less than par.
The Company may be presented with the opportunity to make new investments in connection with the reorganization or liquidation of an issuer of Portfolio Investments, including, without limitation, through a rights offering, litigation financing, bridge financing or other exit financing. The Company may make such investments as
part of an in-court or out-of-court restructuring of
an issuer of Portfolio Investments, and any such investment will be subject to the same risks as other Portfolio Investments of the Company.
Contractual subordination provisions are enforceable when a borrower is in bankruptcy, as are most inter-creditor agreement terms. Furthermore, there are instances where creditors and equity holders may lose their ranking and priority when they take over management and functional operating control of a debtor. In those cases where the Company, by virtue of such action, is found to exercise “domination and control” of a debtor, the Company may lose its priority if the debtor or other creditors can demonstrate that the debtor’s business was adversely impacted or other creditors and/or equity holders were harmed by improper or unfair actions of the Company, whether or not the Company is found to be a controlling party of the debtor. In addition, loans extended to a financially distressed borrower by an entity that owns an equity interest in the borrower may be reclassified as having been an equity capital contribution, rather than a debt obligation.
Notwithstanding the corporate structure of various debtor entities, such as special purpose entities created to hold assets and to structure for bankruptcy remoteness, such entities may, in certain cases, be consolidated in bankruptcy proceedings, which can affect the outcome of such proceedings and the amounts ultimately received by creditors. In addition, if a claim can be asserted against only a parent holding entity, such claim may be structurally subordinated to claims against a subsidiary entity that owns assets.
The U.S. Bankruptcy Code and other laws and regulations affecting debtors’ and creditors’ rights are subject to change, including by way of legislative action or judicial interpretation. In addition, governmental actors have recently shown a willingness to intervene in bankruptcy-related matters (for example, the U.S. government’s bailouts of General Motors and Chrysler), which may increase uncertainty regarding the enforcement of creditors’ rights and the bankruptcy process generally. Any such actions could alter the expected outcome or introduce greater uncertainty regarding the expected outcome of an investment situation of the Company, which may adversely affect such investment or the Company’s investment program.
Lack of Control over Investments
. The Company invests in debt securities, but
may hold a non-controlling interest in
one or more Portfolio Investments. Such investments may not give the Company the ability to influence the management of the company or to elect a representative to the Board. In addition, the management of the company or its shareholders may have economic or business interests which are inconsistent with those of the Company, and they may be in a position to take action contrary to the Company’s objectives. A
non-controlling
interest may be especially adverse to the Company in circumstances, such as certain stressed or distressed situations, where an element of control or influence might be beneficial to the subject investment.
 
Control Positions
. The Company does not expect to, but may have a controlling interest in a Portfolio Investment (because of its equity ownership, representation on the board of directors and/or contractual rights) either on its own or, in certain cases, with another financial partner or investment fund (
e.g.,
 in accordance with the Company’s receipt of equity in connection with a restructuring). The exercise of control over a company may impose additional risks of liability for environmental damage, product defects, failure to supervise management, pension and other fringe benefits, violation of governmental regulations (including securities laws) or other types of related liability. If these liabilities were to arise, the Company might suffer a significant loss in such investment. In addition, if employees of the Adviser serve as directors of certain of the Portfolio Investments, including public companies, they will have duties to persons other than the Company.
To the extent that the Company owns a controlling stake in or is deemed an affiliate of a particular company, it may also be subject to certain additional bankruptcy or securities laws restrictions that could affect both the liquidity of the Company’s interest and the Company’s ability to liquidate its interest without adversely impacting the price thereof, including insider trading restrictions, the affiliate sale restrictions of Rule 144 of the Securities Act and the disclosure requirements of Sections 13 and 16 of the 1934 Act. Further, to the extent that affiliates of the Company or the Adviser are subject to such restrictions, the Company, by virtue of its affiliation with such entities, may be similarly restricted, regardless of whether the Company stands to benefit from such affiliate’s ownership.
If the Company, alone or as part of a group acting together for certain purposes, becomes the beneficial owner of more than 10% of certain classes of securities of a U.S. public company or places a director on the board of directors of such a company, the Company may be subject to certain additional reporting requirements and to liability for short-swing profits under Section 16 of the 1934 Act. Furthermore, the Company may also be subject to similar reporting requirements and
other limitations in non-U.S. jurisdictions where
it holds significant positions in companies in such jurisdictions.
The exercise of control over a company, depending upon the amount and type of securities owned by the Company, contractual arrangements between the company and the Company, and other relevant factual circumstances, could result in an extension to one year of the
90-day bankruptcy preference
period with respect to payments made to the Company. See “—
Fraudulent Conveyance and Preference Considerations
” below. The exercise of control over a company may also provide grounds for challenges to the priority and enforceability of Portfolio Investments or other claims the Company may have against the company if it is subject to a bankruptcy case or other insolvency proceeding. See “—
Lender Liability Considerations and Equitable Subordination
” below.
Lender Liability Considerations and Equitable Subordination
. In recent years, a number of judicial decisions in the U.S. have upheld the right of borrowers to sue lending institutions on the basis of various evolving legal theories (collectively termed “lender liability”). Generally, lender liability is founded upon the premise that an institutional lender has violated a duty (whether implied or contractual) of good faith and fair dealing owed to the borrower or has assumed a degree of control over the borrower resulting in creation of a fiduciary duty owed to the borrower or its other creditors or shareholders. In addition, courts have in some cases applied the doctrine of equitable subordination to subordinate the claim against a borrower of a creditor, including a lending institution, to claims of other creditors of the borrower when the creditor is found to have engaged in unfair, inequitable or fraudulent conduct. There can be no assurance as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire such claims engaged in any such conduct and, if it did, as to whether the Company would be subject to claims that the Company’s Portfolio Investments should be equitably subordinated based on such conduct. Because of the nature of certain of the Company’s Portfolio Investments, the Company could be subject to allegations of lender liability or to claims that the Company’s Portfolio Investments should be
equitably
subordinated.
Fraudulent Conveyance and Preference Considerations
. Various federal and state laws enacted for the protection of creditors may apply to the purchase of the Company’s Portfolio Investments, or payments or liens related thereto, by virtue of the Company’s role as a creditor with respect to the borrowers under such Portfolio Investments. If a court, in a lawsuit brought by an
unpaid creditor, a debtor-in-possession, a trustee
in bankruptcy, or their respective representatives, were to find that the borrower took any action to intentionally delay or frustrate recoveries by creditors, or did not receive fair consideration or reasonably equivalent value for incurring indebtedness evidenced by an investment and the grant of any security interest or other lien securing such investment, and, after giving effect to such indebtedness and/or grant of any security interest or other lien, the issuer or obligor (i) was insolvent, (ii) was engaged in a business for which the remaining assets of such issuer constituted unreasonably small capital or (iii) intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature, such court could, under certain circumstances, invalidate, in whole or in part, such indebtedness and such security interest or other lien as fraudulent conveyances, could subordinate such indebtedness to existing or future creditors of the borrower and could allow the borrower to recover amounts previously paid by the borrower to the creditor (including to the Company) in satisfaction of such indebtedness or proceeds of such security interest or other lien previously applied in satisfaction of such indebtedness.
 
The measure of insolvency for purposes of the foregoing will vary. Generally, an issuer or obligor would be considered insolvent at a particular time if the sum of its debts were then greater than all of its property at a fair valuation, or if the present fair saleable value of its assets were less than the amount that would be required to pay its probable liabilities on its existing debts as they became absolute and matured. There can be no assurance as to what standard a court would apply in order to determine whether the issuer or obligor was “insolvent” after giving effect to the incurrence of the indebtedness and/or the granting of any security interest or other lien or that, regardless of the method of valuation, a court would not determine that the issuer was “insolvent” upon giving effect to such incurrence of indebtedness and/or grant of security interests or other lien.
The Company may invest in bank debt or other indebtedness issued by a borrower which is guaranteed by other entities within the borrower’s corporate family. In such circumstances, the borrower often has little or no assets other than the stock of its subsidiaries and, as a result, any recovery is often available only, if at all, from the entities that guaranteed the indebtedness. There is a risk, however, that the obligations of such guarantors and any security interests or other liens issued by the guarantors to secure such obligations may be avoided as fraudulent conveyances in the event that a court were to determine that such guarantors did not receive reasonably equivalent value in exchange for the issuance of the guarantees and for the security interests or other liens. A court could determine that the guarantors did not receive reasonably equivalent value or fair consideration in incurring the obligations and granting the security interests or other liens despite the existence of “indirect” benefits to the guarantors, such as the strengthening of the corporate enterprise in the transaction. Additionally, provisions in guarantees and other similar documents governing similar obligations by which fraudulent conveyance exposure is sought to be reduced or
eliminated, such as so-called “savings clauses,”
may not be enforceable. As a result, the Company’s Portfolio Investment in corporate bank debt or other indebtedness could be subject to avoidance as a fraudulent conveyance.
If a transaction is found to have been a fraudulent conveyance, the transferee may be compelled to return the value of the assets transferred as of the time of the transfer, even if the then current value is substantially less. In addition, unless the transferee is deemed to be a “good faith” transferee, the return of the asset may not even provide for the compensation back to the transferee of the value paid to the transferor.
In addition, in the event of the insolvency (as determined by a court based on the law of the jurisdiction which is being applied) of an issuer of a Portfolio Investment, payments made on the Company’s Portfolio Investment, or new liens granted, could be subject to avoidance as a “preference” if made within a certain period of time (which may be as long as one year) before insolvency, depending on a number of factors.
In general, if payments on a Company’s Portfolio Investment are avoidable, whether as a fraudulent conveyance or preference, such payments can be recaptured either from the initial recipient (such as the Company) or from subsequent transferees of such payments, including Unitholders. Additionally, if the grant of a security interest or other lien is avoidable, whether as a fraudulent conveyance or preference, the value of the security interest or other lien can be recovered from the initial transferee or the entity for whose benefit such transfer was made (such as the Company), and such recovery could include the diminution in value of the property which was subject to the security interest or other lien from the date of transfer.
There can be no assurance that a successful cause of action for fraudulent conveyance or preference will not occur, or as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire a Portfolio Investment engaged in any conduct to give rise to such causes of action, and if it did, as to whether such causes of action could be asserted against the Company and/or the Unitholders.
Portfolio Investment Risk
. The Company’s Portfolio Investments may involve a high degree of business and financial risk. Portfolio Investments may be in early stages of development, may have operating losses or significant variations in operating results and may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence. Portfolio Investments will also include companies that are experiencing or are expected to experience financial difficulties, which may never be overcome. In addition, many of them will have weak financial conditions and may require substantial additional capital to support their operations, to finance expansion or to maintain their competitive positions. Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive development, manufacturing, marketing, and other capabilities and a larger number of qualified managerial and technical personnel. In addition, Portfolio Investments in which the Company invests may be required to comply with
numerous U.S. and non-U.S. statutory and
regulatory standards. A Portfolio Investment could be materially and adversely affected as a result of statutory or regulatory changes or changes in judicial or administrative interpretations of existing laws and regulations that impose more comprehensive or stringent requirements on such Portfolio Investment, the markets in which such Portfolio Investment operates or such Portfolio Investment’s industry generally.
 
There can be no assurance that a Portfolio Investment’s management team will be able to operate such Portfolio Investment successfully. In addition, instances of fraud or other illegal practices committed by the management team of a Portfolio Investment may undermine the Company’s investment in such Portfolio Investment and the Company may suffer losses. Additionally, Portfolio Investments need to attract, retain and develop executives and members of their management teams. There can be no assurance that a Portfolio Investment will be able to attract and develop suitable
members
of its management team, which may adversely affect the Company.
Zero-Coupon Bonds, Deferred Interest Rate Bonds and
 Payment-In-Kind
 Securities
. Zero-coupon bonds pay interest only at maturity rather than at intervals during the life of the security. Deferred interest rate bonds generally provide for a period of delay before the regular payment of interest begins. PIK securities are debt obligations that pay “interest” in the form of other debt obligations, instead of in cash. Each of these instruments is normally issued and traded at a deep discount from face value. Zero-coupon bonds, deferred interest rate bonds and PIKs allow an issuer to avoid or delay the need to generate cash to meet current interest payments and, as a result, may involve greater credit risk than bonds that pay interest currently or in cash. In addition, such investments experience greater volatility in market value due to changes in interest rates than debt obligations that provide for regular payments of interest.
To the extent the Company invests in OID instruments, including PIK, zero coupon bonds, and debt securities with attached warrants, investors will be exposed to the risks associated with the inclusion of
such non-cash income
in taxable and accounting income prior to receipt of cash, including the following:
 
   
The interest payments deferred on a PIK loan are subject to the risk that the borrower may default when the deferred payments are due in cash at the maturity of the loan;
 
   
The interest rates on PIK loans are higher to reflect the time-value of money on deferred interest payments and the higher credit risk of borrowers who may need to defer interest payments;
 
   
PIK instruments may have unreliable valuations because the accruals require judgments about ultimate collectability of the deferred payments and the value of the associated collateral;
 
   
An election to defer PIK income payments by adding them to principal increases the Company’s gross assets and, thus, increases future base fees to the Adviser and, because income payments will then be payable on a larger principal amount, the PIK election also increases the Adviser’s future income incentive fees at a compounding rate;
 
   
Market prices of OID instruments are more volatile because they are affected to a greater extent by interest rate changes than instruments that pay interest periodically in cash;
 
   
The deferral of interest on a PIK loan
increases its loan-to-value ratio,
which is a measure of the riskiness of a loan; and
 
   
OID creates the
risk of non-refundable cash
payments to the Adviser
based on non-cash accruals
that may never be realized.
Money Market and Other Liquid Instruments
. The Company may invest its assets in such liquid securities as the Adviser may deem to be advisable, including fixed income securities, money market instruments, money market mutual funds, and debt securities issued or guaranteed by the U.S., certain U.S. government agencies or instrumentalities. Money market instruments are short-term fixed income obligations, which generally have remaining maturities of one year or less, and may include commercial paper, certificates of deposit, and bankers’ acceptances issued by domestic branches of U.S. banks that are members of the FDIC. The Company may be prevented from achieving its investment objective during any period in which its assets are not substantially invested in accordance with its investment strategy. Notwithstanding their general high-quality nature, money market funds and liquid securities are subject to the risk of loss.
Among other liquid investments, the Company may invest cash, pending investment, reinvestment or distribution thereof or in connection with the maintenance of reserves, in money fund products offered from time to time by its Custodian, including the use of bank “sweep” short-term offerings.
Pooled Investment Vehicles and Pass-through Entities
. The Company may invest or take short positions in pooled investment vehicle and pass-through entities, including affiliated or third-party unregistered investment vehicles, investment companies registered under the 1940 Act (including
exchange-traded funds and closed-end companies) and
master limited partnerships (“Pooled Investment Vehicles”). To the extent the Company invests directly in Pooled Investment Vehicles and other “pass-through” entities which are treated as partnerships for U.S. federal income taxation purposes, the Company must rely on such vehicles to deliver to it certain tax information that is necessary to complete the Company’s own tax returns. If this information is not delivered to the Company in a timely fashion, the Company will be delayed in providing tax information to the investors.
 
U.S. Government and Agency Securities
. The Company may invest in debt securities issued or guaranteed by certain U.S. government agencies, instrumentalities and sponsored enterprises. Some U.S. government securities, such as Treasury bills, notes and bonds and MBS guaranteed by Ginnie Mae, are supported by the full faith and credit of the U.S.; others are supported by the right of the issuer to borrow from the U.S. Treasury; others are supported by the discretionary authority of the U.S. government to purchase the agency’s obligations; and still others are supported only by the credit of the instrumentality. Although U.S. government-sponsored enterprises, such as Fannie Mae and Freddie Mac, may be chartered or sponsored by Congress, they are not funded by Congressional appropriations, and their securities are not issued by the U.S. Treasury or supported by the full faith and credit of the U.S. government and involve increased credit risks. In addition, certain governmental entities have been subject to regulatory scrutiny regarding their accounting policies and practices and other concerns that may result in legislation, changes in regulatory oversight and/or other consequences that could adversely affect the credit quality, availability or investment character of securities issued by these entities.
Restricted Securities
. It is expected that a significant portion of the Company’s Portfolio Investments will
b
e securities (“restricted securities”) that have not been registered for sale to the public under the Securities Act pursuant to an exemption from registration (including Section 4(a)(2) of, or Rule 144A under, the Securities Act). Restricted securities are generally only sold to institutional investors in private sales from the issuer or from an affiliate of the issuer. These securities may be less liquid than securities registered for sale to the general public. The liquidity of a restricted security may be affected by a number of factors, including: (i) the credit quality of the issuer; (ii) the frequency of trades and quotes for the security; (iii) the number of dealers willing to purchase or sell the security and the number of other potential purchasers; (iv) dealer undertakings to make a market in the security; and (v) the nature of the security and the nature of marketplace trades. Also, restricted securities may be difficult to value because market quotations may not be readily available.
In addition, a debtor in a reorganization case may be granted a trading restriction order by a bankruptcy court in order to protect such debtor’s net operating losses (a “NOL Order”). Such an order may prohibit or severely restrict the ability of some creditors to sell their claims and interests in the debtor. The Company’s ability to transfer its interests in such a debtor may be impaired, delayed or prohibited as a consequence of a NOL Order. The Company may also incur added expenses if it attempts to challenge or limit the scope of a NOL Order, and such an attempt may not be successful. Similarly, issuers with net operating losses sometimes adopt Unitholder rights plans or similar arrangements in order to preserve the ability to utilize such net operating losses in the future; any such actions could also limit or otherwise adversely impact the Company’s ability to transfer or dispose of its interests in any such issuer.
Risks Related to Disposition of Investments
. The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, IPOs, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized. See, for example, “—
Risks Relating to Bank Loans and Corporate Loans
” above. In particular, certain disposition techniques and structures may expose the Company to liability for (among other things) securities laws violations, breaches of representations and warranties, and repurchase or “putback” obligations with respect to securitizations or similar structures.
     
Effects of Leverage [Text Block]
Leverage
The Company is required to comply with the asset coverage requirements of the 1940 Act. The Company expects to employ leverage and otherwise incur indebtedness with respect to the portfolio both on a recourse and
non-recourse
basis (including and potentially through guarantees, derivatives, forward commitments and reverse repurchase agreements), but will not exceed the maximum amount permitted by the 1940 Act. The Company is generally permitted, under specified conditions, to issue senior securities in amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after such issuance. In connection with the organization of the Company, the Adviser, as the initial Unitholder, has authorized the Company to adopt the 150% asset coverage ratio. In connection with their subscriptions for Units, our Unitholders are required to acknowledge the Company’s ability to operate with an asset coverage ratio that may be as low as 150%. The Company will be exposed to the risks of leverage, which may be considered a speculative investment technique. The use of leverage magnifies the potential for gain and loss on amounts invested and therefore increases the risks associated with investing in our securities. In addition, the costs associated with our borrowings, including any increase in the management fee payable to the Adviser, will be borne by our Unitholders. As of December 31, 2023, the Company held $41.8 million of senior securities, for an asset coverage ratio of 155.0%.
     
NAV Per Share [1] $ 21.47 $ 21.77 $ 21.41 $ 0
Healthcare and Life Science Industries Related Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Healthcare and Life Science Industries’ Related Risks
. The Company intends to make investments in the healthcare and life science industries, although the Company may also opportunistically invest in other sectors in order to accomplish its investment objective. Investing in healthcare companies involves substantial risks. Such risks include, but are not limited to, the following: changes in government policies, including policies regarding reimbursement of medical expenses; certain companies in which the Company may invest may have limited or no operating histories/ or may have limited products, markets and financial resources; rapidly changing technologies may cause products to quickly become obsolete; unanticipated problems often arise in connection with the development of new products, and many such efforts are ultimately unsuccessful; scarcity of management and marketing personnel with appropriate technological or medical training may slow or impede companies’ growth; the possibility of lawsuits related to technological and medical patents could cause delays and expense in product development and implementation; regulatory changes and/or government actions may prevent a company from marketing its products; changing investors’ sentiments and preferences with regard to investments in healthcare companies (which may be perceived as risky) may have an adverse effect on the price of underlying securities; volatility in the U.S. stock markets affecting the prices of securities of healthcare and life sciences companies may cause the Company to experience substantial volatility; and certain healthcare and life sciences companies may be subject to extensive government regulation and affected by government reimbursement policy changes. In addition, many healthcare and life sciences companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or even under normal market conditions or such capital may be obtained on terms that are not favorable.
Also, obtaining government approval for new products from governmental agencies can be lengthy, expensive and uncertain, and withdrawal or curtailment of government support could have an adverse impact on the profitability or market price of healthcare and life sciences companies. Furthermore, delays in generating products (as well as more general ongoing capital requirements) may result in the need for companies to seek additional capital, potentially diluting the interest of existing investors, such as the Company (and indirectly, the Unitholders).
     
Investments in Healthcare Companies [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Investments in Healthcare Companies
. The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally. The Company’s investment strategy is subject to numerous and significant risks and uncertainties, some of which are highlighted generally below. The following is general information and does not purport to describe all risks associated with investing in the healthcare industry.
 
     
Sector Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Sector Risk.
Sector risk is the risk associated with a Company holding a significant amount of investments in similar businesses, which would be similarly affected by particular economic or market events, which may, in certain circumstances, cause the value of the equity and debt securities of companies in a particular sector of the market to change. To the extent a Company has substantial holdings within a particular sector, the risks to a Company associated with that sector increase.
     
Concentration Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Concentration Risk.
The Company’s principal focus is to invest in the healthcare and life sciences industry. The focus of the Company’s portfolio on a specific industry may present more risks than if its portfolio were broadly diversified over numerous industries and sectors of the economy. A downturn in this industry would have a larger impact on the Company than on an investment company that does not concentrate in such industry. At times, the performance of securities of companies in the healthcare industry will lag the performance of other industries or the broader market as a whole.
While investment in multiple opportunities may provide some diversification of investment risk, no assurance can be given that such diversification will occur, or if it does, that it will not reduce, rather than increase, potential net profits.
     
Risks Inherent in HealthcareRelated Assets [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Inherent in Healthcare-Related Assets.
Substantially all of the Company’s investments will be in the healthcare industry. Concentration in one industry involves significant risks greater than those generally associated with diversified acquisition funds, including significant fluctuations in returns. The healthcare industry is challenged by factors such as government regulations; changes in government policies, including policies regarding reimbursement of medical expenses and policies that impact company’s abilities to market products; changes in technology, including changes that may cause products to quickly become obsolete; medical innovations and accompanied unanticipated problems; changes in healthcare practices or delivery systems; scarcity of management and marketing personnel with appropriate technological or medical training; possibilities of lawsuits related to technological and medical patents, and resulting delays and expenses in product development and implementation; changing macroeconomic conditions in the U.S. and globally, intense competition, susceptibility to natural disasters, large capital requirements and the introduction of new, competing healthcare facilities, properties or other leisure activities.
Companies in the healthcare sector are subject to extensive government regulation and their profitability can be significantly affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure (including price discounting), limited product lines and an increased emphasis on the delivery of healthcare through outpatient services. Companies in the healthcare sector are heavily dependent on obtaining and defending patents, which may be time consuming and costly, and the expiration of patents may also adversely affect the profitability of these companies. Healthcare companies are also subject to extensive litigation based on product liability and similar claims. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the healthcare sector require significant research and development and may be subject to regulatory approvals, all of which may be time consuming and costly with no guarantee that any product will come to market.
The Company’s assets will compete in a relatively uncertain political, economic, and regulatory environment, and instability or an overall decline within the healthcare sector will not be balanced by investments in industries not so affected.
In addition, many healthcare companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or such capital may be obtained on terms that are not favorable to existing investors.
     
Regulations of Healthcare Industry [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Regulations of Healthcare Industry.
The regulatory environment surrounding the healthcare industry has intensified both in the amount and type of regulations and in the efforts to enforce those regulations. The extensive federal, state, and local, laws and regulations affecting the healthcare industry include, but are not limited to, laws and regulations relating to licensure, certification as a Medicare and Medicaid provider, conduct of operations, ownership of facilities, addition of facilities and equipment, allowable costs, services, prices for services, quality of care, patient rights, patient abuse and neglect, fraudulent reimbursement practices, and financial and other arrangements which may be entered into by healthcare providers.
Federal and state governments have intensified enforcement policies, resulting in a significant increase in the number of inspections, citations of regulatory deficiencies and other regulatory sanctions, including terminations from the Medicare and Medicaid programs, bans on Medicare and Medicaid payments for new admissions, civil monetary penalties and even criminal penalties. The Company’s investments could be forced to expend considerable resources on responding to an investigation or other enforcement action under applicable laws or regulations, The Company is unable to predict the future course of federal, state and local regulation or legislation, including the Medicare and Medicaid statutes and regulations. Changes in regulatory framework could have a material adverse effect on the Company’s Portfolio Investments and the Company.
     
Prepayment Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Prepayment Risk
. The terms of loans in which the Company invests may permit borrowers to voluntarily prepay loans at any time,
either
with no or a nominal prepayment premium. This prepayment right could result in the borrower repaying the principal on an obligation held by the Company earlier than expected. This may happen when there is a decline in interest rates or when the borrower’s improved credit or operating or financial performance allows the refinancing of certain classes of debt with lower cost debt. The yield of the Company’s investment assets may be affected by the rate of prepayments differing from the Adviser’s expectations.
     
Investment Modification Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Investment Modification Risk
. The terms and conditions of loan agreements and related assignments may be amended, modified or waived only by the agreement of the lenders. Generally, any such agreement must include a majority or a super majority (measured by outstanding loans or commitments) or, in certain circumstances, a unanimous vote of the lenders. Consequently, the terms and conditions of the payment obligation arising from Portfolio Investments could be modified, amended or waived in a manner contrary to the preferences of the Company if a sufficient number of the other lenders concurred with such modification, amendment or waiver. There can be no assurance that any obligations arising from a Portfolio Investment will maintain the terms and conditions to which the Company originally agreed.
 
     
Collateral Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Collateral Risk
. The collateral and security arrangements in relation to such secured obligations as the Company may invest in will be subject to such security or collateral having been correctly created and perfected and any applicable legal or regulatory requirements which may restrict the giving of collateral or security by an obligor, such as, for example, thin capitalization, over-indebtedness, financial assistance and corporate benefit requirements. If one or more Portfolio Investments do not benefit from the expected collateral or security arrangements, this may adversely affect the value of or, in the event of default, the recovery of principal or interest from such Portfolio Investments made by the Company. Accordingly, any such failure to properly create or perfect collateral and security interests attaching to the Portfolio Investments could have a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units. A component of the Adviser’s analysis of the desirability of making a given investment relates to the estimated residual or recovery value of such Portfolio Investments in the event of the insolvency of the obligor. This residual or recovery value will be driven primarily by the value of the anticipated future cash flows of the obligor’s business and by the value of any underlying assets constituting the collateral for such Portfolio Investment. The anticipated future cash flows of the obligor’s business and the value of collateral can, however, be extremely difficult to predict as in certain circumstances market quotations and third-party pricing information may not be available. If the recovery value of the collateral associated with the Portfolio Investments in which the Company invests decreases or is materially worse than expected by the Company, such a decrease or deficiency may affect the value of the Portfolio Investments made by the Company. Accordingly, there may be a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units.
     
General Economic and Market Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
General Economic and Market Risk
. The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally, such as real or perceived adverse economic conditions, supply and demand for particular instruments, changes in the general outlook for certain markets or corporate earnings, interest rates, announcements of political information or adverse investor sentiment generally. The market values of the Company’s investments may decline for a number of reasons, including increases in defaults resulting from changes in overall economic conditions and widening of credit spreads. Unfavorable market conditions may also increase funding costs, limit access to the capital markets or result in credit terms changing or credit becoming unavailable. These events could have an adverse effect on the Company’s investments and the Company’s overall performance.
Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may also contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide. Such events, including rising trade tensions between the United States and China, other uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies with other countries, the large-scale invasion of Ukraine by Russia that began in February 2022 and resulting sanctions or other restrictive actions that the United States and other countries have imposed against
Russia, the COVID-19 pandemic,
certain regional bank failures, an inflationary environment and the ongoing war in the Middle East, could adversely affect the Company’s business, financial condition or results of operations. These market and economic disruptions could negatively impact the operating results of the Company’s Portfolio Investments.
Additionally, the Federal Reserve raised the Federal Funds Rate in 2022 and in 2023. Although the Federal Reserve left its benchmark rates steady in the fourth quarter of 2023, it has indicated that additional rate increases in the future may be necessary to mitigate inflationary pressures and there can be no assurance that the Federal Reserve will not make upward adjustments to the federal funds rate in 2024. However, there are reports that the Federal Reserve may begin to cut the benchmark rates. These developments, along with the United States government’s credit and deficit concerns, global economic uncertainties and market volatility and the
impacts of COVID-19, could
cause interest rates to be volatile, which may negatively impact the Company’s ability to access the debt markets and capital markets on favorable terms.
Continuing market uncertainty may have a significant impact on the business of the Company. Among other things, the level of investment opportunities may decline from the Adviser’s current expectations. One possible consequence is that the Company may take a longer than anticipated period to invest capital and/or the Company may be relatively concentrated in a limited number of investments. Consequently, during this period, the returns (if any) realized by Unitholders may be substantially adversely affected by the unfavorable performance of a small number of these investments. Furthermore, market conditions may unfavorably impact the Company’s ability to secure leverage on terms as favorable as more established borrowers in the market, or to obtain any leverage on commercially favorable terms. To the extent the Company is able to secure financing for investments, increases in interest rates or in the risk spread demanded by financing sources would make the use of leverage more expensive and could limit the Company’s ability to structure and consummate its investments. Although the Adviser believes that recent market dislocations will result in attractive investment opportunities, the Company may not be able to time the acquisition or disposition of its investments correctly, which could result in further depreciation in values.
     
Public Health Crises Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Public Health Crises Risk
. Periods of market volatility have occurred and could continue to occur in response to pandemics or other events outside of the Company’s control. These types of events have adversely affected and could continue to adversely affect operating results for the Company and for its Portfolio Investments. For
example, the COVID-19 pandemic
has adversely impacted global commercial activity and contributed to significant volatility in the equity and debt markets. The
COVID-19
pandemic and restrictive measures taken to contain or mitigate its spread have caused, and are continuing to cause, business shutdowns, or
the re-introduction
of business shutdowns, cancellations of events and restrictions on travel, significant reductions in demand for certain goods and services, reductions in business activity and financial transactions, supply chain interruptions, labor shortages, increased inflationary pressure and overall economic and financial market instability both globally and in the United States. Many states, including those in which the Company and Portfolio Investments may operate, have issued orders requiring the closure of, or certain restrictions on the operation of, certain businesses. Such actions and effects remain ongoing and the ultimate duration and severity of
the COVID-19
pandemic,
including COVID-19
variants, remain uncertain.
Despite actions of the U.S. federal government and foreign governments, the uncertainty surrounding
the COVID-19
pandemic, including uncertainty regarding existing or future variants and other factors, has contributed to significant volatility in the global public equity markets and global debt capital markets.
     
General Credit Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
General Credit Risk
. The Company is subject to significant credit risk (
i.e.
, the risk that an issuer or borrower will default in the payment of principal and/or interest on an instrument) in light of its investment strategy. Credit risk also includes the risk that a counterparty to a derivatives transaction (
e.g.
, a swap counterparty) will be unwilling or unable to meet its obligations. Financial strength and solvency of an issuer or borrower are the primary factors influencing credit risk. In addition, degree of
 
subordination, lack or inadequacy of collateral or credit enhancement for a debt instrument may affect its credit risk. The degree of credit risk associated with any particular Portfolio Investment or any collateral relating thereto may be difficult or impossible for the Adviser to determine within reasonable standards of predictability. The Adviser utilizes various third parties that hold Company assets (such as the Custodian and prime brokers) in implementing the Company’s investment strategy, and the Company will therefore also be subject to credit risk with respect to such entities.
Although most of the Company’s investments will not be rated by any credit rating agency, in some cases, the credit risk of some of the Company’s Portfolio Investments may be broadly gauged by the credit ratings of such Portfolio Investments. However, ratings are only the opinions of the agencies issuing them, may change less quickly than relevant circumstances, are not absolute guarantees of the quality of the rated securities and are subject to downgrade. Credit ratings and ratings agencies have recently been criticized for ratings which did not fully reflect the risks of certain securities or which did not reflect such risks in a timely manner. For most investments, however, the Adviser will rely on its own independent analysis of the credit quality and risks associated with individual securities considered for the Company, rather than relying on ratings agencies or third-party research. Therefore, the Adviser’s capabilities in analyzing credit quality and associated risks will be particularly important (especially since it is currently anticipated that most of the Company’s assets will not be rated by a ratings agency or will be rated below investment grade), and there can be no assurance that the Adviser will be successful in this regard. See also “—
High Yield Debt and Unrated Securities
” below.
     
General Leverage Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
General Leverage Risks
. The Company employs leverage and otherwise incurs indebtedness with respect to the portfolio both on
a recourse or non-recourse basis (including
through guarantees, derivatives, forward commitments and reverse repurchase agreements). The Company is not required to take any action (including unwinding or liquidating any position) in the event that such guideline is exceeded subsequent to the borrowing date, whether in the event of changes in the market value of the Company’s portfolio or otherwise. Prospective investors in the Company should expect that the effective leverage utilized by the Company may exceed such guideline, which only applies to direct borrowings; for instance, economic leverage inherent in the Company’s derivatives transactions and other investments will not be counted for purposes of such guideline, notwithstanding that such investments will be subject to many of the leverage-related risks described herein. In addition, determinations relating to leverage are inherently subjective and will involve the exercise of discretion by the Adviser (for instance, the Adviser may deem the amount of the Company’s direct borrowings to be reduced by cash and cash equivalents held by the Company or by a counterparty). See “—
Leveraged Companies
” below.
The use of leverage has the potential to magnify the gains or the losses on investments and to make the Company’s returns more volatile. Moreover, if the Company is
required to de-lever as
a result of changing market conditions or otherwise, it may be forced to sell Portfolio Investments at inopportune times or at disadvantageous prices. On the other hand, while the Company will have the flexibility to use leverage, there can be no guarantee that leverage can be obtained, or obtained on terms and pricing the Adviser finds attractive, especially in the current market environment. As a result, prospective investors in the Company should recognize that Portfolio Investments may not be leveraged, or may be leveraged at an amount below any leverage level otherwise expected by the Adviser. Moreover, even if leverage can be arranged, the Company is not obligated to utilize such leverage and may do so at the sole discretion of the Adviser. Should leverage not be obtained or utilized by the Company, the returns for the Company may be lower than they would have been had such leverage been obtained and utilized.
In connection with any leverage utilized by the Company, the Company may secure its obligations with respect thereto with any and all of its assets, including its right to receive capital contributions from the Unitholders, pursuant to a pledge or other security agreement on terms that the Company determines are fair and reasonable to the Company. If the Company were to default on its obligations under such transactions, the counterparty could foreclose on the collateral and take possession of the Company’s assets and/or call capital from the Unitholders for purposes of repaying debt.
The terms of any leverage utilized by the Company are likely to impose significant restrictions on the Company’s operations and investment program, including as to the Company’s ability to pay distributions, incur additional leverage and engage in certain transactions.
     
Hedging Transactions and Related Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Hedging Transactions and Related Risks
. The Company may, but is not required to, engage in hedging transactions. In particular, as many of the Company’s Portfolio Investments are expected to consist of relatively illiquid securities whose price behavior is not particularly correlated to general fixed income or equity index returns, such Portfolio Investments are expected to be difficult or expensive to hedge, and as such the Company may not employ any hedging strategy in respect of such Portfolio Investments (including with respect to their credit risk). To the extent the Adviser employs a hedging strategy for the Company, the success of any such hedging strategy will depend, in part, upon the Adviser’s ability to correctly assess the degree of correlation between the performance of the instruments used in the hedging strategy and the performance of the investments being hedged. Since the characteristics of many securities change as markets change or time passes, the success of the Company’s hedging strategy will also be subject to the Adviser’s ability to continually recalculate, readjust and execute hedges in an efficient and timely manner. While the Company may enter into hedging transactions to seek to reduce risk, such transactions may result in a poorer overall performance for the Company than if it had not engaged in such hedging transactions. For a variety of reasons, the Adviser may not seek to establish a precise correlation between the hedging instruments utilized and the portfolio holdings being hedged. Such an imprecise correlation may prevent the Company from achieving the intended hedge or expose the Company to risk of loss. Additionally, the Adviser may not hedge against a particular risk because it does not regard the probability of the risk occurring to be sufficiently high as to justify the cost of the hedge, or because it does not foresee the occurrence of the risk. Moreover, there is no guarantee that the Company’s intended hedging strategy will be successful in hedging out the subject risks.
     
Due Diligence Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Due Diligence Risk
. When conducting due diligence and making an assessment regarding a Portfolio Investment, the Adviser relies on the resources available to it, including internal sources of information as well as information provided by third parties. The due diligence process may at times be required to rely on limited or incomplete information. The Adviser selects Portfolio Investments in part on the basis of information and data filed with various government regulators and publicly available or made directly available by prospective portfolio companies or third parties. The Adviser expects that it will not be in a position to confirm the completeness, genuineness or accuracy of such information and data, and will therefore be dependent upon the integrity of the management of the entities filing such information and of such portfolio companies and third parties providing such information. In addition, there can be no assurance that any consultants or experts engaged by the Adviser will accurately evaluate such Portfolio Investments. Investment analyses and decisions by the Adviser may be undertaken on an expedited basis to enable the Company to take advantage of investment opportunities with accelerated timelines. In such cases, the available information at the time of an investment decision may be limited, inaccurate and/or incomplete. Accordingly, the Adviser cannot guarantee that its due diligence investigations will reveal or highlight all relevant facts that may be necessary or helpful in evaluating investment opportunities. Furthermore, the Company bears its proportionate share of all due diligence-related fees, costs, expenses and liabilities (including in respect of investments that are not ultimately consummated); such fees, costs, expenses and liabilities may be significant and could reduce Company returns.
     
Interest Rate Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Interest Rate Risk
. Interest rate risk refers to the risks associated with market changes in interest rates. In general, rising interest rates, such as the recent economic period, will negatively impact the price of fixed rate debt instruments and falling interest rates will have a positive effect on the price of such debt instruments. Many of the Company’s investments are expected to be variable rate loans with interest that adjusts with market rates. These loans will generally also react to interest rate changes in a similar manner although generally to a lesser degree (depending, however, on the characteristics of the reset terms, including the index chosen, frequency of reset and reset caps or floors, among other factors). The Company’s other investments and transactions may also be affected by changes in interest rates. Declines in market value, if not offset by any corresponding gains on hedging instruments, may ultimately reduce earnings or result in losses to the Company.
The prices of long-term debt obligations generally fluctuate more than prices of short-term debt obligations as interest rates change. To the extent the Company invests in longer-term Portfolio Investments, it will be impacted to a greater degree by changes in market interest rates than if the Company invested primarily in short-term debt securities.
To the extent the Company borrows money or issues preferred Units to make investments, its net investment income will depend, in part, upon the difference between the rate at which it borrows funds or pays distributions on preferred Units and the rate at which the Company invests those funds. As a result, the Company can offer no assurance that a significant change in market interest rates will not have a material adverse effect on its net investment income in the event the Company uses debt to finance investments. In periods of rising interest rates, such as the recent economic period, the Company’s cost of funds will increase because the interest rates on the amounts borrowed under the Company’s credit facilities or certain other financing arrangements will typically be floating, which could reduce the Company’s net investment income to the extent any Portfolio Investments have fixed interest rates, and the interest rate on Portfolio Investments with an interest rate floor (such as a SOFR (as defined below) floor) above then-current levels will not increase until interest rates exceed the applicable minimum interest rate floor. Rising interest rates may also increase the cost of debt for the Portfolio Investments, which could adversely impact the Portfolio Investment’s financial performance and ability to meet ongoing obligations to the Company.
 
 
The Company expects that its long-term fixed-rate investments will be financed primarily with equity and long-term debt. The Company may use interest rate risk management techniques in an effort to limit its exposure to interest rate fluctuations. Such techniques may include various interest rate hedging activities to the extent permitted by the 1940 Act. These activities could limit the Company’s ability to participate in the benefits of lower interest rates with respect to the hedged borrowings. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on the Company’s business, financial condition and results of operations.
Also, an increase in interest rates available to investors could make an investment in the Company’s Units less attractive if the Company is not able to increase its distribution rate, which could reduce the value of the Company’s Units.
     
Liquidity Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Liquidity Risk
. Most of the Company’s Portfolio Investments at any given time are expected to be illiquid, such that either no market exists for them or they are restricted as to their transferability under federal, state or foreign securities laws. Similarly, the Adviser may from time to
time possess material, non-public information about
an issuer, which could limit the ability of the Company to buy and sell Portfolio Investments. The illiquid nature of the Company’s positions may make it difficult, if not impossible, for the Company to (i) close out unprofitable positions and redeploy capital, except when a viable exit strategy can be developed (which may require a much longer commitment than the Adviser had anticipated), and (ii) meet margin calls or similar requirements of Company transaction counterparties to furnish additional liquid collateral. In addition, the sale of the Company’s investments may be made at substantial discounts and/or otherwise disadvantageous terms.
     
InflationDeflation Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Inflation/Deflation Risk
. Inflation risk results from the variation in the value of cash flows from a security due to inflation, as measured in terms of purchasing power. The Company is exposed to inflation risk with respect to any fixed rate investments that it makes, if any, because the interest rate the issuer has to pay the Company is fixed for the life of the security. To the extent that interest rates reflect the expected inflation rate, floating rate loans have a lower level of inflation risk.
Any disruptions in the capital markets, as a result of inflation and a rising interest environment or otherwise, may increase the spread between the yields realized on risk-free and higher risk securities and can result in illiquidity in parts of the capital markets, significant write-offs in the financial sector
and re-pricing of
credit risk in the broadly syndicated market. These and any other unfavorable economic conditions could increase the Company’s funding costs, limit the Company’s access to the capital markets or result in a decision by lenders not to extend credit to the Company. In addition, market conditions (including inflation, supply chain issues and decreased consumer demand) could impact the operations of certain of the Company’s Portfolio Investments. If the financial results of middle-market companies, like those in which the Company intends to invest, experience deterioration, it could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults, and further deterioration in market conditions will further depress the outlook for those companies. Further, adverse economic conditions may decrease the value of collateral securing some of the Company’s loans and the value of the Company’s equity investments. Such may require the Company to modify the payment terms of its investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of the Company’s Portfolio Investments may be negatively impacted by these economic or other conditions, which can result in the Company’s receipt of reduced interest income from its Portfolio Investments and/or realized and unrealized losses related to its Portfolio Investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations.
     
Management Risk and Reliance on Management [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Management Risk and Reliance on Management
. The Company is subject to management risk because the Adviser actively manages its investment portfolio. The Adviser will apply investment and disposition techniques and risk analyses in making investment and disposition decisions for the Company, but there can be no guarantee that these will produce the desired results. In addition, as Unitholders may not participate in the management of the Company, only investors who are willing to entrust all aspects of the management of the Company to the Adviser should subscribe for Units.
The success of the Company is highly dependent upon the financial and managerial experience of the Adviser and any consultants or other Service Providers retained by the Company. The success of the Adviser is highly dependent on the financial and managerial experience of the investment professionals, who may not continue to be employed by or associated with the Adviser during the entire term of the Company. In
addition
, a number of members of the professional staff of the Adviser are
 
investors in other investment vehicles advised by SLR and are actively involved in managing the investment decisions of these investment vehicles, as well as investment decisions of other clients of SLR. Accordingly, the members of the professional staff of the Adviser have demands on their time for the investment, monitoring and other functions of other funds and other clients advised by SLR. In addition, competition in the financial services, private equity and alternative asset management industries for qualified investment professionals is intense. The Adviser’s continued ability to effectively manage the Company’s investments depends on its ability to attract new investment professionals and to retain and motivate its existing investment professionals.
Notwithstanding the foregoing, at any time during the Company’s term, the Adviser may assign the full and exclusive authority and responsibility granted to it under the Investment Management Agreement to an investment adviser under common control with the Adviser, subject to applicable law. The Adviser may take any actions that are necessary or incidental to any such assignment, including assigning the Investment Management Agreement or causing the Company to enter into a new Investment Management Agreement. Although it is expected that (x) any new investment adviser would be a registered investment adviser under the Advisers Act, (y) the management fee and incentive fee payable by the Company to such entities would be identical to that payable to the Adviser and (z) certain investment professionals would continue to be responsible for managing the Company’s assets, there is no guarantee that any or all of such characteristics will apply to any such new investment adviser.
The Investment
Committee may delegate non-investment decisions (including
decisions relating to cash management
and similar non-material transactions
(which shall not be considered “investments” for these purposes), diligence decisions, decisions relating to
transactions involving material non-public information and
decisions relating to the engagement of consultants, law firms and other Service Providers) to other investment professionals in their sole discretion. Any decisions made by such subset or other investment professionals may be materially different and/or less optimal than decisions that would have been made by the Investment Committee.
     
Model Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Model Risks
. The Adviser may employ financial/analytical models to aid in the selection of the Portfolio Investments, to allocate investments across various strategies and risks and to determine the risk profile of the Company. If any such models are employed, the success of the Company’s investment activities will depend, in large part, upon the viability of these models. There can be no assurance that the models are currently viable, or will remain viable during the term of the Company, due to various factors, including the quality of the data input into the models and the assumptions underlying such models, which to varying degrees involve the exercise of judgment, as well as the possibility of errors in constructing or of using the model. Even if the models function as anticipated, they cannot account for all factors that may influence the returns on the Portfolio Investments. Also, there can be no assurance that the investment professionals utilizing the models will be able to (i) determine that any model is or will become not viable or not completely viable or (ii) notice, predict or adequately react to any change in the viability of a model. The use of a model that is not viable or not materially viable could, at any time, have a material adverse effect on the performance of the Company.
     
Risks Related to Electronic CommunicationsCybersecurity Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Related to Electronic Communications/Cybersecurity Risk
. The Company provides to Unitholders statements, reports and other communications relating to the Company and/or the Unitholder’s Interest in electronic form, such
as e-mail or
via a password protected website (“Electronic Communications”). There are certain costs and possible risks associated with the use of Electronic Communications. Electronic Communications may be modified, corrupted, or contain viruses or malicious code, and may not be compatible with a Unitholder’s electronic system. The Company cannot provide any assurance that Electronic Communications are secure and will not be responsible for any computer viruses, problems or malfunctions resulting from the use of Electronic Communications. In addition, reliance on Electronic Communications involves the risk of inaccessibility, power outages or slowdowns for a variety of reasons. These periods of inaccessibility may delay or prevent receipt of reports or other information by the Unitholders.
The Company relies on the Adviser’s enterprise-wide cybersecurity program, to protect its information, including due oversight of the cybersecurity programs of the Company’s key Service Providers and processes for the assessment, identification, and management of material risks from cybersecurity threats, including those associated with the use of third-party Service Providers. While the Adviser employs various measures to address cybersecurity-related issues, the Adviser, the Administrative Coordinator, the Company and their respective Service Providers may nevertheless be subject to operational and information security risks resulting from cybersecurity incidents. A cybersecurity incident refers to both intentional and unintentional events that may cause the Adviser, the Company or their respective Service Providers to lose or compromise confidential information, suffer data corruption or lose operational capacity. Cybersecurity incidents include stealing or corrupting data maintained online or digitally, denial of service attacks on websites, the unauthorized release of confidential information or various other operational disruptions. If unauthorized parties gain access to such information and technology systems, they may be able to steal, publish, delete or modify private and sensitive information, including nonpublic personal information related to Unitholders (and their beneficial owners) and material nonpublic information. The systems the Adviser has implemented to manage risks relating to these types of events could prove to be inadequate and, if compromised, could become inoperable for extended periods of time, cease to function properly or fail to adequately secure private information. Breaches such as those involving covertly introduced malware, impersonation of authorized users and industrial or other espionage may not be identified even with sophisticated prevention and detection systems, potentially resulting in further harm and preventing them from being addressed appropriately. The failure of these systems or of disaster recovery plans for any reason could cause significant interruptions in the Company’s and the Adviser’s operations and result in a failure to maintain the security, confidentiality or privacy of sensitive data, including personal information relating to Unitholders, material nonpublic information and other sensitive information in the Adviser’s possession.
 
A disaster or a disruption in the infrastructure that supports the Adviser’s business, including a disruption involving Electronic Communications or other services used by the Adviser or third parties with whom the Adviser conducts business, or directly affecting the Adviser’s headquarters, could have a material adverse impact on the Adviser’s ability to continue to operate its business without interruption and to protect the Company, insofar as is practicable, from the hazards of cybersecurity threats and vulnerabilities in accordance with applicable legal requirements and guidance. The Adviser’s disaster recovery programs may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse the Adviser for its losses, if at all.
Although the Company is not currently aware of any cyber-attacks or other incidents that, individually or in the aggregate, have materially affected, or would reasonably be expected to materially affect, its operations or financial condition, there has been an increase in the frequency and sophistication of the cyber and security threats faced in the marketplace. Cyber-attacks and other security threats could originate from a wide variety of sources, including cyber criminals, nation state hackers, hacktivists and other outside or inside parties. The Company may be a target for attacks because, as a specialty finance company, it holds confidential and other sensitive information, including price information, about existing and potential investments. Further, the Company is dependent on third-party vendors for hosting hardware, software and data processing systems that it does not control. The Company also relies on third-party Service Providers for certain aspects of its business, including for certain information systems, technology and administration of its Portfolio Investments and compliance matters. While the Company relies on the cybersecurity strategy and policies implemented by the Adviser, its reliance on the Adviser and third-party Service Providers removes certain cybersecurity functions from outside of the Company’s immediate control, and cyber-attacks on the Adviser, on the Company or on third-party Service Providers could adversely affect the Company, its business, and its reputation. The costs related to cyber-attacks or other security threats or disruptions may not be fully insured or indemnified by others, including by the
Company’s
third-party providers.
As the Company’s reliance on computer hardware and software systems, data processing systems, and other technology has increased, so have the risks posed to such systems, both those the Adviser controls and those provided by third-party vendors. Cyber-attacks may originate from a wide variety of sources, and while the Adviser has implemented processes, procedures, and internal controls designed to mitigate cybersecurity risks and cyber-attacks, these measures do not guarantee that a cyber-attack will not occur or that the Company’s financial results, operations, or confidential information, personal, or other sensitive information will not be negatively impacted by such an incident, especially because the techniques of threat actors change frequently and are often not recognized until launched. The Adviser relies on industry accepted security measures and technology to securely maintain confidential and proprietary information maintained on its information systems, as well as on policies and procedures to protect against the unauthorized or unlawful disclosure of confidential, personal, or other sensitive information. Although the Adviser takes protective measures and endeavors to strengthen its computer systems, software, technology assets, and networks to prevent and address potential cyber-attacks, there can be no assurance that any of these measures prove effective. The Adviser expects to be required to devote increasing levels of funding and resources, which may in part be allocated to the Company, to comply with evolving cybersecurity and privacy laws and regulations and to continually monitor and enhance its cybersecurity procedures and controls. In addition, the Company, the Adviser, the Administrative Coordinator, or their employees, if any, may also be the target of fraudulent emails or other targeted attempts to gain unauthorized access to confidential, personal, or other sensitive information. The result of any cyber-attack or other security incidents may include disrupted operations, misstated or unreliable financial data, fraudulent transfers or requests for transfers of money, liability for stolen information (including personal information), investigations, misappropriation of assets, increased cybersecurity protection and insurance costs, litigation and damage to the Company’s business relationships, regulatory fines or penalties, or other adverse effects on its business, financial condition or results of operations. The Adviser may be required to expend significant additional resources to modify its protective measures and to investigate and remediate vulnerabilities or other exposures arising from operational and security risks related to cyber-attacks. The rapid evolution and increasing prevalence of artificial intelligence technologies may also increase cybersecurity risks.
In addition, cybersecurity has become a top priority for global lawmakers and regulators around the world, and some jurisdictions have proposed or enacted laws requiring companies to notify regulators and individuals of data security breaches involving certain types of personal data. In particular, state and federal laws and regulations related to cybersecurity compliance continue to evolve and change, which may require substantial investments in new technology, software and personnel, which could affect the Company’s profitability. These changes may also result in enhanced and unforeseen consequences for cyber- related breaches and incidents, which may further adversely affect the Company’s profitability. If the Adviser fails to comply with the relevant and increasing laws and regulations, the Adviser could suffer financial losses, a disruption of its businesses, liability to investors, regulatory intervention or reputational damage.
 
Policies of remote working, whether by the Adviser, the Administrative Coordinator, the Company or by their respective Service Providers, could strain technology resources, introduce operational risks and otherwise heighten the risks described above. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts.
Cybersecurity risks are exacerbated by the rapidly increasing volume of highly sensitive data, including the Company’s proprietary business information, personal information of the Adviser’s employees, the Company’s investors and others, and other sensitive information that the Adviser collects, processes, and stores in its data centers and on its networks or those of third-party Service Providers. The secure processing, maintenance, and transmission of this information are critical to the Company’s operations. There is a risk that encryption and other protective measures against cyber-attacks may be circumvented, particularly to the extent that new computing technologies increase the speed and computing power available. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and, in fact, may not be detected. A significant actual or potential theft, loss, corruption, exposure, fraudulent use or misuse of investor or other personal information, proprietary business data or other sensitive information, whether by third parties or as a result of malfeasance by the Adviser’s employees or otherwise,
non-compliance
with applicable contractual or other legal obligations regarding such data or intellectual property or a violation of applicable privacy and security policies with respect to such data could result in significant investigation, remediation and other costs, fines, penalties, litigation or regulatory actions against the Company and significant reputational harm, any of which could harm the Company’s business and results of operations. Cybersecurity risks require continuous and increasing attention and other resources from the Adviser to, among other actions, identify and quantify these risks and upgrade and expand its technologies, systems and processes to adequately address such risks. Such attention diverts time and other resources from other activities and there is no assurance that the Adviser’s efforts will be effective.
Cybersecurity incidents may adversely impact the Company and its Unitholders. There is no guarantee that the Company, the Adviser, and/or their respective Service Providers will be successful in protecting against cybersecurity incidents.
     
Technological Innovation Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Technological Innovation Risks
. Technological innovations have disrupted traditional approaches in multiple industries and can permit younger companies to achieve success and in the process disrupt markets and market practices. The Company can provide no assurance that new businesses and approaches will not be created that would compete with the Company and/or its Portfolio Investments or alter the market practices in which the Adviser and its affiliates and the Company have been designed to function within and on which the Company depends on for its investment return. New approaches could damage the Company’s investments, disrupt the market in which it operates and subject it to increased competition, which could materially and adversely affect the Company’s business, financial condition and results of investments.
 
     
Corporate Social Responsibility Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Corporate Social Responsibility Risks
. The Company’s business (including that of its Portfolio Investments) faces increasing public scrutiny related to environmental, social and governance (“ESG”) activities, which are increasingly considered to contribute to reducing a company’s operational risk, market risk and reputational risk, which may in turn impact the long-term sustainability of a company’s performance. A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG ratings and measures to their investment decisions.
The Company risks damage to its brand and reputation if it fails to act responsibly in a number of areas, including, but not limited to, diversity, equity and inclusion, human rights, climate change, environmental stewardship, support for local communities, corporate governance, transparency and consideration of ESG factors in the Company’s investment processes. Adverse incidents with respect to ESG activities could impact the value of the Company’s brand, its relationship with existing and future Portfolio Investments, the cost of the Company’s operations and relationships with investors, all of which could adversely affect its business and results of operations.
However, regional and investor specific sentiment may differ in what constitutes a material positive or negative ESG corporate practice. There is no guarantee that the Company’s ESG and sustainability practices will uniformly fit every investor’s definition of best practices for all environmental, social and governance considerations across geographies and investor types. If we do not successfully manage expectations across varied stakeholder interests, it could erode stakeholder trust, impact our reputation and constrain our investment opportunities.
There is also a growing regulatory interest across jurisdictions in improving transparency regarding the definition, measurement and disclosure of ESG factors in order to allow investors to validate and better understand sustainability claims. For example, the SEC has proposed, or has announced that it is working on proposals for, rules that, among other matters, would establish a framework for reporting of climate-related risks, corporate and fund carbon emissions, broad diversity and capital management. At this time, there is uncertainty regarding the scope of such proposals or when they would become effective (if at all). In 2021, the SEC established an enforcement task force to look into ESG practices and disclosures by public companies and investment managers and has started to bring enforcement actions based on ESG disclosures not matching actual investment processes. Further, in 2022 the SEC issued a proposed rule regarding the enhancement and standardization of mandatory climate-related disclosures for investors that would mandate extensive disclosure of climate-related data, risks and opportunities for certain public companies.
The Company and its Portfolio Investments are subject to the risk that similar measures might be introduced in other jurisdictions in the future. Additionally, compliance with any new laws or regulations increases the Company’s regulatory burden and could make compliance more difficult and expensive, affect the manner in which the Company or its Portfolio Investments conduct its businesses and adversely affect the Company’s profitability.
     
Climate Change Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Climate Change Risks
. There may be evidence of global climate change. Climate change creates physical and financial risk and some of the Company’s Portfolio Investments may be adversely affected by climate change. For example, the needs of customers of energy companies vary with weather conditions, primarily temperature and humidity. To the extent weather conditions are affected by climate change, energy use could increase or decrease depending on the duration and magnitude of
 
any changes. Increases in the cost of energy could adversely affect the cost of operations of the Company’s Portfolio Investments if the use of energy products or services is material to their business. A decrease in energy use due to weather changes may affect some of the Company’s Portfolio Investments’ financial condition, through decreased revenues. Extreme weather conditions in general require more system backup, adding to costs, and can contribute to increased system stresses, including service interruptions. Energy companies could also be affected by the potential for lawsuits against or taxes or other regulatory costs imposed on greenhouse gas emitters, based on links drawn between greenhouse gas emissions and climate change.
In December 2015 the United Nations, of which the U.S. is a member, adopted a climate accord with the long-term goal of limiting global warming and the short-term goal of significantly reducing greenhouse gas emissions. As a result, some of the Company’s Portfolio Investments may become subject to new or strengthened regulations or legislation, which could increase their operating costs and/or decrease their revenues.
     
Senior Secured Loans [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Senior Secured Loans
. With respect to the Company’s investments in senior secured loans (including first lien loans), the Company will generally have a security interest in assets of the company, which should mitigate the risk that the Company will not be repaid. However, the collateral securing the Company’s loans may decrease in value over time, may be difficult to sell in a timely manner, may be difficult to appraise, and may fluctuate in value based upon the success of the business and market conditions, including as a result of the inability of the company to raise additional capital. In some circumstances, the Company’s lien could be subordinated to claims of other creditors. In addition, deterioration in a company’s financial condition and prospects, including its inability to raise additional capital, may be accompanied by deterioration in the value of the collateral for the loan. Consequently, the fact that a loan is secured does not guarantee that the Company will receive principal and interest payments according to the loan’s terms, or at all, or that the Company will be able to collect on the loan should it be forced to enforce its remedies. Furthermore, if a secured loan is foreclosed, the Company could own the underlying collateral (
e.g.
, real estate), and would be subject to the risks, costs and liabilities associated with owning and disposing of the collateral.
     
Subordinated Loans [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Subordinated Loans
. The Company may invest in subordinated loans. In the event of a loss of value of the underlying assets that collateralize the loans, the subordinate portions of the loans may suffer a loss prior to the more senior portions suffering a loss. If a borrower defaults and lacks sufficient assets to satisfy the Company’s loan, the Company may suffer a loss of principal or interest. If a borrower declares bankruptcy, the Company may not have full recourse to the assets of the borrower, or the assets of the borrower may not be sufficient to satisfy the loan. In addition, certain of the Company’s loans may be subordinate to other debt of the borrower. As a result, if a borrower defaults on the Company’s loan or on debt senior to the Company’s loan, or in the event of the bankruptcy of a borrower, the Company’s loan will be satisfied only after all senior debt is paid in full. The Company’s ability to amend the terms of the Company’s loans, assign the Company’s loans, accept prepayments, exercise the Company’s remedies (through “standstill periods”) and control decisions made in bankruptcy proceedings relating to borrowers may be limited by intercreditor arrangements if debt senior to the Company’s loans exists. In addition, the Company will be subject to the potential risks of foreclosure and ownership of underlying collateral described in “
—Senior Secured Loans
” above.
     
Mezzanine Securities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Mezzanine Securities
. The Company may invest in unsecured securities that are senior to common stock or other equity securities (“Mezzanine Securities”). Mezzanine Securities are subordinated to substantial amounts of senior debt, all or a portion of which may be secured. As a result, holders of Mezzanine Securities are generally not entitled to receive any payments in bankruptcy or liquidation until senior creditors are paid in full. In addition, the legal remedies available to holders of Mezzanine Securities are normally limited by restrictions benefiting senior creditors. In the event a company in which the Company holds Mezzanine Securities cannot generate adequate cash flow to meet senior debt service, the Company may suffer a partial or total loss of capital invested. Because issuers of Mezzanine Securities are often highly leveraged,
their relatively high debt-to-equity ratios create
increased risks that their operations will not be able to generate adequate cash flow to meet senior debt service.
     
Unsecured Loans or Debt [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Unsecured Loans or Debt
. The Company may invest in unsecured loans which are not secured by collateral. In the event of default on an unsecured loan, the first priority lien holder has first claim to the underlying collateral of the loan. It is possible that no collateral value would remain for an unsecured holder and therefore result in a loss of investment to the Company. Because unsecured loans are lower in priority of payment to secured loans, they are subject to the additional risk that the cash flow of the borrower may be insufficient to meet scheduled payments after giving effect to the secured obligations of the borrower. Unsecured loans generally have greater price volatility than secured loans and may be less liquid.
     
Defaults [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Defaults
. The Company may make investments in loans, or securities backed by loans, that may be at the time of their acquisition, or may become
after acquisition, non-performing loans.
In the event of any default under a loan directly held by the Company or a loan underlying a security held by the Company, the Company will bear a risk of loss of principal to the extent of any deficiency between the value of the collateral and the principal and accrued interest of the loan, which could have a material adverse effect on the Company’s cash flow
from operations. Other non-performing loans may
require workout negotiations and/or restructuring, which may entail, among other things, a substantial reduction in the interest rate and/or a substantial write-down of the original principal amount of such loans. Further, even if a restructuring were successfully accomplished, unless the restructuring provided for full amortization on or prior to maturity and the borrower strictly complied with that restructuring, a risk exists that upon maturity of such loans, replacement financing will not be available and such loans may not be repaid. In the event of the bankruptcy of a borrower, the loan to that borrower will be deemed to be secured only to the extent of the value of the underlying collateral at the time of bankruptcy (as determined by the bankruptcy court), the lien securing the loan will be subject to the avoidance powers of the
bankruptcy trustee or debtor-in-possession to the
extent the lien is unenforceable under state law, and realizing any value under such circumstances can be an expensive and lengthy process that could have a substantial negative effect on the anticipated return on the loan and on the security backed by such loan. Other risks attendant to a bankruptcy filing are described below. The foregoing statement does not apply in the context of a borrower insolvency case commenced under chapter 13 of the U.S. Bankruptcy Code where the underlying collateral is used as the principal residence of the borrower, but in such instances, the lender will nonetheless be stayed from the collection of its claim, taking possession of the collateral, and enforcing its lien unless and until the lender obtains relief from the automatic stay under the U.S. Bankruptcy Code.
     
Litigation and Related Risks Associated with Origination and Servicing [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Litigation and Related Risks Associated with Origination and Servicing
. Loan origination and servicing companies are routinely involved in legal proceedings concerning matters that arise in the ordinary course of their business. These legal proceedings range from actions involving a single plaintiff to class action lawsuits with potentially tens of thousands of class members. In addition, a number of participants in the loan origination and servicing industry (including control persons of industry participants) have been the subject of regulatory actions by state regulators, including state Attorneys General, and by the federal government. Governmental investigations, examinations or regulatory actions, or private lawsuits, including purported class action lawsuits, may adversely affect such companies’ financial results. To the extent the Company seeks to engage in origination and/or servicing directly, or has a financial interest in, or is otherwise affiliated with, an origination or servicing company, the Company will be subject to enhanced risks of litigation, regulatory actions and other proceedings. As a result, the Company may be required to pay legal fees, settlement costs, damages, penalties or other charges, any or all of which could materially adversely affect the Company and its investments.
     
Ability to Originate Loans on Advantageous Terms Competition and Supply [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Ability to Originate Loans on Advantageous Terms; Competition and Supply
. The Company’s success depends, in part, on the ability of the Company or its affiliates to originate loans on advantageous terms. In originating and purchasing loans, the Company or its affiliates will compete with a broad spectrum of lenders. Increased competition for, or a diminishment in the available supply of, qualifying loans could result in lower yields on such loans, which could reduce returns (if any) to investors. The Company intends to originate certain investments and later offer to syndicate all or a portion of one or more investments to certain other funds or accounts managed by the Adviser and its affiliates, in each case subject to their own investment-review
process, and to co-investors and/or third
parties. Prior to such syndication, or if such syndication is not successful, the Company’s exposure to the originated investment may exceed the exposure that the Company intends to have over the long-term or would have had if it had purchased such investment in the secondary market rather than originating it. Where
 
syndication is not successful, the Company may elect to sell all or a portion of an originated investment at a loss in order to rebalance the Company’s portfolio. The level of analytical sophistication, both financial and legal, necessary for successful financing to companies, particularly companies experiencing significant business and financial difficulties is unusually high. There is no assurance that the Adviser will correctly evaluate the value of the assets collateralizing the Company loans, the prospects for successful repayment or a successful reorganization or similar action.
     
Risks Relating to Bank Loans and Corporate Loans [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Relating to Bank Loans and Corporate Loans
. Bank loans and corporate loans (which the Company will originate, invest in or otherwise gain exposure to) may not be readily marketable and may be subject to restrictions on resale. In some cases, negotiations involved in disposing of indebtedness may require weeks to complete. Consequently, some indebtedness may be difficult or impossible to dispose of readily at what the Adviser believes to be a fair price. In addition, bank loans and corporate loans are often less liquid than other types of debt securities, particularly in times of significant market dislocation. Loans to small and middle market entities (“SMEs”) may involve certain heightened risks. See “—
Investments in Smaller and Middle Market Companies
” below.
Holders of bank loans, corporate loans and other forms of direct indebtedness depend primarily upon the creditworthiness of the corporate or other borrower for payment of principal and interest. If the Company does not receive scheduled interest or principal payments on such indebtedness, the value of the Company’s investments could be adversely affected. The Company may invest in secured and unsecured bank loans and corporate loans. Bank loans and corporate loans that are fully secured may offer the Company more protection than an unsecured loan in
the event of non-payment of scheduled
interest or principal. However, there is no assurance that the liquidation of any collateral from a secured bank loan or corporate loan would satisfy the borrower’s obligation, or that such collateral could be liquidated. In the event of the bankruptcy of a borrower, the Company could experience delays or limitations in its ability to realize the benefits of any collateral securing a loan and could be compelled to accept new instruments or interests in respect of its claims under the bank loan in a plan of reorganization. These new instruments or interests may be on terms different from prevailing market terms for similar instruments and interests.
Bank loans usually require, in addition to scheduled payments of interest and principal, the prepayment of the bank loan from free cash flow. The degree to which borrowers prepay bank loans, whether as a contractual requirement or at their election, may be affected by general business conditions, the financial condition of the borrower and competitive conditions among lenders, among others. As such, prepayments cannot be predicted with accuracy. Upon a prepayment, either in part or in full, the actual outstanding debt on which the Company derives interest income will be reduced. The effect of prepayments on the Company’s performance may or may not be mitigated by the receipt of prepayment fees and/or the Company’s reinvestment of prepayments in other bank loans that have similar or identical yields.
The Company may purchase “assignments” of bank loans from lenders. The purchaser of an assignment typically succeeds to all the rights and obligations under the loan agreement with the same rights and obligations as the assigning lender. Assignments may, however, be arranged through private negotiations between potential assignees and potential assignors, and the rights and obligations acquired by the purchaser of an assignment may differ from, and be more limited than, those held by the assigning lender.
The Company may also invest in “participations” in bank loans. Participations by the Company in a lender’s portion of a bank loan typically will result in the Company having a contractual relationship only with such lender, not with the borrower. As a result, the Company may have the right to receive payments of principal, interest and any fees to which it is entitled only from the lender selling the participation and only upon receipt by
such lender of such payments from the borrower. In connection with purchasing participations, the Company generally will have no right to enforce compliance by the borrower with the terms of the loan agreement, nor any rights with respect to any funds acquired by
other lenders through set-off against the
borrower, and the Company may not directly benefit from any collateral supporting the bank loan in which it has purchased the participation. As a result, the Company assumes the credit risk of both the borrower and the lender selling the participation.
In many cases bank loans and loan participations would not be deemed to be securities for purposes of U.S. federal and/or state securities laws. As a result, an investment in bank loans would not be afforded the same protections as an investment in securities, such as the extensive disclosure requirements under U.S. federal and/or state securities laws, which may adversely impact the Company’s ability to seek recourse in respect of such investments. Similarly, the documentation evidencing bank loans and loan participations will not necessarily be maintained with the Company’s custodian.
     
Investments in Smaller and Middle Market Companies [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Investments in Smaller and Middle Market Companies
. The Company generally invests in smaller and middle market companies. While smaller and middle market companies generally have potential for rapid growth, they often involve higher risks because they may lack the management experience, financial resources, product diversification, competitive strength and access to capital of larger companies. In addition, in many instances, the frequency and volume of the trading of securities for such companies may be substantially less than is typical of larger companies. As a result, the securities of smaller and middle market companies may be subject to wider price fluctuations. When liquidating positions in smaller and middle market companies, the Company may have to sell portfolio holdings at discounts from quoted prices or may have to make a series of small transactions over an extended period of time. Investments in such companies may also be particularly difficult to analyze due to (among other factors) limited attention from analysts and large institutional investors, limited access to liquidity sources and, in certain cases, limited publicly available financial information. With respect to the Company’s investments in SMEs and similar loans, the Company may receive less borrower information, receive less collateral and be subject to heightened default risk as compared to loans made to other types of entities.
 
     
Financial Fraud [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Financial Fraud
. Instances of fraud and other deceptive practices committed by management, employees or Service Providers of the Company’s Portfolio Investments or by other financial institutions may undermine the Adviser’s due diligence efforts with respect to, and/or negatively affect the valuation of, the Company’s Portfolio Investments. In addition, financial fraud may contribute to overall market volatility, which can negatively impact the Company’s investment program.
     
OFAC, FCPA and Related Considerations [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
OFAC, FCPA and Related Considerations
. Economic sanction laws in the U.S. and other jurisdictions may prohibit the Adviser, its personnel and the Company from transacting with or in certain countries and with certain individuals and companies. In the U.S., the U.S. Department of the Treasury’s Office of Foreign Assets Control administers and enforces laws, Executive Orders and regulations establishing U.S. economic and trade sanctions. Such sanctions prohibit, among other things, transactions with, and the provision of services to, certain foreign countries, territories, entities and individuals. These types of sanctions may restrict the Company’s investment activities.
In some countries, there is a greater acceptance than in the U.S. of government involvement in commercial activities, and of corruption. The Company may be adversely affected because of its unwillingness to participate in transactions that violate such laws or regulations. Such laws and regulations may make it difficult in certain circumstances for the Company to act successfully on investment opportunities and for Portfolio Investments to obtain or retain business.
 
In recent years, the U.S. Department of Justice and the SEC have devoted greater resources to enforcement of the U.S. Foreign Corrupt Practices Act (the “FCPA”). In addition, the United Kingdom has recently significantly expanded the reach of its anti-bribery laws. Violations of the FCPA or other applicable anti-corruption laws or anti-bribery laws could result in, among other things, civil and criminal penalties, material fines, profit disgorgement, injunctions on future conduct, securities litigation and a general loss of investor confidence, any one of which could adversely affect the Company’s ability to achieve its investment objective and/or conduct its operations.
     
Risks Relating to Waivers or Deferrals of Covenants and CovenantLite Loans [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Relating to Waivers or Deferrals of Covenants and Covenant-Lite Loans
. The Company structures the debt in its Portfolio Investments to include business and financial covenants placing affirmative and negative obligations on the operation of the company’s business and its financial condition. However, from time to time the Company may elect to waive breaches of these covenants, including its right to payment, or waive or defer enforcement of remedies, such as acceleration of obligations or foreclosure on collateral, depending upon the financial condition and prospects of the particular Portfolio Investment. These actions may reduce the likelihood of the Company receiving the full amount of future payments of interest or principal and be accompanied by a deterioration in the value of the underlying collateral as many of these companies may have limited financial resources, may be unable to meet future obligations and may go bankrupt. This could negatively impact the Company’s ability to pay distributions, could adversely affect its results of operation and financial condition and cause the loss of all or part of your investment.
In addition, some of the loans in which the Company may invest may be “covenant-lite” loans. The Company uses the term “covenant-lite” loans to refer generally to loans that do not have a complete set of financial maintenance covenants. Generally, “covenant-lite” loans provide borrower companies more freedom to negatively impact lenders because their covenants are incurrence-based, which means they are only tested and can only be breached following an affirmative action of the borrower, rather than by a deterioration in the borrower’s financial condition. Accordingly, to the extent the Company invests in “covenant-lite” loans, the Company may have fewer rights against a borrower and may have a greater risk of loss on such investments as compared to investments in or exposure to loans with financial maintenance covenants.
     
Risk of Loss [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risk of Loss
. An investment in the Company is highly risky. There can be no assurance that the Company will achieve its investment objective or any particular level of returns. An investor may lose all of its money by investing in the Company. Among other things, the Company may invest in assets that are underperforming or non performing and/or in securities of issuers who are under financial stress. By their nature, such investments are considered speculative and entail substantial risks that are generally higher than the risks of investments in performing assets and securities of issuers that are not under financial stress. Any losses in the Company will be borne solely by investors in the Company and not by the Adviser or any of its respective affiliates (except to the extent they invest capital in the Company, in which case they, with respect to such capital invested, will bear their pro rata portion of such loss).
     
Referral Relationships with Financial Sponsors [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Referral Relationships with Financial Sponsors
. The Adviser expects that the professional staff of the Adviser will maintain and develop their relationships with financial sponsors, including venture capital sponsors, and the Company will rely to a significant extent upon these relationships to provide the Company with potential investment opportunities. If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio. In addition, individuals with whom the professional staff of the Adviser have relationships are not obligated to provide the Company with investment opportunities, and, therefore, there is no assurance that such relationships will generate investment opportunities for the Company. If the Adviser is unable to source investment opportunities, the Company may hold a greater percentage of its assets in cash and cash equivalents than anticipated, which could impact potential returns on the Company’s portfolio.
     
Recourse to the Companys Assets [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Recourse to the Company’s Assets
. The Company’s assets, including any Portfolio Investments made by the Company and any capital held by the Company, are available to satisfy all liabilities and other obligations of the Company. In addition, the Company may pledge its right to call capital from Unitholders. If the Company becomes subject to a liability, parties seeking to have the liability satisfied may have recourse to the Company’s assets generally and may not be limited to any particular asset, such as the Portfolio Investment giving rise to the liability. To the extent the Company chooses to use special-purpose entities for individual transactions to reduce recourse risk (and it may, but will be under no obligation to do so), the
 bona fides
 of such entities may be subject to later challenge based on a number of theories, including veil piercing or substantive consolidation.
     
Unspecified Use of Proceeds [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Unspecified Use of Proceeds
. The proceeds from the issuance of the Units are intended to be invested in Portfolio Investments. Unitholders will not have an opportunity to evaluate for themselves the relevant economic, financial and other information regarding the investments in which the proceeds from the issuance of the Units will be invested and, accordingly, are dependent upon the judgment and ability of the Adviser in investing and managing the capital of the Company.
     
Identification of Potential Investment Opportunities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Identification of Potential Investment Opportunities
. There is no assurance that the Adviser’s analysis in this regard, as implemented, will take into consideration all appropriate factors or appropriately weigh the factors that are considered in its analysis, especially given the heightened difficulty of the analysis required to evaluate certain Portfolio Investments. In particular, catalysts and/or exit strategies that initially appear to be viable may be precluded over time due to economic, legal, political or other factors. In addition, because the successful implementation of the Company’s investment strategy depends, in part, on its ability to successfully predict and take advantage of changing market conditions, to the extent it is unable to do so, returns may be adversely affected. These considerations are particularly relevant in light of the current uncertain economic and regulatory environment. See “—
Regulatory Risks Relating to the Company
” below.
 
     
Competition Potential for Insufficient Investment Opportunities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Competition; Potential for Insufficient Investment Opportunities
. The business of identifying and effecting investments of the types contemplated by the Adviser is competitive and there can be no assurance that the Adviser will be able to identify and obtain a sufficient number of investment opportunities to invest the full amount of capital that may be committed to the Company. Increased competition for, or a diminishment in the available supply of, potential Portfolio Investments could result in lower returns on such Portfolio Investments. The Company may engage in auction or similar bidding processes with respect to certain Portfolio Investments, which processes are often highly competitive and may involve numerous other bidders about which the Company possesses limited or no information; as a result, the foregoing considerations will be applicable with respect to any such processes.
     
Insufficient Capital for FollowOn Investments [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Insufficient Capital for
Follow-On
 Investments
. Following its initial investment in a Portfolio Investment, the Company may have the opportunity to increase its investment in such Portfolio Investment. There is no assurance that the
Company will make follow-on investments or
that the Company will have sufficient resources to, or be permitted to, make such investments. Any decision
not to make follow-on investments or the
Company’s inability to make them may have a substantial negative impact on the company in need of such an investment, may result in missed opportunities for the Company or may result in dilution of the Company’s investment.
     
Concentration of Portfolio Investments [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Concentration of Portfolio Investments
. The Company may participate in a limited number of Portfolio Investments and, as a consequence, the aggregate return of the Company may be substantially adversely affected by the unfavorable performance of any single investment. The Company has a broad and flexible investment mandate, and, beyond the asset diversification requirements associated with the Company’s intention to comply with the requirements to qualify as a RIC for U.S. tax purposes, and except as noted above, the Company is not subject to any limits or proportions with respect to the mix of permitted Portfolio Investments. As a result, the Company’s Portfolio Investments could potentially be concentrated in relatively few strategies, issuers, industries, markets, geographies or
investment types. Such non-diversification would make the
Company more susceptible to risks associated with a single economic, political or regulatory occurrence than a more diversified portfolio might be. The Company could be subject to significant losses if it holds a relatively large position in a single strategy, issuer, industry, market, geographic region or a particular type of Portfolio Investment that declines in value, and the losses could increase even further if the Portfolio Investments cannot be liquidated without adverse market reaction or are otherwise adversely affected by changes in market conditions or circumstances.
     
ThirdParty Involvement [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Third-Party Involvement
. The Company may hold a portion of its investments through partnerships, joint ventures, securitization vehicles or other entities with third-party investors (collectively, “joint ventures”). Joint venture investments involve various risks, including the risk that the Company will not be able to implement investment decisions or exit strategies because of limitations on the Company’s control under applicable agreements with joint venture partners, the risk that a joint venture partner may become bankrupt or may at any time have economic or business interests or goals that are inconsistent with those of the Company, the risk that a joint venture partner may be in a position to take action contrary to the Company’s objectives, the risk of liability based upon the actions of a joint venture partner and the risk of disputes or litigation with such partner and the inability to enforce fully all rights (or the incurrence of additional risk in connection with enforcement of rights) one partner may have against the other, including in connection with foreclosure on partner loans, because of risks arising under state law. In addition, the Company may be liable for actions of its joint venture partners.
     
Leveraged Companies [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Leveraged Companies
. The Company will invest in Portfolio Investments whose capital structures have significant leverage. Such Portfolio Investments are inherently more sensitive to declines in revenues and asset values and to increases in expenses and interest rates. The leveraged capital structure of such Portfolio Investments will increase the exposure of the Portfolio Investments to adverse economic factors such as downturns in the economy or deterioration in the condition of the Portfolio Investment, its underlying assets or its industry. Additionally, the securities acquired by the Company may be the most junior securities in what may be a complex capital structure, and thus subject to the greatest risk of loss.
     
Portfolio Turnover [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Portfolio Turnover
. The Company will not place any limit on the rate of portfolio turnover, and Portfolio Investments may be sold or otherwise disposed of without regard to the time they have been held when, in the judgment of the Adviser, investment considerations warrant such action. A high rate of portfolio turnover involves correspondingly greater expenses than a lower rate, may act to reduce the Company’s investment gains or create a loss for investors and may result in significant tax costs for investors
depending
on the tax provisions applicable to such investors.
     
U.S. Dollar Denomination of Units [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
U.S.
 Dollar Denomination of Units
. Units are denominated in U.S. Dollars. Investors subscribing for Units in any country in which U.S. Dollars are not the local currency should note that changes in the rate of exchange between U.S. Dollars and such currency may have an adverse effect on the value, price or income of the investment to such investor. There may be foreign exchange regulations applicable
to investments in non-U.S. currencies in certain
jurisdictions. Each prospective investor should consult with its own counsel and advisors as to all legal, tax, financial and related matters concerning an investment in the Units.
     
Projections [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Projections
. The Company may rely upon projections, forecasts or estimates developed by the Adviser, the Company or an issuer in which the Company is invested concerning the issuer’s future performance and cash flow. Projections, forecasts and estimates are forward-looking statements, are inherently uncertain and are based upon certain assumptions. Actual events are difficult to predict and beyond the Company’s control. Actual events may differ from those assumed. Some important factors which could cause actual results to differ materially from those in any forward-looking statements include changes in interest rates; domestic and foreign business, market, financial or legal conditions; leverage amounts and costs; and the degree to which the Portfolio Investments are hedged and the effectiveness of such hedges. Accordingly, there can be no assurance that estimated returns or projections can be realized or that actual returns or results will not be materially lower than those estimated therein.
     
Valuation of Illiquid Assets [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Valuation of Illiquid Assets
. It is expected that the majority of the Company’s investments will be in securities or other financial instruments for which market quotations are not available. The process of valuing securities for which reliable market quotations are not available is based on inherent uncertainties, and the resulting values may differ from values that would have been determined had a ready market existed for such securities, from values placed on such securities by other investors and from prices at which such securities may ultimately be sold. In addition, third-party pricing information may at times not be available regarding certain of the Company’s assets or, if available, may not be considered reliable. In particular, recent disruptions in the credit markets have resulted in a severe lack of liquidity for many securities, making them more difficult to value and, in many cases, putting significant downward pressure on prices. Subject to approval by the Board, the Adviser will determine the fair value of securities, loans or other instruments for which market quotes are not readily available (or if extraordinary events occur after the last readily available quotation). The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by
Rule 2a-5 under
the 1940 Act; and (6) maintain recordkeeping requirements under
Rule 2a-5.
There can be no assurance that such valuations will be reliable, accurate or reflective of the prices at which such investments are ultimately realized. In addition, certain of the securities or other assets that the Company seeks to sell or acquire via cross trade may be illiquid and difficult to value, therefore there can be no assurance that such valuation will be accurate.
     
Regulatory Investigations or ThirdParty Litigation [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Regulatory Investigations or Third-Party Litigation
. The Company as well as the Adviser and its affiliates participate in a highly regulated industry and are each subject to regulatory examinations in the ordinary course of business. There can be no assurance that the Company and the Adviser and/or any of its affiliates will avoid regulatory investigation and possible enforcement actions stemming therefrom. The Adviser is a registered investment adviser and, as such, is subject to the provisions of the Advisers Act. The Company and the Adviser are each, from time to time, subject to formal and informal examinations, investigations, inquiries, audits and reviews from numerous regulatory authorities both in response to issues and questions raised in such examinations or investigations and in connection with the changing priorities of the applicable regulatory authorities across the market in general.
The Company’s investment activities may subject it to the risks and costs of becoming involved in litigation with third parties due to, among other reasons, the fact that different investor groups may have qualitatively different, and frequently conflicting, interests with respect to certain Portfolio Investments. The risk of litigation with third parties will be elevated in situations where an issuer is stressed or distressed. See “—
Litigation and Related Risks Associated with Origination and Servicing
” above. The expense of defending against claims by third parties and
paying
any amounts pursuant to settlements or judgments, or bringing claims against third parties, would generally be borne by the Company and would reduce net assets. In addition, the Company’s investment activities may subject it to certain risks inherent in restructuring, bankruptcy and similar proceedings. See “—
Risks Associated with Bankruptcy and Insolvency Cases
” below.
     
Broad Indemnification [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Broad Indemnification
. The Company and/or the Adviser on behalf of the Company may enter into various agreements or arrangements which limit the liability of its Service Providers, including the Adviser and its affiliates, the Administrative Coordinator, the Custodian, and their affiliates, employees, officers and directors, and require the Company to indemnify and/or provide broad representations, warranties and covenants in favor of such persons. U.S. federal and state securities laws impose liabilities under certain circumstances on persons that cannot be waived by contract, other agreements or documents. Therefore, nothing in those agreements should be deemed or construed in a manner that purports to waive or limit any right to the extent prohibited by law.
The Company is required to indemnify the Adviser and its respective affiliates, each of the former, current and future shareholders, partners, members, other equity holders, officers, directors, employees, managers, trustees, agents and other representatives of the Adviser and its respective affiliates, and other persons set forth in the LLC Agreement as an “Indemnitee” for Claims (as defined in the LLC Agreement) that may accrue to or be incurred by an Indemnitee, in connection with any claim, demand, investigation, suit, proceeding or action in which an Indemnitee may become involved, as a party or otherwise, or with which an Indemnitee may be threatened, relating to or arising out of the investments or other activities of the Company, activities undertaken in connection with the Company, or otherwise relating to or arising out of the LLC Agreement or the Subscription Agreement, and otherwise as provided in the LLC Agreement or the Subscription Agreement. Such Claims may be material and have an adverse effect on the returns to the Unitholders. The Company may also provide broad indemnities, representations, warranties and covenants in connection with the acquisition, management and disposition of Portfolio Investments or otherwise in connection with the Company’s investment program.
Any indemnification obligations of the Company would be payable from the assets of the Company, including the unfunded Commitments of the Unitholders, and would adversely affect the Company’s returns.
     
Distributions in Kind [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Distributions in Kind
. If distributions are made of assets held by the Company in lieu of cash, the amount of any such distribution will be accounted for at the fair market value of such assets as determined in accordance with procedures set forth in the LLC Agreement. An independent appraisal generally will not be required and is not expected to be obtained. Assets distributed in kind may not be readily marketable or disposable, and Unitholders therefore must be prepared to bear the risks of owning such assets for an indefinite period of time (and to incur costs and expenses in connection with any disposition thereof). In addition, there can be no
assurance
that the value of such assets as determined in accordance with procedures set forth in the LLC Agreement will ultimately be realized.
     
Failure to Qualify as a RIC [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Failure to Qualify as a RIC
. Although the Company has obtained qualification as a RIC, no assurance can be given that it will be able to maintain qualification as a RIC. To maintain qualification as a RIC, the Company must meet
source-of-income, asset
diversification, and distribution requirements on an ongoing basis.
The income source requirement will be satisfied if the Company obtains at least 90% of gross income for each year from dividends, interest, foreign currency, payments with respect to loans of certain securities, gains from the sale of Units or other securities, net income from certain “qualifiedpublicly traded partnerships,” or similar sources.
The asset diversification requirement will be satisfied if the Company meets certain asset diversification requirements at the end of each quarter of the taxable year. Failure to meet those requirements may result in the Company having to dispose of certain investments quickly in order to prevent the loss of qualification as a RIC. Because most of the Company’s investments will be relatively illiquid, any such dispositions could be made at disadvantageous prices and could result in substantial losses.
The annual distribution requirement will be satisfied if the Company distributes to its Unitholders on an annual basis at least 90% of net ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any. Because the Company may use debt financing, it is subject to certain asset coverage ratio requirements under the 1940 Act and financial covenants under loan and credit agreements that could, under certain circumstances, restrict the Company from making distributions necessary to satisfy the distribution requirement. If the Company is unable to obtain cash from other sources, it could fail to qualify as a RIC.
If the Company fails to qualify as a RIC for any reason and therefore becomes subject to corporate income tax, the resulting corporate taxes could substantially reduce net assets, the amount of income available for distribution and the amount of distributions.
     
Recognizing Income Before or Without Receiving Cash [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Recognizing Income Before or Without Receiving Cash
. For U.S. federal income tax purposes, the Company will include in income certain amounts that the Company has not yet received in cash, such as the accrual of original issue discount (“OID”). This may arise if the Company receives warrants in connection with the making of a loan and in other circumstances, or
through contracted payment-in-kind (“PIK”) interest,
which represents contractual interest added to the loan balance and due at the end of the loan term. Such OID, which could be significant relative to the Company’s overall investment activities, and increases in loan balances as a result of contracted PIK arrangements will be included in income before the Company receives any corresponding cash payments. The Company also may be required to include in income certain other amounts that the Company will not currently receive in cash.
Since in certain cases the Company may recognize income before or without receiving cash representing such income, the Company may have difficulty meeting the requirement to timely distribute at least 90% of its net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any, to maintain its qualification as a RIC. In such a case, the Company may have to sell some of its Portfolio Investments at times the Company would not consider advantageous or raise additional debt or equity capital or reduce new investment originations to meet these distribution requirements. If the Company is not able to obtain cash from other sources and is otherwise unable to satisfy such distribution requirement, the Company may fail to maintain its qualification as a RIC and become subject to corporate-level U.S. federal income tax.
     
Tax Considerations Regarding Dividends for Private BDCs [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Tax Considerations Regarding Dividends for Private BDCs
. The Company does not currently qualify as a “publicly offered regulated investment company,” as defined in the Code. Accordingly, U.S. individual and other noncorporate Unitholders will be taxed as though they received a distribution of some of the Company’s expenses. A “publicly offered regulated investment company” is a RIC whose Units are either (i) continuously offered pursuant to a public offering, (ii) regularly traded on an established securities market, or (iii) held by at least 500 persons at all times during the taxable year. The Company anticipates that it will not qualify as a publicly offered RIC for the 2023 tax year, and cannot determine when it will qualify as a publicly offered RIC. Since the Company is not a publicly offered RIC,
a non-corporate Unitholder’s
allocable portion of the Company’s affected expenses, including a portion of its management fees, will be treated as an additional distribution to the Unitholders.
A non-corporate Unitholder’s
allocable portion of these expenses are treated as miscellaneous itemized deductions that are not currently deductible by such Unitholder (and beginning in 2026, will be deductible by such Unitholder for regular U.S. federal income tax purposes but not for alternative minimum tax purposes only to the extent they exceed 2% of such Unitholder’s adjusted gross income).
     
Potential Dividend Deferrals [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Potential Dividend Deferrals
. In order to maintain its tax status as a RIC, the Company must distribute to Unitholders for each taxable year at least 90% of its investment company taxable income (i.e., net ordinary income plus realized net short-term capital gains in excess of realized net long-term capital losses). If the Company qualifies for taxation as a RIC, it generally will not be subject to corporate-level U.S. federal income tax on its investment company taxable income and net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) that it timely distributes to Unitholders. The Company will be subject to a 4% U.S. federal excise tax on undistributed earnings of a RIC unless it distributes each calendar year at least the sum of (i) 98.0% of its ordinary income for the calendar year, (ii) 98.2% of its capital gains in excess of capital losses for
the one-year period
ending on October 31 of the calendar year, and (iii) any ordinary income and net capital gains for preceding years that were not distributed during such years and on which it paid no U.S. federal income tax.
Under the Code, the Company may pay certain RIC dividends after the end of the current year. In particular, if the Company pays a distribution in January of the following year that was declared in October, November, or December of the current year and is payable to Unitholders of record in the current year, the dividend will be treated for all U.S. federal income tax purposes as if it were paid on December 31 of the current year. In addition, under the Code, the Company may pay dividends, referred to as “spillover dividends,” that are paid during the following taxable year that will allow the Company to maintain its qualification for taxation as a RIC and eliminate its liability for corporate-level U.S. federal income tax. Under these spillover dividend procedures, the Company may defer distributions of income earned during the current year until December of the following year. For example, the Company may defer distributions of income earned during 2024 until as late as December 31, 2025. If the Company chooses to pay a spillover dividend, it will incur the 4% U.S. federal excise tax on some or all of the distribution.
Due to events such as
the COVID-19 pandemic,
certain regional bank failures, the Russian invasion of Ukraine, the ongoing war in the Middle East or other disruptions in the economy, such as the recent inflationary environment, the Company may take certain actions with respect to the timing and amounts of its distributions in order to preserve cash and maintain flexibility. For example, the Company may reduce and/or defer dividends to the following year as discussed above. To further preserve cash, the Company may combine these deferrals of dividends with one or more distributions that are payable partially in Units as discussed below under “
In-Kind
 Dividend Considerations
.”
     
InKind Dividend Considerations [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
In-Kind
 Dividend Considerations
. The Company may distribute taxable dividends that are payable in part in Units. In accordance with certain applicable U.S. Treasury regulations and published IRS guidance, a RIC may treat a distribution of its own shares as fulfilling the RIC distribution requirements if each Unitholder may elect to receive the entire distribution in either cash or shares of the RIC. The IRS has published a revenue procedure indicating that, in the case of publicly offered RICs, this rule will apply where the total amount of cash to be distributed is not less than 20% of the total distribution. Under this revenue procedure, if too many Unitholders elect to receive cash, the cash available for distribution must be allocated among the Unitholders electing to receive cash (with the balance of the distribution paid in Units). Because the Company is not currently a publicly offered RIC, its ability to rely on the revenue procedure and other guidance is uncertain. If the Company elects to pay a distribution in its own Units consistent with the revenue procedure and other guidance, for U.S. federal income tax purposes, the amount of the dividend paid in Units will be equal to the amount of cash that could have been received instead of Units. Taxable Unitholders receiving such dividends will be required to include the amount of the dividends as ordinary income (or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of the Company’s current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a Unitholder may be required to pay tax with respect to such dividends in excess of any cash received, and, the Company may be required to withhold U.S. tax with respect to dividends payable in Units
to non-U.S. Unitholders.
     
Changes in Tax Law [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Changes in Tax Law
. Legislative or other actions relating to taxes could have a negative effect on the Company. The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. New legislation and any other tax law developments including new or revised U.S. Treasury regulations, administrative interpretations or court decisions, could negatively and perhaps retroactively affect the U.S. federal income tax consequences to the Company and its Unitholders, or could have other adverse consequences. Investors are urged to consult with their tax advisor regarding tax legislative, regulatory, or administrative developments and proposals and their potential effect on an investment in the Company.
 
     
Permissible Incurred Leverage [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Permissible Incurred Leverage
. Leverage magnifies the potential for loss on investments and on invested equity capital. As the Company uses leverage to partially finance its investments, Unitholders will experience increased risks of investing in the Company’s securities. If the value of the Company’s assets increases, then leveraging would cause the NAV attributable to the Company’s Units to increase more sharply than it would have had the Company not leveraged. Conversely, if the value of the Company’s assets decreases, leveraging would cause NAV to decline more sharply than it otherwise would have had the Company not leveraged its business. Similarly, any increase in the Company’s income in excess of interest payable on the borrowed funds would cause net investment income to increase more than it would without the leverage, while any decrease in the Company’s income would cause net investment income to decline more sharply than it would have had the Company not borrowed. Such a decline could negatively affect the Company’s ability to pay dividends on Units, scheduled debt payments or other payments related to securities. Leverage is generally considered a speculative investment technique.
     
Distribution and Asset Coverage Ratio Requirements [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Distribution and Asset Coverage Ratio Requirements
. In order to satisfy the requirements applicable to RICs and to avoid payment of excise taxes, the Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain net income except for certain net capital gains, which it intends to retain and to elect to treat as deemed distributions to Unitholders. The Company may issue debt securities, other evidences of indebtedness or preferred Units, and may borrow money from banks or other financial institutions, which are referred to collectively herein as “senior securities,” up to the maximum amount permitted by the 1940 Act. The 1940 Act permits the Company to issue senior securities in
amounts
such that its asset coverage, as defined in the 1940 Act, equals at least 150% after each issuance of senior securities. The Company’s ability to pay dividends or issue additional senior securities would be restricted if the asset coverage ratio were not at least 150%. If the value of the Company’s assets declines, the Company may be unable to satisfy this test. If that happens, the Company may be required to liquidate a portion of its investments and repay a portion of its indebtedness at a time when such sales or repayment may be disadvantageous. As a result of issuing senior securities, the Company will also be exposed to typical risks associated with leverage, including an increased risk of loss. If the Company issues preferred Units, such preferred Units will rank “senior” to common Units in the Company’s capital structure, preferred Unitholders will have separate voting rights for certain purposes and may have rights, preferences or privileges more favorable than those of the Company’s common Units and the issuance of preferred Units could have the effect of delaying, deferring or preventing a transaction or a change of control that might involve a premium price for Unitholders or otherwise be in the best interest of Unitholders.
To the extent the Company is constrained in its ability to issue debt or other senior securities, it will depend on issuances of capital interests to finance operations. As a BDC, the Company is generally not able to issue Units at a price below NAV without first obtaining required approvals of Unitholders and independent directors in accordance with the conditions set forth in Section 63(2) of the 1940 Act. If the Company raises additional funds by issuing more common Units or senior securities convertible into, or exchangeable for, common Units, the percentage ownership of Unitholders at that time would decrease and Unitholders may experience dilution. In addition to issuing securities to raise capital as described above, the Company could, in the future, securitize loans to generate cash for funding new investments. An inability to successfully securitize its loan portfolio could limit the Company’s ability to grow its business, fully execute its business strategy and improve profitability.
     
Unrealized Depreciation [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Unrealized Depreciation
. As a BDC, the Company is required to carry investments at market value or, if no market value is ascertainable, at fair value as determined in good faith by the Board. Decreases in the market values or fair values of investments will be recorded as unrealized depreciation. Any unrealized depreciation in the Company’s loan portfolio could be an indication of a Portfolio Investment’s inability to meet its repayment obligations with respect to the loans whose market values or fair values decreased. This could result in realized losses in the future and ultimately in reductions of income available for distribution in future periods.
     
Qualifying Asset Requirements [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Qualifying Asset Requirements
. As a BDC, the Company may not acquire any assets other than “qualifying assets” unless, at the time of such acquisition, at least 70% of its total assets are qualifying assets. Therefore, the Company may be precluded from investing in what it believes are attractive investments if such investments are not qualifying assets. Similarly, these rules could prevent the Company from making additional investments in existing Portfolio Investments, which could result in the dilution of its position, or could require disposal of investments at an inopportune time to comply with the 1940 Act. If the Company were forced to
sell non-qualifying investments
for compliance purposes, the proceeds from such sale could be significantly less than the current value of such investments. Conversely, if the Company failed to invest a sufficient portion of assets in qualifying assets, it could lose status as a BDC, which would subject the Company to substantially more regulatory restrictions and significantly decrease operating flexibility.
 
     
Exemptive Relief [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Exemptive Relief
. The Company and the other BDCs for which SLR is the investment adviser (SLR Investment Corp. (Nasdaq: SLRC) (“SLRC”), SCP Private Credit Income BDC LLC (“PCI BDC”) and SLR Private Credit BDC II LLC (“PC BDC,” and, together with SLRC and PCI BDC, the “SLR BDCs”) are substantially limited in their
ability to co-invest in privately
negotiated transactions with affiliated funds other than as permitted by the Order. While the Order permits the Company to participate
in negotiated co-investment transactions with
the SLR BDCs and other affiliated funds, such participation is subject to numerous conditions. If the Company and the SLR BDCs are unable to comply with these conditions or are otherwise unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although SLR will endeavor to allocate investment opportunities in a fair and equitable manner, the Company could be adversely affected to the extent investment opportunities are allocated among the Company and other investment vehicles managed or sponsored by, or affiliated with SLR and its affiliates, including the SLR BDCs, pursuant to the conditions of the Order.
     
Risks Related to Changes in Regulatory Policy [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Related to Changes in Regulatory Policy
. The U.S. government has recently called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new and
difficult-to-quantify
macroeconomic and political risks with potentially
far-reaching
implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas.
 
     
Financial Services and Government Intervention [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Financial Services and Government Intervention
. From time to time, certain governments and regulatory authorities, such as the U.S. federal government, the U.S. Federal Reserve and the governments and regulatory authorities of certain member countries of the EU, have taken actions to provide or arrange credit support to financial institutions whose operations have been compromised by credit market dislocations and to restore liquidity and stability to the financial system in such jurisdictions. The implementation of any current or future governmental interventions (which may be significantly altered or terminated prior to implementation or during their terms), and their impact on both the credit markets generally and the Company’s investment program in particular, are uncertain.
     
U.S. DoddFrank Wall Street Reform and Consumer Protection Act [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act
. In response to the recent disruption in the credit markets and the global economic downturn, various agencies and regulatory bodies of the U.S. federal government have taken or are considering taking various actions. These actions include, but are not limited to, the enactment of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), which was signed into law on July 21, 2010, and which imposes a new regulatory framework over the U.S.
financial services industry, non-U.S. financial entities
that are regulated by or affiliated with entities regulated by U.S. financial regulators, and the consumer credit markets in general, and proposed and final regulations adopted thereunder, as well as proposed and final regulations to implement the Basel III regulatory capital accords. Given the broad scope and sweeping nature of these changes and the fact that certain final implementing rules and regulations have not yet been adopted or implemented, the potential impact of these actions on the Adviser and the Company is unknown, and no assurance can be made that the impact of such changes would not have a material adverse effect on the Adviser or the Company. For example, the U.S. Financial Stability Oversight Council (“FSOC”) created by the Dodd-Frank Act has the authority to designate asset management firms as a “systemically important financial institution” (“SIFI”). If the Adviser, or one of its affiliates, were designated as a SIFI, it would be subject to a variety of regulations, including capital requirements and limitations on leverage, which could have a material adverse effect on the ability of the Company to pursue its investment strategy. In addition, the Dodd-Frank Act created a new regulator for the credit industry in the U.S. known as the U.S. Consumer Financial Protection Bureau (“CFPB”). The CFPB may, among other things, regulate interest rates and other charges, require certain disclosures and regulate foreclosure practices. Future regulatory actions authorized by the Dodd-Frank Act (including any regulatory actions or other measures taken by the FSOC and/or the CFPB) may significantly reduce the profitability of the Company and its Portfolio Investments.
     
Changes to Derivatives Regulation [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Changes to Derivatives Regulation
. Through comprehensive new global regulatory regimes impacting derivatives (
e.g.
, the Dodd-Frank Act, European Market Infrastructure Regulation (“EMIR”), Markets in Financial Investments Regulation (“MIFIR”)/Markets in Financial Instruments Directive
(“MIFID II”)), certain over-the-counter derivatives transactions
in which the Company may engage are either now or will soon be subject to various requirements, such as mandatory central clearing of transactions which include additional margin requirements and in certain cases trading on electronic platforms,
pre-and
post-trade transparency reporting
requirements and mandatory bi-lateral exchange of
initial margin for non-cleared swaps.
The Dodd-Frank Act also created new categories of regulated market participants, such as “swap dealers,” “security-based swap dealers,” “major swap participants,” and “major security-based swap participants” who are subject to significant new capital, registration, recordkeeping, reporting, disclosure, business conduct and other regulatory requirements. The EU and some other jurisdictions are implementing similar requirements. Because these requirements are new and evolving (and some of the rules are not yet final), their ultimate impact remains unclear. However, even if the Company itself is not located in a particular jurisdiction or directly subject to the jurisdiction’s derivatives regulations, the Company may still be impacted to the extent the Company enters into a derivatives transaction with a regulated market participant or counterparty that is organized in that jurisdiction or otherwise subject to that jurisdiction’s derivatives regulations.
Based on information available as of the date of this annual report
on Form 10-K, the
effect of such requirements will be likely to (directly or indirectly) increase the Company’s overall costs of entering into derivatives transactions. In particular, new margin requirements, position limits and significantly higher capital charges resulting from new global capital regulations, even if not directly applicable to the Company, may cause an increase in the pricing of derivatives transactions entered into by market participants to whom such requirements apply or affect the overall ability of the Company to enter into derivatives transactions with certain counterparties. Such new global capital regulations and the need to satisfy the various requirements by counterparties are resulting in increased funding costs and increased overall transaction costs and are significantly affecting balance sheets, thereby resulting in changes to financing terms and potentially impacting the Company’s ability to obtain financing. Administrative costs, due to new requirements such as registration, recordkeeping, reporting, and compliance, even if not directly applicable to the Company, may also be reflected in the Company’s derivatives transactions. New requirements to trade certain derivatives transactions on electronic trading platforms and trade reporting requirements may lead to (among other things) fragmentation of the markets, higher transaction costs or reduced availability of derivatives, and/or a reduced ability to hedge, all of which could adversely affect the performance of certain of the Company’s investing strategies. In addition, changes to derivatives regulations may impact the tax and/or accounting treatment of certain derivatives, which could adversely impact the Company.
 
In November 2020, the SEC adopted new rules regarding the ability of a BDC (or a registered investment company) to use derivatives and other transactions that create future payment or delivery obligations. BDCs that use derivatives will be subject to a
value-at-risk
leverage limit, certain other derivatives risk management program and testing requirements and requirements related to board reporting. These new requirements would apply unless the BDC qualified as a “limited derivatives user,” as defined in the adopted rules. A BDC that enters into reverse repurchase agreements or similar financing transactions would need to aggregate the amount of indebtedness associated with the reverse repurchase agreements or similar financing transactions and could either (i) comply with the asset coverage requirements of Section 18 of the 1940 Act when engaging in reverse repurchase agreements or (ii) choose to treat such agreements as derivative transactions under the adopted rules. Under the adopted rules, a BDC may enter into an unfunded commitment agreement that is not a derivatives transaction, such as an agreement to provide financing to a Portfolio Investment, if the BDC has a reasonable belief, at the time it enters into such an agreement, that it will have sufficient cash and cash equivalents to meet its obligations with respect to all of its unfunded commitment agreements, in each case as it becomes due. If the BDC cannot meet this test, it is required to treat unfunded commitments as a derivatives transaction subject to the requirements of the rule. Collectively, these requirements may limit the Company’s ability to use derivatives and/or enter into certain other financial contracts.
     
Uncertainty of the U.S. Political Climate [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Uncertainty of the U.S. Political Climate
. The current administration has called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new
and difficult-to-quantify
macroeconomic and political risks with
potentially far-reaching
implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although the Company cannot predict the impact, if any, of these changes to its business, they could adversely affect the Company’s business, financial condition, operating results and cash flows. Until the Company knows what policy changes are made and how those changes impact its business and the business of the Company’s competitors over the long term, the Company will not know if, overall, it will benefit from them or be negatively affected by them.
Bad Actor” Restrictions for Private Placements Conducted Under Rule 506 of Regulation D
. An issuer is precluded from conducting offerings that rely on the exemption from registration under the Securities Act provided by Rule 506 of Regulation D (“Rule 506 Offerings”) if a “covered person” of the issuer has been the subject of a “disqualifying event” (each as defined below). “Covered persons” include, among others, the issuer, affiliated issuers, any investment manager or solicitor of the issuer, any director, executive officer or other officer participating in the offering of the issuer, any general partner or managing member of the foregoing entities, any promoter of the issuer and any beneficial owner of 20% or more of the issuer’s outstanding voting equity securities, calculated on the basis of voting power. A “disqualifying event” includes, among other things, certain (a) criminal convictions and court injunctions and restraining orders issued in connection with the purchase or sale of a security or false filings with the SEC, (b) final orders from the CFTC, U.S. Federal banking agencies and certain other regulators that bar a person from associating with a regulated entity or engaging in the business of securities, insurance or banking or that are based on certain fraudulent conduct, (c) SEC disciplinary orders relating to investment advisers, brokers, dealers and their associated
persons, (d) SEC cease-and-desist orders relating
to violations of certain anti-fraud provisions and registration requirements of the U.S. federal securities laws, (e) suspensions or expulsions from membership in a self-regulatory organization (“SRO”) or from association with an SRO member, and (f) U.S. Postal Service false representation orders.
A disqualification will occur only in the case of a disqualifying event of a covered person that occurs on or after September 23, 2013, although issuers must disclose to potential investors in a Rule 506 Offering disqualifying events of covered persons that occurred before September 23, 2013. The rule provides an exception from disqualification if the issuer can show that it did not know and, in the exercise of reasonable care could not have known, that the issuer or any other covered person had a disqualifying event, although an issuer will not be able to establish that it has exercised reasonable care unless it has made, in light of the circumstances, factual inquiry into whether any disqualifications exist.
The Adviser has made, and on a periodic basis will continue to make, inquiries into whether any persons that the Adviser has determined to be affiliated issuers have been subject to any disqualifying events; however, in some circumstances the Adviser’s ability to determine whether the Company would be disqualified from relying on Rule 506 may depend on cooperation of third parties over whom the Company may have limited control and influence.
If any of the Adviser’s covered persons, including any affiliated issuer of the Company, is subject to a disqualifying event, the Company could lose the ability to raise capital in a future Rule 506 offering for a significant period of time and the Company’s business, financial condition and results of operations could be materially and adversely affected.
     
Changes to Accounting Standards [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Changes to Accounting Standards
. The Financial Accounting Standards Board’s Accounting Codification Standards and updates, and additional provisions of U.S. generally accepted accounting principles (“U.S. GAAP”) (or to the extent applicable, International Financial Reporting Standards or other applicable accounting or financial reporting standards), that may be adopted in the future may impose additional, or different, specific requirements as to the valuation of assets and liabilities for purposes of U.S. GAAP-compliant financial reporting.
     
Licensing Requirements [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Licensing Requirements
. Various licensing requirements could apply to the Company or the Adviser with respect to investments in, or the origination, holding, servicing and disposing of, loans and similar assets. The licensing requirements could apply depending on the location of the borrower, the location of the collateral securing the loan, or the location where the Company or the Adviser operates or has offices. Moreover, the Company’s ability to invest in certain properties, participate in the secondary mortgage market, obtain financing for investments, lease properties to tenants and/or engage in lending, advisory, servicing and/or broker activities may be subject to the issuance of permits or licenses. If the Company applies for such licenses, this process may be costly and take several months. There is no assurance that the Company will obtain all of the licenses that it desires or that the Company would not experience significant delays in seeking these licenses. In states and other jurisdictions in which it is licensed, the Company or the Adviser is required to comply with applicable laws and regulations, including possible information requirements and consumer protection and anti-fraud laws, which could impose restrictions on the Company’s or the Adviser’s ability to take certain actions to protect the value of its investments in such assets and impose compliance costs. Failure to comply with such laws and regulations could lead to, among other penalties, a loss of the Company’s or the Adviser’s license, which in turn could restrict the Company’s investment options or require the Company to divest assets located in or secured by real property located in that jurisdiction. These risks also apply to issuers and entities in which the Company invests that hold similar assets, as well as any origination company or servicer in which the Company owns an interest.
     
Reporting Company Filing Requirements [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Reporting Company Filing Requirements
. As a BDC, the Company is subject to the reporting requirements of the 1934 Act and requirements of the Sarbanes-Oxley Act. These requirements may place a strain on systems and resources. The 1934 Act requires that the Company file annual, quarterly and current reports with respect to business and financial condition. The Sarbanes-Oxley Act requires that the Company maintain effective disclosure controls and procedures and internal controls over financial reporting, which are discussed below. In order to maintain and improve the effectiveness of disclosure controls and procedures and internal controls, significant resources and management oversight are required. The Company has implemented procedures, processes, policies and practices for the purpose of addressing the standards and requirements applicable to reporting companies. These activities may divert management’s attention from other business concerns, which could have a material adverse effect on business, financial condition, results of operations and cash flows. The Company incurs significant additional annual expenses related to these steps and, among other things, directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, additional administrative expenses payable to the Administrative Coordinator to compensate them for hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses.
The systems and resources necessary to comply with public company reporting requirements will increase further once the Company ceases to be an “emerging growth company” under the JOBS Act. As long as the Company remains an emerging growth company, it intends to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. The Company will remain an emerging growth company for up to five years following any future IPO (however, the Company does not anticipate engaging in an IPO of its Units), although if the market value of the Units that are held by
non-affiliates
exceeds $700 million as of any June 30 before that time, the Company would cease to be an emerging growth company as of the following December 31.
Additionally, because the Units are registered under the 1934 Act, ownership information for any person who beneficially owns 5% or more of the Units will have to be disclosed in a Schedule 13G or other filings with the SEC. Beneficial ownership for these purposes is determined in accordance with the rules of the SEC, and includes having voting or investment power over the securities. In some circumstances, Unitholders who choose to reinvest their dividends may see their percentage stake in the Company increased to more than 5%, thus triggering this filing requirement. Each Unitholder is responsible for determining their filing obligations and preparing the filings. In addition, Unitholders who hold more than 10% of a class of Units may be subject to Section 16(b) of the 1934 Act, which recaptures for the benefit of the Company profits from the purchase and sale of registered
Units within a six-month period.
     
Documentation of Internal Controls [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Documentation of Internal Controls
. The Company is obligated to maintain proper and effective internal control over financial reporting, including the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act (“Section 404”). The Company is not required to comply with all of the requirements under Section 404 until the date it is no longer an emerging growth company under the JOBS Act. Accordingly, the Company’s internal controls over financial
 
reporting do not currently meet all of the standards contemplated by Section 404 that they will eventually be required to meet. Specifically, the Company is required to conduct annual management assessments of the effectiveness of its internal controls over financial reporting. However, the Company’s independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial reporting until the date it is no longer an emerging growth company under the JOBS Act.
The Company’s internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If the Company fails to maintain the adequacy of its internal controls, including any failure to implement required new or improved controls, or if the Company experiences difficulties in their implementation, the Company’s business and operating results could be harmed and it could fail to meet its financial reporting obligations.
     
High Yield Debt and Unrated Securities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
High Yield Debt and Unrated Securities
. High yield securities are typically junior to the obligations of companies to senior creditors, trade creditors and employees. High yield securities and unrated securities (which are not rated by a rating agency) may be more susceptible to real or perceived adverse economic and competitive industry conditions than investment-grade securities. A projection of an economic downturn or of a period of rising interest rates, such as the recent economic period, for example, could cause a decline in the prices of high yield securities and unrated securities, because the advent of a recession could lessen the ability of an issuer to make principal and interest payments on its debt obligations. In addition, such securities have historically experienced greater default rates than investment grade securities. The ability of holders of high yield debt to influence a company’s affairs will be substantially less than that of senior creditors, especially during periods of financial distress or following insolvency.
As with other Portfolio Investments, there may not be a liquid market for certain high yield debt which is held by the Company, which could result in the Company being unable to sell such securities for an extended period of time, if at all. In addition, as with other types of Portfolio Investments, the market for high yield debt has historically been subject to disruptions that have caused substantial volatility in the prices of such securities. Consolidation in the financial services industry has resulted in there being fewer market makers for high yield debt, which may result in further risk of illiquidity and volatility with respect to high yield debt held by the Company, and this trend may continue in the future. Furthermore, high yield debt which is held by the Company may not be registered under the Securities Act, and, unless so registered, the Company is not able to sell such high yield debt except pursuant to an exemption from registration under the Securities Act. Unrated securities may be less liquid than comparable rated securities and may also involve the risk that the Adviser may not accurately evaluate the security’s comparative credit rating.
Analysis of creditworthiness of issuers of high yield and unrated securities may be more complex than for issuers of higher-quality fixed income securities. Since it is expected that most of the Company’s assets will not be rated by any rating agency or will be rated below investment grade, the Company is more dependent on the Adviser’s creditworthiness analysis than if the Company invested exclusively in higher-quality and rated securities. Securities rated below investment grade are often referred to as “leveraged loans,” “high yield” or “junk” securities, and may be considered “high risk” compared to debt instruments that are rated investment grade. See “—
General Credit Risk
” above.
     
EquityRelated Securities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Equity-Related Securities
. As with other Portfolio Investments, the value of equity or equity-related securities held by the Company may be adversely affected by actual or perceived negative events relating to the issuer of such securities, the industry or geographic areas in which such issuer operates or the financial markets generally. However, equity securities may be even more susceptible to such events given their subordinate position in the issuer’s capital structure. As such, equity securities generally have greater price volatility than fixed income securities, and the market price of equity securities owned by the Company is more susceptible to moving up or down in a rapid or unpredictable manner. In addition, equity securities
often
lose a significant amount of their value and may become worthless as a result of a bankruptcy proceeding or reorganization.
     
Convertible Securities Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Convertible Securities Risk
. Convertible securities generally offer lower interest or dividend yields than
non-convertible
debt securities of similar quality. The market values of convertible securities tend to decline as interest rates increase and, conversely, to increase as interest rates decline. However, a convertible security’s market value tends to reflect the market price of the common stock of the issuing company when that stock price approaches or is greater than the convertible security’s “conversion price.” The conversion price is defined as the predetermined price at which the convertible security could be exchanged for the associated stock. As the market price of the underlying common stock declines, the price of the convertible security tends to be influenced more by the yield of the convertible security. Thus, it may not decline in price to the same extent as the underlying common stock. Generally, in the event of a liquidation of the issuing company, holders of
 
convertible securities would be paid before the company’s common stockholders but after holders of any senior debt obligations of the company. Consequently, the issuer’s convertible securities generally entail less risk than its common stock but more risk than its debt obligations. There is also a risk that, under certain circumstances, a bankruptcy court may order that convertible securities are treated as equity.
The Company may invest in synthetic convertible securities, which are created through a combination of separate securities that possess the two principal characteristics of a traditional convertible security,
i.e.
, an income-producing security (“income-producing component”) and the right to acquire an equity security (“convertible component”). The income-producing component is achieved by investing in
non-convertible,
income-producing securities such as bonds, preferred stocks and money market instruments. The convertible component is achieved by purchasing warrants or options to buy common stock at a certain exercise price, or options on a stock index. The values of synthetic convertible securities will respond differently to market fluctuations than a traditional convertible security because a synthetic convertible is composed of two or more separate securities or instruments, each with its own market value. Synthetic convertible securities are also subject to the risks associated with derivatives. In addition, if the value of the underlying common stock or the level of the index involved in the convertible element falls below the strike price of the warrant or option, the warrant or option may lose all value.
     
Preferred Securities Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Preferred Securities Risk
. In addition to credit risk, investment in preferred stocks involves certain other risks. Certain preferred stocks contain provisions that allow an issuer under certain conditions to skip or defer distributions. If the Company owns preferred stock that is deferring its distribution, the Company may be required to report income for U.S. federal income tax purposes despite the fact that it is not receiving current income on this position. Preferred stock often is subject to legal provisions that allow for redemption in the event of certain tax or legal changes or at the issuer’s call. In the event of redemption, the Company may not be able to reinvest the proceeds at comparable rates of return. Preferred stock is subordinated to bonds and other debt securities in an issuer’s capital structure in terms of priority for corporate income and liquidation payments and, therefore, will be subject to greater credit risk than those debt securities. Preferred stock may trade less frequently and in a more limited volume and may be subject to more abrupt or erratic price movements than many other securities, such as common stocks, corporate debt securities and U.S. government securities.
     
Forwards and Derivatives Transactions [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Forwards and Derivatives Transactions
. The Company may engage in a variety of derivatives transactions. A
derivative
is a financial contract the value of which depends upon, or is derived from, the value of underlying assets, reference rates or indices. Derivatives may relate to securities, interest rates, currencies or currency exchange rates, inflation rates, commodities and related indices, and include foreign currency contracts, swap contracts, options, forward and futures contracts (including options thereon), repurchase or reverse repurchase
agreements or other over-the-counter contracts. The
Company may use derivatives for many purposes, including as a substitute for direct investment, as a way to adjust its exposure to various securities, markets and currencies without actually having to sell existing investments and/or make new investments, and as a means to hedge other investments and to manage liquidity and excess cash. The Company’s use of derivatives may result in losses, reduce the Company’s return, and/or increase the volatility of the Company (particularly since many derivatives are inherently leveraged), especially in unusual or extreme
market
conditions
.
All derivatives transactions involve risks different from, and potentially greater than, the risks associated with investing directly in securities and other more traditional assets, including:
     
Market Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Market Risk
. This is the general risk that the value of a particular investment or transaction will change in a way detrimental to the Company’s interests.
     
Management Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Management Risk
. Derivatives contracts are specialized contracts that require investment techniques and risk analyses with additional levels of complexity associated with the underlying investments. In addition to risks associated with the underlying instruments, counterparty and unsecured risk (among others) need to be computed and tracked in relation to the Company’s overall risk profile.
     
Documentation Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Documentation Risk
. Many derivatives transactions also have documentation risk. Because contracts for
over-the-counter
derivatives transactions are individually negotiated with specific counterparties, there exists the risk that the parties may interpret contractual terms (
e.g.
, the definition of default) differently than the Company. If that occurs, the cost and unpredictability of the legal proceedings required for the Company to enforce its contractual rights may lead the Company to decide not to pursue its claims against the counterparty. The Company, therefore, assumes the risk that it may be unable to obtain payments the Adviser believes are owed to it under derivatives transactions, or those payments may be delayed or made only after the Company has incurred the costs of litigation. Also, payment amounts calculated in connection with standard industry conventions for resolving contractual issues (
e.g.
, ISDA Protocols and auction processes) may be different than would be realized if a counterparty were required to comply with the literal terms of the derivatives transaction (
e.g.
, physical delivery). There is little case law interpreting the terms of most derivatives or characterizing their tax treatment.
 
     
Regulatory Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Regulatory Risk
. The derivatives market is subject to various risks related to existing as well as new and evolving regulation both within and outside the U.S. Additional regulation of the derivatives markets may make derivatives more costly, may limit the availability of derivatives, or may otherwise adversely affect the value or performance of derivatives. Any such adverse future developments could impair the effectiveness of a Company’s derivatives transactions and cause the Company to lose value. They may also render certain strategies in which the Company might otherwise engage impossible or so costly that they will no longer be economical to implement. See “—
Changes to Derivatives Regulation
” above.
     
Other Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Other Risks
. Derivatives also involve the risk that changes in their value may not correlate perfectly with the assets, rates or indices they are designed to track. Suitable derivatives may not be available in all circumstances. Under the terms of certain contracts governing derivatives transactions, the occurrence of certain events with respect to the Company (such as a decline in the Company’s NAV) may cause the Company’s derivatives transactions to be terminated early, including at an inopportune time or at an unfavorable price.
     
Warrants and Rights [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Warrants and Rights
. The Company may purchase or otherwise receive warrants or rights. Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a stated price. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of options. Unlike most options, however, warrants and rights are issued in specific amounts, and warrants generally have longer terms than options. Warrants and rights are not likely to be as liquid as exchange-traded options backed by a recognized clearing agency. In addition, the terms of warrants or rights may limit the Company’s ability to exercise the warrants or rights at such time, or in such quantities, as the Company would otherwise wish.
     
Risks Relating to Reference Rates [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks
 Relating to Reference Rates
. The London Interbank Offered Rate (“LIBOR”) is an index rate that historically was widely used in lending transactions and was a common reference rate for setting the floating interest rate on private loans. LIBOR was typically the reference rate used in floating-rate loans extended to the Company’s Portfolio Investments.
The ICE Benchmark Administration (“IBA”) (the entity that is responsible for calculating LIBOR) ceased providing overnight, one, three, six and twelve months USD LIBOR tenors on June 30, 2023. In addition, the United Kingdom’s Financial Conduct Authority (“FCA”), which oversees the IBA, now prohibits entities supervised by the FCA from using LIBORs, including USD LIBOR, except in very limited circumstances.
In the United States, SOFR is the preferred alternative rate for LIBOR. SOFR is a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. SOFR is published by the Federal Reserve Bank of New York each U.S. Government Securities Business Day, for transactions made on the immediately preceding U.S. Government Securities Business Day. Alternative reference rates that may replace LIBOR, including SOFR for USD transactions, may not yield the same or similar economic results as LIBOR over the lives of such transactions.
As of the filing date of this annual report on Form
10-K,
many of the Company’s loans that referenced LIBOR have been amended to reference the forward-looking term rate published by CME Group Benchmark Administration Limited based on SOFR (“CME Term SOFR”) or CME Term SOFR plus a fixed spread adjustment. CME Term SOFR rates are forward-looking rates that are derived by compounding projected overnight SOFR rates over one, three, and six months taking into account the values of multiple consecutive, executed,
one-month
and three-month CME Group traded SOFR futures contracts and, in some cases,
over-the-counter
SOFR Overnight Indexed Swaps as an indicator of CME Term SOFR reference rate values. CME Term SOFR and the inputs on which it is based are derived from SOFR. Since CME Term SOFR is a relatively new market rate, there will likely be no established trading market for credit agreements or other financial instruments when they are issued, and an established market may never develop or may not be liquid. Market terms for instruments referencing CME Term SOFR rates may be lower than those of later-issued CME Term SOFR indexed instruments. Similarly, if CME Term SOFR does not prove to be widely used, the trading price of instruments referencing CME Term SOFR may be lower than those of instruments indexed to indices that are more widely used. Further, the composition and characteristics of SOFR and CME Term SOFR are not the same as those of LIBOR. Even with the application of a fixed spread adjustment, LIBOR and CME Term SOFR will not have the same composition and characteristics, and there can be no assurance that the replacement rate, as so adjusted, will be a direct substitute for LIBOR.
There can be no guarantee that SOFR will not be discontinued or fundamentally altered in a manner that is materially adverse to the interests of investors in loans referencing SOFR. If the manner in which SOFR or CME Term SOFR is calculated is changed, that change may result in a reduction of the amount of interest payable on such loans and the trading prices of the SOFR Loans. In addition, there can be no guarantee that loans referencing SOFR or CME Term SOFR will continue to reference those rates until maturity or that, in the future, the Company’s loans will reference benchmark rates other than CME Term SOFR. Should any of these events occur, the Company’s loans, and the yield generated thereby, could be affected. Specifically, the anticipated yield on the Company’s loans may not be fully realized and the Company’s loans may be subject to increased pricing volatility and market risk.
     
Risks Related to Economic Recessions [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Related to Economic Recessions
. The recent macroeconomic environment is characterized by record-high inflation, supply chain challenges, labor shortages, high interest rates, foreign currency exchange volatility, volatility in global capital markets and growing recession risk. The risks associated with the Company’s and the Portfolio Investments’ businesses are more severe during periods of economic slowdown or recession.
Many of the Company’s Portfolio Investments may be susceptible to economic slowdowns or recessions and may be unable to repay its loans during these periods. The global outbreak
of COVID-19
has disrupted economic markets, and the prolonged economic impact is uncertain. Many manufacturers of goods have seen a downturn in production due to the suspension of business and temporary closure of factories globally in an attempt to curb the continued spread of the virus. As a result of these disruptions, the
Company’s non-performing
assets may increase and the value of its portfolio may decrease during these periods as the Company is required to record the values of its investments. Adverse economic conditions also may decrease the value of collateral securing some of the Company’s loans and the value of its equity investments at fair value. Economic slowdowns or recessions could lead to financial losses in the Company’s portfolio and a decrease in revenues, net income and assets. Unfavorable economic conditions also could increase the Company’s funding costs, limit its access to the capital markets or result in a decision by lenders not to extend credit to the Company. These events could prevent the Company from increasing investments and result in its receipt of a reduced level of interest income from the Company’s Portfolio Investments and/or losses or charge offs related to its investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations.
A Portfolio Investment’s failure to satisfy financial or operating covenants imposed by the Company or other lenders could lead to defaults and, potentially, acceleration of the time when the loans are due and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize the Portfolio Investment’s ability to meet its obligations under the debt that the Company holds. The Company may incur additional expenses to the extent necessary to seek recovery upon default or to negotiate new terms with a defaulting Portfolio Investment. In addition, if one of the Company’s Portfolio Investments were to go bankrupt, depending on the facts and circumstances, including the extent to which the Company actually provided significant managerial assistance to that Portfolio Investment, a bankruptcy court
might re-characterize
its debt holdings and subordinate all or a portion of the Company’s claim to that of other creditors.
These Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive research and development, manufacturing, marketing and service capabilities and greater number of qualified and experienced managerial and technical personnel. They may need additional financing that they are unable to secure and that the Company is unable or unwilling to provide, or they may be subject to adverse developments unrelated to the technologies they acquire.
The Company’s business is directly influenced by the economic cycle and could be negatively impacted by a downturn in economic activity in the U.S. as well as globally. Fiscal and monetary actions taken by U.S.
and non-U.S.
government and regulatory authorities could have a material adverse impact on the Company’s business. To the extent uncertainty regarding the U.S. or global economy, including as a result of
the COVID-19
pandemic, certain regional bank failures, the Russian invasion of Ukraine and the ongoing war in the Middle East, negatively impacts consumer confidence and consumer credit factors, the Company’s business, financial condition and results of operations could be adversely affected. Moreover, Federal Reserve policy, including with respect to certain interest rates and the decision to end its quantitative easing policy, along with the general policies of the current Presidential administration, may also adversely affect the value, volatility and liquidity of dividend- and interest-paying securities. Market volatility, periods of rising interest rates, such as the recent economic period, and/or a return to unfavorable economic conditions could adversely affect its business.
     
Risks Related to Portfolio Investment Monitoring and Involvement [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Related to Portfolio Investment Monitoring and Involvement
. The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings. See “—
Control Positions
” below. The Company’s investment program may from time to time enable it to place representatives on the creditors’ or steering committees and/or the boards of directors of certain companies in which it has invested. While such involvement may enable the Adviser to enhance the value of the Company’s Portfolio Investments, it may also prevent the Company from freely disposing of such Portfolio Investments, while also exposing it to legal claims and adverse publicity (including claims of breach of duty of loyalty, securities claims and other management-related claims). In addition, if the Adviser’s representatives are serving as directors of companies which are in the “zone of insolvency,” such persons may have a fiduciary obligation to the creditors of such entity as well as the shareholders of such entity. The interests of such parties may be adverse to the interests of the Company. These fiduciary obligations may conflict with the Adviser’s obligation to the Company, and the Adviser may cause its representatives to resign from such positions in order to reduce such conflicts. Any involvement by the Adviser’s representatives (including through serving on a board of directors, or permanent or ad hoc creditors’ or steering committees) may also entail a substantial time commitment, which may limit such representatives’ ability to participate in other Company matters and investments.
     
Risks Associated with Bankruptcy and Insolvency Cases [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Associated with Bankruptcy and Insolvency Cases
. If any issuers of securities held by the Company or any counterparties to the derivatives transactions and other transactions entered into by the Company, or any custodians of the Company’s assets or any obligors in connection with Portfolio Investments are involved in bankruptcy proceedings, the Company will be subject to certain risks inherent in bankruptcy proceedings, including the duration, administrative costs and impact of a bankruptcy case on the value of assets administered in bankruptcy or on a company’s value (including that a bankruptcy case may damage or diminish a company’s relationship with its employees, customers and/or suppliers). Many of the events within a bankruptcy or insolvency case are adversarial and often beyond the control of the creditors. While creditors generally are afforded an opportunity to object to significant actions, or to demand that certain actions take place, there can be no assurance that a court would not approve actions or inaction which may be contrary to the interests of the Company.
Generally, the duration of a bankruptcy or insolvency case can only be roughly estimated. The reorganization of a company usually involves the design of a business plan, the development and negotiation of a plan of reorganization, plan approval by creditors and confirmation by the court. This process can involve substantial legal, professional and administrative costs to the company and to the Company; is subject to unpredictable and lengthy delays; and during the process the company’s competitive position may erode, key management may depart and the company may not be able to invest adequately. In some cases, the company may not be able to reorganize and may be required to liquidate assets. In addition, the debt of companies in financial reorganization may, in some cases, not pay current interest and other charges, may not even accrue interest and other charges during reorganization, may be
relieved of paying pre-payment premiums and
may be adversely affected by an erosion of the issuer’s fundamental value. Further, a debtor seeking to reorganize under U.S. federal bankruptcy law will frequently obtain a “first day” order from the bankruptcy court limiting trading in claims against, and shares of, the debtor in order to maximize the debtor’s ability to utilize net operating losses following a successful reorganization.
During the pendency of a bankruptcy case, an automatic stay will prevent all creditors from taking action against the debtor to foreclose on collateral or otherwise to collect on amounts owed to such creditors. Unless a creditor’s claim in such case is secured by assets having a value in excess of such claim, or the bankruptcy estate is determined to be solvent, no interest will be permitted to accrue and, therefore, a creditor’s return on investment can be adversely affected by the passage of time during which the plan of reorganization of the debtor is being negotiated, approved by the creditors and confirmed by the bankruptcy court.
The priority of perfected liens held by secured creditors as of the commencement of the bankruptcy case is typically recognized in a bankruptcy case, unless avoided. Occasionally, however, a court will
allow a debtor-in-possession financing to
receive
liens that prime pre-existing, valid liens.
The administrative costs in connection with a bankruptcy case are frequently high and will generally be paid out of the debtor’s estate prior to any return to creditors (other than out of assets or proceeds thereof which are subject to valid and enforceable liens and other security interests) and equity holders. In addition, certain unsecured claims that have priority by law over the claims of certain creditors (for example, claims arising post-petition and certain claims for taxes) may be quite high.
U.S. bankruptcy law permits the classification of “substantially similar” claims in determining the classification of claims in a reorganization for the purpose of voting on a plan of reorganization. Because the standard for classification is vague, there exists a significant risk that the Company’s influence with respect to a class of securities can be lost by the inflation of the number and the amount of claims in, or other gerrymandering of, the class.
 
Although a creditor is not typically compelled to release direct claims it may have against
non-debtor
third parties, in certain circumstances a court may compel such release in the context of a plan of reorganization.
Claims in bankruptcy cases are often paid at less than par and, depending on the debtor’s assets and liabilities, there may be no recovery at all for some classes of creditors. The claims of even over-secured secured creditors are often paid out over time, and may receive debt securities that will trade below par. Initially, only the debtor may file a proposed plan of reorganization. While the U.S. Bankruptcy
Code permits other parties-in-interest to file
proposed plans of reorganization after the debtors’ “exclusive period” to do so ends, bankruptcy courts often extend the debtor’s exclusive period, which effectively permits only the debtor to file a proposed reorganization plan. While creditors can vote on the plan of reorganization, the unanimous consent of all creditor classes is not necessarily required for the bankruptcy court to confirm the plan. Therefore, a plan can, subject to the provisions of the U.S. Bankruptcy Code, be “crammed down” on dissenting classes of creditors. Moreover, minority members of a class may be deemed to be members of an accepting class if the requisite majority vote is acquired.
Even if a class of claims is entitled to a recovery in a reorganization or liquidation proceeding, such recovery could be in the form of instruments or interests different from the form of instrument or interest which formed the basis for the claim, including debt securities, equity securities, convertible securities, warrants, options, cash, interests in litigation claims or trusts formed to pursue such litigation claims, interests in liquidation trusts, or other property or interests, any of which could be illiquid and/or difficult to value. Furthermore, the terms of instruments or interests distributed in a bankruptcy or insolvency proceeding may differ from prevailing market terms for similar instruments or interests, and may have a market value of less than par.
The Company may be presented with the opportunity to make new investments in connection with the reorganization or liquidation of an issuer of Portfolio Investments, including, without limitation, through a rights offering, litigation financing, bridge financing or other exit financing. The Company may make such investments as
part of an in-court or out-of-court restructuring of
an issuer of Portfolio Investments, and any such investment will be subject to the same risks as other Portfolio Investments of the Company.
Contractual subordination provisions are enforceable when a borrower is in bankruptcy, as are most inter-creditor agreement terms. Furthermore, there are instances where creditors and equity holders may lose their ranking and priority when they take over management and functional operating control of a debtor. In those cases where the Company, by virtue of such action, is found to exercise “domination and control” of a debtor, the Company may lose its priority if the debtor or other creditors can demonstrate that the debtor’s business was adversely impacted or other creditors and/or equity holders were harmed by improper or unfair actions of the Company, whether or not the Company is found to be a controlling party of the debtor. In addition, loans extended to a financially distressed borrower by an entity that owns an equity interest in the borrower may be reclassified as having been an equity capital contribution, rather than a debt obligation.
Notwithstanding the corporate structure of various debtor entities, such as special purpose entities created to hold assets and to structure for bankruptcy remoteness, such entities may, in certain cases, be consolidated in bankruptcy proceedings, which can affect the outcome of such proceedings and the amounts ultimately received by creditors. In addition, if a claim can be asserted against only a parent holding entity, such claim may be structurally subordinated to claims against a subsidiary entity that owns assets.
The U.S. Bankruptcy Code and other laws and regulations affecting debtors’ and creditors’ rights are subject to change, including by way of legislative action or judicial interpretation. In addition, governmental actors have recently shown a willingness to intervene in bankruptcy-related matters (for example, the U.S. government’s bailouts of General Motors and Chrysler), which may increase uncertainty regarding the enforcement of creditors’ rights and the bankruptcy process generally. Any such actions could alter the expected outcome or introduce greater uncertainty regarding the expected outcome of an investment situation of the Company, which may adversely affect such investment or the Company’s investment program.
     
Lack of Control over Investments [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Lack of Control over Investments
. The Company invests in debt securities, but
may hold a non-controlling interest in
one or more Portfolio Investments. Such investments may not give the Company the ability to influence the management of the company or to elect a representative to the Board. In addition, the management of the company or its shareholders may have economic or business interests which are inconsistent with those of the Company, and they may be in a position to take action contrary to the Company’s objectives. A
non-controlling
interest may be especially adverse to the Company in circumstances, such as certain stressed or distressed situations, where an element of control or influence might be beneficial to the subject investment.
 
     
Control Positions [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Control Positions
. The Company does not expect to, but may have a controlling interest in a Portfolio Investment (because of its equity ownership, representation on the board of directors and/or contractual rights) either on its own or, in certain cases, with another financial partner or investment fund (
e.g.,
 in accordance with the Company’s receipt of equity in connection with a restructuring). The exercise of control over a company may impose additional risks of liability for environmental damage, product defects, failure to supervise management, pension and other fringe benefits, violation of governmental regulations (including securities laws) or other types of related liability. If these liabilities were to arise, the Company might suffer a significant loss in such investment. In addition, if employees of the Adviser serve as directors of certain of the Portfolio Investments, including public companies, they will have duties to persons other than the Company.
To the extent that the Company owns a controlling stake in or is deemed an affiliate of a particular company, it may also be subject to certain additional bankruptcy or securities laws restrictions that could affect both the liquidity of the Company’s interest and the Company’s ability to liquidate its interest without adversely impacting the price thereof, including insider trading restrictions, the affiliate sale restrictions of Rule 144 of the Securities Act and the disclosure requirements of Sections 13 and 16 of the 1934 Act. Further, to the extent that affiliates of the Company or the Adviser are subject to such restrictions, the Company, by virtue of its affiliation with such entities, may be similarly restricted, regardless of whether the Company stands to benefit from such affiliate’s ownership.
If the Company, alone or as part of a group acting together for certain purposes, becomes the beneficial owner of more than 10% of certain classes of securities of a U.S. public company or places a director on the board of directors of such a company, the Company may be subject to certain additional reporting requirements and to liability for short-swing profits under Section 16 of the 1934 Act. Furthermore, the Company may also be subject to similar reporting requirements and
other limitations in non-U.S. jurisdictions where
it holds significant positions in companies in such jurisdictions.
The exercise of control over a company, depending upon the amount and type of securities owned by the Company, contractual arrangements between the company and the Company, and other relevant factual circumstances, could result in an extension to one year of the
90-day bankruptcy preference
period with respect to payments made to the Company. See “—
Fraudulent Conveyance and Preference Considerations
” below. The exercise of control over a company may also provide grounds for challenges to the priority and enforceability of Portfolio Investments or other claims the Company may have against the company if it is subject to a bankruptcy case or other insolvency proceeding. See “—
Lender Liability Considerations and Equitable Subordination
” below.
     
Lender Liability Considerations and Equitable Subordination [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Lender Liability Considerations and Equitable Subordination
. In recent years, a number of judicial decisions in the U.S. have upheld the right of borrowers to sue lending institutions on the basis of various evolving legal theories (collectively termed “lender liability”). Generally, lender liability is founded upon the premise that an institutional lender has violated a duty (whether implied or contractual) of good faith and fair dealing owed to the borrower or has assumed a degree of control over the borrower resulting in creation of a fiduciary duty owed to the borrower or its other creditors or shareholders. In addition, courts have in some cases applied the doctrine of equitable subordination to subordinate the claim against a borrower of a creditor, including a lending institution, to claims of other creditors of the borrower when the creditor is found to have engaged in unfair, inequitable or fraudulent conduct. There can be no assurance as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire such claims engaged in any such conduct and, if it did, as to whether the Company would be subject to claims that the Company’s Portfolio Investments should be equitably subordinated based on such conduct. Because of the nature of certain of the Company’s Portfolio Investments, the Company could be subject to allegations of lender liability or to claims that the Company’s Portfolio Investments should be
equitably
subordinated.
     
Fraudulent Conveyance and Preference Considerations [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Fraudulent Conveyance and Preference Considerations
. Various federal and state laws enacted for the protection of creditors may apply to the purchase of the Company’s Portfolio Investments, or payments or liens related thereto, by virtue of the Company’s role as a creditor with respect to the borrowers under such Portfolio Investments. If a court, in a lawsuit brought by an
unpaid creditor, a debtor-in-possession, a trustee
in bankruptcy, or their respective representatives, were to find that the borrower took any action to intentionally delay or frustrate recoveries by creditors, or did not receive fair consideration or reasonably equivalent value for incurring indebtedness evidenced by an investment and the grant of any security interest or other lien securing such investment, and, after giving effect to such indebtedness and/or grant of any security interest or other lien, the issuer or obligor (i) was insolvent, (ii) was engaged in a business for which the remaining assets of such issuer constituted unreasonably small capital or (iii) intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature, such court could, under certain circumstances, invalidate, in whole or in part, such indebtedness and such security interest or other lien as fraudulent conveyances, could subordinate such indebtedness to existing or future creditors of the borrower and could allow the borrower to recover amounts previously paid by the borrower to the creditor (including to the Company) in satisfaction of such indebtedness or proceeds of such security interest or other lien previously applied in satisfaction of such indebtedness.
 
The measure of insolvency for purposes of the foregoing will vary. Generally, an issuer or obligor would be considered insolvent at a particular time if the sum of its debts were then greater than all of its property at a fair valuation, or if the present fair saleable value of its assets were less than the amount that would be required to pay its probable liabilities on its existing debts as they became absolute and matured. There can be no assurance as to what standard a court would apply in order to determine whether the issuer or obligor was “insolvent” after giving effect to the incurrence of the indebtedness and/or the granting of any security interest or other lien or that, regardless of the method of valuation, a court would not determine that the issuer was “insolvent” upon giving effect to such incurrence of indebtedness and/or grant of security interests or other lien.
The Company may invest in bank debt or other indebtedness issued by a borrower which is guaranteed by other entities within the borrower’s corporate family. In such circumstances, the borrower often has little or no assets other than the stock of its subsidiaries and, as a result, any recovery is often available only, if at all, from the entities that guaranteed the indebtedness. There is a risk, however, that the obligations of such guarantors and any security interests or other liens issued by the guarantors to secure such obligations may be avoided as fraudulent conveyances in the event that a court were to determine that such guarantors did not receive reasonably equivalent value in exchange for the issuance of the guarantees and for the security interests or other liens. A court could determine that the guarantors did not receive reasonably equivalent value or fair consideration in incurring the obligations and granting the security interests or other liens despite the existence of “indirect” benefits to the guarantors, such as the strengthening of the corporate enterprise in the transaction. Additionally, provisions in guarantees and other similar documents governing similar obligations by which fraudulent conveyance exposure is sought to be reduced or
eliminated, such as so-called “savings clauses,”
may not be enforceable. As a result, the Company’s Portfolio Investment in corporate bank debt or other indebtedness could be subject to avoidance as a fraudulent conveyance.
If a transaction is found to have been a fraudulent conveyance, the transferee may be compelled to return the value of the assets transferred as of the time of the transfer, even if the then current value is substantially less. In addition, unless the transferee is deemed to be a “good faith” transferee, the return of the asset may not even provide for the compensation back to the transferee of the value paid to the transferor.
In addition, in the event of the insolvency (as determined by a court based on the law of the jurisdiction which is being applied) of an issuer of a Portfolio Investment, payments made on the Company’s Portfolio Investment, or new liens granted, could be subject to avoidance as a “preference” if made within a certain period of time (which may be as long as one year) before insolvency, depending on a number of factors.
In general, if payments on a Company’s Portfolio Investment are avoidable, whether as a fraudulent conveyance or preference, such payments can be recaptured either from the initial recipient (such as the Company) or from subsequent transferees of such payments, including Unitholders. Additionally, if the grant of a security interest or other lien is avoidable, whether as a fraudulent conveyance or preference, the value of the security interest or other lien can be recovered from the initial transferee or the entity for whose benefit such transfer was made (such as the Company), and such recovery could include the diminution in value of the property which was subject to the security interest or other lien from the date of transfer.
There can be no assurance that a successful cause of action for fraudulent conveyance or preference will not occur, or as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire a Portfolio Investment engaged in any conduct to give rise to such causes of action, and if it did, as to whether such causes of action could be asserted against the Company and/or the Unitholders.
     
Portfolio Investment Risk [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Portfolio Investment Risk
. The Company’s Portfolio Investments may involve a high degree of business and financial risk. Portfolio Investments may be in early stages of development, may have operating losses or significant variations in operating results and may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence. Portfolio Investments will also include companies that are experiencing or are expected to experience financial difficulties, which may never be overcome. In addition, many of them will have weak financial conditions and may require substantial additional capital to support their operations, to finance expansion or to maintain their competitive positions. Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive development, manufacturing, marketing, and other capabilities and a larger number of qualified managerial and technical personnel. In addition, Portfolio Investments in which the Company invests may be required to comply with
numerous U.S. and non-U.S. statutory and
regulatory standards. A Portfolio Investment could be materially and adversely affected as a result of statutory or regulatory changes or changes in judicial or administrative interpretations of existing laws and regulations that impose more comprehensive or stringent requirements on such Portfolio Investment, the markets in which such Portfolio Investment operates or such Portfolio Investment’s industry generally.
 
There can be no assurance that a Portfolio Investment’s management team will be able to operate such Portfolio Investment successfully. In addition, instances of fraud or other illegal practices committed by the management team of a Portfolio Investment may undermine the Company’s investment in such Portfolio Investment and the Company may suffer losses. Additionally, Portfolio Investments need to attract, retain and develop executives and members of their management teams. There can be no assurance that a Portfolio Investment will be able to attract and develop suitable
members
of its management team, which may adversely affect the Company.
     
ZeroCoupon Bonds, Deferred Interest Rate Bonds and PaymentInKind Securities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Zero-Coupon Bonds, Deferred Interest Rate Bonds and
 Payment-In-Kind
 Securities
. Zero-coupon bonds pay interest only at maturity rather than at intervals during the life of the security. Deferred interest rate bonds generally provide for a period of delay before the regular payment of interest begins. PIK securities are debt obligations that pay “interest” in the form of other debt obligations, instead of in cash. Each of these instruments is normally issued and traded at a deep discount from face value. Zero-coupon bonds, deferred interest rate bonds and PIKs allow an issuer to avoid or delay the need to generate cash to meet current interest payments and, as a result, may involve greater credit risk than bonds that pay interest currently or in cash. In addition, such investments experience greater volatility in market value due to changes in interest rates than debt obligations that provide for regular payments of interest.
To the extent the Company invests in OID instruments, including PIK, zero coupon bonds, and debt securities with attached warrants, investors will be exposed to the risks associated with the inclusion of
such non-cash income
in taxable and accounting income prior to receipt of cash, including the following:
 
   
The interest payments deferred on a PIK loan are subject to the risk that the borrower may default when the deferred payments are due in cash at the maturity of the loan;
 
   
The interest rates on PIK loans are higher to reflect the time-value of money on deferred interest payments and the higher credit risk of borrowers who may need to defer interest payments;
 
   
PIK instruments may have unreliable valuations because the accruals require judgments about ultimate collectability of the deferred payments and the value of the associated collateral;
 
   
An election to defer PIK income payments by adding them to principal increases the Company’s gross assets and, thus, increases future base fees to the Adviser and, because income payments will then be payable on a larger principal amount, the PIK election also increases the Adviser’s future income incentive fees at a compounding rate;
 
   
Market prices of OID instruments are more volatile because they are affected to a greater extent by interest rate changes than instruments that pay interest periodically in cash;
 
   
The deferral of interest on a PIK loan
increases its loan-to-value ratio,
which is a measure of the riskiness of a loan; and
 
   
OID creates the
risk of non-refundable cash
payments to the Adviser
based on non-cash accruals
that may never be realized.
     
Money Market and Other Liquid Instruments [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Money Market and Other Liquid Instruments
. The Company may invest its assets in such liquid securities as the Adviser may deem to be advisable, including fixed income securities, money market instruments, money market mutual funds, and debt securities issued or guaranteed by the U.S., certain U.S. government agencies or instrumentalities. Money market instruments are short-term fixed income obligations, which generally have remaining maturities of one year or less, and may include commercial paper, certificates of deposit, and bankers’ acceptances issued by domestic branches of U.S. banks that are members of the FDIC. The Company may be prevented from achieving its investment objective during any period in which its assets are not substantially invested in accordance with its investment strategy. Notwithstanding their general high-quality nature, money market funds and liquid securities are subject to the risk of loss.
Among other liquid investments, the Company may invest cash, pending investment, reinvestment or distribution thereof or in connection with the maintenance of reserves, in money fund products offered from time to time by its Custodian, including the use of bank “sweep” short-term offerings.
     
Pooled Investment Vehicles and Passthrough Entities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Pooled Investment Vehicles and Pass-through Entities
. The Company may invest or take short positions in pooled investment vehicle and pass-through entities, including affiliated or third-party unregistered investment vehicles, investment companies registered under the 1940 Act (including
exchange-traded funds and closed-end companies) and
master limited partnerships (“Pooled Investment Vehicles”). To the extent the Company invests directly in Pooled Investment Vehicles and other “pass-through” entities which are treated as partnerships for U.S. federal income taxation purposes, the Company must rely on such vehicles to deliver to it certain tax information that is necessary to complete the Company’s own tax returns. If this information is not delivered to the Company in a timely fashion, the Company will be delayed in providing tax information to the investors.
 
     
U.S. Government and Agency Securities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
U.S. Government and Agency Securities
. The Company may invest in debt securities issued or guaranteed by certain U.S. government agencies, instrumentalities and sponsored enterprises. Some U.S. government securities, such as Treasury bills, notes and bonds and MBS guaranteed by Ginnie Mae, are supported by the full faith and credit of the U.S.; others are supported by the right of the issuer to borrow from the U.S. Treasury; others are supported by the discretionary authority of the U.S. government to purchase the agency’s obligations; and still others are supported only by the credit of the instrumentality. Although U.S. government-sponsored enterprises, such as Fannie Mae and Freddie Mac, may be chartered or sponsored by Congress, they are not funded by Congressional appropriations, and their securities are not issued by the U.S. Treasury or supported by the full faith and credit of the U.S. government and involve increased credit risks. In addition, certain governmental entities have been subject to regulatory scrutiny regarding their accounting policies and practices and other concerns that may result in legislation, changes in regulatory oversight and/or other consequences that could adversely affect the credit quality, availability or investment character of securities issued by these entities.
     
Restricted Securities [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Restricted Securities
. It is expected that a significant portion of the Company’s Portfolio Investments will
b
e securities (“restricted securities”) that have not been registered for sale to the public under the Securities Act pursuant to an exemption from registration (including Section 4(a)(2) of, or Rule 144A under, the Securities Act). Restricted securities are generally only sold to institutional investors in private sales from the issuer or from an affiliate of the issuer. These securities may be less liquid than securities registered for sale to the general public. The liquidity of a restricted security may be affected by a number of factors, including: (i) the credit quality of the issuer; (ii) the frequency of trades and quotes for the security; (iii) the number of dealers willing to purchase or sell the security and the number of other potential purchasers; (iv) dealer undertakings to make a market in the security; and (v) the nature of the security and the nature of marketplace trades. Also, restricted securities may be difficult to value because market quotations may not be readily available.
In addition, a debtor in a reorganization case may be granted a trading restriction order by a bankruptcy court in order to protect such debtor’s net operating losses (a “NOL Order”). Such an order may prohibit or severely restrict the ability of some creditors to sell their claims and interests in the debtor. The Company’s ability to transfer its interests in such a debtor may be impaired, delayed or prohibited as a consequence of a NOL Order. The Company may also incur added expenses if it attempts to challenge or limit the scope of a NOL Order, and such an attempt may not be successful. Similarly, issuers with net operating losses sometimes adopt Unitholder rights plans or similar arrangements in order to preserve the ability to utilize such net operating losses in the future; any such actions could also limit or otherwise adversely impact the Company’s ability to transfer or dispose of its interests in any such issuer.
     
Risks Related to the Russian Invasion of Ukraine [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Related to the Russian Invasion of Ukraine
. On February 24, 2022, the Russian military commenced a full-scale invasion of
Russia’s pre-positioned forces
into Ukraine, which could have a negative impact on the economy and business activity globally (including in the countries in which the Company invests), and therefore could adversely affect the performance of the Company’s Portfolio Investments. Following such invasion, the United States and several European nations announced sanctions against Russia. Furthermore, the conflict between the two nations and the varying involvement of the United States and other NATO countries could preclude prediction as to their ultimate adverse impact on global economic and market conditions, and, as a result, presents material uncertainty and risk with respect to the Company and the performance of its investments or operations, and the ability of the Company to achieve its investment objectives. Additionally, to the extent that third parties, investors, or related customer bases have material operations or assets in Russia or Ukraine, they may have adverse consequences related to the ongoing conflict.
     
No Market for Units [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
No Market for Units
. Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed. A Unitholder is not expected to be able to sell, assign or transfer its Units. In addition, transfers of Units may be affected by restrictions on resales imposed by federal and state securities laws. The Units are not registered under the Securities Act or any state securities laws and may not be transferred unless registered under applicable federal and state securities laws or unless an exemption from such laws is available. The Company has no plans, and is under no obligation, to register the Units under the Securities Act or any state securities laws. No market exists for the Units, and none is expected to develop. Therefore, an investment in the Company must be considered illiquid and must only be made by
persons
that are able to bear the risk of their investment in the Company for an indefinite period of time.
     
No Assurance of Cash Distributions [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
No Assurance of Cash Distributions
. Subject to the Board’s discretion and applicable legal restrictions, the Company expects to declare and pay distributions quarterly. The Company expects to pay these distributions out of assets legally available for distribution. However, there are no assurances that the Company will achieve investment results that will allow a targeted level
 
of
cash distributions or year-to-year increases in cash
distributions. All distributions that are made will be at the discretion of the Board and will depend on earnings, financial condition, maintenance of RIC status and other factors as the Board may deem to be relevant. The Company’s ability to pay distributions might be adversely affected by the impact of one or more of the risk
 
factors described in this annual report on Form
10-K.
If the Company violates certain covenants under its existing or future credit facilities or other leverage, the Company may be limited in its ability to make distributions. To the extent the Company makes distributions to Unitholders that include a return of capital, such portion of the distribution essentially constitutes a return of the Unitholder’s investment. In addition, the inability to satisfy the asset coverage test applicable to a BDC may limit the Company’s ability to pay distributions. There can be no assurances that the Company will pay distributions to Unitholders in the future.
In certain cases, the Company may recognize income before or without receiving the accompanying cash. Depending on the amount of noncash income, this could result in difficulty satisfying the annual distribution requirement applicable to RICs. Accordingly, the Company may have to sell some Portfolio Investments at times it would not consider advantageous, raise additional debt or equity capital or reduce new investments to meet these distribution
requirements
.
     
Assets Believed to Be Undervalued or Incorrectly Valued [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Assets Believed to Be Undervalued or Incorrectly Valued
. Securities that the Adviser believes are fundamentally undervalued or incorrectly valued may not ultimately be valued in the capital markets at prices and/or within the timeframe the Adviser anticipates. As a result, the Company may lose all or substantially all of its investment in any particular instance.
 
     
Forward Looking Statements [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Forward-Looking Statements
. This
annual
report on Form
10-K
contains forward-looking statements, including observations about market and industry and regulatory trends as of the original date of this annual report
on Form 10-K. Those forward-looking
statements reflect the Adviser’s current view in respect of future events. Actual events could differ materially from those in the forward-looking statements as a result of factors beyond the Adviser’s or the Company’s control. Investors are cautioned not to place undue reliance on such statements. No party has an obligation to update any of the forward-looking statements in this annual report
on Form 10-K.
     
Risks Related to the U.S. Debt Ceiling [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Related to the U.S.’ Debt Ceiling
. The significant debt in the U.S. is expected to hinder growth in the U.S. for the foreseeable future. In the future, the U.S. government may not be able to meet its debt payments unless the federal debt ceiling is raised. If legislation increasing the debt ceiling is not enacted, as needed, and the debt ceiling is reached, the U.S. federal government may stop or delay making payments on its obligations. Any default by the U.S. government on its obligations or any prolonged U.S. government shutdown could negatively impact the U.S. economy and our Portfolio Investments. In addition, concerns over the United States’ debt ceiling and budget-deficit have driven downgrades by rating agencies to the U.S. government’s credit rating. Downgrades by rating agencies to the U.S. government’s credit rating or concerns about its credit and deficit levels in general could cause interest rates and borrowing costs to rise, which may negatively impact both the perception of credit risk associated with our debt portfolio and our ability to access the debt markets on favorable terms. In addition, a decreased U.S. government credit rating, any default by the U.S. government on its obligations, or any prolonged U.S. government shutdown, could create broader financial turmoil and uncertainty, which may weigh heavily on our financial performance and the value of our common stock. U.S. debt ceiling and budget deficit concerns have
increased
the possibility of additional credit-rating downgrades and economic slowdowns or a recession in the U.S.
 
     
Adverse Consequences of Default [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Adverse Consequences of Default
. A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment. When a Unitholder defaults, the Board, in its discretion, may cause the defaulting Unitholder to forfeit a portion of the distributions to which the defaulting Unitholder may otherwise have been entitled. The Board may also require a forced sale of the defaulting Unitholder’s Interest. In addition, the Board may pursue any available legal or equitable remedies, with the expenses of collection of the unpaid amount, including attorneys’ fees, to be paid by the defaulting Unitholder.
 
Upon the default of a Unitholder, the Company may deliver an amended funding notice to the
non-defaulting
Unitholders increasing their capital contributions by up to an aggregate amount equal to the capital contribution that the defaulting Unitholder failed to make, not in excess of a Unitholder’s unfunded Commitment.
The Board may require a defaulting Unitholder to contribute the entirety of its remaining Commitment to the Company. For any such Unitholder, the return on its Company investment may be materially lower than returns to Unitholders
who do not pre-fund their Commitments.
     
Machine Learning Technology Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Machine Learning Technology Risks
. Recent technological advances in artificial intelligence and machine learning technology (“Machine Learning Technology”) pose risks to the Company and its Portfolio Investments. The Company and its Portfolio Investments could be exposed to the risks of Machine Learning Technology if third-party service providers or any counterparties use Machine Learning Technology in their business activities. The Company and the Adviser are not in a position to control the use of Machine Learning Technology in third-party products or services. Use of Machine Learning Technology could include the input of confidential information in contravention of applicable policies, contractual or other obligations or restrictions, resulting in such confidential information becoming part accessible by other third-party Machine Learning Technology applications and users. Machine Learning Technology and its applications continue to develop rapidly, and the Company cannot predict the risks that may arise from such developments.
Machine Learning Technology is generally highly reliant on the collection and analysis of large amounts of data, and it is not possible or practicable to incorporate all relevant data into the model that Machine Learning Technology utilizes to operate. Certain data in such models will inevitably contain a degree of inaccuracy and error and could otherwise be inadequate or flawed, which would be likely to degrade the effectiveness of Machine Learning Technology. To the extent the Company or its Portfolio Investments are exposed to the risks of Machine Learning Technology use, any such inaccuracies or errors could adversely impact the Company or its Portfolio Investments.
     
Financial Services Industry Risks [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Financial Services Industry Risks
. Cash not held in custody accounts and held by the Company, the Adviser and the Portfolio Investments in
non-interest-bearing
and interest-bearing operating accounts could, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, the Company, the Adviser, or the Portfolio Investments could lose all or a portion of those amounts held in excess of such insurance limits. In addition, actual events involving limited liquidity, defaults,
non-performance
or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect the Company, the Adviser’s and the Portfolio Investments’ business, financial condition, results of operations, or prospects.
Although the Company and the Adviser assess its and the Portfolio Investments’ banking and financing relationships as the Company believes necessary or appropriate, the Company and the Portfolio Investments’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which the Company, the Adviser or the Portfolio Investments have arrangements directly or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company, the Adviser or the Portfolio Investments have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.
In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for the Company, the Adviser, or the Portfolio Investments to acquire financing on acceptable terms or at all.
     
Risks Related to Disposition of Investments [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Risks Related to Disposition of Investments
. The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, IPOs, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized. See, for example, “—
Risks Relating to Bank Loans and Corporate Loans
” above. In particular, certain disposition techniques and structures may expose the Company to liability for (among other things) securities laws violations, breaches of representations and warranties, and repurchase or “putback” obligations with respect to securitizations or similar structures.
     
Regulatory Risks Relating to the Company [Member]        
General Description of Registrant [Abstract]        
Risk [Text Block]
Regulatory Risks Relating to the Company
. Legal and regulatory changes could occur during the term of the Company that may adversely affect the Company. The Company may be subject to, and adversely affected by, new federal, state or non-U.S. laws or new regulation by the SEC, the Commodity Futures Trading Commission (the “CFTC”), the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the FDIC, the European Commission and other federal, state and
non-U.S.
securities or banking regulators, and other governmental regulatory authorities or self-regulatory organizations that supervise the financial markets. The Company may also be adversely affected by changes in the enforcement or interpretation of existing statutes and rules by courts and/or these governmental regulatory authorities or self-regulatory organizations. For example, a recent court decision casts doubt on whether federal or state usury laws apply with respect to loans originated by national banks and then sold to
non-bank
investors such as the Company; this decision could significantly disrupt the bank loan secondary market and adversely impact the Company’s investment program. In addition, the approach taken by a federal court in the “Sun Capital” decision may significantly expand the scope of potential joint and several liability for pension obligations of portfolio companies commonly held by affiliated funds; this decision could create significant uncertainty with respect to such investments and adversely impact the Company. Moreover, legal and regulatory changes may adversely affect the Company’s ability to obtain financing by (among other things) reducing the availability of financing and/or adversely impacting financing costs and other terms.
The financial services industry is subject to extensive regulation. Banking regulators have broad and largely discretionary powers, which include prohibiting “unsafe or unsound” practices; requiring affirmative actions to correct any violation or practice; issuing administrative orders that can be judicially enforced; directing increases in capital; directing the sale of subsidiaries or other assets; limiting dividends and distributions; restricting growth; assessing civil monetary penalties; removing officers and directors; and terminating deposit insurance. These actions and other regulatory requirements could have a material adverse effect on an investment in the Company. The financial institutions in which the Company will invest and with which the Company will transact are subject to laws, regulations, administrative actions and policies in each location in which they operate. The regulatory environment for private investment funds is evolving, and changes in the regulation or taxation of private investment funds may adversely affect the value of the investments held by the Company and the ability of the Company to execute its investment strategy.
In addition, the securities and futures markets are subject to comprehensive statutes, regulations and margin requirements. The SEC and
other U.S. and non-U.S. regulators, self-regulatory organizations
and exchanges are authorized to take extraordinary actions in the event of market emergencies. The regulation of derivatives transactions and funds that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action. The effect of any future regulatory change on the Company could be substantial and adverse.
     
[1] Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively.
[2] Commencement of operations
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization
Note 1. Organization
SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on July 7, 2020 as a
closed-end,
externally managed investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a BDC and a RIC, we are required to comply with certain regulatory requirements. The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below. SLR Capital Partners, LLC (the “Adviser” or “SLR”) serves as the Company’s investment adviser pursuant to an investment management agreement with the Company (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”).
In connection with the Company’s formation, the Company issued and sold 40 units to the Adviser (the “Initial Unitholder”), which were acquired for an initial capital contribution of $1 on January 5, 2021 in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. The Company’s capital commitments total $83,850. The Company’s initial drawdown occurred on March 8, 2021 with the sale and issuance of units at an aggregate purchase price of $3,500 or $29.30 per unit. Prior to the issuance of units on March 8, 2021, the Initial Unitholder’s initial seed capital was withdrawn from the Company and its Units were canceled. As of December 31, 2023, $24,000 of capital commitments were drawn and $59,850 were unfunded.
The Company pursues a corporate lending strategy focused on direct sourcing, underwriting and managing a diverse portfolio of private loans to U.S. healthcare companies. The Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”. The Company’s principal focus is to invest in two differentiated strategies: first lien healthcare cash flow loans and first lien life science loans. First lien healthcare cash flow loans are expected to be made to private equity-owned upper middle market healthcare companies with EBITDA between approximately $25,000 and $100,000. These aggregate loan tranches are expected to range in size from $100,000 to $300,000. Healthcare cash flow loans are generally expected to have a
five
to six year final maturity and are often repaid within three years. First lien life science loans are expected to be made to venture capital owned
pre-commercialization
or early revenue drug and device development companies. These aggregate loan tranches are expected to range in size from $25,000 to $150,000. Loans to life science companies are generally expected to have an initial interest-only period and then straight-line amortization with a
four
to five year final maturity. These loans are often repaid within
two
to three years. The Company expects to primarily invest in
non-investment
grade debt instruments. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments.
The Company is organized for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). The Company was permitted to hold closings at any time during the offering period (the “Offering Period”), which ended on December 31, 2022. The term of the Company is expected to be seven years from the Company’s final closing with the Access Fund, which was held on February 11, 2021, unless the Company is terminated earlier or causes the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange (an “Exchange Listing”) as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a
non-1940
Act vote as described in Item 11 of the Company’s Form 10. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31.
At any time prior to the end of the term, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange. In connection with any such Exchange Listing, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the Company to complete (i) an initial public offering, (ii) a merger with another entity, including an affiliated company, subject to any limitations under the 1940 Act, (iii) the sale, exchange or disposition of all or a portion of the assets of the Company, or (iv) a conversion of the Company into a corporation incorporated in a state determined by the board of directors, either through a conversion in accordance with applicable law, a merger with or into an existing corporation, or otherwise, in which all units will be converted into or exchanged for shares of common stock of the resulting corporation. If the Company is unable to effectuate an Exchange Listing prior to the end of the term, the Company will use commercially reasonable efforts to wind down or liquidate pursuant to the procedures set forth in the LLC Agreement.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 2. Summary of Significant Accounting Policies
The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”), and include the accounts of the Company and certain wholly-owned subsidiaries, if any. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform to current period presentation.
The preparation of consolidated financial statements in conformity with GAAP and pursuant to the requirements for reporting on Form
10-K
and Regulation
S-X,
as appropriate, also requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reported periods. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially.
In the opinion of management, all adjustments which are of a normal recurring nature and considered necessary for the fair presentation of financial statements, have been included.
The significant accounting policies consistently followed by the Company are:
 
  (a)
Investment transactions are accounted for on the trade date.
 
  (b)
In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows:
 
  (i)
securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation;
 
  (ii)
exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes;
 
  (iii)
short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and
  (iv)
securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below:
 
  a.
the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment;
 
  b.
preliminary valuation conclusions are then documented and discussed with senior management of the Adviser;
 
  c.
the audit committee of the Board of Directors (the “Board”) reviews the preliminary valuations of the Adviser and third-party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and
 
  d.
the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third-party valuation specialist, if any, which may from time to time be engaged by the Board.
The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion.
The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule
2a-5
under the 1940 Act; and (6) maintain recordkeeping requirements under Rule
2a-5.
When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.
Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC
820-10,
certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the fiscal year ended December 31, 2023, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process.
ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy:
Level
 1
: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date.
Level
 2
: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices.
Level
 3
: Unobservable inputs for the asset or liability.
In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience.
 
  (c)
Gains or losses on investments are calculated by using the specific identification method.
 
  (d)
The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other
non-recurring
fee income as well as management fee and other fee income for services rendered, if any, are recorded as other income when earned.
 
  (e)
The Company intends to comply with the applicable provisions of the Code pertaining to RICs to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate.
 
  (f)
Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP; accordingly at December 31, 2023, $23 was reclassified on our balance sheet between accumulated distributable net loss and common Unitholders’ capital. Total earnings and net asset value are not affected.
 
  (g)
Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually.
 
  (h)
In accordance with Regulation
S-X
and ASC Topic 810—
Consolidation
, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company.
 
  (i)
The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company.
 
  (j)
In accordance with ASC
835-30,
the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method.
 
  (k)
The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC
946-20-25.
 
  (l)
Investments that are expected to pay regularly scheduled interest in cash are generally placed on
non-accrual
status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such
non-accrual
investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment.
 
  (m)
The Company records expenses directly related to its organization as incurred.
 
  (n)
The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Agreements and Related Party Transactions
12 Months Ended
Dec. 31, 2023
Agreements And Related Party Transactions [Abstract]  
Agreements and Related Party Transactions
Note 3. Agreements and Related Party Transactions
Pursuant to the Investment Management Agreement we have entered into with the Adviser, we will pay the Adviser certain management and incentive fees prior to and following an Exchange Listing. Prior to an Exchange Listing, the Adviser has been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay an administration fee to the Administrative Coordinator for such administrative and coordination services, each as defined and described further below. Following an Exchange Listing, we intend to enter into a separate administration agreement with an affiliate pursuant to which administrative services would be provided to the Company, as described further below. The cost of the base management fee, the incentive fee and the administration fee will ultimately be borne by our Unitholders.
Management Fees
The Company pays the Adviser a management fee prior to an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the
“Pre-Exchange
Listing Management Fee”) and will pay a management fee following an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the “Post-Exchange Listing Management Fee” and, together with the
Pre-Exchange
Listing Management Fee, the “Management Fee”). The Management Fee will be payable quarterly in arrears, as
follows:
 
 
   
Pre-Exchange
Listing
. Prior to an Exchange Listing, the
Pre-Exchange
Listing Management Fee will be calculated as of the close of business on the last day of each calendar quarter in an amount equal to 1.50%
per annum
of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company used to make Portfolio Investments and (ii) the total amount of credit drawn on subscription or similarly structured credit facilities).
 
   
Post-Exchange Listing
. Following an Exchange Listing, the Post-Exchange Listing Management Fee will be an amount equal to 1.50% per annum of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters; provided, however, the Post-Exchange Listing Management Fee will be calculated at an annual rate of 1.00% of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters that exceeds the product of (i) 200% and (ii) the value of the Company’s total net assets at the end of the immediately preceding calendar quarter.
The Management Fee will be appropriately adjusted for any stub period. The Adviser may arrange for the Company to direct to a placement agent any portion of the Management Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent.
The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, the Management Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such Management Fee may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the Management Fee. No Management Fees have been waived as of December 31, 2023.
Incentive Fee
Distributions
. Prior to an Exchange Listing, the Company makes distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, prepayment fees and exit fees, other than Disposition Proceeds, less Company expenses. The Adviser apportions each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds.
Pre-Exchange
Listing Incentive Fee
.
 
Prior to an Exchange Listing, and subject to availability, the Company will cause distributable cash to be distributed to Unitholders and to be paid to the Adviser as an incentive fee (the
“Pre-Exchange
Listing Incentive Fee”). Amounts of Investment Proceeds apportioned to Unitholders are divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority:
(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a
Pre-Exchange
Listing Incentive Fee, on the other hand, in the following amounts and order of priority:
(A) First, Return of Capital Contributions: 100% to such Unitholder until such Unitholders has received cumulative distributions of Investment Proceeds pursuant to this clause (A) equal to such Unitholder’s total capital contributions to the Company (including amounts contributed to pay
Pre-Exchange
Listing Management Fees,
Pre-Exchange
Listing Administration Fees (defined below), Organizational Expenses (defined below) and other Company
expenses);
 
 
(B) Second, Unitholder Preferred Return: 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and clause (ii)(A) and (ii)(C) below equal to 6% per annum, compounded annually, on Unitholders’ capital contributions to the Company (including amounts contributed to pay
Pre-Exchange
Listing Management Fees,
Pre-Exchange
Listing Administration Fees, Organizational Expenses and other Company expenses), determined on the basis of all capital contributions made by such Unitholder and considering all distributions (including the subject distribution) under this
“—Pre-Exchange
Listing Incentive Fee” made to such Unitholder (computed from the dates that such capital contributions were due (or, if actually made later, the date on which such capital contributions were actually made) until the date that the Company, in its sole discretion, designates distributable cash as available for distribution or, if no such designation is made, the occurrence of an Event of Dissolution, as defined in the LLC Agreement) (the “Preferred Return”);
(C) Third, Adviser Catch Up: 100% of all remaining Disposition Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee, until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) below equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (B) above and this clause (C) and clause (ii)(A) and (ii)(B) below; and
(D) Fourth, 90%/10%: 90% of all remaining Disposition Proceeds to Unitholders and 10% of all remaining Disposition Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee.
In no event will the Adviser receive amounts of
Pre-Exchange
Listing Incentive Fees under clause (i)(C) and (i)(D) above in excess of the percentage of the Disposition Proceeds actually distributed to Unitholders pursuant to clause (i)(B), (i)(C) and (i)(D) above.
In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation.
(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a
Pre-Exchange
Listing Incentive Fee, on the other hand, in the following amounts and order of priority:
(A) First, Unitholder Preferred Return: 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) above equal to the Preferred Return;
(B) Second, Adviser Catch Up: Second, 100% of all remaining Current Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) above equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (A) above and this clause (B) and pursuant to clause (i)(B) and clause (i)(C) above; and
(C) Third, 90%/10%: Thereafter, 90% of all remaining Current Proceeds to Unitholders and 10% of all remaining Current Proceeds to the Adviser as a
Pre-Exchange
Listing Incentive Fee.
 
 
In no event will the Adviser receive amounts of
Pre-Exchange
Listing Incentive Fees under clause (ii)(B) and (ii)(C) above in excess of the percentage of the Current Proceeds actually distributed to Unitholders pursuant to clause (ii)(A), (ii)(B) and (ii)(C) above.
Post-Exchange Listing Incentive Fee
. Following an Exchange Listing, the Company will pay an incentive fee to the Adviser consisting of two parts, as follows (the “Post-Exchange Listing Incentive Fee”):
 
  (i)
Pre-Incentive
Fee Net Investment Income. One part will be calculated and payable quarterly in arrears based on the net investment income for the immediately preceding calendar quarter.
 
  a.
For this purpose,
Pre-Incentive
Fee Net Investment Income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies) accrued by the Company during the calendar quarter, minus the Company’s operating expenses for the quarter (including the Post-Exchange Listing Management Fees, expenses payable under an administration agreement, and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the Post-Exchange Listing Incentive Fee).
 
  b.
Pre-Incentive
Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation.
Pre-Incentive
Fee Net Investment Income, expressed as a rate of return on the value of the Company’s net assets at the end of the immediately preceding calendar quarter, will be compared to a “hurdle rate” of 1.50% per quarter (6.00% annualized). The Company’s
Pre-Incentive
Fee Net Investment Income used to calculate this part of the Post-Exchange Listing Incentive Fee is also included in the amount of its gross assets used to calculate the 1.50% Post-Exchange Listing Management Fees.
 
  c.
The Company will pay the Adviser a Post-Exchange Listing Incentive Fee with respect to the Company’s
Pre-Incentive
Fee Net Investment Income in each calendar quarter as follows:
 
  i.
no Post-Exchange Listing Incentive Fee in any calendar quarter in which the Company’s
Pre-Incentive
Fee Net Investment Income does not exceed the quarterly hurdle rate of 1.50%;
 
  ii.
100% of the Company’s
Pre-Incentive
Fee Net Investment Income with respect to that portion of such
Pre-Incentive
Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 1.875% in any calendar quarter (7.5% annualized); this portion of the
Pre-Incentive
Fee Net Investment Income (which exceeds the hurdle but is less than 1.875%) is referred to herein as the
“catch-up.”
The
“catch-up”
is meant to provide the Adviser with 20% of the Company’s
Pre-Incentive
Fee Net Investment Income as if a hurdle did not apply if this
Pre-Incentive
Fee Net Investment Income exceeds 1.875% in any calendar quarter; and
 
  iii.
20% of the amount of the Company’s
Pre-Incentive
Fee Net Investment Income, if any, that exceeds 1.875% in any calendar quarter (7.5% annualized) payable to the Adviser (once the hurdle is reached and the
catch-up
is achieved, 20% of all
Pre-Incentive
Fee Net Investment Income thereafter is allocated to the Adviser).
These calculations will be
appropriately pro-rated for
any period of less than three months.
Capital Gains Fee
. The second part of the Post-Exchange Listing Incentive Fee, the “Capital Gains Fee”, will be determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement as set forth below), commencing as of the end of the first fiscal year following an Exchange Listing, and will equal 20.0% of the Company’s realized capital gains, if any, on a cumulative basis through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation as of each fiscal year end, less the amount of any previously paid capital gain Post-Exchange Listing Incentive Fees, with respect to the Company; provided that the Post-Exchange Listing Incentive Fee determined as of the end of the fiscal year in which an Exchange Listing is completed will be calculated for a period of shorter than twelve calendar months to take into account any realized capital gains computed net of all realized capital losses and unrealized capital depreciation. In the event that the Investment Management Agreement will terminate as of a date that is not a calendar year end, the termination date will be treated as though it were a calendar year end for purposes of calculating and paying a Capital Gains Fee.
The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, all or any portion of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such
Pre-Exchange
Listing Incentive Fees or Post-Exchange Listing Incentive Fees may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee.
The Adviser may arrange for the Company to direct to a placement agent any portion of the
Pre-Exchange
Listing Incentive Fee or Post-Exchange Listing Incentive Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent.
Administration Fees and Expenses
Pre-Exchange
Listing Administration Fees
. The Company will pay SLR, in its capacity as the Administrative Coordinator, a fee (the
“Pre-Exchange
Listing Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as, as of any date, the aggregate accreted and amortized cost of all Portfolio Investments, including (i) any amounts reinvested in Portfolio Investments and (ii) the cost of Portfolio Investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The
Pre-Exchange
Listing Administration Fee will not offset any fees paid to the Adviser. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain
on-going,
routine,
non-investment-related
administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company and (iii) certain Unitholder servicing functions.
The
Pre-Exchange
Listing Administration Fee will be appropriately adjusted for any stub period.
 
The Administrative Coordinator will have the right, in its sole discretion, to waive, as well as recoup in a subsequent period, the
Pre-Exchange
Listing Administration Fee to which it is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such
Pre-Exchange
Listing Administration Fee may be recouped by the Administrative Coordinator in a future calendar quarter within three years of the date of the applicable waiver of the
Pre-Exchange
Listing Administration Fee.
Post-Exchange Listing Administration Expenses
. In connection with an Exchange Listing, and subject to Board approval, the Company intends to enter into an administration agreement with SLR Capital Management, LLC (“SCM”) pursuant to which SCM will provide administrative services to the Company. For providing these services, facilities and personnel, the Company will reimburse SCM for the Company’s allocable portion of overhead and other expenses incurred by SCM in performing its obligations under the administration agreement (together with the
Pre-Exchange
Listing Administration Fee, the “Administration Expenses”).
For the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021, the Company incurred $565, $419 and $224, respectively, in Management Fees, $42, $27 and $9, respectively, in Administration Fees and $0, $0 and $0, respectively in Incentive Fees.
In addition, prior to an Exchange Listing, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company will not exceed the following limits in any fiscal year: (A) if the Company has less than or equal to $400,000 in Commitments, an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in Commitments, $2,250 (such figure, the “Operating Expense Cap”). Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, (i) the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder, (ii) the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the Company’s portfolio investments at each quarter end and (iii) the Operating Expense Cap will no longer apply upon the effectuation of an Exchange Listing.
The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (the “Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) will be reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. The Company will be responsible for and pay (or reimburse) the Organizational Expenses subject to the cap described in the preceding sentence. Accordingly, in 2021, $177 of offering expenses were charged to capital and $229 of organizational costs were expensed.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value
Note 4. Fair Value
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows:
Level
 1.
 Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access.
Level
 2.
 Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:
 
  a)
Quoted prices for similar assets or liabilities in active markets;
 
  b)
Quoted prices for identical or similar assets or liabilities in
non-active
markets;
 
  c)
Pricing models whose inputs are observable for substantially the full term of the asset or liability; and
 
  d)
Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability.
Level
 3.
Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use in pricing the asset or liability.
When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3).
Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).
A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1.
 
 
The following tables present the balances of assets measured at fair value on a recurring basis, as of December 31, 2023 and December 31, 2022:
Fair Value Measurements
As of December 31, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $    $ —     $ 63,268      $ 63,268  
Warrants
     1        —         6        7  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 1      $ —       $ 63,274      $ 63,275  
  
 
 
    
 
 
    
 
 
    
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2023, the fair value of the SPV Facility and the Subscription Facility would be $24,210 and $17,550, respectively.
Fair Value Measurements
As of December 31, 2022
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $ —     $ —     $ 43,886      $ 43,886  
Warrants
     —         —         11        11  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ —       $ —       $ 43,897      $ 43,897  
  
 
 
    
 
 
    
 
 
    
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2022, the fair value of the SPV Facility and the Subscription Facility would be $14,675 and $13,800, respectively.
 
The following tables provides a summary of the changes in fair value of Level 3 assets for the years ended December 31, 2023 and 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2023 and 2022:
 
    
Bank Debt/Senior
Secured Loans
    
Warrants
    
Total
 
Fair value, December 31, 2022
   $ 43,886      $ 11      $ 43,897  
Total gains or losses included in earnings:
        
Net realized gain
     —         —         —   
Net change in unrealized gain (loss)
     254        (15      239  
Purchase of investment securities*
     26,306        15        26,321  
Proceeds from dispositions of investment securities
     (7,178      (5      (7,183
Transfers into Level 3
     —         —         —   
Transfers out of Level 3
     —         —         —   
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2023
   $ 63,268      $ 6      $ 63,274  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 259      $ (18    $ 241  
  
 
 
    
 
 
    
 
 
 
 
    
Bank Debt/Senior
Secured Loans
    
Warrants
    
Total
 
Fair value, December 31, 2021
   $ 27,286      $ —       $ 27,286  
Total gains or losses included in earnings:
        
Net realized gain
     —         —         —   
Net change in unrealized gain (loss)
     192        (14      178  
Purchase of investment securities*
     28,713        25        28,738  
Proceeds from dispositions of investment securities
     (12,305      —         (12,305
Transfers into Level 3
     —         —         —   
Transfers out of Level 3
     —         —         —   
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2022
   $ 43,886      $ 11      $ 43,897  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 243      $ (14    $ 229  
  
 
 
    
 
 
    
 
 
 
 
*
Includes PIK capitalization and accretion of discount
 
Quantitative Information about Level 3 Fair Value Measurements
The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company.
Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2023 is summarized in the table below:
 
    
Asset or
Liability
    
Fair Value at
December 31,
2023
    
Principal Valuation

Technique/Methodology
    
Unobservable Input
    
Range (Weighted
Average)
 
Bank Debt / Senior Secured Loans
     Asset      $ 63,268        Income Approach        Market Yield        10.6% – 17.6%
(13.0%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Warrants
     Asset      $ 6        Market Approach        Volatility        18.9% – 18.9%
(18.9%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below:
 
    
Asset or
Liability
    
Fair Value at
December 31,
2022
    
Principal Valuation

Technique/Methodology
    
Unobservable Input
    
Range (Weighted
Average)
 
Bank Debt / Senior Secured Loans
     Asset      $ 43,886        Income Approach        Market Yield        9.8% – 18.2%
(12.5%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Warrants
     Asset      $ 11        Market Approach        Volatility        26.0% – 26.0%
(26.0%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Debt
Note 5. Debt
SPV Facility
—On February 18, 2022, the Company, through its wholly-owned subsidiary, SLR HC BDC SPV LLC (the “SPV”), entered into the $50,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. On May 30, 2023, the SPV Facility was amended, increasing commitments to $75,000. The stated interest rate on the SPV Facility is Term SOFR plus 3.07% with no SOFR floor requirement and the final maturity date is February 18, 2027. The fee on undrawn commitments is currently 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $24,210 of borrowings outstanding under the SPV Facility.
Subscription Facility
—On March 19, 2021, the Company established the $25,000 Subscription Facility with ING Capital LLC. The stated interest rate on the Subscription Facility is SOFR plus
2.75-3.00%
and the current stated maturity date is March 15, 2024. On December 14, 2021, the Subscription Facility was amended, allowing for increased borrowing base availability, among other changes. On June 14, 2023, the Subscription Facility entered into a second amendment, which replaced the benchmark rate of LIBOR with SOFR. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $17,550 of borrowings outstanding under the Subscription Facility.
The average annualized interest cost for borrowings for the years ended December 31, 2023 and 2022 was 8.11% and 4.88%, respectively. These costs are exclusive of other credit facility expenses such as unused fees. The maximum amount borrowed on the credit facilities during the years ended December 31, 2023 and 2022 was $44,010 and $32,775, respectively.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 6. Commitments and Contingencies
The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of December 31, 2023 and December 31, 2022 is $11,545 and $15,513, respectively, comprised of the following:
 
    
December 31,
2023
    
December 31,
2022
 
AAH Topco, LLC
   $ 2,262      $ —   
OIS Management Services, LLC
     1,710        —   
Southern Orthodontic Partners Management, LLC
     1,347        670  
Ardelyx, Inc.
     1,345        696  
CVAUSA Management, LLC
     1,059        —   
Retina Midco, Inc.
     966        —   
Orthopedic Care Partners Management, LLC
     901        566  
United Digestive MSO Parent, LLC
     391        —   
SCP Eye Care, LLC
     343        968  
Vertos Medical, Inc.
     283        —   
Medrina, LLC
     239        —   
UVP Management, LLC
     218        —   
Urology Management Holdings, Inc.
     151        —   
SunMed Group Holdings, LLC
     132        69  
Exactcare Parent, Inc.
     102        —   
WCI-BXC
Purchaser, LLC
     96        —   
Outset Medical, Inc.
     —         3,052  
Apeel Technology, Inc.
     —         2,852  
Glooko, Inc.
     —         1,633  
Arcutis Biotherapeutics, Inc.
     —         786  
Oral Surgery Partners Holdings, LLC
     —         843  
Plastics Management, LLC
     —         794  
Spectrum Pharmaceuticals, Inc.
     —         763  
Cerapedics, Inc.
     —         623  
Pediatric Home Respiratory Services, LLC
     —         630  
Meditrina, Inc.
     —         312  
Ivy Fertility Services, LLC
     —         128  
BayMark Health Services, Inc.
     —         128  
  
 
 
    
 
 
 
Total Commitments
   $ 11,545      $  15,513  
  
 
 
    
 
 
 
The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of December 31, 2023, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.
In the normal course of our business, we invest or trade in various financial instruments and may enter into various investment activities with
off-balance
sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of
off-balance
sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Statement of Assets and Liabilities.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Unitholders' Capital
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Unitholders' Capital
Note 7. Unitholders’ Capital
Transactions in Unitholders’ capital were as follows:
 
    
Year ended
December 31,
2023
    
Year ended
December 31,
2022
 
Units at beginning of period
     888,565        682,427  
Units issued
     181,077        206,138  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     1,069,642        888,565  
  
 
 
    
 
 
 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Highlights
12 Months Ended
Dec. 31, 2023
Investment Company, Financial Highlights [Abstract]  
Financial Highlights
Note 8. Financial Highlights
The following is a schedule of financial highlights for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021:
 
    
Year ended
December 31,
2023
   
Year ended
December 31,
2022
   
For the period
January 5, 2021*
to December 31,
2021
 
Per Unit Data: (a)
      
Net asset value per unit, beginning of period
   $ 21.77     $ 21.41     $ —   
  
 
 
   
 
 
   
 
 
 
Net investment income (loss)
     1.33       1.07       (2.97
Net realized and unrealized gain
     0.28 **      0.26       0.40  
  
 
 
   
 
 
   
 
 
 
Net increase (decrease) in Unitholders’ capital resulting from operations
     1.61       1.33       (2.57
Issuance of initial units
     —        —        24.62 ** 
Offering costs
     —        —        (0.64
Distributions to Unitholders:
      
From distributable earnings
     (1.85     (0.97     —   
From return of capital
     (0.06     —        —   
  
 
 
   
 
 
   
 
 
 
Net asset value per unit, end of period
   $ 21.47     $ 21.77     $ 21.41  
  
 
 
   
 
 
   
 
 
 
Total Return(b)(c)
     7.40     6.21     (26.93 )% 
Unitholders’ capital, end of period
   $ 22,969     $ 19,348     $ 14,612  
Units outstanding, end of period
     1,069,642       888,565       682,427  
Ratios to average net assets of Unitholders’ Capital (c):
      
Net investment income (loss)
     6.08     4.91     (16.59 )% 
  
 
 
   
 
 
   
 
 
 
Operating expenses
     5.99     6.61     29.12
Interest and other credit facility expenses
     18.08     12.33     8.02
  
 
 
   
 
 
   
 
 
 
Total expenses
     24.07     18.94     37.14
  
 
 
   
 
 
   
 
 
 
Average debt outstanding
   $ 31,744     $ 20,453     $ 7,352  
Portfolio turnover ratio
     13.9     36.5     59.7
 
(a)
Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively.
(b)
Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load.
(c)
Not annualized for periods less than one year.
*
Commencement of operations
**
Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Tax Information and Distributions to Unitholders
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Tax Information and Distributions to Unitholders
Note 9(a). Income Tax Information and Distributions to Unitholders
The tax character of distributions for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 were as follows(1):
 
    
2023
   
2022
   
2021
 
Ordinary income
   $ 1,817        92.6   $ 603        86.5   $        0.0
Capital gains
     53        2.7     94        13.5            0.0
Return of capital
     92        4.7            0.0            0.0
  
 
 
    
 
 
   
 
 
    
 
 
   
 
 
    
 
 
 
Total distributions
   $ 1,962        100.0   $ 697        100.0   $        0.0
  
 
 
    
 
 
   
 
 
    
 
 
   
 
 
    
 
 
 
As of December 31, 2023, 2022 and 2021 the total accumulated earnings (loss) on a tax basis were as follows(1):
 
    
2023
    
2022
    
2021
 
Undistributed ordinary income
   $ —       $ 155      $ —   
Undistributed long-term net capital gains
     —         —         —   
  
 
 
    
 
 
    
 
 
 
Total undistributed net earnings
     —         155        —   
Post-October capital losses
     —         —         —   
Capital loss carryforward
     —         —         —   
Other book/tax temporary differences
     (183      (197      (213
Net unrealized depreciation
     (241      (71      (136
  
 
 
    
 
 
    
 
 
 
Total tax accumulated loss
   $ (424    $ (113    $ (349
  
 
 
    
 
 
    
 
 
 
 
(1)
Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year.
The Company recognizes in its consolidated financial statements the tax effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. To the best of our knowledge, we did not have any uncertain tax positions that met the recognition or measurement criteria of ASC
740-10-25
nor did we have any unrecognized tax benefits as of the periods presented herein. Although we file federal and state tax returns, our major tax jurisdiction is federal. Our tax returns for federal tax years since 2021 remain subject to examination by the Internal Revenue Service and the state department of revenue.
Note 9(b). Other Tax Information (unaudited)
For the fiscal years ended December 31, 2023 and December 31, 2022, none of the ordinary distributions paid during the year were eligible for qualified dividend income treatment or the dividends received deduction for corporate stockholders. For the fiscal years ended December 31, 2023 and December 31, 2022, 98.16% and 99.58%, respectively, of each of the ordinary distributions paid during the year represent interest-related dividends. For the fiscal years ended December 31, 2023 and December 31, 2022, 0.90% and 0%, respectively, of the distributions represent short-term capital gains dividends. There were no distributions during the period January 5, 2021 (commencement of operations) to December 31, 2021.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events
Note 10. Subsequent Events
The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the financial statements were issued.
On January 23, 2024, the Company, through the SPV, reduced the size of its $75,000 SPV Facility to $35,000.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value (Tables)
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Summary of Assets Measured at Fair Value on a Recurring Basis
The following tables present the balances of assets measured at fair value on a recurring basis, as of December 31, 2023 and December 31, 2022:
Fair Value Measurements
As of December 31, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $    $ —     $ 63,268      $ 63,268  
Warrants
     1        —         6        7  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 1      $ —       $ 63,274      $ 63,275  
  
 
 
    
 
 
    
 
 
    
 
 
 
Fair Value Measurements
As of December 31, 2022
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $ —     $ —     $ 43,886      $ 43,886  
Warrants
     —         —         11        11  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ —       $ —       $ 43,897      $ 43,897  
  
 
 
    
 
 
    
 
 
    
 
 
 
Summary of Changes in Fair Value of Level 3 Assets
The following tables provides a summary of the changes in fair value of Level 3 assets for the years ended December 31, 2023 and 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2023 and 2022:
 
    
Bank Debt/Senior
Secured Loans
    
Warrants
    
Total
 
Fair value, December 31, 2022
   $ 43,886      $ 11      $ 43,897  
Total gains or losses included in earnings:
        
Net realized gain
     —         —         —   
Net change in unrealized gain (loss)
     254        (15      239  
Purchase of investment securities*
     26,306        15        26,321  
Proceeds from dispositions of investment securities
     (7,178      (5      (7,183
Transfers into Level 3
     —         —         —   
Transfers out of Level 3
     —         —         —   
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2023
   $ 63,268      $ 6      $ 63,274  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 259      $ (18    $ 241  
  
 
 
    
 
 
    
 
 
 
 
    
Bank Debt/Senior
Secured Loans
    
Warrants
    
Total
 
Fair value, December 31, 2021
   $ 27,286      $ —       $ 27,286  
Total gains or losses included in earnings:
        
Net realized gain
     —         —         —   
Net change in unrealized gain (loss)
     192        (14      178  
Purchase of investment securities*
     28,713        25        28,738  
Proceeds from dispositions of investment securities
     (12,305      —         (12,305
Transfers into Level 3
     —         —         —   
Transfers out of Level 3
     —         —         —   
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2022
   $ 43,886      $ 11      $ 43,897  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 243      $ (14    $ 229  
  
 
 
    
 
 
    
 
 
 
 
*
Includes PIK capitalization and accretion of discount
Summary of Company's Level 3
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2023 is summarized in the table below:
 
    
Asset or
Liability
    
Fair Value at
December 31,
2023
    
Principal Valuation

Technique/Methodology
    
Unobservable Input
    
Range (Weighted
Average)
 
Bank Debt / Senior Secured Loans
     Asset      $ 63,268        Income Approach        Market Yield        10.6% – 17.6%
(13.0%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Warrants
     Asset      $ 6        Market Approach        Volatility        18.9% – 18.9%
(18.9%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below:
 
    
Asset or
Liability
    
Fair Value at
December 31,
2022
    
Principal Valuation

Technique/Methodology
    
Unobservable Input
    
Range (Weighted
Average)
 
Bank Debt / Senior Secured Loans
     Asset      $ 43,886        Income Approach        Market Yield        9.8% – 18.2%
(12.5%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Warrants
     Asset      $ 11        Market Approach        Volatility        26.0% – 26.0%
(26.0%
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Summary of Unfunded Commitments
    
December 31,
2023
    
December 31,
2022
 
AAH Topco, LLC
   $ 2,262      $ —   
OIS Management Services, LLC
     1,710        —   
Southern Orthodontic Partners Management, LLC
     1,347        670  
Ardelyx, Inc.
     1,345        696  
CVAUSA Management, LLC
     1,059        —   
Retina Midco, Inc.
     966        —   
Orthopedic Care Partners Management, LLC
     901        566  
United Digestive MSO Parent, LLC
     391        —   
SCP Eye Care, LLC
     343        968  
Vertos Medical, Inc.
     283        —   
Medrina, LLC
     239        —   
UVP Management, LLC
     218        —   
Urology Management Holdings, Inc.
     151        —   
SunMed Group Holdings, LLC
     132        69  
Exactcare Parent, Inc.
     102        —   
WCI-BXC
Purchaser, LLC
     96        —   
Outset Medical, Inc.
     —         3,052  
Apeel Technology, Inc.
     —         2,852  
Glooko, Inc.
     —         1,633  
Arcutis Biotherapeutics, Inc.
     —         786  
Oral Surgery Partners Holdings, LLC
     —         843  
Plastics Management, LLC
     —         794  
Spectrum Pharmaceuticals, Inc.
     —         763  
Cerapedics, Inc.
     —         623  
Pediatric Home Respiratory Services, LLC
     —         630  
Meditrina, Inc.
     —         312  
Ivy Fertility Services, LLC
     —         128  
BayMark Health Services, Inc.
     —         128  
  
 
 
    
 
 
 
Total Commitments
   $ 11,545      $  15,513  
  
 
 
    
 
 
 
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Unitholders' Capital (Tables)
12 Months Ended
Dec. 31, 2023
Limited Liability Company (LLC) Members' Equity [Abstract]  
Summary of Limited Liability Company Unit Holders Capital
Transactions in Unitholders’ capital were as follows:
 
    
Year ended
December 31,
2023
    
Year ended
December 31,
2022
 
Units at beginning of period
     888,565        682,427  
Units issued
     181,077        206,138  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     1,069,642        888,565  
  
 
 
    
 
 
 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Highlights (Tables)
12 Months Ended
Dec. 31, 2023
Investment Company, Financial Highlights [Abstract]  
Summary of Financial Highlights
The following is a schedule of financial highlights for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021:
 
    
Year ended
December 31,
2023
   
Year ended
December 31,
2022
   
For the period
January 5, 2021*
to December 31,
2021
 
Per Unit Data: (a)
      
Net asset value per unit, beginning of period
   $ 21.77     $ 21.41     $ —   
  
 
 
   
 
 
   
 
 
 
Net investment income (loss)
     1.33       1.07       (2.97
Net realized and unrealized gain
     0.28 **      0.26       0.40  
  
 
 
   
 
 
   
 
 
 
Net increase (decrease) in Unitholders’ capital resulting from operations
     1.61       1.33       (2.57
Issuance of initial units
     —        —        24.62 ** 
Offering costs
     —        —        (0.64
Distributions to Unitholders:
      
From distributable earnings
     (1.85     (0.97     —   
From return of capital
     (0.06     —        —   
  
 
 
   
 
 
   
 
 
 
Net asset value per unit, end of period
   $ 21.47     $ 21.77     $ 21.41  
  
 
 
   
 
 
   
 
 
 
Total Return(b)(c)
     7.40     6.21     (26.93 )% 
Unitholders’ capital, end of period
   $ 22,969     $ 19,348     $ 14,612  
Units outstanding, end of period
     1,069,642       888,565       682,427  
Ratios to average net assets of Unitholders’ Capital (c):
      
Net investment income (loss)
     6.08     4.91     (16.59 )% 
  
 
 
   
 
 
   
 
 
 
Operating expenses
     5.99     6.61     29.12
Interest and other credit facility expenses
     18.08     12.33     8.02
  
 
 
   
 
 
   
 
 
 
Total expenses
     24.07     18.94     37.14
  
 
 
   
 
 
   
 
 
 
Average debt outstanding
   $ 31,744     $ 20,453     $ 7,352  
Portfolio turnover ratio
     13.9     36.5     59.7
 
(a)
Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively.
(b)
Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load.
(c)
Not annualized for periods less than one year.
*
Commencement of operations
**
Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Tax Information and Distributions to Unitholders (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Investment Company, Distribution To Shareholders
The tax character of distributions for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 were as follows(1):
 
    
2023
   
2022
   
2021
 
Ordinary income
   $ 1,817        92.6   $ 603        86.5   $        0.0
Capital gains
     53        2.7     94        13.5            0.0
Return of capital
     92        4.7            0.0            0.0
  
 
 
    
 
 
   
 
 
    
 
 
   
 
 
    
 
 
 
Total distributions
   $ 1,962        100.0   $ 697        100.0   $        0.0
  
 
 
    
 
 
   
 
 
    
 
 
   
 
 
    
 
 
 
Schedule Of Total Accumulated Earnings (Loss)
As of December 31, 2023, 2022 and 2021 the total accumulated earnings (loss) on a tax basis were as follows(1):
 
    
2023
    
2022
    
2021
 
Undistributed ordinary income
   $ —       $ 155      $ —   
Undistributed long-term net capital gains
     —         —         —   
  
 
 
    
 
 
    
 
 
 
Total undistributed net earnings
     —         155        —   
Post-October capital losses
     —         —         —   
Capital loss carryforward
     —         —         —   
Other book/tax temporary differences
     (183      (197      (213
Net unrealized depreciation
     (241      (71      (136
  
 
 
    
 
 
    
 
 
 
Total tax accumulated loss
   $ (424    $ (113    $ (349
  
 
 
    
 
 
    
 
 
 
 
(1)
Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year.
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Organization - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Mar. 08, 2021
Jan. 05, 2021
Dec. 31, 2023
Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Unfunded commitments     $ 11,545 $ 15,513
Initial Unitholder [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Issuance of common shares shares   40    
Share price $ 29.3 $ 1    
Capital commitments     83,850  
Issuance of common shares value $ 3,500      
Withdrawal of capital commitments     24,000  
Unfunded commitments     $ 59,850  
First Lien Health Care Cash Flow Loans [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Debt instrument maturity date     five to six year  
Debt Instrument, Frequency of Periodic Payment     three years  
Debt Instrument, Payment Terms     often repaid within three years  
First Lien Health Care Cash Flow Loans [Member] | Maximum [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Debt instrument carrying amount     $ 300,000  
Debt Instrument, Term     6 years  
First Lien Health Care Cash Flow Loans [Member] | Maximum [Member] | EBITDA Concentration Risk [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Earnings Before Interest Tax Depreciation And Amortization     $ 100,000  
First Lien Health Care Cash Flow Loans [Member] | Minimum [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Debt instrument carrying amount     $ 100,000  
Debt Instrument, Term     5 years  
First Lien Health Care Cash Flow Loans [Member] | Minimum [Member] | EBITDA Concentration Risk [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Earnings Before Interest Tax Depreciation And Amortization     $ 25,000  
First Lien Life Science Loans [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Debt instrument maturity date     four to five year  
Debt Instrument, Payment Terms     often repaid within two to three years  
First Lien Life Science Loans [Member] | Maximum [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Debt instrument carrying amount     $ 150,000  
Debt Instrument, Term     5 years  
Debt Instrument, Frequency of Periodic Payment     three years  
First Lien Life Science Loans [Member] | Minimum [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Debt instrument carrying amount     $ 25,000  
Debt Instrument, Term     4 years  
Debt Instrument, Frequency of Periodic Payment     two years  
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Schedule Of Significant Accounting Policies [Line Items]  
Excise tax rate 4.00%
Amount of Reclassification $ 23
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Agreements and Related Party Transactions - Additional Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Agreements And Related Party Transactions [Line Items]        
Percentage of pre exchange management fee on invested capital   1.50%    
Percentage of Post-Exchange Listing Management Fee on Entity Average Assets   1.50%    
Percentage of Entity Average Assets Threshold   1.00%    
Precentage of product payment   200.00%    
Percentage of cummulative capital realized gains   20.00%    
Percentage of Post-Exchange Listing Management Fee on Entity Gross Assets   1.50%    
Percentage pre incentive fee net investment income   100.00%    
Percentage of realized capital gains   20.00%    
Percentage of average cost basis   0.08%    
Management fee expense   $ 565 $ 419 $ 224 [1]
Administrative fees expense   42 27 9 [1]
Incentive fee expense   $ 0 $ 0 $ 0
Product of capital commitment   0.0025    
Affiliate Costs   $ 500    
Offering expenses $ 177      
Organizational costs $ 229      
Type of agreement, First [Member]        
Agreements And Related Party Transactions [Line Items]        
Precentage of return of capital contributions   100.00%    
Percentage of current proceeds to unitholders   100.00%    
Type of agreement, Second [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of remaining disposition proceeds to unitholders   100.00%    
Percentage of current proceeds to advisers   100.00%    
Type of agreement, Third [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of remaining disposition proceeds to adviser   100.00%    
Quarterly [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of hurdle rate   1.50%    
Percentage pre incentive fee net investment income   1.875%    
Annually [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of hurdle rate   6.00%    
Percentage pre incentive fee net investment income   7.50%    
Pre Exchange Listing Incentive Fee [Member] | Type of agreement, Third [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of current proceeds to unitholders   90.00%    
Percentage of current proceeds to advisers   10.00%    
Pre Exchange Listing Incentive Fee [Member] | Type of agreement, Fourth [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of remaining disposition proceeds to unitholders   90.00%    
Percentage of remaining disposition proceeds to adviser   10.00%    
Adviser [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage pre incentive fee net investment income   20.00%    
Minimum [Member]        
Agreements And Related Party Transactions [Line Items]        
Commitments   $ 400,000    
Capital commitments   $ 1,250    
Minimum [Member] | Type of agreement, Second [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of remaining disposition proceeds to unitholders   6.00%    
Minimum [Member] | Type of agreement, Third [Member]        
Agreements And Related Party Transactions [Line Items]        
Pecentage of amount due to unitholders   10.00%    
Percentage of current proceeds to unitholders   10.00%    
Minimum [Member] | Type of agreement, Fourth [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of remaining disposition proceeds to unitholders   10.00%    
Maximum [Member]        
Agreements And Related Party Transactions [Line Items]        
Commitments   $ 400,000    
Capital commitments   $ 2,250    
Maximum [Member] | Type of agreement, Second [Member]        
Agreements And Related Party Transactions [Line Items]        
Pecentage of amount due to unitholders   10.00%    
Maximum [Member] | Type of agreement, Third [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of current proceeds to unitholders   90.00%    
Maximum [Member] | Type of agreement, Fourth [Member]        
Agreements And Related Party Transactions [Line Items]        
Percentage of remaining disposition proceeds to unitholders   90.00%    
[1] Commencement of operations
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure $ 63,275 $ 43,897
Fair Value, Inputs, Level 1 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 1 0
Fair Value, Inputs, Level 2 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 63,274 43,897
Bank Debt Senior Secured Loans [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 63,268 43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 1 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 0 0
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 2 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 0 0
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 63,268 43,886
Warrant [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 7 11
Warrant [Member] | Fair Value, Inputs, Level 1 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 1 0
Warrant [Member] | Fair Value, Inputs, Level 2 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure 0 0
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]    
Assets, Fair Value Disclosure [Abstract]    
Investments, Fair Value Disclosure $ 6 $ 11
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail) - Investments [Member] - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning balance $ 43,897 $ 27,286
Total gains or losses included in earnings:    
Purchase of investment securities [1] 26,321 28,738
Proceeds from dispositions of investment securities (7,183) (12,305)
Transfers into Level 3 0 0
Transfers out of Level 3 0 0
Closing balance 63,274 43,897
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:    
Net change in unrealized gain (loss) 241 229
Realized Investment Gains Losses [Member]    
Total gains or losses included in earnings:    
Unrealized gain (loss) 0 0
Unrealized Gain Loss On Investments [Member]    
Total gains or losses included in earnings:    
Unrealized gain (loss) 239 178
Bank Debt Senior Secured Loans [Member]    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning balance 43,886 27,286
Total gains or losses included in earnings:    
Purchase of investment securities [1] 26,306 28,713
Proceeds from dispositions of investment securities (7,178) (12,305)
Transfers into Level 3 0 0
Transfers out of Level 3 0 0
Closing balance 63,268 43,886
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:    
Net change in unrealized gain (loss) 259 243
Bank Debt Senior Secured Loans [Member] | Realized Investment Gains Losses [Member]    
Total gains or losses included in earnings:    
Unrealized gain (loss) 0 0
Bank Debt Senior Secured Loans [Member] | Unrealized Gain Loss On Investments [Member]    
Total gains or losses included in earnings:    
Unrealized gain (loss) 254 192
Warrant [Member]    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning balance 11 0
Total gains or losses included in earnings:    
Purchase of investment securities [1] 15 25
Proceeds from dispositions of investment securities (5) 0
Transfers into Level 3 0 0
Transfers out of Level 3 0 0
Closing balance 6 11
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:    
Net change in unrealized gain (loss) (18) (14)
Warrant [Member] | Realized Investment Gains Losses [Member]    
Total gains or losses included in earnings:    
Unrealized gain (loss) 0 0
Warrant [Member] | Unrealized Gain Loss On Investments [Member]    
Total gains or losses included in earnings:    
Unrealized gain (loss) $ (15) $ (14)
[1] Includes PIK capitalization and accretion of discount
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value - Summary of Company's Level 3 (Detail) - Fair Value, Recurring [Member]
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure $ 63,275 $ 43,897
Fair Value, Inputs, Level 3 [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure 63,274 43,897
Bank Debt Senior Secured Loans [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure 63,268 43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure $ 63,268 $ 43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Asset or Liability Asset Asset
Investments, Fair Value Disclosure $ 63,268 $ 43,886
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Debt Securities, Trading, Measurement Input 10.6 9.8
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Debt Securities, Trading, Measurement Input 17.6 18.2
Bank Debt Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Weighted Average [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Debt Securities, Trading, Measurement Input 13 12.5
Warrant [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure $ 7 $ 11
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure $ 6 $ 11
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Asset or Liability Asset Asset
Investments, Fair Value Disclosure $ 6 $ 11
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative Asset, Measurement Input 18.9 26
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative Asset, Measurement Input 18.9 26
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Weighted Average [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative Asset, Measurement Input 18.9 26
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value - Additional Information (Detail) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
SPV Facility [Member]    
Fair Value [Line Items]    
Debt instrument carrying amount $ 24,210 $ 14,675
Subscription Facility [Member]    
Fair Value [Line Items]    
Debt instrument carrying amount $ 17,550 $ 13,800
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Debt - Additional Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Feb. 18, 2022
Mar. 19, 2021
Line of Credit Facility [Line Items]        
Long-Term Debt, Weighted Average Interest Rate, over Time 8.11% 4.88%    
Line of Credit Facility, Maximum Amount Outstanding During Period $ 44,010 $ 32,775    
SPV Facility [Member]        
Line of Credit Facility [Line Items]        
Long-Term Debt, Gross 24,210 14,675    
Subscription Facility [Member]        
Line of Credit Facility [Line Items]        
Long-Term Debt, Gross $ 17,550 $ 13,800    
JPMorgan Chase Bank, N.A. [Member] | SPV Facility [Member]        
Line of Credit Facility [Line Items]        
Line of Credit Facility, Expiration Date Feb. 18, 2027      
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.875%      
Line of Credit Facility, Collateral The SPV Facility is secured by all of the assets held by the SPV      
Long-Term Debt, Gross $ 24,210      
JPMorgan Chase Bank, N.A. [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | SPV Facility [Member]        
Line of Credit Facility [Line Items]        
Debt Instrument, Basis Spread on Variable Rate 3.07%      
Debt Instrument, Description of Variable Rate Basis Term SOFR      
Debt Instrument, Description Of Floor Requirement no SOFR      
JPMorgan Chase Bank, N.A. [Member] | Maximum [Member] | SPV Facility [Member]        
Line of Credit Facility [Line Items]        
Line of Credit Facility, Maximum Borrowing Capacity     $ 75,000  
JPMorgan Chase Bank, N.A. [Member] | Minimum [Member] | SPV Facility [Member]        
Line of Credit Facility [Line Items]        
Line of Credit Facility, Maximum Borrowing Capacity     $ 50,000  
ING Capital LLC [Member] | Subscription Facility [Member]        
Line of Credit Facility [Line Items]        
Line of Credit Facility, Maximum Borrowing Capacity       $ 25,000
Line of Credit Facility, Expiration Date Mar. 15, 2024      
ING Capital LLC [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]        
Line of Credit Facility [Line Items]        
Debt Instrument, Description of Variable Rate Basis SOFR      
ING Capital LLC [Member] | Maximum [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]        
Line of Credit Facility [Line Items]        
Debt Instrument, Basis Spread on Variable Rate 3.00%      
ING Capital LLC [Member] | Minimum [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]        
Line of Credit Facility [Line Items]        
Debt Instrument, Basis Spread on Variable Rate 2.75%      
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Summary of Unfunded Commitments (Detail) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments $ 11,545 $ 15,513
Outset Medical, Inc [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 3,052
Apeel Technology, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 2,852
Glooko, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 1,633
SCP Eye Care, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 343 968
Oral Surgery Partners Holdings, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 843
Plastics Management, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 794
Arcutis Biotherapetics, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 786
Spectrum Pharmaceuticals, Inc [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 763
Ardelyx, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 1,345 696
Southern Orthodonic Partners Management, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 1,347 670
Pediatric Home Respiratory Services, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 630
Cerapedics Inc [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 623
Orthopedic Care Partners Management, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 901 566
Meditrina, Inc [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 312
Ivy Fertility Services, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 128
BayMark Health Services, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 0 128
SunMed Group Holdings, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 132 69
OIS Management Services, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 1,710 0
WCIBXC Purchaser, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 96 0
Exactcare Parent, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 102 0
Urology Management Holdings, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 151 0
UVP Management, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 218 0
Medrina, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 239 0
Vertos Medical, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 283 0
United Digestive MSO Parent, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 391 0
Retina Midco, Inc. [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 966 0
CVAUSA Management, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments 1,059 0
AAH Topco, LLC [Member]    
Summary Of Unfunded Commitments [Line Items]    
Unfunded Commitments $ 2,262 $ 0
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Unfunded Commitments $ 11,545 $ 15,513
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Units at beginning of period [1],[2] 888,565 682,427 [3]
Units issued 181,077 206,138
Units issued at end of period 1,069,642 888,565
Units outstanding at end of period [1],[2] 1,069,642 888,565
[1] Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load.
[2] Not annualized for periods less than one year.
[3] Commencement of operations
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Highlights - Summary of Financial Highlights (Detail) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
[2]
Investment Company, Financial Highlights [Line Items]      
Net asset value per unit, beginning of period [1] $ 21.77 $ 21.41 [2] $ 0
Net investment income (loss) [1] 1.33 1.07 (2.97)
Net realized and unrealized gain [1] 0.28 [3] 0.26 0.4
Net increase (decrease) in Unitholders' capital resulting from operations [1] 1.61 1.33 (2.57)
Issuance of initial units [1] 0 0 24.62 [3]
Offering costs [1] 0 0 (0.64)
From distributable earnings [1] (1.85) (0.97) 0
From return of capital [1] (0.06) 0 0
Net asset value per unit, end of period [1] $ 21.47 $ 21.77 $ 21.41
Total Return [4],[5] 7.40% 6.21% (26.93%)
Unitholders' capital, end of period [4],[5] $ 22,969 $ 19,348 $ 14,612
Units outstanding, end of period [4],[5] 1,069,642 888,565 682,427
Ratios to average net assets of Unitholders' Capital :      
Net investment income (loss) [5] 6.08% 4.91% (16.59%)
Operating expenses [5] 5.99% 6.61% 29.12%
Interest and other credit facility expenses [5] 18.08% 12.33% 8.02%
Total expenses [5] 24.07% 18.94% 37.14%
Portfolio turnover ratio [5] 13.90% 36.50% 59.70%
Average debt outstanding [5] $ 31,744 $ 20,453 $ 7,352
[1] Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively.
[2] Commencement of operations
[3] Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end.
[4] Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load.
[5] Not annualized for periods less than one year.
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Investment Company, Financial Highlights [Line Items]      
Weighted average number of units outstanding 1,029,458 720,266 276,929
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Tax Information and Distributions to Unitholders - Schedule of Investment Company, Distribution To Shareholders (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2021
Schedule of Investments [Line Items]        
Ordinary income $ 1,817 $ 603 $ 0  
Capital gains 53 94 0  
Return of capital 92 0 0 $ 0 [1]
Total distributions $ 1,962 $ 697 $ 0 $ 0
Ordinary income Percent 92.60% 86.50% 0.00%  
Capital gains Percent 2.70% 13.50% 0.00%  
Return of capital Percent 4.70% 0.00% 0.00%  
Total distributions Percent 100.00% 100.00% 0.00%  
[1] Commencement of operations
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Tax Information and Distributions to Unitholders - Schedule Of Total Accumulated Earnings (Loss) (Detail) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Investments, Owned, Federal Income Tax Note [Line Items]      
Undistributed ordinary income [1] $ 0 $ 155 $ 0
Undistributed long-term net capital gains [1] 0 0 0
Total undistributed net earnings [1] 0 155 0
Post-October capital losses [1] 0 0 0
Capital loss carryforward [1] 0 0 0
Other book/tax temporary differences [1] (183) (197) (213)
Net unrealized depreciation [1] (241) (71) (136)
Total tax accumulated loss [1] $ (424) $ (113) $ (349)
[1] Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year.
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Tax Information and Distributions to Unitholders - Additional information (Detail)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Income Tax Disclosure [Abstract]        
Investment Company,Dividend Distribution, eligible for qualified dividend income treatment or the dividends received deduction for corporate stockholders Percent 0 0    
Investment Company, Dividend Distribution, interestrelated dividends Percent 98.16 99.58    
Investment Company, Dividend Distribution, shortterm capital gains, Percent 0.9 0    
Investment Company, Dividend Distribution $ 1,962 $ 697 $ 0 $ 0
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events - Additional information (Detail) - SPV Facility [Member] - Subsequent Event [Member]
$ in Thousands
Jan. 23, 2024
USD ($)
Maximum [Member]  
Subsequent Event [Line Items]  
Line of credit facility maximum borrowing capacity $ 75,000
Minimum [Member]  
Subsequent Event [Line Items]  
Line of credit facility maximum borrowing capacity $ 35,000
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 443 250 1 true 186 0 false 5 false false R1.htm 1001 - Document - Cover Page Sheet http://www.slrhbl.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Consolidated Statements of Assets and Liabilities Sheet http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities Consolidated Statements of Assets and Liabilities Statements 2 false false R3.htm 1003 - Statement - Consolidated Statements of Assets and Liabilities (Parenthetical) Sheet http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical Consolidated Statements of Assets and Liabilities (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Consolidated Statements of Operations Sheet http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Consolidated Statements of Changes in Unitholders' Capital Sheet http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital Consolidated Statements of Changes in Unitholders' Capital Statements 5 false false R6.htm 1006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1007 - Statement - Consolidated Schedule of Investments Sheet http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments Consolidated Schedule of Investments Statements 7 false false R8.htm 1009 - Statement - Consolidated Schedule of Investments (Parenthetical) Sheet http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical Consolidated Schedule of Investments (Parenthetical) Statements 8 false false R9.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 9 false false R10.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 10 false false R11.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 11 false false R12.htm 999002 - Disclosure - Organization Sheet http://www.slrhbl.com/role/Organization Organization Notes 12 false false R13.htm 999003 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.slrhbl.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 13 false false R14.htm 999004 - Disclosure - Agreements and Related Party Transactions Sheet http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactions Agreements and Related Party Transactions Notes 14 false false R15.htm 999005 - Disclosure - Fair Value Sheet http://www.slrhbl.com/role/FairValue Fair Value Notes 15 false false R16.htm 999006 - Disclosure - Debt Sheet http://www.slrhbl.com/role/Debt Debt Notes 16 false false R17.htm 999007 - Disclosure - Commitments and Contingencies Sheet http://www.slrhbl.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 999008 - Disclosure - Unitholders' Capital Sheet http://www.slrhbl.com/role/UnitholdersCapital Unitholders' Capital Notes 18 false false R19.htm 999009 - Disclosure - Financial Highlights Sheet http://www.slrhbl.com/role/FinancialHighlights Financial Highlights Notes 19 false false R20.htm 999010 - Disclosure - Income Tax Information and Distributions to Unitholders Sheet http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholders Income Tax Information and Distributions to Unitholders Notes 20 false false R21.htm 999011 - Disclosure - Subsequent Events Sheet http://www.slrhbl.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 999012 - Disclosure - Fair Value (Tables) Sheet http://www.slrhbl.com/role/FairValueTables Fair Value (Tables) Tables http://www.slrhbl.com/role/FairValue 22 false false R23.htm 999013 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.slrhbl.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.slrhbl.com/role/CommitmentsAndContingencies 23 false false R24.htm 999014 - Disclosure - Unitholders' Capital (Tables) Sheet http://www.slrhbl.com/role/UnitholdersCapitalTables Unitholders' Capital (Tables) Tables http://www.slrhbl.com/role/UnitholdersCapital 24 false false R25.htm 999015 - Disclosure - Financial Highlights (Tables) Sheet http://www.slrhbl.com/role/FinancialHighlightsTables Financial Highlights (Tables) Tables http://www.slrhbl.com/role/FinancialHighlights 25 false false R26.htm 999016 - Disclosure - Income Tax Information and Distributions to Unitholders (Tables) Sheet http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersTables Income Tax Information and Distributions to Unitholders (Tables) Tables http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholders 26 false false R27.htm 999017 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 27 false false R28.htm 999018 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 28 false false R29.htm 999019 - Disclosure - Agreements and Related Party Transactions - Additional Information (Detail) Sheet http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail Agreements and Related Party Transactions - Additional Information (Detail) Details 29 false false R30.htm 999020 - Disclosure - Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) Details 30 false false R31.htm 999021 - Disclosure - Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail) Sheet http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail) Details 31 false false R32.htm 999022 - Disclosure - Fair Value - Summary of Company's Level 3 (Detail) Sheet http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail Fair Value - Summary of Company's Level 3 (Detail) Details 32 false false R33.htm 999023 - Disclosure - Fair Value - Additional Information (Detail) Sheet http://www.slrhbl.com/role/FairValueAdditionalInformationDetail Fair Value - Additional Information (Detail) Details 33 false false R34.htm 999024 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.slrhbl.com/role/DebtAdditionalInformationDetail Debt - Additional Information (Detail) Details 34 false false R35.htm 999025 - Disclosure - Commitments and Contingencies - Summary of Unfunded Commitments (Detail) Sheet http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail Commitments and Contingencies - Summary of Unfunded Commitments (Detail) Details 35 false false R36.htm 999026 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.slrhbl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 36 false false R37.htm 999027 - Disclosure - Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) Sheet http://www.slrhbl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) Details 37 false false R38.htm 999028 - Disclosure - Financial Highlights - Summary of Financial Highlights (Detail) Sheet http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail Financial Highlights - Summary of Financial Highlights (Detail) Details 38 false false R39.htm 999029 - Disclosure - Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail) Sheet http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsParentheticalDetail Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail) Details 39 false false R40.htm 999030 - Disclosure - Income Tax Information and Distributions to Unitholders - Schedule of Investment Company, Distribution To Shareholders (Detail) Sheet http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail Income Tax Information and Distributions to Unitholders - Schedule of Investment Company, Distribution To Shareholders (Detail) Details 40 false false R41.htm 999031 - Disclosure - Income Tax Information and Distributions to Unitholders - Schedule Of Total Accumulated Earnings (Loss) (Detail) Sheet http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail Income Tax Information and Distributions to Unitholders - Schedule Of Total Accumulated Earnings (Loss) (Detail) Details 41 false false R42.htm 999032 - Disclosure - Income Tax Information and Distributions to Unitholders - Additional information (Detail) Sheet http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersAdditionalInformationDetail Income Tax Information and Distributions to Unitholders - Additional information (Detail) Details 42 false false R43.htm 999033 - Disclosure - Subsequent Events - Additional information (Detail) Sheet http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail Subsequent Events - Additional information (Detail) Details 43 false false All Reports Book All Reports cik0001832148-20231231.xsd cik0001832148-20231231_cal.xml cik0001832148-20231231_def.xml cik0001832148-20231231_lab.xml cik0001832148-20231231_pre.xml d774279d10k.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/cef/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d774279d10k.htm": { "nsprefix": "cik0001832148", "nsuri": "http://www.slrhbl.com/20231231", "dts": { "schema": { "local": [ "cik0001832148-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/cef/2023/cef-2023.xsd", "https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "cik0001832148-20231231_cal.xml" ] }, "definitionLink": { "local": [ "cik0001832148-20231231_def.xml" ] }, "labelLink": { "local": [ "cik0001832148-20231231_lab.xml" ] }, "presentationLink": { "local": [ "cik0001832148-20231231_pre.xml" ] }, "inline": { "local": [ "d774279d10k.htm" ] } }, "keyStandard": 181, "keyCustom": 69, "axisStandard": 21, "axisCustom": 2, "memberStandard": 15, "memberCustom": 170, "hidden": { "total": 7, "http://fasb.org/us-gaap/2023": 3, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 443, "entityCount": 1, "segmentCount": 186, "elementCount": 811, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 893, "http://xbrl.sec.gov/cef/2023": 111, "http://xbrl.sec.gov/dei/2023": 35, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.slrhbl.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentPeriodEndDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R2": { "role": "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "longName": "1002 - Statement - Consolidated Statements of Assets and Liabilities", "shortName": "Consolidated Statements of Assets and Liabilities", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:Cash", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:Cash", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "longName": "1003 - Statement - Consolidated Statements of Assets and Liabilities (Parenthetical)", "shortName": "Consolidated Statements of Assets and Liabilities (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "cik0001832148:CashEquivalentsAtCost", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R4": { "role": "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations", "longName": "1004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:GrossInvestmentIncomeOperating", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:GrossInvestmentIncomeOperating", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "longName": "1005 - Statement - Consolidated Statements of Changes in Unitholders' Capital", "shortName": "Consolidated Statements of Changes in Unitholders' Capital", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NetInvestmentIncome", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:InvestmentCompanyDistributionOrdinaryIncomeOne", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R6": { "role": "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "longName": "1006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:DeferredFinancingCosts", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R7": { "role": "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "longName": "1007 - Statement - Consolidated Schedule of Investments", "shortName": "Consolidated Schedule of Investments", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "cik0001832148:CashAndCashEquivalentsAtFairValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R8": { "role": "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "longName": "1009 - Statement - Consolidated Schedule of Investments (Parenthetical)", "shortName": "Consolidated Schedule of Investments (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:PercentageOfNonQualifyingAssetsInThePortfolioOfTotalAssets", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:PercentageOfNonQualifyingAssetsInThePortfolioOfTotalAssets", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://xbrl.sec.gov/cef/role/N2", "longName": "995470 - Disclosure - N-2", "shortName": "N-2", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:EntityFileNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cef:RiskFactorsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R12": { "role": "http://www.slrhbl.com/role/Organization", "longName": "999002 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPolicies", "longName": "999003 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactions", "longName": "999004 - Disclosure - Agreements and Related Party Transactions", "shortName": "Agreements and Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.slrhbl.com/role/FairValue", "longName": "999005 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.slrhbl.com/role/Debt", "longName": "999006 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.slrhbl.com/role/CommitmentsAndContingencies", "longName": "999007 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.slrhbl.com/role/UnitholdersCapital", "longName": "999008 - Disclosure - Unitholders' Capital", "shortName": "Unitholders' Capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:MembersEquityNotesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:MembersEquityNotesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.slrhbl.com/role/FinancialHighlights", "longName": "999009 - Disclosure - Financial Highlights", "shortName": "Financial Highlights", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholders", "longName": "999010 - Disclosure - Income Tax Information and Distributions to Unitholders", "shortName": "Income Tax Information and Distributions to Unitholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.slrhbl.com/role/SubsequentEvents", "longName": "999011 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.slrhbl.com/role/FairValueTables", "longName": "999012 - Disclosure - Fair Value (Tables)", "shortName": "Fair Value (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.slrhbl.com/role/CommitmentsAndContingenciesTables", "longName": "999013 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:ScheduleOfUnfundedCommitmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:ScheduleOfUnfundedCommitmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.slrhbl.com/role/UnitholdersCapitalTables", "longName": "999014 - Disclosure - Unitholders' Capital (Tables)", "shortName": "Unitholders' Capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:ScheduleOfMembersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:ScheduleOfMembersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.slrhbl.com/role/FinancialHighlightsTables", "longName": "999015 - Disclosure - Financial Highlights (Tables)", "shortName": "Financial Highlights (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersTables", "longName": "999016 - Disclosure - Income Tax Information and Distributions to Unitholders (Tables)", "shortName": "Income Tax Information and Distributions to Unitholders (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:InvestmentCompanyDistributionToShareholdersTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:InvestmentCompanyDistributionToShareholdersTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "longName": "999017 - Disclosure - Organization - Additional Information (Detail)", "shortName": "Organization - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "cik0001832148:UnfundedCommitments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_05_2021To01_05_2021_InitialUnitholderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R28": { "role": "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "999018 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:ExciseTaxRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:ExciseTaxRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "longName": "999019 - Disclosure - Agreements and Related Party Transactions - Additional Information (Detail)", "shortName": "Agreements and Related Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:PercentageOfPreExchangeManagementFeeOnInvestedCapital", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:PercentageOfPreExchangeManagementFeeOnInvestedCapital", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "longName": "999020 - Disclosure - Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)", "shortName": "Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R31": { "role": "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail", "longName": "999021 - Disclosure - Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail)", "shortName": "Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "PAsOn12_31_2022_InvestmentsMemberusgaapFairValueByAssetClassAxis", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2021_InvestmentsMemberusgaapFairValueByAssetClassAxis", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R32": { "role": "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail", "longName": "999022 - Disclosure - Fair Value - Summary of Company's Level 3 (Detail)", "shortName": "Fair Value - Summary of Company's Level 3 (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_BankDebtSeniorSecuredLoansMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_IncomeApproachValuationTechniqueMemberusgaapValuationTechniqueAxis_MeasurementInputmarketyieldMemberusgaapMeasurementInputTypeAxis", "name": "cik0001832148:Fairvaluemeasurementsassetorliabilitydescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R33": { "role": "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail", "longName": "999023 - Disclosure - Fair Value - Additional Information (Detail)", "shortName": "Fair Value - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "PAsOn12_31_2023_SpvFacilityMemberusgaapCreditFacilityAxis", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "longName": "999024 - Disclosure - Debt - Additional Information (Detail)", "shortName": "Debt - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "longName": "999025 - Disclosure - Commitments and Contingencies - Summary of Unfunded Commitments (Detail)", "shortName": "Commitments and Contingencies - Summary of Unfunded Commitments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "cik0001832148:UnfundedCommitments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_OutsetMedicalIncMemberdeiLegalEntityAxis", "name": "cik0001832148:UnfundedCommitments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "cik0001832148:ScheduleOfUnfundedCommitmentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R36": { "role": "http://www.slrhbl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "longName": "999026 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "cik0001832148:UnfundedCommitments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://www.slrhbl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail", "longName": "999027 - Disclosure - Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail)", "shortName": "Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:SharesOutstanding", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:SharesIssued", "td", "tr", "table", "cik0001832148:ScheduleOfMembersEquityTableTextBlock", "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:PartnersCapitalAccountUnitsSaleOfUnits", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "cik0001832148:ScheduleOfMembersEquityTableTextBlock", "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R38": { "role": "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail", "longName": "999028 - Disclosure - Financial Highlights - Summary of Financial Highlights (Detail)", "shortName": "Financial Highlights - Summary of Financial Highlights (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:NetAssetValuePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:InvestmentCompanyInvestmentIncomeLossPerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "unique": true } }, "R39": { "role": "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsParentheticalDetail", "longName": "999029 - Disclosure - Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail)", "shortName": "Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "td", "tr", "table", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "td", "tr", "table", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail", "longName": "999030 - Disclosure - Income Tax Information and Distributions to Unitholders - Schedule of Investment Company, Distribution To Shareholders (Detail)", "shortName": "Income Tax Information and Distributions to Unitholders - Schedule of Investment Company, Distribution To Shareholders (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:InvestmentCompanyDistributionOrdinaryIncome", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "cik0001832148:InvestmentCompanyDistributionToShareholdersTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:InvestmentCompanyDistributionOrdinaryIncome", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "cik0001832148:InvestmentCompanyDistributionToShareholdersTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail", "longName": "999031 - Disclosure - Income Tax Information and Distributions to Unitholders - Schedule Of Total Accumulated Earnings (Loss) (Detail)", "shortName": "Income Tax Information and Distributions to Unitholders - Schedule Of Total Accumulated Earnings (Loss) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FederalIncomeTaxNoteTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FederalIncomeTaxNoteTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersAdditionalInformationDetail", "longName": "999032 - Disclosure - Income Tax Information and Distributions to Unitholders - Additional information (Detail)", "shortName": "Income Tax Information and Distributions to Unitholders - Additional information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:InvestmentCompanydividendDistributionEligibleForQualifiedDividendIncomeTreatmentOrTheDividendsReceivedDeductionForCorporateStockholdersPercent", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "cik0001832148:InvestmentCompanydividendDistributionEligibleForQualifiedDividendIncomeTreatmentOrTheDividendsReceivedDeductionForCorporateStockholdersPercent", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "cik0001832148:InvestmentCompanydividendDistributionEligibleForQualifiedDividendIncomeTreatmentOrTheDividendsReceivedDeductionForCorporateStockholdersPercent", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "cik0001832148:InvestmentCompanydividendDistributionEligibleForQualifiedDividendIncomeTreatmentOrTheDividendsReceivedDeductionForCorporateStockholdersPercent", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail", "longName": "999033 - Disclosure - Subsequent Events - Additional information (Detail)", "shortName": "Subsequent Events - Additional information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "PAsOn01_23_2024_MaximumMembersrtRangeAxis_SpvFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn01_23_2024_MaximumMembersrtRangeAxis_SpvFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d774279d10k.htm", "first": true, "unique": true } } }, "tag": { "cik0001832148_AahTopcoLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AahTopcoLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "AAH Topco, LLC [Member]" } } }, "auth_ref": [] }, "cik0001832148_AbilityToOriginateLoansOnAdvantageousTermsCompetitionAndSupplyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AbilityToOriginateLoansOnAdvantageousTermsCompetitionAndSupplyMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Ability to Originate Loans on Advantageous Terms Competition and Supply [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Other liabilities and accrued expenses", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "auth_ref": [ "r572" ] }, "cef_AcquiredFundFeesAndExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "auth_ref": [ "r573" ] }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "auth_ref": [ "r574" ] }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "auth_ref": [ "r575" ] }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "auth_ref": [ "r576" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r628" ] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r671" ] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r671" ] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r670" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r634" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r634" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r634" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r634" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net increase (decrease) in unitholders' capital resulting from operations to net cash used in operating activities:" } } }, "auth_ref": [] }, "cik0001832148_AdministrationFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AdministrationFeePayable", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Administration fee payable", "terseLabel": "Administration fee payable (see note 3)", "documentation": "Administration fee payable." } } }, "auth_ref": [] }, "us-gaap_AdministrativeFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdministrativeFeesExpense", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Administrative Fees Expense", "terseLabel": "Administration fees (see note 3)", "verboseLabel": "Administrative fees expense", "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost." } } }, "auth_ref": [ "r34", "r358", "r727" ] }, "cik0001832148_AdverseConsequencesOfDefaultMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AdverseConsequencesOfDefaultMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Adverse Consequences of Default [Member]" } } }, "auth_ref": [] }, "cik0001832148_AdviserMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AdviserMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Adviser [Member]", "documentation": "Adviser." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r525", "r537", "r618", "r646" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r528", "r540", "r621", "r649" ] }, "cik0001832148_AgreementsAndRelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AgreementsAndRelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Agreements And Related Party Transactions [Abstract]", "documentation": "Agreements and related party transactions." } } }, "auth_ref": [] }, "cik0001832148_AgreementsAndRelatedPartyTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AgreementsAndRelatedPartyTransactionsLineItems", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreements And Related Party Transactions [Line Items]", "documentation": "Agreements and related party transactions." } } }, "auth_ref": [] }, "cik0001832148_AgreementsAndRelatedPartyTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AgreementsAndRelatedPartyTransactionsTable", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreements And Related Party Transactions [Table]", "documentation": "Agreements and related party transactions." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r634" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r641" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r532", "r541", "r622", "r641", "r650", "r654", "r662" ] }, "cef_AllRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AllRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r660" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "cef_AnnualCoverageReturnRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualCoverageReturnRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "auth_ref": [ "r602" ] }, "cef_AnnualDividendPayment": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPayment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "auth_ref": [ "r601" ] }, "cef_AnnualDividendPaymentCurrent": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentCurrent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "auth_ref": [ "r601" ] }, "cef_AnnualDividendPaymentInitial": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentInitial", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "auth_ref": [ "r601" ] }, "cef_AnnualExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "auth_ref": [ "r580" ] }, "cef_AnnualInterestRateCurrentPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateCurrentPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "auth_ref": [ "r601" ] }, "cef_AnnualInterestRateInitialPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateInitialPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "auth_ref": [ "r601" ] }, "cef_AnnualInterestRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "auth_ref": [ "r601" ] }, "cik0001832148_AnnuallyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AnnuallyMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annually [Member]", "documentation": "Annually ." } } }, "auth_ref": [] }, "cik0001832148_ApeelTechnologyInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ApeelTechnologyInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Apeel Technology, Inc. [Member]" } } }, "auth_ref": [] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "cik0001832148_ArcutisBiotherapeticsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ArcutisBiotherapeticsInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Arcutis Biotherapetics, Inc. [Member]" } } }, "auth_ref": [] }, "cik0001832148_ArdelyxInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ArdelyxInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Ardelyx, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r64", "r74", "r89", "r114", "r117", "r119", "r122", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r215", "r217", "r231", "r257", "r351", "r504", "r516", "r697", "r698", "r705" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "cik0001832148_AssetsBelievedToBeUndervaluedOrIncorrectlyValuedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "AssetsBelievedToBeUndervaluedOrIncorrectlyValuedMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Assets Believed to Be Undervalued or Incorrectly Valued [Member]", "documentation": "Assets believed to be undervalued or incorrectly valued." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNet", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Net Assets", "periodEndLabel": "Unitholders' capital, end of period", "periodStartLabel": "Unitholders' capital, beginning of period", "terseLabel": "Net Assets", "documentation": "Amount of net assets (liabilities)." } } }, "auth_ref": [ "r7" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r519", "r520", "r533" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r519", "r520", "r533" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r519", "r520", "r533" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r657" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r658" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r653" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r653" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r653" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r653" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r653" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r653" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r655" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r654" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r654" ] }, "cik0001832148_BankDebtSeniorSecuredLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "BankDebtSeniorSecuredLoansMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Bank Debt Senior Secured Loans [Member]", "documentation": "Bank debt senior secured loans." } } }, "auth_ref": [] }, "cef_BasisOfTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BasisOfTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "auth_ref": [ "r578" ] }, "cik0001832148_BaymarkHealthServicesInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "BaymarkHealthServicesInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "BayMark Health Services, Inc. [Member]" } } }, "auth_ref": [] }, "cef_BdcFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BdcFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "auth_ref": [] }, "cik0001832148_BiotechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "BiotechnologyMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Biotechnology [Member]" } } }, "auth_ref": [] }, "cik0001832148_BridgebioPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "BridgebioPharmaIncMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "BridgeBio Pharma Inc [Member]", "documentation": "BridgeBio pharma inc." } } }, "auth_ref": [] }, "cik0001832148_BroadIndemnificationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "BroadIndemnificationMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Broad Indemnification [Member]" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r520", "r533" ] }, "cef_BusinessDevelopmentCompanyFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BusinessDevelopmentCompanyFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "auth_ref": [ "r545" ] }, "cik0001832148_CancellationOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CancellationOfUnits", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cancellation of units", "terseLabel": "Cancellation of units", "documentation": "Cancellation of units." } } }, "auth_ref": [] }, "cik0001832148_CapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CapitalCommitments", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Capital Commitments", "terseLabel": "Capital commitments", "documentation": "Capital commitments." } } }, "auth_ref": [] }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "auth_ref": [ "r546" ] }, "cef_CapitalStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "auth_ref": [ "r547" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r69", "r259", "r309", "r345", "r504", "r516", "r681" ] }, "cik0001832148_CashAndCashEquivalentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CashAndCashEquivalentsAtFairValue", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents At Fair Value", "terseLabel": "Investments Cash and Cash Equivalents at Fair Value.", "documentation": "Investments cash and cash equivalents at fair value." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r24", "r52", "r86" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r52" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "verboseLabel": "Cash equivalents (cost: $9,919 and $29,828, respectively)", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r681", "r716" ] }, "cik0001832148_CashEquivalentsAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CashEquivalentsAtCost", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "lang": { "en-us": { "role": { "label": "Cash equivalents, at Cost", "terseLabel": "Cash equivalents, at Cost", "documentation": "Cash equivalents, at cost." } } }, "auth_ref": [] }, "cik0001832148_CerapedicsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CerapedicsIncMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Cerapedics Inc [Member]", "documentation": "Cerapedics inc." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r632" ] }, "cik0001832148_ChangesInTaxLawMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ChangesInTaxLawMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Changes in Tax Law [Member]" } } }, "auth_ref": [] }, "cik0001832148_ChangesToAccountingStandardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ChangesToAccountingStandardsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Changes to Accounting Standards [Member]" } } }, "auth_ref": [] }, "cik0001832148_ChangesToDerivativesRegulationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ChangesToDerivativesRegulationMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Changes to Derivatives Regulation [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r71", "r75", "r76", "r77", "r89", "r102", "r103", "r105", "r106", "r111", "r113", "r122", "r131", "r133", "r134", "r135", "r138", "r139", "r167", "r168", "r169", "r170", "r171", "r231", "r278", "r279", "r280", "r281", "r292", "r295", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r337", "r361", "r386", "r477", "r478", "r479", "r480", "r481", "r679", "r686", "r689" ] }, "cik0001832148_ClimateChangeRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ClimateChangeRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Climate Change Risks [Member]", "documentation": "Climate Change Risks." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r633" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r633" ] }, "cik0001832148_CollateralRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CollateralRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Collateral Risk [Member]", "documentation": "Collateral Risk" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (see note 6)", "terseLabel": "Commitments and contingencies (see note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r19", "r37", "r258", "r336" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r57", "r125", "r126", "r487", "r696" ] }, "us-gaap_CommonUnitIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssuanceValue", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_MembersEquity", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Common Unit, Issuance Value", "verboseLabel": "Common Unitholders' capital (1,069,642 and 888,565 units, respectively, issued and outstanding, see note 2f)", "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_CommonUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssued", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Unit, Issued", "terseLabel": "Common unit, Issued", "documentation": "Number of common units issued of limited liability company (LLC)." } } }, "auth_ref": [ "r60" ] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitOutstanding", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Unit, Outstanding", "terseLabel": "Common unit, Outstanding", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r638" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r637" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r639" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r636" ] }, "cik0001832148_CompetitionPotentialForInsufficientInvestmentOpportunitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CompetitionPotentialForInsufficientInvestmentOpportunitiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Competition Potential for Insufficient Investment Opportunities [Member]" } } }, "auth_ref": [] }, "cik0001832148_ConcentrationOfPortfolioInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ConcentrationOfPortfolioInvestmentsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Concentration of Portfolio Investments [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r25", "r26", "r32", "r33", "r121", "r486", "r680" ] }, "cik0001832148_ConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ConcentrationRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Member]", "documentation": "Concentration Risk." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r25", "r26", "r32", "r33", "r121", "r486" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "cik0001832148_ControlPositionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ControlPositionsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Control Positions [Member]" } } }, "auth_ref": [] }, "cik0001832148_ConvertibleSecuritiesRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ConvertibleSecuritiesRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Convertible Securities Risk [Member]" } } }, "auth_ref": [] }, "cik0001832148_CorporateSocialResponsibilityRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CorporateSocialResponsibilityRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Corporate Social Responsibility Risks [Member]", "documentation": "Corporate Social Responsibility Risks." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "cik0001832148_CvausaManagementLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "CvausaManagementLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "CVAUSA Management, LLC [Member]", "documentation": "CVAUSA management, llc." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.slrhbl.com/role/Debt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r58", "r88", "r140", "r146", "r147", "r148", "r149", "r150", "r151", "r156", "r163", "r164", "r165" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r41", "r42", "r65", "r66", "r91", "r141", "r142", "r143", "r144", "r145", "r147", "r152", "r153", "r154", "r155", "r157", "r158", "r159", "r160", "r161", "r162", "r233", "r494", "r495", "r496", "r497", "r498", "r687" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail", "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Long term debt, Gross", "verboseLabel": "Debt instrument carrying amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r13", "r66", "r166" ] }, "cik0001832148_DebtInstrumentDescriptionOfFloorRequirement": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DebtInstrumentDescriptionOfFloorRequirement", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Description Of Floor Requirement", "documentation": "Debt instrument, description of floor requirement ." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Description of Variable Rate Basis", "documentation": "Description of reference rate used for variable rate of debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt Instrument, Frequency of Periodic Payment", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": [ "r18", "r38" ] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDateDescription", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date, Description", "terseLabel": "Debt instrument maturity date", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r18", "r91", "r141", "r142", "r143", "r144", "r145", "r147", "r152", "r153", "r154", "r155", "r157", "r158", "r159", "r160", "r161", "r162", "r233", "r494", "r495", "r496", "r497", "r498", "r687" ] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPaymentTerms", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Payment Terms", "verboseLabel": "Debt Instrument, Payment Terms", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": [ "r17", "r38" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "verboseLabel": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "terseLabel": "Debt issuance costs, Line of credit arrangements, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DebtSecuritiesTradingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesTradingMeasurementInput", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading, Measurement Input", "verboseLabel": "Debt Securities, Trading, Measurement Input", "documentation": "Value of input used to measure investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r225" ] }, "cik0001832148_DefaultsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DefaultsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Defaults [Member]" } } }, "auth_ref": [] }, "cik0001832148_DeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DeferredFinancingCosts", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Financing Costs", "terseLabel": "Deferred financing costs", "documentation": "Deferred financing costs." } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r544", "r545", "r625" ] }, "us-gaap_DerivativeAssetMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetMeasurementInput", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Measurement Input", "verboseLabel": "Derivative Asset, Measurement Input", "documentation": "Value of input used to measure derivative asset." } } }, "auth_ref": [ "r225" ] }, "cik0001832148_DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Agreements And Related Party Transactions [Text Block]", "terseLabel": "Agreements and Related Party Transactions", "documentation": "Disclosure of agreements and related party transactions." } } }, "auth_ref": [] }, "cik0001832148_DistributionAndAssetCoverageRatioRequirementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DistributionAndAssetCoverageRatioRequirementsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distribution and Asset Coverage Ratio Requirements [Member]" } } }, "auth_ref": [] }, "cef_DistributionServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "auth_ref": [ "r584" ] }, "cik0001832148_DistributionsInKindMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DistributionsInKindMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distributions in Kind [Member]" } } }, "auth_ref": [] }, "cef_DistributionsMayReducePrincipalTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionsMayReducePrincipalTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "auth_ref": [ "r554" ] }, "cik0001832148_DistributorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DistributorsMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Distributors [Member]", "documentation": "Distributors." } } }, "auth_ref": [] }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendAndInterestExpensesOnShortSalesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "auth_ref": [ "r584" ] }, "cef_DividendExpenseOnPreferredSharesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendExpenseOnPreferredSharesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "auth_ref": [ "r584" ] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r544", "r545", "r625" ] }, "cef_DividendReinvestmentAndCashPurchaseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendReinvestmentAndCashPurchaseFees", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "auth_ref": [ "r570" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r519", "r520", "r533" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r519", "r520", "r533", "r642" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r517" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r626" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "cik0001832148_DocumentationOfInternalControlsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DocumentationOfInternalControlsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Documentation of Internal Controls [Member]" } } }, "auth_ref": [] }, "cik0001832148_DocumentationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DocumentationRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Documentation Risk [Member]" } } }, "auth_ref": [] }, "cik0001832148_DueDiligenceRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "DueDiligenceRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Due Diligence Risk [Member]", "documentation": "Due Diligence Risk." } } }, "auth_ref": [] }, "cik0001832148_EarningsBeforeInterestTaxDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "EarningsBeforeInterestTaxDepreciationAndAmortization", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Earnings Before Interest Tax Depreciation And Amortization", "terseLabel": "Earnings Before Interest Tax Depreciation And Amortization", "documentation": "Earnings before interest tax depreciation and amortization." } } }, "auth_ref": [] }, "cik0001832148_EbitdaConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "EbitdaConcentrationRiskMember", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "EBITDA Concentration Risk [Member]" } } }, "auth_ref": [] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r675" ] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r675" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r676" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r675" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r676" ] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r674" ] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r676" ] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r678" ] }, "cef_EffectsOfLeveragePurposeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeveragePurposeTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "auth_ref": [ "r603" ] }, "cef_EffectsOfLeverageTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "auth_ref": [ "r603" ] }, "cef_EffectsOfLeverageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "auth_ref": [ "r600" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r518" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r518" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r677" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r518" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r668" ] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r667" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r518" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r518" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r518" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r518" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r669" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesByIndustryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesByIndustryAxis", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Industry Sector [Axis]", "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate." } } }, "auth_ref": [ "r313", "r317", "r320", "r398", "r413", "r434", "r468", "r493", "r508" ] }, "us-gaap_EquitySecuritiesIndustryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesIndustryMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Industry Sector [Domain]", "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate." } } }, "auth_ref": [ "r313", "r317", "r320", "r398", "r413", "r434", "r468", "r508" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r635" ] }, "cik0001832148_EquityrelatedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "EquityrelatedSecuritiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "EquityRelated Securities [Member]" } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r525", "r537", "r618", "r646" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r522", "r534", "r615", "r643" ] }, "cik0001832148_ExactcareParentInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ExactcareParentInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Exactcare Parent, Inc. [Member]" } } }, "auth_ref": [] }, "cik0001832148_ExciseTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ExciseTaxRate", "presentation": [ "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Excise Tax Rate", "terseLabel": "Excise tax rate", "documentation": "Excise tax rate." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r641" ] }, "cik0001832148_ExemptiveReliefMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ExemptiveReliefMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exemptive Relief [Member]" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r673" ] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r673" ] }, "cef_ExpenseExampleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "auth_ref": [ "r570" ] }, "cef_ExpenseExampleYear01": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYear01", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "auth_ref": [ "r577" ] }, "cef_ExpenseExampleYears1to10": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to10", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "auth_ref": [ "r577" ] }, "cef_ExpenseExampleYears1to3": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "auth_ref": [ "r577" ] }, "cef_ExpenseExampleYears1to5": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to5", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "auth_ref": [ "r577" ] }, "cik0001832148_FailureToQualifyAsARicMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FailureToQualifyAsARicMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Failure to Qualify as a RIC [Member]" } } }, "auth_ref": [] }, "cik0001832148_FairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FairValueAbstract", "lang": { "en-us": { "role": { "label": "Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r222", "r229" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r221", "r222", "r229" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r9" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.slrhbl.com/role/FairValueTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Company's Level 3", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r9" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings [Abstract]", "terseLabel": "Total gains or losses included in earnings:" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Net change in unrealized gain (loss)", "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r228" ] }, "cik0001832148_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLossAbstract", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss [Abstract]", "terseLabel": "Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:", "documentation": "Fair value assets measured on recurring basis change in unrealized gain loss." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.slrhbl.com/role/FairValueTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets Measured at Fair Value on a Recurring Basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r29", "r63" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r10" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r10", "r31" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.slrhbl.com/role/FairValueTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of Level 3 Assets", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r10", "r31" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r29", "r31" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r154", "r173", "r174", "r175", "r176", "r177", "r178", "r222", "r239", "r240", "r241", "r495", "r496", "r500", "r501", "r502" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r221", "r222", "r224", "r225", "r230" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.slrhbl.com/role/FairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r220" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r154", "r173", "r178", "r222", "r239", "r500", "r501", "r502" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r154", "r173", "r178", "r222", "r240", "r495", "r496", "r500", "r501", "r502" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r154", "r173", "r174", "r175", "r176", "r177", "r178", "r222", "r241", "r495", "r496", "r500", "r501", "r502" ] }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsQuantitativeInformationAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]" } } }, "auth_ref": [] }, "cik0001832148_FairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FairValueLineItems", "presentation": [ "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value [Line Items]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Unrealized gain (loss)", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r226" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchase of investment securities", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r30" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "terseLabel": "Proceeds from dispositions of investment securities", "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r30" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfers into Level\u00a03", "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r227" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "terseLabel": "Transfers out of Level\u00a03", "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r227" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Closing balance", "periodStartLabel": "Beginning balance", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r10" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r154", "r173", "r174", "r175", "r176", "r177", "r178", "r239", "r240", "r241", "r495", "r496", "r500", "r501", "r502" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r220", "r230" ] }, "cik0001832148_FairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FairValueTable", "presentation": [ "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value [Table]" } } }, "auth_ref": [] }, "cik0001832148_Fairvaluemeasurementsassetorliabilitydescription": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "Fairvaluemeasurementsassetorliabilitydescription", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "FairValueMeasurementsAssetOrLiabilityDescription", "verboseLabel": "Asset or Liability", "documentation": "FairValueMeasurementsAssetOrLiabilityDescription" } } }, "auth_ref": [] }, "us-gaap_FederalIncomeTaxNoteTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxNoteTable", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Federal Income Tax Note [Table]", "terseLabel": "Federal Income Tax Note [Table]", "documentation": "Table of federal income tax note for schedule of investments. The federal income tax note may be qualified for security investments, non-security investments and/or for the combination of security and non-security investments." } } }, "auth_ref": [ "r718" ] }, "us-gaap_FederalIncomeTaxNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxNoteTextBlock", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersTables" ], "lang": { "en-us": { "role": { "label": "Federal Income Tax Note [Table Text Block]", "terseLabel": "Schedule Of Total Accumulated Earnings (Loss)", "documentation": "Tabular disclosure of the federal tax basis of investment holdings. This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book." } } }, "auth_ref": [ "r718" ] }, "cef_FeeTableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FeeTableAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "auth_ref": [ "r570" ] }, "cik0001832148_FinancialFraudMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FinancialFraudMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Financial Fraud [Member]" } } }, "auth_ref": [] }, "cef_FinancialHighlightsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FinancialHighlightsAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "auth_ref": [ "r585" ] }, "cik0001832148_FinancialServicesAndGovernmentInterventionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FinancialServicesAndGovernmentInterventionMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Financial Services and Government Intervention [Member]" } } }, "auth_ref": [] }, "cik0001832148_FinancialServicesIndustryRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FinancialServicesIndustryRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Financial Services Industry Risks [Member]" } } }, "auth_ref": [] }, "cik0001832148_FirstLienHealthCareCashFlowLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FirstLienHealthCareCashFlowLoansMember", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "First Lien Health Care Cash Flow Loans [Member]" } } }, "auth_ref": [] }, "cik0001832148_FirstLienLifeScienceLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FirstLienLifeScienceLoansMember", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "First Lien Life Science Loans [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r529", "r541", "r622", "r650" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r529", "r541", "r622", "r650" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r529", "r541", "r622", "r650" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r529", "r541", "r622", "r650" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r529", "r541", "r622", "r650" ] }, "cik0001832148_ForwardLookingStatementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ForwardLookingStatementsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Forward Looking Statements [Member]", "documentation": "Forward-looking statements." } } }, "auth_ref": [] }, "cik0001832148_ForwardsAndDerivativesTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ForwardsAndDerivativesTransactionsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Forwards and Derivatives Transactions [Member]" } } }, "auth_ref": [] }, "cik0001832148_FraudulentConveyanceAndPreferenceConsiderationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "FraudulentConveyanceAndPreferenceConsiderationsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Fraudulent Conveyance and Preference Considerations [Member]" } } }, "auth_ref": [] }, "cik0001832148_GeneralCreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "GeneralCreditRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "General Credit Risk [Member]", "documentation": "General Credit Risk." } } }, "auth_ref": [] }, "cef_GeneralDescriptionOfRegistrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "GeneralDescriptionOfRegistrantAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "auth_ref": [ "r597" ] }, "cik0001832148_GeneralEconomicAndMarketRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "GeneralEconomicAndMarketRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "General Economic and Market Risk [Member]", "documentation": "General Economic and Market Risk." } } }, "auth_ref": [] }, "cik0001832148_GeneralLeverageRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "GeneralLeverageRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "General Leverage Risks [Member]", "documentation": "General Leverage Risks." } } }, "auth_ref": [] }, "cik0001832148_GlookoInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "GlookoInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Glooko, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_GrossInvestmentIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossInvestmentIncomeOperating", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetInvestmentIncome", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Investment Income, Operating", "totalLabel": "Total investment income", "documentation": "Amount, before investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": [ "r263", "r514", "r726" ] }, "cik0001832148_HealthCareEquipmentSuppliesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "HealthCareEquipmentSuppliesMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Health Care Equipment Supplies [Member]" } } }, "auth_ref": [] }, "cik0001832148_HealthCareProvidersServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "HealthCareProvidersServicesMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Health Care Providers Services [Member]" } } }, "auth_ref": [] }, "cik0001832148_HealthCareTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "HealthCareTechnologyMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Health Care Technology [Member]" } } }, "auth_ref": [] }, "cik0001832148_HealthcareAndLifeScienceIndustriesRelatedRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "HealthcareAndLifeScienceIndustriesRelatedRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Healthcare and Life Science Industries Related Risks [Member]", "documentation": "Healthcare and life science industries related risks." } } }, "auth_ref": [] }, "cik0001832148_HedgingTransactionsAndRelatedRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "HedgingTransactionsAndRelatedRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Hedging Transactions and Related Risks [Member]", "documentation": "Hedging Transactions and Related Risks." } } }, "auth_ref": [] }, "cik0001832148_HighYieldDebtAndUnratedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "HighYieldDebtAndUnratedSecuritiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "High Yield Debt and Unrated Securities [Member]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "auth_ref": [ "r604" ] }, "cef_HighestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "auth_ref": [ "r608" ] }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [ "r609" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.slrhbl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r519", "r520", "r533" ] }, "cik0001832148_IdentificationOfPotentialInvestmentOpportunitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "IdentificationOfPotentialInvestmentOpportunitiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Identification of Potential Investment Opportunities [Member]", "documentation": "Identification of Potential Investment Opportunities [Member]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "auth_ref": [ "r575" ] }, "cef_IncentiveAllocationMinimumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMinimumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "auth_ref": [ "r575" ] }, "cef_IncentiveAllocationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "auth_ref": [ "r575" ] }, "us-gaap_IncentiveFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncentiveFeeExpense", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Incentive Fee Expense", "terseLabel": "Incentive fee expense", "documentation": "Amount of expense for incentive fee based on performance under arrangement to manage operations, including, but not limited to, investment." } } }, "auth_ref": [ "r34", "r727" ] }, "cef_IncentiveFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "auth_ref": [ "r584" ] }, "us-gaap_IncomeApproachValuationTechniqueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeApproachValuationTechniqueMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Valuation, Income Approach [Member]", "documentation": "Valuation approach converting future amounts to single current discounted amount." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r123", "r124", "r367" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r124", "r367" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholders" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax Information and Distributions to Unitholders", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r90", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r286" ] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Interest receivable", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Other liabilities and accrued expenses", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r685" ] }, "cik0001832148_IncreaseDecreaseInAdministrationFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "IncreaseDecreaseInAdministrationFeePayable", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Administration fee payable", "terseLabel": "Administration fee payable", "documentation": "Increase decrease In Administration fee payable." } } }, "auth_ref": [] }, "cik0001832148_IncreaseDecreaseInCapitalizationOfpaymentinkindincome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "IncreaseDecreaseInCapitalizationOfpaymentinkindincome", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Capitalization ofpaymentinkindincome", "negatedLabel": "Capitalization of\u00a0payment-in-kind\u00a0income", "documentation": "Increase decrease in capitalization of\u00a0payment-in-kind\u00a0income." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Interest payable", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInManagementFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInManagementFeePayable", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Management Fee Payable", "terseLabel": "Management fee payable", "documentation": "Amount of increase (decrease) in fee payable for management of fund or trust." } } }, "auth_ref": [ "r729" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase) decrease in operating assets:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities [Abstract]", "terseLabel": "Increase (decrease) in operating liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPayableForInvestmentPurchased": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPayableForInvestmentPurchased", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Payable for Investment Purchased", "terseLabel": "Payable for cash equivalents purchased", "documentation": "Amount of increase (decrease) in payable for purchase of investment." } } }, "auth_ref": [ "r729" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r532", "r541", "r622", "r641", "r650", "r654", "r662" ] }, "cik0001832148_InflationdeflationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InflationdeflationRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "InflationDeflation Risk [Member]", "documentation": "Inflation/Deflation Risk." } } }, "auth_ref": [] }, "cik0001832148_IngCapitalLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "IngCapitalLlcMember", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "ING Capital LLC [Member]" } } }, "auth_ref": [] }, "cik0001832148_InitialUnitholderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InitialUnitholderMember", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Initial Unitholder [Member]" } } }, "auth_ref": [] }, "cik0001832148_InkindDividendConsiderationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InkindDividendConsiderationsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "InKind Dividend Considerations [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r660" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r521", "r666" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r521", "r666" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r521", "r666" ] }, "cik0001832148_InsufficientCapitalForFollowonInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InsufficientCapitalForFollowonInvestmentsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Insufficient Capital for FollowOn Investments [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestAndDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDebtExpense", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest and Debt Expense", "terseLabel": "Interest and other credit facility expenses (see note 5)", "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity." } } }, "auth_ref": [ "r6" ] }, "cef_InterestExpensesOnBorrowingsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "InterestExpensesOnBorrowingsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "auth_ref": [ "r583" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r82", "r84", "r85" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Interest Payable", "terseLabel": "Interest payable (see note 5)", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r36", "r714" ] }, "us-gaap_InterestRateRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Rate Risk [Member]", "documentation": "The risk associated with changes in interest rates that effect the value of an interest-bearing asset or liability, and a servicing asset or liability." } } }, "auth_ref": [] }, "cik0001832148_InterestRateRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InterestRateRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Rate Risks [Member]", "documentation": "Interest Rate Risks." } } }, "auth_ref": [] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivable", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Interest Receivable", "terseLabel": "Interest receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r682", "r730" ] }, "cef_IntervalFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IntervalFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "auth_ref": [ "r545" ] }, "us-gaap_InvestmentAcquisitionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentAcquisitionDate", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Investment, Acquisition Date", "terseLabel": "Acquisition Date", "documentation": "Date when investment is acquired, in YYYY-MM-DD format." } } }, "auth_ref": [ "r400", "r409", "r425", "r467" ] }, "us-gaap_InvestmentBasisSpreadVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentBasisSpreadVariableRate", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Investment, Basis Spread, Variable Rate", "terseLabel": "Spread above Index", "documentation": "Percentage added to reference rate used to compute variable rate on investment." } } }, "auth_ref": [ "r393", "r412", "r416", "r450" ] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r545", "r612", "r613", "r614" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r627" ] }, "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyCapitalShareTransactionsAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Investment Company, Capital Share Transaction, Increase (Decrease) [Abstract]", "terseLabel": "Increase (decrease) in unitholders' capital resulting from capital activity (see note 7):" } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyCommittedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyCommittedCapital", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Committed Capital", "terseLabel": "Capital commitments", "documentation": "Amount of funds committed to investment company from investors." } } }, "auth_ref": [ "r298" ] }, "cik0001832148_InvestmentCompanyDistributableEarningsLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributableEarningsLoss", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company Distributable Earnings Loss", "negatedTotalLabel": "Total undistributed net earnings", "documentation": "Investment company distributable earnings loss." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail": { "parentTag": "cik0001832148_InvestmentCompanyTaxAccumulatedLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distributable Earnings (Loss), Accumulated Capital Loss Carryforward", "terseLabel": "Capital loss carryforward", "documentation": "Amount of accumulated undistributed deficit from capital loss carryforward of investment company." } } }, "auth_ref": [ "r285" ] }, "us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedLongTermCapitalGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedLongTermCapitalGainLoss", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distributable Earnings (Loss), Accumulated Long-Term Capital Gain (Loss)", "terseLabel": "Undistributed long-term net capital gains", "documentation": "Amount of accumulated undistributed earnings (deficit) from long-term capital gain (loss) of investment company." } } }, "auth_ref": [ "r284" ] }, "us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distributable Earnings (Loss), Accumulated Ordinary Income (Loss)", "negatedLabel": "Undistributed ordinary income", "documentation": "Amount of accumulated undistributed earnings (deficit) from ordinary income (loss) of investment company." } } }, "auth_ref": [ "r283" ] }, "cik0001832148_InvestmentCompanyDistributableEarningsLossotherBooktaxTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributableEarningsLossotherBooktaxTemporaryDifferences", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail": { "parentTag": "cik0001832148_InvestmentCompanyTaxAccumulatedLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distributable Earnings (Loss),Other booktax temporary differences", "negatedLabel": "Other book/tax temporary differences", "documentation": "Investment company, distributable earnings (loss),other book/tax temporary differences." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyDistributableEarningsLosspostoctoberCapitalLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributableEarningsLosspostoctoberCapitalLosses", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail": { "parentTag": "cik0001832148_InvestmentCompanyTaxAccumulatedLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distributable Earnings (Loss),PostOctober capital losses", "negatedLabel": "Post-October capital losses", "documentation": "Investment company, distributable earnings (loss),post-october capital losses." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyDistributionLongTermCapitalGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyDistributionLongTermCapitalGain", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distribution, Long-Term Capital Gain", "terseLabel": "Capital gains", "documentation": "Amount of dividend distribution by investment company from long-term capital gain." } } }, "auth_ref": [ "r289", "r483" ] }, "cik0001832148_InvestmentCompanyDistributionLongTermCapitalGainPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributionLongTermCapitalGainPercent", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company Distribution Long Term Capital Gain Percent", "terseLabel": "Capital gains Percent", "documentation": "Investment company distribution long term capital gain percent." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyDistributionLongtermCapitalGainPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributionLongtermCapitalGainPerShare", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distribution, LongTerm Capital Gain per share", "terseLabel": "From return of capital", "documentation": "Investment company, distribution, long-Term capital gain per share." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyDistributionOrdinaryIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyDistributionOrdinaryIncome", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distribution, Ordinary Income", "terseLabel": "Ordinary income", "documentation": "Amount of dividend distribution by investment company from ordinary income." } } }, "auth_ref": [ "r289", "r482" ] }, "cik0001832148_InvestmentCompanyDistributionOrdinaryIncomeOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributionOrdinaryIncomeOne", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_InvestmentCompanyDividendDistribution", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Investment Company Distribution Ordinary Income One", "verboseLabel": "From distributable earnings", "documentation": "Investment company distribution ordinary income one." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyDistributionOrdinaryIncomePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributionOrdinaryIncomePerShare", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distribution, Ordinary Income per share", "terseLabel": "From distributable earnings", "documentation": "Investment company, distribution, ordinary income per share." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyDistributionOrdinaryIncomePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributionOrdinaryIncomePercent", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company Distribution Ordinary Income Percent", "terseLabel": "Ordinary income Percent", "documentation": "Investment company distribution ordinary income percent." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyDistributionToShareholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyDistributionToShareholdersAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distribution to Shareholders [Abstract]", "terseLabel": "Distributions to unitholders (see note 9a):" } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyDistributionToShareholdersTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDistributionToShareholdersTableTextBlock", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersTables" ], "lang": { "en-us": { "role": { "label": "Investment Company, Distribution To Shareholders [Table Text Block]", "terseLabel": "Schedule of Investment Company, Distribution To Shareholders", "documentation": "Investment company, distribution to shareholders." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyDividendDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyDividendDistribution", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_StockholdersEquityPeriodIncreaseDecrease", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersAdditionalInformationDetail", "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Dividend Distribution", "negatedTotalLabel": "Net distributions to Unitholders", "verboseLabel": "Total distributions", "documentation": "Amount of dividend distribution from ordinary income and capital gain. Excludes distribution for tax return of capital." } } }, "auth_ref": [ "r289", "r291", "r292", "r385" ] }, "cik0001832148_InvestmentCompanyDividendDistributionInterestrelatedDividendsPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDividendDistributionInterestrelatedDividendsPercent", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Dividend Distribution, interestrelated dividends Percent", "terseLabel": "Investment Company, Dividend Distribution, interestrelated dividends Percent", "documentation": "Investment company, dividend distribution, interest-related dividends percent." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyDividendDistributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDividendDistributionPercent", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company Dividend Distribution Percent", "terseLabel": "Total distributions Percent", "documentation": "Investment company dividend distribution percent." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyDividendDistributionShorttermCapitalGainsPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyDividendDistributionShorttermCapitalGainsPercent", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Dividend Distribution, shortterm capital gains, Percent", "terseLabel": "Investment Company, Dividend Distribution, shortterm capital gains, Percent", "documentation": "Investment company, dividend distribution, short-term capital gains, percent." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyExpenseRatioAfterIncentiveAllocation": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyExpenseRatioAfterIncentiveAllocation", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Expense Ratio after Incentive Allocation", "totalLabel": "Total expenses", "documentation": "Percentage of expense, after incentive allocation, to average net assets." } } }, "auth_ref": [ "r720" ] }, "us-gaap_InvestmentCompanyFinancialHighlightsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyFinancialHighlightsAbstract", "lang": { "en-us": { "role": { "label": "Investment Company, Financial Highlights [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyFinancialHighlightsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyFinancialHighlightsLineItems", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail", "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Financial Highlights [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r295", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308" ] }, "us-gaap_InvestmentCompanyFinancialHighlightsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyFinancialHighlightsTable", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail", "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Financial Highlights [Table]", "documentation": "Disclosure of information about financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver." } } }, "auth_ref": [ "r295", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308" ] }, "us-gaap_InvestmentCompanyFinancialHighlightsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyFinancialHighlightsTableTextBlock", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsTables" ], "lang": { "en-us": { "role": { "label": "Investment Company, Financial Highlights [Table Text Block]", "terseLabel": "Summary of Financial Highlights", "documentation": "Tabular disclosure of financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver." } } }, "auth_ref": [ "r293" ] }, "us-gaap_InvestmentCompanyFinancialHighlightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyFinancialHighlightsTextBlock", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlights" ], "lang": { "en-us": { "role": { "label": "Investment Company, Financial Highlights [Text Block]", "terseLabel": "Financial Highlights", "documentation": "The entire disclosure of financial highlights reported by investment company." } } }, "auth_ref": [ "r288", "r293", "r297", "r303" ] }, "us-gaap_InvestmentCompanyFinancialRatiosAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyFinancialRatiosAbstract", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Financial Ratios [Abstract]", "terseLabel": "Ratios to average net assets of Unitholders' Capital :" } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyGainLossOnInvestmentPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyGainLossOnInvestmentPerShare", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Gain (Loss) on Investment, Per Share", "terseLabel": "Net realized and unrealized gain", "documentation": "Per share or unit amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r303" ] }, "cik0001832148_InvestmentCompanyInterestAndOtherCreditFacilityExpensesToAverageNetAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyInterestAndOtherCreditFacilityExpensesToAverageNetAssets", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Interest And Other Credit Facility Expenses To Average Net Assets", "terseLabel": "Interest and other credit facility expenses", "documentation": "Investment company interest and other credit facility expenses to average net assets." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyInternalRateOfReturnSinceInception", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Internal Rate of Return since Inception", "terseLabel": "Percentage of hurdle rate", "documentation": "Rate since inception resulting in zero net present value of cash flows from investment." } } }, "auth_ref": [ "r296" ] }, "us-gaap_InvestmentCompanyInvestmentIncomeLossFromOperationsPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyInvestmentIncomeLossFromOperationsPerShare", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Investment Income (Loss) from Operations, Per Share", "terseLabel": "Net increase (decrease) in Unitholders' capital resulting from operations", "documentation": "Per share or unit amount of investment income (loss) and realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r304" ] }, "us-gaap_InvestmentCompanyInvestmentIncomeLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyInvestmentIncomeLossPerShare", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Investment Income (Loss), Per Share", "terseLabel": "Net investment income (loss)", "documentation": "Per share or unit amount, after investment expense, of dividend and interest investment income (loss)." } } }, "auth_ref": [ "r302" ] }, "us-gaap_InvestmentCompanyInvestmentIncomeLossRatio": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyInvestmentIncomeLossRatio", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Investment Income (Loss) Ratio", "terseLabel": "Net investment income (loss)", "documentation": "Percentage of investment income (loss) to average net assets." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyIssuanceOfUnitsPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyIssuanceOfUnitsPerShare", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Issuance Of Units, Per Share", "terseLabel": "Issuance of initial units", "documentation": "Investment company issuance of units per share." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyNetAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyNetAssetsRollForward", "lang": { "en-us": { "role": { "label": "Investment Company, Net Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyOfferingCostsPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyOfferingCostsPerShare", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Offering Costs, Per Share", "terseLabel": "Offering costs", "documentation": "Investment company offering costs per share." } } }, "auth_ref": [] }, "cik0001832148_InvestmentCompanyOperatingExpensesToAverageNetAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyOperatingExpensesToAverageNetAssets", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Operating Expenses To Average Net Assets", "terseLabel": "Operating expenses", "documentation": "Investment company operating expenses to average net assets." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyPortfolioTurnover": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyPortfolioTurnover", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Portfolio Turnover", "terseLabel": "Portfolio turnover ratio", "documentation": "Percentage of lesser of purchase or sale of portfolio securities to average value of portfolio securities owned." } } }, "auth_ref": [ "r721" ] }, "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Company, Realized and Unrealized Gain (Loss) on Investment and Foreign Currency", "totalLabel": "Net realized and unrealized gain on non-controlled/non-affiliated investments and cash equivalents", "documentation": "Amount, before tax, of realized and unrealized gain (loss) on investment and derivative, classified as operating, and foreign currency transaction. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity." } } }, "auth_ref": [ "r359", "r485", "r514", "r728" ] }, "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrencyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrencyAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Company, Realized and Unrealized Gain (Loss) on Investment and Foreign Currency [Abstract]", "terseLabel": "Realized and unrealized gain (loss) on investments and cash equivalents:" } } }, "auth_ref": [] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r627" ] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r627" ] }, "us-gaap_InvestmentCompanyRegistrationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyRegistrationExpense", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Company, Registration Expense", "terseLabel": "Organizational expenses", "documentation": "Amount of registration fee expense for issuance of shares or units." } } }, "auth_ref": [ "r725" ] }, "us-gaap_InvestmentCompanyShareholderServiceFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyShareholderServiceFeeExpense", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Company, Shareholder Service Fee Expense", "terseLabel": "Services fee", "documentation": "Amount of expense for shareholder services. Includes, but is not limited to, fee and expense for transfer and dividend disbursing agent." } } }, "auth_ref": [ "r724" ] }, "cik0001832148_InvestmentCompanyTaxAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyTaxAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company Tax Accumulated Loss", "totalLabel": "Total tax accumulated loss", "documentation": "Investment company, Tax Accumulated Loss." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyTaxReturnOfCapitalDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyTaxReturnOfCapitalDistribution", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_InvestmentCompanyDividendDistribution", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Tax Return of Capital Distribution", "negatedLabel": "From return of capital", "terseLabel": "Return of capital", "documentation": "Amount of distribution in excess of tax-basis earnings and profit of investment company." } } }, "auth_ref": [ "r289", "r291", "r384", "r484" ] }, "cik0001832148_InvestmentCompanyTaxReturnOfCapitalDistributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanyTaxReturnOfCapitalDistributionPercent", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company Tax Return Of Capital Distribution Percent", "terseLabel": "Return of capital Percent", "documentation": "Investment company tax return of capital distribution percent." } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyTotalReturn": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyTotalReturn", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company, Total Return", "terseLabel": "Total Return", "documentation": "Percentage increase (decrease) in fund net asset value, assuming reinvestment of dividends and capital gain distributions." } } }, "auth_ref": [ "r287", "r294", "r299" ] }, "cik0001832148_InvestmentCompanydividendDistributionEligibleForQualifiedDividendIncomeTreatmentOrTheDividendsReceivedDeductionForCorporateStockholdersPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentCompanydividendDistributionEligibleForQualifiedDividendIncomeTreatmentOrTheDividendsReceivedDeductionForCorporateStockholdersPercent", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Company,Dividend Distribution, eligible for qualified dividend income treatment or the dividends received deduction for corporate stockholders Percent", "terseLabel": "Investment Company,Dividend Distribution, eligible for qualified dividend income treatment or the dividends received deduction for corporate stockholders Percent", "documentation": "Investment company ,dividend distribution, eligible for qualified dividend income treatment or the dividends received deduction for corporate stockholders percent." } } }, "auth_ref": [] }, "us-gaap_InvestmentIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIdentifierAxis", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Investment, Identifier [Axis]", "documentation": "Identification of investment in security, including, but not limited to, name, title, and other identifying information." } } }, "auth_ref": [ "r311", "r312", "r313", "r318", "r319", "r320", "r324", "r325", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r400", "r401", "r402", "r403", "r404", "r406", "r407", "r408", "r409", "r410", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r436", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r457", "r458", "r459", "r460", "r462", "r463", "r464", "r465", "r467", "r469", "r470", "r471", "r508" ] }, "us-gaap_InvestmentIncomeAmortizationOfDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeAmortizationOfDiscount", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Investment Income, Amortization of Discount", "negatedLabel": "Net accretion of discount on investments", "documentation": "Amount of accretion of purchase discount on nonoperating securities." } } }, "auth_ref": [ "r50" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossInvestmentIncomeOperating", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income from\u00a0non-controlled/non-affiliated\u00a0investments", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r49", "r115" ] }, "us-gaap_InvestmentIncomeInvestmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInvestmentExpense", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetInvestmentIncome", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Investment Expense", "totalLabel": "Total expenses", "documentation": "Amount of expenses related to the generation of investment income." } } }, "auth_ref": [ "r51", "r514", "r717" ] }, "cik0001832148_InvestmentIncomeInvestmentExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentIncomeInvestmentExpenseAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income Investment Expense [Abstract]", "terseLabel": "Expenses:" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Net [Abstract]", "terseLabel": "Investment Income:" } } }, "auth_ref": [] }, "us-gaap_InvestmentInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentInterestRate", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Investment Interest Rate", "terseLabel": "Interest Rate", "documentation": "Rate of interest on investment." } } }, "auth_ref": [ "r392", "r393", "r411", "r412", "r416", "r417", "r449", "r450", "r508", "r690", "r692" ] }, "us-gaap_InvestmentInterestRateFloor": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentInterestRateFloor", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Investment, Interest Rate, Floor", "terseLabel": "Floor", "documentation": "Minimum rate of interest on investment." } } }, "auth_ref": [ "r731", "r732", "r733", "r734" ] }, "us-gaap_InvestmentInterestRatePaidInKind": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentInterestRatePaidInKind", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Investment, Interest Rate, Paid in Kind", "terseLabel": "Rate of coupon as PIK", "documentation": "Rate of interest paid in kind on investment." } } }, "auth_ref": [ "r393", "r412", "r416", "r450" ] }, "us-gaap_InvestmentIssuerAffiliationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerAffiliationAxis", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment, Issuer Affiliation [Axis]", "documentation": "Information by affiliation of issuer of investment." } } }, "auth_ref": [ "r273", "r290", "r316", "r326", "r340", "r341", "r363", "r364", "r365", "r366", "r370", "r371", "r376", "r377", "r398", "r399", "r405", "r430", "r434", "r435", "r453", "r454", "r456", "r457", "r461", "r462", "r466", "r467", "r468" ] }, "us-gaap_InvestmentIssuerAffiliationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerAffiliationDomain", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment, Issuer Affiliation [Domain]", "documentation": "Affiliation of issuer of investment." } } }, "auth_ref": [ "r273", "r290", "r316", "r326", "r340", "r341", "r363", "r364", "r365", "r366", "r370", "r371", "r376", "r377", "r398", "r399", "r405", "r430", "r434", "r435", "r453", "r454", "r456", "r457", "r461", "r462", "r466", "r467", "r468" ] }, "us-gaap_InvestmentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentMaturityDate", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Investment Maturity Date", "terseLabel": "Maturity Date", "documentation": "Maturity date of investment, in YYYY-MM-DD format." } } }, "auth_ref": [ "r392", "r393", "r411", "r412", "r416", "r417", "r449", "r450", "r508", "r691", "r693" ] }, "cik0001832148_InvestmentModificationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentModificationRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Modification Risk [Member]", "documentation": "Investment Modification Risk." } } }, "auth_ref": [] }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "InvestmentObjectivesAndPracticesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "auth_ref": [ "r598" ] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "lang": { "en-us": { "role": { "label": "Investment Owned, at Cost", "terseLabel": "Investment owned, at Cost", "verboseLabel": "Cost", "documentation": "Cost of the investment." } } }, "auth_ref": [ "r273", "r318", "r319", "r402", "r410", "r427", "r467", "r508", "r516", "r722" ] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Investment Owned, at Fair Value", "definitionGuidance": "Non-controlled/non-affiliated investments (cost: $62,743 and $43,602, respectively)", "verboseLabel": "Fair Value", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r273", "r311", "r312", "r313", "r315", "r317", "r318", "r319", "r321", "r326", "r328", "r340", "r341", "r389", "r398", "r399", "r408", "r420", "r421", "r434", "r435", "r436", "r444", "r447", "r466", "r468", "r471", "r508", "r516", "r722" ] }, "cik0001832148_InvestmentOwnedAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentOwnedAtFairValueAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Investment Owned At Fair Value [Abstract]", "terseLabel": "Investments at fair value:" } } }, "auth_ref": [] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Investment Owned, Balance, Principal Amount", "terseLabel": "Par Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": [ "r311", "r321", "r396", "r424", "r452", "r508" ] }, "us-gaap_InvestmentOwnedPercentOfNetAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedPercentOfNetAssets", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Investment Owned, Net Assets, Percentage", "documentation": "Percentage of investment owned to net assets." } } }, "auth_ref": [ "r314", "r318", "r319", "r398", "r420", "r434", "r437", "r468", "r508", "r722" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations", "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail", "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r312", "r314", "r315", "r318", "r321", "r389", "r398", "r413", "r421", "r434", "r438", "r439", "r468", "r472", "r473", "r474", "r475", "r508" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations", "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail", "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r312", "r314", "r315", "r318", "r321", "r389", "r398", "r413", "r421", "r434", "r438", "r439", "r468", "r472", "r473", "r474", "r475", "r508" ] }, "cik0001832148_InvestmentsAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentsAndCashEquivalentsMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investments and cash equivalents [Member]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments, Fair Value Disclosure", "verboseLabel": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r221" ] }, "cik0001832148_InvestmentsInHealthcareCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentsInHealthcareCompaniesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investments in Healthcare Companies [Member]", "documentation": "Investments in Healthcare Companies." } } }, "auth_ref": [] }, "cik0001832148_InvestmentsInSmallerAndMiddleMarketCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "InvestmentsInSmallerAndMiddleMarketCompaniesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investments in Smaller and Middle Market Companies [Member]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Investments [Member]", "documentation": "Assets held for their financial return, rather than for the entity's operations." } } }, "auth_ref": [] }, "us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsOwnedFederalIncomeTaxNoteLineItems", "presentation": [ "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Investments, Owned, Federal Income Tax Note [Line Items]", "terseLabel": "Investments, Owned, Federal Income Tax Note [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r718" ] }, "cik0001832148_IvyFertilityServicesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "IvyFertilityServicesLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Ivy Fertility Services, LLC [Member]" } } }, "auth_ref": [] }, "cik0001832148_JpmorganChaseBankN.a.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "JpmorganChaseBankN.a.Member", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "JPMorgan Chase Bank, N.A. [Member]" } } }, "auth_ref": [] }, "cik0001832148_LackOfControlOverInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LackOfControlOverInvestmentsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lack of Control over Investments [Member]" } } }, "auth_ref": [] }, "cef_LatestNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest NAV (Deprecated 2023-01-31)" } } }, "auth_ref": [ "r610" ] }, "cef_LatestPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [ "r610" ] }, "cef_LatestSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestSharePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Share Price (Deprecated 2023-01-31)" } } }, "auth_ref": [ "r610" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "cik0001832148_LenderLiabilityConsiderationsAndEquitableSubordinationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LenderLiabilityConsiderationsAndEquitableSubordinationMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lender Liability Considerations and Equitable Subordination [Member]" } } }, "auth_ref": [] }, "cik0001832148_LeveragedCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LeveragedCompaniesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Leveraged Companies [Member]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r15", "r89", "r122", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r216", "r217", "r218", "r231", "r335", "r490", "r516", "r697", "r705", "r706" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and unitholders' capital", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r46", "r67", "r261", "r504", "r688", "r694", "r703" ] }, "cik0001832148_LiabilitiesInExcessOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LiabilitiesInExcessOfOtherAssets", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Liabilities In Excess of Other Assets", "terseLabel": "Liabilities in Excess of Other Assets", "documentation": "Liabilities in excess of other assets." } } }, "auth_ref": [] }, "cik0001832148_LicensingRequirementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LicensingRequirementsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Licensing Requirements [Member]" } } }, "auth_ref": [] }, "cik0001832148_LifeSciencesToolsServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LifeSciencesToolsServicesMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Life Sciences Tools Services [Member]" } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyLLCMembersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyLLCMembersEquityAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Limited Liability Company (LLC) Members' Equity [Abstract]", "terseLabel": "Capital unit activity (see note 7):" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r13", "r66", "r715" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r14", "r687" ] }, "us-gaap_LineOfCreditFacilityCollateral": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCollateral", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Collateral", "documentation": "Discussion of whether the borrowings under the credit facility are secured or unsecured and, if secured, a description of collateral (for example, accounts receivable less than 120 days old, finished goods inventory)." } } }, "auth_ref": [ "r13", "r40", "r56", "r65", "r66" ] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Expiration Date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r14" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r14", "r687" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r687" ] }, "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Amount Outstanding During Period", "documentation": "Maximum amount borrowed under the credit facility at any time during the period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r14" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r14", "r687" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "cik0001832148_LiquidityRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LiquidityRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Liquidity Risk [Member]", "documentation": "Liquidity Risk." } } }, "auth_ref": [] }, "cik0001832148_LitigationAndRelatedRisksAssociatedWithOriginationAndServicingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "LitigationAndRelatedRisksAssociatedWithOriginationAndServicingMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Litigation and Related Risks Associated with Origination and Servicing [Member]" } } }, "auth_ref": [] }, "cef_LoanServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LoanServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "auth_ref": [ "r584" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAverageAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAverageAmountOutstanding", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Average Amount Outstanding", "terseLabel": "Average debt outstanding", "documentation": "Average amount outstanding of long-term debt." } } }, "auth_ref": [ "r71", "r72", "r368" ] }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "auth_ref": [ "r561" ] }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "auth_ref": [ "r562" ] }, "cef_LongTermDebtPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtPrincipal", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "auth_ref": [ "r559" ] }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [ "r563" ] }, "cef_LongTermDebtStructuringTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtStructuringTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "auth_ref": [ "r560" ] }, "cef_LongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "auth_ref": [ "r559" ] }, "cef_LongTermDebtTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "auth_ref": [ "r559" ] }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "cef_LowestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "auth_ref": [ "r604" ] }, "cef_LowestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "auth_ref": [ "r608" ] }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [ "r609" ] }, "cik0001832148_MachineLearningTechnologyRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "MachineLearningTechnologyRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Machine Learning Technology Risks [Member]" } } }, "auth_ref": [] }, "us-gaap_ManagementFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementFeeExpense", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Management Fee Expense", "terseLabel": "Management fees (see note 3)", "verboseLabel": "Management fee expense", "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment." } } }, "auth_ref": [ "r34", "r364", "r514", "r723" ] }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "auth_ref": [ "r582" ] }, "us-gaap_ManagementFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementFeePayable", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Management Fee Payable", "terseLabel": "Management fee payable (see note 3)", "documentation": "Amount of fee payable for management of fund or trust." } } }, "auth_ref": [ "r329" ] }, "cef_ManagementFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "auth_ref": [ "r581" ] }, "cik0001832148_ManagementRiskAndRelianceOnManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ManagementRiskAndRelianceOnManagementMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Risk and Reliance on Management [Member]", "documentation": "Management Risk and Reliance on Management." } } }, "auth_ref": [] }, "cik0001832148_ManagementRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ManagementRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Risk [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketApproachValuationTechniqueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketApproachValuationTechniqueMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Valuation, Market Approach [Member]", "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities." } } }, "auth_ref": [ "r9" ] }, "cik0001832148_MarketRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "MarketRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Market Risk [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail", "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r127", "r128", "r129", "r130", "r180", "r243", "r268", "r322", "r323", "r392", "r411", "r417", "r418", "r449", "r488", "r489", "r492", "r499", "r503", "r505", "r699", "r707", "r708", "r709", "r710", "r711", "r712" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r633" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r633" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r702" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r223" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "cik0001832148_MeasurementInputmarketyieldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "MeasurementInputmarketyieldMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Market Yield [Member]", "documentation": "Measurement InputMarket\u00a0Yield" } } }, "auth_ref": [] }, "cik0001832148_MeditrinaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "MeditrinaIncMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Meditrina, Inc [Member]", "documentation": "Meditrina, inc." } } }, "auth_ref": [] }, "cik0001832148_MedrinaLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "MedrinaLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Medrina, LLC [Member]", "documentation": "Medrina, llc." } } }, "auth_ref": [] }, "us-gaap_MembersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersEquity", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail" ], "lang": { "en-us": { "role": { "label": "Members' Equity", "totalLabel": "Total unitholders' capital", "terseLabel": "Unitholders' capital, end of period", "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity." } } }, "auth_ref": [ "r60", "r109", "r110", "r111", "r113" ] }, "us-gaap_MembersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersEquityAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Members' Equity [Abstract]", "terseLabel": "Unitholders' Capital" } } }, "auth_ref": [] }, "us-gaap_MembersEquityNotesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersEquityNotesDisclosureTextBlock", "presentation": [ "http://www.slrhbl.com/role/UnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Members' Equity Notes Disclosure [Text Block]", "terseLabel": "Unitholders' Capital", "documentation": "The entire disclosure for the formation, structure, control and ownership of a limited liability company (LLC)." } } }, "auth_ref": [ "r107", "r112", "r113" ] }, "cik0001832148_MezzanineSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "MezzanineSecuritiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Mezzanine Securities [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail", "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r127", "r128", "r129", "r130", "r180", "r243", "r268", "r322", "r323", "r392", "r411", "r417", "r418", "r449", "r488", "r489", "r492", "r499", "r503", "r505", "r699", "r707", "r708", "r709", "r710", "r711", "r712" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r653" ] }, "cik0001832148_ModelRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ModelRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Model Risks [Member]", "documentation": "Model Risks." } } }, "auth_ref": [] }, "cik0001832148_MoneyMarketAndOtherLiquidInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "MoneyMarketAndOtherLiquidInstrumentsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Money Market and Other Liquid Instruments [Member]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r661" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r634" ] }, "us-gaap_NetAssetValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetAssetValuePerShare", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "terseLabel": "Net asset value per unit", "periodEndLabel": "Net asset value per unit, end of period", "periodStartLabel": "Net asset value per unit, beginning of period", "label": "NAV Per Share", "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure." } } }, "auth_ref": [ "r0", "r1", "r11", "r301", "r308", "r310", "r339", "r357", "r477", "r516" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r83" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r52", "r53", "r54" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "cik0001832148_NetChangeInUnrealizedGainOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "NetChangeInUnrealizedGainOnInvestments", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Change In Unrealized Gain On Investments", "negatedLabel": "Net change in unrealized gain on investments", "documentation": "Net change in unrealized gain on investments." } } }, "auth_ref": [] }, "cef_NetExpenseOverAssetsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NetExpenseOverAssetsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "auth_ref": [ "r584" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_StockholdersEquityPeriodIncreaseDecrease", "weight": 1.0, "order": 6.0 }, "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Unitholders' Capital Resulting From Operations", "verboseLabel": "Net Increase (Decrease) in Unitholders' Capital Resulting From Operations", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r47", "r54", "r68", "r73", "r79", "r80", "r81", "r89", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r104", "r114", "r116", "r118", "r120", "r122", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r219", "r231", "r262", "r360", "r382", "r383", "r491", "r514", "r697" ] }, "us-gaap_NetIncomeLossAttributableToReportingEntityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToReportingEntityAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Increase (decrease) in unitholders' capital resulting from operations:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossPerOutstandingLimitedPartnershipUnitBasicNetOfTax": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossPerOutstandingLimitedPartnershipUnitBasicNetOfTax", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Per Outstanding Limited Partnership Unit, Basic, Net of Tax", "verboseLabel": "Net Income (Loss) Per Unit", "documentation": "Per unit of ownership amount after tax of income (loss) available to outstanding limited partnership (LP) unit-holder." } } }, "auth_ref": [ "r61" ] }, "us-gaap_NetInvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentIncome", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Investment Income", "totalLabel": "Net investment income (loss)", "terseLabel": "Net investment income (loss)", "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": [ "r70", "r264", "r265", "r369", "r514" ] }, "cef_NewCefOrBdcRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NewCefOrBdcRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "auth_ref": [ "r545" ] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r545", "r612", "r613", "r614" ] }, "cik0001832148_NoAssuranceOfCashDistributionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "NoAssuranceOfCashDistributionsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Assurance of Cash Distributions [Member]" } } }, "auth_ref": [] }, "cik0001832148_NoMarketForUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "NoMarketForUnitsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Market for Units [Member]" } } }, "auth_ref": [] }, "cef_NoPublicTradingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NoPublicTradingTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "auth_ref": [ "r607" ] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r672" ] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r672" ] }, "cef_NoTradingHistoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NoTradingHistoryTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "auth_ref": [ "r611" ] }, "cik0001832148_NonControlledNonAffiliatedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "NonControlledNonAffiliatedInvestmentsMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Non Controlled Non Affiliated Investments [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r633" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r529", "r541", "r622", "r641", "r650" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r631" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r630" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r641" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r661" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r661" ] }, "cik0001832148_OfacFcpaAndRelatedConsiderationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OfacFcpaAndRelatedConsiderationsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "OFAC, FCPA and Related Considerations [Member]" } } }, "auth_ref": [] }, "cik0001832148_OfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OfferingExpenses", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Offering Expenses", "terseLabel": "Offering expenses", "documentation": "Offering expenses." } } }, "auth_ref": [] }, "cik0001832148_OisManagementServicesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OisManagementServicesLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "OIS Management Services, LLC [Member]" } } }, "auth_ref": [] }, "cik0001832148_OralSurgeryPartnersHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OralSurgeryPartnersHoldingsLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Oral Surgery Partners Holdings, LLC [Member]", "documentation": "Oral surgery partners holdings, llc." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.slrhbl.com/role/Organization" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r39", "r62", "r271", "r272" ] }, "cik0001832148_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "auth_ref": [] }, "cik0001832148_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "auth_ref": [] }, "cik0001832148_OrganizationalCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OrganizationalCosts", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Organizational Costs", "terseLabel": "Organizational costs", "documentation": "Organizational costs." } } }, "auth_ref": [] }, "cik0001832148_OrthopedicCarePartnersManagementLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OrthopedicCarePartnersManagementLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Orthopedic Care Partners Management, LLC [Member]", "documentation": "Orthopedic care partners management, llc." } } }, "auth_ref": [] }, "cef_OtherAnnualExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "auth_ref": [ "r584" ] }, "cef_OtherAnnualExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "auth_ref": [ "r584" ] }, "cef_OtherAnnualExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "auth_ref": [ "r584" ] }, "cef_OtherAnnualExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "auth_ref": [ "r584" ] }, "cef_OtherAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "auth_ref": [ "r584" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitment", "terseLabel": "Commitments", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "cef_OtherExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "auth_ref": [ "r580" ] }, "cef_OtherFeederFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherFeederFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "auth_ref": [ "r584" ] }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other General and Administrative Expense", "terseLabel": "Other general and administrative expenses", "documentation": "Amount of general and administrative expense classified as other." } } }, "auth_ref": [ "r48", "r727" ] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossInvestmentIncomeOperating", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Income", "terseLabel": "Other income from\u00a0non-controlled/non-affiliated\u00a0investments", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r267", "r362", "r460", "r461", "r463" ] }, "cef_OtherMasterFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherMasterFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "auth_ref": [ "r584" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r633" ] }, "cik0001832148_OtherRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OtherRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Risks [Member]" } } }, "auth_ref": [] }, "cef_OtherSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "auth_ref": [ "r564" ] }, "cef_OtherSecurityDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "auth_ref": [ "r564" ] }, "cef_OtherSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "auth_ref": [ "r564" ] }, "cef_OtherTransactionExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionFeesBasisMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximum", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionFeesBasisMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "auth_ref": [ "r579" ] }, "cef_OtherTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "auth_ref": [ "r579" ] }, "cik0001832148_OutsetMedicalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "OutsetMedicalIncMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Outset Medical, Inc [Member]", "documentation": "Outset medical, inc." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r527", "r539", "r620", "r648" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r530", "r542", "r623", "r651" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r530", "r542", "r623", "r651" ] }, "cef_OutstandingSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "auth_ref": [ "r565" ] }, "cef_OutstandingSecurityAuthorizedShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityAuthorizedShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "auth_ref": [ "r567" ] }, "cef_OutstandingSecurityHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "auth_ref": [ "r568" ] }, "cef_OutstandingSecurityNotHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityNotHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "auth_ref": [ "r569" ] }, "cef_OutstandingSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "auth_ref": [ "r566" ] }, "cik0001832148_PartnersCapitalAccountCancellation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PartnersCapitalAccountCancellation", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_PartnersCapitalAccountPeriodIncreaseDecrease", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Partners Capital Account Cancellation", "negatedLabel": "Cancellation", "documentation": "Partners capital account cancellation." } } }, "auth_ref": [] }, "us-gaap_PartnersCapitalAccountContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PartnersCapitalAccountContributions", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_PartnersCapitalAccountPeriodIncreaseDecrease", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Partners' Capital Account, Contributions", "terseLabel": "Contributions", "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners)." } } }, "auth_ref": [ "r59", "r60" ] }, "cik0001832148_PartnersCapitalAccountOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PartnersCapitalAccountOfferingCosts", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_PartnersCapitalAccountPeriodIncreaseDecrease", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Partners Capital Account Offering Costs", "negatedLabel": "Less offering costs", "documentation": "Partners capital account offering costs." } } }, "auth_ref": [] }, "us-gaap_PartnersCapitalAccountPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PartnersCapitalAccountPeriodIncreaseDecrease", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_StockholdersEquityPeriodIncreaseDecrease", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Partners' Capital", "totalLabel": "Net increase in unitholders' capital resulting from capital activity", "documentation": "Changes in the ownership interest during the period of each class of partners. Partners include general, limited and preferred partners." } } }, "auth_ref": [ "r60", "r61" ] }, "cik0001832148_PartnersCapitalAccountUnitsCanceled": { "xbrltype": "sharesItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PartnersCapitalAccountUnitsCanceled", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_PartnersCapitalAccountUnitsPeriodIncreaseDecrease", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Partners Capital Account Units Canceled", "terseLabel": "Units canceled", "documentation": "Partners capital accounts units canceled." } } }, "auth_ref": [] }, "us-gaap_PartnersCapitalAccountUnitsContributed": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PartnersCapitalAccountUnitsContributed", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": "us-gaap_PartnersCapitalAccountUnitsPeriodIncreaseDecrease", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Partners' Capital Account, Units, Contributed", "terseLabel": "Units issued", "documentation": "Units contributed by each class of partners during the year. Units represent shares of ownership of the general, limited, and preferred partners." } } }, "auth_ref": [ "r60", "r61" ] }, "us-gaap_PartnersCapitalAccountUnitsPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PartnersCapitalAccountUnitsPeriodIncreaseDecrease", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Partners' Capital Account, Units, Period Increase (Decrease)", "totalLabel": "Net increase from capital unit activity", "documentation": "Total net change in the units of each class of partners' capital accounts during the year. Units represent shares of ownership of the general, limited, and preferred partners." } } }, "auth_ref": [ "r60", "r61" ] }, "us-gaap_PartnersCapitalAccountUnitsSaleOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PartnersCapitalAccountUnitsSaleOfUnits", "presentation": [ "http://www.slrhbl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail" ], "lang": { "en-us": { "role": { "label": "Partners' Capital Account, Units, Sale of Units", "terseLabel": "Units issued", "documentation": "Total units issued during the year due to the sale of units. All partners include general, limited and preferred partners." } } }, "auth_ref": [ "r60" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r629" ] }, "us-gaap_PayableInvestmentPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayableInvestmentPurchase", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Payable, Investment, Purchase", "terseLabel": "Payable for cash equivalents purchased", "documentation": "Amount of payable for purchase of investment." } } }, "auth_ref": [ "r327", "r476", "r516" ] }, "us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForPurchaseOfSecuritiesOperatingActivities", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Purchase of Securities, Operating Activities", "negatedLabel": "Purchase of investments", "documentation": "Cash paid to purchase debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Dividends", "negatedLabel": "Cash distributions paid", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r22" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Offering costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r21" ] }, "cik0001832148_PecentageOfAmountDueToUnitholders": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PecentageOfAmountDueToUnitholders", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pecentage of Amount Due to Unitholders", "terseLabel": "Pecentage of amount due to unitholders", "documentation": "Pecentage of amount due to unitholders." } } }, "auth_ref": [] }, "cik0001832148_PediatricHomeRespiratoryServicesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PediatricHomeRespiratoryServicesLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Pediatric Home Respiratory Services, LLC [Member]", "documentation": "Pediatric home respiratory services, llc." } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r632" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r632" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r631" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r641" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r634" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r630" ] }, "cik0001832148_PercentageOfAverageCostBasis": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfAverageCostBasis", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Average Cost Basis", "terseLabel": "Percentage of average cost basis", "documentation": "Percentage of average cost basis." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfCummulativeCapitalRealizedGains": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfCummulativeCapitalRealizedGains", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Cummulative Capital Realized Gains", "terseLabel": "Percentage of cummulative capital realized gains", "documentation": "Percentage of cummulative capital realized gains." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfCurrentProceedsToAdvisers": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfCurrentProceedsToAdvisers", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Current Proceeds to Advisers", "terseLabel": "Percentage of current proceeds to advisers", "documentation": "Percentage of current proceeds to advisers." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfCurrentProceedsToUnitholders": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfCurrentProceedsToUnitholders", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Current Proceeds to Unitholders", "terseLabel": "Percentage of current proceeds to unitholders", "documentation": "Percentage of current proceeds to unitholders." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfEntityAverageAssetsThreshold1": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfEntityAverageAssetsThreshold1", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Entity Average Assets Threshold 1", "terseLabel": "Percentage of Entity Average Assets Threshold", "documentation": "Percentage of entity average assets threshold 1." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfNonQualifyingAssetsInThePortfolioOfTotalAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfNonQualifyingAssetsInThePortfolioOfTotalAssets", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Of Non Qualifying Assets In The Portfolio Of Total Assets", "terseLabel": "Percentage of Non Qualifying Assets in the Portfolio of Total Assets", "documentation": "Percentage of non qualifying assets in the portfolio of total assets." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfPostExchangeListingManagementFeeOnEntityAverageAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfPostExchangeListingManagementFeeOnEntityAverageAssets", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Post Exchange Listing Management Fee on Entity Average Assets", "terseLabel": "Percentage of Post-Exchange Listing Management Fee on Entity Average Assets", "documentation": "Percentage of post exchange listing management fee on entity average assets." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfPostExchangeListingManagementFeeOnEntityGrossAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfPostExchangeListingManagementFeeOnEntityGrossAssets", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Post Exchange Listing Management Fee on Entity Gross Assets", "terseLabel": "Percentage of Post-Exchange Listing Management Fee on Entity Gross Assets", "documentation": "Percentage of post exchange listing management fee on entity gross assets." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfPreExchangeManagementFeeOnInvestedCapital": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfPreExchangeManagementFeeOnInvestedCapital", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage Of Pre Exchange Management Fee On Invested Capital", "terseLabel": "Percentage of pre exchange management fee on invested capital", "documentation": "Percentage of pre exchange management fee on invested capital." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfRealizedCapitalGains": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfRealizedCapitalGains", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Realized Capital Gains", "terseLabel": "Percentage of realized capital gains", "documentation": "Percentage of realized capital gains." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfRemainingDispositionProceedsToAdviser": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfRemainingDispositionProceedsToAdviser", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Remaining Disposition Proceeds To Adviser", "terseLabel": "Percentage of remaining disposition proceeds to adviser", "documentation": "Percentage of remaining disposition proceeds to adviser." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfRemainingDispositionProceedsToUnitholders": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfRemainingDispositionProceedsToUnitholders", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Remaining Disposition Proceeds To Unitholders", "terseLabel": "Percentage of remaining disposition proceeds to unitholders", "documentation": "Percentage of remaining disposition proceeds to unitholders." } } }, "auth_ref": [] }, "cik0001832148_PercentageOfTotalInvestmentsAtFairValue": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageOfTotalInvestmentsAtFairValue", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Percentage of Total Investments at Fair Value", "terseLabel": "Percentage of Total Investments", "documentation": "Percentage of total investments at fair value." } } }, "auth_ref": [] }, "cik0001832148_PercentagePreIncentivefeeNetInvestmentIncome": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentagePreIncentivefeeNetInvestmentIncome", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage Pre IncentiveFee Net Investment Income", "terseLabel": "Percentage pre incentive\u00a0fee net investment income", "documentation": "Percentage pre incentive\u00a0fee net investment income." } } }, "auth_ref": [] }, "cik0001832148_PercentageRepresentingBankDebtOrSeniorSecuredLoansOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageRepresentingBankDebtOrSeniorSecuredLoansOwned", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Representing Bank Debt Or Senior Secured Loans Owned", "documentation": "Percentage representing bank debt or senior secured loans owned." } } }, "auth_ref": [] }, "cik0001832148_PercentageRepresentingCashEquivalentsInInvestmentsOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageRepresentingCashEquivalentsInInvestmentsOwned", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Representing Cash Equivalents In Investments Owned", "documentation": "Percentage representing cash equivalents in investments owned." } } }, "auth_ref": [] }, "cik0001832148_PercentageRepresentingLiabilitiesInExcessOfOtherAssetsInInvestmentsOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageRepresentingLiabilitiesInExcessOfOtherAssetsInInvestmentsOwned", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Representing Liabilities In Excess Of Other Assets In Investments Owned", "documentation": "Percentage representing liabilities in excess of other assets in investments owned." } } }, "auth_ref": [] }, "cik0001832148_PercentageRepresentingSharesOrWarrantsOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageRepresentingSharesOrWarrantsOwned", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Representing Shares Or Warrants Owned", "terseLabel": "Percentage Representing Shares/Warrants Owned", "documentation": "Percentage representing shares or warrants owned." } } }, "auth_ref": [] }, "cik0001832148_PercentageRepresentingTotalInvestmentsAndCashEquivalentsInInvestmentsOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageRepresentingTotalInvestmentsAndCashEquivalentsInInvestmentsOwned", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Representing Total Investments And Cash Equivalents In Investments Owned", "documentation": "Percentage representing total investments and cash equivalents in investments owned." } } }, "auth_ref": [] }, "cik0001832148_PercentageRepresentingTotalInvestmentsInInvestmentsOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageRepresentingTotalInvestmentsInInvestmentsOwned", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Representing Total Investments In Investments Owned", "documentation": "Percentage representing total investments in investments owned." } } }, "auth_ref": [] }, "cik0001832148_PercentageRepresentingWarrantsOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PercentageRepresentingWarrantsOwned", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage Representing Warrants Owned", "verboseLabel": "Percentage Representing Warrants Owned", "documentation": "Percentage representing warrants owned." } } }, "auth_ref": [] }, "cik0001832148_PeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PeriodAxis", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Period [Axis]", "documentation": "Period." } } }, "auth_ref": [] }, "cik0001832148_PeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PeriodDomain", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Period [Domain]", "documentation": "Period." } } }, "auth_ref": [] }, "cik0001832148_PermissibleIncurredLeverageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PermissibleIncurredLeverageMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Permissible Incurred Leverage [Member]" } } }, "auth_ref": [] }, "cik0001832148_PharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PharmaceuticalsMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments" ], "lang": { "en-us": { "role": { "label": "Pharmaceuticals [Member]" } } }, "auth_ref": [] }, "cik0001832148_PlasticsManagementLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PlasticsManagementLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Plastics Management, LLC [Member]" } } }, "auth_ref": [] }, "cik0001832148_PooledInvestmentVehiclesAndPassthroughEntitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PooledInvestmentVehiclesAndPassthroughEntitiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pooled Investment Vehicles and Passthrough Entities [Member]" } } }, "auth_ref": [] }, "cik0001832148_PortfolioInvestmentRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PortfolioInvestmentRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Portfolio Investment Risk [Member]" } } }, "auth_ref": [] }, "cik0001832148_PortfolioTurnoverMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PortfolioTurnoverMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Portfolio Turnover [Member]" } } }, "auth_ref": [] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r517" ] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r517" ] }, "cik0001832148_PotentialDividendDeferralsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PotentialDividendDeferralsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Potential Dividend Deferrals [Member]" } } }, "auth_ref": [] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r517" ] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r517" ] }, "cik0001832148_PreExchangeListingIncentiveFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PreExchangeListingIncentiveFeeMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pre Exchange Listing Incentive Fee [Member]", "documentation": "Pre exchange listing incentive fee." } } }, "auth_ref": [] }, "cik0001832148_PrecentageOfProductPayment": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PrecentageOfProductPayment", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Precentage of Product Payment", "terseLabel": "Precentage of product payment", "documentation": "Precentage of product payment." } } }, "auth_ref": [] }, "cik0001832148_PrecentageOfReturnOfCapitalContributionsToUnitHolders": { "xbrltype": "percentItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PrecentageOfReturnOfCapitalContributionsToUnitHolders", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Precentage of Return of Capital Contributions To Unit Holders", "terseLabel": "Precentage of return of capital contributions", "documentation": "Precentage of return of capital contributions to unitholders." } } }, "auth_ref": [] }, "cik0001832148_PreferredSecuritiesRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PreferredSecuritiesRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Securities Risk [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Liquidating Preference", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r27", "r28", "r43", "r686", "r700" ] }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsArrearageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "auth_ref": [ "r555" ] }, "cef_PreferredStockRestrictionsOtherTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsOtherTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "auth_ref": [ "r556" ] }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense", "terseLabel": "Prepaid expenses", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs." } } }, "auth_ref": [ "r35", "r78", "r350", "r713" ] }, "cik0001832148_PrepaymentRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PrepaymentRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Prepayment Risks [Member]", "documentation": "Prepayment Risks." } } }, "auth_ref": [] }, "cef_PrimaryShelfFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "auth_ref": [ "r545" ] }, "cef_PrimaryShelfQualifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfQualifiedFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "auth_ref": [ "r545" ] }, "us-gaap_PriorPeriodReclassificationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustment", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Prior Period Reclassification Adjustment", "terseLabel": "Amount of Reclassification", "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromContributionsFromParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromContributionsFromParent", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Contributions from Parent", "terseLabel": "Contributions from unitholders", "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from borrowings", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r683" ] }, "us-gaap_ProceedsFromSaleOfSecuritiesOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfSecuritiesOperatingActivities", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Securities, Operating Activities", "terseLabel": "Proceeds from disposition of investments", "documentation": "Cash received from sale of investments in debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating." } } }, "auth_ref": [ "r23" ] }, "cik0001832148_ProductOfCapitalCommitment": { "xbrltype": "decimalItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ProductOfCapitalCommitment", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Product Of Capital Commitment", "terseLabel": "Product of capital commitment", "documentation": "Product of capital commitment ." } } }, "auth_ref": [] }, "cik0001832148_ProjectionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ProjectionsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Projections [Member]" } } }, "auth_ref": [] }, "cef_ProspectusLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusLineItems", "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "auth_ref": [ "r545" ] }, "cef_ProspectusTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusTable", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "auth_ref": [ "r545" ] }, "cik0001832148_PublicHealthCrisesRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "PublicHealthCrisesRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Public Health Crises Risk [Member]", "documentation": "Public Health Crises Risk." } } }, "auth_ref": [] }, "cef_PurposeOfFeeTableNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PurposeOfFeeTableNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "auth_ref": [ "r571" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r629" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r629" ] }, "cik0001832148_QualifyingAssetRequirementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "QualifyingAssetRequirementsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Qualifying Asset Requirements [Member]" } } }, "auth_ref": [] }, "cik0001832148_QuarterlyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "QuarterlyMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Quarterly [Member]", "documentation": "Quarterly." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail", "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r127", "r128", "r129", "r130", "r172", "r180", "r203", "r204", "r205", "r242", "r243", "r268", "r322", "r323", "r392", "r411", "r417", "r418", "r449", "r488", "r489", "r492", "r499", "r503", "r505", "r508", "r695", "r699", "r708", "r709", "r710", "r711", "r712" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail", "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r127", "r128", "r129", "r130", "r172", "r180", "r203", "r204", "r205", "r242", "r243", "r268", "r322", "r323", "r392", "r411", "r417", "r418", "r449", "r488", "r489", "r492", "r499", "r503", "r505", "r508", "r695", "r699", "r708", "r709", "r710", "r711", "r712" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency", "weight": 1.0, "order": 3.0 }, "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Realized Investment Gains (Losses)", "presentationGuidance": "Net realized loss on\u00a0non-controlled/non-affiliated\u00a0investments and cash equivalents", "verboseLabel": "Net realized loss", "negatedLabel": "Net realized loss on investments and cash equivalents", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r266" ] }, "cik0001832148_RealizedInvestmentGainsLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RealizedInvestmentGainsLossesMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Realized Investment Gains Losses [Member]", "documentation": "Realized investment gains losses." } } }, "auth_ref": [] }, "cik0001832148_RecognizingIncomeBeforeOrWithoutReceivingCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RecognizingIncomeBeforeOrWithoutReceivingCashMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Recognizing Income Before or Without Receiving Cash [Member]" } } }, "auth_ref": [] }, "cik0001832148_RecourseToTheCompanysAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RecourseToTheCompanysAssetsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Recourse to the Companys Assets [Member]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r522", "r534", "r615", "r643" ] }, "cik0001832148_ReferralRelationshipsWithFinancialSponsorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ReferralRelationshipsWithFinancialSponsorsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Referral Relationships with Financial Sponsors [Member]" } } }, "auth_ref": [] }, "cef_RegisteredClosedEndFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RegisteredClosedEndFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "auth_ref": [ "r545" ] }, "cik0001832148_RegulationsOfHealthcareIndustryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RegulationsOfHealthcareIndustryMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Regulations of Healthcare Industry [Member]" } } }, "auth_ref": [] }, "cik0001832148_RegulatoryInvestigationsOrThirdpartyLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RegulatoryInvestigationsOrThirdpartyLitigationMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Regulatory Investigations or ThirdParty Litigation [Member]" } } }, "auth_ref": [] }, "cik0001832148_RegulatoryRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RegulatoryRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Regulatory Risk [Member]" } } }, "auth_ref": [] }, "cik0001832148_RegulatoryRisksRelatingToTheCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RegulatoryRisksRelatingToTheCompanyMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Regulatory Risks Relating to the Company [Member]" } } }, "auth_ref": [] }, "cik0001832148_ReimbursementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ReimbursementExpense", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Reimbursement Expense", "terseLabel": "Affiliate Costs", "documentation": "Reimbursement expense." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r179", "r234", "r235", "r330", "r331", "r332", "r333", "r334", "r356", "r358", "r388" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r234", "r235", "r704" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r179", "r234", "r235", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r330", "r331", "r332", "r333", "r334", "r356", "r358", "r388", "r704" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "negatedLabel": "Repayments of borrowings", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r684" ] }, "cik0001832148_ReportingCompanyFilingRequirementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ReportingCompanyFilingRequirementsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Reporting Company Filing Requirements [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r523", "r535", "r616", "r644" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r524", "r536", "r617", "r645" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r531", "r543", "r624", "r652" ] }, "cik0001832148_RestrictedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RestrictedSecuritiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Restricted Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "parentTag": "us-gaap_MembersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated distributable net loss (see note 2f)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r45", "r60", "r260", "r269", "r270", "r282", "r338", "r504" ] }, "cik0001832148_RetinaMidcoInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RetinaMidcoInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Retina Midco, Inc. [Member]" } } }, "auth_ref": [] }, "cef_ReturnAtMinusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "auth_ref": [ "r603" ] }, "cef_ReturnAtMinusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "auth_ref": [ "r603" ] }, "cef_ReturnAtPlusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtPlusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "auth_ref": [ "r603" ] }, "cef_ReturnAtPlusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtPlusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "auth_ref": [ "r603" ] }, "cef_ReturnAtZeroPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtZeroPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "auth_ref": [ "r603" ] }, "cik0001832148_RevolvingCreditFacilityDueFebruaryTwoThousandAndTwentySevenTheSpvFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RevolvingCreditFacilityDueFebruaryTwoThousandAndTwentySevenTheSpvFacilityMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility Due February Two Thousand and Twenty Seven the SPV Facility [Member]", "documentation": "Revolving credit facility due february two thousand and twenty seven the SPV facility." } } }, "auth_ref": [] }, "cik0001832148_RevolvingCreditFacilityDueMarchTwoThousandAndTwentyFourTheSubscriptionFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RevolvingCreditFacilityDueMarchTwoThousandAndTwentyFourTheSubscriptionFacilityMember", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility Due March Two Thousand and Twenty Four the Subscription Facility [Member]", "documentation": "Revolving credit facility due march two thousand and twenty four the subscription facility." } } }, "auth_ref": [] }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [ "r558" ] }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "auth_ref": [ "r557" ] }, "cef_RiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "auth_ref": [] }, "cef_RiskFactorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskFactorsTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "auth_ref": [ "r599" ] }, "cik0001832148_RiskOfLossMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RiskOfLossMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk of Loss [Member]" } } }, "auth_ref": [] }, "cef_RiskTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "auth_ref": [] }, "cik0001832148_RisksAssociatedWithBankruptcyAndInsolvencyCasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksAssociatedWithBankruptcyAndInsolvencyCasesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Associated with Bankruptcy and Insolvency Cases [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksInherentInHealthcarerelatedAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksInherentInHealthcarerelatedAssetsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Inherent in HealthcareRelated Assets [Member]", "documentation": "Risks Inherent in Healthcare-Related Assets." } } }, "auth_ref": [] }, "cik0001832148_RisksRelatedToChangesInRegulatoryPolicyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatedToChangesInRegulatoryPolicyMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Related to Changes in Regulatory Policy [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatedToDispositionOfInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatedToDispositionOfInvestmentsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Related to Disposition of Investments [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatedToEconomicRecessionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatedToEconomicRecessionsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Related to Economic Recessions [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatedToElectronicCommunicationscybersecurityRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatedToElectronicCommunicationscybersecurityRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Related to Electronic CommunicationsCybersecurity Risk [Member]", "documentation": "Risks Related to Electronic Communications/Cybersecurity Risk." } } }, "auth_ref": [] }, "cik0001832148_RisksRelatedToPortfolioInvestmentMonitoringAndInvolvementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatedToPortfolioInvestmentMonitoringAndInvolvementMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Related to Portfolio Investment Monitoring and Involvement [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatedToTheRussianInvasionOfUkraineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatedToTheRussianInvasionOfUkraineMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Related to the Russian Invasion of Ukraine [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatedToTheU.s.DebtCeilingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatedToTheU.s.DebtCeilingMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Related to the U.S. Debt Ceiling [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatingToBankLoansAndCorporateLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatingToBankLoansAndCorporateLoansMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Relating to Bank Loans and Corporate Loans [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatingToReferenceRatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatingToReferenceRatesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Relating to Reference Rates [Member]" } } }, "auth_ref": [] }, "cik0001832148_RisksRelatingToWaiversOrDeferralsOfCovenantsAndCovenantliteLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "RisksRelatingToWaiversOrDeferralsOfCovenantsAndCovenantliteLoansMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risks Relating to Waivers or Deferrals of Covenants and CovenantLite Loans [Member]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r661" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r661" ] }, "cef_SalesLoadPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SalesLoadPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "auth_ref": [ "r570" ] }, "us-gaap_ScheduleOfInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsLineItems", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r466", "r467", "r468", "r469", "r470", "r471" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestments", "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfInvestmentCompanyDistributionToShareholdersDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r442", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r466", "r467", "r468", "r469", "r470", "r471" ] }, "cik0001832148_ScheduleOfMembersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ScheduleOfMembersEquityTableTextBlock", "presentation": [ "http://www.slrhbl.com/role/UnitholdersCapitalTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Members Equity [Table Text Block]", "terseLabel": "Summary of Limited Liability Company Unit Holders Capital", "documentation": "Schedule of members equity." } } }, "auth_ref": [] }, "cik0001832148_ScheduleOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ScheduleOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule Of Significant Accounting Policies [Line Items]", "documentation": "Schedule of significant accounting policies." } } }, "auth_ref": [] }, "cik0001832148_ScheduleOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ScheduleOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule Of Significant Accounting Policies [Table]", "documentation": "Schedule of significant accounting policies." } } }, "auth_ref": [] }, "cik0001832148_ScheduleOfUnfundedCommitmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ScheduleOfUnfundedCommitmentsTableTextBlock", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Unfunded Commitments [Table Text Block]", "terseLabel": "Summary of Unfunded Commitments", "documentation": "Schedule of unfunded commitments." } } }, "auth_ref": [] }, "cik0001832148_ScpEyeCareLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ScpEyeCareLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "SCP Eye Care, LLC [Member]", "documentation": "SCP eye care, llc." } } }, "auth_ref": [] }, "cik0001832148_SectorRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SectorRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Sector Risk [Member]", "documentation": "Sector Risk." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r701" ] }, "cef_SecurityDividendsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityDividendsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "auth_ref": [ "r548" ] }, "cef_SecurityLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityLiabilitiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "auth_ref": [ "r551" ] }, "cef_SecurityLiquidationRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityLiquidationRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "auth_ref": [ "r550" ] }, "cef_SecurityObligationsOfOwnershipTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityObligationsOfOwnershipTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "auth_ref": [ "r553" ] }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "auth_ref": [ "r552" ] }, "cef_SecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "auth_ref": [ "r547" ] }, "cef_SecurityVotingRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityVotingRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "auth_ref": [ "r549" ] }, "cik0001832148_SeniorSecuredLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SeniorSecuredLoansMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Secured Loans [Member]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Amount (Deprecated 2023-01-31)" } } }, "auth_ref": [ "r590" ] }, "cef_SeniorSecuritiesAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "auth_ref": [ "r590" ] }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "auth_ref": [ "r593" ] }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "auth_ref": [ "r595" ] }, "cef_SeniorSecuritiesCoveragePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesCoveragePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit (Deprecated 2023-01-31)" } } }, "auth_ref": [ "r591" ] }, "cef_SeniorSecuritiesCvgPerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesCvgPerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "auth_ref": [ "r591" ] }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "auth_ref": [ "r596" ] }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "auth_ref": [ "r587", "r594" ] }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "auth_ref": [ "r588", "r594" ] }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)" } } }, "auth_ref": [ "r592" ] }, "cef_SeniorSecuritiesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "auth_ref": [ "r586", "r594" ] }, "cef_SeniorSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "auth_ref": [ "r589" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "terseLabel": "Share price", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "cef_SharePriceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePriceTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "auth_ref": [ "r605" ] }, "cef_SharePricesNotActualTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePricesNotActualTransactionsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "auth_ref": [ "r606" ] }, "cef_ShareholderTransactionExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ShareholderTransactionExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "auth_ref": [ "r570" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.slrhbl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail" ], "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodEndLabel": "Units issued at end of period", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsDetail", "http://www.slrhbl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Units outstanding at end of period", "periodStartLabel": "Units at beginning of period", "terseLabel": "Units outstanding, end of period", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.slrhbl.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r55", "r87" ] }, "cik0001832148_SouthernOrthodonicPartnersManagementLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SouthernOrthodonicPartnersManagementLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Southern Orthodonic Partners Management, LLC [Member]" } } }, "auth_ref": [] }, "cik0001832148_SpectrumPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SpectrumPharmaceuticalsIncMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Spectrum Pharmaceuticals, Inc [Member]", "documentation": "Spectrum pharmaceuticals, inc." } } }, "auth_ref": [] }, "cik0001832148_SpvFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SpvFacilityMember", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail", "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "SPV Facility [Member]", "documentation": "SPV facility." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.slrhbl.com/role/CoverPage", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r71", "r75", "r76", "r77", "r89", "r102", "r103", "r105", "r106", "r111", "r113", "r122", "r131", "r133", "r134", "r135", "r138", "r139", "r167", "r168", "r169", "r170", "r171", "r231", "r278", "r279", "r280", "r281", "r292", "r295", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r337", "r361", "r386", "r477", "r478", "r479", "r480", "r481", "r679", "r686", "r689" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r92", "r93", "r94", "r108", "r244", "r273", "r310", "r326", "r330", "r331", "r332", "r333", "r334", "r337", "r340", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r352", "r353", "r354", "r355", "r356", "r358", "r363", "r364", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r386", "r509" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.slrhbl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows", "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r92", "r93", "r94", "r108", "r244", "r273", "r310", "r326", "r330", "r331", "r332", "r333", "r334", "r337", "r340", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r352", "r353", "r354", "r355", "r356", "r358", "r363", "r364", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r386", "r509" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r526", "r538", "r619", "r647" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common shares shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r43", "r44", "r60", "r278", "r386", "r478" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common shares value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r43", "r44", "r60", "r292", "r386", "r478", "r515" ] }, "us-gaap_StockholdersEquityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPeriodIncreaseDecrease", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Period Increase (Decrease)", "totalLabel": "Total increase in unitholders' capital", "documentation": "The increase (decrease) in stockholders' equity during the period." } } }, "auth_ref": [ "r8", "r60", "r387", "r481", "r515", "r719" ] }, "cik0001832148_SubordinatedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SubordinatedLoansMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Subordinated Loans [Member]" } } }, "auth_ref": [] }, "cik0001832148_SubscriptionFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SubscriptionFacilityMember", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail", "http://www.slrhbl.com/role/FairValueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subscription Facility [Member]", "documentation": "Subscription facility." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r232", "r237" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r232", "r237" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r232", "r237" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r232", "r237" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.slrhbl.com/role/SubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r232", "r237" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.slrhbl.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r236", "r238" ] }, "cik0001832148_SummaryOfUnfundedCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SummaryOfUnfundedCommitmentsLineItems", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Summary Of Unfunded Commitments [Line Items]", "documentation": "Summary of unfunded commitments." } } }, "auth_ref": [] }, "cik0001832148_SummaryOfUnfundedCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SummaryOfUnfundedCommitmentsTable", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Summary Of Unfunded Commitments [Table]", "documentation": "Summary of unfunded commitments." } } }, "auth_ref": [] }, "cik0001832148_SunmedGroupHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "SunmedGroupHoldingsLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "SunMed Group Holdings, LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r640" ] }, "us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxBasisOfInvestmentsCostForIncomeTaxPurposes", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tax Basis of Investments, Cost for Income Tax Purposes", "terseLabel": "Tax Basis of Investments, Cost for Income Tax Purposes", "documentation": "Amount of cost of investment for federal income tax purpose." } } }, "auth_ref": [ "r277" ] }, "us-gaap_TaxBasisOfInvestmentsGrossUnrealizedAppreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxBasisOfInvestmentsGrossUnrealizedAppreciation", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tax Basis of Investments, Gross, Unrealized Appreciation", "terseLabel": "Tax Basis of Investments, Gross, Unrealized Appreciation", "documentation": "Amount of cumulative increase in investment from unrealized gain when value exceeds cost for federal income tax purpose." } } }, "auth_ref": [ "r274" ] }, "us-gaap_TaxBasisOfInvestmentsGrossUnrealizedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxBasisOfInvestmentsGrossUnrealizedDepreciation", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tax Basis of Investments, Gross, Unrealized Depreciation", "terseLabel": "Tax Basis of Investments, Gross, Unrealized Depreciation", "documentation": "Amount of cumulative decrease in investment from unrealized loss when cost for federal income tax purpose exceeds value." } } }, "auth_ref": [ "r275" ] }, "us-gaap_TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet", "crdr": "debit", "calculation": { "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail": { "parentTag": "cik0001832148_InvestmentCompanyTaxAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "http://www.slrhbl.com/role/IncomeTaxInformationAndDistributionsToUnitholdersScheduleOfTotalAccumulatedEarningsLossDetail" ], "lang": { "en-us": { "role": { "label": "Tax Basis of Investments, Unrealized Appreciation (Depreciation), Net", "terseLabel": "Tax Basis of Investments, Unrealized Appreciation (Depreciation), Net", "verboseLabel": "Net unrealized depreciation", "documentation": "Amount of cumulative increase (decrease) in investment from unrealized gain (loss) when value exceeds (is less than) cost for federal income tax purpose." } } }, "auth_ref": [ "r276" ] }, "cik0001832148_TaxConsiderationsRegardingDividendsForPrivateBdcsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TaxConsiderationsRegardingDividendsForPrivateBdcsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Tax Considerations Regarding Dividends for Private BDCs [Member]" } } }, "auth_ref": [] }, "cik0001832148_TechnologicalInnovationRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TechnologicalInnovationRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Technological Innovation Risks [Member]", "documentation": "Technological Innovation Risks." } } }, "auth_ref": [] }, "cik0001832148_ThirdpartyInvolvementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ThirdpartyInvolvementMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "ThirdParty Involvement [Member]" } } }, "auth_ref": [] }, "cef_TotalAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "TotalAnnualExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "auth_ref": [ "r583" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r632" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r639" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r660" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r662" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r663" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r664" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r662" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r662" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r665" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r663" ] }, "cik0001832148_TypeOfAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TypeOfAgreementAxis", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of agreement [Axis]" } } }, "auth_ref": [] }, "cik0001832148_TypeOfAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TypeOfAgreementDomain", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of agreement [Domain]" } } }, "auth_ref": [] }, "cik0001832148_TypeOfAgreementFirstMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TypeOfAgreementFirstMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of agreement, First [Member]" } } }, "auth_ref": [] }, "cik0001832148_TypeOfAgreementFourthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TypeOfAgreementFourthMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of agreement, Fourth [Member]" } } }, "auth_ref": [] }, "cik0001832148_TypeOfAgreementSecondMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TypeOfAgreementSecondMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of agreement, Second [Member]" } } }, "auth_ref": [] }, "cik0001832148_TypeOfAgreementThirdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "TypeOfAgreementThirdMember", "presentation": [ "http://www.slrhbl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of agreement, Third [Member]" } } }, "auth_ref": [] }, "cik0001832148_U.s.DoddfrankWallStreetReformAndConsumerProtectionActMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "U.s.DoddfrankWallStreetReformAndConsumerProtectionActMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "U.S. DoddFrank Wall Street Reform and Consumer Protection Act [Member]" } } }, "auth_ref": [] }, "cik0001832148_U.s.DollarDenominationOfUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "U.s.DollarDenominationOfUnitsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "U.S. Dollar Denomination of Units [Member]" } } }, "auth_ref": [] }, "cik0001832148_U.s.GovernmentAndAgencySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "U.s.GovernmentAndAgencySecuritiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "U.S. Government and Agency Securities [Member]" } } }, "auth_ref": [] }, "cik0001832148_UncertaintyOfTheU.s.PoliticalClimateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UncertaintyOfTheU.s.PoliticalClimateMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Uncertainty of the U.S. Political Climate [Member]" } } }, "auth_ref": [] }, "cef_UnderwritersCompensationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "UnderwritersCompensationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "auth_ref": [ "r579" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r659" ] }, "cik0001832148_UnfundedCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UnfundedCommitments", "crdr": "credit", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Unfunded Commitments", "verboseLabel": "Unfunded commitments", "terseLabel": "Unfunded Commitments", "documentation": "Unfunded commitments." } } }, "auth_ref": [] }, "cik0001832148_UnitedDigestiveMsoParentLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UnitedDigestiveMsoParentLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "United Digestive MSO Parent, LLC [Member]", "documentation": "United digestive MSO parent, llc." } } }, "auth_ref": [] }, "cik0001832148_UnrealizedDepreciationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UnrealizedDepreciationMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Unrealized Depreciation [Member]" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.slrhbl.com/role/ConsolidatedStatementsOfChangesInUnitholdersCapital", "http://www.slrhbl.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Investments", "presentationGuidance": "Net change in unrealized gain on non-controlled/non-affiliated investments and cash equivalents", "verboseLabel": "Net change in unrealized gain", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r5" ] }, "cik0001832148_UnrealizedGainLossOnInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UnrealizedGainLossOnInvestmentsMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain Loss On Investments [Member]", "documentation": "Unrealized gain loss on investments." } } }, "auth_ref": [] }, "cik0001832148_UnsecuredLoansOrDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UnsecuredLoansOrDebtMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Unsecured Loans or Debt [Member]" } } }, "auth_ref": [] }, "cik0001832148_UnspecifiedUseOfProceedsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UnspecifiedUseOfProceedsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Unspecified Use of Proceeds [Member]" } } }, "auth_ref": [] }, "cik0001832148_UrologyManagementHoldingsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UrologyManagementHoldingsInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Urology Management Holdings, Inc. [Member]" } } }, "auth_ref": [] }, "cik0001832148_UvpManagementLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "UvpManagementLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "UVP Management, LLC [Member]", "documentation": "UVP management, llc." } } }, "auth_ref": [] }, "cik0001832148_ValuationOfIlliquidAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ValuationOfIlliquidAssetsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Valuation of Illiquid Assets [Member]" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r9" ] }, "cik0001832148_VapothermInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "VapothermInc.Member", "presentation": [ "http://www.slrhbl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical" ], "lang": { "en-us": { "role": { "label": "Vapotherm, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.slrhbl.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "cik0001832148_VertosMedicalInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "VertosMedicalInc.Member", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "Vertos Medical, Inc. [Member]", "documentation": "Vertos medical, inc." } } }, "auth_ref": [] }, "cef_WaiversAndReimbursementsOfFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WaiversAndReimbursementsOfFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "auth_ref": [ "r584" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.slrhbl.com/role/FairValueSummaryOfChangesInFairValueOfLevel3AssetsDetail", "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r506", "r507", "r510", "r511", "r512", "r513" ] }, "cik0001832148_WarrantsAndRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "WarrantsAndRightsMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights [Member]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "auth_ref": [ "r564" ] }, "cef_WarrantsOrRightsCalledPeriodDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledPeriodDate", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "auth_ref": [ "r564" ] }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "auth_ref": [ "r564" ] }, "cef_WarrantsOrRightsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsExercisePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "auth_ref": [ "r564" ] }, "cik0001832148_WcibxcPurchaserLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "WcibxcPurchaserLlcMember", "presentation": [ "http://www.slrhbl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "lang": { "en-us": { "role": { "label": "WCIBXC Purchaser, LLC [Member]", "documentation": "WCI-BXC purchaser, llc." } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.slrhbl.com/role/FairValueSummaryOfCompanysLevel3Detail" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r488", "r489", "r707", "r709", "r712" ] }, "us-gaap_WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted", "presentation": [ "http://www.slrhbl.com/role/FinancialHighlightsSummaryOfFinancialHighlightsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted", "terseLabel": "Weighted average number of units outstanding", "documentation": "The average number of limited partnership and general partnership units issued and outstanding that are used in calculating basic and diluted earnings per limited partnership and general partnership unit." } } }, "auth_ref": [] }, "cik0001832148_WithdrawalOfCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "WithdrawalOfCapitalCommitments", "crdr": "debit", "presentation": [ "http://www.slrhbl.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Withdrawal Of Capital Commitments", "terseLabel": "Withdrawal of capital commitments", "documentation": "Withdrawal of capital commitments." } } }, "auth_ref": [] }, "cik0001832148_ZerocouponBondsDeferredInterestRateBondsAndPaymentinkindSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.slrhbl.com/20231231", "localname": "ZerocouponBondsDeferredInterestRateBondsAndPaymentinkindSecuritiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "ZeroCoupon Bonds, Deferred Interest Rate Bonds and PaymentInKind Securities [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "59", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-59" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479910/205-30-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "SubTopic": "30", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "220", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-5" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//272/tableOfContent" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-4" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(2)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(2)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-12" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-12" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-12" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-7" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-8" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-18" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-23" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-24" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-25" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(10)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-5" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-5" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-5" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-36" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a", "Subparagraph": "1" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a", "Subparagraph": "2" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a", "Subparagraph": "3" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a", "Subparagraph": "4" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a", "Subparagraph": "5" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a", "Subparagraph": "6" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "a", "Subparagraph": "Instruction 2" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "b", "Subparagraph": "1" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "b", "Subparagraph": "2" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "c" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "1", "Paragraph": "d" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "2" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "2", "Paragraph": "a" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "2", "Paragraph": "b" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "2", "Paragraph": "c" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "2", "Paragraph": "e" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "3" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "5" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "5", "Paragraph": "1" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "5", "Paragraph": "2" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "5", "Paragraph": "3" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 10", "Subsection": "5", "Paragraph": "4" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 1" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 10", "Subparagraph": "a" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 10", "Subparagraph": "a, g, h" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 10", "Subparagraph": "f" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 10", "Subparagraph": "g" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 10", "Subparagraph": "i" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 11" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 4" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 5" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 6" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 7", "Subparagraph": "a" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 7", "Subparagraph": "b" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 8" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 3", "Subsection": "1", "Paragraph": "Instruction 9" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "1", "Paragraph": "Instruction 2" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "1", "Paragraph": "Instruction 3" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "1", "Paragraph": "Instruction 8" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3", "Paragraph": "2" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3", "Paragraph": "3", "Subparagraph": "Instruction 2" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3", "Paragraph": "4", "Subparagraph": "Instruction 3" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3", "Paragraph": "5" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3", "Paragraph": "Instruction 1" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3", "Paragraph": "Instruction 4" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 4", "Subsection": "3", "Paragraph": "Instruction 5" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "2", "Paragraph": "b, d" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "3", "Paragraph": "a" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "3", "Paragraph": "b" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "3", "Paragraph": "b", "Subparagraph": "1" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "3", "Paragraph": "b", "Subparagraph": "2" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "3", "Paragraph": "b", "Subparagraph": "3" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "b" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "b", "Subparagraph": "4" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "b", "Subparagraph": "Instruction 2" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "b", "Subparagraph": "Instruction 3" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "b", "Subparagraph": "Instruction 4" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "b", "Subparagraph": "Instructions 4, 5" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "c" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2", "Section": "Item 8", "Subsection": "5", "Paragraph": "e" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r679": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-13" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480369/946-230-45-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 66 0001193125-24-047942-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-047942-xbrl.zip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

8/COF3%URU42.S\#>K M\%LX1P@E':"C6>%G--$-T.J%=8#5B")H.V;6SAI6"4;V@F96#.;+HEUI:!UQ ME_.PFM.?I+5GEAD<&]&PSR)[R/2'36G$=)R'3&XJZ(*5W;M,>3P;$'Q4W=+H M36+4WM/D5&U2=B(%*O_JK=>-< 'HEAP%\ XOD,F3U_T5,LF6R*2_1B;_X^_; M9O-3ME3XPTPASE^WN&U[3A2\ILGGF$G^_/$=+_:?W[_K)KG->6/L UQU][7Y M?[?AGEWLWG9O/U>S ] $;\8OM9=WV6G]$.5MI>M,HA.&77W7P?)9"@8VIT+9 M_W?\4I68]/?3M+9#Z.7/*F9RXG"Q>&H: J M,1&[)P%XE)P* =7E41QI2SQ:#.)99@OO<-FE#9ZYY2WKG@@IIX3!G/8Z#3/ M(@RI=W^P\' XT?0_FKCCDMXE)!W)(YU\88I4("2+&+BT,X5&,.I^14LB/&WV MC;$=EMU300\VCQAC.'9(_BP<=JL]B +_/AU7AA6P3LV2ZU,=;I ;7645_BL0 M3&T@STBH]TUQ5E(Q.F3@.A===V1ACF6!5D7+PYJVE)/A@2"ICD)]%FUE]XZFF@L8G 0-@@J0;@$D)Z"5/WCQ_/'D[VV3A M:BN:EJ_2><@+1:JC(S_!AK$=X/SA+YLB'+@H.V"_&+$._'K2.1R'4DSMI]PS ML\AVJV (@G'1#_Z>V5K'\=W2 M'ABD+&\,(TX Z"29S\C11G>W_&P'UJ M_XL%@*EBJ**;@'B\KN]BO'@\[F+<[<28&Y )C\B$AX2L#1F4B8T*Z,W4]Z", M$P((JH41%]ADO6WI$DV9@[4F@ MI<*_B!W9\2:U#CNJ"0T/XA%T)FM;0%LY5 MTYZ>&FT+EM9LUFXYQ" *>TN&)0 #@&6GR.9/']\KLIER@%7G"DJRBT7>V5%D MHRV$HF=&HAJQ4ER2S=\$ %/$D].2ZMFQ&(;O[KLE$E9D9T2+EWC_^AXZM4C&*/)^X,QU3:265BC1,X7*.7QJ!B/B'=LHAS1]LWL'%RD5[+ &06-J8[3UV= ]2X'Z($MK1,=^I1[M$O%83?ZFB+Y' 3<0*$[#D;6(*"R:'7VJ&'8;05:M2^ MXJ?WGBV\'P)-8<='T4_>GJ5E%IJ_](9KSR(5BO-!J_3ZQNAU;-!I$N.IX.H, MNS ?M8H @SLR -"<#$M"8[5[8$O"%YDN)^Q047P&:G:2N# $+"KHJ'8B8["3 M*23 L'GM)C!(8KQ<^MVK&JRP.J/72+49H_&4(5N36GD]:Y,/B<&W]\?;+5:KS%S@C3-H^!F_9U [7'L3A\USVZ0TN.? ;'QYBA,':\/TZIY MO4>KYDZB*%X?IOKR^MF=0U&\/HQ+Y?4>+I6[BZ*XZYB)P_A>7K^X6::.K\7W M=TG-QV>%0K_7,'5PHGXCGO]-^?-\=D")[(NGS^XG>4<8DTDZ*!,;E8D-"X(' M,C#(+@[4S$[FC>#6H\F9A$O$$;'8>D-523'%6R9P>BD)M6![(94_I7&JO6OF M!'Y&.AR5DE/)GYOPI.-U#4LH1E5\%%*->XJTS-EMU03>+CJW16H!0 ]^/.?- MR&>4U/U0I[7/E1H*EPB=T5.O6@>A@=0191<&\(/G]':@>H=U&L//Z( MJ.6#2G_-36ECMH,CL[Z((N90I!(8[G)XA#Y#&=3-7G[Q^+'(F712J"%6Y7S; MJO6=Y@M28/VFFE5K 'F3_".-;V_ M= W6HVO8(X42SO4*^1LM_PD&*LK0=3<)VR#JGA*?P&\C<>P3@8<;'ZVW-S=: M76G#@FWH>KFJNEEPKXH:WE!%U*:4;)B3HR,.#R$'10UP_ZB9&<@FW"Z1>,B3LA[N]:O,WM7C MHQ&IM+\R:E?T]*JQ&1A.&1R[K7NAM"Y;#.F%'X5W;$2*R?-_28L/())PU(5'!--J\N;U MH[@@\S6F)D;R*+:JZ(=/[8=[QC0=.SSR%A(&&2*[S=/Z=TOADT/2#PBNP_]I\)N6I2&B@JVE%,HN M2Z+Z$6P39WKW61XL/+K+79/PEG\O@D?>[O2)BX:*W77 9;SA3LW"0]F?DGF? M3O[67 CR.$R5H9<'VJ:AT] &C9@FX(X%8OJM>6O^MU.!#\@EE!N-2N)PI80X=D:W%K3, M^$,CG0L4)R>Y$GF2:%R8J< W:']P>? *XGI/3 [;QK1!:2%4PP,U-0\SO#Z+2^]_;<=QQM:):S) M\3='.>K>U?6NT__^?']R9,WFMT.:V]5S21?;8>J4>&0S%"F"?-Y MVW55 <1@H:K!OW\CNA19( K$O2Q:/:G^6LWG81_^4G#9"L>/O-:+?$]$;E+ M0\L4MU6]X"(%.H<=&4U_56Y02*^("_$5PFE^5:> MEG30\DT@)_IM.6(WOF,^UB?_4=7S)(=U6VV_U:?S3C?W- U,FX_*=^KMAPL^ MDFS97%N3-N: @,&S-_56QZ6^G%9NL MR'9$[."*7-6R(KRUH979)^1PDZ;8:TO_X^4!BQ(;YV'8=Y1!$ S8IB%?-^)IT511GG>.K20,$)X(;Z>@[K]8#04> MD9IV:G33N_.>L%/8D$\0EIEWP7I#&R];-@?&D<$(XYV6$@A'B!L49%FTGE\A M=1K^+9,'!L%47." S.)(M\V*?1!2^DI2N!2-% M!711B4+C57.;%587^7&9#>4:#L3WGK^0S4(2=&0B?R H>8X1S^L;X=FKZ!74 M$.["T$OC^]P5QNOPYEW$)F;UJ$%Y0J][)$[B$6B^F$GB8QTVQJ_%Y0%VX?-Q MO9>[;1=*EVE^"3X2>JTFSZ]:GL\TLH)1%J^6 =U\6_C"%I:;=5JGS,?1)!6! M?+DS*^:<9UP\0&[-V%H[@BW;R= 11$]M2"E4O7#97N M0R:6"Y_(Q-#BF=3<>E^2S<9%4#01CJY !"5,Z2,,W+*X3)6\8ZI=J!"HJ>2< MCAIUQ!!!&5KB@-TPN)M$8=K2)#4IN!?<[DC?/95AU_$6O;DP%N?%FF9I0^)X M^I?(\3)V=M'XAH.B!*Q^1%+'[4S1N+6)3X7-_<,>"2P90N%A(K?MF?'8 [>O MEVO%PUF08 VGO)7@D@8YSN74D8Z@&=G8)7,A1[=PDLITAS=%HI.X3@M?DYJ5 MLEX1F?L1,.WUE?9N&5S[XO%QP+6'B:R]WB.R=C?!M8<)F+U^=?? M8>1R+W> M0R)W=\&U?A&+=:$;.^D!W9(G,O8U25(L?R+>IK,VV+KS$YXB6$%VLTX&0RYW M$L%[&)O>ZSY/M/_1 M!)-R MP*1D960+0_SM[7].B@W[D9KG'GHR^SF.\2,75 M."+$PSE_1,>3\.Q9VO\Z75."J]"UD5Y1CR#(-:-5-=S,6 ]UW08GM,P$D@4O M"HO([>*@C.J1P)I,_%2K-55O4OR!TZ9MF\MR+HH[OFO,[N+L,+91\TE))T/K M"]GNY^Z@+G593EA6^EIMOU8[]@[Z%4.M_9;JV<(>UK?FQTFP78 LP330X&() M3R?=[+R0(1]R' D="I)U'D>9ID09 I@8 MPO!Y)0N$_QP]%!U$ZTTB-]##LTTC$LTUC'QOT:DGL(1&X26O0D=T&)%YGJ[> M@XV$I!J3)M".]'Q6O".5)%W.3?I6.6=Q1>3:!:TD&YQA #LY4,)95)="_T( M"K?1(PN-TQM+M.8\$$JE,W$$448$!#@&CBKKJDFXN#2-NUWKG;HJO@-I+D'A M-5D[&TZZ2HM^STV64PF M(F73(%.1@3*3/AQD:4EX\7E!/L7P WQ\FBFX -3* MJU1R([$ M:/(DGW(#6X)9)=O:4(X-%.S4EABSF/0,#8MP.]L@AYF^*'$18!!U%%>ER;UH MX ^PVEXF!J.H4#G?\$.5Y>,7R"%)AV+8.\L2#-!DBRW"'=3R:B1KC*GJQI(^ MOHL:!O:[.1\U%^Q$2DG"AHNP.\+)@V(\QC@!A-TJ?1U77$$&BR/HB%BJS(5R MEC0B%LSR,1+(AN9/N:K"80IN.7ANFZOYLFU-]K89WI+SBZ591^"=&Q7[ MK;HH=284+&G"U]V0COJQM]\4=\GR%7!X9>H22+ZIL]&CU9_U8G_8X3^_S^I? M$I/7\U!PZV3-H%80\\*@,W+)U U95"T-/6@K6#Q-SKAP#K;-A<#@_%PRT0WW M!SJ=X>NF>)8#1I#]CW3C=.J'M0%-Q,D7#N)PJ/GELP=/'^H6B#=O=GJ \Z/S MUPY[9:<[._.POY(]TPQ,##4J'&-YCR3NESC]TPF_H?P>7B$@+/9_XKAMM]=AAYBVL6=&:'JR35-.WE*/UP452M_QRZ1C'85Q4IC;PZY!>.-'@SSWM08X M=E_".T/QG.'C@"Y&F#0SUB5!?I_=/($TD.F<,&GC/?P=<_=1E3E5?D#K6(0I^$I^*04@>J\1^3A*VPZZC+2-F<0/$8\DPW II:O!**O* M"ZGQI^ _HR&2PZ1:*.E&:G/XXVU>>4R60G$+A8-3A'S4=$ M&""*BAOFYDG\R^4R L7BO"@!IG5&\KE<"F>BEBGB$D @TO##W%A$8)"\,O0^ MHGLWKIC-@B;YZAG,^'CZ805/7H!_,_R>" TK:,'&.(8EN/J+T#$K+^EJ\'7\ MV.N\6"Z5:_B/+(? IJ2/K,*R=S(^&E8RL'DZ(&9Q1VV6I CIGQ@F\^0X,)G# M=.+>[-&)NY,PF3>'*:Z]>7+G8#)O#F,)?+.')?#NPF3N.(+ES6%,AF_&>=TF M T?'T36@XO'KY* 49.M.[]M2@_KE>[E:DWGTF:RFQ0$V])OQLK@[+0-E/9YP MEX?*O30LS(8QY+@6D+6G*_;+KY_))T;8V'%7$WJ5*)_HS]&*"X]LUX\F#_Y6 M=//B[_\/_?C=0R--I_]25N_IY,N[WXRD[QWK0RB'_/MWDU]_?6>_^^W=1_I, M?XKVTGNS7]///G[,?@EKP6CY4#K0G)7H*"P^:A,>*"]AZRDV&,,1W\PBZ,!HD1#U63^7:"E9!N '])F_]#8.$G6%QRS H,) M(1(Q1^& K\MV()@^(M">5G.-O@X._T#-HU]NO)[=(R[*<*HO2V5#G"._L0YC MVK38Z5QI$->_'I)6'&%_2\@6_;*>)F2>60Y'9E7.DF-HMJC) 8M##8ZO3;@ M9:"N;P6\?/S\GD;2KFMYN=(H8:3URK=22<5KMYD1%XPG2*4ZQS0-+=E> C , M"3$GU5)9["N>K7Q&#.P36JV44)(R'Q$]I%"!LHBU0X5W)/>;_3T\))8IZ7WW MY9<84UPUI4?HL)"-?6/O8/R[_"AZ6/O_#>R4W_&5+E:/A@'-MBR>!#A4"*AP6O_'+ M64=;[EB7<@Q'"Z&V.%,LRTHP7E);C-&A@PJ2TK;R@O]TWL2'A&6P.'%_;MJS MHJ[^H6(,M.:Z[9J4H@48'<%AG&,8P*R95/30.K.EKVPZ->* (@21E;$Q*%!B MG0A<;03HP7'4TQT7N9G.+U_V-]'WC!RG4(:?M*B.TK($=VJVIQMFJ"O]XF!5 M8UH>6Q3PT7Y1\H!AP4N1PN"A8DT,83@RS EQ0BUO)VY*ZXW>)>NMLC(\3W4D M4_T3H[;B2' ,0W],7L28TP(/H1<&=LHA,>4-%5Z*%7A\2,P9G?[KMOFK"U6 M&:$;,&T$F&"RT6\ECJ#"YH-G3Y:>NB;;L,,Y<:_>C76*EG/:I?+[VO2T9^%X M /#':BS^:"HI"^^ SEIF?&L$:<.Z=KD\/"!F#Z/L.B$>@*D4BNW,E!Z>@!G( M]!)!):,WV/2773^9<<5$T8P_EU,A[P]"T/8E$PK7=Y#-?#2US7B>THT$/="J MGF^#C;W+_"(8L1W%'^(%^VCR<^\6$#J'L ?FZ%7P6LZ$DC4L#B4G6S>7*,H5 M)+-P,X2=5(U8!\"\\4-^,EQ-5IL+@+F*7+(\]A_!4)YQS$!NC_E/@G[B MC)X#"P@BQ_\=6UAN'[B\Q[P"+8O MYR6R=83*9KUP7+U='.BXAI/LC /C)X7WE,%O:>5I$?9U"YO3=>M!XIQ.K6:I M$+H0'G(&JQ9/:.1K&F30 )&N?KHZIY-]%?!^%-;A,)V)(PG4-7P[ 1_8FW>2 MDBJ%9" .FJ/N$_):CH^Y0>% 3]BB)4$O@>9$74%JWCA;V!-T BTZ\LC1@S,! M7OLS6V^(H0B).Q>SL)('; UX]\>16\TO;V?B0A!7O 2Q-?-%0;=E6Y[+L:@& M8K),!!9,S^ZY!#%8!/W'Q+[()+)<&^TA97 Z"Y1\_M":F_$% N#$VZ+>F:U"'X!$W(9 MJQ8ZATD8E"?+",W*^@R58(*@3[Y:01M"=PVUN@!*O;A4;F$WP^0M&L=M6.+1 MM,>7]2J0;G&3(] :.72&&O4LE(QGQ*7SG?2VLX:.$F*QP$HY_]H8PTP,.?Q& MY]HA898G3^]KF"7&5G@M._(9%X+A ?&I&-"5N&5"G'#LNU$U8K :A&G:6\BZ M@S9"*0X]G&DX5\-=?3XKP+:V6E5GW"_0=97AYU@>[E5NC>$"VL$[$?XVXB;! M&=<"&7E= ]TQR?AS+7\UOT_15>KN@-09Y4J7I $I#EP,6-"M*-\*V_TS>[A" M\PLC8:9*)Y/9$H@_VE6<-R\)M.E;SGCT3=L0;>PN0@=S9\Y@6&XWWM1%T8:+(1@TX=OJI*]0 M7RE!"Z#@L.;!YU9D2K2KLJ#J@L5VV:O-]E,9[$N05K Y+64AK4:J%\ML&^@5 MI%_!]IF$ WZ[TGL\^!YRG$936+9(O_8#>_!=\/I:J67T2"IO]9$]1_$9,6ZS M7&4#T]"H3JS6$BD6_VB$3>30C580*, M;U[76S)$ ?-.3P12)E;^OY7\P$^DB# MA/K)0TI[7CZ[I_J=-A@3'0U<"W$\)GY U$#^0!!FA6O3_Y]:'6TT)K5:>BAO MDJH>)-2 \0'N,LL3;AJ6N-[;4)DI[5NQ LB,JO3;*A) __+[5&IL$>YW04>J M-JOFK)[1MC!09HQOZK9(_\<:SUX0BZ! ,P4[R6?Q(\9_#/&FH MR7@N6B112BE5K\14[C8N\)UFUCI.7*KW_,0!A\$T1YPD.8#H8$2#!B!)6+2M&+^1O]WGKBL)H#^<.NY$ M22.0"]]H,:H?-E\]JRODZMS/I$I5DA@#9%3.1Z@K[-XW\_F""N/_*[3]RZ8M MJ;(HW.BKMZP;0&_YK0T> 9^0L\TA)]-]I8G%QJ>1.?D S@ :FPD/SH1'!Y.L MXS.) T3%(HYY?:OB]E+YF4*'4ZM)%(H)"$V M.$D>OJXL.?3!#X]N@H9P3PE_BC (J0@I.$H!2"9'X&D'__MV*1')IQ!">O*8 M=[HDDE9"QC!Q2! :T;!+5N5ETWZ;0!#)AO7F760]1C66RK>CHCLYM38=BL-F MOP0 +JP" SB*4$-4<#[=#4&\]'?I%WD-V1&?@S8$V\53EBUGNISY>)PZ=MIR M+IYU'1_'M\Z\66/Q4"@ VSB) %WQ:W^\,]ZFZ,KEY./'CTD(50O=03,0%O5? MJG"Q<)X?B4?.C>.>NRS+-0K6"UQ))JEK86OI_H(SS93GDRN?6V?-09H3N ^W M6^/E3!MG5VXD\"&#T+3Q]Z6PG<=TO=Y+VB3=E!(:?BO0[.Q*8LF ;V&!UCPA M-'[Y\BKAPC?M)4BD]*!!>0FY)++4=<]S18<&*:51@ZC6B M*T*A>BUXMG H=,9)^6",%?CB@#&F^6;#OG_\\%$;:L!@&1E@+B$.M>A!+%%T M:*T4%0!ZV#2R\.5*I'1XEYP]2U*/$:ZI.R'E/*N%3:&P]910#%IQYO6F?3R' M!WCHGA1>+[^6S62,[R;'=50YY9,H(A+JN+RP 1)/P.Z&XG)ZF64#2!.[&+UV(S6)0Q637"V@]6GRF_:OV+L)^.,,[8^X)Y_!?="/BM&_ MR?8">_6?2LVXY]$!6,0L)?P[5@C_C7D2=0&_@)[QE<='$+]3DW_D#?Q?>B M^V[WZ4,QC.7D%.1!N)-.PLR<(/:BL :WD/KE04GV;! 3!+HE1@F042T:7Z%3 M=$ ""=0U39U=R.I+^1K^ +CGLBR876V156TEJ#='M#" %)'$ MIMTF,V#+-H);5]XLG$IM4X?C,HSWAORPT+0;G[VPXT\*5=(C]H;-";)0;@K6 M!?'=J=P1M?'&6^&')X.VV"3P?YY6)W33MN942:I05M;"$>K?<%E;M3%/CB=5 MG#Q?R8#UH15OW66QSO6#;AO]F5D/0,ZK348G.A4DG34:[HP.I40;K8PNV0=J M8X?^0#*G;"/KJO$W F:U.SD%4^2^KZZ*/P@M0=](7N'G> MY'@N#XK@[L.XAO%G*=^I,#E]8[]R&A?ZU%EZTTA"1FCS[6QS-3R2S=!??F>_ M%<++^'H2@$6;$Y^T8Y*7[%%.U*[+*9';TN 1AH-Z$%_*%IRXNFWT;.$/E$3DPAT"54L?^MN2R!TR9$1TXM$FS"3:IR M]VX8(;Q!O4GX5 JLJD[+0+02.7R8CT(L'4V&(?OF5>-P%(#ES]B#B)32E23X M >/F*BS&.1=P#]!*15UO84@B2W+SX$@YBS^$%O&_GCP^^0\Q/4)CY R..#Z< M;,D6TD+;9?6-4+)A_!_8VD09D?[7PPAT&77&\J8<2! O5GB;4*I 23MGW\>0@]M3NL=I M-]M(I-SKKO]3UMO& >4X@]6_)Y)2,9M&$9\8*(T-G^Z&KB3H!YXK:5*/%5ZC MIXIOUKG8 UFF=^Z?F50?UVUP(%HAH;!_*"W:5Y>B<>"8[8<,4*E"<^^1,+'. M7^5)F96^,U:=Q+_I /B3+'X/=V6:IL/8<=DUJZUVYV4I!*EM>;I+&^'P4;'Z MA2O$&\%'.@#AGP3G^;C>-=%&X;O_ M_Y,?@S0=)F#W9H^ W=T$_AVFV_;FS=T#_AW&;A?:<1^1?_<."TCC?-B\'+Y! M=5O?(CPOW!Y_"V87H&5/'S]]S,XIRL(D@PR3!:ZXTY=-DW(@TF2A\@+TXVM[^<7.6QMQ,X$\[5W$J7K$S0+4E(A!\3:4&L)'_$5$CX8?X2 M]9>2[.;=#U:CY/&DV)Q0@4425#8%0OA5$<;((YE<_B2#XK+1BA[C\MJN;V!Q MBM!]X 3/3L$^8I:9HGEZ=BVGD]G+8>IC!E.$=<(,K95FH"5VII ?W_(M9;0M MSM;3'-(5BM49#&\\7IN&KYR/D'B3XG, M'/>_.#NC;;!A;UH4FW+UJ5RIAK%;?ZX9;/A34R15\*!ZJ$QE*>MPKFGDIR6T M-%&[>/(ZE[I@W1]D)L1MNK+E#RIKRGG3"%P-JE_LW<0O%]ZG2/O'$N4#T_K[ M\!^F J;1^XQ6"(A\R)#)8VRW\ M@Z8]'!_JG1FA_CX:?:<9MW<4@0#APO(9UD/'_.'$N=B1KVNX%.I[\-9IM-$" M4[H"Z"136N!%,_!F <^,13NS8&R^XC683 "-J-5FC.0]W_(Z,B #EQBY4&XE MI@=R1/9 O2@T/ 4?]*S$F]/^L+*V3XMP6/_>_:95>^^XI/$ 2.ZK\6*!NPTN M<*.0@%IM+"8R&+Z2=J3BCK;R?]?1'K6.]NX;:I;_/;"8UM@Z>G6T-Y\ZC_%- M207_=S'M?Q?3]HMIC;O4)Q_D#E\3'G+F,;VP-GL6PN83MNJF72#P)M=JQX(D>=9P]9Z12<-Y?9 M3$MD,U'WTDR)?3"NG+@N-Q7(J0S]OVPD^S"@A4E#32T-8SO5K$B4\#L-1^8B M_ ?R8N&W*[ AEGTI;$-IKHZ2:Q5/[K;N\)^+.3DH47;SL]?=H*M86;Q_6Q8S MV<;O&/L 34KR(SX'.W#RXO%+FBJ'>WMO$D"LBTA&7)>+Y@B.0BBKD"65:(/G M32Z9)CW\%W[D$SO.R?D2>7Z@Y9KK(D&SK,O?-)6&&Z=]J)ZU/ J6PM M;+2((E?Z).ZDG>VXS\6,;MQ#PBPX115R%/RPYB>B87P[(J@FOZ+;[:S!&$IY##^!*BF;39FU MG?.=]4ZV.@X^B#S2UYZ2+E3+;-7)KV)2?[LA!A_*3\"1QX%5JY>##*KW? UJ+[0@T(#!6VU0G$+R5]6:8@#!)5_! LB M?@J*.1$&%4(\=)EQB4U=EP[V@L2:1BIH?0C776'(+!:$6W;DQB^QB^V'8.I] M:EOA!/0!/ MR=3I\#%C;":_?1+%5Z7)\V2YL'^DD.M4L3%6;]06V_EVR0%;G'5A+&8R%A03 M)GA9%2Q$,&G)L+2._KDOZQ#:<=HVW_ / =BYNE@7*+O[)KZ<8P+3>3"/XZ*8 MX3">!$X]H2(;U5/@45*B,QZJQ!T@6*\R0B8%W^0ZG&!*^'KHW'9P=\I0M",I MV'24!"P$8 $T87PI5QO,#Y2;/H,Q:;/"%P@ M]KGY3#42EZ$Z>7M6@ER?R1OQYHHQ'GT+K%K MF/'N^ZQTAE%O1*OD!J0RPH[-< YYSJMYM(N+.LH'AXN]G54\["[ .N-ZY*3 M4&H68UDBOXO&/%RV4D653L\YL<@.#9.;B,*,1K/>B?Y;\#RM$D"K"SU'5HFSP6=7.MBNZY&=TU%/IZ!;336?!C@.0RL7- M9E ZV!W3BA^-Y5<+-V./"A8A+T0#M9J)]8$1U+PJ M?%-PP &';+KM^W9(EN MLI&S@W[4W.;XB7Q#AA43/P7AE9/)\"T8"AQ;@ZP/B?>G M59AQPM3[(!^#"R[B-J;P0Q1TGS7&UR%(UG8^44@>_$Z $7/T,;JOZ3=$IYNE M!.$6RVT)GMUC4*$RAT>S&!S![#SR%:BH\LMG-7/%IQFMYLB.3B(>43+2I[M[ M6NZR?G*^CD^2,OK'>VCG,\8WV(<:Q0AZA"2?P4M?BP'CZ[MPK5(,@LJWQ>7$K_[R]NUOYG@^8)XNEPF*D/@I$\-9WB5V]K/AS6/; MHR9"Q-2[UC1MPFFCO^_T]P_%V1"6,46PB.RN)3O6%A8ZT;H5 MU6T-/^<)+P<42^G\E#,(P#;]YI2!+:$+,PI[R-NH)$?)$$G$0>6D5F&/GALT M 3@^QSUE(8 DFRJC*."VC2W+LHO!I;*KVK*S\'C?)Z>@3OF=G+<2A6;.HYN7 M84E\NF^M9N@YCP-UMQ5KKJ6$ M8=Y]#GNYJ^B+OD*VAPMUHB%^9H?RJHJ!4Q=I$ M/#JN&%[I##@S'1S/I9XU._^U7NVWXL(9SX2"0[NE-.R&ZG_E"ASD2.$^R"ZE MVRB[8Q)$&F\0N[ZTY("[@#1"._R6YA(7F&&3CJ,E*[:5-.(#\I _:ON\NJ>V M3S2X=2YX' 9-H;<=([[3(S$-ZS'Z=[!JU&#NSYXSU4A>Y"!?^%*TIT5==B>? MOB_+'7W5UG(.%%X3S(2B>\A-T\G&M'Z6LVZV[4QUA.S%\IBN?]$L2 V=J0>F M5"71AL&4.U#Q:MRY/G [@20-! Q%[:G7MSVM(3(-G+5,0T# B<@NHG'B3@DY M9^7<"ST'.-TA[T\&W7*8X$ER92?)P$D,;(R1V\1C[$K'&: M ?_1-DZ3*]TFCU&&L7BF,?Y(KG'GZS?5@"6[T9%NNE=/U:IY8)YVK=' 6R;SBTG:/[OB97!1*H?@Y=E$'X/,A^@]GG"IK85 O; M=MUQ5G$(OV*BA#(L;,:);*%^%I5.#7D1?SE9E,S,N.]P8IEH*FQ8D E^!NY0 M_,[W)>47L#ZMBYVO^,]H"-XUK("VX<@($(EU)W5,*RRZ^ MC-YV#!U-U8B-_8@2[<,/Y8H;BBK/.S.HP]8,>X7\0X<\,0BC $$BZ\?@$!B@ M*#U]Q +VHRBX)'$]F/,[Y_OF[+E[2<^Y03J.%ACEUC943#2,A$DJW9X_?G[% M%9\ZC3R>>X83>V:[9C:1L ]V94$@L689#B=-2TJ [^-OGR8/+&WL9VW>E%** M5EM8P..[PNOIQ^+1_%Z'_WWH$2">VR+5Q\1WX]2H1.:M2&9'EF%E+OH^*\NP MRO[O5X\?3\*&7,)=[%2GX=^W=3EY]EAA)&QZ0(RC[W?/F+I(]\W89$0BIS@# M[\/.!@;SV9/CH(3LY*3JLM/(?R:3(>3I6AX=-[?:AE,&>0KB*GKCB\8C'4 < M%X&A2_%@7O10H?S66"K(@ZA (2$[^S([+PGS-WGR["\QVCV$BR1*MQ2-BH8N M3';>0LM5@KN NTY\-G"R8T$L:LK]S2=D0,"14HL=?#4)>S$N-2+I(\"-(RT] M3,840T$.)/F=-'RQ4+4M)6#'B,2Y*1V#F*TLY?,U^6)\4'8X.%/*''?U0;23 M5W4=)H76]);*%:NS,]%%H' 7#[ _LAY-?B$\=6PIQW>@ ('XS )E[SRLE8F- MR(-\52?;D^6ZL&"H3&=&%I,/"CSLV/8GA#,&8&U9L&W-"ZH?#TQ+BE\^.'V8 MNUMJ'P9CJ%BSI*W:N5K-D+%=,:FS0]W&XF.R(033Z[;3C9]LZ"WWB1:M$F@6 M@IVLOI\@&,G_R:B.C#WS%@,([YO9UCB./BTDI;5\)][,GZ>5?OWDF8\Q/+FO M^95DH&C)Z%!-=*Q\YM.%%61'R8Y6_Y.C7QR[,K\X=R;W^+LQ[HH@>O[#,J;Q M%$$>,ZH_;M]$=&[VDXR /O:>;)+1X'(,I"=-X@NMUZJM%6&!8[&2\GM8L1C* MT4M]T/S%51*^+!7< X'/*Z(/_T1\5"^.R$>% ^&:^(WPW1_DHR+4QV$HD3U" MAW<44768BN"3QZ_N(*+J,-JP)X_W\(;=7435_HT3F;O_U__,SP&Z?$YD/D1, MX+28?3M#(?0)3QN,%+NP)H.%*W<3R'48I]J3QV\.?H\>(+>(LXK!C'F#ZTYB M[.&6 U.)N^5BP!6FV6IMJE:]RT[#Z!)% *YX"R?MM$PN5'K'H\D70?6PRY@E M-M+[5SF\$!HTCV M:,B6@&,+?!>"-X;4NDZK1QM]PV;&D4*25QDOX]TE+TPJ\B^,$PV)\%75 6P@ MY+P2AK#Q/ >@S,LSY58I(P*,W>U\NZ+!:]M&%@3[UB*DB9A!:&1;S:5(-F94 M4/]5;.?!M26:VG&#N4.YC^F5UM#WL:J8B._(TUYH+3S=:#,O"G+7DT*QA=<6 MM:'I053"+Y==8NTCTC@/2[>8[4;W45Z+L(CX@:@D9^N?Z$Q8E(UR6/-TM#*. M^H@WZ2;&*R+9\HT*BSHETN']FN0&^YP)5C!P7K0KD<6K-O(Q]25ACQI8BE+G MZ'GX1N'VP_MI\N1U?T--LATUZ6^IR?_X^[;9_)3M+/YP2(U'# 78"3U'\1," M7Y\!6/@<\T.#NE&3W(*^*;?^WT(#_[^J7,[?EZ>;M_7\]YK0://(%G +.#Y M^ 7Z\BY[[#0&$PS"A$8!"U+&P=$FJ->.;^_P;5?H2J'6S6XM GM_;.LJ(H)] MJ S'E60FP'5>XILL^P9Q2F&UU@_8\PZ@A-L3BNFV'NDG+Z:(BG0.2%9T@EEWUE$)*.<*GK:C768:UXPA? M#*F>G*&;/I+ZEL[C/P3JAD3LSRLJWI55'&^#>;!@B$^+ MKOQ%$4YQD0+,)G72G]2O:637A5R4H6^GSA M^RRTNGDQL+%PB_/713V;UT&7WM=SRC0+ M"4K)IG89I:M$\5SS<[2T-<6:#[?@^SI+U+F;/ 57\+V=YQ\X8[JM-?G:$2HN M7U.<1^*2B#D74[I21&9R@N.3K4T+').LZK[R-\M:* M_ .#'.W9N5]GQ D6MI(@+K(C(>LZ:W.&ML[%^Y0"C&@6BDQR/"S/"]4@L8(- MXLS ."]*2D!))^D0:+NAONK$T9J(TZ88 ?#RDE&YY&52"?>=ZU9N[_;&D- GFD+WS/2@)>F7^6!*,^4WFC*T1BK;N\;]IN?U M(AO>6\5YXYA,@/5?BUHJMG^(>^F1&1=NI\@%C.;*)L9QAF.P1?-ZOREDL(%V M#:B!^^V78_N?&/*.HWO0J&3&$O'V#S$+YG<<7]0WIDX+IB$+M#0$DOV,O$LUL MLKF_5'1+L7 5&/=;JWX)!_DT_]::9;J%3%H.O MYCA5_ -I+^DO>4-PLW H5$Z2-,K5"T@][1T-0ZE/QBP\_6ER6Q[-7X0F[!WO MVL_&Y6[97W%6S.73]1U[[O25[7R(LX*R%5(X^% M'ZZX4F_'CUR>I^4 )0-.'J9R25P\9794@A[/N;4Y+QWG16;W"*^>VC3AH6A7 MXEK!S!.\:AD5Y,1XRI'P7#TEA??1L/WC9I8 M9N;RK^."<.\CG%1O_O56R 9CU0#RM%TCF$OB\D!HA=D*Y@>!#6NA7X7]$39+ M3>Q\B:7>;X#?3GTA0CK>55 "]<.''0QKC@CMKR;('\*)AY\*C M)M(Y,N5G.\:]EW/!&_"4KID%GR.A#015L<&@1@UMX)%G<4FRL*&:1!; MJ\K+AD,7:XF#(QY**^'!P2Z3!\UV!\>DBBX+>45,.%P??DS'N@.-^V/O=_)$ M=ZP60XV(9FR"_C5TMXC[#1Y32.(TJQ55+&W"%O(THK%:9,=2(#"D^&O\@&(= M-G,Q.^?;(9QE>HA*P*?5]0XV(R0YE&9\;#M%Q4:*WN$;&1H^WV4X&*PZD3)[[W;V[$6J[ MW>L=]]AA>V;B/E\V0!*4,"8!#D!*YOSZ6WGRI;( D)(\,BU[&3'18TDD4"AD M5>7+R7-6#=#]&E.Z3"F/0?R$)FRAQHC1;'N2X\%ONJ@CT5[,E7),G#3BMXQG MZ).+WQ#DZLDN)0"?W!YI$3[[R9"K.RK,G6Y1F'N8D*O3.VJUG9X^/,C5Z1VI MQDZW4(U]39"KAXZ&.KTC0=KIH[OK ,K:_HQHJ UNCO%1+K)B$OMU\DX]R)\= MNO%3=Q=SV;JC@/P**0:U*V+.-6'E6,K9AX@&H*QA;^QWDS]*R(ABQGE<3<-R M.2XYMFFD.'/3SW1+=N^5=H0I#6)J=RCY91/>3OM/DEB(.<[IK);^9B@=]C\* M"MDJGM-(?+=K>!(S5!FO3;,NP[M8HJNO;]"^JUN%?Y:7-5/ETL2/E*,!A4$D MM5/GFN4Y &S#:U]>5Z[,2@KQV9AZBYLP"+8J%I*6OM4^+VDXZ&Z ]&^*-H#/ M_)<(QMWU*!E1C+L?+X[S8^\%#)ES@F+HHP7$CL O_0 MLA'8RI"C'3/+!U5$DH1 O*R?HLX5.13:?&?/ZH;JE31 MAJDC U*TP:@*[C4UW6L"&\N],>F@M3KW+G-\["*0UORTGUM:DL#7G]5U)GJ( MRK<"7H9UNM-04MKWV3)S-9STH?\NJ)'Y*X2W_,BCBF'I36M0FU@AUA1YY)B! M1:NS,TJ890X0JT&!(^WE8N=J6V+?4T=AGWQX-U-SXT^9-JVDU1G[*,D?Z9A4/T MUK0,:(Q_?M"Y0 .GX:1JI C#:..Z^- *'L6\HH4,^W_- H;(Y(77+W.V"YG! M-[K$[IA=BWFS'[[6PH(]^J:LF;,K0+FE=AL^,?1U*03KK8U*[*=I:XF0,0?_ MR CF6E^C-R;=:LJNR?4PPL\X"%/+9W'PL+!^/A2B0: MD%NC&*C2*BX @ ]\*G>AM%8JM0*/%&>,J6;@*5.3*%O([Y?9Q]A[/ E;7B$E M=*+%'RC%FP'1J::")2R<.G*52A06M=QP/'C3>B NAJ:,0\QMT3_/4V2Z)PI) M:&=1=-II^,2P!58X=("<,KT[>6',;AKS M4 :X0\(5<)TI@"T]VM^:LG1K4=.7%91=D[%WGY_FE9&A""VFM88I@@$D]ALZ M\I38@N4+?7W;#0:?S$84':"66-.F-)8#8$[J[%K1IOW=A"J\PZT.CS^6&J\1 MV'X; -6";3=J?_H'_OP5F1=5?4T]->?EY'D\A=\[3>@['!X_GGREAX?. EZ( MFX>!GXB^#F76O59FSPP<+3FC.C?() /3N[4>$0=[C'!I M!JM%Q;RKA6A]BWY%JW3N7"GE\L,2 ]S42L_!B6+V53\SC*:; 2=5M12O4M Q M[_!C\3/EIW5'831J8>KW:!5-XD+1LKX,)V&J,-U2N[S.$BW+ZVSA?Q;O'F*G M]-JY867%A CVN<%!;"BQ6(*VLZH\''H9=IPO'7'VAZ^D%77$52-+_I^>4OX9 M'NLH_'B$;C+]K4W1,?\<%D32C.D71UNA>\KB?&MS%9*^'3)T8$N+Y6HI7!N@ M[G(>VI _=ITAB,HF?R?=)?)I\H\+9IPC+2_A2O)VJ9B)R.0WYA"-:'R6@OA@ M2(* .@!\A$0/1]6Q\T1H>H$\IUZBA T8]%PT1I+FA1=WF4^(VPD'1NLR' E2 M'^$@!: 2MI*XW;+F,MES[-26?K))9U$JQ'56,<5=.#!7*1&678,]BZ$^CQ5$ ML4M$'$:+%>2 ^9-7LXR8$1O _O!2$RUVN!&7&O :3NTP 9T7! E=-8*U"5LZ MT1ALWQ\E%.TFWSJ?C*ZT[MV[@&@&F]FT]QL@E>-@2PC(WLPJU*8/G91TAUOB MYYCYX=7"\]KR,]CZF%C&I1=TW[=5^-,.O([?\0KO&)K^^'1WG51?(#/)<^)" MUNAO%"!SHO>O4J7(] R52+E9&]\LG)ATAK4VJ5;JSAV#G=Q,_R[7 MN8!+6(I_0M:_%KB[,F9CZ =>YO@P'-FF1$=9)YQ MQCTN'?).'[Z7WW;A$T]]\UQ@-P!>D)WB,K^HEFXQFA".6WF*=*YS=IJ;GKX; M%4+D6B9],;B@-JGD!G+>Z> +FU)^?-&J$]+H@7XKM&@J;9^':6%'X7?/M'Z. M+*VIRPIY S7$\#YE:.+$U;:,IN!U'0^)0N6<;A1'2 MKTW".YQP%S1).% 7EUQCEA5$T7M!9+9+&7'<89-X)$GR$4G$/&^_^,*DEV)K MI,B!6+K0-V6-\AE5]]@,JVO>J\-%.%&^R6A%9X8RAW95N2VT0?()*\,KMP6# M(OR4@#*\%'5=?4TXUTBZZ4)@TN=AGQCJ+02=W7@=]QXU=.6N2;K A;NCD10U M]=)R42N^0"1J'^)J>/GN^?G@35TMJ[%RNVO:3S ^5M-4KEA[*'16.>?FC)L!LSX9R0HI?(&$"Q,^\JHU_@6(KSTIMVRENY9<9H)85WTR1 Q.X$ M/2QK[K2A*%&.S/:5>#I1OBNLB24CCD1=IEHMJ?$8IQTJI)'6W7^MY]S7-#_Y M'LC/)W_D7O<&4%:XQ50:YLZ3JZR8.2_%PZ2 OB&_V"@1-@?F,JI2S;4-.*Z=.7M$XHN1BL.-5 MP:W#[<*=(H1X'YIQ:IX2]1[$3CPIRJ!B48"#CDENBO$DJ AMC);I$LA)<+G? M*\]D0@K6WI3^?_Y4#PUZ)W,V'"8HG:C)O-U F MM-9G!$)F^AQ%K9B$T::;XCF0AK(LK62IN,1LWVO1,,@AS-L*,C4VD+[Y5P)% M&B(CVD?HI!:F)NJ3$8C/$4!Z$X/1C+C*PIR+P?HN2JY*S7(62V&NGQ84/-GQ MNC;2\N:V2$,;WM]AM_V%J-&:-C=F8\.NSK_X!W%<*?=$JOO%*:UHR^$_ESM1 M,"53>BL\).^KMPK>>DLGTEUVG2=?Z:[C#_[/=(O/>W7.HKUU5#+V$@=OHY@7 M;Z*OJG(2-C&(IU KV^ U$JL3?-*ZBEZ]_.7U6^M+*D16EQHA:J8U(S8_S_UW M#6K!":WBE4A2B4AY-Y"XQIDO"-<4+,BJXN'Y3?!H5F7+#@_I@/D$KNB?X*PZ M'F#$N'2DB\4FGEY?!Z?7/:KM&I%.<4.]MI=):&-+BDX354C* M3LM[>_G+N;VU P1]M-VL#<+?EJ'2D@/-,&;PD'7:)L+A#>0B_,"PKX6=K 0M M6IWGI++ZD0O>(3:_RD7/??"7=\_E582Y))K=,#A2B6,;?70R'-"FT[,ODTA3 MN.V?PATGU=SF_(5A5I\)J;+ M8@2@G\I5-ZL%$48VD=LG7(U)!U>-S4H",;1''"IY8; GRK\;2+SE;N_ 0*2- M0";QW9+AK^]>OWBKL)_8U)'-P'L.=+"M.3S0L7T#P$,@(:V5E^GW1B&88>96 M"+@ZVQA7,PIR:JG'A-E$TN5]C0NM$QPE8+=TB*.YK(R8LVI$_)UPM9-O'\EY M[]"Q*2!:!P[Q@N;2O4YI,7F;TY7SP2^TYX4'H[-E4%W8MI8:B9 Q'83%:K M%@N,9HD90&=-L,\T3-/0D!E(ELH?0ENM2K@JA;.2R8=]E)>QB?/-N#@DS&3I M[.^&N5=U(5DH#^(0^!6.)ZAI2)M1>!TOJGI^_]"*TY.C/VG;*C=P]!-2\GDB MP"AYD1.94/C)H,H-[T"/F_BZ\80,*C^:5=4''(3!9^6EFICWL]]_'?Q65ZO% MYG/AE>Q(MM)@);IQT@7>T[7IMW9N!+-(_C!8S%;:KMA=$+)R&JYN+O["L$=_#K$2\4<]@);9!W$7 M*I4PB8E5+GB2]L)BQLR482TN$=H%EWY,(*[A_5M-&"TK#(KE<)MW&#S_UKU' M"7)X*7>Z"= .5:@N9@9@]E>.'L*3OK;W_))<3)J ZVS!-'0E)\0@=TV%K=34 M4M^.7W';'K6IOB@7*R9Q%S[D93R"O#GB[*=O*AMM>KF"N?%FV*:!:KK6N@8- M0M%+R$I+6#NB('= ZL:Z>(&>AO9+Y!/G!K;84>$U7-4'\KRHPNDE64(.V*5Q MH$QN9NS6--@KH%]0)M"*A"0-.>8FA!L^SG'R-&WKMAFGP?Z5;!F^26&C-J;SVI'G_'1]-R-6U7[RI+4-[1?(&+OR04%]FV1JP;_) MGIA@9BEO$W_8M(T/Y7CJWM-HE5E[6.]\PT,8MR95R\(<\B*("D &YQ.'AL5U ML((R,(OST.A=:MMGIIT\K?X>>>[=Q&')XURL,DK]Y/(XZ72)1+,6K:%[$,ZX MC 'R5/:;,=DZ=YF"!=0"M3FM%F[AT"*?4L0J@IX-D@)1BK/0K$->AS=LWL9> MJK@X[F#5-XRV<]@7*0ZMD>H&EI35.EI=0AGW!_ER:F0<]3H:C$^07!@/5[?G M9+%&.6D:TBN.\-LAX[8WT3\5W:?E-@9Y16U'C)85;VLL21;>B21[^3T9GQX? MU?VB33P2(?'0:X_,7Q.G!OL\]IID?&$7O$1:,/J:C7$'H_"RY::1W9;]?D[5 M,H=/&,=HK;(LM+2$M[A/R"XJVD^4P["_3,./ZHZ4Z6K& F <$NIP-G\O;:>. M4MQD%"PB;OUDW('-YR[0U7=&D7T]5(4_[@B/=D#2KVN23]]6ODKYYJ\I7=RGZS9>X4]G81"GP5<^1*ULGHWKRO)=>7E5U!4GYMC94> S9R:HMEA/CB!9 M8?0"1-.Q("AY^#AA)B[#89D3!&08HIP1I=4NJWJ9X1?RS93/H$,U8$P&\80; MMF21+F;5B*@;A&C%MZ)?2$HV"I_QD?A^8[MO;WU3CN?>,H=\RC0H)<4C=&!7 MY(QUQ;]LEIL03($''UT*,LB=>.R_;\G2]2M"FA^24/IW'J5)GB6*!B4=*J1H MND8[#/LX,D7LQLE$\6N2MUNMEC@1/T,2:LK.S+/7?WWY_.CTJ21@J%]%=+H( M&Z-/*=857<@0:*.V[SY#T,(Q5LVJ%-B/],>%F5\195-PBIDK]*(BBT#\V"#S M&84'F=Q*HX?)*E)$OZ/#S*L-Y&$H%K5":!L)A(V Q6#0C#O0 "OR\G9\:.\;V_HY:!\@LCUD0! M@X:+: J1%8^X!2[2TWL(*8O<+LS&YVC0EL_V&6(;D- 2KN:=L)5+91U=5PP] M;VM8.BXR0.B2823#C04DJ141%20(O;8EV7N?6L@R$YZ,)0L*"U;UUYO6LTI' M9JQT;2DX9L38A%2+TXU$7'Q2M .'N&U%VW^9&UD9$WW0RR2H3@2:;9P_@?5Z MEHWV(*:224?KV5 0+30MV1A\(++ VB<)=Y!92$^=?5A]HS5*^;24IR+/*<_1PH[BQ%$C7C?-B80*?Q$8RB3R-=KXJP1Q= M^_9;OE"7R*N5_B=B6YE.$T1ZR]J'EI%G!A1 G]N@;J/)$SRFO77LAIDE>J+Z M*W]O0XRM]3E O/(ZVV$!KG?RHM%%L>PFC*J9KMVBJ6JG5SVN@BT ,%4(O6A+ M5<<2WVIVZ5J4GEFIASBRDR$,?":SHML&P)R:+-=- ^X*OP?RQ>P886/3OG\% MYWK5SO R+RY .!>LY(E$2)_8\.5E 7Y1^PZP/; .BC MJM2R!K,U=*,(P@4#YG70#]+K[GO>+D5K56[[7?()$17&8M7(IQ7V-.JY7 M-0P*D1#LJ&'\1I-G->';B;4Y]N4,G7,<[JF48H"LTORS>BV=S;P5*/62WKM< M45Q/LPRUHVDA>56O*>UM$MXR\;!0-TSX2$-=Y3/7JP,>$[N2TP#H>/"B:,9B!D23OJ2MW3HCL@]Y:3BM^^<&+"$K9S;,&PDR0?46N1_XF'TE"SPT^DKZ/8.7)Z69AZI+R.A=T)LO^ MCQD@346.PGFBUQU>P1@1WOMLA5'TQN?AP29Y>.=#ZZPA+62L5*!WQ>V2B/3M M*IQ!+!V?:>3\EP]U!F$S"91"%%\)T;W:S^_%9!(L\M>L60Z=*?* >*Z!0R%B M#N+O+:>D 3=6&];?BNT M,[3!?HMP%HR3]]AN2-)9;6FWZ619$ 2&E E.3<'PBXXG!R]ZHXR2)#'%IEQK M^',1RYK*6/TFW)*FC2>'71=!#8CJIX&7.KMD/QMXT4,A.62)K&U0U1+K_JSC/3S,>% MOONB_"Y]=UI]1<,,W'0";$)]J]?RQR MSG&7382]J\%E@8B&,MA@H8P?5(XBBL]"* )[4;G[E]VZ>YL#NX4_0,?&/.3(0^6%4#QO)P2JU+12.NXRUY82.:^1;X8(!8TKX?+ M3X9N\*Z M7X/W7ZY=[K=#-'ZY6B*OSXNVX\7$&\F1*HWY&U296V%A^$K8GLLF8I 3?+N: M83*-=/W1:G*1TS((-E@(;&E20Y28!@O9\ ;%':<+7\1@N/64+6EW^=;QX/F] M70LI)WW8;$14PJ#0$D@@(@A^%J%)I'*0'"T\\]P8VW.(.;P^B*BX=S#7G 9' M .VW!B8%9/UICUMH\.U6$)8&$P M9@L7,/+T'XDENP6&L+0WS9ZY2J7?\K]A2JFGGP#A^60@S]D=%2;/SMB+^,\; MAM5^.V0O1P)]$:X&ZM,)AWEP.XX8(8/HR)R+0<29?\ISW5&A\>S1UP90.KLC M)=A9FQ+L 0"4SNY(^G76)OW: Y3N Z!T1]JRLR>?$Z!D[E[T]GZO2DH/AT/C MO)R\9&(5_/[VH=73S<0T7Q=RJ<\;'L0)PE'JIJB'%..F:@GCCT5-$BQ0E!#T MUY]3>R.E1A\\&#F7#9 (9DJB.3/T__GG-[FNC>W M8M;Y@D+47D287::W+3!L/$Y'$6UF6 MJ=4C4[6QSC^MUCW3#1:_Q%+@F-%E8="[JM"F[<&F9(FZ-'*,O MW)5T^',$($)TC:E=L0\[J];9C/QRIW+AKBMB%\:4?Z1U"/[,8;_,I$RLJ]>G MM@$:?2KR<$XY?R_KYIY1)BY*8?@DY.%3;QFQR@8A] %N%H"H%B782A.^ME]5!5F74\*C\21=,>T;6\/2P]X MI&_0?"U*/H?7O(PYUO:,=Q_36*8UEE+KCY12##%)7Q4P3Y3+8A/FQ]*-A5Z, MB#Y7JHZ#3^@ )>GBUZ!$HS>9R(&O3;/8LEH,Q&2Q221[Q% ( X.QBE1'-AE< M5N/;;D&'<07GK+,M&DH99Z:Q\?''N889(UD&%^')6\^AMW3A?SQ+8-B\PB). M@?;Z1G+577Z-SYWK/;>,QM^":?UB%7IX)[KRF:_2SVNTU/GQSP] M^5H)N]B1.6_E@N+.BLS? ])F:*FO(,V46[QQQ([ZD/J,N+HC^+Y4+T$6^ ME;I2^JO\K^&HH_F.ND?7Z4:A=UHURVI29&5[GXIX'<9ARN>Q]4@S7IN^?0/R MC"533%K8 4.<#Y5*@?:H8%IM$.]#);.V73#%OTQ66G3R1:@K9:_'DI22Z[0% M7P$'6YEZ#S(K>BUM,=SV7C(#P.TOR"-%T$SRZMWC(; 1Z9/$T]D M'B#4JW'H90;$8-G94;ZN2M4&8'=5JX(1,<->7#R?(\T:+CR=TMF#3F]E+90M MMC*;\%681-Z $'1S0V^HZ7A4 /NUW2;+5O=N)N E9BZC:D>VX(9LO1@F1A6C M[,P8J00*X\RV.P0[P'3\II,[3!9#Q]9[7C/-#90@2(J CNKP3])1(\3"1-M. MDM"HFD8K'4"U;F9>@F;&X73PW378"F^D5 $10\? JA2%9Q>GC[+DK[_QD'_/ M;XC0 VMG7E+'GQ;!A5@*YI<--+Q?D0\3308\L@:'WDF 8SZ$CA&G=L7J>W<4 M=4 58U>V2;=^;K%$.Y$3P9!)9#%FG\\8\R+$#5[:JC"+*G$U"M TJ( 0*GK/CA@O8>TMD MACT47\62$>'B@LH/OM.,"YD4FZ". M.%VU#7DGQ\5SM\D00)T.@SZW:(CFHU6X248JX&&C%-]-LR1@9K8]F%\$U_+E MR/3B23*MU(LB@'7X7:YI)F'"A=S-;":=!*HPI$)('*E&=^,O#('(['X#"1 )N4Q+^8F+T[^L\:+#8\+9G'(P+#M8 M1(OW'[I17(#71!/N0M^+4FA#]9GL5KVGYGN#/6ZJ(M*J8Z%R)Q:<(J\ MC-&:VH5[AHAYJ^9S @UR!7[:>1@QKZ6A]VPXW+R\![F17%<'RCP>OQ^., M'0]RY8SCV-Q4,IR'SY>5T3XGYP[_'UO/47B!"^R%](S\%P-K\X_+*B'74C;L M>Q\B7KK<,@0">F0&JXG'J:IW#/E785LHY #&MQ4-O"/C[75">Z+T;J0)(KMX MJJ*=&R2V9$TQ+*,-*2L@.I(N>MMX9)_#,L*65:X=*C*NF -'!B-7BUD&B>%5 M1G[J,L6)I,JLD+8 5O6#:\E+-7ICQEUNP=;)R7?V\9D2;@8Q5'%)6!* M8,HYVT8Q8L?$T%LQ&6\%C?C44VAW9R36,30W0Y"GP>R71]::@6U1+\ ?!%8P M^^CTXN@9EBV4T?$)5Z9BZ BP[MZ:/)T16E'HSH> MW>O%SV;M0TB1E(M5O1"JL*MJ:?GD_J,KRI6B J#B@Z"J2V]>4-KF8F7Y A'N MS)(,1"KAV:V^2;-$!Y^=\=U:V4$YKV=$2BOGHI$SZ/*33AF-V"(AEG&S$(?G<^K](+>2SW+?%()R>_L_I)R(= M[B@-=O;#5X<*NB,QTUF;F.DAH(+N2+UTUJ9>^BI00;< ] T,1G=_6+H'#T:Z M(V?5HY.[WT1LN[,V6RT-I%>!G; M4LX[\;R>F=_3\MQ%^ADU%[CF1 O)&>&,?E-SMJ#3,M[.3TDM"\U5UI.KOHYX MFV45&^4S3NQ R +I5/(AN/7+95S>)_XP\J8@2E:ONB>23I\&H0$\:VC,:*98 M8S[D?YW'!-<+,0LXIAD*1;- _GVA_ DH9;B$!2!00.)0Y,%D#9O>-9>L#,OM MBL //^9^5DTT=&6G75+%])(U6XQU0T&XADL:=1@54P*L&P&I,@B&V$T*-6(F0M/1%HJT+*Y[#!"*)[$"" ME[9%@ LG-8@V]B\\;K> 21Y["#JL5KRI2$5_6Y7A%W/2! 5#.WOM/EEJ:TIV M7Z6M*) U:FG<=_+:2(TBJV8C$>%L31IB<.,,/&\65$M1Z:I@?B"),MJV_@P% MI)$AML9U1J(0Z(NPQ#L)7C3T8 )1Z]D?8D]KB/HXG)X#=B+*G1P5F39]/K>D MJ?\8BC'4P*/W49@:9JFA$'F>_9TOC[=#[.;<33_9R>X-KNIBZL,\/21%I$5. MTBQNL'TA+K'W2%$LQ9\.]?"2+ULCL5+WDDY$B]D;U0NM1T?A>:N4=+_COR*+ MB3[$5+O$,5\T9H^2"(\0A]96/=0$C/]5,-@P?&:C\[]7[;%AU'8C79:A>P B MA@Z?%DBXD26*Y+-*VWV-!&W+:]-:)=ZLL=I'3_:"A=Z\;[Y M95.A)N..JGF;%5^54S:-(![)1F+ /=8*DDE\D5US5^C.(8@]3PO9 I1 _YCX M?3P_5T_F=-D#=4@7)6](HI 8?MB$)]:%,<2%R<]!)=(.B%I\<-':J^A]X>/. M:"TQ'O;BNIA'Q;6R$52[6[9?3!XU#]I+T"I0( M55Y^/Q[O"Z"/GHF^"^D71?HE.<74VR#GW^?RP6>627=OCC TB8#0;\X$K8U M-X[,>S)^,FVU;>^O=2[ 1(T)KQD(EE0FTS(!@X$K3A<7]2"<2A^TL\0* E&R M!"@SA"\.9P,VME4YEL92SQAG.#F%20@'0-4(7D6&F* X1VOB\USR=LML%6,! MZ],>OBHGB9:G>&R3:JXO0 JP=&_SW>(04E2F/3]8-_6)BZ3^:SM/ZA=/\GE5 MK41A;4=J2:GOX6,BF$6= G6^E)69O-M([D!056[#@K/.;$;T M=BZ)W"0;"(]=*>RYN&J('O+44JU#3%M9TJ*VI0MZZ$!&(& ?P9EXS<1D4DP1[6=1(G#-W> *H@% M;:#'F[D:[K$#Z54V_O!Z*NVKI(?GG-+;-T0_??SC5]I(1,^O%3=X>N0:NCGH MZ7B6%R;PB%8*)1S4GX%3-1-*/-KC$X06%5N2SLMJOD63;_,8JP^G M'I4YRDBEV4^V<<*%0H!7TONWDT'77>UL"!S"-+!1. 2F?*":. .?SH6C=/YV MV7N>G.Y&@.O1'46%'IU^;4B61W=D)GIT]O"0+(_NR$+T: L+T<-%LCQT2,FC M.S(E/7I\O_PVXJD8T\@=O+0GF[VT!TU;LX%=)?7*3)J7O?EP/?;&7"7$)X=\ MEB;KY\$Y& D0-15W"9%9."(OB\4P<6"J4DO,79X$38F-7K8)AXV59FIB17RG[J VE 6F3*%AD3=29)9GADS0HERA1@36URUJ?EW;)V.LMZW]6C5C84ILSND-*( M^?33R MG/5R;;M\'7'@9^XY9"6X.I?RC1'K9);;)9GCYU>*"WJ_#+T\>/]>'>Q5DZ'\='(AEN4?@1>)!5 M^][E_=@7M M+KF1[;E)9MV:IP66@.PV7YQZ##G/-I-^3"WD^-&BD-!P_0:;H",]LF>,X;*> MO3M9I"_;D?],KR9FZU&S2 Q4RI4<-NJJ)MZ$P(2M9%NPI;%D3$9+C!]FSP2E< M9LOP[E_R,L(W(X*D4>\G%2?AG_X>WF@SD17)OT*VQ#236& K.7@32K"$;@'O M,KGDSDHU-[M>'OD,;2_7) 5C"6Y+V\RORXY8VS!QIH%&NY!W.LJ7UWFN:'%' M]-'.XO'Y3_CR*YK0J5RLE>GB\\TI%)8JM\3I/MH3UGE6JZW>NSD]/3F:: 8X M'L[6\0J4X%A-A9&UG78V(^F?$PB[K9S89A/Z"\SESP5X/E>8MW7PAB(0*U(#;6AA)%^63(\Q6X!-)"ZN1CV^ [A@" M0AM2TTTI:;?P-EG0 =NBF^GAN-++]T('=_GN7D$5P)E8+T#< P(GXDMA2!2S3L*^:0XI37/;@<:[$ R\=OMDA M37)BAP)W"\A:PV=8F/E *$FXQ8# 9^$\D47#6I_101$C/3P>.'JN]H<,>!2N M8X<8N'L:Y2@K_9!!4X5+$&DN!_DY='J)$_9 '>,0OLP*KJ&XT^V01)TVYUOE!+_K;);)E_B44\X=*IPK@-91HS*/ M[89[(HG5 H3!XXNUN8[:"II'8!()%10QE& Z$$I5XQ!5, MM;H:9XA9A,E%' MTD#O#M42ASIUW72)X%J?R0T=1*;J"$T:JXA>W%1??;N> =6X+%E>9!<,.6+X M&XTA/EA%N2$[*DFE:C5>2K=(+S%>AA6CA@3^XQ6UF?4\C /, R&'@*NK/\J@ M=%$51'K1?I)6#8*SS?!QN.Z*$O4=!_ M+(<80RZEL]H"/8V@-%*5R5 C^X!V\V<*9VLEI&[)4NT?;MSS<.2"F.S1M+O1 M<,7\7YV"K;(K<7YX:_>SM(M3.OJ$T24,AW-T"-.SZ5]GP3W[\6ERB#_^2@_Q M3W:FCP=_E1-3.=W IP:>&&3Y1#TL,GC4U5+R[A[.Q?YUV*4-W[!8U<&M[J F M;EHEE*\P&;%:&&-,?Y4V/91S?&ZJMV90S7)6S+2-MQT(^7U:DPZ;">&9+)B/ MJ"&7BFA^PGHA_:458 K S_\1HI52>V['#7:N7A5EBM4<9SM/8KPN6DLB:JL0^2#OB58:%Q6U34YQ_Q$C)9RE-53X! ME"B_8DU296)T53A-.EQ0JQR#"M==]B,G.Q_,7OY."?^TH#+D4Y2;=R\*N+FY M0)$K_; ;EY0<[W)O/JVT":966NG!07$H.2DH/A@[WD'A_^ =@(BTHIF+OD7P MD#,F$U)J*[7L/_5\6]OLI6L:7F)<@98ULJ[P]W[H F%V=*PF*!JN<6MC$HU&-8!Y<"(G? M7?ZLD!>C:@Z-G9.D*]29Q?(B#!$8>C\< @Z]T M9C:KN5;8V4B0E^ 3!%^ MZ5K_/[P=]KYPS\@'X"IQ3-NC3^1>I!$9YN3GT# M88)62V69)Z=CM$RQP=7& MA4IFIQ];*-KG>YOO+\)CMW'_\;5LV89.H $B/$@UX7RWO?:N%D9\=(NLY+FW M/2RRV)O""O^P6X.,+K5K^GA?A&Y"A!$D4)6NV5A5>) SB=SH7?7#"Y6 M&3UGSI\0*@?M,!5Y%N_?.MD'[8_E(;,P \*(-%9(D^E@4Z(%WD MRPYV#8K,NKJM=;-@E3]NRI?D_E (@)741FF;,F((OW8C=-$#48N;.W;)SYQU!0[=E,J1>E2)NWW32.WK?%6PR=YFD4A91T< M,+HCV9;&]8E89690K>[9\>%B]Q(OG1J*+GDIV_0R:6G/N9.WB R$3LXKS*DA MH&C1..:,\.'6FQ+V:P$D3:JQL/P*S!BYDVO6U)D M!HG^(0ZCY5)AP @D6ZRAS I_V1)DE2-'OUWS?BE_A%.K_Y9/#)E84OQ1.+6J MYB/[7#-("KOZUFV,*B5>6M5S."'*($XP,!YP>A MC&^Q;L5((EQ.C238*(9A\GH&VF4@727"*P>)C!PY914KZ2K\[W# F1\WT2V2 M5X^/F3+MPZY,0]@4X-7%0AL-Z5:[*+3_,*$C(I0PE,'&'9%3L3K70Y7FE1M+ MD!<.ZVR!Z$^;H,S1+)@:ECY2+ HT8_DCV]+"5:UP\5'#4AEN;7I1X'6G7^0O M)74/"" E/<5EWXJEDQNCMJ+YU^:GL^7>=,,XA>0\4*6V/75^CZJC][Z6B@QU M/BGB'G.DGT>4B"71.^7#6)UH<5ORU(K6%OD'*W4#DR>S+ 8O*+I;FS7MAF>W M1YU(TXL.?5?1Y79M2B<29D@2.;*G'5A/KSUP!HJ.I6JLY:PO@N_9T!C9@OHH MRB>,#SP1M>B B7+72I)LRH$&4==-6*#>[\0-OL.!Y!_(95V2Q;T+'A6;ISA- M=)7[P*K\&+$JCT].OU;%YEY#HED11 J'!.]OZ0DTFMB!&FC&ZD@1X&C59P3( M47PRW.YXR_68S"-'%U/P32_8!IWNZ3 "NCLZ@:!FC=T9!$G-K#TC?IHCF,8K M;+KE%**Q8D)D_I0" .&4/(EDF+3IM(49]W*H$+PAC")E68.QY0A0^A\:^PSP M\;IYQSX2WLUJ9D>JP[ZK'*;ZN[$PA]G?J%: M3O\\"A_/7>_F=9Y]<%>G':>(B03FGU=(8IP*UYVDR 'NS:56((&IR)OA1KA* M[H$'S+C#HQ(ER:*$6\C?ZA-R;;:95O#W6)FT;/+X;?;5U2-QO^8].[X,O'NM M"W@UU1#RUT@=HG-,^E*N\K;1EBLTMS!=+1,"XY].(C5;Q#0^4F_!_Z\OPE^B MT_J/539CVD+N:C:!Z64^OBQ)AT)::\M\UGJO_3-3E#WGDM(K]>C/TH3,UCP; M]\^50^= M9+D1.S-"@_8U[)%:+E5\.'7;:E6:=0.?[%R!7)OO3N@G6Q$#5@+ M!P_$BSN*D"Z'"\=6[\_8);LG9P^Q'^D_PS0;'I\6<*I)EU+5L2R$UF]ZJ?48 M4,/-\S [>BUU?BFF1QOA$GWM)+^5M+V6FZ%VRO%$IND,8^/G9>'*QKOI4Z[; M>$)(L;7GE?N&$!R/=HK@N+VB4OCL)R,X[JC;]&B+;M,#17#<49SH\WY'OZO'9)R X?MP!@F-[K+UUSW>$@Z!Q9:%TX1BFG0?K=]K*7*BREVA0(Z0"0J MN76CZ^,3H >_QKP#S=+1,TS3 -,Q'.A,#72J!C17_->!^?&?:T"?^>H/O@^% M/6:QR*.7Y=&?"IMR_]^O(*TW8K6"$OUN"=D)T!1F?Y;3"Y+QD,1YGO MA.=?=#2NLEDSF*P,3A%"\4ZYX#@:MUV<2]^X:90-]Z7.S-6ZN+-&*EE<-+T M=E%**(P DRN/\K#D&XF'W[S\D^?LH"Q12Y] (D=Z$<0048*X20D.<()8RDG>;X 61.P MC\B](&$C,E"=MS<$Z=O&:48'WLL_-=(F$8NB6I=$4Q)FFAY7#U1^.TMT/U\B MZ93G2RNG] MKD!@-Q/"OD1\:K+*(ZU^PP A-WN"0MU@-*/\(NQMO=S@KU\^]W;H M,WW!.(:#?P:K&J16Q6Y+*J#)/(?+9;!O4LLRW36^$T&UU D"%"AVY:ON4%.- MBRQ1VL) &FEMN?<-/F*!P#X=K$C;M"C?&[L&E]E'N&5(=XVQ]+B0!0I^4+%( M4Y'R0*K"G#4)8:^@-8:!=5]\?*E/8CIG8W8GS>;\GW]GKW&/7O]ZM7YFW>__J3_V)[7:9O=" #FGTY\W$XC ML4#?I2F8Q.XG;"CXT"0-.;__+C[0T.>F+*06>Q#OZ_?ZRJY<^MF>9?^OD>\#IW=Q_@]@,O MB*U4J0PJ[F[!=@P 2T%'($D*M3GW=#7VM+JB")M/,TKJ&FN$735N]37OGK(M M#^0RYB^(&T W_]F"CS#UX3\U_8;\R]BOCLZ\,2OMU\I^K>QT MK="J\+&)P0FHV9T:J:112['?PD4#O.IX7*\H!-1*]]]7DPM9%2-BP56!L8&0 M73GBN@V'BBRF-M97_46Z#KGT1!6^7R?[=;+#=7)>#K3F$+=O7CP<':@-$W9Y MHL' '/V)=?A,L8 &&^N4)0!&RYI?U$1<'I4%J0"]XBA-OB5\"(2)'DSSR!)I MS,KT)5VB[8$A* /R?83?2F=5A%7$<7++)1? Z1GMR169XYY"[FU/(6.4NX?_ MHS3OE8Q7>I7F"VH3 /@H+.?]6MZOY9VNY=\Y!00R=J1J6HD1D0L._Y'44>[/ MO36#SQ4$ [B;IIHD_S):I_ZG)9B03O)WZB:]./-)\\H-Q!1=[5?(?H7L/()B M]RR;)0GV-*OP\&L[=E9)QF\I_Z#AAVGF6$]4VKV_4+=+]3=+50ZN5B;FKVQ>U] 9.@\:=4TYM#KG'H]R!"E<38<4DKW MKOYFRS>]]Y&A,U"&5O:E]S4^E8'AJ$T0WS6Q%?_34XIV5NUG)!G]G;)+[(J< MEY/75%E\!569E]$_N#T>XO3DAZ\4#X%Y&(A/1ELHIF+ ;9-"*+ MC(*.6*4G*0(G08LDNSE,(] ._9H[YF)-9UI\1.8/\8Q7UN7TH-03D[I:\I?Y M"AH.M& V%-2D!DRT)0FA!_J&CM\=#ZT%M"6:/0C;;@C9&'(<1Y Q:/YX\/N& M$7(Y )(GU'.;/F)2V.83,%;I111<.1,EW2_*+U%WHD;[]-!Z(5PSQYPD$B 3 MMZ"V;'HR=*@LM;<%W0O\56J/SYU0^GB<+P3C%ADV)J1?$W;OP8C069=\&4P4 M?=VUC:28K\&+YR^?=8UI!+8B:E/6%L9L?%GD8*%AJ:>(]U:E7,5 T#4$N&!P M<6>5- 9JH4O[S/F"TKO64J%KW9")12_6QX,_5TOZ -#\DFHH:GU-R$4?H35B MN1:ZZ)9-PA@QQ3U+9$.IB+B@JQMY!N]GKSF?4R^S=EABA*[(WY79D2V R[$+ M:T",4/XZ3V7/(0AD)T5O45=*JIM."[.5.^XKOA9@M_,R5&2H0$ M5+ULP@W813TYXH9<2O9?$(%-W7MY W=(AY V@;DO,>,L6?#IT\0HMY]U\(?M+JEY1H\R@#X6BA*0,25IMV9P M($MQ\^N.(ATW0W&LJSF\TAL,B+= Y8IP+UCW@TCW9;+Q2\0#$]6$LX<@H!+. M1:58EP.?8"_8[J(J7+*_KBB+1;AB[992J^!$^*RXXD)JL30_)5PR7)U0EW4Y]$[ER_[(>0D.TM788J41@1"BR:Y;-$(OQS&$(%&3B0^P[8[ MHW[', M5F3Z; I4 ?>,SF&%=V([;#Z%,>P)S^J9UWA_O1N?]\1T5Q!]O41!_ MF#U5C^^HSOWX\0/LJ;HC=_'C+=S%#[>GZL%W4'U_O[KM?VE^LT@R>'#G%$NN M/Z47X_319M&Q!RWCCM/P-Q=.AQ.7IV'01%\L-N(,\$ M-XO@!%:@)C+^OW $O:,3O'TMGZ50RISW-3+8(<(-9U[X?3@XYI$:#TT M8^%APVJ[K#P@L3U55)]7A1B@3?#ZHQL2DR$_ MBR0-N0R] T#/A(PBG8?TC8;X_7Q&.M'!36\-YZCW+<>7^"+3UX'!O @?G.#G MLAT>IV26G-G2[W B">AX#3%"1+8@823E#A@K.*>IV MLH NDA*>)J^+V^'O:C;)TB@GUD2@!9V)A]IU!-QDC25R]>8I1VI"E^;P' GC M>A4VYK40'L?\BL.$+ZI9,=:E&;LJ'7M%5891:*\ \X&H7NN,PJ:9T"6[W@,W M!AIX@[4A'$)V5685&RL?BJA?]/7^R01)(FBH?+JFXN5#NF TI*]4MW1ND]?: M1+K=720;WIIJ]Z>=25\K+U%\[IY#Z"7"J$AV(P1?B0ASK1HAMV4Q%&S0UF[4 M$8_ 9\ M*H[ZZNZO&A#S&+'FF$0U+WW> .+;V'&\/DXF,J*C5>0KCL*BB 8=[X^W5#][TZ5/4RNA%;U3+[0$E:)F[Z M0 1A5I5IC9ON=G#E1VYZC_VCLC_S%<.R'>538;L$(<)WKJO*HOLK+X)R]_:%7+,PHQ M*_,53X3U#%/"A%JTV3#'OM.Z!O^LEW 0S<$HQ55%V&.9+[L,; =&\_KGUZ\& MK^DZ,4_X#CZ=7IX&&JY_68R*)9LA9;1F:QLH>Z<106C@2?K9GL)ICAG[)A>AW$78&=6I5YJZ<"$BQ1I:+HVUK_! RA7E MW!?>56Q:NMEPA9JNB!Z*'%0Z]$J:5:9JS,*I&K;^1OHW63>=I1KG!<]6,PYO MI'4CQQ:*3F9:+4M[PFCLSH1]+[3#DDMAH)E]1 P"5,%8G)V##T -N!^TAQP5L6['Q? M/$ M6!.>I<2V 61%LPU:H=]EYG.X0W18A0?[D(%LTK'+4Q0L9]<_-21]^>8U_9K+ MXL%@_,==+!:LZ2)7_0XBDM62&GWTBF,CCK*8/'8^,OUNK@P+&0PEC(>:9/ S MF!9XG$L]ZBVE]_= .UFF_&,1J_VZZ"=A/R+B>')U\H\9U4Z&>KQ@;9[]/-B! M"8G+] L5J%]Q.UV8UF,SQB#=SR73-H830G)>80T2 M2:0X*]Q.GA1PEI53IJ:9.<@<=( (U"^:0^_T@#^0Y>[9AJ@:H*@1+PNK)B3] M[^@]Q:U,K=:$AN_/K#G"FC+_;:,V!\'\7$W;I#]66O:I)8??_CA\=D/ M3__GT1_Z0(JG/VY%*7KLX:UABW_H)O8E.8_*7H;#EJ;HY/3GTU^.PP%) M;*$S4D1]MPQ!!+U47CN;:%?< SVYCQWWSU69>JW)1#[^*B;RV?'@V9IP31H8 MW&+R!CVSM^MGH"UE\'NDLZ*U]4ZWO%T9P-^8L/ZB)*<*P>><\B>*\\E8=)IX M:4E2>5E,UT92"R8NP< Q[RQO[<_XD MC+"8H,$T>@Q0%1,>]6'G@;+9&*.!\&HD.XJZ(B>,Y(0X1RQ/B>& 6U@N.TL M9%PNZVH&CRD#XFT00E#2O@MSQK^%/49C=)8H,4%JC%\[H^R3[].=8&MZX5-+ M_G>NKS^08G;[O]@H_O/?VU/D^P:D;8!AMQ_G\)?'/ M6$#&/L\(IKZ>U5AK.[HF2J?.*KVHL[G/ -&Z=- @'],0*4JLWJAX6]\%&3,= MKO0A)TW!^JH8Y\HJ56ME23<(37#R%L"@5MD&"#QM&Y0CB$1*\-9GDX_*R,ON M"U$$G.J1@YUQ<_"H 'L5X).#K_?>"E33Z')45QEG38*'X)XGG"'S_+JJ/XAB M!^GV]+XHG*Q4$T&XVW^@Z9OD!NNFFF90-"D:K>9QK&K)^'XK-8YW6Y9'"TNB^924@+H/1@F ML[UV"T,"M44>;B&E(!JM!*Z\;'NW 1A"+%J8:;I@@X4_"6.Y M0'JSSJ^*_+KA'4=?E*E8P#_(D&@$[V_8!)IU$UQ (O*#&P0%R[$:$G^IHO6' M=20?1MHM?-SV]1EV1%QWP3H[[(G9:N<\ MRR\522M?9KJ@&=<:O&4'RWRG3_=;>(B%%25?OOLMEB KG1%.0%(Q+*8RTCE" MS$^&:;M>VTS\PO,#>4_)BW">AOC%!O'>QM#>*"%4HBLJEI(P&+;$UFX2',M+ M:D7'HB,*!)F*:LDT=%! M9P;WY88SO*&6O;!)1)")H\50J=/.*>L.]:C@5%E0Q#X^VI8().6D+/+RDF9& M-QRWT2:;1!_WMX[]A@GB_44-MV^&=0_U&SOR[J6$)P1"QP]W.K-Z-,N1P%_F M"]F*FDM5":%6A=+/HD=,4\4[JC=N&KTX.O,%0^)M>R;S%8URMU?U/TF8H,YR M$5.5:0SCI(>CPU;:U?K&] EO*:*$L'U*N';#YOD@TDB_Z\'_DHL]%&@DL\MI MWUTE8^A]Q8VPL#'=Y+N2?:T8B\$GM; ?!D,N+RIH5F5AYV.OX+*Z%JU 7)7+ M85[JAO%3R5ZCF?A6&H1UL_BH[@I!83S""TL2U;+53XX'SR-C)[&>B[709B8>']3PK\BM)7W0FA8J[ MHK;EM+=GQ0>*K !L:'UA> _3B'3*=%4OF7BY&=?%J!U/\=SH0XBPE:;FR:JF M63%C4B(Y7NRKYG6%.;NF^KDT"$/FL-9"-?I!F\&J)%>4*)*D7Y,>+ZPJ;APR M\4EUSEKAF/AG\))GA..$P!9T*E$[Q]5<;55%#&W^;J30V]5 P_&@*_8M]5J\>RO26&FCL#S^T'17(++4N\&.>U#P]B5G-A[_S,N8FE,E2]29?.H),SV1F'Q(TW"\?JTL*BH6(&Z$:U+JGH;M+NOC&^;WNR MAB:PE"*IE%_E[(I4BV+<6)D(3CO,8U,F;W MOM4'?^8HBL6KQB&>V5[ID>Y2%U4VDZ70-NRN=="YS&[BEKP)X(;B.GE9GQ@) M>D="@Z:MH09M=19(\6B86(X\"'ZFW'FM_0%F_^.HH37(*^8TA8U(%N V/@?2 M>B[)/R'C.*XJ,CK)B8W!5#DG?M?%+$_FJ')MJ8[(5OD\@MS>F MWL3Z$<*5DY9T/>US2FU!B*U9\ATL%#_HAZA_PH3=7)VQL9 WS;O(+S< M=Z_>]A4$D&+(Z[DM&$<%X. 1YZ0DS2GHO\5 #>^?S@$>LD\9LX\O0F,LX)K_ M \E&6OUI+JTAM!Y*'T _S4Q!W7%C?:TEY"?[$O*F$O+.J[O)=O2D=SO:3J:W MZ]WHT?'@%:IT;\AKRB?HX=@9.BTO.,%.G5.\9(DZJI@46:TK/*;WO?PZ4+MR M%*GPHXV?6G_KH2;4/P0O;$:NZQ!GXK9ORCF64UE5<^4K^$/MH1T/7K2)CY#9 MZGL*;2(:L"])OH@ 0SLC5W [NR(UMV@(7Y+L93Y<]=_T]1YVJ<,Z'EN=G$8E M('W.< "+DXV74FO=D$@Y'KSV^Z@Z%>Y51/WSJ%?M11MC4ZAK_O0#CQ.M]1_, MP&K)7&TJ+\9SE>IN^\N,0U#!_0T+:AD9Q[B7)YLPT)1ZK)!YY/["@8K#-'ER M+<0O7,&,QL)A]P#:431;?1E1]CH10]" M+/AYT1#I$(I2NP.R+EVQ[*L_LW_8G]D/YLS>S1F=$-[RT]QY2;XY?_M^\/)E M=]$E6\J/_5M*3RKN"VXIWQ\K(2HYZV^EJ]DI21-4/NRHO_YCA?85;>YY%^&Q MX0(<(Y+O_Y);B]](YP+V7_ZN[W3^2I#C,C,>>K&K?99Z^N0 9+:/G/N]K:U9 M/!0P6. 3P0? #^&P:] .ZY"@J=SW*]>9ZA7I0BPY]O M;I-'%[$U0 =W@;(,<6@]<:B[[KN-UU55;!"O::_^/%HJG?R8(PZ!2V*$3?@* M*LV6'5,=B"M$7$Q,B=F$VG:%6&8M[9HM+!<\AOD8U*BR>@WR7"/H= M)/A_D6YL-CXRGE&.3/0X/GS"+T"S3IVY4,SU+7%B="@N@T\%E]'WJ%2B0S7 MI=+$W(+GP:A^T1DN ^/6O\N<:IPEFAW"Y)-P_6NUDZ3S-JRDH;64HI^X1(I#.L&'K16"E6'SV^&U M=$"D=B\96';R,=*65/IF1@KE?FT34HCK/U:ZH55L$@XS@2( TCD+#A1:DZE% M@Y6*L*K?OP@SRS!DEBKF'F?0#(^)9V)9-,S&P%W$6O)/1B=+3N]WB$23! 2Q M[JUS*;&4]&SJ2\-T\$LS'5Q,ZW'8/<:(VRYF:%LPBV5^R5'N^1A&1"*-,"W< MK9H'VU0&8L=9HULMWAK1\LPH@D'.#M05#+;X,X\Q#G'HQJ=F95;EFQ$I3&.$ M6U@IX?I9K:PY^N/0"(O,E$>$FYCPEDH2:#U6^#4@@_Z+.VQV=JZ>PU)>Y*-Z M%>:5E^39HV'8SL\>#[D+-[S<\)]' VG^X79-K0?:N?,U3.[;G!S<$"[.A*O< MD^_>S1V[MR[(H=5KLU(; &;$\('>;R;1!7Q&\0<)A]C,QG!6D(L)Q/\.XGR8"T MEY]+]7P61WJ/QE!-IR=/GPZRZ5)\Y[R<&/ E+/9R$DXUTD<(OB^+Y/UC!:Z^ MV3J]'Q -#?TUDAQP]\/2,]%1-FUS \Z:)9>Q]WC M7&7-[5-@]^.8:Z,G*%O-W0T#5KZ;MR^?B0/Y;C4*EK8@R_@]4K--8I\'BS4Y*<&O@)-F;S2-8Y.G)=WH 6EI<>+T9NRXOB]Z<4_Q(WUU! M1&IC4;-*OC*KRHOT&\PS$Z<=7HXIM9+.!7Q23PR%T-";98NN,5,VS&M?T(#B M H>,\;F3P:4/<=#-T-&_32SI7Q(C<]>C6Q;C'JFQX_S8[US##1/8,^4]+X:G M^="9=Q<>=-NIE[:>9(>YSH6_UM$%$3@+:0("H< @N6DO&?@T88[I*/QT;)NZ@N3JA/SW !V13@3]-"E/2ZKAG<.JRDY<)'4G=8;7A[1_XEV M@6PE#DS)E2GLBA>Y;F^VJZGY7W/,&(R4$A?*787-T_.D M)B7!L*H*]%X*^P#0%^$+HW D3A'^V\IQ;T.*:JDVAKR-UMONR:S]=G[^AH&' MT#/0M!0O0E5&*DI]0)T!MKJ(:S<*S34.X7%>7(E/#M4;!>]IY9) UP]?GU'4 MXH["]O"A4"D..>O5\^"4B7'SI(^H5C&91/D':%..LAE> :9O1"U<.?=H5ANX=7%)[,>(GMROB3>O-$TAD69Y\O806+MPZVCLL]%Z)KO0/PK M$P.I!M7(-#SBLKAY&7SE-<(@[M3?J./D?%IKE?GL7%HU MKOYVB+HK/TUP)N%1R27QD:>"241T1PXP((YZG#)'A@>W;#-$Y.G7 !%Y @)I M8O2%'5U")S]*JJ/H"EGGHM=LN ^)X* M\.?;3V_)0 MJI<2IIUX;J@5DFY&/*04&&2X/4K\F;2Q2T),TKP:.1*?S3Q3!9\06O]=&Q*S M$848#DO!(;Y>1CX.'XC.W^AU) *K'"Q,5N%@E@N@Y6 JL\3U9D%Y(#,0#GP6 M8B"<:D5]7QJ0*M+%2LB- 0SD3_QHG5]S K#S:[!HMW])/D7[=U10;_U*17<>Y.UV?A_>,UE8Y^-* MH="]#I"_"6*#>AV5B%;36]=X?8 0"#%M>$&B"\06S&^&G4QC*=AL]:97T5T' MIC:%^TLFR^-\M).FW:Y^X^(=,D-^N&I4QASEZTH,5L@6N8'/*R#(+ FE$JUU M1M](OL%RC!6^!MR&T1Y(9R153V7*&+%"WLTX4Y5GY.PV3I9/5VG" !DX87'N MG@EQPW\2_<:-;F3J-OZ??^<&H7$^FRTHBU5>_,G7^YMVO/^D_MCN0[2-I!(*9GTZ\^T8C,7_/N88%^N-^RJZJ8H(/ M35+OZ?OOX@,M)ST?>/3=SU?431:V6O&OPM1TW*T_,%GUDTU7.>V[RL8[W^J& MGX:NO168MN/">'0M;C_PM)!:(?G#?P*YSXNPDU;WAME*!ELJ7A71FY_-@PE3 M$_Y3TW_(TO:6N[?[49H5P7&BN4E$- MKODHMH,+>'L#W1OHSC=57VQ+](H87B*U3 C,1UK:@;"=[BUV;[$[WU*9)T2Y MVYQ+*])>2H2DJH<,,E\;J;1NR?PIR8((-2;'DJC;TVZ]M^^]?7]!EX&*9T1& M!@3K!)@<:D26'$.BX"G 'L8N8 EXCWEOQWL[WKD=.S'+3425+K>PA+#E/L.P M-]DO:+),XBM"02F@:A.&8^BP#-0/C.SP90;X5UF96+/(TO+^O+?MO6WOU+8% MTFA4+4TL[/DL+[QG+GM0+9$4@,VC8(HQ_GIPJO$W\(MR\Y. R/>6O;?LG:

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d774279d10k_htm.xml IDEA: XBRL DOCUMENT 0001832148 2022-01-01 2022-12-31 0001832148 2023-01-01 2023-12-31 0001832148 2021-01-05 2021-12-31 0001832148 2022-12-31 0001832148 2021-12-31 0001832148 2023-12-31 0001832148 2024-02-23 0001832148 2021-12-31 2021-12-31 0001832148 2023-06-30 0001832148 2021-01-01 2021-12-31 0001832148 2021-01-04 0001832148 cik0001832148:SpvFacilityMember 2022-12-31 0001832148 cik0001832148:SubscriptionFacilityMember 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Apeel Technology Inc. | Biotechnology | S+625 | 1.00% | 8.75% | 6/29/2022 | 6/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ivy Fertility Services LLC | Health Care Providers & Services | L+625 | 1.00% | 10.39% | 12/22/2021 | 2/25/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Oral Surgery Partners Holdings LLC | Health Care Providers & Services | S+625| 1.00% | 10.92% | 11/29/2022 | 5/10/2024 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Pediatric Home Respiratory Services LLC | Health Care Providers & Services | S+625 | 1.00% | 10.67% | 8/19/2022 |12/4/2024 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Spectrum Pharmaceuticals Inc. | Biotechnology | S+570 | 2.30% | 9.88% | 9/21/2022 | 9/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2022-12-31 0001832148 cik0001832148:UvpManagementLlcMember 2022-12-31 0001832148 cik0001832148:UrologyManagementHoldingsInc.Member 2022-12-31 0001832148 cik0001832148:RetinaMidcoInc.Member 2022-12-31 0001832148 cik0001832148:CvausaManagementLlcMember 2022-12-31 0001832148 cik0001832148:AahTopcoLlcMember 2022-12-31 0001832148 cik0001832148:OisManagementServicesLlcMember 2022-12-31 0001832148 cik0001832148:MedrinaLlcMember 2022-12-31 0001832148 cik0001832148:VertosMedicalInc.Member 2022-12-31 0001832148 cik0001832148:UnitedDigestiveMsoParentLlcMember 2022-12-31 0001832148 cik0001832148:ArcutisBiotherapeticsInc.Member 2022-12-31 0001832148 cik0001832148:PlasticsManagementLlcMember 2022-12-31 0001832148 cik0001832148:GlookoInc.Member 2022-12-31 0001832148 cik0001832148:SunmedGroupHoldingsLlcMember 2022-12-31 0001832148 cik0001832148:IvyFertilityServicesLlcMember 2022-12-31 0001832148 cik0001832148:BaymarkHealthServicesInc.Member 2022-12-31 0001832148 cik0001832148:ArdelyxInc.Member 2022-12-31 0001832148 cik0001832148:SouthernOrthodonicPartnersManagementLlcMember 2022-12-31 0001832148 cik0001832148:CerapedicsIncMember 2022-12-31 0001832148 cik0001832148:OrthopedicCarePartnersManagementLlcMember 2022-12-31 0001832148 cik0001832148:MeditrinaIncMember 2022-12-31 0001832148 cik0001832148:OralSurgeryPartnersHoldingsLlcMember 2022-12-31 0001832148 cik0001832148:SpectrumPharmaceuticalsIncMember 2022-12-31 0001832148 cik0001832148:PediatricHomeRespiratoryServicesLlcMember 2022-12-31 0001832148 cik0001832148:OutsetMedicalIncMember 2022-12-31 0001832148 cik0001832148:ScpEyeCareLlcMember 2022-12-31 0001832148 cik0001832148:ExactcareParentInc.Member 2022-12-31 0001832148 cik0001832148:WcibxcPurchaserLlcMember 2022-12-31 0001832148 cik0001832148:ApeelTechnologyInc.Member 2022-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2022-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueFebruaryTwoThousandAndTwentySevenTheSpvFacilityMember 2022-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueMarchTwoThousandAndTwentyFourTheSubscriptionFacilityMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/30/2022 | 2/23/2023 2022-12-31 0001832148 Warrants | Vapotherm Inc. | Health Care Equipment & Supplies | 2/18/2022 2022-12-31 0001832148 Warrants | Spectrum Pharmaceuticals Inc. | Biotechnology | 9/21/2022 2022-12-31 0001832148 Warrants | Meditrina Inc. | Health Care Equipment & Supplies | 12/20/2022 2022-12-31 0001832148 Total Investments 2022-12-31 0001832148 Total Warrant 2022-12-31 0001832148 Bank Debt/Senior Secured Loans 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001832148 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001832148 cik0001832148:BridgebioPharmaIncMember 2022-12-31 0001832148 cik0001832148:VapothermInc.Member 2022-12-31 0001832148 cik0001832148:BiotechnologyMember 2022-12-31 0001832148 cik0001832148:PharmaceuticalsMember 2022-12-31 0001832148 cik0001832148:HealthCareTechnologyMember 2022-12-31 0001832148 cik0001832148:LifeSciencesToolsServicesMember 2022-12-31 0001832148 cik0001832148:HealthCareEquipmentSuppliesMember 2022-12-31 0001832148 cik0001832148:HealthCareProvidersServicesMember 2022-12-31 0001832148 cik0001832148:SpvFacilityMember 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Retina Midco, Inc | Health Care Providers & Services | S+ 575 |1.00% | 11.38% | 12/18/2023 | 1/31/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | UVP Management LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.79% | 9/18/2023 | 9/15/2025 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Urology Management Holdings Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.93% | 2/7/2023 | 6/15/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | United Digestive MSO Parent LLC | Health Care Providers & Services | S+ 675 |1.00% | 12.29% | 3/30/2023 | 3/30/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | WCI-BXC Purchaser, LLC | Distributors | S+ 625 |1.00% | 11.64% | 11/6/2023 | 11/6/2030 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vertos Medical Inc | Health Care Equipment & Supplies | S+515 | 4.75% | 10.48% | 6/14/2023 | 7/1/2028 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco LLC | Health Care Providers & Services | S+ 650 | 1.00% | 11.63% | 1/4/2023|1/3/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Exactcare Parent, Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.89% | 11/3/2023 | 11/5/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | CVAUSA Management LLC | Health Care Providers & Services | S+ 550 | 1.00% | 11.74% | 5/22/2023 | 5/22/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | ONS MSO LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.62%| 2/10/2023 | 7/8/2025 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | OIS Management Services, LLC | Health Care Providers & Services | S+ 575 |1.00% | 11.20% | 12/29/2023 | 11/16/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Medrina, LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.67% | 10/20/2023 | 10/20/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Maxor Acquisition Inc | Health Care Providers & Services | S+ 675 |1.00% | 12.48%| 3/1/2023 | 3/1/2029 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2023-12-31 0001832148 cik0001832148:CvausaManagementLlcMember 2023-12-31 0001832148 cik0001832148:UvpManagementLlcMember 2023-12-31 0001832148 cik0001832148:UrologyManagementHoldingsInc.Member 2023-12-31 0001832148 cik0001832148:ExactcareParentInc.Member 2023-12-31 0001832148 cik0001832148:RetinaMidcoInc.Member 2023-12-31 0001832148 cik0001832148:OisManagementServicesLlcMember 2023-12-31 0001832148 cik0001832148:MedrinaLlcMember 2023-12-31 0001832148 cik0001832148:VertosMedicalInc.Member 2023-12-31 0001832148 cik0001832148:UnitedDigestiveMsoParentLlcMember 2023-12-31 0001832148 cik0001832148:PlasticsManagementLlcMember 2023-12-31 0001832148 cik0001832148:ArcutisBiotherapeticsInc.Member 2023-12-31 0001832148 cik0001832148:GlookoInc.Member 2023-12-31 0001832148 cik0001832148:SunmedGroupHoldingsLlcMember 2023-12-31 0001832148 cik0001832148:BaymarkHealthServicesInc.Member 2023-12-31 0001832148 cik0001832148:IvyFertilityServicesLlcMember 2023-12-31 0001832148 cik0001832148:ArdelyxInc.Member 2023-12-31 0001832148 cik0001832148:SouthernOrthodonicPartnersManagementLlcMember 2023-12-31 0001832148 cik0001832148:OrthopedicCarePartnersManagementLlcMember 2023-12-31 0001832148 cik0001832148:MeditrinaIncMember 2023-12-31 0001832148 cik0001832148:SpectrumPharmaceuticalsIncMember 2023-12-31 0001832148 cik0001832148:PediatricHomeRespiratoryServicesLlcMember 2023-12-31 0001832148 cik0001832148:CerapedicsIncMember 2023-12-31 0001832148 cik0001832148:AahTopcoLlcMember 2023-12-31 0001832148 cik0001832148:OutsetMedicalIncMember 2023-12-31 0001832148 cik0001832148:ScpEyeCareLlcMember 2023-12-31 0001832148 cik0001832148:OralSurgeryPartnersHoldingsLlcMember 2023-12-31 0001832148 cik0001832148:WcibxcPurchaserLlcMember 2023-12-31 0001832148 cik0001832148:ApeelTechnologyInc.Member 2023-12-31 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member 2023-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2023-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueMarchTwoThousandAndTwentyFourTheSubscriptionFacilityMember 2023-12-31 0001832148 cik0001832148:RevolvingCreditFacilityDueFebruaryTwoThousandAndTwentySevenTheSpvFacilityMember 2023-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001832148 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001832148 cik0001832148:InitialUnitholderMember 2023-12-31 0001832148 srt:MinimumMember 2023-12-31 0001832148 srt:MaximumMember 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2023-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/29/2023 | 2/27/2024 2023-12-31 0001832148 Warrants | Vertos Medical, Inc. | Health Care Equipment & Supplies | 6/14/2023 2023-12-31 0001832148 Warrants | Vapotherm Inc. | Health Care Equipment & Supplies | 2/18/2022 2023-12-31 0001832148 Warrants | Meditrina Inc. | Health Care Equipment & Supplies | 12/20/2022 2023-12-31 0001832148 Common Equity/Warrants | Assertio Holdings Inc Common Stock | Pharmaceuticals | 7/31/2023 2023-12-31 0001832148 Bank Debt/Senior Secured Loans 2023-12-31 0001832148 Total Warrant 2023-12-31 0001832148 Total Investments 2023-12-31 0001832148 srt:MinimumMember cik0001832148:FirstLienLifeScienceLoansMember 2023-12-31 0001832148 srt:MaximumMember cik0001832148:FirstLienLifeScienceLoansMember 2023-12-31 0001832148 srt:MaximumMember cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-12-31 0001832148 srt:MinimumMember cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-12-31 0001832148 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-12-31 0001832148 cik0001832148:VapothermInc.Member 2023-12-31 0001832148 cik0001832148:BridgebioPharmaIncMember 2023-12-31 0001832148 cik0001832148:HealthCareProvidersServicesMember 2023-12-31 0001832148 cik0001832148:PharmaceuticalsMember 2023-12-31 0001832148 cik0001832148:BiotechnologyMember 2023-12-31 0001832148 cik0001832148:HealthCareTechnologyMember 2023-12-31 0001832148 cik0001832148:LifeSciencesToolsServicesMember 2023-12-31 0001832148 cik0001832148:HealthCareEquipmentSuppliesMember 2023-12-31 0001832148 cik0001832148:DistributorsMember 2023-12-31 0001832148 cik0001832148:InvestmentModificationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:CompetitionPotentialForInsufficientInvestmentOpportunitiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RecourseToTheCompanysAssetsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LeveragedCompaniesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PortfolioTurnoverMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToTheRussianInvasionOfUkraineMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AssetsBelievedToBeUndervaluedOrIncorrectlyValuedMember 2023-01-01 2023-12-31 0001832148 cik0001832148:NoAssuranceOfCashDistributionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AdverseConsequencesOfDefaultMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DistributionsInKindMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ThirdpartyInvolvementMember 2023-01-01 2023-12-31 0001832148 cik0001832148:U.s.DollarDenominationOfUnitsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ForwardLookingStatementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ReferralRelationshipsWithFinancialSponsorsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulationsOfHealthcareIndustryMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LitigationAndRelatedRisksAssociatedWithOriginationAndServicingMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AbilityToOriginateLoansOnAdvantageousTermsCompetitionAndSupplyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DefaultsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ConcentrationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SectorRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsInHealthcareCompaniesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:HealthcareAndLifeScienceIndustriesRelatedRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubordinatedLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ReportingCompanyFilingRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LicensingRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:OtherRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:WarrantsAndRightsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatingToReferenceRatesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ManagementRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:HighYieldDebtAndUnratedSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:EquityrelatedSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksAssociatedWithBankruptcyAndInsolvencyCasesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:CollateralRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatingToBankLoansAndCorporateLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MezzanineSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UnsecuredLoansOrDebtMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PrepaymentRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksInherentInHealthcarerelatedAssetsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FinancialFraudMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InterestRateRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LiquidityRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InflationdeflationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:HedgingTransactionsAndRelatedRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ForwardsAndDerivativesTransactionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MarketRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToTheU.s.DebtCeilingMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ConvertibleSecuritiesRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DocumentationRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToEconomicRecessionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PreferredSecuritiesRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulatoryRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToPortfolioInvestmentMonitoringAndInvolvementMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MoneyMarketAndOtherLiquidInstrumentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ZerocouponBondsDeferredInterestRateBondsAndPaymentinkindSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:GeneralEconomicAndMarketRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ManagementRiskAndRelianceOnManagementMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsInSmallerAndMiddleMarketCompaniesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:GeneralLeverageRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:NoMarketForUnitsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PublicHealthCrisesRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DueDiligenceRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:OfacFcpaAndRelatedConsiderationsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatingToWaiversOrDeferralsOfCovenantsAndCovenantliteLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:GeneralCreditRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RiskOfLossMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InsufficientCapitalForFollowonInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PortfolioInvestmentRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FraudulentConveyanceAndPreferenceConsiderationsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RestrictedSecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToDispositionOfInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LenderLiabilityConsiderationsAndEquitableSubordinationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PooledInvestmentVehiclesAndPassthroughEntitiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:U.s.GovernmentAndAgencySecuritiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:LackOfControlOverInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ControlPositionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToElectronicCommunicationscybersecurityRiskMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ProjectionsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ConcentrationOfPortfolioInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulatoryInvestigationsOrThirdpartyLitigationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:BroadIndemnificationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ModelRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ValuationOfIlliquidAssetsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UnspecifiedUseOfProceedsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:IdentificationOfPotentialInvestmentOpportunitiesMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FinancialServicesIndustryRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:MachineLearningTechnologyRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:CorporateSocialResponsibilityRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FailureToQualifyAsARicMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ClimateChangeRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RecognizingIncomeBeforeOrWithoutReceivingCashMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TaxConsiderationsRegardingDividendsForPrivateBdcsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TechnologicalInnovationRisksMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ChangesInTaxLawMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InkindDividendConsiderationsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PotentialDividendDeferralsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ChangesToDerivativesRegulationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UncertaintyOfTheU.s.PoliticalClimateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:U.s.DoddfrankWallStreetReformAndConsumerProtectionActMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FinancialServicesAndGovernmentInterventionMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RisksRelatedToChangesInRegulatoryPolicyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:RegulatoryRisksRelatingToTheCompanyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DistributionAndAssetCoverageRatioRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PermissibleIncurredLeverageMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ChangesToAccountingStandardsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:ExemptiveReliefMember 2023-01-01 2023-12-31 0001832148 cik0001832148:QualifyingAssetRequirementsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:UnrealizedDepreciationMember 2023-01-01 2023-12-31 0001832148 cik0001832148:DocumentationOfInternalControlsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsAndCashEquivalentsMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember 2023-01-01 2023-12-31 0001832148 cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember 2023-01-01 2023-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TypeOfAgreementFirstMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TypeOfAgreementSecondMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:TypeOfAgreementSecondMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:TypeOfAgreementFourthMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:TypeOfAgreementFourthMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PreExchangeListingIncentiveFeeMember cik0001832148:TypeOfAgreementFourthMember 2023-01-01 2023-12-31 0001832148 cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:TypeOfAgreementSecondMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 cik0001832148:PreExchangeListingIncentiveFeeMember cik0001832148:TypeOfAgreementThirdMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AnnuallyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:QuarterlyMember 2023-01-01 2023-12-31 0001832148 cik0001832148:AdviserMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:EbitdaConcentrationRiskMember cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:EbitdaConcentrationRiskMember cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-01-01 2023-12-31 0001832148 cik0001832148:FirstLienLifeScienceLoansMember 2023-01-01 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-01-01 2023-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:FirstLienLifeScienceLoansMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:FirstLienHealthCareCashFlowLoansMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember cik0001832148:FirstLienLifeScienceLoansMember 2023-01-01 2023-12-31 0001832148 srt:MaximumMember 2023-01-01 2023-12-31 0001832148 srt:MinimumMember 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | United Digestive MSO Parent LLC | Health Care Providers & Services | S+ 675 |1.00% | 12.29% | 3/30/2023 | 3/30/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | WCI-BXC Purchaser, LLC | Distributors | S+ 625 |1.00% | 11.64% | 11/6/2023 | 11/6/2030 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | CVAUSA Management LLC | Health Care Providers & Services | S+ 550 | 1.00% | 11.74% | 5/22/2023 | 5/22/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Exactcare Parent, Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.89% | 11/3/2023 | 11/5/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco LLC | Health Care Providers & Services | S+ 650 | 1.00% | 11.63% | 1/4/2023|1/3/2029 2023-01-01 2023-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/29/2023 | 2/27/2024 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vertos Medical Inc | Health Care Equipment & Supplies | S+515 | 4.75% | 10.48% | 6/14/2023 | 7/1/2028 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | UVP Management LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.79% | 9/18/2023 | 9/15/2025 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Urology Management Holdings Inc | Health Care Providers & Services | S+ 650 |1.00% | 11.93% | 2/7/2023 | 6/15/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Maxor Acquisition Inc | Health Care Providers & Services | S+ 675 |1.00% | 12.48%| 3/1/2023 | 3/1/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Medrina, LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.67% | 10/20/2023 | 10/20/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | OIS Management Services, LLC | Health Care Providers & Services | S+ 575 |1.00% | 11.20% | 12/29/2023 | 11/16/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | ONS MSO LLC | Health Care Providers & Services | S+ 625 |1.00% | 11.62%| 2/10/2023 | 7/8/2025 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Retina Midco, Inc | Health Care Providers & Services | S+ 575 |1.00% | 11.38% | 12/18/2023 | 1/31/2026 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2023-01-01 2023-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2023-01-01 2023-12-31 0001832148 cik0001832148:InvestmentsAndCashEquivalentsMember 2021-01-05 2021-12-31 0001832148 us-gaap:InvestmentsMember 2021-01-05 2021-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2021-01-05 2021-12-31 0001832148 cik0001832148:InvestmentsAndCashEquivalentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember 2022-01-01 2022-12-31 0001832148 cik0001832148:NonControlledNonAffiliatedInvestmentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:UnrealizedGainLossOnInvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:RealizedInvestmentGainsLossesMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-01-01 2022-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cik0001832148:BankDebtSeniorSecuredLoansMember cik0001832148:MeasurementInputmarketyieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-01-01 2022-12-31 0001832148 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Apeel Technology Inc. | Biotechnology | S+625 | 1.00% | 8.75% | 6/29/2022 | 6/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics Inc | Pharmaceuticals | S+ 745 | 0.10% | 12.88% | 12/22/2021 | 1/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ardelyx Inc. | Health Care Pharmaceuticals | L+795 | 0.10% | 12.12% | 2/23/2022 | 3/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Oral Surgery Partners Holdings LLC | Health Care Providers & Services | S+625| 1.00% | 10.92% | 11/29/2022 | 5/10/2024 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management LLC | Health Care Providers & Services | S+650 | 1.00% | 10.91% | 8/17/2022 | 5/16/2024 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Outset Medical Inc. | Health Care Equipment & Supplies | S+515 | 2.75% | 9.33% | 11/3/2022 | 11/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Pediatric Home Respiratory Services LLC | Health Care Providers & Services | S+625 | 1.00% | 10.67% | 8/19/2022 |12/4/2024 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Plastics Management LLC | Health Care Providers & Services | S+500 | 1.00% | 9.89% | 8/26/2021 | 8/18/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 10.59% | 8/20/2021 | 8/12/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BayMark Health Services Inc. | Health Care Providers & Services | L+500 | 1.00% | 9.73 | 6/29/2021 | 6/11/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | BridgeBio Pharma Inc. | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Glooko Inc. | Health Care Technology | L+790 | 0.10% | 12.07% | 9/30/2021 | 10/1/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Ivy Fertility Services LLC | Health Care Providers & Services | L+625 | 1.00% | 10.39% | 12/22/2021 | 2/25/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Meditrina Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 9.82% | 12/20/202 | 12/1/2027 2022-01-01 2022-12-31 0001832148 Cash Equivalents | US Treasury Bill | Government | 12/30/2022 | 2/23/2023 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SCP Eye Care LLC | Health Care Providers & Services | S+575 |1.00% | 9.46% | 10/6/2022 | 10/5/2029 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management LLC | Health Care Providers & Services | S+600 | 1.00% | 10.77% | 6/3/2022 | 1/27/2026 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Spectrum Pharmaceuticals Inc. | Biotechnology | S+570 | 2.30% | 9.88% | 9/21/2022 | 9/1/2027 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | SunMed Group Holdings LLC | Health Care Equipment & Supplies | L+575 | 0.75% | 10.48% | 6/16/2021 | 6/16/2028 2022-01-01 2022-12-31 0001832148 Bank Debt/Senior Secured Loans | Vapotherm Inc. | Health Care Equipment & Supplies | S+830 | 1.00% | 12.58% | 2/18/2022 | 2/1/2027 2022-01-01 2022-12-31 0001832148 cik0001832148:InitialUnitholderMember 2021-01-05 2021-01-05 0001832148 cik0001832148:InitialUnitholderMember 2021-01-05 0001832148 cik0001832148:InitialUnitholderMember 2021-03-08 2021-03-08 0001832148 cik0001832148:InitialUnitholderMember 2021-03-08 0001832148 cik0001832148:SubscriptionFacilityMember cik0001832148:IngCapitalLlcMember 2021-03-19 0001832148 srt:MaximumMember cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member 2022-02-18 0001832148 srt:MinimumMember cik0001832148:SpvFacilityMember cik0001832148:JpmorganChaseBankN.a.Member 2022-02-18 0001832148 srt:MaximumMember cik0001832148:SpvFacilityMember us-gaap:SubsequentEventMember 2024-01-23 0001832148 srt:MinimumMember cik0001832148:SpvFacilityMember us-gaap:SubsequentEventMember 2024-01-23 0001832148 us-gaap:InvestmentsMember 2022-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2022-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2023-12-31 0001832148 us-gaap:InvestmentsMember 2023-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2023-12-31 0001832148 us-gaap:InvestmentsMember 2021-12-31 0001832148 us-gaap:InvestmentsMember us-gaap:WarrantMember 2021-12-31 0001832148 us-gaap:InvestmentsMember cik0001832148:BankDebtSeniorSecuredLoansMember 2021-12-31 iso4217:USD pure shares utr:Year iso4217:USD shares false FY 0001832148 NY P5Y P4Y two years 10-K true 2023-12-31 --12-31 2023 false 000-56247 SLR HC BDC LLC DE 85-1801692 500 Park Avenue New York 10022 212 993-1670 No No Yes Yes Non-accelerated Filer false true false false false false 0 1069642 185 KPMG LLP New York, NY <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Summary Risk Factors </div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">General Risks Related to Investment Strategy </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company intends to make investments in the healthcare and life science industries, which involve substantial risks. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Various segments of the life sciences industry are (or may become) (i) highly regulated, (ii) subject to frequent regulatory change and (iii) dependent upon various government or private insurance reimbursement programs. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated with investments in senior secured loans, subordinated loans, Mezzanine Securities (as defined below) and unsecured loans. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company’s loans may permit borrowers to prepay, which could affect the yield of the Company’s investments. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Terms and conditions of the Company’s loan agreements may be amended, modified or waived only by the agreement of the lenders. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company may make investments in loans, or securities backed by loans, that are or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">may be non-performing loans.</div> </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company’s success will depend, in part, on originating loans on advantageous terms. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Bank loans and corporate loans may not be readily marketable and may be subject to restrictions on resale. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Periods of market volatility have occurred and could continue to occur in response to pandemics or other events. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Adviser will rely on information provided by internal sources and third parties when conducting due diligence. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Fixed and floating rate debt instruments are subject to the risks associated with change in interest rates. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated with investments in smaller and middle market companies. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Most of the Company’s Portfolio Investments at any given time are expected to be illiquid. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company is subject to risks related to inflation and deflation. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Economic sanction laws may prohibit investments in certain countries and with certain individuals and companies. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company may choose to waive or defer enforcement of covenants in the debt securities held in its portfolio, which may cause the Company to lose all or part of its investment in these companies. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">General Risks Related to the Company </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">There can be no guarantee of returns and Unitholders may lose all of their money by investing in the Company. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company is subject to management risk because the Adviser actively manages its investment portfolio. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company’s assets are available to satisfy all liabilities and other obligations of the Company. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">There is no assurance that the Adviser’s analysis of potential investments will take into consideration all appropriate factors. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be substantially adversely affected by the unfavorable performance of any single investment. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company will include in its income certain amounts that the Company has not yet received in cash. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">It is expected that the majority of the Company’s investments will not have market quotations available. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Securities that the Adviser believes are not valued correctly may not ultimately be valued as projected. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Adviser may employ financial/analytical models that may not reflect actual results. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company and the Adviser may be subject to the risks and costs of regulatory investigations or becoming involved in litigation with third parties. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company and/or the Adviser may enter into various indemnification agreements or arrangements with third parties. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks related to the Russian invasion of Ukraine. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Unitholders could be subject to cybersecurity risks associated with electronic databases and communications. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Adverse developments affecting the financial services industry could have a material adverse effect on the Company, the Adviser and the Portfolio Investments. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company is subject to technological risks, including those associated with artificial intelligence and machine learning technology. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company is subject to risks associated with ESG (as defined below) initiatives and climate change. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company is subject to risks associated with U.S. government shutdowns, uncertainty over the U.S. debt ceiling and any related downgrades in the U.S.’s credit ratings. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to RICs and BDCs </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">No assurance can be given that the Company will be able to maintain qualification as a RIC. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Unitholders will experience the increased risks pertaining to the Company’s use of leverage to partially finance its investments. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">A BDC must carry investments at market value or at fair value, as determined in good faith by the Board. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">At least 70% of a BDC’s assets must consist of “qualifying assets”. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Risks Relating to the Company </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company and its affiliates are substantially limited in their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ability to co-invest in</div> privately negotiated transactions. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be precluded from conducting Rule 506 Offerings (as defined below) due to “Bad Actor” restrictions. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated with complying with the Sarbanes-Oxley Act (as defined below). </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Other Risks Related to Portfolio Investments </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated with investments in high yield securities, corporate debt securities, convertible securities, preferred stock, reverse repurchase agreements, and distressed companies. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated with the use of warrants and rights. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated with the elimination of LIBOR and use of SOFR. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated with the effect of an economic slowdown on Portfolio Investments. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company could be subject to the risks associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">with investments in zero-coupon bonds, deferred</div> interest rate bonds and PIKs. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, initial public offerings, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized. </div></td></tr></table><div id="tx774279_2" style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Item 1A. Risk Factors. </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase of Units involves a number of significant risks and other important factors relating to investments in BDCs generally, and relating to the strategy and investment objective of the Company in particular. An investment in the Company is a potentially suitable investment only for a sophisticated investor for whom such an investment does not represent a complete investment program and who, in consultation with its investment and tax advisors, fully understands and is capable of assuming the risks of an investment in the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company holds certain investments and conducts certain activities through investing in wholly-owned SPVs. All references to investments by the Company in this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K refer,</div> as the context requires, to investments by either the Company or those SPVs. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company will achieve its investment objective, that the Company will not lose capital, that the Adviser’s judgment will result in profitable investments by the Company or that the Adviser will successfully be able to implement the Company’s investment strategy. An investment in the Company involves investment considerations and risk factors that prospective investors should consider before subscribing. No guarantee or representation is made that the Company’s investments will succeed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the characteristics and risks of the portfolio instruments and investment, hedging, financing and disposition techniques that the Adviser may utilize in managing the Company are set forth below. This is not intended to be a complete description or enumeration of portfolio instruments, investment, hedging, financing or disposition techniques or risks. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s ability to achieve its investment objective may be affected by, among other things, the factors described below. The Company may also invest in instruments or engage in investment, hedging, financing or disposition techniques other than those described below, including instruments or investment, hedging, financing or disposition techniques that are not in existence as of the date of this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K. Consistent</div> with its investment strategy, the Company may invest in instruments and engage in investment, hedging, financing or disposition techniques of any and all types, which exist now or are hereafter created. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion below, to the extent it relates to bankruptcy law or proceedings or to debtors’ and creditors’ rights, is based upon principles of U.S. federal and state laws. Insofar as the Portfolio Investments, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">include obligations of non-U.S. issuers, or</div> bankruptcy, reorganization or similar proceedings in a country other than the U.S., the laws of such other countries, and the rights and obligations of debtors and creditors in such other countries, under factual circumstances similar to those described below, may or may not be analogous to those described below. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">General Risks Related to Investment Strategy </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare and Life Science Industries’ Related Risks</div>. The Company intends to make investments in the healthcare and life science industries, although the Company may also opportunistically invest in other sectors in order to accomplish its investment objective. Investing in healthcare companies involves substantial risks. Such risks include, but are not limited to, the following: changes in government policies, including policies regarding reimbursement of medical expenses; certain companies in which the Company may invest may have limited or no operating histories/ or may have limited products, markets and financial resources; rapidly changing technologies may cause products to quickly become obsolete; unanticipated problems often arise in connection with the development of new products, and many such efforts are ultimately unsuccessful; scarcity of management and marketing personnel with appropriate technological or medical training may slow or impede companies’ growth; the possibility of lawsuits related to technological and medical patents could cause delays and expense in product development and implementation; regulatory changes and/or government actions may prevent a company from marketing its products; changing investors’ sentiments and preferences with regard to investments in healthcare companies (which may be perceived as risky) may have an adverse effect on the price of underlying securities; volatility in the U.S. stock markets affecting the prices of securities of healthcare and life sciences companies may cause the Company to experience substantial volatility; and certain healthcare and life sciences companies may be subject to extensive government regulation and affected by government reimbursement policy changes. In addition, many healthcare and life sciences companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or even under normal market conditions or such capital may be obtained on terms that are not favorable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, obtaining government approval for new products from governmental agencies can be lengthy, expensive and uncertain, and withdrawal or curtailment of government support could have an adverse impact on the profitability or market price of healthcare and life sciences companies. Furthermore, delays in generating products (as well as more general ongoing capital requirements) may result in the need for companies to seek additional capital, potentially diluting the interest of existing investors, such as the Company (and indirectly, the Unitholders). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investments in Healthcare Companies</div>. The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally. The Company’s investment strategy is subject to numerous and significant risks and uncertainties, some of which are highlighted generally below. The following is general information and does not purport to describe all risks associated with investing in the healthcare industry.</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sector Risk. </div></div>Sector risk is the risk associated with a Company holding a significant amount of investments in similar businesses, which would be similarly affected by particular economic or market events, which may, in certain circumstances, cause the value of the equity and debt securities of companies in a particular sector of the market to change. To the extent a Company has substantial holdings within a particular sector, the risks to a Company associated with that sector increase. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration Risk. </div></div>The Company’s principal focus is to invest in the healthcare and life sciences industry. The focus of the Company’s portfolio on a specific industry may present more risks than if its portfolio were broadly diversified over numerous industries and sectors of the economy. A downturn in this industry would have a larger impact on the Company than on an investment company that does not concentrate in such industry. At times, the performance of securities of companies in the healthcare industry will lag the performance of other industries or the broader market as a whole. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While investment in multiple opportunities may provide some diversification of investment risk, no assurance can be given that such diversification will occur, or if it does, that it will not reduce, rather than increase, potential net profits. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Inherent in Healthcare-Related Assets. </div></div>Substantially all of the Company’s investments will be in the healthcare industry. Concentration in one industry involves significant risks greater than those generally associated with diversified acquisition funds, including significant fluctuations in returns. The healthcare industry is challenged by factors such as government regulations; changes in government policies, including policies regarding reimbursement of medical expenses and policies that impact company’s abilities to market products; changes in technology, including changes that may cause products to quickly become obsolete; medical innovations and accompanied unanticipated problems; changes in healthcare practices or delivery systems; scarcity of management and marketing personnel with appropriate technological or medical training; possibilities of lawsuits related to technological and medical patents, and resulting delays and expenses in product development and implementation; changing macroeconomic conditions in the U.S. and globally, intense competition, susceptibility to natural disasters, large capital requirements and the introduction of new, competing healthcare facilities, properties or other leisure activities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companies in the healthcare sector are subject to extensive government regulation and their profitability can be significantly affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure (including price discounting), limited product lines and an increased emphasis on the delivery of healthcare through outpatient services. Companies in the healthcare sector are heavily dependent on obtaining and defending patents, which may be time consuming and costly, and the expiration of patents may also adversely affect the profitability of these companies. Healthcare companies are also subject to extensive litigation based on product liability and similar claims. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the healthcare sector require significant research and development and may be subject to regulatory approvals, all of which may be time consuming and costly with no guarantee that any product will come to market. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s assets will compete in a relatively uncertain political, economic, and regulatory environment, and instability or an overall decline within the healthcare sector will not be balanced by investments in industries not so affected. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, many healthcare companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or such capital may be obtained on terms that are not favorable to existing investors. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations of Healthcare Industry. </div></div>The regulatory environment surrounding the healthcare industry has intensified both in the amount and type of regulations and in the efforts to enforce those regulations. The extensive federal, state, and local, laws and regulations affecting the healthcare industry include, but are not limited to, laws and regulations relating to licensure, certification as a Medicare and Medicaid provider, conduct of operations, ownership of facilities, addition of facilities and equipment, allowable costs, services, prices for services, quality of care, patient rights, patient abuse and neglect, fraudulent reimbursement practices, and financial and other arrangements which may be entered into by healthcare providers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Federal and state governments have intensified enforcement policies, resulting in a significant increase in the number of inspections, citations of regulatory deficiencies and other regulatory sanctions, including terminations from the Medicare and Medicaid programs, bans on Medicare and Medicaid payments for new admissions, civil monetary penalties and even criminal penalties. The Company’s investments could be forced to expend considerable resources on responding to an investigation or other enforcement action under applicable laws or regulations, The Company is unable to predict the future course of federal, state and local regulation or legislation, including the Medicare and Medicaid statutes and regulations. Changes in regulatory framework could have a material adverse effect on the Company’s Portfolio Investments and the Company. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Senior Secured Loans</div>. With respect to the Company’s investments in senior secured loans (including first lien loans), the Company will generally have a security interest in assets of the company, which should mitigate the risk that the Company will not be repaid. However, the collateral securing the Company’s loans may decrease in value over time, may be difficult to sell in a timely manner, may be difficult to appraise, and may fluctuate in value based upon the success of the business and market conditions, including as a result of the inability of the company to raise additional capital. In some circumstances, the Company’s lien could be subordinated to claims of other creditors. In addition, deterioration in a company’s financial condition and prospects, including its inability to raise additional capital, may be accompanied by deterioration in the value of the collateral for the loan. Consequently, the fact that a loan is secured does not guarantee that the Company will receive principal and interest payments according to the loan’s terms, or at all, or that the Company will be able to collect on the loan should it be forced to enforce its remedies. Furthermore, if a secured loan is foreclosed, the Company could own the underlying collateral (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, real estate), and would be subject to the risks, costs and liabilities associated with owning and disposing of the collateral. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Subordinated Loans</div>. The Company may invest in subordinated loans. In the event of a loss of value of the underlying assets that collateralize the loans, the subordinate portions of the loans may suffer a loss prior to the more senior portions suffering a loss. If a borrower defaults and lacks sufficient assets to satisfy the Company’s loan, the Company may suffer a loss of principal or interest. If a borrower declares bankruptcy, the Company may not have full recourse to the assets of the borrower, or the assets of the borrower may not be sufficient to satisfy the loan. In addition, certain of the Company’s loans may be subordinate to other debt of the borrower. As a result, if a borrower defaults on the Company’s loan or on debt senior to the Company’s loan, or in the event of the bankruptcy of a borrower, the Company’s loan will be satisfied only after all senior debt is paid in full. The Company’s ability to amend the terms of the Company’s loans, assign the Company’s loans, accept prepayments, exercise the Company’s remedies (through “standstill periods”) and control decisions made in bankruptcy proceedings relating to borrowers may be limited by intercreditor arrangements if debt senior to the Company’s loans exists. In addition, the Company will be subject to the potential risks of foreclosure and ownership of underlying collateral described in “<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">—Senior Secured Loans</div></div>” above. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mezzanine Securities</div>. The Company may invest in unsecured securities that are senior to common stock or other equity securities (“Mezzanine Securities”). Mezzanine Securities are subordinated to substantial amounts of senior debt, all or a portion of which may be secured. As a result, holders of Mezzanine Securities are generally not entitled to receive any payments in bankruptcy or liquidation until senior creditors are paid in full. In addition, the legal remedies available to holders of Mezzanine Securities are normally limited by restrictions benefiting senior creditors. In the event a company in which the Company holds Mezzanine Securities cannot generate adequate cash flow to meet senior debt service, the Company may suffer a partial or total loss of capital invested. Because issuers of Mezzanine Securities are often highly leveraged, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">their relatively high debt-to-equity ratios create</div></div> increased risks that their operations will not be able to generate adequate cash flow to meet senior debt service. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unsecured Loans or Debt</div>. The Company may invest in unsecured loans which are not secured by collateral. In the event of default on an unsecured loan, the first priority lien holder has first claim to the underlying collateral of the loan. It is possible that no collateral value would remain for an unsecured holder and therefore result in a loss of investment to the Company. Because unsecured loans are lower in priority of payment to secured loans, they are subject to the additional risk that the cash flow of the borrower may be insufficient to meet scheduled payments after giving effect to the secured obligations of the borrower. Unsecured loans generally have greater price volatility than secured loans and may be less liquid. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Prepayment Risk</div>. The terms of loans in which the Company invests may permit borrowers to voluntarily prepay loans at any time, <div style="display:inline;">either </div>with no or a nominal prepayment premium. This prepayment right could result in the borrower repaying the principal on an obligation held by the Company earlier than expected. This may happen when there is a decline in interest rates or when the borrower’s improved credit or operating or financial performance allows the refinancing of certain classes of debt with lower cost debt. The yield of the Company’s investment assets may be affected by the rate of prepayments differing from the Adviser’s expectations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investment Modification Risk</div>. The terms and conditions of loan agreements and related assignments may be amended, modified or waived only by the agreement of the lenders. Generally, any such agreement must include a majority or a super majority (measured by outstanding loans or commitments) or, in certain circumstances, a unanimous vote of the lenders. Consequently, the terms and conditions of the payment obligation arising from Portfolio Investments could be modified, amended or waived in a manner contrary to the preferences of the Company if a sufficient number of the other lenders concurred with such modification, amendment or waiver. There can be no assurance that any obligations arising from a Portfolio Investment will maintain the terms and conditions to which the Company originally agreed. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Collateral Risk</div>. The collateral and security arrangements in relation to such secured obligations as the Company may invest in will be subject to such security or collateral having been correctly created and perfected and any applicable legal or regulatory requirements which may restrict the giving of collateral or security by an obligor, such as, for example, thin capitalization, over-indebtedness, financial assistance and corporate benefit requirements. If one or more Portfolio Investments do not benefit from the expected collateral or security arrangements, this may adversely affect the value of or, in the event of default, the recovery of principal or interest from such Portfolio Investments made by the Company. Accordingly, any such failure to properly create or perfect collateral and security interests attaching to the Portfolio Investments could have a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units. A component of the Adviser’s analysis of the desirability of making a given investment relates to the estimated residual or recovery value of such Portfolio Investments in the event of the insolvency of the obligor. This residual or recovery value will be driven primarily by the value of the anticipated future cash flows of the obligor’s business and by the value of any underlying assets constituting the collateral for such Portfolio Investment. The anticipated future cash flows of the obligor’s business and the value of collateral can, however, be extremely difficult to predict as in certain circumstances market quotations and third-party pricing information may not be available. If the recovery value of the collateral associated with the Portfolio Investments in which the Company invests decreases or is materially worse than expected by the Company, such a decrease or deficiency may affect the value of the Portfolio Investments made by the Company. Accordingly, there may be a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Defaults</div>. The Company may make investments in loans, or securities backed by loans, that may be at the time of their acquisition, or may become <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after acquisition, non-performing loans.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any default under a loan directly held by the Company or a loan underlying a security held by the Company, the Company will bear a risk of loss of principal to the extent of any deficiency between the value of the collateral and the principal and accrued interest of the loan, which could have a material adverse effect on the Company’s cash flow <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">from operations. Other non-performing loans may</div> require workout negotiations and/or restructuring, which may entail, among other things, a substantial reduction in the interest rate and/or a substantial write-down of the original principal amount of such loans. Further, even if a restructuring were successfully accomplished, unless the restructuring provided for full amortization on or prior to maturity and the borrower strictly complied with that restructuring, a risk exists that upon maturity of such loans, replacement financing will not be available and such loans may not be repaid. In the event of the bankruptcy of a borrower, the loan to that borrower will be deemed to be secured only to the extent of the value of the underlying collateral at the time of bankruptcy (as determined by the bankruptcy court), the lien securing the loan will be subject to the avoidance powers of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bankruptcy trustee or debtor-in-possession to the</div></div> extent the lien is unenforceable under state law, and realizing any value under such circumstances can be an expensive and lengthy process that could have a substantial negative effect on the anticipated return on the loan and on the security backed by such loan. Other risks attendant to a bankruptcy filing are described below. The foregoing statement does not apply in the context of a borrower insolvency case commenced under chapter 13 of the U.S. Bankruptcy Code where the underlying collateral is used as the principal residence of the borrower, but in such instances, the lender will nonetheless be stayed from the collection of its claim, taking possession of the collateral, and enforcing its lien unless and until the lender obtains relief from the automatic stay under the U.S. Bankruptcy Code. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Litigation and Related Risks Associated with Origination and Servicing</div>. Loan origination and servicing companies are routinely involved in legal proceedings concerning matters that arise in the ordinary course of their business. These legal proceedings range from actions involving a single plaintiff to class action lawsuits with potentially tens of thousands of class members. In addition, a number of participants in the loan origination and servicing industry (including control persons of industry participants) have been the subject of regulatory actions by state regulators, including state Attorneys General, and by the federal government. Governmental investigations, examinations or regulatory actions, or private lawsuits, including purported class action lawsuits, may adversely affect such companies’ financial results. To the extent the Company seeks to engage in origination and/or servicing directly, or has a financial interest in, or is otherwise affiliated with, an origination or servicing company, the Company will be subject to enhanced risks of litigation, regulatory actions and other proceedings. As a result, the Company may be required to pay legal fees, settlement costs, damages, penalties or other charges, any or all of which could materially adversely affect the Company and its investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Ability to Originate Loans on Advantageous Terms; Competition and Supply</div>. The Company’s success depends, in part, on the ability of the Company or its affiliates to originate loans on advantageous terms. In originating and purchasing loans, the Company or its affiliates will compete with a broad spectrum of lenders. Increased competition for, or a diminishment in the available supply of, qualifying loans could result in lower yields on such loans, which could reduce returns (if any) to investors. The Company intends to originate certain investments and later offer to syndicate all or a portion of one or more investments to certain other funds or accounts managed by the Adviser and its affiliates, in each case subject to their own investment-review <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">process, and to co-investors and/or third</div> parties. Prior to such syndication, or if such syndication is not successful, the Company’s exposure to the originated investment may exceed the exposure that the Company intends to have over the long-term or would have had if it had purchased such investment in the secondary market rather than originating it. Where </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">syndication is not successful, the Company may elect to sell all or a portion of an originated investment at a loss in order to rebalance the Company’s portfolio. The level of analytical sophistication, both financial and legal, necessary for successful financing to companies, particularly companies experiencing significant business and financial difficulties is unusually high. There is no assurance that the Adviser will correctly evaluate the value of the assets collateralizing the Company loans, the prospects for successful repayment or a successful reorganization or similar action. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Bank Loans and Corporate Loans</div>. Bank loans and corporate loans (which the Company will originate, invest in or otherwise gain exposure to) may not be readily marketable and may be subject to restrictions on resale. In some cases, negotiations involved in disposing of indebtedness may require weeks to complete. Consequently, some indebtedness may be difficult or impossible to dispose of readily at what the Adviser believes to be a fair price. In addition, bank loans and corporate loans are often less liquid than other types of debt securities, particularly in times of significant market dislocation. Loans to small and middle market entities (“SMEs”) may involve certain heightened risks. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investments in Smaller and Middle Market Companies</div>” below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of bank loans, corporate loans and other forms of direct indebtedness depend primarily upon the creditworthiness of the corporate or other borrower for payment of principal and interest. If the Company does not receive scheduled interest or principal payments on such indebtedness, the value of the Company’s investments could be adversely affected. The Company may invest in secured and unsecured bank loans and corporate loans. Bank loans and corporate loans that are fully secured may offer the Company more protection than an unsecured loan in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the event of non-payment of scheduled</div> interest or principal. However, there is no assurance that the liquidation of any collateral from a secured bank loan or corporate loan would satisfy the borrower’s obligation, or that such collateral could be liquidated. In the event of the bankruptcy of a borrower, the Company could experience delays or limitations in its ability to realize the benefits of any collateral securing a loan and could be compelled to accept new instruments or interests in respect of its claims under the bank loan in a plan of reorganization. These new instruments or interests may be on terms different from prevailing market terms for similar instruments and interests. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank loans usually require, in addition to scheduled payments of interest and principal, the prepayment of the bank loan from free cash flow. The degree to which borrowers prepay bank loans, whether as a contractual requirement or at their election, may be affected by general business conditions, the financial condition of the borrower and competitive conditions among lenders, among others. As such, prepayments cannot be predicted with accuracy. Upon a prepayment, either in part or in full, the actual outstanding debt on which the Company derives interest income will be reduced. The effect of prepayments on the Company’s performance may or may not be mitigated by the receipt of prepayment fees and/or the Company’s reinvestment of prepayments in other bank loans that have similar or identical yields. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may purchase “assignments” of bank loans from lenders. The purchaser of an assignment typically succeeds to all the rights and obligations under the loan agreement with the same rights and obligations as the assigning lender. Assignments may, however, be arranged through private negotiations between potential assignees and potential assignors, and the rights and obligations acquired by the purchaser of an assignment may differ from, and be more limited than, those held by the assigning lender. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may also invest in “participations” in bank loans. Participations by the Company in a lender’s portion of a bank loan typically will result in the Company having a contractual relationship only with such lender, not with the borrower. As a result, the Company may have the right to receive payments of principal, interest and any fees to which it is entitled only from the lender selling the participation and only upon receipt by </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such lender of such payments from the borrower. In connection with purchasing participations, the Company generally will have no right to enforce compliance by the borrower with the terms of the loan agreement, nor any rights with respect to any funds acquired by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other lenders through set-off against the</div> borrower, and the Company may not directly benefit from any collateral supporting the bank loan in which it has purchased the participation. As a result, the Company assumes the credit risk of both the borrower and the lender selling the participation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In many cases bank loans and loan participations would not be deemed to be securities for purposes of U.S. federal and/or state securities laws. As a result, an investment in bank loans would not be afforded the same protections as an investment in securities, such as the extensive disclosure requirements under U.S. federal and/or state securities laws, which may adversely impact the Company’s ability to seek recourse in respect of such investments. Similarly, the documentation evidencing bank loans and loan participations will not necessarily be maintained with the Company’s custodian. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Economic and Market Risk</div>. The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally, such as real or perceived adverse economic conditions, supply and demand for particular instruments, changes in the general outlook for certain markets or corporate earnings, interest rates, announcements of political information or adverse investor sentiment generally. The market values of the Company’s investments may decline for a number of reasons, including increases in defaults resulting from changes in overall economic conditions and widening of credit spreads. Unfavorable market conditions may also increase funding costs, limit access to the capital markets or result in credit terms changing or credit becoming unavailable. These events could have an adverse effect on the Company’s investments and the Company’s overall performance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may also contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide. Such events, including rising trade tensions between the United States and China, other uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies with other countries, the large-scale invasion of Ukraine by Russia that began in February 2022 and resulting sanctions or other restrictive actions that the United States and other countries have imposed against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Russia, the COVID-19 pandemic,</div> certain regional bank failures, an inflationary environment and the ongoing war in the Middle East, could adversely affect the Company’s business, financial condition or results of operations. These market and economic disruptions could negatively impact the operating results of the Company’s Portfolio Investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Federal Reserve raised the Federal Funds Rate in 2022 and in 2023. Although the Federal Reserve left its benchmark rates steady in the fourth quarter of 2023, it has indicated that additional rate increases in the future may be necessary to mitigate inflationary pressures and there can be no assurance that the Federal Reserve will not make upward adjustments to the federal funds rate in 2024. However, there are reports that the Federal Reserve may begin to cut the benchmark rates. These developments, along with the United States government’s credit and deficit concerns, global economic uncertainties and market volatility and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">impacts of COVID-19, could</div> cause interest rates to be volatile, which may negatively impact the Company’s ability to access the debt markets and capital markets on favorable terms. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Continuing market uncertainty may have a significant impact on the business of the Company. Among other things, the level of investment opportunities may decline from the Adviser’s current expectations. One possible consequence is that the Company may take a longer than anticipated period to invest capital and/or the Company may be relatively concentrated in a limited number of investments. Consequently, during this period, the returns (if any) realized by Unitholders may be substantially adversely affected by the unfavorable performance of a small number of these investments. Furthermore, market conditions may unfavorably impact the Company’s ability to secure leverage on terms as favorable as more established borrowers in the market, or to obtain any leverage on commercially favorable terms. To the extent the Company is able to secure financing for investments, increases in interest rates or in the risk spread demanded by financing sources would make the use of leverage more expensive and could limit the Company’s ability to structure and consummate its investments. Although the Adviser believes that recent market dislocations will result in attractive investment opportunities, the Company may not be able to time the acquisition or disposition of its investments correctly, which could result in further depreciation in values. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Public Health Crises Risk</div>. Periods of market volatility have occurred and could continue to occur in response to pandemics or other events outside of the Company’s control. These types of events have adversely affected and could continue to adversely affect operating results for the Company and for its Portfolio Investments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">example, the COVID-19 pandemic</div> has adversely impacted global commercial activity and contributed to significant volatility in the equity and debt markets. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and restrictive measures taken to contain or mitigate its spread have caused, and are continuing to cause, business shutdowns, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the re-introduction</div> of business shutdowns, cancellations of events and restrictions on travel, significant reductions in demand for certain goods and services, reductions in business activity and financial transactions, supply chain interruptions, labor shortages, increased inflationary pressure and overall economic and financial market instability both globally and in the United States. Many states, including those in which the Company and Portfolio Investments may operate, have issued orders requiring the closure of, or certain restrictions on the operation of, certain businesses. Such actions and effects remain ongoing and the ultimate duration and severity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19</div> pandemic, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">including COVID-19</div> variants, remain uncertain. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite actions of the U.S. federal government and foreign governments, the uncertainty surrounding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19</div> pandemic, including uncertainty regarding existing or future variants and other factors, has contributed to significant volatility in the global public equity markets and global debt capital markets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Credit Risk</div>. The Company is subject to significant credit risk (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i.e.</div></div>, the risk that an issuer or borrower will default in the payment of principal and/or interest on an instrument) in light of its investment strategy. Credit risk also includes the risk that a counterparty to a derivatives transaction (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, a swap counterparty) will be unwilling or unable to meet its obligations. Financial strength and solvency of an issuer or borrower are the primary factors influencing credit risk. In addition, degree of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">subordination, lack or inadequacy of collateral or credit enhancement for a debt instrument may affect its credit risk. The degree of credit risk associated with any particular Portfolio Investment or any collateral relating thereto may be difficult or impossible for the Adviser to determine within reasonable standards of predictability. The Adviser utilizes various third parties that hold Company assets (such as the Custodian and prime brokers) in implementing the Company’s investment strategy, and the Company will therefore also be subject to credit risk with respect to such entities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although most of the Company’s investments will not be rated by any credit rating agency, in some cases, the credit risk of some of the Company’s Portfolio Investments may be broadly gauged by the credit ratings of such Portfolio Investments. However, ratings are only the opinions of the agencies issuing them, may change less quickly than relevant circumstances, are not absolute guarantees of the quality of the rated securities and are subject to downgrade. Credit ratings and ratings agencies have recently been criticized for ratings which did not fully reflect the risks of certain securities or which did not reflect such risks in a timely manner. For most investments, however, the Adviser will rely on its own independent analysis of the credit quality and risks associated with individual securities considered for the Company, rather than relying on ratings agencies or third-party research. Therefore, the Adviser’s capabilities in analyzing credit quality and associated risks will be particularly important (especially since it is currently anticipated that most of the Company’s assets will not be rated by a ratings agency or will be rated below investment grade), and there can be no assurance that the Adviser will be successful in this regard. See also “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">High Yield Debt and Unrated Securities</div>” below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Leverage Risks</div>. The Company employs leverage and otherwise incurs indebtedness with respect to the portfolio both on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a recourse or non-recourse basis (including</div> through guarantees, derivatives, forward commitments and reverse repurchase agreements). The Company is not required to take any action (including unwinding or liquidating any position) in the event that such guideline is exceeded subsequent to the borrowing date, whether in the event of changes in the market value of the Company’s portfolio or otherwise. Prospective investors in the Company should expect that the effective leverage utilized by the Company may exceed such guideline, which only applies to direct borrowings; for instance, economic leverage inherent in the Company’s derivatives transactions and other investments will not be counted for purposes of such guideline, notwithstanding that such investments will be subject to many of the leverage-related risks described herein. In addition, determinations relating to leverage are inherently subjective and will involve the exercise of discretion by the Adviser (for instance, the Adviser may deem the amount of the Company’s direct borrowings to be reduced by cash and cash equivalents held by the Company or by a counterparty). See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Leveraged Companies</div>” below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of leverage has the potential to magnify the gains or the losses on investments and to make the Company’s returns more volatile. Moreover, if the Company is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">required to de-lever as</div> a result of changing market conditions or otherwise, it may be forced to sell Portfolio Investments at inopportune times or at disadvantageous prices. On the other hand, while the Company will have the flexibility to use leverage, there can be no guarantee that leverage can be obtained, or obtained on terms and pricing the Adviser finds attractive, especially in the current market environment. As a result, prospective investors in the Company should recognize that Portfolio Investments may not be leveraged, or may be leveraged at an amount below any leverage level otherwise expected by the Adviser. Moreover, even if leverage can be arranged, the Company is not obligated to utilize such leverage and may do so at the sole discretion of the Adviser. Should leverage not be obtained or utilized by the Company, the returns for the Company may be lower than they would have been had such leverage been obtained and utilized. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with any leverage utilized by the Company, the Company may secure its obligations with respect thereto with any and all of its assets, including its right to receive capital contributions from the Unitholders, pursuant to a pledge or other security agreement on terms that the Company determines are fair and reasonable to the Company. If the Company were to default on its obligations under such transactions, the counterparty could foreclose on the collateral and take possession of the Company’s assets and/or call capital from the Unitholders for purposes of repaying debt. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of any leverage utilized by the Company are likely to impose significant restrictions on the Company’s operations and investment program, including as to the Company’s ability to pay distributions, incur additional leverage and engage in certain transactions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investments in Smaller and Middle Market Companies</div>. The Company generally invests in smaller and middle market companies. While smaller and middle market companies generally have potential for rapid growth, they often involve higher risks because they may lack the management experience, financial resources, product diversification, competitive strength and access to capital of larger companies. In addition, in many instances, the frequency and volume of the trading of securities for such companies may be substantially less than is typical of larger companies. As a result, the securities of smaller and middle market companies may be subject to wider price fluctuations. When liquidating positions in smaller and middle market companies, the Company may have to sell portfolio holdings at discounts from quoted prices or may have to make a series of small transactions over an extended period of time. Investments in such companies may also be particularly difficult to analyze due to (among other factors) limited attention from analysts and large institutional investors, limited access to liquidity sources and, in certain cases, limited publicly available financial information. With respect to the Company’s investments in SMEs and similar loans, the Company may receive less borrower information, receive less collateral and be subject to heightened default risk as compared to loans made to other types of entities. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Hedging Transactions and Related Risks</div>. The Company may, but is not required to, engage in hedging transactions. In particular, as many of the Company’s Portfolio Investments are expected to consist of relatively illiquid securities whose price behavior is not particularly correlated to general fixed income or equity index returns, such Portfolio Investments are expected to be difficult or expensive to hedge, and as such the Company may not employ any hedging strategy in respect of such Portfolio Investments (including with respect to their credit risk). To the extent the Adviser employs a hedging strategy for the Company, the success of any such hedging strategy will depend, in part, upon the Adviser’s ability to correctly assess the degree of correlation between the performance of the instruments used in the hedging strategy and the performance of the investments being hedged. Since the characteristics of many securities change as markets change or time passes, the success of the Company’s hedging strategy will also be subject to the Adviser’s ability to continually recalculate, readjust and execute hedges in an efficient and timely manner. While the Company may enter into hedging transactions to seek to reduce risk, such transactions may result in a poorer overall performance for the Company than if it had not engaged in such hedging transactions. For a variety of reasons, the Adviser may not seek to establish a precise correlation between the hedging instruments utilized and the portfolio holdings being hedged. Such an imprecise correlation may prevent the Company from achieving the intended hedge or expose the Company to risk of loss. Additionally, the Adviser may not hedge against a particular risk because it does not regard the probability of the risk occurring to be sufficiently high as to justify the cost of the hedge, or because it does not foresee the occurrence of the risk. Moreover, there is no guarantee that the Company’s intended hedging strategy will be successful in hedging out the subject risks. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Due Diligence Risk</div>. When conducting due diligence and making an assessment regarding a Portfolio Investment, the Adviser relies on the resources available to it, including internal sources of information as well as information provided by third parties. The due diligence process may at times be required to rely on limited or incomplete information. The Adviser selects Portfolio Investments in part on the basis of information and data filed with various government regulators and publicly available or made directly available by prospective portfolio companies or third parties. The Adviser expects that it will not be in a position to confirm the completeness, genuineness or accuracy of such information and data, and will therefore be dependent upon the integrity of the management of the entities filing such information and of such portfolio companies and third parties providing such information. In addition, there can be no assurance that any consultants or experts engaged by the Adviser will accurately evaluate such Portfolio Investments. Investment analyses and decisions by the Adviser may be undertaken on an expedited basis to enable the Company to take advantage of investment opportunities with accelerated timelines. In such cases, the available information at the time of an investment decision may be limited, inaccurate and/or incomplete. Accordingly, the Adviser cannot guarantee that its due diligence investigations will reveal or highlight all relevant facts that may be necessary or helpful in evaluating investment opportunities. Furthermore, the Company bears its proportionate share of all due diligence-related fees, costs, expenses and liabilities (including in respect of investments that are not ultimately consummated); such fees, costs, expenses and liabilities may be significant and could reduce Company returns. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Interest Rate Risk</div>. Interest rate risk refers to the risks associated with market changes in interest rates. In general, rising interest rates, such as the recent economic period, will negatively impact the price of fixed rate debt instruments and falling interest rates will have a positive effect on the price of such debt instruments. Many of the Company’s investments are expected to be variable rate loans with interest that adjusts with market rates. These loans will generally also react to interest rate changes in a similar manner although generally to a lesser degree (depending, however, on the characteristics of the reset terms, including the index chosen, frequency of reset and reset caps or floors, among other factors). The Company’s other investments and transactions may also be affected by changes in interest rates. Declines in market value, if not offset by any corresponding gains on hedging instruments, may ultimately reduce earnings or result in losses to the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prices of long-term debt obligations generally fluctuate more than prices of short-term debt obligations as interest rates change. To the extent the Company invests in longer-term Portfolio Investments, it will be impacted to a greater degree by changes in market interest rates than if the Company invested primarily in short-term debt securities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company borrows money or issues preferred Units to make investments, its net investment income will depend, in part, upon the difference between the rate at which it borrows funds or pays distributions on preferred Units and the rate at which the Company invests those funds. As a result, the Company can offer no assurance that a significant change in market interest rates will not have a material adverse effect on its net investment income in the event the Company uses debt to finance investments. In periods of rising interest rates, such as the recent economic period, the Company’s cost of funds will increase because the interest rates on the amounts borrowed under the Company’s credit facilities or certain other financing arrangements will typically be floating, which could reduce the Company’s net investment income to the extent any Portfolio Investments have fixed interest rates, and the interest rate on Portfolio Investments with an interest rate floor (such as a SOFR (as defined below) floor) above then-current levels will not increase until interest rates exceed the applicable minimum interest rate floor. Rising interest rates may also increase the cost of debt for the Portfolio Investments, which could adversely impact the Portfolio Investment’s financial performance and ability to meet ongoing obligations to the Company. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects that its long-term fixed-rate investments will be financed primarily with equity and long-term debt. The Company may use interest rate risk management techniques in an effort to limit its exposure to interest rate fluctuations. Such techniques may include various interest rate hedging activities to the extent permitted by the 1940 Act. These activities could limit the Company’s ability to participate in the benefits of lower interest rates with respect to the hedged borrowings. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on the Company’s business, financial condition and results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, an increase in interest rates available to investors could make an investment in the Company’s Units less attractive if the Company is not able to increase its distribution rate, which could reduce the value of the Company’s Units. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity Risk</div>. Most of the Company’s Portfolio Investments at any given time are expected to be illiquid, such that either no market exists for them or they are restricted as to their transferability under federal, state or foreign securities laws. Similarly, the Adviser may from time to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time possess material, non-public information about</div> an issuer, which could limit the ability of the Company to buy and sell Portfolio Investments. The illiquid nature of the Company’s positions may make it difficult, if not impossible, for the Company to (i) close out unprofitable positions and redeploy capital, except when a viable exit strategy can be developed (which may require a much longer commitment than the Adviser had anticipated), and (ii) meet margin calls or similar requirements of Company transaction counterparties to furnish additional liquid collateral. In addition, the sale of the Company’s investments may be made at substantial discounts and/or otherwise disadvantageous terms. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Inflation/Deflation Risk</div>. Inflation risk results from the variation in the value of cash flows from a security due to inflation, as measured in terms of purchasing power. The Company is exposed to inflation risk with respect to any fixed rate investments that it makes, if any, because the interest rate the issuer has to pay the Company is fixed for the life of the security. To the extent that interest rates reflect the expected inflation rate, floating rate loans have a lower level of inflation risk. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any disruptions in the capital markets, as a result of inflation and a rising interest environment or otherwise, may increase the spread between the yields realized on risk-free and higher risk securities and can result in illiquidity in parts of the capital markets, significant write-offs in the financial sector <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and re-pricing of</div> credit risk in the broadly syndicated market. These and any other unfavorable economic conditions could increase the Company’s funding costs, limit the Company’s access to the capital markets or result in a decision by lenders not to extend credit to the Company. In addition, market conditions (including inflation, supply chain issues and decreased consumer demand) could impact the operations of certain of the Company’s Portfolio Investments. If the financial results of middle-market companies, like those in which the Company intends to invest, experience deterioration, it could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults, and further deterioration in market conditions will further depress the outlook for those companies. Further, adverse economic conditions may decrease the value of collateral securing some of the Company’s loans and the value of the Company’s equity investments. Such may require the Company to modify the payment terms of its investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of the Company’s Portfolio Investments may be negatively impacted by these economic or other conditions, which can result in the Company’s receipt of reduced interest income from its Portfolio Investments and/or realized and unrealized losses related to its Portfolio Investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financial Fraud</div>. Instances of fraud and other deceptive practices committed by management, employees or Service Providers of the Company’s Portfolio Investments or by other financial institutions may undermine the Adviser’s due diligence efforts with respect to, and/or negatively affect the valuation of, the Company’s Portfolio Investments. In addition, financial fraud may contribute to overall market volatility, which can negatively impact the Company’s investment program. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">OFAC, FCPA and Related Considerations</div>. Economic sanction laws in the U.S. and other jurisdictions may prohibit the Adviser, its personnel and the Company from transacting with or in certain countries and with certain individuals and companies. In the U.S., the U.S. Department of the Treasury’s Office of Foreign Assets Control administers and enforces laws, Executive Orders and regulations establishing U.S. economic and trade sanctions. Such sanctions prohibit, among other things, transactions with, and the provision of services to, certain foreign countries, territories, entities and individuals. These types of sanctions may restrict the Company’s investment activities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries, there is a greater acceptance than in the U.S. of government involvement in commercial activities, and of corruption. The Company may be adversely affected because of its unwillingness to participate in transactions that violate such laws or regulations. Such laws and regulations may make it difficult in certain circumstances for the Company to act successfully on investment opportunities and for Portfolio Investments to obtain or retain business. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In recent years, the U.S. Department of Justice and the SEC have devoted greater resources to enforcement of the U.S. Foreign Corrupt Practices Act (the “FCPA”). In addition, the United Kingdom has recently significantly expanded the reach of its anti-bribery laws. Violations of the FCPA or other applicable anti-corruption laws or anti-bribery laws could result in, among other things, civil and criminal penalties, material fines, profit disgorgement, injunctions on future conduct, securities litigation and a general loss of investor confidence, any one of which could adversely affect the Company’s ability to achieve its investment objective and/or conduct its operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Waivers or Deferrals of Covenants and Covenant-Lite Loans</div>. The Company structures the debt in its Portfolio Investments to include business and financial covenants placing affirmative and negative obligations on the operation of the company’s business and its financial condition. However, from time to time the Company may elect to waive breaches of these covenants, including its right to payment, or waive or defer enforcement of remedies, such as acceleration of obligations or foreclosure on collateral, depending upon the financial condition and prospects of the particular Portfolio Investment. These actions may reduce the likelihood of the Company receiving the full amount of future payments of interest or principal and be accompanied by a deterioration in the value of the underlying collateral as many of these companies may have limited financial resources, may be unable to meet future obligations and may go bankrupt. This could negatively impact the Company’s ability to pay distributions, could adversely affect its results of operation and financial condition and cause the loss of all or part of your investment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, some of the loans in which the Company may invest may be “covenant-lite” loans. The Company uses the term “covenant-lite” loans to refer generally to loans that do not have a complete set of financial maintenance covenants. Generally, “covenant-lite” loans provide borrower companies more freedom to negatively impact lenders because their covenants are incurrence-based, which means they are only tested and can only be breached following an affirmative action of the borrower, rather than by a deterioration in the borrower’s financial condition. Accordingly, to the extent the Company invests in “covenant-lite” loans, the Company may have fewer rights against a borrower and may have a greater risk of loss on such investments as compared to investments in or exposure to loans with financial maintenance covenants. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">General Risks Related to the Company </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risk of Loss</div>. An investment in the Company is highly risky. There can be no assurance that the Company will achieve its investment objective or any particular level of returns. An investor may lose all of its money by investing in the Company. Among other things, the Company may invest in assets that are underperforming or non performing and/or in securities of issuers who are under financial stress. By their nature, such investments are considered speculative and entail substantial risks that are generally higher than the risks of investments in performing assets and securities of issuers that are not under financial stress. Any losses in the Company will be borne solely by investors in the Company and not by the Adviser or any of its respective affiliates (except to the extent they invest capital in the Company, in which case they, with respect to such capital invested, will bear their pro rata portion of such loss). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Market for Units</div>. Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed. A Unitholder is not expected to be able to sell, assign or transfer its Units. In addition, transfers of Units may be affected by restrictions on resales imposed by federal and state securities laws. The Units are not registered under the Securities Act or any state securities laws and may not be transferred unless registered under applicable federal and state securities laws or unless an exemption from such laws is available. The Company has no plans, and is under no obligation, to register the Units under the Securities Act or any state securities laws. No market exists for the Units, and none is expected to develop. Therefore, an investment in the Company must be considered illiquid and must only be made by <div style="display:inline;">persons </div>that are able to bear the risk of their investment in the Company for an indefinite period of time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Management Risk and Reliance on Management</div>. The Company is subject to management risk because the Adviser actively manages its investment portfolio. The Adviser will apply investment and disposition techniques and risk analyses in making investment and disposition decisions for the Company, but there can be no guarantee that these will produce the desired results. In addition, as Unitholders may not participate in the management of the Company, only investors who are willing to entrust all aspects of the management of the Company to the Adviser should subscribe for Units. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of the Company is highly dependent upon the financial and managerial experience of the Adviser and any consultants or other Service Providers retained by the Company. The success of the Adviser is highly dependent on the financial and managerial experience of the investment professionals, who may not continue to be employed by or associated with the Adviser during the entire term of the Company. In <div style="display:inline;">addition</div>, a number of members of the professional staff of the Adviser are </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investors in other investment vehicles advised by SLR and are actively involved in managing the investment decisions of these investment vehicles, as well as investment decisions of other clients of SLR. Accordingly, the members of the professional staff of the Adviser have demands on their time for the investment, monitoring and other functions of other funds and other clients advised by SLR. In addition, competition in the financial services, private equity and alternative asset management industries for qualified investment professionals is intense. The Adviser’s continued ability to effectively manage the Company’s investments depends on its ability to attract new investment professionals and to retain and motivate its existing investment professionals. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, at any time during the Company’s term, the Adviser may assign the full and exclusive authority and responsibility granted to it under the Investment Management Agreement to an investment adviser under common control with the Adviser, subject to applicable law. The Adviser may take any actions that are necessary or incidental to any such assignment, including assigning the Investment Management Agreement or causing the Company to enter into a new Investment Management Agreement. Although it is expected that (x) any new investment adviser would be a registered investment adviser under the Advisers Act, (y) the management fee and incentive fee payable by the Company to such entities would be identical to that payable to the Adviser and (z) certain investment professionals would continue to be responsible for managing the Company’s assets, there is no guarantee that any or all of such characteristics will apply to any such new investment adviser. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Investment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Committee may delegate non-investment decisions (including</div> decisions relating to cash management <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and similar non-material transactions</div> (which shall not be considered “investments” for these purposes), diligence decisions, decisions relating to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">transactions involving material non-public information and</div> decisions relating to the engagement of consultants, law firms and other Service Providers) to other investment professionals in their sole discretion. Any decisions made by such subset or other investment professionals may be materially different and/or less optimal than decisions that would have been made by the Investment Committee. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Referral Relationships with Financial Sponsors</div>. The Adviser expects that the professional staff of the Adviser will maintain and develop their relationships with financial sponsors, including venture capital sponsors, and the Company will rely to a significant extent upon these relationships to provide the Company with potential investment opportunities. If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio. In addition, individuals with whom the professional staff of the Adviser have relationships are not obligated to provide the Company with investment opportunities, and, therefore, there is no assurance that such relationships will generate investment opportunities for the Company. If the Adviser is unable to source investment opportunities, the Company may hold a greater percentage of its assets in cash and cash equivalents than anticipated, which could impact potential returns on the Company’s portfolio. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Recourse to the Company’s Assets</div>. The Company’s assets, including any Portfolio Investments made by the Company and any capital held by the Company, are available to satisfy all liabilities and other obligations of the Company. In addition, the Company may pledge its right to call capital from Unitholders. If the Company becomes subject to a liability, parties seeking to have the liability satisfied may have recourse to the Company’s assets generally and may not be limited to any particular asset, such as the Portfolio Investment giving rise to the liability. To the extent the Company chooses to use special-purpose entities for individual transactions to reduce recourse risk (and it may, but will be under no obligation to do so), the<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> bona fides</div></div> of such entities may be subject to later challenge based on a number of theories, including veil piercing or substantive consolidation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unspecified Use of Proceeds</div>. The proceeds from the issuance of the Units are intended to be invested in Portfolio Investments. Unitholders will not have an opportunity to evaluate for themselves the relevant economic, financial and other information regarding the investments in which the proceeds from the issuance of the Units will be invested and, accordingly, are dependent upon the judgment and ability of the Adviser in investing and managing the capital of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Identification of Potential Investment Opportunities</div>. There is no assurance that the Adviser’s analysis in this regard, as implemented, will take into consideration all appropriate factors or appropriately weigh the factors that are considered in its analysis, especially given the heightened difficulty of the analysis required to evaluate certain Portfolio Investments. In particular, catalysts and/or exit strategies that initially appear to be viable may be precluded over time due to economic, legal, political or other factors. In addition, because the successful implementation of the Company’s investment strategy depends, in part, on its ability to successfully predict and take advantage of changing market conditions, to the extent it is unable to do so, returns may be adversely affected. These considerations are particularly relevant in light of the current uncertain economic and regulatory environment. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Risks Relating to the Company</div>” below. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Competition; Potential for Insufficient Investment Opportunities</div>. The business of identifying and effecting investments of the types contemplated by the Adviser is competitive and there can be no assurance that the Adviser will be able to identify and obtain a sufficient number of investment opportunities to invest the full amount of capital that may be committed to the Company. Increased competition for, or a diminishment in the available supply of, potential Portfolio Investments could result in lower returns on such Portfolio Investments. The Company may engage in auction or similar bidding processes with respect to certain Portfolio Investments, which processes are often highly competitive and may involve numerous other bidders about which the Company possesses limited or no information; as a result, the foregoing considerations will be applicable with respect to any such processes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Insufficient Capital for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Follow-On</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Investments</div>. Following its initial investment in a Portfolio Investment, the Company may have the opportunity to increase its investment in such Portfolio Investment. There is no assurance that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Company will make follow-on investments or</div> that the Company will have sufficient resources to, or be permitted to, make such investments. Any decision <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not to make follow-on investments or the</div> Company’s inability to make them may have a substantial negative impact on the company in need of such an investment, may result in missed opportunities for the Company or may result in dilution of the Company’s investment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Portfolio Investments</div>. The Company may participate in a limited number of Portfolio Investments and, as a consequence, the aggregate return of the Company may be substantially adversely affected by the unfavorable performance of any single investment. The Company has a broad and flexible investment mandate, and, beyond the asset diversification requirements associated with the Company’s intention to comply with the requirements to qualify as a RIC for U.S. tax purposes, and except as noted above, the Company is not subject to any limits or proportions with respect to the mix of permitted Portfolio Investments. As a result, the Company’s Portfolio Investments could potentially be concentrated in relatively few strategies, issuers, industries, markets, geographies or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">investment types. Such non-diversification would make the</div> Company more susceptible to risks associated with a single economic, political or regulatory occurrence than a more diversified portfolio might be. The Company could be subject to significant losses if it holds a relatively large position in a single strategy, issuer, industry, market, geographic region or a particular type of Portfolio Investment that declines in value, and the losses could increase even further if the Portfolio Investments cannot be liquidated without adverse market reaction or are otherwise adversely affected by changes in market conditions or circumstances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Third-Party Involvement</div>. The Company may hold a portion of its investments through partnerships, joint ventures, securitization vehicles or other entities with third-party investors (collectively, “joint ventures”). Joint venture investments involve various risks, including the risk that the Company will not be able to implement investment decisions or exit strategies because of limitations on the Company’s control under applicable agreements with joint venture partners, the risk that a joint venture partner may become bankrupt or may at any time have economic or business interests or goals that are inconsistent with those of the Company, the risk that a joint venture partner may be in a position to take action contrary to the Company’s objectives, the risk of liability based upon the actions of a joint venture partner and the risk of disputes or litigation with such partner and the inability to enforce fully all rights (or the incurrence of additional risk in connection with enforcement of rights) one partner may have against the other, including in connection with foreclosure on partner loans, because of risks arising under state law. In addition, the Company may be liable for actions of its joint venture partners. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Leveraged Companies</div>. The Company will invest in Portfolio Investments whose capital structures have significant leverage. Such Portfolio Investments are inherently more sensitive to declines in revenues and asset values and to increases in expenses and interest rates. The leveraged capital structure of such Portfolio Investments will increase the exposure of the Portfolio Investments to adverse economic factors such as downturns in the economy or deterioration in the condition of the Portfolio Investment, its underlying assets or its industry. Additionally, the securities acquired by the Company may be the most junior securities in what may be a complex capital structure, and thus subject to the greatest risk of loss. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Portfolio Turnover</div>. The Company will not place any limit on the rate of portfolio turnover, and Portfolio Investments may be sold or otherwise disposed of without regard to the time they have been held when, in the judgment of the Adviser, investment considerations warrant such action. A high rate of portfolio turnover involves correspondingly greater expenses than a lower rate, may act to reduce the Company’s investment gains or create a loss for investors and may result in significant tax costs for investors <div style="display:inline;">depending </div>on the tax provisions applicable to such investors. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Assurance of Cash Distributions</div>. Subject to the Board’s discretion and applicable legal restrictions, the Company expects to declare and pay distributions quarterly. The Company expects to pay these distributions out of assets legally available for distribution. However, there are no assurances that the Company will achieve investment results that will allow a targeted level<div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"> </div></div>of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash distributions or year-to-year increases in cash</div></div> distributions. All distributions that are made will be at the discretion of the Board and will depend on earnings, financial condition, maintenance of RIC status and other factors as the Board may deem to be relevant. The Company’s ability to pay distributions might be adversely affected by the impact of one or more of the risk </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">factors described in this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> If the Company violates certain covenants under its existing or future credit facilities or other leverage, the Company may be limited in its ability to make distributions. To the extent the Company makes distributions to Unitholders that include a return of capital, such portion of the distribution essentially constitutes a return of the Unitholder’s investment. In addition, the inability to satisfy the asset coverage test applicable to a BDC may limit the Company’s ability to pay distributions. There can be no assurances that the Company will pay distributions to Unitholders in the future. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain cases, the Company may recognize income before or without receiving the accompanying cash. Depending on the amount of noncash income, this could result in difficulty satisfying the annual distribution requirement applicable to RICs. Accordingly, the Company may have to sell some Portfolio Investments at times it would not consider advantageous, raise additional debt or equity capital or reduce new investments to meet these distribution <div style="display:inline;">requirements</div>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Dollar Denomination of Units</div>. Units are denominated in U.S. Dollars. Investors subscribing for Units in any country in which U.S. Dollars are not the local currency should note that changes in the rate of exchange between U.S. Dollars and such currency may have an adverse effect on the value, price or income of the investment to such investor. There may be foreign exchange regulations applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to investments in non-U.S. currencies in certain</div> jurisdictions. Each prospective investor should consult with its own counsel and advisors as to all legal, tax, financial and related matters concerning an investment in the Units. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Forward-Looking Statements</div>. This <div style="display:inline;">annual </div>report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> contains forward-looking statements, including observations about market and industry and regulatory trends as of the original date of this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K. Those forward-looking</div> statements reflect the Adviser’s current view in respect of future events. Actual events could differ materially from those in the forward-looking statements as a result of factors beyond the Adviser’s or the Company’s control. Investors are cautioned not to place undue reliance on such statements. No party has an obligation to update any of the forward-looking statements in this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Projections</div>. The Company may rely upon projections, forecasts or estimates developed by the Adviser, the Company or an issuer in which the Company is invested concerning the issuer’s future performance and cash flow. Projections, forecasts and estimates are forward-looking statements, are inherently uncertain and are based upon certain assumptions. Actual events are difficult to predict and beyond the Company’s control. Actual events may differ from those assumed. Some important factors which could cause actual results to differ materially from those in any forward-looking statements include changes in interest rates; domestic and foreign business, market, financial or legal conditions; leverage amounts and costs; and the degree to which the Portfolio Investments are hedged and the effectiveness of such hedges. Accordingly, there can be no assurance that estimated returns or projections can be realized or that actual returns or results will not be materially lower than those estimated therein. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Valuation of Illiquid Assets</div>. It is expected that the majority of the Company’s investments will be in securities or other financial instruments for which market quotations are not available. The process of valuing securities for which reliable market quotations are not available is based on inherent uncertainties, and the resulting values may differ from values that would have been determined had a ready market existed for such securities, from values placed on such securities by other investors and from prices at which such securities may ultimately be sold. In addition, third-party pricing information may at times not be available regarding certain of the Company’s assets or, if available, may not be considered reliable. In particular, recent disruptions in the credit markets have resulted in a severe lack of liquidity for many securities, making them more difficult to value and, in many cases, putting significant downward pressure on prices. Subject to approval by the Board, the Adviser will determine the fair value of securities, loans or other instruments for which market quotes are not readily available (or if extraordinary events occur after the last readily available quotation). The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule 2a-5 under</div> the 1940 Act; and (6) maintain recordkeeping requirements under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule 2a-5.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that such valuations will be reliable, accurate or reflective of the prices at which such investments are ultimately realized. In addition, certain of the securities or other assets that the Company seeks to sell or acquire via cross trade may be illiquid and difficult to value, therefore there can be no assurance that such valuation will be accurate. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Assets Believed to Be Undervalued or Incorrectly Valued</div>. Securities that the Adviser believes are fundamentally undervalued or incorrectly valued may not ultimately be valued in the capital markets at prices and/or within the timeframe the Adviser anticipates. As a result, the Company may lose all or substantially all of its investment in any particular instance. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Model Risks</div>. The Adviser may employ financial/analytical models to aid in the selection of the Portfolio Investments, to allocate investments across various strategies and risks and to determine the risk profile of the Company. If any such models are employed, the success of the Company’s investment activities will depend, in large part, upon the viability of these models. There can be no assurance that the models are currently viable, or will remain viable during the term of the Company, due to various factors, including the quality of the data input into the models and the assumptions underlying such models, which to varying degrees involve the exercise of judgment, as well as the possibility of errors in constructing or of using the model. Even if the models function as anticipated, they cannot account for all factors that may influence the returns on the Portfolio Investments. Also, there can be no assurance that the investment professionals utilizing the models will be able to (i) determine that any model is or will become not viable or not completely viable or (ii) notice, predict or adequately react to any change in the viability of a model. The use of a model that is not viable or not materially viable could, at any time, have a material adverse effect on the performance of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Investigations or Third-Party Litigation</div>. The Company as well as the Adviser and its affiliates participate in a highly regulated industry and are each subject to regulatory examinations in the ordinary course of business. There can be no assurance that the Company and the Adviser and/or any of its affiliates will avoid regulatory investigation and possible enforcement actions stemming therefrom. The Adviser is a registered investment adviser and, as such, is subject to the provisions of the Advisers Act. The Company and the Adviser are each, from time to time, subject to formal and informal examinations, investigations, inquiries, audits and reviews from numerous regulatory authorities both in response to issues and questions raised in such examinations or investigations and in connection with the changing priorities of the applicable regulatory authorities across the market in general. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s investment activities may subject it to the risks and costs of becoming involved in litigation with third parties due to, among other reasons, the fact that different investor groups may have qualitatively different, and frequently conflicting, interests with respect to certain Portfolio Investments. The risk of litigation with third parties will be elevated in situations where an issuer is stressed or distressed. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Litigation and Related Risks Associated with Origination and Servicing</div>” above. The expense of defending against claims by third parties and <div style="display:inline;">paying </div>any amounts pursuant to settlements or judgments, or bringing claims against third parties, would generally be borne by the Company and would reduce net assets. In addition, the Company’s investment activities may subject it to certain risks inherent in restructuring, bankruptcy and similar proceedings. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Associated with Bankruptcy and Insolvency Cases</div>” below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Broad Indemnification</div>. The Company and/or the Adviser on behalf of the Company may enter into various agreements or arrangements which limit the liability of its Service Providers, including the Adviser and its affiliates, the Administrative Coordinator, the Custodian, and their affiliates, employees, officers and directors, and require the Company to indemnify and/or provide broad representations, warranties and covenants in favor of such persons. U.S. federal and state securities laws impose liabilities under certain circumstances on persons that cannot be waived by contract, other agreements or documents. Therefore, nothing in those agreements should be deemed or construed in a manner that purports to waive or limit any right to the extent prohibited by law. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to indemnify the Adviser and its respective affiliates, each of the former, current and future shareholders, partners, members, other equity holders, officers, directors, employees, managers, trustees, agents and other representatives of the Adviser and its respective affiliates, and other persons set forth in the LLC Agreement as an “Indemnitee” for Claims (as defined in the LLC Agreement) that may accrue to or be incurred by an Indemnitee, in connection with any claim, demand, investigation, suit, proceeding or action in which an Indemnitee may become involved, as a party or otherwise, or with which an Indemnitee may be threatened, relating to or arising out of the investments or other activities of the Company, activities undertaken in connection with the Company, or otherwise relating to or arising out of the LLC Agreement or the Subscription Agreement, and otherwise as provided in the LLC Agreement or the Subscription Agreement. Such Claims may be material and have an adverse effect on the returns to the Unitholders. The Company may also provide broad indemnities, representations, warranties and covenants in connection with the acquisition, management and disposition of Portfolio Investments or otherwise in connection with the Company’s investment program. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any indemnification obligations of the Company would be payable from the assets of the Company, including the unfunded Commitments of the Unitholders, and would adversely affect the Company’s returns. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Adverse Consequences of Default</div>. A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment. When a Unitholder defaults, the Board, in its discretion, may cause the defaulting Unitholder to forfeit a portion of the distributions to which the defaulting Unitholder may otherwise have been entitled. The Board may also require a forced sale of the defaulting Unitholder’s Interest. In addition, the Board may pursue any available legal or equitable remedies, with the expenses of collection of the unpaid amount, including attorneys’ fees, to be paid by the defaulting Unitholder. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the default of a Unitholder, the Company may deliver an amended funding notice to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-defaulting</div> Unitholders increasing their capital contributions by up to an aggregate amount equal to the capital contribution that the defaulting Unitholder failed to make, not in excess of a Unitholder’s unfunded Commitment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board may require a defaulting Unitholder to contribute the entirety of its remaining Commitment to the Company. For any such Unitholder, the return on its Company investment may be materially lower than returns to Unitholders <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">who do not pre-fund their Commitments.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Distributions in Kind</div>. If distributions are made of assets held by the Company in lieu of cash, the amount of any such distribution will be accounted for at the fair market value of such assets as determined in accordance with procedures set forth in the LLC Agreement. An independent appraisal generally will not be required and is not expected to be obtained. Assets distributed in kind may not be readily marketable or disposable, and Unitholders therefore must be prepared to bear the risks of owning such assets for an indefinite period of time (and to incur costs and expenses in connection with any disposition thereof). In addition, there can be no <div style="display:inline;">assurance </div>that the value of such assets as determined in accordance with procedures set forth in the LLC Agreement will ultimately be realized. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Russian Invasion of Ukraine</div>. On February 24, 2022, the Russian military commenced a full-scale invasion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Russia’s pre-positioned forces</div> into Ukraine, which could have a negative impact on the economy and business activity globally (including in the countries in which the Company invests), and therefore could adversely affect the performance of the Company’s Portfolio Investments. Following such invasion, the United States and several European nations announced sanctions against Russia. Furthermore, the conflict between the two nations and the varying involvement of the United States and other NATO countries could preclude prediction as to their ultimate adverse impact on global economic and market conditions, and, as a result, presents material uncertainty and risk with respect to the Company and the performance of its investments or operations, and the ability of the Company to achieve its investment objectives. Additionally, to the extent that third parties, investors, or related customer bases have material operations or assets in Russia or Ukraine, they may have adverse consequences related to the ongoing conflict. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Electronic Communications/Cybersecurity Risk</div>. The Company provides to Unitholders statements, reports and other communications relating to the Company and/or the Unitholder’s Interest in electronic form, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as e-mail or</div> via a password protected website (“Electronic Communications”). There are certain costs and possible risks associated with the use of Electronic Communications. Electronic Communications may be modified, corrupted, or contain viruses or malicious code, and may not be compatible with a Unitholder’s electronic system. The Company cannot provide any assurance that Electronic Communications are secure and will not be responsible for any computer viruses, problems or malfunctions resulting from the use of Electronic Communications. In addition, reliance on Electronic Communications involves the risk of inaccessibility, power outages or slowdowns for a variety of reasons. These periods of inaccessibility may delay or prevent receipt of reports or other information by the Unitholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company relies on the Adviser’s enterprise-wide cybersecurity program, to protect its information, including due oversight of the cybersecurity programs of the Company’s key Service Providers and processes for the assessment, identification, and management of material risks from cybersecurity threats, including those associated with the use of third-party Service Providers. While the Adviser employs various measures to address cybersecurity-related issues, the Adviser, the Administrative Coordinator, the Company and their respective Service Providers may nevertheless be subject to operational and information security risks resulting from cybersecurity incidents. A cybersecurity incident refers to both intentional and unintentional events that may cause the Adviser, the Company or their respective Service Providers to lose or compromise confidential information, suffer data corruption or lose operational capacity. Cybersecurity incidents include stealing or corrupting data maintained online or digitally, denial of service attacks on websites, the unauthorized release of confidential information or various other operational disruptions. If unauthorized parties gain access to such information and technology systems, they may be able to steal, publish, delete or modify private and sensitive information, including nonpublic personal information related to Unitholders (and their beneficial owners) and material nonpublic information. The systems the Adviser has implemented to manage risks relating to these types of events could prove to be inadequate and, if compromised, could become inoperable for extended periods of time, cease to function properly or fail to adequately secure private information. Breaches such as those involving covertly introduced malware, impersonation of authorized users and industrial or other espionage may not be identified even with sophisticated prevention and detection systems, potentially resulting in further harm and preventing them from being addressed appropriately. The failure of these systems or of disaster recovery plans for any reason could cause significant interruptions in the Company’s and the Adviser’s operations and result in a failure to maintain the security, confidentiality or privacy of sensitive data, including personal information relating to Unitholders, material nonpublic information and other sensitive information in the Adviser’s possession. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A disaster or a disruption in the infrastructure that supports the Adviser’s business, including a disruption involving Electronic Communications or other services used by the Adviser or third parties with whom the Adviser conducts business, or directly affecting the Adviser’s headquarters, could have a material adverse impact on the Adviser’s ability to continue to operate its business without interruption and to protect the Company, insofar as is practicable, from the hazards of cybersecurity threats and vulnerabilities in accordance with applicable legal requirements and guidance. The Adviser’s disaster recovery programs may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse the Adviser for its losses, if at all. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company is not currently aware of any cyber-attacks or other incidents that, individually or in the aggregate, have materially affected, or would reasonably be expected to materially affect, its operations or financial condition, there has been an increase in the frequency and sophistication of the cyber and security threats faced in the marketplace. Cyber-attacks and other security threats could originate from a wide variety of sources, including cyber criminals, nation state hackers, hacktivists and other outside or inside parties. The Company may be a target for attacks because, as a specialty finance company, it holds confidential and other sensitive information, including price information, about existing and potential investments. Further, the Company is dependent on third-party vendors for hosting hardware, software and data processing systems that it does not control. The Company also relies on third-party Service Providers for certain aspects of its business, including for certain information systems, technology and administration of its Portfolio Investments and compliance matters. While the Company relies on the cybersecurity strategy and policies implemented by the Adviser, its reliance on the Adviser and third-party Service Providers removes certain cybersecurity functions from outside of the Company’s immediate control, and cyber-attacks on the Adviser, on the Company or on third-party Service Providers could adversely affect the Company, its business, and its reputation. The costs related to cyber-attacks or other security threats or disruptions may not be fully insured or indemnified by others, including by the <div style="display:inline;">Company’s </div>third-party providers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company’s reliance on computer hardware and software systems, data processing systems, and other technology has increased, so have the risks posed to such systems, both those the Adviser controls and those provided by third-party vendors. Cyber-attacks may originate from a wide variety of sources, and while the Adviser has implemented processes, procedures, and internal controls designed to mitigate cybersecurity risks and cyber-attacks, these measures do not guarantee that a cyber-attack will not occur or that the Company’s financial results, operations, or confidential information, personal, or other sensitive information will not be negatively impacted by such an incident, especially because the techniques of threat actors change frequently and are often not recognized until launched. The Adviser relies on industry accepted security measures and technology to securely maintain confidential and proprietary information maintained on its information systems, as well as on policies and procedures to protect against the unauthorized or unlawful disclosure of confidential, personal, or other sensitive information. Although the Adviser takes protective measures and endeavors to strengthen its computer systems, software, technology assets, and networks to prevent and address potential cyber-attacks, there can be no assurance that any of these measures prove effective. The Adviser expects to be required to devote increasing levels of funding and resources, which may in part be allocated to the Company, to comply with evolving cybersecurity and privacy laws and regulations and to continually monitor and enhance its cybersecurity procedures and controls. In addition, the Company, the Adviser, the Administrative Coordinator, or their employees, if any, may also be the target of fraudulent emails or other targeted attempts to gain unauthorized access to confidential, personal, or other sensitive information. The result of any cyber-attack or other security incidents may include disrupted operations, misstated or unreliable financial data, fraudulent transfers or requests for transfers of money, liability for stolen information (including personal information), investigations, misappropriation of assets, increased cybersecurity protection and insurance costs, litigation and damage to the Company’s business relationships, regulatory fines or penalties, or other adverse effects on its business, financial condition or results of operations. The Adviser may be required to expend significant additional resources to modify its protective measures and to investigate and remediate vulnerabilities or other exposures arising from operational and security risks related to cyber-attacks. The rapid evolution and increasing prevalence of artificial intelligence technologies may also increase cybersecurity risks. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, cybersecurity has become a top priority for global lawmakers and regulators around the world, and some jurisdictions have proposed or enacted laws requiring companies to notify regulators and individuals of data security breaches involving certain types of personal data. In particular, state and federal laws and regulations related to cybersecurity compliance continue to evolve and change, which may require substantial investments in new technology, software and personnel, which could affect the Company’s profitability. These changes may also result in enhanced and unforeseen consequences for cyber- related breaches and incidents, which may further adversely affect the Company’s profitability. If the Adviser fails to comply with the relevant and increasing laws and regulations, the Adviser could suffer financial losses, a disruption of its businesses, liability to investors, regulatory intervention or reputational damage. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Policies of remote working, whether by the Adviser, the Administrative Coordinator, the Company or by their respective Service Providers, could strain technology resources, introduce operational risks and otherwise heighten the risks described above. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybersecurity risks are exacerbated by the rapidly increasing volume of highly sensitive data, including the Company’s proprietary business information, personal information of the Adviser’s employees, the Company’s investors and others, and other sensitive information that the Adviser collects, processes, and stores in its data centers and on its networks or those of third-party Service Providers. The secure processing, maintenance, and transmission of this information are critical to the Company’s operations. There is a risk that encryption and other protective measures against cyber-attacks may be circumvented, particularly to the extent that new computing technologies increase the speed and computing power available. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and, in fact, may not be detected. A significant actual or potential theft, loss, corruption, exposure, fraudulent use or misuse of investor or other personal information, proprietary business data or other sensitive information, whether by third parties or as a result of malfeasance by the Adviser’s employees or otherwise, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with applicable contractual or other legal obligations regarding such data or intellectual property or a violation of applicable privacy and security policies with respect to such data could result in significant investigation, remediation and other costs, fines, penalties, litigation or regulatory actions against the Company and significant reputational harm, any of which could harm the Company’s business and results of operations. Cybersecurity risks require continuous and increasing attention and other resources from the Adviser to, among other actions, identify and quantify these risks and upgrade and expand its technologies, systems and processes to adequately address such risks. Such attention diverts time and other resources from other activities and there is no assurance that the Adviser’s efforts will be effective. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybersecurity incidents may adversely impact the Company and its Unitholders. There is no guarantee that the Company, the Adviser, and/or their respective Service Providers will be successful in protecting against cybersecurity incidents. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financial Services Industry Risks</div>. Cash not held in custody accounts and held by the Company, the Adviser and the Portfolio Investments in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> and interest-bearing operating accounts could, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, the Company, the Adviser, or the Portfolio Investments could lose all or a portion of those amounts held in excess of such insurance limits. In addition, actual events involving limited liquidity, defaults, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance</div> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect the Company, the Adviser’s and the Portfolio Investments’ business, financial condition, results of operations, or prospects. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company and the Adviser assess its and the Portfolio Investments’ banking and financing relationships as the Company believes necessary or appropriate, the Company and the Portfolio Investments’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which the Company, the Adviser or the Portfolio Investments have arrangements directly or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company, the Adviser or the Portfolio Investments have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for the Company, the Adviser, or the Portfolio Investments to acquire financing on acceptable terms or at all. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Technological Innovation Risks</div>. Technological innovations have disrupted traditional approaches in multiple industries and can permit younger companies to achieve success and in the process disrupt markets and market practices. The Company can provide no assurance that new businesses and approaches will not be created that would compete with the Company and/or its Portfolio Investments or alter the market practices in which the Adviser and its affiliates and the Company have been designed to function within and on which the Company depends on for its investment return. New approaches could damage the Company’s investments, disrupt the market in which it operates and subject it to increased competition, which could materially and adversely affect the Company’s business, financial condition and results of investments. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Machine Learning Technology Risks</div>. Recent technological advances in artificial intelligence and machine learning technology (“Machine Learning Technology”) pose risks to the Company and its Portfolio Investments. The Company and its Portfolio Investments could be exposed to the risks of Machine Learning Technology if third-party service providers or any counterparties use Machine Learning Technology in their business activities. The Company and the Adviser are not in a position to control the use of Machine Learning Technology in third-party products or services. Use of Machine Learning Technology could include the input of confidential information in contravention of applicable policies, contractual or other obligations or restrictions, resulting in such confidential information becoming part accessible by other third-party Machine Learning Technology applications and users. Machine Learning Technology and its applications continue to develop rapidly, and the Company cannot predict the risks that may arise from such developments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Machine Learning Technology is generally highly reliant on the collection and analysis of large amounts of data, and it is not possible or practicable to incorporate all relevant data into the model that Machine Learning Technology utilizes to operate. Certain data in such models will inevitably contain a degree of inaccuracy and error and could otherwise be inadequate or flawed, which would be likely to degrade the effectiveness of Machine Learning Technology. To the extent the Company or its Portfolio Investments are exposed to the risks of Machine Learning Technology use, any such inaccuracies or errors could adversely impact the Company or its Portfolio Investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Social Responsibility Risks</div>. The Company’s business (including that of its Portfolio Investments) faces increasing public scrutiny related to environmental, social and governance (“ESG”) activities, which are increasingly considered to contribute to reducing a company’s operational risk, market risk and reputational risk, which may in turn impact the long-term sustainability of a company’s performance. A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG ratings and measures to their investment decisions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company risks damage to its brand and reputation if it fails to act responsibly in a number of areas, including, but not limited to, diversity, equity and inclusion, human rights, climate change, environmental stewardship, support for local communities, corporate governance, transparency and consideration of ESG factors in the Company’s investment processes. Adverse incidents with respect to ESG activities could impact the value of the Company’s brand, its relationship with existing and future Portfolio Investments, the cost of the Company’s operations and relationships with investors, all of which could adversely affect its business and results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, regional and investor specific sentiment may differ in what constitutes a material positive or negative ESG corporate practice. There is no guarantee that the Company’s ESG and sustainability practices will uniformly fit every investor’s definition of best practices for all environmental, social and governance considerations across geographies and investor types. If we do not successfully manage expectations across varied stakeholder interests, it could erode stakeholder trust, impact our reputation and constrain our investment opportunities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is also a growing regulatory interest across jurisdictions in improving transparency regarding the definition, measurement and disclosure of ESG factors in order to allow investors to validate and better understand sustainability claims. For example, the SEC has proposed, or has announced that it is working on proposals for, rules that, among other matters, would establish a framework for reporting of climate-related risks, corporate and fund carbon emissions, broad diversity and capital management. At this time, there is uncertainty regarding the scope of such proposals or when they would become effective (if at all). In 2021, the SEC established an enforcement task force to look into ESG practices and disclosures by public companies and investment managers and has started to bring enforcement actions based on ESG disclosures not matching actual investment processes. Further, in 2022 the SEC issued a proposed rule regarding the enhancement and standardization of mandatory climate-related disclosures for investors that would mandate extensive disclosure of climate-related data, risks and opportunities for certain public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and its Portfolio Investments are subject to the risk that similar measures might be introduced in other jurisdictions in the future. Additionally, compliance with any new laws or regulations increases the Company’s regulatory burden and could make compliance more difficult and expensive, affect the manner in which the Company or its Portfolio Investments conduct its businesses and adversely affect the Company’s profitability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Climate Change Risks</div>. There may be evidence of global climate change. Climate change creates physical and financial risk and some of the Company’s Portfolio Investments may be adversely affected by climate change. For example, the needs of customers of energy companies vary with weather conditions, primarily temperature and humidity. To the extent weather conditions are affected by climate change, energy use could increase or decrease depending on the duration and magnitude of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any changes. Increases in the cost of energy could adversely affect the cost of operations of the Company’s Portfolio Investments if the use of energy products or services is material to their business. A decrease in energy use due to weather changes may affect some of the Company’s Portfolio Investments’ financial condition, through decreased revenues. Extreme weather conditions in general require more system backup, adding to costs, and can contribute to increased system stresses, including service interruptions. Energy companies could also be affected by the potential for lawsuits against or taxes or other regulatory costs imposed on greenhouse gas emitters, based on links drawn between greenhouse gas emissions and climate change. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2015 the United Nations, of which the U.S. is a member, adopted a climate accord with the long-term goal of limiting global warming and the short-term goal of significantly reducing greenhouse gas emissions. As a result, some of the Company’s Portfolio Investments may become subject to new or strengthened regulations or legislation, which could increase their operating costs and/or decrease their revenues. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Risks Related to RICs and BDCs </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Failure to Qualify as a RIC</div>. Although the Company has obtained qualification as a RIC, no assurance can be given that it will be able to maintain qualification as a RIC. To maintain qualification as a RIC, the Company must meet</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">source-of-income, asset</div></div> diversification, and distribution requirements on an ongoing basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income source requirement will be satisfied if the Company obtains at least 90% of gross income for each year from dividends, interest, foreign currency, payments with respect to loans of certain securities, gains from the sale of Units or other securities, net income from certain “qualifiedpublicly traded partnerships,” or similar sources. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The asset diversification requirement will be satisfied if the Company meets certain asset diversification requirements at the end of each quarter of the taxable year. Failure to meet those requirements may result in the Company having to dispose of certain investments quickly in order to prevent the loss of qualification as a RIC. Because most of the Company’s investments will be relatively illiquid, any such dispositions could be made at disadvantageous prices and could result in substantial losses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual distribution requirement will be satisfied if the Company distributes to its Unitholders on an annual basis at least 90% of net ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any. Because the Company may use debt financing, it is subject to certain asset coverage ratio requirements under the 1940 Act and financial covenants under loan and credit agreements that could, under certain circumstances, restrict the Company from making distributions necessary to satisfy the distribution requirement. If the Company is unable to obtain cash from other sources, it could fail to qualify as a RIC. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company fails to qualify as a RIC for any reason and therefore becomes subject to corporate income tax, the resulting corporate taxes could substantially reduce net assets, the amount of income available for distribution and the amount of distributions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Recognizing Income Before or Without Receiving Cash</div>. For U.S. federal income tax purposes, the Company will include in income certain amounts that the Company has not yet received in cash, such as the accrual of original issue discount (“OID”). This may arise if the Company receives warrants in connection with the making of a loan and in other circumstances, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">through contracted payment-in-kind (“PIK”) interest,</div></div> which represents contractual interest added to the loan balance and due at the end of the loan term. Such OID, which could be significant relative to the Company’s overall investment activities, and increases in loan balances as a result of contracted PIK arrangements will be included in income before the Company receives any corresponding cash payments. The Company also may be required to include in income certain other amounts that the Company will not currently receive in cash. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since in certain cases the Company may recognize income before or without receiving cash representing such income, the Company may have difficulty meeting the requirement to timely distribute at least 90% of its net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any, to maintain its qualification as a RIC. In such a case, the Company may have to sell some of its Portfolio Investments at times the Company would not consider advantageous or raise additional debt or equity capital or reduce new investment originations to meet these distribution requirements. If the Company is not able to obtain cash from other sources and is otherwise unable to satisfy such distribution requirement, the Company may fail to maintain its qualification as a RIC and become subject to corporate-level U.S. federal income tax. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Tax Considerations Regarding Dividends for Private BDCs</div>. The Company does not currently qualify as a “publicly offered regulated investment company,” as defined in the Code. Accordingly, U.S. individual and other noncorporate Unitholders will be taxed as though they received a distribution of some of the Company’s expenses. A “publicly offered regulated investment company” is a RIC whose Units are either (i) continuously offered pursuant to a public offering, (ii) regularly traded on an established securities market, or (iii) held by at least 500 persons at all times during the taxable year. The Company anticipates that it will not qualify as a publicly offered RIC for the 2023 tax year, and cannot determine when it will qualify as a publicly offered RIC. Since the Company is not a publicly offered RIC, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a non-corporate Unitholder’s</div> allocable portion of the Company’s affected expenses, including a portion of its management fees, will be treated as an additional distribution to the Unitholders. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A non-corporate Unitholder’s</div> allocable portion of these expenses are treated as miscellaneous itemized deductions that are not currently deductible by such Unitholder (and beginning in 2026, will be deductible by such Unitholder for regular U.S. federal income tax purposes but not for alternative minimum tax purposes only to the extent they exceed 2% of such Unitholder’s adjusted gross income). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Potential Dividend Deferrals</div>. In order to maintain its tax status as a RIC, the Company must distribute to Unitholders for each taxable year at least 90% of its investment company taxable income (i.e., net ordinary income plus realized net short-term capital gains in excess of realized net long-term capital losses). If the Company qualifies for taxation as a RIC, it generally will not be subject to corporate-level U.S. federal income tax on its investment company taxable income and net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) that it timely distributes to Unitholders. The Company will be subject to a 4% U.S. federal excise tax on undistributed earnings of a RIC unless it distributes each calendar year at least the sum of (i) 98.0% of its ordinary income for the calendar year, (ii) 98.2% of its capital gains in excess of capital losses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the one-year period</div> ending on October 31 of the calendar year, and (iii) any ordinary income and net capital gains for preceding years that were not distributed during such years and on which it paid no U.S. federal income tax. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Code, the Company may pay certain RIC dividends after the end of the current year. In particular, if the Company pays a distribution in January of the following year that was declared in October, November, or December of the current year and is payable to Unitholders of record in the current year, the dividend will be treated for all U.S. federal income tax purposes as if it were paid on December 31 of the current year. In addition, under the Code, the Company may pay dividends, referred to as “spillover dividends,” that are paid during the following taxable year that will allow the Company to maintain its qualification for taxation as a RIC and eliminate its liability for corporate-level U.S. federal income tax. Under these spillover dividend procedures, the Company may defer distributions of income earned during the current year until December of the following year. For example, the Company may defer distributions of income earned during 2024 until as late as December 31, 2025. If the Company chooses to pay a spillover dividend, it will incur the 4% U.S. federal excise tax on some or all of the distribution. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to events such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19 pandemic,</div> certain regional bank failures, the Russian invasion of Ukraine, the ongoing war in the Middle East or other disruptions in the economy, such as the recent inflationary environment, the Company may take certain actions with respect to the timing and amounts of its distributions in order to preserve cash and maintain flexibility. For example, the Company may reduce and/or defer dividends to the following year as discussed above. To further preserve cash, the Company may combine these deferrals of dividends with one or more distributions that are payable partially in Units as discussed below under “<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Kind</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Dividend Considerations</div>.” </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Kind</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Dividend Considerations</div>. The Company may distribute taxable dividends that are payable in part in Units. In accordance with certain applicable U.S. Treasury regulations and published IRS guidance, a RIC may treat a distribution of its own shares as fulfilling the RIC distribution requirements if each Unitholder may elect to receive the entire distribution in either cash or shares of the RIC. The IRS has published a revenue procedure indicating that, in the case of publicly offered RICs, this rule will apply where the total amount of cash to be distributed is not less than 20% of the total distribution. Under this revenue procedure, if too many Unitholders elect to receive cash, the cash available for distribution must be allocated among the Unitholders electing to receive cash (with the balance of the distribution paid in Units). Because the Company is not currently a publicly offered RIC, its ability to rely on the revenue procedure and other guidance is uncertain. If the Company elects to pay a distribution in its own Units consistent with the revenue procedure and other guidance, for U.S. federal income tax purposes, the amount of the dividend paid in Units will be equal to the amount of cash that could have been received instead of Units. Taxable Unitholders receiving such dividends will be required to include the amount of the dividends as ordinary income (or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of the Company’s current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a Unitholder may be required to pay tax with respect to such dividends in excess of any cash received, and, the Company may be required to withhold U.S. tax with respect to dividends payable in Units <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to non-U.S. Unitholders.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Tax Law</div>. Legislative or other actions relating to taxes could have a negative effect on the Company. The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. New legislation and any other tax law developments including new or revised U.S. Treasury regulations, administrative interpretations or court decisions, could negatively and perhaps retroactively affect the U.S. federal income tax consequences to the Company and its Unitholders, or could have other adverse consequences. Investors are urged to consult with their tax advisor regarding tax legislative, regulatory, or administrative developments and proposals and their potential effect on an investment in the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Permissible Incurred Leverage</div>. Leverage magnifies the potential for loss on investments and on invested equity capital. As the Company uses leverage to partially finance its investments, Unitholders will experience increased risks of investing in the Company’s securities. If the value of the Company’s assets increases, then leveraging would cause the NAV attributable to the Company’s Units to increase more sharply than it would have had the Company not leveraged. Conversely, if the value of the Company’s assets decreases, leveraging would cause NAV to decline more sharply than it otherwise would have had the Company not leveraged its business. Similarly, any increase in the Company’s income in excess of interest payable on the borrowed funds would cause net investment income to increase more than it would without the leverage, while any decrease in the Company’s income would cause net investment income to decline more sharply than it would have had the Company not borrowed. Such a decline could negatively affect the Company’s ability to pay dividends on Units, scheduled debt payments or other payments related to securities. Leverage is generally considered a speculative investment technique. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Distribution and Asset Coverage Ratio Requirements</div>. In order to satisfy the requirements applicable to RICs and to avoid payment of excise taxes, the Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain net income except for certain net capital gains, which it intends to retain and to elect to treat as deemed distributions to Unitholders. The Company may issue debt securities, other evidences of indebtedness or preferred Units, and may borrow money from banks or other financial institutions, which are referred to collectively herein as “senior securities,” up to the maximum amount permitted by the 1940 Act. The 1940 Act permits the Company to issue senior securities in <div style="display:inline;">amounts </div>such that its asset coverage, as defined in the 1940 Act, equals at least 150% after each issuance of senior securities. The Company’s ability to pay dividends or issue additional senior securities would be restricted if the asset coverage ratio were not at least 150%. If the value of the Company’s assets declines, the Company may be unable to satisfy this test. If that happens, the Company may be required to liquidate a portion of its investments and repay a portion of its indebtedness at a time when such sales or repayment may be disadvantageous. As a result of issuing senior securities, the Company will also be exposed to typical risks associated with leverage, including an increased risk of loss. If the Company issues preferred Units, such preferred Units will rank “senior” to common Units in the Company’s capital structure, preferred Unitholders will have separate voting rights for certain purposes and may have rights, preferences or privileges more favorable than those of the Company’s common Units and the issuance of preferred Units could have the effect of delaying, deferring or preventing a transaction or a change of control that might involve a premium price for Unitholders or otherwise be in the best interest of Unitholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company is constrained in its ability to issue debt or other senior securities, it will depend on issuances of capital interests to finance operations. As a BDC, the Company is generally not able to issue Units at a price below NAV without first obtaining required approvals of Unitholders and independent directors in accordance with the conditions set forth in Section 63(2) of the 1940 Act. If the Company raises additional funds by issuing more common Units or senior securities convertible into, or exchangeable for, common Units, the percentage ownership of Unitholders at that time would decrease and Unitholders may experience dilution. In addition to issuing securities to raise capital as described above, the Company could, in the future, securitize loans to generate cash for funding new investments. An inability to successfully securitize its loan portfolio could limit the Company’s ability to grow its business, fully execute its business strategy and improve profitability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized Depreciation</div>. As a BDC, the Company is required to carry investments at market value or, if no market value is ascertainable, at fair value as determined in good faith by the Board. Decreases in the market values or fair values of investments will be recorded as unrealized depreciation. Any unrealized depreciation in the Company’s loan portfolio could be an indication of a Portfolio Investment’s inability to meet its repayment obligations with respect to the loans whose market values or fair values decreased. This could result in realized losses in the future and ultimately in reductions of income available for distribution in future periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Qualifying Asset Requirements</div>. As a BDC, the Company may not acquire any assets other than “qualifying assets” unless, at the time of such acquisition, at least 70% of its total assets are qualifying assets. Therefore, the Company may be precluded from investing in what it believes are attractive investments if such investments are not qualifying assets. Similarly, these rules could prevent the Company from making additional investments in existing Portfolio Investments, which could result in the dilution of its position, or could require disposal of investments at an inopportune time to comply with the 1940 Act. If the Company were forced to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sell non-qualifying investments</div> for compliance purposes, the proceeds from such sale could be significantly less than the current value of such investments. Conversely, if the Company failed to invest a sufficient portion of assets in qualifying assets, it could lose status as a BDC, which would subject the Company to substantially more regulatory restrictions and significantly decrease operating flexibility. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Regulatory Risks Relating to the Company </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exemptive Relief</div>. The Company and the other BDCs for which SLR is the investment adviser (SLR Investment Corp. (Nasdaq: SLRC) (“SLRC”), SCP Private Credit Income BDC LLC (“PCI BDC”) and SLR Private Credit BDC II LLC (“PC BDC,” and, together with SLRC and PCI BDC, the “SLR BDCs”) are substantially limited in their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ability to co-invest in privately</div> negotiated transactions with affiliated funds other than as permitted by the Order. While the Order permits the Company to participate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in negotiated co-investment transactions with</div> the SLR BDCs and other affiliated funds, such participation is subject to numerous conditions. If the Company and the SLR BDCs are unable to comply with these conditions or are otherwise unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although SLR will endeavor to allocate investment opportunities in a fair and equitable manner, the Company could be adversely affected to the extent investment opportunities are allocated among the Company and other investment vehicles managed or sponsored by, or affiliated with SLR and its affiliates, including the SLR BDCs, pursuant to the conditions of the Order. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Risks Relating to the Company</div>. Legal and regulatory changes could occur during the term of the Company that may adversely affect the Company. The Company may be subject to, and adversely affected by, new federal, state or non-U.S. laws or new regulation by the SEC, the Commodity Futures Trading Commission (the “CFTC”), the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the FDIC, the European Commission and other federal, state and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> securities or banking regulators, and other governmental regulatory authorities or self-regulatory organizations that supervise the financial markets. The Company may also be adversely affected by changes in the enforcement or interpretation of existing statutes and rules by courts and/or these governmental regulatory authorities or self-regulatory organizations. For example, a recent court decision casts doubt on whether federal or state usury laws apply with respect to loans originated by national banks and then sold to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-bank</div> investors such as the Company; this decision could significantly disrupt the bank loan secondary market and adversely impact the Company’s investment program. In addition, the approach taken by a federal court in the “Sun Capital” decision may significantly expand the scope of potential joint and several liability for pension obligations of portfolio companies commonly held by affiliated funds; this decision could create significant uncertainty with respect to such investments and adversely impact the Company. Moreover, legal and regulatory changes may adversely affect the Company’s ability to obtain financing by (among other things) reducing the availability of financing and/or adversely impacting financing costs and other terms. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial services industry is subject to extensive regulation. Banking regulators have broad and largely discretionary powers, which include prohibiting “unsafe or unsound” practices; requiring affirmative actions to correct any violation or practice; issuing administrative orders that can be judicially enforced; directing increases in capital; directing the sale of subsidiaries or other assets; limiting dividends and distributions; restricting growth; assessing civil monetary penalties; removing officers and directors; and terminating deposit insurance. These actions and other regulatory requirements could have a material adverse effect on an investment in the Company. The financial institutions in which the Company will invest and with which the Company will transact are subject to laws, regulations, administrative actions and policies in each location in which they operate. The regulatory environment for private investment funds is evolving, and changes in the regulation or taxation of private investment funds may adversely affect the value of the investments held by the Company and the ability of the Company to execute its investment strategy. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the securities and futures markets are subject to comprehensive statutes, regulations and margin requirements. The SEC and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other U.S. and non-U.S. regulators, self-regulatory organizations</div> and exchanges are authorized to take extraordinary actions in the event of market emergencies. The regulation of derivatives transactions and funds that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action. The effect of any future regulatory change on the Company could be substantial and adverse. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Changes in Regulatory Policy</div>. The U.S. government has recently called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">difficult-to-quantify</div></div> macroeconomic and political risks with potentially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">far-reaching</div> implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financial Services and Government Intervention</div>. From time to time, certain governments and regulatory authorities, such as the U.S. federal government, the U.S. Federal Reserve and the governments and regulatory authorities of certain member countries of the EU, have taken actions to provide or arrange credit support to financial institutions whose operations have been compromised by credit market dislocations and to restore liquidity and stability to the financial system in such jurisdictions. The implementation of any current or future governmental interventions (which may be significantly altered or terminated prior to implementation or during their terms), and their impact on both the credit markets generally and the Company’s investment program in particular, are uncertain. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act</div>. In response to the recent disruption in the credit markets and the global economic downturn, various agencies and regulatory bodies of the U.S. federal government have taken or are considering taking various actions. These actions include, but are not limited to, the enactment of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), which was signed into law on July 21, 2010, and which imposes a new regulatory framework over the U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">financial services industry, non-U.S. financial entities</div> that are regulated by or affiliated with entities regulated by U.S. financial regulators, and the consumer credit markets in general, and proposed and final regulations adopted thereunder, as well as proposed and final regulations to implement the Basel III regulatory capital accords. Given the broad scope and sweeping nature of these changes and the fact that certain final implementing rules and regulations have not yet been adopted or implemented, the potential impact of these actions on the Adviser and the Company is unknown, and no assurance can be made that the impact of such changes would not have a material adverse effect on the Adviser or the Company. For example, the U.S. Financial Stability Oversight Council (“FSOC”) created by the Dodd-Frank Act has the authority to designate asset management firms as a “systemically important financial institution” (“SIFI”). If the Adviser, or one of its affiliates, were designated as a SIFI, it would be subject to a variety of regulations, including capital requirements and limitations on leverage, which could have a material adverse effect on the ability of the Company to pursue its investment strategy. In addition, the Dodd-Frank Act created a new regulator for the credit industry in the U.S. known as the U.S. Consumer Financial Protection Bureau (“CFPB”). The CFPB may, among other things, regulate interest rates and other charges, require certain disclosures and regulate foreclosure practices. Future regulatory actions authorized by the Dodd-Frank Act (including any regulatory actions or other measures taken by the FSOC and/or the CFPB) may significantly reduce the profitability of the Company and its Portfolio Investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes to Derivatives Regulation</div>. Through comprehensive new global regulatory regimes impacting derivatives (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, the Dodd-Frank Act, European Market Infrastructure Regulation (“EMIR”), Markets in Financial Investments Regulation (“MIFIR”)/Markets in Financial Instruments Directive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“MIFID II”)), certain over-the-counter derivatives transactions</div></div> in which the Company may engage are either now or will soon be subject to various requirements, such as mandatory central clearing of transactions which include additional margin requirements and in certain cases trading on electronic platforms, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-and</div> post-trade transparency reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">requirements and mandatory bi-lateral exchange of</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">initial margin for non-cleared swaps.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dodd-Frank Act also created new categories of regulated market participants, such as “swap dealers,” “security-based swap dealers,” “major swap participants,” and “major security-based swap participants” who are subject to significant new capital, registration, recordkeeping, reporting, disclosure, business conduct and other regulatory requirements. The EU and some other jurisdictions are implementing similar requirements. Because these requirements are new and evolving (and some of the rules are not yet final), their ultimate impact remains unclear. However, even if the Company itself is not located in a particular jurisdiction or directly subject to the jurisdiction’s derivatives regulations, the Company may still be impacted to the extent the Company enters into a derivatives transaction with a regulated market participant or counterparty that is organized in that jurisdiction or otherwise subject to that jurisdiction’s derivatives regulations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on information available as of the date of this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K, the</div> effect of such requirements will be likely to (directly or indirectly) increase the Company’s overall costs of entering into derivatives transactions. In particular, new margin requirements, position limits and significantly higher capital charges resulting from new global capital regulations, even if not directly applicable to the Company, may cause an increase in the pricing of derivatives transactions entered into by market participants to whom such requirements apply or affect the overall ability of the Company to enter into derivatives transactions with certain counterparties. Such new global capital regulations and the need to satisfy the various requirements by counterparties are resulting in increased funding costs and increased overall transaction costs and are significantly affecting balance sheets, thereby resulting in changes to financing terms and potentially impacting the Company’s ability to obtain financing. Administrative costs, due to new requirements such as registration, recordkeeping, reporting, and compliance, even if not directly applicable to the Company, may also be reflected in the Company’s derivatives transactions. New requirements to trade certain derivatives transactions on electronic trading platforms and trade reporting requirements may lead to (among other things) fragmentation of the markets, higher transaction costs or reduced availability of derivatives, and/or a reduced ability to hedge, all of which could adversely affect the performance of certain of the Company’s investing strategies. In addition, changes to derivatives regulations may impact the tax and/or accounting treatment of certain derivatives, which could adversely impact the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, the SEC adopted new rules regarding the ability of a BDC (or a registered investment company) to use derivatives and other transactions that create future payment or delivery obligations. BDCs that use derivatives will be subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-at-risk</div></div> leverage limit, certain other derivatives risk management program and testing requirements and requirements related to board reporting. These new requirements would apply unless the BDC qualified as a “limited derivatives user,” as defined in the adopted rules. A BDC that enters into reverse repurchase agreements or similar financing transactions would need to aggregate the amount of indebtedness associated with the reverse repurchase agreements or similar financing transactions and could either (i) comply with the asset coverage requirements of Section 18 of the 1940 Act when engaging in reverse repurchase agreements or (ii) choose to treat such agreements as derivative transactions under the adopted rules. Under the adopted rules, a BDC may enter into an unfunded commitment agreement that is not a derivatives transaction, such as an agreement to provide financing to a Portfolio Investment, if the BDC has a reasonable belief, at the time it enters into such an agreement, that it will have sufficient cash and cash equivalents to meet its obligations with respect to all of its unfunded commitment agreements, in each case as it becomes due. If the BDC cannot meet this test, it is required to treat unfunded commitments as a derivatives transaction subject to the requirements of the rule. Collectively, these requirements may limit the Company’s ability to use derivatives and/or enter into certain other financial contracts. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Uncertainty of the U.S. Political Climate</div>. The current administration has called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and difficult-to-quantify</div></div> macroeconomic and political risks with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">potentially far-reaching</div> implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although the Company cannot predict the impact, if any, of these changes to its business, they could adversely affect the Company’s business, financial condition, operating results and cash flows. Until the Company knows what policy changes are made and how those changes impact its business and the business of the Company’s competitors over the long term, the Company will not know if, overall, it will benefit from them or be negatively affected by them. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Bad Actor” Restrictions for Private Placements Conducted Under Rule 506 of Regulation D</div>. An issuer is precluded from conducting offerings that rely on the exemption from registration under the Securities Act provided by Rule 506 of Regulation D (“Rule 506 Offerings”) if a “covered person” of the issuer has been the subject of a “disqualifying event” (each as defined below). “Covered persons” include, among others, the issuer, affiliated issuers, any investment manager or solicitor of the issuer, any director, executive officer or other officer participating in the offering of the issuer, any general partner or managing member of the foregoing entities, any promoter of the issuer and any beneficial owner of 20% or more of the issuer’s outstanding voting equity securities, calculated on the basis of voting power. A “disqualifying event” includes, among other things, certain (a) criminal convictions and court injunctions and restraining orders issued in connection with the purchase or sale of a security or false filings with the SEC, (b) final orders from the CFTC, U.S. Federal banking agencies and certain other regulators that bar a person from associating with a regulated entity or engaging in the business of securities, insurance or banking or that are based on certain fraudulent conduct, (c) SEC disciplinary orders relating to investment advisers, brokers, dealers and their associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">persons, (d) SEC cease-and-desist orders relating</div></div> to violations of certain anti-fraud provisions and registration requirements of the U.S. federal securities laws, (e) suspensions or expulsions from membership in a self-regulatory organization (“SRO”) or from association with an SRO member, and (f) U.S. Postal Service false representation orders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A disqualification will occur only in the case of a disqualifying event of a covered person that occurs on or after September 23, 2013, although issuers must disclose to potential investors in a Rule 506 Offering disqualifying events of covered persons that occurred before September 23, 2013. The rule provides an exception from disqualification if the issuer can show that it did not know and, in the exercise of reasonable care could not have known, that the issuer or any other covered person had a disqualifying event, although an issuer will not be able to establish that it has exercised reasonable care unless it has made, in light of the circumstances, factual inquiry into whether any disqualifications exist. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adviser has made, and on a periodic basis will continue to make, inquiries into whether any persons that the Adviser has determined to be affiliated issuers have been subject to any disqualifying events; however, in some circumstances the Adviser’s ability to determine whether the Company would be disqualified from relying on Rule 506 may depend on cooperation of third parties over whom the Company may have limited control and influence. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the Adviser’s covered persons, including any affiliated issuer of the Company, is subject to a disqualifying event, the Company could lose the ability to raise capital in a future Rule 506 offering for a significant period of time and the Company’s business, financial condition and results of operations could be materially and adversely affected. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes to Accounting Standards</div>. The Financial Accounting Standards Board’s Accounting Codification Standards and updates, and additional provisions of U.S. generally accepted accounting principles (“U.S. GAAP”) (or to the extent applicable, International Financial Reporting Standards or other applicable accounting or financial reporting standards), that may be adopted in the future may impose additional, or different, specific requirements as to the valuation of assets and liabilities for purposes of U.S. GAAP-compliant financial reporting. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Licensing Requirements</div>. Various licensing requirements could apply to the Company or the Adviser with respect to investments in, or the origination, holding, servicing and disposing of, loans and similar assets. The licensing requirements could apply depending on the location of the borrower, the location of the collateral securing the loan, or the location where the Company or the Adviser operates or has offices. Moreover, the Company’s ability to invest in certain properties, participate in the secondary mortgage market, obtain financing for investments, lease properties to tenants and/or engage in lending, advisory, servicing and/or broker activities may be subject to the issuance of permits or licenses. If the Company applies for such licenses, this process may be costly and take several months. There is no assurance that the Company will obtain all of the licenses that it desires or that the Company would not experience significant delays in seeking these licenses. In states and other jurisdictions in which it is licensed, the Company or the Adviser is required to comply with applicable laws and regulations, including possible information requirements and consumer protection and anti-fraud laws, which could impose restrictions on the Company’s or the Adviser’s ability to take certain actions to protect the value of its investments in such assets and impose compliance costs. Failure to comply with such laws and regulations could lead to, among other penalties, a loss of the Company’s or the Adviser’s license, which in turn could restrict the Company’s investment options or require the Company to divest assets located in or secured by real property located in that jurisdiction. These risks also apply to issuers and entities in which the Company invests that hold similar assets, as well as any origination company or servicer in which the Company owns an interest. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Reporting Company Filing Requirements</div>. As a BDC, the Company is subject to the reporting requirements of the 1934 Act and requirements of the Sarbanes-Oxley Act. These requirements may place a strain on systems and resources. The 1934 Act requires that the Company file annual, quarterly and current reports with respect to business and financial condition. The Sarbanes-Oxley Act requires that the Company maintain effective disclosure controls and procedures and internal controls over financial reporting, which are discussed below. In order to maintain and improve the effectiveness of disclosure controls and procedures and internal controls, significant resources and management oversight are required. The Company has implemented procedures, processes, policies and practices for the purpose of addressing the standards and requirements applicable to reporting companies. These activities may divert management’s attention from other business concerns, which could have a material adverse effect on business, financial condition, results of operations and cash flows. The Company incurs significant additional annual expenses related to these steps and, among other things, directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, additional administrative expenses payable to the Administrative Coordinator to compensate them for hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The systems and resources necessary to comply with public company reporting requirements will increase further once the Company ceases to be an “emerging growth company” under the JOBS Act. As long as the Company remains an emerging growth company, it intends to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. The Company will remain an emerging growth company for up to five years following any future IPO (however, the Company does not anticipate engaging in an IPO of its Units), although if the market value of the Units that are held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700 million as of any June 30 before that time, the Company would cease to be an emerging growth company as of the following December 31. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, because the Units are registered under the 1934 Act, ownership information for any person who beneficially owns 5% or more of the Units will have to be disclosed in a Schedule 13G or other filings with the SEC. Beneficial ownership for these purposes is determined in accordance with the rules of the SEC, and includes having voting or investment power over the securities. In some circumstances, Unitholders who choose to reinvest their dividends may see their percentage stake in the Company increased to more than 5%, thus triggering this filing requirement. Each Unitholder is responsible for determining their filing obligations and preparing the filings. In addition, Unitholders who hold more than 10% of a class of Units may be subject to Section 16(b) of the 1934 Act, which recaptures for the benefit of the Company profits from the purchase and sale of registered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Units within a six-month period.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Documentation of Internal Controls</div>. The Company is obligated to maintain proper and effective internal control over financial reporting, including the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act (“Section 404”). The Company is not required to comply with all of the requirements under Section 404 until the date it is no longer an emerging growth company under the JOBS Act. Accordingly, the Company’s internal controls over financial </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">reporting do not currently meet all of the standards contemplated by Section 404 that they will eventually be required to meet. Specifically, the Company is required to conduct annual management assessments of the effectiveness of its internal controls over financial reporting. However, the Company’s independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial reporting until the date it is no longer an emerging growth company under the JOBS Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If the Company fails to maintain the adequacy of its internal controls, including any failure to implement required new or improved controls, or if the Company experiences difficulties in their implementation, the Company’s business and operating results could be harmed and it could fail to meet its financial reporting obligations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Other Risks Related to Portfolio Investments </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">High Yield Debt and Unrated Securities</div>. High yield securities are typically junior to the obligations of companies to senior creditors, trade creditors and employees. High yield securities and unrated securities (which are not rated by a rating agency) may be more susceptible to real or perceived adverse economic and competitive industry conditions than investment-grade securities. A projection of an economic downturn or of a period of rising interest rates, such as the recent economic period, for example, could cause a decline in the prices of high yield securities and unrated securities, because the advent of a recession could lessen the ability of an issuer to make principal and interest payments on its debt obligations. In addition, such securities have historically experienced greater default rates than investment grade securities. The ability of holders of high yield debt to influence a company’s affairs will be substantially less than that of senior creditors, especially during periods of financial distress or following insolvency. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As with other Portfolio Investments, there may not be a liquid market for certain high yield debt which is held by the Company, which could result in the Company being unable to sell such securities for an extended period of time, if at all. In addition, as with other types of Portfolio Investments, the market for high yield debt has historically been subject to disruptions that have caused substantial volatility in the prices of such securities. Consolidation in the financial services industry has resulted in there being fewer market makers for high yield debt, which may result in further risk of illiquidity and volatility with respect to high yield debt held by the Company, and this trend may continue in the future. Furthermore, high yield debt which is held by the Company may not be registered under the Securities Act, and, unless so registered, the Company is not able to sell such high yield debt except pursuant to an exemption from registration under the Securities Act. Unrated securities may be less liquid than comparable rated securities and may also involve the risk that the Adviser may not accurately evaluate the security’s comparative credit rating. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Analysis of creditworthiness of issuers of high yield and unrated securities may be more complex than for issuers of higher-quality fixed income securities. Since it is expected that most of the Company’s assets will not be rated by any rating agency or will be rated below investment grade, the Company is more dependent on the Adviser’s creditworthiness analysis than if the Company invested exclusively in higher-quality and rated securities. Securities rated below investment grade are often referred to as “leveraged loans,” “high yield” or “junk” securities, and may be considered “high risk” compared to debt instruments that are rated investment grade. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Credit Risk</div>” above. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Related Securities</div>. As with other Portfolio Investments, the value of equity or equity-related securities held by the Company may be adversely affected by actual or perceived negative events relating to the issuer of such securities, the industry or geographic areas in which such issuer operates or the financial markets generally. However, equity securities may be even more susceptible to such events given their subordinate position in the issuer’s capital structure. As such, equity securities generally have greater price volatility than fixed income securities, and the market price of equity securities owned by the Company is more susceptible to moving up or down in a rapid or unpredictable manner. In addition, equity securities <div style="display:inline;">often</div> lose a significant amount of their value and may become worthless as a result of a bankruptcy proceeding or reorganization. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Securities Risk</div>. Convertible securities generally offer lower interest or dividend yields than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities of similar quality. The market values of convertible securities tend to decline as interest rates increase and, conversely, to increase as interest rates decline. However, a convertible security’s market value tends to reflect the market price of the common stock of the issuing company when that stock price approaches or is greater than the convertible security’s “conversion price.” The conversion price is defined as the predetermined price at which the convertible security could be exchanged for the associated stock. As the market price of the underlying common stock declines, the price of the convertible security tends to be influenced more by the yield of the convertible security. Thus, it may not decline in price to the same extent as the underlying common stock. Generally, in the event of a liquidation of the issuing company, holders of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">convertible securities would be paid before the company’s common stockholders but after holders of any senior debt obligations of the company. Consequently, the issuer’s convertible securities generally entail less risk than its common stock but more risk than its debt obligations. There is also a risk that, under certain circumstances, a bankruptcy court may order that convertible securities are treated as equity. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may invest in synthetic convertible securities, which are created through a combination of separate securities that possess the two principal characteristics of a traditional convertible security, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i.e.</div></div>, an income-producing security (“income-producing component”) and the right to acquire an equity security (“convertible component”). The income-producing component is achieved by investing in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible,</div> income-producing securities such as bonds, preferred stocks and money market instruments. The convertible component is achieved by purchasing warrants or options to buy common stock at a certain exercise price, or options on a stock index. The values of synthetic convertible securities will respond differently to market fluctuations than a traditional convertible security because a synthetic convertible is composed of two or more separate securities or instruments, each with its own market value. Synthetic convertible securities are also subject to the risks associated with derivatives. In addition, if the value of the underlying common stock or the level of the index involved in the convertible element falls below the strike price of the warrant or option, the warrant or option may lose all value. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Securities Risk</div>. In addition to credit risk, investment in preferred stocks involves certain other risks. Certain preferred stocks contain provisions that allow an issuer under certain conditions to skip or defer distributions. If the Company owns preferred stock that is deferring its distribution, the Company may be required to report income for U.S. federal income tax purposes despite the fact that it is not receiving current income on this position. Preferred stock often is subject to legal provisions that allow for redemption in the event of certain tax or legal changes or at the issuer’s call. In the event of redemption, the Company may not be able to reinvest the proceeds at comparable rates of return. Preferred stock is subordinated to bonds and other debt securities in an issuer’s capital structure in terms of priority for corporate income and liquidation payments and, therefore, will be subject to greater credit risk than those debt securities. Preferred stock may trade less frequently and in a more limited volume and may be subject to more abrupt or erratic price movements than many other securities, such as common stocks, corporate debt securities and U.S. government securities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Forwards and Derivatives Transactions</div>. The Company may engage in a variety of derivatives transactions. A <div style="display:inline;">derivative </div>is a financial contract the value of which depends upon, or is derived from, the value of underlying assets, reference rates or indices. Derivatives may relate to securities, interest rates, currencies or currency exchange rates, inflation rates, commodities and related indices, and include foreign currency contracts, swap contracts, options, forward and futures contracts (including options thereon), repurchase or reverse repurchase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">agreements or other over-the-counter contracts. The</div></div> Company may use derivatives for many purposes, including as a substitute for direct investment, as a way to adjust its exposure to various securities, markets and currencies without actually having to sell existing investments and/or make new investments, and as a means to hedge other investments and to manage liquidity and excess cash. The Company’s use of derivatives may result in losses, reduce the Company’s return, and/or increase the volatility of the Company (particularly since many derivatives are inherently leveraged), especially in unusual or extreme <div style="display:inline;">market </div><div style="display:inline;">conditions</div>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All derivatives transactions involve risks different from, and potentially greater than, the risks associated with investing directly in securities and other more traditional assets, including: </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market Risk</div></div>. This is the general risk that the value of a particular investment or transaction will change in a way detrimental to the Company’s interests. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management Risk</div></div>. Derivatives contracts are specialized contracts that require investment techniques and risk analyses with additional levels of complexity associated with the underlying investments. In addition to risks associated with the underlying instruments, counterparty and unsecured risk (among others) need to be computed and tracked in relation to the Company’s overall risk profile. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Documentation Risk</div></div>. Many derivatives transactions also have documentation risk. Because contracts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> derivatives transactions are individually negotiated with specific counterparties, there exists the risk that the parties may interpret contractual terms (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, the definition of default) differently than the Company. If that occurs, the cost and unpredictability of the legal proceedings required for the Company to enforce its contractual rights may lead the Company to decide not to pursue its claims against the counterparty. The Company, therefore, assumes the risk that it may be unable to obtain payments the Adviser believes are owed to it under derivatives transactions, or those payments may be delayed or made only after the Company has incurred the costs of litigation. Also, payment amounts calculated in connection with standard industry conventions for resolving contractual issues (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, ISDA Protocols and auction processes) may be different than would be realized if a counterparty were required to comply with the literal terms of the derivatives transaction (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, physical delivery). There is little case law interpreting the terms of most derivatives or characterizing their tax treatment. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulatory Risk</div></div>. The derivatives market is subject to various risks related to existing as well as new and evolving regulation both within and outside the U.S. Additional regulation of the derivatives markets may make derivatives more costly, may limit the availability of derivatives, or may otherwise adversely affect the value or performance of derivatives. Any such adverse future developments could impair the effectiveness of a Company’s derivatives transactions and cause the Company to lose value. They may also render certain strategies in which the Company might otherwise engage impossible or so costly that they will no longer be economical to implement. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes to Derivatives Regulation</div>” above. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Risks</div></div>. Derivatives also involve the risk that changes in their value may not correlate perfectly with the assets, rates or indices they are designed to track. Suitable derivatives may not be available in all circumstances. Under the terms of certain contracts governing derivatives transactions, the occurrence of certain events with respect to the Company (such as a decline in the Company’s NAV) may cause the Company’s derivatives transactions to be terminated early, including at an inopportune time or at an unfavorable price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Warrants and Rights</div>. The Company may purchase or otherwise receive warrants or rights. Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a stated price. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of options. Unlike most options, however, warrants and rights are issued in specific amounts, and warrants generally have longer terms than options. Warrants and rights are not likely to be as liquid as exchange-traded options backed by a recognized clearing agency. In addition, the terms of warrants or rights may limit the Company’s ability to exercise the warrants or rights at such time, or in such quantities, as the Company would otherwise wish. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Relating to Reference Rates</div>. The London Interbank Offered Rate (“LIBOR”) is an index rate that historically was widely used in lending transactions and was a common reference rate for setting the floating interest rate on private loans. LIBOR was typically the reference rate used in floating-rate loans extended to the Company’s Portfolio Investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ICE Benchmark Administration (“IBA”) (the entity that is responsible for calculating LIBOR) ceased providing overnight, one, three, six and twelve months USD LIBOR tenors on June 30, 2023. In addition, the United Kingdom’s Financial Conduct Authority (“FCA”), which oversees the IBA, now prohibits entities supervised by the FCA from using LIBORs, including USD LIBOR, except in very limited circumstances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, SOFR is the preferred alternative rate for LIBOR. SOFR is a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. SOFR is published by the Federal Reserve Bank of New York each U.S. Government Securities Business Day, for transactions made on the immediately preceding U.S. Government Securities Business Day. Alternative reference rates that may replace LIBOR, including SOFR for USD transactions, may not yield the same or similar economic results as LIBOR over the lives of such transactions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the filing date of this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> many of the Company’s loans that referenced LIBOR have been amended to reference the forward-looking term rate published by CME Group Benchmark Administration Limited based on SOFR (“CME Term SOFR”) or CME Term SOFR plus a fixed spread adjustment. CME Term SOFR rates are forward-looking rates that are derived by compounding projected overnight SOFR rates over one, three, and six months taking into account the values of multiple consecutive, executed, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-month</div> and three-month CME Group traded SOFR futures contracts and, in some cases, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> SOFR Overnight Indexed Swaps as an indicator of CME Term SOFR reference rate values. CME Term SOFR and the inputs on which it is based are derived from SOFR. Since CME Term SOFR is a relatively new market rate, there will likely be no established trading market for credit agreements or other financial instruments when they are issued, and an established market may never develop or may not be liquid. Market terms for instruments referencing CME Term SOFR rates may be lower than those of later-issued CME Term SOFR indexed instruments. Similarly, if CME Term SOFR does not prove to be widely used, the trading price of instruments referencing CME Term SOFR may be lower than those of instruments indexed to indices that are more widely used. Further, the composition and characteristics of SOFR and CME Term SOFR are not the same as those of LIBOR. Even with the application of a fixed spread adjustment, LIBOR and CME Term SOFR will not have the same composition and characteristics, and there can be no assurance that the replacement rate, as so adjusted, will be a direct substitute for LIBOR. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no guarantee that SOFR will not be discontinued or fundamentally altered in a manner that is materially adverse to the interests of investors in loans referencing SOFR. If the manner in which SOFR or CME Term SOFR is calculated is changed, that change may result in a reduction of the amount of interest payable on such loans and the trading prices of the SOFR Loans. In addition, there can be no guarantee that loans referencing SOFR or CME Term SOFR will continue to reference those rates until maturity or that, in the future, the Company’s loans will reference benchmark rates other than CME Term SOFR. Should any of these events occur, the Company’s loans, and the yield generated thereby, could be affected. Specifically, the anticipated yield on the Company’s loans may not be fully realized and the Company’s loans may be subject to increased pricing volatility and market risk. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Economic Recessions</div>. The recent macroeconomic environment is characterized by record-high inflation, supply chain challenges, labor shortages, high interest rates, foreign currency exchange volatility, volatility in global capital markets and growing recession risk. The risks associated with the Company’s and the Portfolio Investments’ businesses are more severe during periods of economic slowdown or recession. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the Company’s Portfolio Investments may be susceptible to economic slowdowns or recessions and may be unable to repay its loans during these periods. The global outbreak <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of COVID-19</div> has disrupted economic markets, and the prolonged economic impact is uncertain. Many manufacturers of goods have seen a downturn in production due to the suspension of business and temporary closure of factories globally in an attempt to curb the continued spread of the virus. As a result of these disruptions, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Company’s non-performing</div> assets may increase and the value of its portfolio may decrease during these periods as the Company is required to record the values of its investments. Adverse economic conditions also may decrease the value of collateral securing some of the Company’s loans and the value of its equity investments at fair value. Economic slowdowns or recessions could lead to financial losses in the Company’s portfolio and a decrease in revenues, net income and assets. Unfavorable economic conditions also could increase the Company’s funding costs, limit its access to the capital markets or result in a decision by lenders not to extend credit to the Company. These events could prevent the Company from increasing investments and result in its receipt of a reduced level of interest income from the Company’s Portfolio Investments and/or losses or charge offs related to its investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Portfolio Investment’s failure to satisfy financial or operating covenants imposed by the Company or other lenders could lead to defaults and, potentially, acceleration of the time when the loans are due and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize the Portfolio Investment’s ability to meet its obligations under the debt that the Company holds. The Company may incur additional expenses to the extent necessary to seek recovery upon default or to negotiate new terms with a defaulting Portfolio Investment. In addition, if one of the Company’s Portfolio Investments were to go bankrupt, depending on the facts and circumstances, including the extent to which the Company actually provided significant managerial assistance to that Portfolio Investment, a bankruptcy court <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">might re-characterize</div> its debt holdings and subordinate all or a portion of the Company’s claim to that of other creditors. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive research and development, manufacturing, marketing and service capabilities and greater number of qualified and experienced managerial and technical personnel. They may need additional financing that they are unable to secure and that the Company is unable or unwilling to provide, or they may be subject to adverse developments unrelated to the technologies they acquire. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s business is directly influenced by the economic cycle and could be negatively impacted by a downturn in economic activity in the U.S. as well as globally. Fiscal and monetary actions taken by U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and non-U.S.</div> government and regulatory authorities could have a material adverse impact on the Company’s business. To the extent uncertainty regarding the U.S. or global economy, including as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19</div> pandemic, certain regional bank failures, the Russian invasion of Ukraine and the ongoing war in the Middle East, negatively impacts consumer confidence and consumer credit factors, the Company’s business, financial condition and results of operations could be adversely affected. Moreover, Federal Reserve policy, including with respect to certain interest rates and the decision to end its quantitative easing policy, along with the general policies of the current Presidential administration, may also adversely affect the value, volatility and liquidity of dividend- and interest-paying securities. Market volatility, periods of rising interest rates, such as the recent economic period, and/or a return to unfavorable economic conditions could adversely affect its business. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the U.S.’ Debt Ceiling</div>. The significant debt in the U.S. is expected to hinder growth in the U.S. for the foreseeable future. In the future, the U.S. government may not be able to meet its debt payments unless the federal debt ceiling is raised. If legislation increasing the debt ceiling is not enacted, as needed, and the debt ceiling is reached, the U.S. federal government may stop or delay making payments on its obligations. Any default by the U.S. government on its obligations or any prolonged U.S. government shutdown could negatively impact the U.S. economy and our Portfolio Investments. In addition, concerns over the United States’ debt ceiling and budget-deficit have driven downgrades by rating agencies to the U.S. government’s credit rating. Downgrades by rating agencies to the U.S. government’s credit rating or concerns about its credit and deficit levels in general could cause interest rates and borrowing costs to rise, which may negatively impact both the perception of credit risk associated with our debt portfolio and our ability to access the debt markets on favorable terms. In addition, a decreased U.S. government credit rating, any default by the U.S. government on its obligations, or any prolonged U.S. government shutdown, could create broader financial turmoil and uncertainty, which may weigh heavily on our financial performance and the value of our common stock. U.S. debt ceiling and budget deficit concerns have <div style="display:inline;">increased </div>the possibility of additional credit-rating downgrades and economic slowdowns or a recession in the U.S. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Portfolio Investment Monitoring and Involvement</div>. The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Control Positions</div>” below. The Company’s investment program may from time to time enable it to place representatives on the creditors’ or steering committees and/or the boards of directors of certain companies in which it has invested. While such involvement may enable the Adviser to enhance the value of the Company’s Portfolio Investments, it may also prevent the Company from freely disposing of such Portfolio Investments, while also exposing it to legal claims and adverse publicity (including claims of breach of duty of loyalty, securities claims and other management-related claims). In addition, if the Adviser’s representatives are serving as directors of companies which are in the “zone of insolvency,” such persons may have a fiduciary obligation to the creditors of such entity as well as the shareholders of such entity. The interests of such parties may be adverse to the interests of the Company. These fiduciary obligations may conflict with the Adviser’s obligation to the Company, and the Adviser may cause its representatives to resign from such positions in order to reduce such conflicts. Any involvement by the Adviser’s representatives (including through serving on a board of directors, or permanent or ad hoc creditors’ or steering committees) may also entail a substantial time commitment, which may limit such representatives’ ability to participate in other Company matters and investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Associated with Bankruptcy and Insolvency Cases</div>. If any issuers of securities held by the Company or any counterparties to the derivatives transactions and other transactions entered into by the Company, or any custodians of the Company’s assets or any obligors in connection with Portfolio Investments are involved in bankruptcy proceedings, the Company will be subject to certain risks inherent in bankruptcy proceedings, including the duration, administrative costs and impact of a bankruptcy case on the value of assets administered in bankruptcy or on a company’s value (including that a bankruptcy case may damage or diminish a company’s relationship with its employees, customers and/or suppliers). Many of the events within a bankruptcy or insolvency case are adversarial and often beyond the control of the creditors. While creditors generally are afforded an opportunity to object to significant actions, or to demand that certain actions take place, there can be no assurance that a court would not approve actions or inaction which may be contrary to the interests of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the duration of a bankruptcy or insolvency case can only be roughly estimated. The reorganization of a company usually involves the design of a business plan, the development and negotiation of a plan of reorganization, plan approval by creditors and confirmation by the court. This process can involve substantial legal, professional and administrative costs to the company and to the Company; is subject to unpredictable and lengthy delays; and during the process the company’s competitive position may erode, key management may depart and the company may not be able to invest adequately. In some cases, the company may not be able to reorganize and may be required to liquidate assets. In addition, the debt of companies in financial reorganization may, in some cases, not pay current interest and other charges, may not even accrue interest and other charges during reorganization, may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">relieved of paying pre-payment premiums and</div> may be adversely affected by an erosion of the issuer’s fundamental value. Further, a debtor seeking to reorganize under U.S. federal bankruptcy law will frequently obtain a “first day” order from the bankruptcy court limiting trading in claims against, and shares of, the debtor in order to maximize the debtor’s ability to utilize net operating losses following a successful reorganization. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the pendency of a bankruptcy case, an automatic stay will prevent all creditors from taking action against the debtor to foreclose on collateral or otherwise to collect on amounts owed to such creditors. Unless a creditor’s claim in such case is secured by assets having a value in excess of such claim, or the bankruptcy estate is determined to be solvent, no interest will be permitted to accrue and, therefore, a creditor’s return on investment can be adversely affected by the passage of time during which the plan of reorganization of the debtor is being negotiated, approved by the creditors and confirmed by the bankruptcy court. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The priority of perfected liens held by secured creditors as of the commencement of the bankruptcy case is typically recognized in a bankruptcy case, unless avoided. Occasionally, however, a court will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">allow a debtor-in-possession financing to</div></div> receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">liens that prime pre-existing, valid liens.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrative costs in connection with a bankruptcy case are frequently high and will generally be paid out of the debtor’s estate prior to any return to creditors (other than out of assets or proceeds thereof which are subject to valid and enforceable liens and other security interests) and equity holders. In addition, certain unsecured claims that have priority by law over the claims of certain creditors (for example, claims arising post-petition and certain claims for taxes) may be quite high. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. bankruptcy law permits the classification of “substantially similar” claims in determining the classification of claims in a reorganization for the purpose of voting on a plan of reorganization. Because the standard for classification is vague, there exists a significant risk that the Company’s influence with respect to a class of securities can be lost by the inflation of the number and the amount of claims in, or other gerrymandering of, the class. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although a creditor is not typically compelled to release direct claims it may have against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-debtor</div> third parties, in certain circumstances a court may compel such release in the context of a plan of reorganization. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Claims in bankruptcy cases are often paid at less than par and, depending on the debtor’s assets and liabilities, there may be no recovery at all for some classes of creditors. The claims of even over-secured secured creditors are often paid out over time, and may receive debt securities that will trade below par. Initially, only the debtor may file a proposed plan of reorganization. While the U.S. Bankruptcy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Code permits other parties-in-interest to file</div></div> proposed plans of reorganization after the debtors’ “exclusive period” to do so ends, bankruptcy courts often extend the debtor’s exclusive period, which effectively permits only the debtor to file a proposed reorganization plan. While creditors can vote on the plan of reorganization, the unanimous consent of all creditor classes is not necessarily required for the bankruptcy court to confirm the plan. Therefore, a plan can, subject to the provisions of the U.S. Bankruptcy Code, be “crammed down” on dissenting classes of creditors. Moreover, minority members of a class may be deemed to be members of an accepting class if the requisite majority vote is acquired. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a class of claims is entitled to a recovery in a reorganization or liquidation proceeding, such recovery could be in the form of instruments or interests different from the form of instrument or interest which formed the basis for the claim, including debt securities, equity securities, convertible securities, warrants, options, cash, interests in litigation claims or trusts formed to pursue such litigation claims, interests in liquidation trusts, or other property or interests, any of which could be illiquid and/or difficult to value. Furthermore, the terms of instruments or interests distributed in a bankruptcy or insolvency proceeding may differ from prevailing market terms for similar instruments or interests, and may have a market value of less than par. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may be presented with the opportunity to make new investments in connection with the reorganization or liquidation of an issuer of Portfolio Investments, including, without limitation, through a rights offering, litigation financing, bridge financing or other exit financing. The Company may make such investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">part of an in-court or out-of-court restructuring of</div></div></div> an issuer of Portfolio Investments, and any such investment will be subject to the same risks as other Portfolio Investments of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contractual subordination provisions are enforceable when a borrower is in bankruptcy, as are most inter-creditor agreement terms. Furthermore, there are instances where creditors and equity holders may lose their ranking and priority when they take over management and functional operating control of a debtor. In those cases where the Company, by virtue of such action, is found to exercise “domination and control” of a debtor, the Company may lose its priority if the debtor or other creditors can demonstrate that the debtor’s business was adversely impacted or other creditors and/or equity holders were harmed by improper or unfair actions of the Company, whether or not the Company is found to be a controlling party of the debtor. In addition, loans extended to a financially distressed borrower by an entity that owns an equity interest in the borrower may be reclassified as having been an equity capital contribution, rather than a debt obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the corporate structure of various debtor entities, such as special purpose entities created to hold assets and to structure for bankruptcy remoteness, such entities may, in certain cases, be consolidated in bankruptcy proceedings, which can affect the outcome of such proceedings and the amounts ultimately received by creditors. In addition, if a claim can be asserted against only a parent holding entity, such claim may be structurally subordinated to claims against a subsidiary entity that owns assets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Bankruptcy Code and other laws and regulations affecting debtors’ and creditors’ rights are subject to change, including by way of legislative action or judicial interpretation. In addition, governmental actors have recently shown a willingness to intervene in bankruptcy-related matters (for example, the U.S. government’s bailouts of General Motors and Chrysler), which may increase uncertainty regarding the enforcement of creditors’ rights and the bankruptcy process generally. Any such actions could alter the expected outcome or introduce greater uncertainty regarding the expected outcome of an investment situation of the Company, which may adversely affect such investment or the Company’s investment program. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lack of Control over Investments</div>. The Company invests in debt securities, but <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">may hold a non-controlling interest in</div> one or more Portfolio Investments. Such investments may not give the Company the ability to influence the management of the company or to elect a representative to the Board. In addition, the management of the company or its shareholders may have economic or business interests which are inconsistent with those of the Company, and they may be in a position to take action contrary to the Company’s objectives. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest may be especially adverse to the Company in circumstances, such as certain stressed or distressed situations, where an element of control or influence might be beneficial to the subject investment. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Control Positions</div>. The Company does not expect to, but may have a controlling interest in a Portfolio Investment (because of its equity ownership, representation on the board of directors and/or contractual rights) either on its own or, in certain cases, with another financial partner or investment fund (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.,</div></div> in accordance with the Company’s receipt of equity in connection with a restructuring). The exercise of control over a company may impose additional risks of liability for environmental damage, product defects, failure to supervise management, pension and other fringe benefits, violation of governmental regulations (including securities laws) or other types of related liability. If these liabilities were to arise, the Company might suffer a significant loss in such investment. In addition, if employees of the Adviser serve as directors of certain of the Portfolio Investments, including public companies, they will have duties to persons other than the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that the Company owns a controlling stake in or is deemed an affiliate of a particular company, it may also be subject to certain additional bankruptcy or securities laws restrictions that could affect both the liquidity of the Company’s interest and the Company’s ability to liquidate its interest without adversely impacting the price thereof, including insider trading restrictions, the affiliate sale restrictions of Rule 144 of the Securities Act and the disclosure requirements of Sections 13 and 16 of the 1934 Act. Further, to the extent that affiliates of the Company or the Adviser are subject to such restrictions, the Company, by virtue of its affiliation with such entities, may be similarly restricted, regardless of whether the Company stands to benefit from such affiliate’s ownership. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company, alone or as part of a group acting together for certain purposes, becomes the beneficial owner of more than 10% of certain classes of securities of a U.S. public company or places a director on the board of directors of such a company, the Company may be subject to certain additional reporting requirements and to liability for short-swing profits under Section 16 of the 1934 Act. Furthermore, the Company may also be subject to similar reporting requirements and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other limitations in non-U.S. jurisdictions where</div> it holds significant positions in companies in such jurisdictions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise of control over a company, depending upon the amount and type of securities owned by the Company, contractual arrangements between the company and the Company, and other relevant factual circumstances, could result in an extension to one year of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day bankruptcy preference</div> period with respect to payments made to the Company. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Fraudulent Conveyance and Preference Considerations</div>” below. The exercise of control over a company may also provide grounds for challenges to the priority and enforceability of Portfolio Investments or other claims the Company may have against the company if it is subject to a bankruptcy case or other insolvency proceeding. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lender Liability Considerations and Equitable Subordination</div>” below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lender Liability Considerations and Equitable Subordination</div>. In recent years, a number of judicial decisions in the U.S. have upheld the right of borrowers to sue lending institutions on the basis of various evolving legal theories (collectively termed “lender liability”). Generally, lender liability is founded upon the premise that an institutional lender has violated a duty (whether implied or contractual) of good faith and fair dealing owed to the borrower or has assumed a degree of control over the borrower resulting in creation of a fiduciary duty owed to the borrower or its other creditors or shareholders. In addition, courts have in some cases applied the doctrine of equitable subordination to subordinate the claim against a borrower of a creditor, including a lending institution, to claims of other creditors of the borrower when the creditor is found to have engaged in unfair, inequitable or fraudulent conduct. There can be no assurance as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire such claims engaged in any such conduct and, if it did, as to whether the Company would be subject to claims that the Company’s Portfolio Investments should be equitably subordinated based on such conduct. Because of the nature of certain of the Company’s Portfolio Investments, the Company could be subject to allegations of lender liability or to claims that the Company’s Portfolio Investments should be <div style="display:inline;">equitably </div>subordinated. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Fraudulent Conveyance and Preference Considerations</div>. Various federal and state laws enacted for the protection of creditors may apply to the purchase of the Company’s Portfolio Investments, or payments or liens related thereto, by virtue of the Company’s role as a creditor with respect to the borrowers under such Portfolio Investments. If a court, in a lawsuit brought by an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">unpaid creditor, a debtor-in-possession, a trustee</div></div> in bankruptcy, or their respective representatives, were to find that the borrower took any action to intentionally delay or frustrate recoveries by creditors, or did not receive fair consideration or reasonably equivalent value for incurring indebtedness evidenced by an investment and the grant of any security interest or other lien securing such investment, and, after giving effect to such indebtedness and/or grant of any security interest or other lien, the issuer or obligor (i) was insolvent, (ii) was engaged in a business for which the remaining assets of such issuer constituted unreasonably small capital or (iii) intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature, such court could, under certain circumstances, invalidate, in whole or in part, such indebtedness and such security interest or other lien as fraudulent conveyances, could subordinate such indebtedness to existing or future creditors of the borrower and could allow the borrower to recover amounts previously paid by the borrower to the creditor (including to the Company) in satisfaction of such indebtedness or proceeds of such security interest or other lien previously applied in satisfaction of such indebtedness. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The measure of insolvency for purposes of the foregoing will vary. Generally, an issuer or obligor would be considered insolvent at a particular time if the sum of its debts were then greater than all of its property at a fair valuation, or if the present fair saleable value of its assets were less than the amount that would be required to pay its probable liabilities on its existing debts as they became absolute and matured. There can be no assurance as to what standard a court would apply in order to determine whether the issuer or obligor was “insolvent” after giving effect to the incurrence of the indebtedness and/or the granting of any security interest or other lien or that, regardless of the method of valuation, a court would not determine that the issuer was “insolvent” upon giving effect to such incurrence of indebtedness and/or grant of security interests or other lien. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may invest in bank debt or other indebtedness issued by a borrower which is guaranteed by other entities within the borrower’s corporate family. In such circumstances, the borrower often has little or no assets other than the stock of its subsidiaries and, as a result, any recovery is often available only, if at all, from the entities that guaranteed the indebtedness. There is a risk, however, that the obligations of such guarantors and any security interests or other liens issued by the guarantors to secure such obligations may be avoided as fraudulent conveyances in the event that a court were to determine that such guarantors did not receive reasonably equivalent value in exchange for the issuance of the guarantees and for the security interests or other liens. A court could determine that the guarantors did not receive reasonably equivalent value or fair consideration in incurring the obligations and granting the security interests or other liens despite the existence of “indirect” benefits to the guarantors, such as the strengthening of the corporate enterprise in the transaction. Additionally, provisions in guarantees and other similar documents governing similar obligations by which fraudulent conveyance exposure is sought to be reduced or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">eliminated, such as so-called “savings clauses,”</div> may not be enforceable. As a result, the Company’s Portfolio Investment in corporate bank debt or other indebtedness could be subject to avoidance as a fraudulent conveyance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a transaction is found to have been a fraudulent conveyance, the transferee may be compelled to return the value of the assets transferred as of the time of the transfer, even if the then current value is substantially less. In addition, unless the transferee is deemed to be a “good faith” transferee, the return of the asset may not even provide for the compensation back to the transferee of the value paid to the transferor. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the event of the insolvency (as determined by a court based on the law of the jurisdiction which is being applied) of an issuer of a Portfolio Investment, payments made on the Company’s Portfolio Investment, or new liens granted, could be subject to avoidance as a “preference” if made within a certain period of time (which may be as long as one year) before insolvency, depending on a number of factors. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, if payments on a Company’s Portfolio Investment are avoidable, whether as a fraudulent conveyance or preference, such payments can be recaptured either from the initial recipient (such as the Company) or from subsequent transferees of such payments, including Unitholders. Additionally, if the grant of a security interest or other lien is avoidable, whether as a fraudulent conveyance or preference, the value of the security interest or other lien can be recovered from the initial transferee or the entity for whose benefit such transfer was made (such as the Company), and such recovery could include the diminution in value of the property which was subject to the security interest or other lien from the date of transfer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that a successful cause of action for fraudulent conveyance or preference will not occur, or as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire a Portfolio Investment engaged in any conduct to give rise to such causes of action, and if it did, as to whether such causes of action could be asserted against the Company and/or the Unitholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Portfolio Investment Risk</div>. The Company’s Portfolio Investments may involve a high degree of business and financial risk. Portfolio Investments may be in early stages of development, may have operating losses or significant variations in operating results and may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence. Portfolio Investments will also include companies that are experiencing or are expected to experience financial difficulties, which may never be overcome. In addition, many of them will have weak financial conditions and may require substantial additional capital to support their operations, to finance expansion or to maintain their competitive positions. Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive development, manufacturing, marketing, and other capabilities and a larger number of qualified managerial and technical personnel. In addition, Portfolio Investments in which the Company invests may be required to comply with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">numerous U.S. and non-U.S. statutory and</div> regulatory standards. A Portfolio Investment could be materially and adversely affected as a result of statutory or regulatory changes or changes in judicial or administrative interpretations of existing laws and regulations that impose more comprehensive or stringent requirements on such Portfolio Investment, the markets in which such Portfolio Investment operates or such Portfolio Investment’s industry generally. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that a Portfolio Investment’s management team will be able to operate such Portfolio Investment successfully. In addition, instances of fraud or other illegal practices committed by the management team of a Portfolio Investment may undermine the Company’s investment in such Portfolio Investment and the Company may suffer losses. Additionally, Portfolio Investments need to attract, retain and develop executives and members of their management teams. There can be no assurance that a Portfolio Investment will be able to attract and develop suitable <div style="display:inline;">members </div>of its management team, which may adversely affect the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Zero-Coupon Bonds, Deferred Interest Rate Bonds and</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> Payment-In-Kind</div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Securities</div>. Zero-coupon bonds pay interest only at maturity rather than at intervals during the life of the security. Deferred interest rate bonds generally provide for a period of delay before the regular payment of interest begins. PIK securities are debt obligations that pay “interest” in the form of other debt obligations, instead of in cash. Each of these instruments is normally issued and traded at a deep discount from face value. Zero-coupon bonds, deferred interest rate bonds and PIKs allow an issuer to avoid or delay the need to generate cash to meet current interest payments and, as a result, may involve greater credit risk than bonds that pay interest currently or in cash. In addition, such investments experience greater volatility in market value due to changes in interest rates than debt obligations that provide for regular payments of interest. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company invests in OID instruments, including PIK, zero coupon bonds, and debt securities with attached warrants, investors will be exposed to the risks associated with the inclusion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">such non-cash income</div> in taxable and accounting income prior to receipt of cash, including the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The interest payments deferred on a PIK loan are subject to the risk that the borrower may default when the deferred payments are due in cash at the maturity of the loan; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The interest rates on PIK loans are higher to reflect the time-value of money on deferred interest payments and the higher credit risk of borrowers who may need to defer interest payments; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">PIK instruments may have unreliable valuations because the accruals require judgments about ultimate collectability of the deferred payments and the value of the associated collateral; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">An election to defer PIK income payments by adding them to principal increases the Company’s gross assets and, thus, increases future base fees to the Adviser and, because income payments will then be payable on a larger principal amount, the PIK election also increases the Adviser’s future income incentive fees at a compounding rate; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Market prices of OID instruments are more volatile because they are affected to a greater extent by interest rate changes than instruments that pay interest periodically in cash; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The deferral of interest on a PIK loan <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">increases its loan-to-value ratio,</div></div> which is a measure of the riskiness of a loan; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">OID creates the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">risk of non-refundable cash</div> payments to the Adviser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">based on non-cash accruals</div> that may never be realized. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Money Market and Other Liquid Instruments</div>. The Company may invest its assets in such liquid securities as the Adviser may deem to be advisable, including fixed income securities, money market instruments, money market mutual funds, and debt securities issued or guaranteed by the U.S., certain U.S. government agencies or instrumentalities. Money market instruments are short-term fixed income obligations, which generally have remaining maturities of one year or less, and may include commercial paper, certificates of deposit, and bankers’ acceptances issued by domestic branches of U.S. banks that are members of the FDIC. The Company may be prevented from achieving its investment objective during any period in which its assets are not substantially invested in accordance with its investment strategy. Notwithstanding their general high-quality nature, money market funds and liquid securities are subject to the risk of loss. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other liquid investments, the Company may invest cash, pending investment, reinvestment or distribution thereof or in connection with the maintenance of reserves, in money fund products offered from time to time by its Custodian, including the use of bank “sweep” short-term offerings. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pooled Investment Vehicles and Pass-through Entities</div>. The Company may invest or take short positions in pooled investment vehicle and pass-through entities, including affiliated or third-party unregistered investment vehicles, investment companies registered under the 1940 Act (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">exchange-traded funds and closed-end companies) and</div> master limited partnerships (“Pooled Investment Vehicles”). To the extent the Company invests directly in Pooled Investment Vehicles and other “pass-through” entities which are treated as partnerships for U.S. federal income taxation purposes, the Company must rely on such vehicles to deliver to it certain tax information that is necessary to complete the Company’s own tax returns. If this information is not delivered to the Company in a timely fashion, the Company will be delayed in providing tax information to the investors. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government and Agency Securities</div>. The Company may invest in debt securities issued or guaranteed by certain U.S. government agencies, instrumentalities and sponsored enterprises. Some U.S. government securities, such as Treasury bills, notes and bonds and MBS guaranteed by Ginnie Mae, are supported by the full faith and credit of the U.S.; others are supported by the right of the issuer to borrow from the U.S. Treasury; others are supported by the discretionary authority of the U.S. government to purchase the agency’s obligations; and still others are supported only by the credit of the instrumentality. Although U.S. government-sponsored enterprises, such as Fannie Mae and Freddie Mac, may be chartered or sponsored by Congress, they are not funded by Congressional appropriations, and their securities are not issued by the U.S. Treasury or supported by the full faith and credit of the U.S. government and involve increased credit risks. In addition, certain governmental entities have been subject to regulatory scrutiny regarding their accounting policies and practices and other concerns that may result in legislation, changes in regulatory oversight and/or other consequences that could adversely affect the credit quality, availability or investment character of securities issued by these entities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Securities</div>. It is expected that a significant portion of the Company’s Portfolio Investments will <div style="display:inline;">b</div>e securities (“restricted securities”) that have not been registered for sale to the public under the Securities Act pursuant to an exemption from registration (including Section 4(a)(2) of, or Rule 144A under, the Securities Act). Restricted securities are generally only sold to institutional investors in private sales from the issuer or from an affiliate of the issuer. These securities may be less liquid than securities registered for sale to the general public. The liquidity of a restricted security may be affected by a number of factors, including: (i) the credit quality of the issuer; (ii) the frequency of trades and quotes for the security; (iii) the number of dealers willing to purchase or sell the security and the number of other potential purchasers; (iv) dealer undertakings to make a market in the security; and (v) the nature of the security and the nature of marketplace trades. Also, restricted securities may be difficult to value because market quotations may not be readily available. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a debtor in a reorganization case may be granted a trading restriction order by a bankruptcy court in order to protect such debtor’s net operating losses (a “NOL Order”). Such an order may prohibit or severely restrict the ability of some creditors to sell their claims and interests in the debtor. The Company’s ability to transfer its interests in such a debtor may be impaired, delayed or prohibited as a consequence of a NOL Order. The Company may also incur added expenses if it attempts to challenge or limit the scope of a NOL Order, and such an attempt may not be successful. Similarly, issuers with net operating losses sometimes adopt Unitholder rights plans or similar arrangements in order to preserve the ability to utilize such net operating losses in the future; any such actions could also limit or otherwise adversely impact the Company’s ability to transfer or dispose of its interests in any such issuer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Disposition of Investments</div>. The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, IPOs, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized. See, for example, “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Bank Loans and Corporate Loans</div>” above. In particular, certain disposition techniques and structures may expose the Company to liability for (among other things) securities laws violations, breaches of representations and warranties, and repurchase or “putback” obligations with respect to securitizations or similar structures. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare and Life Science Industries’ Related Risks</div>. The Company intends to make investments in the healthcare and life science industries, although the Company may also opportunistically invest in other sectors in order to accomplish its investment objective. Investing in healthcare companies involves substantial risks. Such risks include, but are not limited to, the following: changes in government policies, including policies regarding reimbursement of medical expenses; certain companies in which the Company may invest may have limited or no operating histories/ or may have limited products, markets and financial resources; rapidly changing technologies may cause products to quickly become obsolete; unanticipated problems often arise in connection with the development of new products, and many such efforts are ultimately unsuccessful; scarcity of management and marketing personnel with appropriate technological or medical training may slow or impede companies’ growth; the possibility of lawsuits related to technological and medical patents could cause delays and expense in product development and implementation; regulatory changes and/or government actions may prevent a company from marketing its products; changing investors’ sentiments and preferences with regard to investments in healthcare companies (which may be perceived as risky) may have an adverse effect on the price of underlying securities; volatility in the U.S. stock markets affecting the prices of securities of healthcare and life sciences companies may cause the Company to experience substantial volatility; and certain healthcare and life sciences companies may be subject to extensive government regulation and affected by government reimbursement policy changes. In addition, many healthcare and life sciences companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or even under normal market conditions or such capital may be obtained on terms that are not favorable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, obtaining government approval for new products from governmental agencies can be lengthy, expensive and uncertain, and withdrawal or curtailment of government support could have an adverse impact on the profitability or market price of healthcare and life sciences companies. Furthermore, delays in generating products (as well as more general ongoing capital requirements) may result in the need for companies to seek additional capital, potentially diluting the interest of existing investors, such as the Company (and indirectly, the Unitholders). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investments in Healthcare Companies</div>. The success of the Company’s investments will depend on the successful implementation of its investment strategy and the healthcare industry generally. The Company’s investment strategy is subject to numerous and significant risks and uncertainties, some of which are highlighted generally below. The following is general information and does not purport to describe all risks associated with investing in the healthcare industry.</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sector Risk. </div></div>Sector risk is the risk associated with a Company holding a significant amount of investments in similar businesses, which would be similarly affected by particular economic or market events, which may, in certain circumstances, cause the value of the equity and debt securities of companies in a particular sector of the market to change. To the extent a Company has substantial holdings within a particular sector, the risks to a Company associated with that sector increase. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration Risk. </div></div>The Company’s principal focus is to invest in the healthcare and life sciences industry. The focus of the Company’s portfolio on a specific industry may present more risks than if its portfolio were broadly diversified over numerous industries and sectors of the economy. A downturn in this industry would have a larger impact on the Company than on an investment company that does not concentrate in such industry. At times, the performance of securities of companies in the healthcare industry will lag the performance of other industries or the broader market as a whole. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While investment in multiple opportunities may provide some diversification of investment risk, no assurance can be given that such diversification will occur, or if it does, that it will not reduce, rather than increase, potential net profits. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Inherent in Healthcare-Related Assets. </div></div>Substantially all of the Company’s investments will be in the healthcare industry. Concentration in one industry involves significant risks greater than those generally associated with diversified acquisition funds, including significant fluctuations in returns. The healthcare industry is challenged by factors such as government regulations; changes in government policies, including policies regarding reimbursement of medical expenses and policies that impact company’s abilities to market products; changes in technology, including changes that may cause products to quickly become obsolete; medical innovations and accompanied unanticipated problems; changes in healthcare practices or delivery systems; scarcity of management and marketing personnel with appropriate technological or medical training; possibilities of lawsuits related to technological and medical patents, and resulting delays and expenses in product development and implementation; changing macroeconomic conditions in the U.S. and globally, intense competition, susceptibility to natural disasters, large capital requirements and the introduction of new, competing healthcare facilities, properties or other leisure activities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companies in the healthcare sector are subject to extensive government regulation and their profitability can be significantly affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure (including price discounting), limited product lines and an increased emphasis on the delivery of healthcare through outpatient services. Companies in the healthcare sector are heavily dependent on obtaining and defending patents, which may be time consuming and costly, and the expiration of patents may also adversely affect the profitability of these companies. Healthcare companies are also subject to extensive litigation based on product liability and similar claims. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the healthcare sector require significant research and development and may be subject to regulatory approvals, all of which may be time consuming and costly with no guarantee that any product will come to market. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s assets will compete in a relatively uncertain political, economic, and regulatory environment, and instability or an overall decline within the healthcare sector will not be balanced by investments in industries not so affected. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, many healthcare companies may have substantial and ongoing capital needs for research and development, clinical trials and marketing and may have difficulty obtaining such funding under various market conditions or such capital may be obtained on terms that are not favorable to existing investors. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulations of Healthcare Industry. </div></div>The regulatory environment surrounding the healthcare industry has intensified both in the amount and type of regulations and in the efforts to enforce those regulations. The extensive federal, state, and local, laws and regulations affecting the healthcare industry include, but are not limited to, laws and regulations relating to licensure, certification as a Medicare and Medicaid provider, conduct of operations, ownership of facilities, addition of facilities and equipment, allowable costs, services, prices for services, quality of care, patient rights, patient abuse and neglect, fraudulent reimbursement practices, and financial and other arrangements which may be entered into by healthcare providers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Federal and state governments have intensified enforcement policies, resulting in a significant increase in the number of inspections, citations of regulatory deficiencies and other regulatory sanctions, including terminations from the Medicare and Medicaid programs, bans on Medicare and Medicaid payments for new admissions, civil monetary penalties and even criminal penalties. The Company’s investments could be forced to expend considerable resources on responding to an investigation or other enforcement action under applicable laws or regulations, The Company is unable to predict the future course of federal, state and local regulation or legislation, including the Medicare and Medicaid statutes and regulations. Changes in regulatory framework could have a material adverse effect on the Company’s Portfolio Investments and the Company. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Senior Secured Loans</div>. With respect to the Company’s investments in senior secured loans (including first lien loans), the Company will generally have a security interest in assets of the company, which should mitigate the risk that the Company will not be repaid. However, the collateral securing the Company’s loans may decrease in value over time, may be difficult to sell in a timely manner, may be difficult to appraise, and may fluctuate in value based upon the success of the business and market conditions, including as a result of the inability of the company to raise additional capital. In some circumstances, the Company’s lien could be subordinated to claims of other creditors. In addition, deterioration in a company’s financial condition and prospects, including its inability to raise additional capital, may be accompanied by deterioration in the value of the collateral for the loan. Consequently, the fact that a loan is secured does not guarantee that the Company will receive principal and interest payments according to the loan’s terms, or at all, or that the Company will be able to collect on the loan should it be forced to enforce its remedies. Furthermore, if a secured loan is foreclosed, the Company could own the underlying collateral (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, real estate), and would be subject to the risks, costs and liabilities associated with owning and disposing of the collateral. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Subordinated Loans</div>. The Company may invest in subordinated loans. In the event of a loss of value of the underlying assets that collateralize the loans, the subordinate portions of the loans may suffer a loss prior to the more senior portions suffering a loss. If a borrower defaults and lacks sufficient assets to satisfy the Company’s loan, the Company may suffer a loss of principal or interest. If a borrower declares bankruptcy, the Company may not have full recourse to the assets of the borrower, or the assets of the borrower may not be sufficient to satisfy the loan. In addition, certain of the Company’s loans may be subordinate to other debt of the borrower. As a result, if a borrower defaults on the Company’s loan or on debt senior to the Company’s loan, or in the event of the bankruptcy of a borrower, the Company’s loan will be satisfied only after all senior debt is paid in full. The Company’s ability to amend the terms of the Company’s loans, assign the Company’s loans, accept prepayments, exercise the Company’s remedies (through “standstill periods”) and control decisions made in bankruptcy proceedings relating to borrowers may be limited by intercreditor arrangements if debt senior to the Company’s loans exists. In addition, the Company will be subject to the potential risks of foreclosure and ownership of underlying collateral described in “<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">—Senior Secured Loans</div></div>” above. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mezzanine Securities</div>. The Company may invest in unsecured securities that are senior to common stock or other equity securities (“Mezzanine Securities”). Mezzanine Securities are subordinated to substantial amounts of senior debt, all or a portion of which may be secured. As a result, holders of Mezzanine Securities are generally not entitled to receive any payments in bankruptcy or liquidation until senior creditors are paid in full. In addition, the legal remedies available to holders of Mezzanine Securities are normally limited by restrictions benefiting senior creditors. In the event a company in which the Company holds Mezzanine Securities cannot generate adequate cash flow to meet senior debt service, the Company may suffer a partial or total loss of capital invested. Because issuers of Mezzanine Securities are often highly leveraged, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">their relatively high debt-to-equity ratios create</div></div> increased risks that their operations will not be able to generate adequate cash flow to meet senior debt service. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unsecured Loans or Debt</div>. The Company may invest in unsecured loans which are not secured by collateral. In the event of default on an unsecured loan, the first priority lien holder has first claim to the underlying collateral of the loan. It is possible that no collateral value would remain for an unsecured holder and therefore result in a loss of investment to the Company. Because unsecured loans are lower in priority of payment to secured loans, they are subject to the additional risk that the cash flow of the borrower may be insufficient to meet scheduled payments after giving effect to the secured obligations of the borrower. Unsecured loans generally have greater price volatility than secured loans and may be less liquid. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Prepayment Risk</div>. The terms of loans in which the Company invests may permit borrowers to voluntarily prepay loans at any time, <div style="display:inline;">either </div>with no or a nominal prepayment premium. This prepayment right could result in the borrower repaying the principal on an obligation held by the Company earlier than expected. This may happen when there is a decline in interest rates or when the borrower’s improved credit or operating or financial performance allows the refinancing of certain classes of debt with lower cost debt. The yield of the Company’s investment assets may be affected by the rate of prepayments differing from the Adviser’s expectations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investment Modification Risk</div>. The terms and conditions of loan agreements and related assignments may be amended, modified or waived only by the agreement of the lenders. Generally, any such agreement must include a majority or a super majority (measured by outstanding loans or commitments) or, in certain circumstances, a unanimous vote of the lenders. Consequently, the terms and conditions of the payment obligation arising from Portfolio Investments could be modified, amended or waived in a manner contrary to the preferences of the Company if a sufficient number of the other lenders concurred with such modification, amendment or waiver. There can be no assurance that any obligations arising from a Portfolio Investment will maintain the terms and conditions to which the Company originally agreed. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Collateral Risk</div>. The collateral and security arrangements in relation to such secured obligations as the Company may invest in will be subject to such security or collateral having been correctly created and perfected and any applicable legal or regulatory requirements which may restrict the giving of collateral or security by an obligor, such as, for example, thin capitalization, over-indebtedness, financial assistance and corporate benefit requirements. If one or more Portfolio Investments do not benefit from the expected collateral or security arrangements, this may adversely affect the value of or, in the event of default, the recovery of principal or interest from such Portfolio Investments made by the Company. Accordingly, any such failure to properly create or perfect collateral and security interests attaching to the Portfolio Investments could have a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units. A component of the Adviser’s analysis of the desirability of making a given investment relates to the estimated residual or recovery value of such Portfolio Investments in the event of the insolvency of the obligor. This residual or recovery value will be driven primarily by the value of the anticipated future cash flows of the obligor’s business and by the value of any underlying assets constituting the collateral for such Portfolio Investment. The anticipated future cash flows of the obligor’s business and the value of collateral can, however, be extremely difficult to predict as in certain circumstances market quotations and third-party pricing information may not be available. If the recovery value of the collateral associated with the Portfolio Investments in which the Company invests decreases or is materially worse than expected by the Company, such a decrease or deficiency may affect the value of the Portfolio Investments made by the Company. Accordingly, there may be a material adverse effect on the performance of the Company, and, by extension, the Company’s business, financial condition, results of operations and the value of the Units. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Defaults</div>. The Company may make investments in loans, or securities backed by loans, that may be at the time of their acquisition, or may become <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after acquisition, non-performing loans.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any default under a loan directly held by the Company or a loan underlying a security held by the Company, the Company will bear a risk of loss of principal to the extent of any deficiency between the value of the collateral and the principal and accrued interest of the loan, which could have a material adverse effect on the Company’s cash flow <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">from operations. Other non-performing loans may</div> require workout negotiations and/or restructuring, which may entail, among other things, a substantial reduction in the interest rate and/or a substantial write-down of the original principal amount of such loans. Further, even if a restructuring were successfully accomplished, unless the restructuring provided for full amortization on or prior to maturity and the borrower strictly complied with that restructuring, a risk exists that upon maturity of such loans, replacement financing will not be available and such loans may not be repaid. In the event of the bankruptcy of a borrower, the loan to that borrower will be deemed to be secured only to the extent of the value of the underlying collateral at the time of bankruptcy (as determined by the bankruptcy court), the lien securing the loan will be subject to the avoidance powers of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bankruptcy trustee or debtor-in-possession to the</div></div> extent the lien is unenforceable under state law, and realizing any value under such circumstances can be an expensive and lengthy process that could have a substantial negative effect on the anticipated return on the loan and on the security backed by such loan. Other risks attendant to a bankruptcy filing are described below. The foregoing statement does not apply in the context of a borrower insolvency case commenced under chapter 13 of the U.S. Bankruptcy Code where the underlying collateral is used as the principal residence of the borrower, but in such instances, the lender will nonetheless be stayed from the collection of its claim, taking possession of the collateral, and enforcing its lien unless and until the lender obtains relief from the automatic stay under the U.S. Bankruptcy Code. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Litigation and Related Risks Associated with Origination and Servicing</div>. Loan origination and servicing companies are routinely involved in legal proceedings concerning matters that arise in the ordinary course of their business. These legal proceedings range from actions involving a single plaintiff to class action lawsuits with potentially tens of thousands of class members. In addition, a number of participants in the loan origination and servicing industry (including control persons of industry participants) have been the subject of regulatory actions by state regulators, including state Attorneys General, and by the federal government. Governmental investigations, examinations or regulatory actions, or private lawsuits, including purported class action lawsuits, may adversely affect such companies’ financial results. To the extent the Company seeks to engage in origination and/or servicing directly, or has a financial interest in, or is otherwise affiliated with, an origination or servicing company, the Company will be subject to enhanced risks of litigation, regulatory actions and other proceedings. As a result, the Company may be required to pay legal fees, settlement costs, damages, penalties or other charges, any or all of which could materially adversely affect the Company and its investments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Ability to Originate Loans on Advantageous Terms; Competition and Supply</div>. The Company’s success depends, in part, on the ability of the Company or its affiliates to originate loans on advantageous terms. In originating and purchasing loans, the Company or its affiliates will compete with a broad spectrum of lenders. Increased competition for, or a diminishment in the available supply of, qualifying loans could result in lower yields on such loans, which could reduce returns (if any) to investors. The Company intends to originate certain investments and later offer to syndicate all or a portion of one or more investments to certain other funds or accounts managed by the Adviser and its affiliates, in each case subject to their own investment-review <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">process, and to co-investors and/or third</div> parties. Prior to such syndication, or if such syndication is not successful, the Company’s exposure to the originated investment may exceed the exposure that the Company intends to have over the long-term or would have had if it had purchased such investment in the secondary market rather than originating it. Where </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">syndication is not successful, the Company may elect to sell all or a portion of an originated investment at a loss in order to rebalance the Company’s portfolio. The level of analytical sophistication, both financial and legal, necessary for successful financing to companies, particularly companies experiencing significant business and financial difficulties is unusually high. There is no assurance that the Adviser will correctly evaluate the value of the assets collateralizing the Company loans, the prospects for successful repayment or a successful reorganization or similar action. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Bank Loans and Corporate Loans</div>. Bank loans and corporate loans (which the Company will originate, invest in or otherwise gain exposure to) may not be readily marketable and may be subject to restrictions on resale. In some cases, negotiations involved in disposing of indebtedness may require weeks to complete. Consequently, some indebtedness may be difficult or impossible to dispose of readily at what the Adviser believes to be a fair price. In addition, bank loans and corporate loans are often less liquid than other types of debt securities, particularly in times of significant market dislocation. Loans to small and middle market entities (“SMEs”) may involve certain heightened risks. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investments in Smaller and Middle Market Companies</div>” below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of bank loans, corporate loans and other forms of direct indebtedness depend primarily upon the creditworthiness of the corporate or other borrower for payment of principal and interest. If the Company does not receive scheduled interest or principal payments on such indebtedness, the value of the Company’s investments could be adversely affected. The Company may invest in secured and unsecured bank loans and corporate loans. Bank loans and corporate loans that are fully secured may offer the Company more protection than an unsecured loan in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the event of non-payment of scheduled</div> interest or principal. However, there is no assurance that the liquidation of any collateral from a secured bank loan or corporate loan would satisfy the borrower’s obligation, or that such collateral could be liquidated. In the event of the bankruptcy of a borrower, the Company could experience delays or limitations in its ability to realize the benefits of any collateral securing a loan and could be compelled to accept new instruments or interests in respect of its claims under the bank loan in a plan of reorganization. These new instruments or interests may be on terms different from prevailing market terms for similar instruments and interests. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank loans usually require, in addition to scheduled payments of interest and principal, the prepayment of the bank loan from free cash flow. The degree to which borrowers prepay bank loans, whether as a contractual requirement or at their election, may be affected by general business conditions, the financial condition of the borrower and competitive conditions among lenders, among others. As such, prepayments cannot be predicted with accuracy. Upon a prepayment, either in part or in full, the actual outstanding debt on which the Company derives interest income will be reduced. The effect of prepayments on the Company’s performance may or may not be mitigated by the receipt of prepayment fees and/or the Company’s reinvestment of prepayments in other bank loans that have similar or identical yields. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may purchase “assignments” of bank loans from lenders. The purchaser of an assignment typically succeeds to all the rights and obligations under the loan agreement with the same rights and obligations as the assigning lender. Assignments may, however, be arranged through private negotiations between potential assignees and potential assignors, and the rights and obligations acquired by the purchaser of an assignment may differ from, and be more limited than, those held by the assigning lender. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may also invest in “participations” in bank loans. Participations by the Company in a lender’s portion of a bank loan typically will result in the Company having a contractual relationship only with such lender, not with the borrower. As a result, the Company may have the right to receive payments of principal, interest and any fees to which it is entitled only from the lender selling the participation and only upon receipt by </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such lender of such payments from the borrower. In connection with purchasing participations, the Company generally will have no right to enforce compliance by the borrower with the terms of the loan agreement, nor any rights with respect to any funds acquired by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other lenders through set-off against the</div> borrower, and the Company may not directly benefit from any collateral supporting the bank loan in which it has purchased the participation. As a result, the Company assumes the credit risk of both the borrower and the lender selling the participation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In many cases bank loans and loan participations would not be deemed to be securities for purposes of U.S. federal and/or state securities laws. As a result, an investment in bank loans would not be afforded the same protections as an investment in securities, such as the extensive disclosure requirements under U.S. federal and/or state securities laws, which may adversely impact the Company’s ability to seek recourse in respect of such investments. Similarly, the documentation evidencing bank loans and loan participations will not necessarily be maintained with the Company’s custodian. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Economic and Market Risk</div>. The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally, such as real or perceived adverse economic conditions, supply and demand for particular instruments, changes in the general outlook for certain markets or corporate earnings, interest rates, announcements of political information or adverse investor sentiment generally. The market values of the Company’s investments may decline for a number of reasons, including increases in defaults resulting from changes in overall economic conditions and widening of credit spreads. Unfavorable market conditions may also increase funding costs, limit access to the capital markets or result in credit terms changing or credit becoming unavailable. These events could have an adverse effect on the Company’s investments and the Company’s overall performance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may also contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide. Such events, including rising trade tensions between the United States and China, other uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies with other countries, the large-scale invasion of Ukraine by Russia that began in February 2022 and resulting sanctions or other restrictive actions that the United States and other countries have imposed against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Russia, the COVID-19 pandemic,</div> certain regional bank failures, an inflationary environment and the ongoing war in the Middle East, could adversely affect the Company’s business, financial condition or results of operations. These market and economic disruptions could negatively impact the operating results of the Company’s Portfolio Investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Federal Reserve raised the Federal Funds Rate in 2022 and in 2023. Although the Federal Reserve left its benchmark rates steady in the fourth quarter of 2023, it has indicated that additional rate increases in the future may be necessary to mitigate inflationary pressures and there can be no assurance that the Federal Reserve will not make upward adjustments to the federal funds rate in 2024. However, there are reports that the Federal Reserve may begin to cut the benchmark rates. These developments, along with the United States government’s credit and deficit concerns, global economic uncertainties and market volatility and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">impacts of COVID-19, could</div> cause interest rates to be volatile, which may negatively impact the Company’s ability to access the debt markets and capital markets on favorable terms. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Continuing market uncertainty may have a significant impact on the business of the Company. Among other things, the level of investment opportunities may decline from the Adviser’s current expectations. One possible consequence is that the Company may take a longer than anticipated period to invest capital and/or the Company may be relatively concentrated in a limited number of investments. Consequently, during this period, the returns (if any) realized by Unitholders may be substantially adversely affected by the unfavorable performance of a small number of these investments. Furthermore, market conditions may unfavorably impact the Company’s ability to secure leverage on terms as favorable as more established borrowers in the market, or to obtain any leverage on commercially favorable terms. To the extent the Company is able to secure financing for investments, increases in interest rates or in the risk spread demanded by financing sources would make the use of leverage more expensive and could limit the Company’s ability to structure and consummate its investments. Although the Adviser believes that recent market dislocations will result in attractive investment opportunities, the Company may not be able to time the acquisition or disposition of its investments correctly, which could result in further depreciation in values. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Public Health Crises Risk</div>. Periods of market volatility have occurred and could continue to occur in response to pandemics or other events outside of the Company’s control. These types of events have adversely affected and could continue to adversely affect operating results for the Company and for its Portfolio Investments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">example, the COVID-19 pandemic</div> has adversely impacted global commercial activity and contributed to significant volatility in the equity and debt markets. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and restrictive measures taken to contain or mitigate its spread have caused, and are continuing to cause, business shutdowns, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the re-introduction</div> of business shutdowns, cancellations of events and restrictions on travel, significant reductions in demand for certain goods and services, reductions in business activity and financial transactions, supply chain interruptions, labor shortages, increased inflationary pressure and overall economic and financial market instability both globally and in the United States. Many states, including those in which the Company and Portfolio Investments may operate, have issued orders requiring the closure of, or certain restrictions on the operation of, certain businesses. Such actions and effects remain ongoing and the ultimate duration and severity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19</div> pandemic, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">including COVID-19</div> variants, remain uncertain. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite actions of the U.S. federal government and foreign governments, the uncertainty surrounding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19</div> pandemic, including uncertainty regarding existing or future variants and other factors, has contributed to significant volatility in the global public equity markets and global debt capital markets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Credit Risk</div>. The Company is subject to significant credit risk (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i.e.</div></div>, the risk that an issuer or borrower will default in the payment of principal and/or interest on an instrument) in light of its investment strategy. Credit risk also includes the risk that a counterparty to a derivatives transaction (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, a swap counterparty) will be unwilling or unable to meet its obligations. Financial strength and solvency of an issuer or borrower are the primary factors influencing credit risk. In addition, degree of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">subordination, lack or inadequacy of collateral or credit enhancement for a debt instrument may affect its credit risk. The degree of credit risk associated with any particular Portfolio Investment or any collateral relating thereto may be difficult or impossible for the Adviser to determine within reasonable standards of predictability. The Adviser utilizes various third parties that hold Company assets (such as the Custodian and prime brokers) in implementing the Company’s investment strategy, and the Company will therefore also be subject to credit risk with respect to such entities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although most of the Company’s investments will not be rated by any credit rating agency, in some cases, the credit risk of some of the Company’s Portfolio Investments may be broadly gauged by the credit ratings of such Portfolio Investments. However, ratings are only the opinions of the agencies issuing them, may change less quickly than relevant circumstances, are not absolute guarantees of the quality of the rated securities and are subject to downgrade. Credit ratings and ratings agencies have recently been criticized for ratings which did not fully reflect the risks of certain securities or which did not reflect such risks in a timely manner. For most investments, however, the Adviser will rely on its own independent analysis of the credit quality and risks associated with individual securities considered for the Company, rather than relying on ratings agencies or third-party research. Therefore, the Adviser’s capabilities in analyzing credit quality and associated risks will be particularly important (especially since it is currently anticipated that most of the Company’s assets will not be rated by a ratings agency or will be rated below investment grade), and there can be no assurance that the Adviser will be successful in this regard. See also “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">High Yield Debt and Unrated Securities</div>” below. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Leverage Risks</div>. The Company employs leverage and otherwise incurs indebtedness with respect to the portfolio both on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a recourse or non-recourse basis (including</div> through guarantees, derivatives, forward commitments and reverse repurchase agreements). The Company is not required to take any action (including unwinding or liquidating any position) in the event that such guideline is exceeded subsequent to the borrowing date, whether in the event of changes in the market value of the Company’s portfolio or otherwise. Prospective investors in the Company should expect that the effective leverage utilized by the Company may exceed such guideline, which only applies to direct borrowings; for instance, economic leverage inherent in the Company’s derivatives transactions and other investments will not be counted for purposes of such guideline, notwithstanding that such investments will be subject to many of the leverage-related risks described herein. In addition, determinations relating to leverage are inherently subjective and will involve the exercise of discretion by the Adviser (for instance, the Adviser may deem the amount of the Company’s direct borrowings to be reduced by cash and cash equivalents held by the Company or by a counterparty). See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Leveraged Companies</div>” below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of leverage has the potential to magnify the gains or the losses on investments and to make the Company’s returns more volatile. Moreover, if the Company is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">required to de-lever as</div> a result of changing market conditions or otherwise, it may be forced to sell Portfolio Investments at inopportune times or at disadvantageous prices. On the other hand, while the Company will have the flexibility to use leverage, there can be no guarantee that leverage can be obtained, or obtained on terms and pricing the Adviser finds attractive, especially in the current market environment. As a result, prospective investors in the Company should recognize that Portfolio Investments may not be leveraged, or may be leveraged at an amount below any leverage level otherwise expected by the Adviser. Moreover, even if leverage can be arranged, the Company is not obligated to utilize such leverage and may do so at the sole discretion of the Adviser. Should leverage not be obtained or utilized by the Company, the returns for the Company may be lower than they would have been had such leverage been obtained and utilized. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with any leverage utilized by the Company, the Company may secure its obligations with respect thereto with any and all of its assets, including its right to receive capital contributions from the Unitholders, pursuant to a pledge or other security agreement on terms that the Company determines are fair and reasonable to the Company. If the Company were to default on its obligations under such transactions, the counterparty could foreclose on the collateral and take possession of the Company’s assets and/or call capital from the Unitholders for purposes of repaying debt. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of any leverage utilized by the Company are likely to impose significant restrictions on the Company’s operations and investment program, including as to the Company’s ability to pay distributions, incur additional leverage and engage in certain transactions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Investments in Smaller and Middle Market Companies</div>. The Company generally invests in smaller and middle market companies. While smaller and middle market companies generally have potential for rapid growth, they often involve higher risks because they may lack the management experience, financial resources, product diversification, competitive strength and access to capital of larger companies. In addition, in many instances, the frequency and volume of the trading of securities for such companies may be substantially less than is typical of larger companies. As a result, the securities of smaller and middle market companies may be subject to wider price fluctuations. When liquidating positions in smaller and middle market companies, the Company may have to sell portfolio holdings at discounts from quoted prices or may have to make a series of small transactions over an extended period of time. Investments in such companies may also be particularly difficult to analyze due to (among other factors) limited attention from analysts and large institutional investors, limited access to liquidity sources and, in certain cases, limited publicly available financial information. With respect to the Company’s investments in SMEs and similar loans, the Company may receive less borrower information, receive less collateral and be subject to heightened default risk as compared to loans made to other types of entities. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Hedging Transactions and Related Risks</div>. The Company may, but is not required to, engage in hedging transactions. In particular, as many of the Company’s Portfolio Investments are expected to consist of relatively illiquid securities whose price behavior is not particularly correlated to general fixed income or equity index returns, such Portfolio Investments are expected to be difficult or expensive to hedge, and as such the Company may not employ any hedging strategy in respect of such Portfolio Investments (including with respect to their credit risk). To the extent the Adviser employs a hedging strategy for the Company, the success of any such hedging strategy will depend, in part, upon the Adviser’s ability to correctly assess the degree of correlation between the performance of the instruments used in the hedging strategy and the performance of the investments being hedged. Since the characteristics of many securities change as markets change or time passes, the success of the Company’s hedging strategy will also be subject to the Adviser’s ability to continually recalculate, readjust and execute hedges in an efficient and timely manner. While the Company may enter into hedging transactions to seek to reduce risk, such transactions may result in a poorer overall performance for the Company than if it had not engaged in such hedging transactions. For a variety of reasons, the Adviser may not seek to establish a precise correlation between the hedging instruments utilized and the portfolio holdings being hedged. Such an imprecise correlation may prevent the Company from achieving the intended hedge or expose the Company to risk of loss. Additionally, the Adviser may not hedge against a particular risk because it does not regard the probability of the risk occurring to be sufficiently high as to justify the cost of the hedge, or because it does not foresee the occurrence of the risk. Moreover, there is no guarantee that the Company’s intended hedging strategy will be successful in hedging out the subject risks. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Due Diligence Risk</div>. When conducting due diligence and making an assessment regarding a Portfolio Investment, the Adviser relies on the resources available to it, including internal sources of information as well as information provided by third parties. The due diligence process may at times be required to rely on limited or incomplete information. The Adviser selects Portfolio Investments in part on the basis of information and data filed with various government regulators and publicly available or made directly available by prospective portfolio companies or third parties. The Adviser expects that it will not be in a position to confirm the completeness, genuineness or accuracy of such information and data, and will therefore be dependent upon the integrity of the management of the entities filing such information and of such portfolio companies and third parties providing such information. In addition, there can be no assurance that any consultants or experts engaged by the Adviser will accurately evaluate such Portfolio Investments. Investment analyses and decisions by the Adviser may be undertaken on an expedited basis to enable the Company to take advantage of investment opportunities with accelerated timelines. In such cases, the available information at the time of an investment decision may be limited, inaccurate and/or incomplete. Accordingly, the Adviser cannot guarantee that its due diligence investigations will reveal or highlight all relevant facts that may be necessary or helpful in evaluating investment opportunities. Furthermore, the Company bears its proportionate share of all due diligence-related fees, costs, expenses and liabilities (including in respect of investments that are not ultimately consummated); such fees, costs, expenses and liabilities may be significant and could reduce Company returns. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Interest Rate Risk</div>. Interest rate risk refers to the risks associated with market changes in interest rates. In general, rising interest rates, such as the recent economic period, will negatively impact the price of fixed rate debt instruments and falling interest rates will have a positive effect on the price of such debt instruments. Many of the Company’s investments are expected to be variable rate loans with interest that adjusts with market rates. These loans will generally also react to interest rate changes in a similar manner although generally to a lesser degree (depending, however, on the characteristics of the reset terms, including the index chosen, frequency of reset and reset caps or floors, among other factors). The Company’s other investments and transactions may also be affected by changes in interest rates. Declines in market value, if not offset by any corresponding gains on hedging instruments, may ultimately reduce earnings or result in losses to the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prices of long-term debt obligations generally fluctuate more than prices of short-term debt obligations as interest rates change. To the extent the Company invests in longer-term Portfolio Investments, it will be impacted to a greater degree by changes in market interest rates than if the Company invested primarily in short-term debt securities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company borrows money or issues preferred Units to make investments, its net investment income will depend, in part, upon the difference between the rate at which it borrows funds or pays distributions on preferred Units and the rate at which the Company invests those funds. As a result, the Company can offer no assurance that a significant change in market interest rates will not have a material adverse effect on its net investment income in the event the Company uses debt to finance investments. In periods of rising interest rates, such as the recent economic period, the Company’s cost of funds will increase because the interest rates on the amounts borrowed under the Company’s credit facilities or certain other financing arrangements will typically be floating, which could reduce the Company’s net investment income to the extent any Portfolio Investments have fixed interest rates, and the interest rate on Portfolio Investments with an interest rate floor (such as a SOFR (as defined below) floor) above then-current levels will not increase until interest rates exceed the applicable minimum interest rate floor. Rising interest rates may also increase the cost of debt for the Portfolio Investments, which could adversely impact the Portfolio Investment’s financial performance and ability to meet ongoing obligations to the Company. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects that its long-term fixed-rate investments will be financed primarily with equity and long-term debt. The Company may use interest rate risk management techniques in an effort to limit its exposure to interest rate fluctuations. Such techniques may include various interest rate hedging activities to the extent permitted by the 1940 Act. These activities could limit the Company’s ability to participate in the benefits of lower interest rates with respect to the hedged borrowings. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on the Company’s business, financial condition and results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, an increase in interest rates available to investors could make an investment in the Company’s Units less attractive if the Company is not able to increase its distribution rate, which could reduce the value of the Company’s Units. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity Risk</div>. Most of the Company’s Portfolio Investments at any given time are expected to be illiquid, such that either no market exists for them or they are restricted as to their transferability under federal, state or foreign securities laws. Similarly, the Adviser may from time to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time possess material, non-public information about</div> an issuer, which could limit the ability of the Company to buy and sell Portfolio Investments. The illiquid nature of the Company’s positions may make it difficult, if not impossible, for the Company to (i) close out unprofitable positions and redeploy capital, except when a viable exit strategy can be developed (which may require a much longer commitment than the Adviser had anticipated), and (ii) meet margin calls or similar requirements of Company transaction counterparties to furnish additional liquid collateral. In addition, the sale of the Company’s investments may be made at substantial discounts and/or otherwise disadvantageous terms. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Inflation/Deflation Risk</div>. Inflation risk results from the variation in the value of cash flows from a security due to inflation, as measured in terms of purchasing power. The Company is exposed to inflation risk with respect to any fixed rate investments that it makes, if any, because the interest rate the issuer has to pay the Company is fixed for the life of the security. To the extent that interest rates reflect the expected inflation rate, floating rate loans have a lower level of inflation risk. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any disruptions in the capital markets, as a result of inflation and a rising interest environment or otherwise, may increase the spread between the yields realized on risk-free and higher risk securities and can result in illiquidity in parts of the capital markets, significant write-offs in the financial sector <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and re-pricing of</div> credit risk in the broadly syndicated market. These and any other unfavorable economic conditions could increase the Company’s funding costs, limit the Company’s access to the capital markets or result in a decision by lenders not to extend credit to the Company. In addition, market conditions (including inflation, supply chain issues and decreased consumer demand) could impact the operations of certain of the Company’s Portfolio Investments. If the financial results of middle-market companies, like those in which the Company intends to invest, experience deterioration, it could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults, and further deterioration in market conditions will further depress the outlook for those companies. Further, adverse economic conditions may decrease the value of collateral securing some of the Company’s loans and the value of the Company’s equity investments. Such may require the Company to modify the payment terms of its investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of the Company’s Portfolio Investments may be negatively impacted by these economic or other conditions, which can result in the Company’s receipt of reduced interest income from its Portfolio Investments and/or realized and unrealized losses related to its Portfolio Investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financial Fraud</div>. Instances of fraud and other deceptive practices committed by management, employees or Service Providers of the Company’s Portfolio Investments or by other financial institutions may undermine the Adviser’s due diligence efforts with respect to, and/or negatively affect the valuation of, the Company’s Portfolio Investments. In addition, financial fraud may contribute to overall market volatility, which can negatively impact the Company’s investment program. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">OFAC, FCPA and Related Considerations</div>. Economic sanction laws in the U.S. and other jurisdictions may prohibit the Adviser, its personnel and the Company from transacting with or in certain countries and with certain individuals and companies. In the U.S., the U.S. Department of the Treasury’s Office of Foreign Assets Control administers and enforces laws, Executive Orders and regulations establishing U.S. economic and trade sanctions. Such sanctions prohibit, among other things, transactions with, and the provision of services to, certain foreign countries, territories, entities and individuals. These types of sanctions may restrict the Company’s investment activities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries, there is a greater acceptance than in the U.S. of government involvement in commercial activities, and of corruption. The Company may be adversely affected because of its unwillingness to participate in transactions that violate such laws or regulations. Such laws and regulations may make it difficult in certain circumstances for the Company to act successfully on investment opportunities and for Portfolio Investments to obtain or retain business. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In recent years, the U.S. Department of Justice and the SEC have devoted greater resources to enforcement of the U.S. Foreign Corrupt Practices Act (the “FCPA”). In addition, the United Kingdom has recently significantly expanded the reach of its anti-bribery laws. Violations of the FCPA or other applicable anti-corruption laws or anti-bribery laws could result in, among other things, civil and criminal penalties, material fines, profit disgorgement, injunctions on future conduct, securities litigation and a general loss of investor confidence, any one of which could adversely affect the Company’s ability to achieve its investment objective and/or conduct its operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Waivers or Deferrals of Covenants and Covenant-Lite Loans</div>. The Company structures the debt in its Portfolio Investments to include business and financial covenants placing affirmative and negative obligations on the operation of the company’s business and its financial condition. However, from time to time the Company may elect to waive breaches of these covenants, including its right to payment, or waive or defer enforcement of remedies, such as acceleration of obligations or foreclosure on collateral, depending upon the financial condition and prospects of the particular Portfolio Investment. These actions may reduce the likelihood of the Company receiving the full amount of future payments of interest or principal and be accompanied by a deterioration in the value of the underlying collateral as many of these companies may have limited financial resources, may be unable to meet future obligations and may go bankrupt. This could negatively impact the Company’s ability to pay distributions, could adversely affect its results of operation and financial condition and cause the loss of all or part of your investment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, some of the loans in which the Company may invest may be “covenant-lite” loans. The Company uses the term “covenant-lite” loans to refer generally to loans that do not have a complete set of financial maintenance covenants. Generally, “covenant-lite” loans provide borrower companies more freedom to negatively impact lenders because their covenants are incurrence-based, which means they are only tested and can only be breached following an affirmative action of the borrower, rather than by a deterioration in the borrower’s financial condition. Accordingly, to the extent the Company invests in “covenant-lite” loans, the Company may have fewer rights against a borrower and may have a greater risk of loss on such investments as compared to investments in or exposure to loans with financial maintenance covenants. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risk of Loss</div>. An investment in the Company is highly risky. There can be no assurance that the Company will achieve its investment objective or any particular level of returns. An investor may lose all of its money by investing in the Company. Among other things, the Company may invest in assets that are underperforming or non performing and/or in securities of issuers who are under financial stress. By their nature, such investments are considered speculative and entail substantial risks that are generally higher than the risks of investments in performing assets and securities of issuers that are not under financial stress. Any losses in the Company will be borne solely by investors in the Company and not by the Adviser or any of its respective affiliates (except to the extent they invest capital in the Company, in which case they, with respect to such capital invested, will bear their pro rata portion of such loss). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Market for Units</div>. Pursuant to the LLC Agreement, Units are not generally transferable and voluntary withdrawal of Units is not allowed. A Unitholder is not expected to be able to sell, assign or transfer its Units. In addition, transfers of Units may be affected by restrictions on resales imposed by federal and state securities laws. The Units are not registered under the Securities Act or any state securities laws and may not be transferred unless registered under applicable federal and state securities laws or unless an exemption from such laws is available. The Company has no plans, and is under no obligation, to register the Units under the Securities Act or any state securities laws. No market exists for the Units, and none is expected to develop. Therefore, an investment in the Company must be considered illiquid and must only be made by <div style="display:inline;">persons </div>that are able to bear the risk of their investment in the Company for an indefinite period of time. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Management Risk and Reliance on Management</div>. The Company is subject to management risk because the Adviser actively manages its investment portfolio. The Adviser will apply investment and disposition techniques and risk analyses in making investment and disposition decisions for the Company, but there can be no guarantee that these will produce the desired results. In addition, as Unitholders may not participate in the management of the Company, only investors who are willing to entrust all aspects of the management of the Company to the Adviser should subscribe for Units. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of the Company is highly dependent upon the financial and managerial experience of the Adviser and any consultants or other Service Providers retained by the Company. The success of the Adviser is highly dependent on the financial and managerial experience of the investment professionals, who may not continue to be employed by or associated with the Adviser during the entire term of the Company. In <div style="display:inline;">addition</div>, a number of members of the professional staff of the Adviser are </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investors in other investment vehicles advised by SLR and are actively involved in managing the investment decisions of these investment vehicles, as well as investment decisions of other clients of SLR. Accordingly, the members of the professional staff of the Adviser have demands on their time for the investment, monitoring and other functions of other funds and other clients advised by SLR. In addition, competition in the financial services, private equity and alternative asset management industries for qualified investment professionals is intense. The Adviser’s continued ability to effectively manage the Company’s investments depends on its ability to attract new investment professionals and to retain and motivate its existing investment professionals. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, at any time during the Company’s term, the Adviser may assign the full and exclusive authority and responsibility granted to it under the Investment Management Agreement to an investment adviser under common control with the Adviser, subject to applicable law. The Adviser may take any actions that are necessary or incidental to any such assignment, including assigning the Investment Management Agreement or causing the Company to enter into a new Investment Management Agreement. Although it is expected that (x) any new investment adviser would be a registered investment adviser under the Advisers Act, (y) the management fee and incentive fee payable by the Company to such entities would be identical to that payable to the Adviser and (z) certain investment professionals would continue to be responsible for managing the Company’s assets, there is no guarantee that any or all of such characteristics will apply to any such new investment adviser. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Investment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Committee may delegate non-investment decisions (including</div> decisions relating to cash management <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and similar non-material transactions</div> (which shall not be considered “investments” for these purposes), diligence decisions, decisions relating to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">transactions involving material non-public information and</div> decisions relating to the engagement of consultants, law firms and other Service Providers) to other investment professionals in their sole discretion. Any decisions made by such subset or other investment professionals may be materially different and/or less optimal than decisions that would have been made by the Investment Committee. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Referral Relationships with Financial Sponsors</div>. The Adviser expects that the professional staff of the Adviser will maintain and develop their relationships with financial sponsors, including venture capital sponsors, and the Company will rely to a significant extent upon these relationships to provide the Company with potential investment opportunities. If the professional staff of the Adviser fail to maintain their existing relationships or develop new relationships with other sponsors or sources of investment opportunities, the Company will not be able to grow its investment portfolio. In addition, individuals with whom the professional staff of the Adviser have relationships are not obligated to provide the Company with investment opportunities, and, therefore, there is no assurance that such relationships will generate investment opportunities for the Company. If the Adviser is unable to source investment opportunities, the Company may hold a greater percentage of its assets in cash and cash equivalents than anticipated, which could impact potential returns on the Company’s portfolio. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Recourse to the Company’s Assets</div>. The Company’s assets, including any Portfolio Investments made by the Company and any capital held by the Company, are available to satisfy all liabilities and other obligations of the Company. In addition, the Company may pledge its right to call capital from Unitholders. If the Company becomes subject to a liability, parties seeking to have the liability satisfied may have recourse to the Company’s assets generally and may not be limited to any particular asset, such as the Portfolio Investment giving rise to the liability. To the extent the Company chooses to use special-purpose entities for individual transactions to reduce recourse risk (and it may, but will be under no obligation to do so), the<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> bona fides</div></div> of such entities may be subject to later challenge based on a number of theories, including veil piercing or substantive consolidation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unspecified Use of Proceeds</div>. The proceeds from the issuance of the Units are intended to be invested in Portfolio Investments. Unitholders will not have an opportunity to evaluate for themselves the relevant economic, financial and other information regarding the investments in which the proceeds from the issuance of the Units will be invested and, accordingly, are dependent upon the judgment and ability of the Adviser in investing and managing the capital of the Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Identification of Potential Investment Opportunities</div>. There is no assurance that the Adviser’s analysis in this regard, as implemented, will take into consideration all appropriate factors or appropriately weigh the factors that are considered in its analysis, especially given the heightened difficulty of the analysis required to evaluate certain Portfolio Investments. In particular, catalysts and/or exit strategies that initially appear to be viable may be precluded over time due to economic, legal, political or other factors. In addition, because the successful implementation of the Company’s investment strategy depends, in part, on its ability to successfully predict and take advantage of changing market conditions, to the extent it is unable to do so, returns may be adversely affected. These considerations are particularly relevant in light of the current uncertain economic and regulatory environment. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Risks Relating to the Company</div>” below. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Competition; Potential for Insufficient Investment Opportunities</div>. The business of identifying and effecting investments of the types contemplated by the Adviser is competitive and there can be no assurance that the Adviser will be able to identify and obtain a sufficient number of investment opportunities to invest the full amount of capital that may be committed to the Company. Increased competition for, or a diminishment in the available supply of, potential Portfolio Investments could result in lower returns on such Portfolio Investments. The Company may engage in auction or similar bidding processes with respect to certain Portfolio Investments, which processes are often highly competitive and may involve numerous other bidders about which the Company possesses limited or no information; as a result, the foregoing considerations will be applicable with respect to any such processes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Insufficient Capital for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Follow-On</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Investments</div>. Following its initial investment in a Portfolio Investment, the Company may have the opportunity to increase its investment in such Portfolio Investment. There is no assurance that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Company will make follow-on investments or</div> that the Company will have sufficient resources to, or be permitted to, make such investments. Any decision <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">not to make follow-on investments or the</div> Company’s inability to make them may have a substantial negative impact on the company in need of such an investment, may result in missed opportunities for the Company or may result in dilution of the Company’s investment. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Portfolio Investments</div>. The Company may participate in a limited number of Portfolio Investments and, as a consequence, the aggregate return of the Company may be substantially adversely affected by the unfavorable performance of any single investment. The Company has a broad and flexible investment mandate, and, beyond the asset diversification requirements associated with the Company’s intention to comply with the requirements to qualify as a RIC for U.S. tax purposes, and except as noted above, the Company is not subject to any limits or proportions with respect to the mix of permitted Portfolio Investments. As a result, the Company’s Portfolio Investments could potentially be concentrated in relatively few strategies, issuers, industries, markets, geographies or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">investment types. Such non-diversification would make the</div> Company more susceptible to risks associated with a single economic, political or regulatory occurrence than a more diversified portfolio might be. The Company could be subject to significant losses if it holds a relatively large position in a single strategy, issuer, industry, market, geographic region or a particular type of Portfolio Investment that declines in value, and the losses could increase even further if the Portfolio Investments cannot be liquidated without adverse market reaction or are otherwise adversely affected by changes in market conditions or circumstances. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Third-Party Involvement</div>. The Company may hold a portion of its investments through partnerships, joint ventures, securitization vehicles or other entities with third-party investors (collectively, “joint ventures”). Joint venture investments involve various risks, including the risk that the Company will not be able to implement investment decisions or exit strategies because of limitations on the Company’s control under applicable agreements with joint venture partners, the risk that a joint venture partner may become bankrupt or may at any time have economic or business interests or goals that are inconsistent with those of the Company, the risk that a joint venture partner may be in a position to take action contrary to the Company’s objectives, the risk of liability based upon the actions of a joint venture partner and the risk of disputes or litigation with such partner and the inability to enforce fully all rights (or the incurrence of additional risk in connection with enforcement of rights) one partner may have against the other, including in connection with foreclosure on partner loans, because of risks arising under state law. In addition, the Company may be liable for actions of its joint venture partners. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Leveraged Companies</div>. The Company will invest in Portfolio Investments whose capital structures have significant leverage. Such Portfolio Investments are inherently more sensitive to declines in revenues and asset values and to increases in expenses and interest rates. The leveraged capital structure of such Portfolio Investments will increase the exposure of the Portfolio Investments to adverse economic factors such as downturns in the economy or deterioration in the condition of the Portfolio Investment, its underlying assets or its industry. Additionally, the securities acquired by the Company may be the most junior securities in what may be a complex capital structure, and thus subject to the greatest risk of loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Portfolio Turnover</div>. The Company will not place any limit on the rate of portfolio turnover, and Portfolio Investments may be sold or otherwise disposed of without regard to the time they have been held when, in the judgment of the Adviser, investment considerations warrant such action. A high rate of portfolio turnover involves correspondingly greater expenses than a lower rate, may act to reduce the Company’s investment gains or create a loss for investors and may result in significant tax costs for investors <div style="display:inline;">depending </div>on the tax provisions applicable to such investors. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Assurance of Cash Distributions</div>. Subject to the Board’s discretion and applicable legal restrictions, the Company expects to declare and pay distributions quarterly. The Company expects to pay these distributions out of assets legally available for distribution. However, there are no assurances that the Company will achieve investment results that will allow a targeted level<div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"> </div></div>of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash distributions or year-to-year increases in cash</div></div> distributions. All distributions that are made will be at the discretion of the Board and will depend on earnings, financial condition, maintenance of RIC status and other factors as the Board may deem to be relevant. The Company’s ability to pay distributions might be adversely affected by the impact of one or more of the risk </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">factors described in this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> If the Company violates certain covenants under its existing or future credit facilities or other leverage, the Company may be limited in its ability to make distributions. To the extent the Company makes distributions to Unitholders that include a return of capital, such portion of the distribution essentially constitutes a return of the Unitholder’s investment. In addition, the inability to satisfy the asset coverage test applicable to a BDC may limit the Company’s ability to pay distributions. There can be no assurances that the Company will pay distributions to Unitholders in the future. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain cases, the Company may recognize income before or without receiving the accompanying cash. Depending on the amount of noncash income, this could result in difficulty satisfying the annual distribution requirement applicable to RICs. Accordingly, the Company may have to sell some Portfolio Investments at times it would not consider advantageous, raise additional debt or equity capital or reduce new investments to meet these distribution <div style="display:inline;">requirements</div>. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Dollar Denomination of Units</div>. Units are denominated in U.S. Dollars. Investors subscribing for Units in any country in which U.S. Dollars are not the local currency should note that changes in the rate of exchange between U.S. Dollars and such currency may have an adverse effect on the value, price or income of the investment to such investor. There may be foreign exchange regulations applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to investments in non-U.S. currencies in certain</div> jurisdictions. Each prospective investor should consult with its own counsel and advisors as to all legal, tax, financial and related matters concerning an investment in the Units. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Forward-Looking Statements</div>. This <div style="display:inline;">annual </div>report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> contains forward-looking statements, including observations about market and industry and regulatory trends as of the original date of this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K. Those forward-looking</div> statements reflect the Adviser’s current view in respect of future events. Actual events could differ materially from those in the forward-looking statements as a result of factors beyond the Adviser’s or the Company’s control. Investors are cautioned not to place undue reliance on such statements. No party has an obligation to update any of the forward-looking statements in this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Projections</div>. The Company may rely upon projections, forecasts or estimates developed by the Adviser, the Company or an issuer in which the Company is invested concerning the issuer’s future performance and cash flow. Projections, forecasts and estimates are forward-looking statements, are inherently uncertain and are based upon certain assumptions. Actual events are difficult to predict and beyond the Company’s control. Actual events may differ from those assumed. Some important factors which could cause actual results to differ materially from those in any forward-looking statements include changes in interest rates; domestic and foreign business, market, financial or legal conditions; leverage amounts and costs; and the degree to which the Portfolio Investments are hedged and the effectiveness of such hedges. Accordingly, there can be no assurance that estimated returns or projections can be realized or that actual returns or results will not be materially lower than those estimated therein. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Valuation of Illiquid Assets</div>. It is expected that the majority of the Company’s investments will be in securities or other financial instruments for which market quotations are not available. The process of valuing securities for which reliable market quotations are not available is based on inherent uncertainties, and the resulting values may differ from values that would have been determined had a ready market existed for such securities, from values placed on such securities by other investors and from prices at which such securities may ultimately be sold. In addition, third-party pricing information may at times not be available regarding certain of the Company’s assets or, if available, may not be considered reliable. In particular, recent disruptions in the credit markets have resulted in a severe lack of liquidity for many securities, making them more difficult to value and, in many cases, putting significant downward pressure on prices. Subject to approval by the Board, the Adviser will determine the fair value of securities, loans or other instruments for which market quotes are not readily available (or if extraordinary events occur after the last readily available quotation). The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule 2a-5 under</div> the 1940 Act; and (6) maintain recordkeeping requirements under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule 2a-5.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that such valuations will be reliable, accurate or reflective of the prices at which such investments are ultimately realized. In addition, certain of the securities or other assets that the Company seeks to sell or acquire via cross trade may be illiquid and difficult to value, therefore there can be no assurance that such valuation will be accurate. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Assets Believed to Be Undervalued or Incorrectly Valued</div>. Securities that the Adviser believes are fundamentally undervalued or incorrectly valued may not ultimately be valued in the capital markets at prices and/or within the timeframe the Adviser anticipates. As a result, the Company may lose all or substantially all of its investment in any particular instance. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Model Risks</div>. The Adviser may employ financial/analytical models to aid in the selection of the Portfolio Investments, to allocate investments across various strategies and risks and to determine the risk profile of the Company. If any such models are employed, the success of the Company’s investment activities will depend, in large part, upon the viability of these models. There can be no assurance that the models are currently viable, or will remain viable during the term of the Company, due to various factors, including the quality of the data input into the models and the assumptions underlying such models, which to varying degrees involve the exercise of judgment, as well as the possibility of errors in constructing or of using the model. Even if the models function as anticipated, they cannot account for all factors that may influence the returns on the Portfolio Investments. Also, there can be no assurance that the investment professionals utilizing the models will be able to (i) determine that any model is or will become not viable or not completely viable or (ii) notice, predict or adequately react to any change in the viability of a model. The use of a model that is not viable or not materially viable could, at any time, have a material adverse effect on the performance of the Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Investigations or Third-Party Litigation</div>. The Company as well as the Adviser and its affiliates participate in a highly regulated industry and are each subject to regulatory examinations in the ordinary course of business. There can be no assurance that the Company and the Adviser and/or any of its affiliates will avoid regulatory investigation and possible enforcement actions stemming therefrom. The Adviser is a registered investment adviser and, as such, is subject to the provisions of the Advisers Act. The Company and the Adviser are each, from time to time, subject to formal and informal examinations, investigations, inquiries, audits and reviews from numerous regulatory authorities both in response to issues and questions raised in such examinations or investigations and in connection with the changing priorities of the applicable regulatory authorities across the market in general. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s investment activities may subject it to the risks and costs of becoming involved in litigation with third parties due to, among other reasons, the fact that different investor groups may have qualitatively different, and frequently conflicting, interests with respect to certain Portfolio Investments. The risk of litigation with third parties will be elevated in situations where an issuer is stressed or distressed. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Litigation and Related Risks Associated with Origination and Servicing</div>” above. The expense of defending against claims by third parties and <div style="display:inline;">paying </div>any amounts pursuant to settlements or judgments, or bringing claims against third parties, would generally be borne by the Company and would reduce net assets. In addition, the Company’s investment activities may subject it to certain risks inherent in restructuring, bankruptcy and similar proceedings. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Associated with Bankruptcy and Insolvency Cases</div>” below. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Broad Indemnification</div>. The Company and/or the Adviser on behalf of the Company may enter into various agreements or arrangements which limit the liability of its Service Providers, including the Adviser and its affiliates, the Administrative Coordinator, the Custodian, and their affiliates, employees, officers and directors, and require the Company to indemnify and/or provide broad representations, warranties and covenants in favor of such persons. U.S. federal and state securities laws impose liabilities under certain circumstances on persons that cannot be waived by contract, other agreements or documents. Therefore, nothing in those agreements should be deemed or construed in a manner that purports to waive or limit any right to the extent prohibited by law. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to indemnify the Adviser and its respective affiliates, each of the former, current and future shareholders, partners, members, other equity holders, officers, directors, employees, managers, trustees, agents and other representatives of the Adviser and its respective affiliates, and other persons set forth in the LLC Agreement as an “Indemnitee” for Claims (as defined in the LLC Agreement) that may accrue to or be incurred by an Indemnitee, in connection with any claim, demand, investigation, suit, proceeding or action in which an Indemnitee may become involved, as a party or otherwise, or with which an Indemnitee may be threatened, relating to or arising out of the investments or other activities of the Company, activities undertaken in connection with the Company, or otherwise relating to or arising out of the LLC Agreement or the Subscription Agreement, and otherwise as provided in the LLC Agreement or the Subscription Agreement. Such Claims may be material and have an adverse effect on the returns to the Unitholders. The Company may also provide broad indemnities, representations, warranties and covenants in connection with the acquisition, management and disposition of Portfolio Investments or otherwise in connection with the Company’s investment program. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any indemnification obligations of the Company would be payable from the assets of the Company, including the unfunded Commitments of the Unitholders, and would adversely affect the Company’s returns. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Adverse Consequences of Default</div>. A Unitholder in default with respect to its unfunded Commitment may experience material adverse effects on its investment. When a Unitholder defaults, the Board, in its discretion, may cause the defaulting Unitholder to forfeit a portion of the distributions to which the defaulting Unitholder may otherwise have been entitled. The Board may also require a forced sale of the defaulting Unitholder’s Interest. In addition, the Board may pursue any available legal or equitable remedies, with the expenses of collection of the unpaid amount, including attorneys’ fees, to be paid by the defaulting Unitholder. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the default of a Unitholder, the Company may deliver an amended funding notice to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-defaulting</div> Unitholders increasing their capital contributions by up to an aggregate amount equal to the capital contribution that the defaulting Unitholder failed to make, not in excess of a Unitholder’s unfunded Commitment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board may require a defaulting Unitholder to contribute the entirety of its remaining Commitment to the Company. For any such Unitholder, the return on its Company investment may be materially lower than returns to Unitholders <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">who do not pre-fund their Commitments.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Distributions in Kind</div>. If distributions are made of assets held by the Company in lieu of cash, the amount of any such distribution will be accounted for at the fair market value of such assets as determined in accordance with procedures set forth in the LLC Agreement. An independent appraisal generally will not be required and is not expected to be obtained. Assets distributed in kind may not be readily marketable or disposable, and Unitholders therefore must be prepared to bear the risks of owning such assets for an indefinite period of time (and to incur costs and expenses in connection with any disposition thereof). In addition, there can be no <div style="display:inline;">assurance </div>that the value of such assets as determined in accordance with procedures set forth in the LLC Agreement will ultimately be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Russian Invasion of Ukraine</div>. On February 24, 2022, the Russian military commenced a full-scale invasion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Russia’s pre-positioned forces</div> into Ukraine, which could have a negative impact on the economy and business activity globally (including in the countries in which the Company invests), and therefore could adversely affect the performance of the Company’s Portfolio Investments. Following such invasion, the United States and several European nations announced sanctions against Russia. Furthermore, the conflict between the two nations and the varying involvement of the United States and other NATO countries could preclude prediction as to their ultimate adverse impact on global economic and market conditions, and, as a result, presents material uncertainty and risk with respect to the Company and the performance of its investments or operations, and the ability of the Company to achieve its investment objectives. Additionally, to the extent that third parties, investors, or related customer bases have material operations or assets in Russia or Ukraine, they may have adverse consequences related to the ongoing conflict. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Electronic Communications/Cybersecurity Risk</div>. The Company provides to Unitholders statements, reports and other communications relating to the Company and/or the Unitholder’s Interest in electronic form, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as e-mail or</div> via a password protected website (“Electronic Communications”). There are certain costs and possible risks associated with the use of Electronic Communications. Electronic Communications may be modified, corrupted, or contain viruses or malicious code, and may not be compatible with a Unitholder’s electronic system. The Company cannot provide any assurance that Electronic Communications are secure and will not be responsible for any computer viruses, problems or malfunctions resulting from the use of Electronic Communications. In addition, reliance on Electronic Communications involves the risk of inaccessibility, power outages or slowdowns for a variety of reasons. These periods of inaccessibility may delay or prevent receipt of reports or other information by the Unitholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company relies on the Adviser’s enterprise-wide cybersecurity program, to protect its information, including due oversight of the cybersecurity programs of the Company’s key Service Providers and processes for the assessment, identification, and management of material risks from cybersecurity threats, including those associated with the use of third-party Service Providers. While the Adviser employs various measures to address cybersecurity-related issues, the Adviser, the Administrative Coordinator, the Company and their respective Service Providers may nevertheless be subject to operational and information security risks resulting from cybersecurity incidents. A cybersecurity incident refers to both intentional and unintentional events that may cause the Adviser, the Company or their respective Service Providers to lose or compromise confidential information, suffer data corruption or lose operational capacity. Cybersecurity incidents include stealing or corrupting data maintained online or digitally, denial of service attacks on websites, the unauthorized release of confidential information or various other operational disruptions. If unauthorized parties gain access to such information and technology systems, they may be able to steal, publish, delete or modify private and sensitive information, including nonpublic personal information related to Unitholders (and their beneficial owners) and material nonpublic information. The systems the Adviser has implemented to manage risks relating to these types of events could prove to be inadequate and, if compromised, could become inoperable for extended periods of time, cease to function properly or fail to adequately secure private information. Breaches such as those involving covertly introduced malware, impersonation of authorized users and industrial or other espionage may not be identified even with sophisticated prevention and detection systems, potentially resulting in further harm and preventing them from being addressed appropriately. The failure of these systems or of disaster recovery plans for any reason could cause significant interruptions in the Company’s and the Adviser’s operations and result in a failure to maintain the security, confidentiality or privacy of sensitive data, including personal information relating to Unitholders, material nonpublic information and other sensitive information in the Adviser’s possession. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A disaster or a disruption in the infrastructure that supports the Adviser’s business, including a disruption involving Electronic Communications or other services used by the Adviser or third parties with whom the Adviser conducts business, or directly affecting the Adviser’s headquarters, could have a material adverse impact on the Adviser’s ability to continue to operate its business without interruption and to protect the Company, insofar as is practicable, from the hazards of cybersecurity threats and vulnerabilities in accordance with applicable legal requirements and guidance. The Adviser’s disaster recovery programs may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse the Adviser for its losses, if at all. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company is not currently aware of any cyber-attacks or other incidents that, individually or in the aggregate, have materially affected, or would reasonably be expected to materially affect, its operations or financial condition, there has been an increase in the frequency and sophistication of the cyber and security threats faced in the marketplace. Cyber-attacks and other security threats could originate from a wide variety of sources, including cyber criminals, nation state hackers, hacktivists and other outside or inside parties. The Company may be a target for attacks because, as a specialty finance company, it holds confidential and other sensitive information, including price information, about existing and potential investments. Further, the Company is dependent on third-party vendors for hosting hardware, software and data processing systems that it does not control. The Company also relies on third-party Service Providers for certain aspects of its business, including for certain information systems, technology and administration of its Portfolio Investments and compliance matters. While the Company relies on the cybersecurity strategy and policies implemented by the Adviser, its reliance on the Adviser and third-party Service Providers removes certain cybersecurity functions from outside of the Company’s immediate control, and cyber-attacks on the Adviser, on the Company or on third-party Service Providers could adversely affect the Company, its business, and its reputation. The costs related to cyber-attacks or other security threats or disruptions may not be fully insured or indemnified by others, including by the <div style="display:inline;">Company’s </div>third-party providers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company’s reliance on computer hardware and software systems, data processing systems, and other technology has increased, so have the risks posed to such systems, both those the Adviser controls and those provided by third-party vendors. Cyber-attacks may originate from a wide variety of sources, and while the Adviser has implemented processes, procedures, and internal controls designed to mitigate cybersecurity risks and cyber-attacks, these measures do not guarantee that a cyber-attack will not occur or that the Company’s financial results, operations, or confidential information, personal, or other sensitive information will not be negatively impacted by such an incident, especially because the techniques of threat actors change frequently and are often not recognized until launched. The Adviser relies on industry accepted security measures and technology to securely maintain confidential and proprietary information maintained on its information systems, as well as on policies and procedures to protect against the unauthorized or unlawful disclosure of confidential, personal, or other sensitive information. Although the Adviser takes protective measures and endeavors to strengthen its computer systems, software, technology assets, and networks to prevent and address potential cyber-attacks, there can be no assurance that any of these measures prove effective. The Adviser expects to be required to devote increasing levels of funding and resources, which may in part be allocated to the Company, to comply with evolving cybersecurity and privacy laws and regulations and to continually monitor and enhance its cybersecurity procedures and controls. In addition, the Company, the Adviser, the Administrative Coordinator, or their employees, if any, may also be the target of fraudulent emails or other targeted attempts to gain unauthorized access to confidential, personal, or other sensitive information. The result of any cyber-attack or other security incidents may include disrupted operations, misstated or unreliable financial data, fraudulent transfers or requests for transfers of money, liability for stolen information (including personal information), investigations, misappropriation of assets, increased cybersecurity protection and insurance costs, litigation and damage to the Company’s business relationships, regulatory fines or penalties, or other adverse effects on its business, financial condition or results of operations. The Adviser may be required to expend significant additional resources to modify its protective measures and to investigate and remediate vulnerabilities or other exposures arising from operational and security risks related to cyber-attacks. The rapid evolution and increasing prevalence of artificial intelligence technologies may also increase cybersecurity risks. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, cybersecurity has become a top priority for global lawmakers and regulators around the world, and some jurisdictions have proposed or enacted laws requiring companies to notify regulators and individuals of data security breaches involving certain types of personal data. In particular, state and federal laws and regulations related to cybersecurity compliance continue to evolve and change, which may require substantial investments in new technology, software and personnel, which could affect the Company’s profitability. These changes may also result in enhanced and unforeseen consequences for cyber- related breaches and incidents, which may further adversely affect the Company’s profitability. If the Adviser fails to comply with the relevant and increasing laws and regulations, the Adviser could suffer financial losses, a disruption of its businesses, liability to investors, regulatory intervention or reputational damage. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Policies of remote working, whether by the Adviser, the Administrative Coordinator, the Company or by their respective Service Providers, could strain technology resources, introduce operational risks and otherwise heighten the risks described above. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybersecurity risks are exacerbated by the rapidly increasing volume of highly sensitive data, including the Company’s proprietary business information, personal information of the Adviser’s employees, the Company’s investors and others, and other sensitive information that the Adviser collects, processes, and stores in its data centers and on its networks or those of third-party Service Providers. The secure processing, maintenance, and transmission of this information are critical to the Company’s operations. There is a risk that encryption and other protective measures against cyber-attacks may be circumvented, particularly to the extent that new computing technologies increase the speed and computing power available. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and, in fact, may not be detected. A significant actual or potential theft, loss, corruption, exposure, fraudulent use or misuse of investor or other personal information, proprietary business data or other sensitive information, whether by third parties or as a result of malfeasance by the Adviser’s employees or otherwise, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with applicable contractual or other legal obligations regarding such data or intellectual property or a violation of applicable privacy and security policies with respect to such data could result in significant investigation, remediation and other costs, fines, penalties, litigation or regulatory actions against the Company and significant reputational harm, any of which could harm the Company’s business and results of operations. Cybersecurity risks require continuous and increasing attention and other resources from the Adviser to, among other actions, identify and quantify these risks and upgrade and expand its technologies, systems and processes to adequately address such risks. Such attention diverts time and other resources from other activities and there is no assurance that the Adviser’s efforts will be effective. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybersecurity incidents may adversely impact the Company and its Unitholders. There is no guarantee that the Company, the Adviser, and/or their respective Service Providers will be successful in protecting against cybersecurity incidents. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financial Services Industry Risks</div>. Cash not held in custody accounts and held by the Company, the Adviser and the Portfolio Investments in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> and interest-bearing operating accounts could, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, the Company, the Adviser, or the Portfolio Investments could lose all or a portion of those amounts held in excess of such insurance limits. In addition, actual events involving limited liquidity, defaults, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance</div> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect the Company, the Adviser’s and the Portfolio Investments’ business, financial condition, results of operations, or prospects. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company and the Adviser assess its and the Portfolio Investments’ banking and financing relationships as the Company believes necessary or appropriate, the Company and the Portfolio Investments’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which the Company, the Adviser or the Portfolio Investments have arrangements directly or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company, the Adviser or the Portfolio Investments have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for the Company, the Adviser, or the Portfolio Investments to acquire financing on acceptable terms or at all. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Technological Innovation Risks</div>. Technological innovations have disrupted traditional approaches in multiple industries and can permit younger companies to achieve success and in the process disrupt markets and market practices. The Company can provide no assurance that new businesses and approaches will not be created that would compete with the Company and/or its Portfolio Investments or alter the market practices in which the Adviser and its affiliates and the Company have been designed to function within and on which the Company depends on for its investment return. New approaches could damage the Company’s investments, disrupt the market in which it operates and subject it to increased competition, which could materially and adversely affect the Company’s business, financial condition and results of investments. </div><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Machine Learning Technology Risks</div>. Recent technological advances in artificial intelligence and machine learning technology (“Machine Learning Technology”) pose risks to the Company and its Portfolio Investments. The Company and its Portfolio Investments could be exposed to the risks of Machine Learning Technology if third-party service providers or any counterparties use Machine Learning Technology in their business activities. The Company and the Adviser are not in a position to control the use of Machine Learning Technology in third-party products or services. Use of Machine Learning Technology could include the input of confidential information in contravention of applicable policies, contractual or other obligations or restrictions, resulting in such confidential information becoming part accessible by other third-party Machine Learning Technology applications and users. Machine Learning Technology and its applications continue to develop rapidly, and the Company cannot predict the risks that may arise from such developments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Machine Learning Technology is generally highly reliant on the collection and analysis of large amounts of data, and it is not possible or practicable to incorporate all relevant data into the model that Machine Learning Technology utilizes to operate. Certain data in such models will inevitably contain a degree of inaccuracy and error and could otherwise be inadequate or flawed, which would be likely to degrade the effectiveness of Machine Learning Technology. To the extent the Company or its Portfolio Investments are exposed to the risks of Machine Learning Technology use, any such inaccuracies or errors could adversely impact the Company or its Portfolio Investments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Social Responsibility Risks</div>. The Company’s business (including that of its Portfolio Investments) faces increasing public scrutiny related to environmental, social and governance (“ESG”) activities, which are increasingly considered to contribute to reducing a company’s operational risk, market risk and reputational risk, which may in turn impact the long-term sustainability of a company’s performance. A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG ratings and measures to their investment decisions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company risks damage to its brand and reputation if it fails to act responsibly in a number of areas, including, but not limited to, diversity, equity and inclusion, human rights, climate change, environmental stewardship, support for local communities, corporate governance, transparency and consideration of ESG factors in the Company’s investment processes. Adverse incidents with respect to ESG activities could impact the value of the Company’s brand, its relationship with existing and future Portfolio Investments, the cost of the Company’s operations and relationships with investors, all of which could adversely affect its business and results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, regional and investor specific sentiment may differ in what constitutes a material positive or negative ESG corporate practice. There is no guarantee that the Company’s ESG and sustainability practices will uniformly fit every investor’s definition of best practices for all environmental, social and governance considerations across geographies and investor types. If we do not successfully manage expectations across varied stakeholder interests, it could erode stakeholder trust, impact our reputation and constrain our investment opportunities. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is also a growing regulatory interest across jurisdictions in improving transparency regarding the definition, measurement and disclosure of ESG factors in order to allow investors to validate and better understand sustainability claims. For example, the SEC has proposed, or has announced that it is working on proposals for, rules that, among other matters, would establish a framework for reporting of climate-related risks, corporate and fund carbon emissions, broad diversity and capital management. At this time, there is uncertainty regarding the scope of such proposals or when they would become effective (if at all). In 2021, the SEC established an enforcement task force to look into ESG practices and disclosures by public companies and investment managers and has started to bring enforcement actions based on ESG disclosures not matching actual investment processes. Further, in 2022 the SEC issued a proposed rule regarding the enhancement and standardization of mandatory climate-related disclosures for investors that would mandate extensive disclosure of climate-related data, risks and opportunities for certain public companies. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and its Portfolio Investments are subject to the risk that similar measures might be introduced in other jurisdictions in the future. Additionally, compliance with any new laws or regulations increases the Company’s regulatory burden and could make compliance more difficult and expensive, affect the manner in which the Company or its Portfolio Investments conduct its businesses and adversely affect the Company’s profitability. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Climate Change Risks</div>. There may be evidence of global climate change. Climate change creates physical and financial risk and some of the Company’s Portfolio Investments may be adversely affected by climate change. For example, the needs of customers of energy companies vary with weather conditions, primarily temperature and humidity. To the extent weather conditions are affected by climate change, energy use could increase or decrease depending on the duration and magnitude of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any changes. Increases in the cost of energy could adversely affect the cost of operations of the Company’s Portfolio Investments if the use of energy products or services is material to their business. A decrease in energy use due to weather changes may affect some of the Company’s Portfolio Investments’ financial condition, through decreased revenues. Extreme weather conditions in general require more system backup, adding to costs, and can contribute to increased system stresses, including service interruptions. Energy companies could also be affected by the potential for lawsuits against or taxes or other regulatory costs imposed on greenhouse gas emitters, based on links drawn between greenhouse gas emissions and climate change. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2015 the United Nations, of which the U.S. is a member, adopted a climate accord with the long-term goal of limiting global warming and the short-term goal of significantly reducing greenhouse gas emissions. As a result, some of the Company’s Portfolio Investments may become subject to new or strengthened regulations or legislation, which could increase their operating costs and/or decrease their revenues. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Failure to Qualify as a RIC</div>. Although the Company has obtained qualification as a RIC, no assurance can be given that it will be able to maintain qualification as a RIC. To maintain qualification as a RIC, the Company must meet</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">source-of-income, asset</div></div> diversification, and distribution requirements on an ongoing basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income source requirement will be satisfied if the Company obtains at least 90% of gross income for each year from dividends, interest, foreign currency, payments with respect to loans of certain securities, gains from the sale of Units or other securities, net income from certain “qualifiedpublicly traded partnerships,” or similar sources. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The asset diversification requirement will be satisfied if the Company meets certain asset diversification requirements at the end of each quarter of the taxable year. Failure to meet those requirements may result in the Company having to dispose of certain investments quickly in order to prevent the loss of qualification as a RIC. Because most of the Company’s investments will be relatively illiquid, any such dispositions could be made at disadvantageous prices and could result in substantial losses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual distribution requirement will be satisfied if the Company distributes to its Unitholders on an annual basis at least 90% of net ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any. Because the Company may use debt financing, it is subject to certain asset coverage ratio requirements under the 1940 Act and financial covenants under loan and credit agreements that could, under certain circumstances, restrict the Company from making distributions necessary to satisfy the distribution requirement. If the Company is unable to obtain cash from other sources, it could fail to qualify as a RIC. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company fails to qualify as a RIC for any reason and therefore becomes subject to corporate income tax, the resulting corporate taxes could substantially reduce net assets, the amount of income available for distribution and the amount of distributions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Recognizing Income Before or Without Receiving Cash</div>. For U.S. federal income tax purposes, the Company will include in income certain amounts that the Company has not yet received in cash, such as the accrual of original issue discount (“OID”). This may arise if the Company receives warrants in connection with the making of a loan and in other circumstances, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">through contracted payment-in-kind (“PIK”) interest,</div></div> which represents contractual interest added to the loan balance and due at the end of the loan term. Such OID, which could be significant relative to the Company’s overall investment activities, and increases in loan balances as a result of contracted PIK arrangements will be included in income before the Company receives any corresponding cash payments. The Company also may be required to include in income certain other amounts that the Company will not currently receive in cash. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since in certain cases the Company may recognize income before or without receiving cash representing such income, the Company may have difficulty meeting the requirement to timely distribute at least 90% of its net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any, to maintain its qualification as a RIC. In such a case, the Company may have to sell some of its Portfolio Investments at times the Company would not consider advantageous or raise additional debt or equity capital or reduce new investment originations to meet these distribution requirements. If the Company is not able to obtain cash from other sources and is otherwise unable to satisfy such distribution requirement, the Company may fail to maintain its qualification as a RIC and become subject to corporate-level U.S. federal income tax. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Tax Considerations Regarding Dividends for Private BDCs</div>. The Company does not currently qualify as a “publicly offered regulated investment company,” as defined in the Code. Accordingly, U.S. individual and other noncorporate Unitholders will be taxed as though they received a distribution of some of the Company’s expenses. A “publicly offered regulated investment company” is a RIC whose Units are either (i) continuously offered pursuant to a public offering, (ii) regularly traded on an established securities market, or (iii) held by at least 500 persons at all times during the taxable year. The Company anticipates that it will not qualify as a publicly offered RIC for the 2023 tax year, and cannot determine when it will qualify as a publicly offered RIC. Since the Company is not a publicly offered RIC, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a non-corporate Unitholder’s</div> allocable portion of the Company’s affected expenses, including a portion of its management fees, will be treated as an additional distribution to the Unitholders. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A non-corporate Unitholder’s</div> allocable portion of these expenses are treated as miscellaneous itemized deductions that are not currently deductible by such Unitholder (and beginning in 2026, will be deductible by such Unitholder for regular U.S. federal income tax purposes but not for alternative minimum tax purposes only to the extent they exceed 2% of such Unitholder’s adjusted gross income). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Potential Dividend Deferrals</div>. In order to maintain its tax status as a RIC, the Company must distribute to Unitholders for each taxable year at least 90% of its investment company taxable income (i.e., net ordinary income plus realized net short-term capital gains in excess of realized net long-term capital losses). If the Company qualifies for taxation as a RIC, it generally will not be subject to corporate-level U.S. federal income tax on its investment company taxable income and net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) that it timely distributes to Unitholders. The Company will be subject to a 4% U.S. federal excise tax on undistributed earnings of a RIC unless it distributes each calendar year at least the sum of (i) 98.0% of its ordinary income for the calendar year, (ii) 98.2% of its capital gains in excess of capital losses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the one-year period</div> ending on October 31 of the calendar year, and (iii) any ordinary income and net capital gains for preceding years that were not distributed during such years and on which it paid no U.S. federal income tax. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Code, the Company may pay certain RIC dividends after the end of the current year. In particular, if the Company pays a distribution in January of the following year that was declared in October, November, or December of the current year and is payable to Unitholders of record in the current year, the dividend will be treated for all U.S. federal income tax purposes as if it were paid on December 31 of the current year. In addition, under the Code, the Company may pay dividends, referred to as “spillover dividends,” that are paid during the following taxable year that will allow the Company to maintain its qualification for taxation as a RIC and eliminate its liability for corporate-level U.S. federal income tax. Under these spillover dividend procedures, the Company may defer distributions of income earned during the current year until December of the following year. For example, the Company may defer distributions of income earned during 2024 until as late as December 31, 2025. If the Company chooses to pay a spillover dividend, it will incur the 4% U.S. federal excise tax on some or all of the distribution. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to events such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19 pandemic,</div> certain regional bank failures, the Russian invasion of Ukraine, the ongoing war in the Middle East or other disruptions in the economy, such as the recent inflationary environment, the Company may take certain actions with respect to the timing and amounts of its distributions in order to preserve cash and maintain flexibility. For example, the Company may reduce and/or defer dividends to the following year as discussed above. To further preserve cash, the Company may combine these deferrals of dividends with one or more distributions that are payable partially in Units as discussed below under “<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Kind</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Dividend Considerations</div>.” </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Kind</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Dividend Considerations</div>. The Company may distribute taxable dividends that are payable in part in Units. In accordance with certain applicable U.S. Treasury regulations and published IRS guidance, a RIC may treat a distribution of its own shares as fulfilling the RIC distribution requirements if each Unitholder may elect to receive the entire distribution in either cash or shares of the RIC. The IRS has published a revenue procedure indicating that, in the case of publicly offered RICs, this rule will apply where the total amount of cash to be distributed is not less than 20% of the total distribution. Under this revenue procedure, if too many Unitholders elect to receive cash, the cash available for distribution must be allocated among the Unitholders electing to receive cash (with the balance of the distribution paid in Units). Because the Company is not currently a publicly offered RIC, its ability to rely on the revenue procedure and other guidance is uncertain. If the Company elects to pay a distribution in its own Units consistent with the revenue procedure and other guidance, for U.S. federal income tax purposes, the amount of the dividend paid in Units will be equal to the amount of cash that could have been received instead of Units. Taxable Unitholders receiving such dividends will be required to include the amount of the dividends as ordinary income (or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of the Company’s current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a Unitholder may be required to pay tax with respect to such dividends in excess of any cash received, and, the Company may be required to withhold U.S. tax with respect to dividends payable in Units <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to non-U.S. Unitholders.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Tax Law</div>. Legislative or other actions relating to taxes could have a negative effect on the Company. The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. New legislation and any other tax law developments including new or revised U.S. Treasury regulations, administrative interpretations or court decisions, could negatively and perhaps retroactively affect the U.S. federal income tax consequences to the Company and its Unitholders, or could have other adverse consequences. Investors are urged to consult with their tax advisor regarding tax legislative, regulatory, or administrative developments and proposals and their potential effect on an investment in the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Permissible Incurred Leverage</div>. Leverage magnifies the potential for loss on investments and on invested equity capital. As the Company uses leverage to partially finance its investments, Unitholders will experience increased risks of investing in the Company’s securities. If the value of the Company’s assets increases, then leveraging would cause the NAV attributable to the Company’s Units to increase more sharply than it would have had the Company not leveraged. Conversely, if the value of the Company’s assets decreases, leveraging would cause NAV to decline more sharply than it otherwise would have had the Company not leveraged its business. Similarly, any increase in the Company’s income in excess of interest payable on the borrowed funds would cause net investment income to increase more than it would without the leverage, while any decrease in the Company’s income would cause net investment income to decline more sharply than it would have had the Company not borrowed. Such a decline could negatively affect the Company’s ability to pay dividends on Units, scheduled debt payments or other payments related to securities. Leverage is generally considered a speculative investment technique. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Distribution and Asset Coverage Ratio Requirements</div>. In order to satisfy the requirements applicable to RICs and to avoid payment of excise taxes, the Company intends to distribute to Unitholders substantially all of its ordinary income and capital gain net income except for certain net capital gains, which it intends to retain and to elect to treat as deemed distributions to Unitholders. The Company may issue debt securities, other evidences of indebtedness or preferred Units, and may borrow money from banks or other financial institutions, which are referred to collectively herein as “senior securities,” up to the maximum amount permitted by the 1940 Act. The 1940 Act permits the Company to issue senior securities in <div style="display:inline;">amounts </div>such that its asset coverage, as defined in the 1940 Act, equals at least 150% after each issuance of senior securities. The Company’s ability to pay dividends or issue additional senior securities would be restricted if the asset coverage ratio were not at least 150%. If the value of the Company’s assets declines, the Company may be unable to satisfy this test. If that happens, the Company may be required to liquidate a portion of its investments and repay a portion of its indebtedness at a time when such sales or repayment may be disadvantageous. As a result of issuing senior securities, the Company will also be exposed to typical risks associated with leverage, including an increased risk of loss. If the Company issues preferred Units, such preferred Units will rank “senior” to common Units in the Company’s capital structure, preferred Unitholders will have separate voting rights for certain purposes and may have rights, preferences or privileges more favorable than those of the Company’s common Units and the issuance of preferred Units could have the effect of delaying, deferring or preventing a transaction or a change of control that might involve a premium price for Unitholders or otherwise be in the best interest of Unitholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company is constrained in its ability to issue debt or other senior securities, it will depend on issuances of capital interests to finance operations. As a BDC, the Company is generally not able to issue Units at a price below NAV without first obtaining required approvals of Unitholders and independent directors in accordance with the conditions set forth in Section 63(2) of the 1940 Act. If the Company raises additional funds by issuing more common Units or senior securities convertible into, or exchangeable for, common Units, the percentage ownership of Unitholders at that time would decrease and Unitholders may experience dilution. In addition to issuing securities to raise capital as described above, the Company could, in the future, securitize loans to generate cash for funding new investments. An inability to successfully securitize its loan portfolio could limit the Company’s ability to grow its business, fully execute its business strategy and improve profitability. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized Depreciation</div>. As a BDC, the Company is required to carry investments at market value or, if no market value is ascertainable, at fair value as determined in good faith by the Board. Decreases in the market values or fair values of investments will be recorded as unrealized depreciation. Any unrealized depreciation in the Company’s loan portfolio could be an indication of a Portfolio Investment’s inability to meet its repayment obligations with respect to the loans whose market values or fair values decreased. This could result in realized losses in the future and ultimately in reductions of income available for distribution in future periods. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Qualifying Asset Requirements</div>. As a BDC, the Company may not acquire any assets other than “qualifying assets” unless, at the time of such acquisition, at least 70% of its total assets are qualifying assets. Therefore, the Company may be precluded from investing in what it believes are attractive investments if such investments are not qualifying assets. Similarly, these rules could prevent the Company from making additional investments in existing Portfolio Investments, which could result in the dilution of its position, or could require disposal of investments at an inopportune time to comply with the 1940 Act. If the Company were forced to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sell non-qualifying investments</div> for compliance purposes, the proceeds from such sale could be significantly less than the current value of such investments. Conversely, if the Company failed to invest a sufficient portion of assets in qualifying assets, it could lose status as a BDC, which would subject the Company to substantially more regulatory restrictions and significantly decrease operating flexibility. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exemptive Relief</div>. The Company and the other BDCs for which SLR is the investment adviser (SLR Investment Corp. (Nasdaq: SLRC) (“SLRC”), SCP Private Credit Income BDC LLC (“PCI BDC”) and SLR Private Credit BDC II LLC (“PC BDC,” and, together with SLRC and PCI BDC, the “SLR BDCs”) are substantially limited in their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ability to co-invest in privately</div> negotiated transactions with affiliated funds other than as permitted by the Order. While the Order permits the Company to participate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in negotiated co-investment transactions with</div> the SLR BDCs and other affiliated funds, such participation is subject to numerous conditions. If the Company and the SLR BDCs are unable to comply with these conditions or are otherwise unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although SLR will endeavor to allocate investment opportunities in a fair and equitable manner, the Company could be adversely affected to the extent investment opportunities are allocated among the Company and other investment vehicles managed or sponsored by, or affiliated with SLR and its affiliates, including the SLR BDCs, pursuant to the conditions of the Order. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Risks Relating to the Company</div>. Legal and regulatory changes could occur during the term of the Company that may adversely affect the Company. The Company may be subject to, and adversely affected by, new federal, state or non-U.S. laws or new regulation by the SEC, the Commodity Futures Trading Commission (the “CFTC”), the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the FDIC, the European Commission and other federal, state and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> securities or banking regulators, and other governmental regulatory authorities or self-regulatory organizations that supervise the financial markets. The Company may also be adversely affected by changes in the enforcement or interpretation of existing statutes and rules by courts and/or these governmental regulatory authorities or self-regulatory organizations. For example, a recent court decision casts doubt on whether federal or state usury laws apply with respect to loans originated by national banks and then sold to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-bank</div> investors such as the Company; this decision could significantly disrupt the bank loan secondary market and adversely impact the Company’s investment program. In addition, the approach taken by a federal court in the “Sun Capital” decision may significantly expand the scope of potential joint and several liability for pension obligations of portfolio companies commonly held by affiliated funds; this decision could create significant uncertainty with respect to such investments and adversely impact the Company. Moreover, legal and regulatory changes may adversely affect the Company’s ability to obtain financing by (among other things) reducing the availability of financing and/or adversely impacting financing costs and other terms. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial services industry is subject to extensive regulation. Banking regulators have broad and largely discretionary powers, which include prohibiting “unsafe or unsound” practices; requiring affirmative actions to correct any violation or practice; issuing administrative orders that can be judicially enforced; directing increases in capital; directing the sale of subsidiaries or other assets; limiting dividends and distributions; restricting growth; assessing civil monetary penalties; removing officers and directors; and terminating deposit insurance. These actions and other regulatory requirements could have a material adverse effect on an investment in the Company. The financial institutions in which the Company will invest and with which the Company will transact are subject to laws, regulations, administrative actions and policies in each location in which they operate. The regulatory environment for private investment funds is evolving, and changes in the regulation or taxation of private investment funds may adversely affect the value of the investments held by the Company and the ability of the Company to execute its investment strategy. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the securities and futures markets are subject to comprehensive statutes, regulations and margin requirements. The SEC and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other U.S. and non-U.S. regulators, self-regulatory organizations</div> and exchanges are authorized to take extraordinary actions in the event of market emergencies. The regulation of derivatives transactions and funds that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action. The effect of any future regulatory change on the Company could be substantial and adverse. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Changes in Regulatory Policy</div>. The U.S. government has recently called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">difficult-to-quantify</div></div> macroeconomic and political risks with potentially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">far-reaching</div> implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financial Services and Government Intervention</div>. From time to time, certain governments and regulatory authorities, such as the U.S. federal government, the U.S. Federal Reserve and the governments and regulatory authorities of certain member countries of the EU, have taken actions to provide or arrange credit support to financial institutions whose operations have been compromised by credit market dislocations and to restore liquidity and stability to the financial system in such jurisdictions. The implementation of any current or future governmental interventions (which may be significantly altered or terminated prior to implementation or during their terms), and their impact on both the credit markets generally and the Company’s investment program in particular, are uncertain. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act</div>. In response to the recent disruption in the credit markets and the global economic downturn, various agencies and regulatory bodies of the U.S. federal government have taken or are considering taking various actions. These actions include, but are not limited to, the enactment of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), which was signed into law on July 21, 2010, and which imposes a new regulatory framework over the U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">financial services industry, non-U.S. financial entities</div> that are regulated by or affiliated with entities regulated by U.S. financial regulators, and the consumer credit markets in general, and proposed and final regulations adopted thereunder, as well as proposed and final regulations to implement the Basel III regulatory capital accords. Given the broad scope and sweeping nature of these changes and the fact that certain final implementing rules and regulations have not yet been adopted or implemented, the potential impact of these actions on the Adviser and the Company is unknown, and no assurance can be made that the impact of such changes would not have a material adverse effect on the Adviser or the Company. For example, the U.S. Financial Stability Oversight Council (“FSOC”) created by the Dodd-Frank Act has the authority to designate asset management firms as a “systemically important financial institution” (“SIFI”). If the Adviser, or one of its affiliates, were designated as a SIFI, it would be subject to a variety of regulations, including capital requirements and limitations on leverage, which could have a material adverse effect on the ability of the Company to pursue its investment strategy. In addition, the Dodd-Frank Act created a new regulator for the credit industry in the U.S. known as the U.S. Consumer Financial Protection Bureau (“CFPB”). The CFPB may, among other things, regulate interest rates and other charges, require certain disclosures and regulate foreclosure practices. Future regulatory actions authorized by the Dodd-Frank Act (including any regulatory actions or other measures taken by the FSOC and/or the CFPB) may significantly reduce the profitability of the Company and its Portfolio Investments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes to Derivatives Regulation</div>. Through comprehensive new global regulatory regimes impacting derivatives (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, the Dodd-Frank Act, European Market Infrastructure Regulation (“EMIR”), Markets in Financial Investments Regulation (“MIFIR”)/Markets in Financial Instruments Directive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“MIFID II”)), certain over-the-counter derivatives transactions</div></div> in which the Company may engage are either now or will soon be subject to various requirements, such as mandatory central clearing of transactions which include additional margin requirements and in certain cases trading on electronic platforms, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-and</div> post-trade transparency reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">requirements and mandatory bi-lateral exchange of</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">initial margin for non-cleared swaps.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dodd-Frank Act also created new categories of regulated market participants, such as “swap dealers,” “security-based swap dealers,” “major swap participants,” and “major security-based swap participants” who are subject to significant new capital, registration, recordkeeping, reporting, disclosure, business conduct and other regulatory requirements. The EU and some other jurisdictions are implementing similar requirements. Because these requirements are new and evolving (and some of the rules are not yet final), their ultimate impact remains unclear. However, even if the Company itself is not located in a particular jurisdiction or directly subject to the jurisdiction’s derivatives regulations, the Company may still be impacted to the extent the Company enters into a derivatives transaction with a regulated market participant or counterparty that is organized in that jurisdiction or otherwise subject to that jurisdiction’s derivatives regulations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on information available as of the date of this annual report <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on Form 10-K, the</div> effect of such requirements will be likely to (directly or indirectly) increase the Company’s overall costs of entering into derivatives transactions. In particular, new margin requirements, position limits and significantly higher capital charges resulting from new global capital regulations, even if not directly applicable to the Company, may cause an increase in the pricing of derivatives transactions entered into by market participants to whom such requirements apply or affect the overall ability of the Company to enter into derivatives transactions with certain counterparties. Such new global capital regulations and the need to satisfy the various requirements by counterparties are resulting in increased funding costs and increased overall transaction costs and are significantly affecting balance sheets, thereby resulting in changes to financing terms and potentially impacting the Company’s ability to obtain financing. Administrative costs, due to new requirements such as registration, recordkeeping, reporting, and compliance, even if not directly applicable to the Company, may also be reflected in the Company’s derivatives transactions. New requirements to trade certain derivatives transactions on electronic trading platforms and trade reporting requirements may lead to (among other things) fragmentation of the markets, higher transaction costs or reduced availability of derivatives, and/or a reduced ability to hedge, all of which could adversely affect the performance of certain of the Company’s investing strategies. In addition, changes to derivatives regulations may impact the tax and/or accounting treatment of certain derivatives, which could adversely impact the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, the SEC adopted new rules regarding the ability of a BDC (or a registered investment company) to use derivatives and other transactions that create future payment or delivery obligations. BDCs that use derivatives will be subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">value-at-risk</div></div> leverage limit, certain other derivatives risk management program and testing requirements and requirements related to board reporting. These new requirements would apply unless the BDC qualified as a “limited derivatives user,” as defined in the adopted rules. A BDC that enters into reverse repurchase agreements or similar financing transactions would need to aggregate the amount of indebtedness associated with the reverse repurchase agreements or similar financing transactions and could either (i) comply with the asset coverage requirements of Section 18 of the 1940 Act when engaging in reverse repurchase agreements or (ii) choose to treat such agreements as derivative transactions under the adopted rules. Under the adopted rules, a BDC may enter into an unfunded commitment agreement that is not a derivatives transaction, such as an agreement to provide financing to a Portfolio Investment, if the BDC has a reasonable belief, at the time it enters into such an agreement, that it will have sufficient cash and cash equivalents to meet its obligations with respect to all of its unfunded commitment agreements, in each case as it becomes due. If the BDC cannot meet this test, it is required to treat unfunded commitments as a derivatives transaction subject to the requirements of the rule. Collectively, these requirements may limit the Company’s ability to use derivatives and/or enter into certain other financial contracts. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Uncertainty of the U.S. Political Climate</div>. The current administration has called for significant changes to U.S. trade, healthcare, immigration, foreign and government regulatory policy. In this regard, there is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events have created a climate of heightened uncertainty and introduced new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and difficult-to-quantify</div></div> macroeconomic and political risks with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">potentially far-reaching</div> implications. There has been a corresponding meaningful increase in the uncertainty surrounding interest rates, inflation, foreign exchange rates, trade volumes and fiscal and monetary policy. To the extent the U.S. Congress or the current administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although the Company cannot predict the impact, if any, of these changes to its business, they could adversely affect the Company’s business, financial condition, operating results and cash flows. Until the Company knows what policy changes are made and how those changes impact its business and the business of the Company’s competitors over the long term, the Company will not know if, overall, it will benefit from them or be negatively affected by them. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Bad Actor” Restrictions for Private Placements Conducted Under Rule 506 of Regulation D</div>. An issuer is precluded from conducting offerings that rely on the exemption from registration under the Securities Act provided by Rule 506 of Regulation D (“Rule 506 Offerings”) if a “covered person” of the issuer has been the subject of a “disqualifying event” (each as defined below). “Covered persons” include, among others, the issuer, affiliated issuers, any investment manager or solicitor of the issuer, any director, executive officer or other officer participating in the offering of the issuer, any general partner or managing member of the foregoing entities, any promoter of the issuer and any beneficial owner of 20% or more of the issuer’s outstanding voting equity securities, calculated on the basis of voting power. A “disqualifying event” includes, among other things, certain (a) criminal convictions and court injunctions and restraining orders issued in connection with the purchase or sale of a security or false filings with the SEC, (b) final orders from the CFTC, U.S. Federal banking agencies and certain other regulators that bar a person from associating with a regulated entity or engaging in the business of securities, insurance or banking or that are based on certain fraudulent conduct, (c) SEC disciplinary orders relating to investment advisers, brokers, dealers and their associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">persons, (d) SEC cease-and-desist orders relating</div></div> to violations of certain anti-fraud provisions and registration requirements of the U.S. federal securities laws, (e) suspensions or expulsions from membership in a self-regulatory organization (“SRO”) or from association with an SRO member, and (f) U.S. Postal Service false representation orders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A disqualification will occur only in the case of a disqualifying event of a covered person that occurs on or after September 23, 2013, although issuers must disclose to potential investors in a Rule 506 Offering disqualifying events of covered persons that occurred before September 23, 2013. The rule provides an exception from disqualification if the issuer can show that it did not know and, in the exercise of reasonable care could not have known, that the issuer or any other covered person had a disqualifying event, although an issuer will not be able to establish that it has exercised reasonable care unless it has made, in light of the circumstances, factual inquiry into whether any disqualifications exist. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adviser has made, and on a periodic basis will continue to make, inquiries into whether any persons that the Adviser has determined to be affiliated issuers have been subject to any disqualifying events; however, in some circumstances the Adviser’s ability to determine whether the Company would be disqualified from relying on Rule 506 may depend on cooperation of third parties over whom the Company may have limited control and influence. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the Adviser’s covered persons, including any affiliated issuer of the Company, is subject to a disqualifying event, the Company could lose the ability to raise capital in a future Rule 506 offering for a significant period of time and the Company’s business, financial condition and results of operations could be materially and adversely affected. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes to Accounting Standards</div>. The Financial Accounting Standards Board’s Accounting Codification Standards and updates, and additional provisions of U.S. generally accepted accounting principles (“U.S. GAAP”) (or to the extent applicable, International Financial Reporting Standards or other applicable accounting or financial reporting standards), that may be adopted in the future may impose additional, or different, specific requirements as to the valuation of assets and liabilities for purposes of U.S. GAAP-compliant financial reporting. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Licensing Requirements</div>. Various licensing requirements could apply to the Company or the Adviser with respect to investments in, or the origination, holding, servicing and disposing of, loans and similar assets. The licensing requirements could apply depending on the location of the borrower, the location of the collateral securing the loan, or the location where the Company or the Adviser operates or has offices. Moreover, the Company’s ability to invest in certain properties, participate in the secondary mortgage market, obtain financing for investments, lease properties to tenants and/or engage in lending, advisory, servicing and/or broker activities may be subject to the issuance of permits or licenses. If the Company applies for such licenses, this process may be costly and take several months. There is no assurance that the Company will obtain all of the licenses that it desires or that the Company would not experience significant delays in seeking these licenses. In states and other jurisdictions in which it is licensed, the Company or the Adviser is required to comply with applicable laws and regulations, including possible information requirements and consumer protection and anti-fraud laws, which could impose restrictions on the Company’s or the Adviser’s ability to take certain actions to protect the value of its investments in such assets and impose compliance costs. Failure to comply with such laws and regulations could lead to, among other penalties, a loss of the Company’s or the Adviser’s license, which in turn could restrict the Company’s investment options or require the Company to divest assets located in or secured by real property located in that jurisdiction. These risks also apply to issuers and entities in which the Company invests that hold similar assets, as well as any origination company or servicer in which the Company owns an interest. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Reporting Company Filing Requirements</div>. As a BDC, the Company is subject to the reporting requirements of the 1934 Act and requirements of the Sarbanes-Oxley Act. These requirements may place a strain on systems and resources. The 1934 Act requires that the Company file annual, quarterly and current reports with respect to business and financial condition. The Sarbanes-Oxley Act requires that the Company maintain effective disclosure controls and procedures and internal controls over financial reporting, which are discussed below. In order to maintain and improve the effectiveness of disclosure controls and procedures and internal controls, significant resources and management oversight are required. The Company has implemented procedures, processes, policies and practices for the purpose of addressing the standards and requirements applicable to reporting companies. These activities may divert management’s attention from other business concerns, which could have a material adverse effect on business, financial condition, results of operations and cash flows. The Company incurs significant additional annual expenses related to these steps and, among other things, directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, additional administrative expenses payable to the Administrative Coordinator to compensate them for hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The systems and resources necessary to comply with public company reporting requirements will increase further once the Company ceases to be an “emerging growth company” under the JOBS Act. As long as the Company remains an emerging growth company, it intends to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. The Company will remain an emerging growth company for up to five years following any future IPO (however, the Company does not anticipate engaging in an IPO of its Units), although if the market value of the Units that are held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700 million as of any June 30 before that time, the Company would cease to be an emerging growth company as of the following December 31. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, because the Units are registered under the 1934 Act, ownership information for any person who beneficially owns 5% or more of the Units will have to be disclosed in a Schedule 13G or other filings with the SEC. Beneficial ownership for these purposes is determined in accordance with the rules of the SEC, and includes having voting or investment power over the securities. In some circumstances, Unitholders who choose to reinvest their dividends may see their percentage stake in the Company increased to more than 5%, thus triggering this filing requirement. Each Unitholder is responsible for determining their filing obligations and preparing the filings. In addition, Unitholders who hold more than 10% of a class of Units may be subject to Section 16(b) of the 1934 Act, which recaptures for the benefit of the Company profits from the purchase and sale of registered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Units within a six-month period.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Documentation of Internal Controls</div>. The Company is obligated to maintain proper and effective internal control over financial reporting, including the internal control evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act (“Section 404”). The Company is not required to comply with all of the requirements under Section 404 until the date it is no longer an emerging growth company under the JOBS Act. Accordingly, the Company’s internal controls over financial </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">reporting do not currently meet all of the standards contemplated by Section 404 that they will eventually be required to meet. Specifically, the Company is required to conduct annual management assessments of the effectiveness of its internal controls over financial reporting. However, the Company’s independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial reporting until the date it is no longer an emerging growth company under the JOBS Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If the Company fails to maintain the adequacy of its internal controls, including any failure to implement required new or improved controls, or if the Company experiences difficulties in their implementation, the Company’s business and operating results could be harmed and it could fail to meet its financial reporting obligations. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">High Yield Debt and Unrated Securities</div>. High yield securities are typically junior to the obligations of companies to senior creditors, trade creditors and employees. High yield securities and unrated securities (which are not rated by a rating agency) may be more susceptible to real or perceived adverse economic and competitive industry conditions than investment-grade securities. A projection of an economic downturn or of a period of rising interest rates, such as the recent economic period, for example, could cause a decline in the prices of high yield securities and unrated securities, because the advent of a recession could lessen the ability of an issuer to make principal and interest payments on its debt obligations. In addition, such securities have historically experienced greater default rates than investment grade securities. The ability of holders of high yield debt to influence a company’s affairs will be substantially less than that of senior creditors, especially during periods of financial distress or following insolvency. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As with other Portfolio Investments, there may not be a liquid market for certain high yield debt which is held by the Company, which could result in the Company being unable to sell such securities for an extended period of time, if at all. In addition, as with other types of Portfolio Investments, the market for high yield debt has historically been subject to disruptions that have caused substantial volatility in the prices of such securities. Consolidation in the financial services industry has resulted in there being fewer market makers for high yield debt, which may result in further risk of illiquidity and volatility with respect to high yield debt held by the Company, and this trend may continue in the future. Furthermore, high yield debt which is held by the Company may not be registered under the Securities Act, and, unless so registered, the Company is not able to sell such high yield debt except pursuant to an exemption from registration under the Securities Act. Unrated securities may be less liquid than comparable rated securities and may also involve the risk that the Adviser may not accurately evaluate the security’s comparative credit rating. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Analysis of creditworthiness of issuers of high yield and unrated securities may be more complex than for issuers of higher-quality fixed income securities. Since it is expected that most of the Company’s assets will not be rated by any rating agency or will be rated below investment grade, the Company is more dependent on the Adviser’s creditworthiness analysis than if the Company invested exclusively in higher-quality and rated securities. Securities rated below investment grade are often referred to as “leveraged loans,” “high yield” or “junk” securities, and may be considered “high risk” compared to debt instruments that are rated investment grade. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Credit Risk</div>” above. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Related Securities</div>. As with other Portfolio Investments, the value of equity or equity-related securities held by the Company may be adversely affected by actual or perceived negative events relating to the issuer of such securities, the industry or geographic areas in which such issuer operates or the financial markets generally. However, equity securities may be even more susceptible to such events given their subordinate position in the issuer’s capital structure. As such, equity securities generally have greater price volatility than fixed income securities, and the market price of equity securities owned by the Company is more susceptible to moving up or down in a rapid or unpredictable manner. In addition, equity securities <div style="display:inline;">often</div> lose a significant amount of their value and may become worthless as a result of a bankruptcy proceeding or reorganization. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Securities Risk</div>. Convertible securities generally offer lower interest or dividend yields than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities of similar quality. The market values of convertible securities tend to decline as interest rates increase and, conversely, to increase as interest rates decline. However, a convertible security’s market value tends to reflect the market price of the common stock of the issuing company when that stock price approaches or is greater than the convertible security’s “conversion price.” The conversion price is defined as the predetermined price at which the convertible security could be exchanged for the associated stock. As the market price of the underlying common stock declines, the price of the convertible security tends to be influenced more by the yield of the convertible security. Thus, it may not decline in price to the same extent as the underlying common stock. Generally, in the event of a liquidation of the issuing company, holders of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">convertible securities would be paid before the company’s common stockholders but after holders of any senior debt obligations of the company. Consequently, the issuer’s convertible securities generally entail less risk than its common stock but more risk than its debt obligations. There is also a risk that, under certain circumstances, a bankruptcy court may order that convertible securities are treated as equity. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may invest in synthetic convertible securities, which are created through a combination of separate securities that possess the two principal characteristics of a traditional convertible security, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i.e.</div></div>, an income-producing security (“income-producing component”) and the right to acquire an equity security (“convertible component”). The income-producing component is achieved by investing in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible,</div> income-producing securities such as bonds, preferred stocks and money market instruments. The convertible component is achieved by purchasing warrants or options to buy common stock at a certain exercise price, or options on a stock index. The values of synthetic convertible securities will respond differently to market fluctuations than a traditional convertible security because a synthetic convertible is composed of two or more separate securities or instruments, each with its own market value. Synthetic convertible securities are also subject to the risks associated with derivatives. In addition, if the value of the underlying common stock or the level of the index involved in the convertible element falls below the strike price of the warrant or option, the warrant or option may lose all value. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Securities Risk</div>. In addition to credit risk, investment in preferred stocks involves certain other risks. Certain preferred stocks contain provisions that allow an issuer under certain conditions to skip or defer distributions. If the Company owns preferred stock that is deferring its distribution, the Company may be required to report income for U.S. federal income tax purposes despite the fact that it is not receiving current income on this position. Preferred stock often is subject to legal provisions that allow for redemption in the event of certain tax or legal changes or at the issuer’s call. In the event of redemption, the Company may not be able to reinvest the proceeds at comparable rates of return. Preferred stock is subordinated to bonds and other debt securities in an issuer’s capital structure in terms of priority for corporate income and liquidation payments and, therefore, will be subject to greater credit risk than those debt securities. Preferred stock may trade less frequently and in a more limited volume and may be subject to more abrupt or erratic price movements than many other securities, such as common stocks, corporate debt securities and U.S. government securities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Forwards and Derivatives Transactions</div>. The Company may engage in a variety of derivatives transactions. A <div style="display:inline;">derivative </div>is a financial contract the value of which depends upon, or is derived from, the value of underlying assets, reference rates or indices. Derivatives may relate to securities, interest rates, currencies or currency exchange rates, inflation rates, commodities and related indices, and include foreign currency contracts, swap contracts, options, forward and futures contracts (including options thereon), repurchase or reverse repurchase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">agreements or other over-the-counter contracts. The</div></div> Company may use derivatives for many purposes, including as a substitute for direct investment, as a way to adjust its exposure to various securities, markets and currencies without actually having to sell existing investments and/or make new investments, and as a means to hedge other investments and to manage liquidity and excess cash. The Company’s use of derivatives may result in losses, reduce the Company’s return, and/or increase the volatility of the Company (particularly since many derivatives are inherently leveraged), especially in unusual or extreme <div style="display:inline;">market </div><div style="display:inline;">conditions</div>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All derivatives transactions involve risks different from, and potentially greater than, the risks associated with investing directly in securities and other more traditional assets, including: </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market Risk</div></div>. This is the general risk that the value of a particular investment or transaction will change in a way detrimental to the Company’s interests. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management Risk</div></div>. Derivatives contracts are specialized contracts that require investment techniques and risk analyses with additional levels of complexity associated with the underlying investments. In addition to risks associated with the underlying instruments, counterparty and unsecured risk (among others) need to be computed and tracked in relation to the Company’s overall risk profile. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Documentation Risk</div></div>. Many derivatives transactions also have documentation risk. Because contracts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> derivatives transactions are individually negotiated with specific counterparties, there exists the risk that the parties may interpret contractual terms (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, the definition of default) differently than the Company. If that occurs, the cost and unpredictability of the legal proceedings required for the Company to enforce its contractual rights may lead the Company to decide not to pursue its claims against the counterparty. The Company, therefore, assumes the risk that it may be unable to obtain payments the Adviser believes are owed to it under derivatives transactions, or those payments may be delayed or made only after the Company has incurred the costs of litigation. Also, payment amounts calculated in connection with standard industry conventions for resolving contractual issues (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, ISDA Protocols and auction processes) may be different than would be realized if a counterparty were required to comply with the literal terms of the derivatives transaction (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, physical delivery). There is little case law interpreting the terms of most derivatives or characterizing their tax treatment. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulatory Risk</div></div>. The derivatives market is subject to various risks related to existing as well as new and evolving regulation both within and outside the U.S. Additional regulation of the derivatives markets may make derivatives more costly, may limit the availability of derivatives, or may otherwise adversely affect the value or performance of derivatives. Any such adverse future developments could impair the effectiveness of a Company’s derivatives transactions and cause the Company to lose value. They may also render certain strategies in which the Company might otherwise engage impossible or so costly that they will no longer be economical to implement. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Changes to Derivatives Regulation</div>” above. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Risks</div></div>. Derivatives also involve the risk that changes in their value may not correlate perfectly with the assets, rates or indices they are designed to track. Suitable derivatives may not be available in all circumstances. Under the terms of certain contracts governing derivatives transactions, the occurrence of certain events with respect to the Company (such as a decline in the Company’s NAV) may cause the Company’s derivatives transactions to be terminated early, including at an inopportune time or at an unfavorable price. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Warrants and Rights</div>. The Company may purchase or otherwise receive warrants or rights. Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a stated price. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of options. Unlike most options, however, warrants and rights are issued in specific amounts, and warrants generally have longer terms than options. Warrants and rights are not likely to be as liquid as exchange-traded options backed by a recognized clearing agency. In addition, the terms of warrants or rights may limit the Company’s ability to exercise the warrants or rights at such time, or in such quantities, as the Company would otherwise wish. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Relating to Reference Rates</div>. The London Interbank Offered Rate (“LIBOR”) is an index rate that historically was widely used in lending transactions and was a common reference rate for setting the floating interest rate on private loans. LIBOR was typically the reference rate used in floating-rate loans extended to the Company’s Portfolio Investments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ICE Benchmark Administration (“IBA”) (the entity that is responsible for calculating LIBOR) ceased providing overnight, one, three, six and twelve months USD LIBOR tenors on June 30, 2023. In addition, the United Kingdom’s Financial Conduct Authority (“FCA”), which oversees the IBA, now prohibits entities supervised by the FCA from using LIBORs, including USD LIBOR, except in very limited circumstances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, SOFR is the preferred alternative rate for LIBOR. SOFR is a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. SOFR is published by the Federal Reserve Bank of New York each U.S. Government Securities Business Day, for transactions made on the immediately preceding U.S. Government Securities Business Day. Alternative reference rates that may replace LIBOR, including SOFR for USD transactions, may not yield the same or similar economic results as LIBOR over the lives of such transactions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the filing date of this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> many of the Company’s loans that referenced LIBOR have been amended to reference the forward-looking term rate published by CME Group Benchmark Administration Limited based on SOFR (“CME Term SOFR”) or CME Term SOFR plus a fixed spread adjustment. CME Term SOFR rates are forward-looking rates that are derived by compounding projected overnight SOFR rates over one, three, and six months taking into account the values of multiple consecutive, executed, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-month</div> and three-month CME Group traded SOFR futures contracts and, in some cases, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> SOFR Overnight Indexed Swaps as an indicator of CME Term SOFR reference rate values. CME Term SOFR and the inputs on which it is based are derived from SOFR. Since CME Term SOFR is a relatively new market rate, there will likely be no established trading market for credit agreements or other financial instruments when they are issued, and an established market may never develop or may not be liquid. Market terms for instruments referencing CME Term SOFR rates may be lower than those of later-issued CME Term SOFR indexed instruments. Similarly, if CME Term SOFR does not prove to be widely used, the trading price of instruments referencing CME Term SOFR may be lower than those of instruments indexed to indices that are more widely used. Further, the composition and characteristics of SOFR and CME Term SOFR are not the same as those of LIBOR. Even with the application of a fixed spread adjustment, LIBOR and CME Term SOFR will not have the same composition and characteristics, and there can be no assurance that the replacement rate, as so adjusted, will be a direct substitute for LIBOR. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no guarantee that SOFR will not be discontinued or fundamentally altered in a manner that is materially adverse to the interests of investors in loans referencing SOFR. If the manner in which SOFR or CME Term SOFR is calculated is changed, that change may result in a reduction of the amount of interest payable on such loans and the trading prices of the SOFR Loans. In addition, there can be no guarantee that loans referencing SOFR or CME Term SOFR will continue to reference those rates until maturity or that, in the future, the Company’s loans will reference benchmark rates other than CME Term SOFR. Should any of these events occur, the Company’s loans, and the yield generated thereby, could be affected. Specifically, the anticipated yield on the Company’s loans may not be fully realized and the Company’s loans may be subject to increased pricing volatility and market risk. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Economic Recessions</div>. The recent macroeconomic environment is characterized by record-high inflation, supply chain challenges, labor shortages, high interest rates, foreign currency exchange volatility, volatility in global capital markets and growing recession risk. The risks associated with the Company’s and the Portfolio Investments’ businesses are more severe during periods of economic slowdown or recession. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the Company’s Portfolio Investments may be susceptible to economic slowdowns or recessions and may be unable to repay its loans during these periods. The global outbreak <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of COVID-19</div> has disrupted economic markets, and the prolonged economic impact is uncertain. Many manufacturers of goods have seen a downturn in production due to the suspension of business and temporary closure of factories globally in an attempt to curb the continued spread of the virus. As a result of these disruptions, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Company’s non-performing</div> assets may increase and the value of its portfolio may decrease during these periods as the Company is required to record the values of its investments. Adverse economic conditions also may decrease the value of collateral securing some of the Company’s loans and the value of its equity investments at fair value. Economic slowdowns or recessions could lead to financial losses in the Company’s portfolio and a decrease in revenues, net income and assets. Unfavorable economic conditions also could increase the Company’s funding costs, limit its access to the capital markets or result in a decision by lenders not to extend credit to the Company. These events could prevent the Company from increasing investments and result in its receipt of a reduced level of interest income from the Company’s Portfolio Investments and/or losses or charge offs related to its investments, and, in turn, may adversely affect distributable income and have a material adverse effect on the Company’s results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Portfolio Investment’s failure to satisfy financial or operating covenants imposed by the Company or other lenders could lead to defaults and, potentially, acceleration of the time when the loans are due and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize the Portfolio Investment’s ability to meet its obligations under the debt that the Company holds. The Company may incur additional expenses to the extent necessary to seek recovery upon default or to negotiate new terms with a defaulting Portfolio Investment. In addition, if one of the Company’s Portfolio Investments were to go bankrupt, depending on the facts and circumstances, including the extent to which the Company actually provided significant managerial assistance to that Portfolio Investment, a bankruptcy court <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">might re-characterize</div> its debt holdings and subordinate all or a portion of the Company’s claim to that of other creditors. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive research and development, manufacturing, marketing and service capabilities and greater number of qualified and experienced managerial and technical personnel. They may need additional financing that they are unable to secure and that the Company is unable or unwilling to provide, or they may be subject to adverse developments unrelated to the technologies they acquire. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s business is directly influenced by the economic cycle and could be negatively impacted by a downturn in economic activity in the U.S. as well as globally. Fiscal and monetary actions taken by U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and non-U.S.</div> government and regulatory authorities could have a material adverse impact on the Company’s business. To the extent uncertainty regarding the U.S. or global economy, including as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the COVID-19</div> pandemic, certain regional bank failures, the Russian invasion of Ukraine and the ongoing war in the Middle East, negatively impacts consumer confidence and consumer credit factors, the Company’s business, financial condition and results of operations could be adversely affected. Moreover, Federal Reserve policy, including with respect to certain interest rates and the decision to end its quantitative easing policy, along with the general policies of the current Presidential administration, may also adversely affect the value, volatility and liquidity of dividend- and interest-paying securities. Market volatility, periods of rising interest rates, such as the recent economic period, and/or a return to unfavorable economic conditions could adversely affect its business. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the U.S.’ Debt Ceiling</div>. The significant debt in the U.S. is expected to hinder growth in the U.S. for the foreseeable future. In the future, the U.S. government may not be able to meet its debt payments unless the federal debt ceiling is raised. If legislation increasing the debt ceiling is not enacted, as needed, and the debt ceiling is reached, the U.S. federal government may stop or delay making payments on its obligations. Any default by the U.S. government on its obligations or any prolonged U.S. government shutdown could negatively impact the U.S. economy and our Portfolio Investments. In addition, concerns over the United States’ debt ceiling and budget-deficit have driven downgrades by rating agencies to the U.S. government’s credit rating. Downgrades by rating agencies to the U.S. government’s credit rating or concerns about its credit and deficit levels in general could cause interest rates and borrowing costs to rise, which may negatively impact both the perception of credit risk associated with our debt portfolio and our ability to access the debt markets on favorable terms. In addition, a decreased U.S. government credit rating, any default by the U.S. government on its obligations, or any prolonged U.S. government shutdown, could create broader financial turmoil and uncertainty, which may weigh heavily on our financial performance and the value of our common stock. U.S. debt ceiling and budget deficit concerns have <div style="display:inline;">increased </div>the possibility of additional credit-rating downgrades and economic slowdowns or a recession in the U.S. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Portfolio Investment Monitoring and Involvement</div>. The Company’s Portfolio Investments will require active monitoring and may, at times, involve participation in business strategy or reorganization proceedings. See “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Control Positions</div>” below. The Company’s investment program may from time to time enable it to place representatives on the creditors’ or steering committees and/or the boards of directors of certain companies in which it has invested. While such involvement may enable the Adviser to enhance the value of the Company’s Portfolio Investments, it may also prevent the Company from freely disposing of such Portfolio Investments, while also exposing it to legal claims and adverse publicity (including claims of breach of duty of loyalty, securities claims and other management-related claims). In addition, if the Adviser’s representatives are serving as directors of companies which are in the “zone of insolvency,” such persons may have a fiduciary obligation to the creditors of such entity as well as the shareholders of such entity. The interests of such parties may be adverse to the interests of the Company. These fiduciary obligations may conflict with the Adviser’s obligation to the Company, and the Adviser may cause its representatives to resign from such positions in order to reduce such conflicts. Any involvement by the Adviser’s representatives (including through serving on a board of directors, or permanent or ad hoc creditors’ or steering committees) may also entail a substantial time commitment, which may limit such representatives’ ability to participate in other Company matters and investments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Associated with Bankruptcy and Insolvency Cases</div>. If any issuers of securities held by the Company or any counterparties to the derivatives transactions and other transactions entered into by the Company, or any custodians of the Company’s assets or any obligors in connection with Portfolio Investments are involved in bankruptcy proceedings, the Company will be subject to certain risks inherent in bankruptcy proceedings, including the duration, administrative costs and impact of a bankruptcy case on the value of assets administered in bankruptcy or on a company’s value (including that a bankruptcy case may damage or diminish a company’s relationship with its employees, customers and/or suppliers). Many of the events within a bankruptcy or insolvency case are adversarial and often beyond the control of the creditors. While creditors generally are afforded an opportunity to object to significant actions, or to demand that certain actions take place, there can be no assurance that a court would not approve actions or inaction which may be contrary to the interests of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the duration of a bankruptcy or insolvency case can only be roughly estimated. The reorganization of a company usually involves the design of a business plan, the development and negotiation of a plan of reorganization, plan approval by creditors and confirmation by the court. This process can involve substantial legal, professional and administrative costs to the company and to the Company; is subject to unpredictable and lengthy delays; and during the process the company’s competitive position may erode, key management may depart and the company may not be able to invest adequately. In some cases, the company may not be able to reorganize and may be required to liquidate assets. In addition, the debt of companies in financial reorganization may, in some cases, not pay current interest and other charges, may not even accrue interest and other charges during reorganization, may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">relieved of paying pre-payment premiums and</div> may be adversely affected by an erosion of the issuer’s fundamental value. Further, a debtor seeking to reorganize under U.S. federal bankruptcy law will frequently obtain a “first day” order from the bankruptcy court limiting trading in claims against, and shares of, the debtor in order to maximize the debtor’s ability to utilize net operating losses following a successful reorganization. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the pendency of a bankruptcy case, an automatic stay will prevent all creditors from taking action against the debtor to foreclose on collateral or otherwise to collect on amounts owed to such creditors. Unless a creditor’s claim in such case is secured by assets having a value in excess of such claim, or the bankruptcy estate is determined to be solvent, no interest will be permitted to accrue and, therefore, a creditor’s return on investment can be adversely affected by the passage of time during which the plan of reorganization of the debtor is being negotiated, approved by the creditors and confirmed by the bankruptcy court. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The priority of perfected liens held by secured creditors as of the commencement of the bankruptcy case is typically recognized in a bankruptcy case, unless avoided. Occasionally, however, a court will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">allow a debtor-in-possession financing to</div></div> receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">liens that prime pre-existing, valid liens.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrative costs in connection with a bankruptcy case are frequently high and will generally be paid out of the debtor’s estate prior to any return to creditors (other than out of assets or proceeds thereof which are subject to valid and enforceable liens and other security interests) and equity holders. In addition, certain unsecured claims that have priority by law over the claims of certain creditors (for example, claims arising post-petition and certain claims for taxes) may be quite high. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. bankruptcy law permits the classification of “substantially similar” claims in determining the classification of claims in a reorganization for the purpose of voting on a plan of reorganization. Because the standard for classification is vague, there exists a significant risk that the Company’s influence with respect to a class of securities can be lost by the inflation of the number and the amount of claims in, or other gerrymandering of, the class. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although a creditor is not typically compelled to release direct claims it may have against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-debtor</div> third parties, in certain circumstances a court may compel such release in the context of a plan of reorganization. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Claims in bankruptcy cases are often paid at less than par and, depending on the debtor’s assets and liabilities, there may be no recovery at all for some classes of creditors. The claims of even over-secured secured creditors are often paid out over time, and may receive debt securities that will trade below par. Initially, only the debtor may file a proposed plan of reorganization. While the U.S. Bankruptcy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Code permits other parties-in-interest to file</div></div> proposed plans of reorganization after the debtors’ “exclusive period” to do so ends, bankruptcy courts often extend the debtor’s exclusive period, which effectively permits only the debtor to file a proposed reorganization plan. While creditors can vote on the plan of reorganization, the unanimous consent of all creditor classes is not necessarily required for the bankruptcy court to confirm the plan. Therefore, a plan can, subject to the provisions of the U.S. Bankruptcy Code, be “crammed down” on dissenting classes of creditors. Moreover, minority members of a class may be deemed to be members of an accepting class if the requisite majority vote is acquired. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a class of claims is entitled to a recovery in a reorganization or liquidation proceeding, such recovery could be in the form of instruments or interests different from the form of instrument or interest which formed the basis for the claim, including debt securities, equity securities, convertible securities, warrants, options, cash, interests in litigation claims or trusts formed to pursue such litigation claims, interests in liquidation trusts, or other property or interests, any of which could be illiquid and/or difficult to value. Furthermore, the terms of instruments or interests distributed in a bankruptcy or insolvency proceeding may differ from prevailing market terms for similar instruments or interests, and may have a market value of less than par. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may be presented with the opportunity to make new investments in connection with the reorganization or liquidation of an issuer of Portfolio Investments, including, without limitation, through a rights offering, litigation financing, bridge financing or other exit financing. The Company may make such investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">part of an in-court or out-of-court restructuring of</div></div></div> an issuer of Portfolio Investments, and any such investment will be subject to the same risks as other Portfolio Investments of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contractual subordination provisions are enforceable when a borrower is in bankruptcy, as are most inter-creditor agreement terms. Furthermore, there are instances where creditors and equity holders may lose their ranking and priority when they take over management and functional operating control of a debtor. In those cases where the Company, by virtue of such action, is found to exercise “domination and control” of a debtor, the Company may lose its priority if the debtor or other creditors can demonstrate that the debtor’s business was adversely impacted or other creditors and/or equity holders were harmed by improper or unfair actions of the Company, whether or not the Company is found to be a controlling party of the debtor. In addition, loans extended to a financially distressed borrower by an entity that owns an equity interest in the borrower may be reclassified as having been an equity capital contribution, rather than a debt obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the corporate structure of various debtor entities, such as special purpose entities created to hold assets and to structure for bankruptcy remoteness, such entities may, in certain cases, be consolidated in bankruptcy proceedings, which can affect the outcome of such proceedings and the amounts ultimately received by creditors. In addition, if a claim can be asserted against only a parent holding entity, such claim may be structurally subordinated to claims against a subsidiary entity that owns assets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Bankruptcy Code and other laws and regulations affecting debtors’ and creditors’ rights are subject to change, including by way of legislative action or judicial interpretation. In addition, governmental actors have recently shown a willingness to intervene in bankruptcy-related matters (for example, the U.S. government’s bailouts of General Motors and Chrysler), which may increase uncertainty regarding the enforcement of creditors’ rights and the bankruptcy process generally. Any such actions could alter the expected outcome or introduce greater uncertainty regarding the expected outcome of an investment situation of the Company, which may adversely affect such investment or the Company’s investment program. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lack of Control over Investments</div>. The Company invests in debt securities, but <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">may hold a non-controlling interest in</div> one or more Portfolio Investments. Such investments may not give the Company the ability to influence the management of the company or to elect a representative to the Board. In addition, the management of the company or its shareholders may have economic or business interests which are inconsistent with those of the Company, and they may be in a position to take action contrary to the Company’s objectives. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest may be especially adverse to the Company in circumstances, such as certain stressed or distressed situations, where an element of control or influence might be beneficial to the subject investment. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Control Positions</div>. The Company does not expect to, but may have a controlling interest in a Portfolio Investment (because of its equity ownership, representation on the board of directors and/or contractual rights) either on its own or, in certain cases, with another financial partner or investment fund (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.,</div></div> in accordance with the Company’s receipt of equity in connection with a restructuring). The exercise of control over a company may impose additional risks of liability for environmental damage, product defects, failure to supervise management, pension and other fringe benefits, violation of governmental regulations (including securities laws) or other types of related liability. If these liabilities were to arise, the Company might suffer a significant loss in such investment. In addition, if employees of the Adviser serve as directors of certain of the Portfolio Investments, including public companies, they will have duties to persons other than the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that the Company owns a controlling stake in or is deemed an affiliate of a particular company, it may also be subject to certain additional bankruptcy or securities laws restrictions that could affect both the liquidity of the Company’s interest and the Company’s ability to liquidate its interest without adversely impacting the price thereof, including insider trading restrictions, the affiliate sale restrictions of Rule 144 of the Securities Act and the disclosure requirements of Sections 13 and 16 of the 1934 Act. Further, to the extent that affiliates of the Company or the Adviser are subject to such restrictions, the Company, by virtue of its affiliation with such entities, may be similarly restricted, regardless of whether the Company stands to benefit from such affiliate’s ownership. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company, alone or as part of a group acting together for certain purposes, becomes the beneficial owner of more than 10% of certain classes of securities of a U.S. public company or places a director on the board of directors of such a company, the Company may be subject to certain additional reporting requirements and to liability for short-swing profits under Section 16 of the 1934 Act. Furthermore, the Company may also be subject to similar reporting requirements and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other limitations in non-U.S. jurisdictions where</div> it holds significant positions in companies in such jurisdictions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise of control over a company, depending upon the amount and type of securities owned by the Company, contractual arrangements between the company and the Company, and other relevant factual circumstances, could result in an extension to one year of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day bankruptcy preference</div> period with respect to payments made to the Company. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Fraudulent Conveyance and Preference Considerations</div>” below. The exercise of control over a company may also provide grounds for challenges to the priority and enforceability of Portfolio Investments or other claims the Company may have against the company if it is subject to a bankruptcy case or other insolvency proceeding. See “—<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lender Liability Considerations and Equitable Subordination</div>” below. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lender Liability Considerations and Equitable Subordination</div>. In recent years, a number of judicial decisions in the U.S. have upheld the right of borrowers to sue lending institutions on the basis of various evolving legal theories (collectively termed “lender liability”). Generally, lender liability is founded upon the premise that an institutional lender has violated a duty (whether implied or contractual) of good faith and fair dealing owed to the borrower or has assumed a degree of control over the borrower resulting in creation of a fiduciary duty owed to the borrower or its other creditors or shareholders. In addition, courts have in some cases applied the doctrine of equitable subordination to subordinate the claim against a borrower of a creditor, including a lending institution, to claims of other creditors of the borrower when the creditor is found to have engaged in unfair, inequitable or fraudulent conduct. There can be no assurance as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire such claims engaged in any such conduct and, if it did, as to whether the Company would be subject to claims that the Company’s Portfolio Investments should be equitably subordinated based on such conduct. Because of the nature of certain of the Company’s Portfolio Investments, the Company could be subject to allegations of lender liability or to claims that the Company’s Portfolio Investments should be <div style="display:inline;">equitably </div>subordinated. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Fraudulent Conveyance and Preference Considerations</div>. Various federal and state laws enacted for the protection of creditors may apply to the purchase of the Company’s Portfolio Investments, or payments or liens related thereto, by virtue of the Company’s role as a creditor with respect to the borrowers under such Portfolio Investments. If a court, in a lawsuit brought by an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">unpaid creditor, a debtor-in-possession, a trustee</div></div> in bankruptcy, or their respective representatives, were to find that the borrower took any action to intentionally delay or frustrate recoveries by creditors, or did not receive fair consideration or reasonably equivalent value for incurring indebtedness evidenced by an investment and the grant of any security interest or other lien securing such investment, and, after giving effect to such indebtedness and/or grant of any security interest or other lien, the issuer or obligor (i) was insolvent, (ii) was engaged in a business for which the remaining assets of such issuer constituted unreasonably small capital or (iii) intended to incur, or believed that it would incur, debts beyond its ability to pay such debts as they mature, such court could, under certain circumstances, invalidate, in whole or in part, such indebtedness and such security interest or other lien as fraudulent conveyances, could subordinate such indebtedness to existing or future creditors of the borrower and could allow the borrower to recover amounts previously paid by the borrower to the creditor (including to the Company) in satisfaction of such indebtedness or proceeds of such security interest or other lien previously applied in satisfaction of such indebtedness. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The measure of insolvency for purposes of the foregoing will vary. Generally, an issuer or obligor would be considered insolvent at a particular time if the sum of its debts were then greater than all of its property at a fair valuation, or if the present fair saleable value of its assets were less than the amount that would be required to pay its probable liabilities on its existing debts as they became absolute and matured. There can be no assurance as to what standard a court would apply in order to determine whether the issuer or obligor was “insolvent” after giving effect to the incurrence of the indebtedness and/or the granting of any security interest or other lien or that, regardless of the method of valuation, a court would not determine that the issuer was “insolvent” upon giving effect to such incurrence of indebtedness and/or grant of security interests or other lien. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may invest in bank debt or other indebtedness issued by a borrower which is guaranteed by other entities within the borrower’s corporate family. In such circumstances, the borrower often has little or no assets other than the stock of its subsidiaries and, as a result, any recovery is often available only, if at all, from the entities that guaranteed the indebtedness. There is a risk, however, that the obligations of such guarantors and any security interests or other liens issued by the guarantors to secure such obligations may be avoided as fraudulent conveyances in the event that a court were to determine that such guarantors did not receive reasonably equivalent value in exchange for the issuance of the guarantees and for the security interests or other liens. A court could determine that the guarantors did not receive reasonably equivalent value or fair consideration in incurring the obligations and granting the security interests or other liens despite the existence of “indirect” benefits to the guarantors, such as the strengthening of the corporate enterprise in the transaction. Additionally, provisions in guarantees and other similar documents governing similar obligations by which fraudulent conveyance exposure is sought to be reduced or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">eliminated, such as so-called “savings clauses,”</div> may not be enforceable. As a result, the Company’s Portfolio Investment in corporate bank debt or other indebtedness could be subject to avoidance as a fraudulent conveyance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a transaction is found to have been a fraudulent conveyance, the transferee may be compelled to return the value of the assets transferred as of the time of the transfer, even if the then current value is substantially less. In addition, unless the transferee is deemed to be a “good faith” transferee, the return of the asset may not even provide for the compensation back to the transferee of the value paid to the transferor. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the event of the insolvency (as determined by a court based on the law of the jurisdiction which is being applied) of an issuer of a Portfolio Investment, payments made on the Company’s Portfolio Investment, or new liens granted, could be subject to avoidance as a “preference” if made within a certain period of time (which may be as long as one year) before insolvency, depending on a number of factors. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, if payments on a Company’s Portfolio Investment are avoidable, whether as a fraudulent conveyance or preference, such payments can be recaptured either from the initial recipient (such as the Company) or from subsequent transferees of such payments, including Unitholders. Additionally, if the grant of a security interest or other lien is avoidable, whether as a fraudulent conveyance or preference, the value of the security interest or other lien can be recovered from the initial transferee or the entity for whose benefit such transfer was made (such as the Company), and such recovery could include the diminution in value of the property which was subject to the security interest or other lien from the date of transfer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that a successful cause of action for fraudulent conveyance or preference will not occur, or as to whether any fund, lending institution or other party from which the Company may directly or indirectly acquire a Portfolio Investment engaged in any conduct to give rise to such causes of action, and if it did, as to whether such causes of action could be asserted against the Company and/or the Unitholders. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Portfolio Investment Risk</div>. The Company’s Portfolio Investments may involve a high degree of business and financial risk. Portfolio Investments may be in early stages of development, may have operating losses or significant variations in operating results and may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence. Portfolio Investments will also include companies that are experiencing or are expected to experience financial difficulties, which may never be overcome. In addition, many of them will have weak financial conditions and may require substantial additional capital to support their operations, to finance expansion or to maintain their competitive positions. Portfolio Investments may face intense competition, including competition from companies with greater financial resources, more extensive development, manufacturing, marketing, and other capabilities and a larger number of qualified managerial and technical personnel. In addition, Portfolio Investments in which the Company invests may be required to comply with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">numerous U.S. and non-U.S. statutory and</div> regulatory standards. A Portfolio Investment could be materially and adversely affected as a result of statutory or regulatory changes or changes in judicial or administrative interpretations of existing laws and regulations that impose more comprehensive or stringent requirements on such Portfolio Investment, the markets in which such Portfolio Investment operates or such Portfolio Investment’s industry generally. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that a Portfolio Investment’s management team will be able to operate such Portfolio Investment successfully. In addition, instances of fraud or other illegal practices committed by the management team of a Portfolio Investment may undermine the Company’s investment in such Portfolio Investment and the Company may suffer losses. Additionally, Portfolio Investments need to attract, retain and develop executives and members of their management teams. There can be no assurance that a Portfolio Investment will be able to attract and develop suitable <div style="display:inline;">members </div>of its management team, which may adversely affect the Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Zero-Coupon Bonds, Deferred Interest Rate Bonds and</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> Payment-In-Kind</div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> Securities</div>. Zero-coupon bonds pay interest only at maturity rather than at intervals during the life of the security. Deferred interest rate bonds generally provide for a period of delay before the regular payment of interest begins. PIK securities are debt obligations that pay “interest” in the form of other debt obligations, instead of in cash. Each of these instruments is normally issued and traded at a deep discount from face value. Zero-coupon bonds, deferred interest rate bonds and PIKs allow an issuer to avoid or delay the need to generate cash to meet current interest payments and, as a result, may involve greater credit risk than bonds that pay interest currently or in cash. In addition, such investments experience greater volatility in market value due to changes in interest rates than debt obligations that provide for regular payments of interest. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company invests in OID instruments, including PIK, zero coupon bonds, and debt securities with attached warrants, investors will be exposed to the risks associated with the inclusion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">such non-cash income</div> in taxable and accounting income prior to receipt of cash, including the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The interest payments deferred on a PIK loan are subject to the risk that the borrower may default when the deferred payments are due in cash at the maturity of the loan; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The interest rates on PIK loans are higher to reflect the time-value of money on deferred interest payments and the higher credit risk of borrowers who may need to defer interest payments; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">PIK instruments may have unreliable valuations because the accruals require judgments about ultimate collectability of the deferred payments and the value of the associated collateral; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">An election to defer PIK income payments by adding them to principal increases the Company’s gross assets and, thus, increases future base fees to the Adviser and, because income payments will then be payable on a larger principal amount, the PIK election also increases the Adviser’s future income incentive fees at a compounding rate; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Market prices of OID instruments are more volatile because they are affected to a greater extent by interest rate changes than instruments that pay interest periodically in cash; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The deferral of interest on a PIK loan <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">increases its loan-to-value ratio,</div></div> which is a measure of the riskiness of a loan; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">OID creates the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">risk of non-refundable cash</div> payments to the Adviser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">based on non-cash accruals</div> that may never be realized. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Money Market and Other Liquid Instruments</div>. The Company may invest its assets in such liquid securities as the Adviser may deem to be advisable, including fixed income securities, money market instruments, money market mutual funds, and debt securities issued or guaranteed by the U.S., certain U.S. government agencies or instrumentalities. Money market instruments are short-term fixed income obligations, which generally have remaining maturities of one year or less, and may include commercial paper, certificates of deposit, and bankers’ acceptances issued by domestic branches of U.S. banks that are members of the FDIC. The Company may be prevented from achieving its investment objective during any period in which its assets are not substantially invested in accordance with its investment strategy. Notwithstanding their general high-quality nature, money market funds and liquid securities are subject to the risk of loss. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other liquid investments, the Company may invest cash, pending investment, reinvestment or distribution thereof or in connection with the maintenance of reserves, in money fund products offered from time to time by its Custodian, including the use of bank “sweep” short-term offerings. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pooled Investment Vehicles and Pass-through Entities</div>. The Company may invest or take short positions in pooled investment vehicle and pass-through entities, including affiliated or third-party unregistered investment vehicles, investment companies registered under the 1940 Act (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">exchange-traded funds and closed-end companies) and</div> master limited partnerships (“Pooled Investment Vehicles”). To the extent the Company invests directly in Pooled Investment Vehicles and other “pass-through” entities which are treated as partnerships for U.S. federal income taxation purposes, the Company must rely on such vehicles to deliver to it certain tax information that is necessary to complete the Company’s own tax returns. If this information is not delivered to the Company in a timely fashion, the Company will be delayed in providing tax information to the investors. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government and Agency Securities</div>. The Company may invest in debt securities issued or guaranteed by certain U.S. government agencies, instrumentalities and sponsored enterprises. Some U.S. government securities, such as Treasury bills, notes and bonds and MBS guaranteed by Ginnie Mae, are supported by the full faith and credit of the U.S.; others are supported by the right of the issuer to borrow from the U.S. Treasury; others are supported by the discretionary authority of the U.S. government to purchase the agency’s obligations; and still others are supported only by the credit of the instrumentality. Although U.S. government-sponsored enterprises, such as Fannie Mae and Freddie Mac, may be chartered or sponsored by Congress, they are not funded by Congressional appropriations, and their securities are not issued by the U.S. Treasury or supported by the full faith and credit of the U.S. government and involve increased credit risks. In addition, certain governmental entities have been subject to regulatory scrutiny regarding their accounting policies and practices and other concerns that may result in legislation, changes in regulatory oversight and/or other consequences that could adversely affect the credit quality, availability or investment character of securities issued by these entities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Securities</div>. It is expected that a significant portion of the Company’s Portfolio Investments will <div style="display:inline;">b</div>e securities (“restricted securities”) that have not been registered for sale to the public under the Securities Act pursuant to an exemption from registration (including Section 4(a)(2) of, or Rule 144A under, the Securities Act). Restricted securities are generally only sold to institutional investors in private sales from the issuer or from an affiliate of the issuer. These securities may be less liquid than securities registered for sale to the general public. The liquidity of a restricted security may be affected by a number of factors, including: (i) the credit quality of the issuer; (ii) the frequency of trades and quotes for the security; (iii) the number of dealers willing to purchase or sell the security and the number of other potential purchasers; (iv) dealer undertakings to make a market in the security; and (v) the nature of the security and the nature of marketplace trades. Also, restricted securities may be difficult to value because market quotations may not be readily available. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a debtor in a reorganization case may be granted a trading restriction order by a bankruptcy court in order to protect such debtor’s net operating losses (a “NOL Order”). Such an order may prohibit or severely restrict the ability of some creditors to sell their claims and interests in the debtor. The Company’s ability to transfer its interests in such a debtor may be impaired, delayed or prohibited as a consequence of a NOL Order. The Company may also incur added expenses if it attempts to challenge or limit the scope of a NOL Order, and such an attempt may not be successful. Similarly, issuers with net operating losses sometimes adopt Unitholder rights plans or similar arrangements in order to preserve the ability to utilize such net operating losses in the future; any such actions could also limit or otherwise adversely impact the Company’s ability to transfer or dispose of its interests in any such issuer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Disposition of Investments</div>. The Company may dispose of its investments through whatever manner it deems to be advisable, including through asset sales, repackaging transactions, securitizations, IPOs, strategic transactions and other mergers and acquisitions activity, and/or any combination thereof. Therefore, the disposition of Company investments will be subject to the risks associated with the particular exit strategy utilized. See, for example, “— <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Bank Loans and Corporate Loans</div>” above. In particular, certain disposition techniques and structures may expose the Company to liability for (among other things) securities laws violations, breaches of representations and warranties, and repurchase or “putback” obligations with respect to securitizations or similar structures. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leverage </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to comply with the asset coverage requirements of the 1940 Act. The Company expects to employ leverage and otherwise incur indebtedness with respect to the portfolio both on a recourse and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recourse</div> basis (including and potentially through guarantees, derivatives, forward commitments and reverse repurchase agreements), but will not exceed the maximum amount permitted by the 1940 Act. The Company is generally permitted, under specified conditions, to issue senior securities in amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after such issuance. In connection with the organization of the Company, the Adviser, as the initial Unitholder, has authorized the Company to adopt the 150% asset coverage ratio. In connection with their subscriptions for Units, our Unitholders are required to acknowledge the Company’s ability to operate with an asset coverage ratio that may be as low as 150%. The Company will be exposed to the risks of leverage, which may be considered a speculative investment technique. The use of leverage magnifies the potential for gain and loss on amounts invested and therefore increases the risks associated with investing in our securities. In addition, the costs associated with our borrowings, including any increase in the management fee payable to the Adviser, will be borne by our Unitholders. As of December 31, 2023, the Company held $41.8 million of senior securities, for an asset coverage ratio of 155.0%. </div> 62743000 43602000 63275000 43897000 1871000 3986000 9919000 29828000 9919000 29828000 503000 271000 14000 15000 75582000 77997000 24210000 14675000 709000 624000 23501000 14051000 17550000 13800000 28000 49000 17522000 13751000 9919000 29828000 524000 325000 12000 8000 904000 493000 231000 193000 52613000 58649000 1069642 1069642 888565 888565 23393000 19461000 -424000 -113000 22969000 19348000 75582000 77997000 21.47 21.77 6696000 3732000 1018000 71000 16000 1000 6767000 3748000 1019000 565000 419000 224000 42000 27000 9000 4058000 1939000 398000 0 0 250000 0 0 229000 737000 592000 732000 5402000 2977000 1842000 1365000 771000 -823000 -19000 -16000 -5000 237000 178000 117000 218000 162000 112000 1583000 933000 -711000 1.54 1.3 -2.57 1365000 771000 -823000 -19000 -16000 -5000 237000 178000 117000 1583000 933000 -711000 -1870000 -697000 0 92000 0 0 1962000 697000 0 4000000 4500000 15501000 0 0 177000 0 0 1000 4000000 4500000 15323000 3621000 4736000 14612000 19348000 14612000 0 22969000 19348000 14612000 181077 206138 682467 0 0 -40 181077 206138 682427 1583000 933000 -711000 -19000 -16000 -5000 237000 178000 117000 336000 345000 133000 25482000 28404000 33983000 7164000 12289000 6870000 469000 234000 61000 373000 100000 0 232000 100000 171000 -1000 1000 14000 -19909000 9828000 20000000 199000 262000 63000 4000 4000 4000 411000 454000 39000 38000 -221000 414000 -36947000 -5107000 -7529000 4000000 4500000 15501000 0 0 -1000 1962000 697000 0 0 0 177000 30635000 42401000 24723000 17750000 27750000 12050000 14923000 18454000 27996000 -22024000 13347000 20467000 33814000 20467000 0 11790000 33814000 20467000 3647000 1485000 359000 2.754 7.45 0.001 0.129 2021-12-22 2027-01-01 6288000 6422000 6414000 7.95 0.01 0.1332 2022-02-23 2027-03-01 1548000 1559000 1596000 5 0.01 0.1061 2021-06-29 2027-06-11 4026000 4000000 4026000 0.09 2021-11-17 2026-11-17 3767000 3765000 3777000 6.20 0.0275 0.1155 2022-12-27 2028-01-01 3348000 3357000 3348000 6.50 0.01 0.1174 2023-05-22 2029-05-22 1691000 1643000 1691000 6.50 0.01 0.1189 2023-11-03 2029-11-05 934000 909000 908000 6.50 0.01 0.1197 2023-01-04 2029-01-03 2643000 2574000 2643000 7.90 0.001 0.1335 2021-09-30 2026-10-01 907000 919000 948000 6.75 0.01 0.1248 2023-03-01 2029-03-01 1761000 1714000 1761000 5.50 0.0345 0.1085 2022-12-20 2027-12-01 312000 313000 315000 6.25 0.01 0.1167 2023-10-20 2029-10-20 697000 680000 680000 5.75 0.0075 0.112 2023-12-29 2028-11-16 875000 868000 858000 6.25 0.01 0.1162 2023-02-10 2026-07-08 2527000 2469000 2527000 6.50 0.01 0.1211 2022-08-17 2024-05-16 1673000 1669000 1673000 5.15 0.0275 0.105 2022-11-03 2027-11-01 3909000 3918000 3918000 5 0.01 0.1045 2021-08-26 2027-08-18 3861000 3824000 3861000 5.75 0.01 0.1138 2023-12-18 2026-01-31 2897000 2840000 2839000 5.75 0.01 0.1136 2021-08-20 2026-08-12 3992000 3957000 3992000 5.75 0.01 0.1119 2022-10-06 2029-10-05 3499000 3399000 3499000 6.25 0.01 0.1172 2022-06-03 2026-01-27 2075000 2050000 2075000 5.50 0.0075 0.1096 2021-06-16 2028-06-16 1950000 1926000 1950000 6.75 0.01 0.1225 2023-03-30 2029-03-30 982000 955000 982000 6.50 0.01 0.1193 2023-02-07 2026-06-15 920000 897000 913000 6.25 0.01 0.1175 2023-09-18 2025-09-15 1285000 1257000 1253000 9.30 0.01 0.1475 2022-02-18 2027-02-01 3384000 3437000 3435000 5.15 0.0475 0.105 2023-06-14 2028-07-01 567000 563000 567000 6.25 0.01 0.1164 2023-11-06 2030-11-06 840000 820000 819000 62704000 63268000 0.001 2023-07-31 1088000 4000 1000 2022-12-20 2719000 2000 2000 2022-02-18 7029000 29000 2023-06-14 13779000 4000 4000 39000 7000 2.755 62743000 63275000 0.432 2023-12-29 2024-02-27 10000000 9919000 9919000 3.187 72662000 73194000 2.187 -50225000 1 22969000 0.208 -241000 600000 841000 63516000 0.03 0.09 0.509 0.161 0.127 0.113 0.063 0.015 0.012 1 2.268 6.25 0.01 0.0875 2022-06-29 2027-06-01 317000 315000 317000 7.45 0.001 0.1162 2021-12-22 2027-01-01 6288000 6322000 6367000 7.95 0.001 0.1212 2022-02-23 2027-03-01 851000 854000 853000 5 0.01 0.0973 2021-06-29 2027-06-11 4068000 4034000 4068000 0 0 0.09 2021-11-17 2026-11-17 3683000 3656000 3683000 6.20 0.0275 0.1052 2022-12-27 2028-01-01 2494000 2488000 2488000 7.90 0.001 0.1207 2021-09-30 2026-10-01 1452000 1456000 1455000 6.25 0.01 0.1039 2021-12-22 2026-02-25 2697000 2659000 2724000 5.50 0.0345 0.0982 2022-12-20 2027-12-01 312000 309000 311000 6.25 0.01 0.1092 2022-11-29 2024-05-10 567000 557000 556000 6.50 0.01 0.1091 2022-08-17 2024-05-16 1087000 1080000 1087000 5.15 0.0275 0.0933 2022-11-03 2027-11-01 3052000 3034000 3029000 6.25 0.01 0.1067 2022-08-19 2024-12-04 463000 457000 459000 5 0.01 0.0989 2021-08-26 2027-08-18 3107000 3069000 3107000 5.75 0.01 0.1059 2021-08-20 2026-08-12 4033000 3986000 4033000 5.75 0.01 0.0946 2022-10-06 2029-10-05 2905000 2813000 2810000 6 0.01 0.1077 2022-06-03 2026-01-27 489000 485000 489000 5.70 0.023 0.0988 2022-09-21 2027-09-01 915000 905000 906000 5.75 0.0075 0.1048 2021-06-16 2028-06-16 2033000 2004000 2033000 8.30 0.01 0.1258 2022-02-18 2027-02-01 3095000 3094000 3111000 43577000 43886000 0.001 2022-12-20 2719000 2000 2000 2022-09-21 13871000 4000 1000 2022-02-18 3324000 19000 8000 25000 11000 2.269 43602000 43897000 1.541 2022-12-30 2023-02-23 30000000 29828000 29828000 3.81 73430000 73725000 2.81 -54377000 1 19348000 0.179 -71000 318000 389000 43968000 0.03 0.08 0.349 0.193 0.168 0.165 0.092 0.033 1 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 1. Organization </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on July 7, 2020 as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">closed-end,</div> externally managed investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a BDC and a RIC, we are required to comply with certain regulatory requirements. The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below. SLR Capital Partners, LLC (the “Adviser” or “SLR”) serves as the Company’s investment adviser pursuant to an investment management agreement with the Company (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company’s formation, the Company issued and sold 40 units to the Adviser (the “Initial Unitholder”), which were acquired for an initial capital contribution of $1 on January 5, 2021 in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. The Company’s capital commitments total $83,850. The Company’s initial drawdown occurred on March 8, 2021 with the sale and issuance of units at an aggregate purchase price of $3,500 or $29.30 per unit. Prior to the issuance of units on March 8, 2021, the Initial Unitholder’s initial seed capital was withdrawn from the Company and its Units were canceled. As of December 31, 2023, $24,000 of capital commitments were drawn and $59,850 were unfunded. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company pursues a corporate lending strategy focused on direct sourcing, underwriting and managing a diverse portfolio of private loans to U.S. healthcare companies. The Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”. The Company’s principal focus is to invest in two differentiated strategies: first lien healthcare cash flow loans and first lien life science loans. First lien healthcare cash flow loans are expected to be made to private equity-owned upper middle market healthcare companies with EBITDA between approximately $25,000 and $100,000. These aggregate loan tranches are expected to range in size from $100,000 to $300,000. Healthcare cash flow loans are generally expected to have a <div style="-sec-ix-hidden:hidden102416507;display:inline;">five</div> to six year final maturity and are often repaid within three years. First lien life science loans are expected to be made to venture capital owned <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercialization</div> or early revenue drug and device development companies. These aggregate loan tranches are expected to range in size from $25,000 to $150,000. Loans to life science companies are generally expected to have an initial interest-only period and then straight-line amortization with a <div style="-sec-ix-hidden:hidden102416508;display:inline;">four</div> to five year final maturity. These loans are often repaid within <div style="-sec-ix-hidden:hidden102416509;display:inline;">two</div> to three years. The Company expects to primarily invest in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-investment</div> grade debt instruments. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is organized for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). The Company was permitted to hold closings at any time during the offering period (the “Offering Period”), which ended on December 31, 2022. The term of the Company is expected to be seven years from the Company’s final closing with the Access Fund, which was held on February 11, 2021, unless the Company is terminated earlier or causes the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange (an “Exchange Listing”) as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-1940</div> Act vote as described in Item 11 of the Company’s Form 10. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31.</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the end of the term, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange. In connection with any such Exchange Listing, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the Company to complete (i) an initial public offering, (ii) a merger with another entity, including an affiliated company, subject to any limitations under the 1940 Act, (iii) the sale, exchange or disposition of all or a portion of the assets of the Company, or (iv) a conversion of the Company into a corporation incorporated in a state determined by the board of directors, either through a conversion in accordance with applicable law, a merger with or into an existing corporation, or otherwise, in which all units will be converted into or exchanged for shares of common stock of the resulting corporation. If the Company is unable to effectuate an Exchange Listing prior to the end of the term, the Company will use commercially reasonable efforts to wind down or liquidate pursuant to the procedures set forth in the LLC Agreement. </div> 40 1 83850000 3500000 29.3 24000000 59850000 25000000 100000000 100000000 300000000 five to six year P6Y often repaid within three years three years 25000000 150000000 four to five year P5Y often repaid within two to three years three years <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 2. Summary of Significant Accounting Policies </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”), and include the accounts of the Company and certain wholly-owned subsidiaries, if any. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform to current period presentation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with GAAP and pursuant to the requirements for reporting on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> as appropriate, also requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reported periods. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion of management, all adjustments which are of a normal recurring nature and considered necessary for the fair presentation of financial statements, have been included. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant accounting policies consistently followed by the Company are: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Investment transactions are accounted for on the trade date. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows: </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">(i)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">(ii)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">(iii)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and </div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">(iv)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below: </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">a.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">b.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">preliminary valuation conclusions are then documented and discussed with senior management of the Adviser; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">c.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the audit committee of the Board of Directors (the “Board”) reviews the preliminary valuations of the Adviser and third-party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">d.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third-party valuation specialist, if any, which may from time to time be engaged by the Board. </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-5</div> under the 1940 Act; and (6) maintain recordkeeping requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-5.</div> </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">820-10,</div> certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&amp;A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the fiscal year ended December 31, 2023, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy: </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Level</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> 1</div>: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Level</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> 2</div>: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Level</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> 3</div>: Unobservable inputs for the asset or liability. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience. </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(c)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Gains or losses on investments are calculated by using the specific identification method. </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(d)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fee income as well as management fee and other fee income for services rendered, if any, are recorded as other income when earned. </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(e)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company intends to comply with the applicable provisions of the Code pertaining to RICs to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate. </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(f)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP; accordingly at December 31, 2023, $23 was reclassified on our balance sheet between accumulated distributable net loss and common Unitholders’ capital. Total earnings and net asset value are not affected. </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(g)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually. </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(h)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In accordance with Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> and ASC Topic 810—<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consolidation</div></div>, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company. </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(i)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company. </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(j)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">835-30,</div> the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method. </div> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(k)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">946-20-25.</div></div> </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(l)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Investments that are expected to pay regularly scheduled interest in cash are generally placed on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accrual</div> status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accrual</div> investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(m)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company records expenses directly related to its organization as incurred. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(n)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents. </div> </td> </tr> </table> 0.04 23000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 3. Agreements and Related Party Transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Investment Management Agreement we have entered into with the Adviser, we will pay the Adviser certain management and incentive fees prior to and following an Exchange Listing. Prior to an Exchange Listing, the Adviser has been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay an administration fee to the Administrative Coordinator for such administrative and coordination services, each as defined and described further below. Following an Exchange Listing, we intend to enter into a separate administration agreement with an affiliate pursuant to which administrative services would be provided to the Company, as described further below. The cost of the base management fee, the incentive fee and the administration fee will ultimately be borne by our Unitholders. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management Fees </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company pays the Adviser a management fee prior to an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“Pre-Exchange</div> Listing Management Fee”) and will pay a management fee following an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the “Post-Exchange Listing Management Fee” and, together with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Management Fee, the “Management Fee”). The Management Fee will be payable quarterly in arrears, as <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">follows: </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing</div>. Prior to an Exchange Listing, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Management Fee will be calculated as of the close of business on the last day of each calendar quarter in an amount equal to 1.50% <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">per annum </div></div>of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company used to make Portfolio Investments and (ii) the total amount of credit drawn on subscription or similarly structured credit facilities). </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Post-Exchange Listing</div>. Following an Exchange Listing, the Post-Exchange Listing Management Fee will be an amount equal to 1.50% per annum of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters; provided, however, the Post-Exchange Listing Management Fee will be calculated at an annual rate of 1.00% of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters that exceeds the product of (i) 200% and (ii) the value of the Company’s total net assets at the end of the immediately preceding calendar quarter. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Management Fee will be appropriately adjusted for any stub period. The Adviser may arrange for the Company to direct to a placement agent any portion of the Management Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, the Management Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such Management Fee may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the Management Fee. No Management Fees have been waived as of December 31, 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Fee </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Distributions</div>. Prior to an Exchange Listing, the Company makes distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, prepayment fees and exit fees, other than Disposition Proceeds, less Company expenses. The Adviser apportions each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee</div>.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>Prior to an Exchange Listing, and subject to availability, the Company will cause distributable cash to be distributed to Unitholders and to be paid to the Adviser as an incentive fee (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“Pre-Exchange</div> Listing Incentive Fee”). Amounts of Investment Proceeds apportioned to Unitholders are divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority: </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee, on the other hand, in the following amounts and order of priority: </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) First, Return of Capital Contributions: 100% to such Unitholder until such Unitholders has received cumulative distributions of Investment Proceeds pursuant to this clause (A) equal to such Unitholder’s total capital contributions to the Company (including amounts contributed to pay <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Management Fees, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fees (defined below), Organizational Expenses (defined below) and other Company <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">expenses); </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;"> </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="background-color:#ffffff;;display:inline;"> </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;"> </div></div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Second, Unitholder Preferred Return: 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and clause (ii)(A) and (ii)(C) below equal to 6% per annum, compounded annually, on Unitholders’ capital contributions to the Company (including amounts contributed to pay <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Management Fees, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fees, Organizational Expenses and other Company expenses), determined on the basis of all capital contributions made by such Unitholder and considering all distributions (including the subject distribution) under this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“—Pre-Exchange</div> Listing Incentive Fee” made to such Unitholder (computed from the dates that such capital contributions were due (or, if actually made later, the date on which such capital contributions were actually made) until the date that the Company, in its sole discretion, designates distributable cash as available for distribution or, if no such designation is made, the occurrence of an Event of Dissolution, as defined in the LLC Agreement) (the “Preferred Return”); </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Third, Adviser Catch Up: 100% of all remaining Disposition Proceeds to the Adviser as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee, until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) below equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (B) above and this clause (C) and clause (ii)(A) and (ii)(B) below; and </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) Fourth, 90%/10%: 90% of all remaining Disposition Proceeds to Unitholders and 10% of all remaining Disposition Proceeds to the Adviser as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event will the Adviser receive amounts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fees under clause (i)(C) and (i)(D) above in excess of the percentage of the Disposition Proceeds actually distributed to Unitholders pursuant to clause (i)(B), (i)(C) and (i)(D) above. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee, on the other hand, in the following amounts and order of priority: </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) First, Unitholder Preferred Return: 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) above equal to the Preferred Return; </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Second, Adviser Catch Up: Second, 100% of all remaining Current Proceeds to the Adviser as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) above equal to 10% of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (A) above and this clause (B) and pursuant to clause (i)(B) and clause (i)(C) above; and </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Third, 90%/10%: Thereafter, 90% of all remaining Current Proceeds to Unitholders and 10% of all remaining Current Proceeds to the Adviser as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;"> </div></div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event will the Adviser receive amounts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fees under clause (ii)(B) and (ii)(C) above in excess of the percentage of the Current Proceeds actually distributed to Unitholders pursuant to clause (ii)(A), (ii)(B) and (ii)(C) above. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Post-Exchange Listing Incentive Fee</div>. Following an Exchange Listing, the Company will pay an incentive fee to the Adviser consisting of two parts, as follows (the “Post-Exchange Listing Incentive Fee”): </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(i)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income. One part will be calculated and payable quarterly in arrears based on the net investment income for the immediately preceding calendar quarter. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">a.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">For this purpose, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies) accrued by the Company during the calendar quarter, minus the Company’s operating expenses for the quarter (including the Post-Exchange Listing Management Fees, expenses payable under an administration agreement, and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the Post-Exchange Listing Incentive Fee). </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">b.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income, expressed as a rate of return on the value of the Company’s net assets at the end of the immediately preceding calendar quarter, will be compared to a “hurdle rate” of 1.50% per quarter (6.00% annualized). The Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income used to calculate this part of the Post-Exchange Listing Incentive Fee is also included in the amount of its gross assets used to calculate the 1.50% Post-Exchange Listing Management Fees. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:9%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">c.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company will pay the Adviser a Post-Exchange Listing Incentive Fee with respect to the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income in each calendar quarter as follows: </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">i.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">no Post-Exchange Listing Incentive Fee in any calendar quarter in which the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income does not exceed the quarterly hurdle rate of 1.50%; </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">ii.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">100% of the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income with respect to that portion of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 1.875% in any calendar quarter (7.5% annualized); this portion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income (which exceeds the hurdle but is less than 1.875%) is referred to herein as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“catch-up.”</div> The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“catch-up”</div> is meant to provide the Adviser with 20% of the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income as if a hurdle did not apply if this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income exceeds 1.875% in any calendar quarter; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">iii.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">20% of the amount of the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income, if any, that exceeds 1.875% in any calendar quarter (7.5% annualized) payable to the Adviser (once the hurdle is reached and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> is achieved, 20% of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Incentive</div> Fee Net Investment Income thereafter is allocated to the Adviser). </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These calculations will be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">appropriately pro-rated for</div> any period of less than three months. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Capital Gains Fee</div>. The second part of the Post-Exchange Listing Incentive Fee, the “Capital Gains Fee”, will be determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement as set forth below), commencing as of the end of the first fiscal year following an Exchange Listing, and will equal 20.0% of the Company’s realized capital gains, if any, on a cumulative basis through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation as of each fiscal year end, less the amount of any previously paid capital gain Post-Exchange Listing Incentive Fees, with respect to the Company; provided that the Post-Exchange Listing Incentive Fee determined as of the end of the fiscal year in which an Exchange Listing is completed will be calculated for a period of shorter than twelve calendar months to take into account any realized capital gains computed net of all realized capital losses and unrealized capital depreciation. In the event that the Investment Management Agreement will terminate as of a date that is not a calendar year end, the termination date will be treated as though it were a calendar year end for purposes of calculating and paying a Capital Gains Fee. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, all or any portion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee or Post-Exchange Listing Incentive Fee to which the Adviser is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fees or Post-Exchange Listing Incentive Fees may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee or Post-Exchange Listing Incentive Fee. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adviser may arrange for the Company to direct to a placement agent any portion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Incentive Fee or Post-Exchange Listing Incentive Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Administration Fees and Expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fees</div>. The Company will pay SLR, in its capacity as the Administrative Coordinator, a fee (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“Pre-Exchange</div> Listing Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as, as of any date, the aggregate accreted and amortized cost of all Portfolio Investments, including (i) any amounts reinvested in Portfolio Investments and (ii) the cost of Portfolio Investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fee will not offset any fees paid to the Adviser. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going,</div> routine, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-investment-related</div> administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company and (iii) certain Unitholder servicing functions. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fee will be appropriately adjusted for any stub period. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrative Coordinator will have the right, in its sole discretion, to waive, as well as recoup in a subsequent period, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fee to which it is entitled in respect of all Unitholders’ Units in any particular calendar quarter. Any such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fee may be recouped by the Administrative Coordinator in a future calendar quarter within three years of the date of the applicable waiver of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fee. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Post-Exchange Listing Administration Expenses</div>. In connection with an Exchange Listing, and subject to Board approval, the Company intends to enter into an administration agreement with SLR Capital Management, LLC (“SCM”) pursuant to which SCM will provide administrative services to the Company. For providing these services, facilities and personnel, the Company will reimburse SCM for the Company’s allocable portion of overhead and other expenses incurred by SCM in performing its obligations under the administration agreement (together with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Exchange</div> Listing Administration Fee, the “Administration Expenses”). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021, the Company incurred $565, $419 and $224, respectively, in Management Fees, $42, $27 and $9, respectively, in Administration Fees and $0, $0 and $0, respectively in Incentive Fees. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, prior to an Exchange Listing, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company will not exceed the following limits in any fiscal year: (A) if the Company has less than or equal to $400,000 in Commitments, an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in Commitments, $2,250 (such figure, the “Operating Expense Cap”). Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, (i) the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder, (ii) the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the Company’s portfolio investments at each quarter end and (iii) the Operating Expense Cap will no longer apply upon the effectuation of an Exchange Listing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (the “Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) will be reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. The Company will be responsible for and pay (or reimburse) the Organizational Expenses subject to the cap described in the preceding sentence. Accordingly, in 2021, $177 of offering expenses were charged to capital and $229 of organizational costs were expensed. </div> 0.015 0.015 0.01 2 1 1 0.06 1 0.10 0.90 0.10 0.90 0.10 0.20 1 1 0.10 0.90 0.10 0.90 0.10 0.015 0.06 0.015 1 0.01875 0.075 0.20 0.01875 0.20 0.20 0.0008 565000 419000 224000 42000 27000 9000 0 0 0 400000000 0.0025 1250000 400000000 2250000 500000 177000 229000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 4. Fair Value </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows: </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 1.</div></div> Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2.</div></div> Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Quoted prices for similar assets or liabilities in active markets; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Quoted prices for identical or similar assets or liabilities in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-active</div> markets; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">c)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Pricing models whose inputs are observable for substantially the full term of the asset or liability; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">d)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 3. </div></div>Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use in pricing the asset or liability. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the balances of assets measured at fair value on a recurring basis, as of December 31, 2023 and December 31, 2022: </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2023 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:69%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2023, the fair value of the SPV Facility and the Subscription Facility would be $24,210 and $17,550, respectively. </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2022, the fair value of the SPV Facility and the Subscription Facility would be $14,675 and $13,800, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provides a summary of the changes in fair value of Level 3 assets for the years ended December 31, 2023 and 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2023 and 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">254</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">239</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities*</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,306</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,321</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,178</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,183</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">241</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2021</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">192</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities*</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,713</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,738</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,305</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,305</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">243</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">229</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes PIK capitalization and accretion of discount </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Quantitative Information about Level 3 Fair Value Measurements </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2023 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:46%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal Valuation</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt / Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Income Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Yield</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.6% – 17.6%<br/> (13.0%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Volatility</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.9% – 18.9%<br/> (18.9%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bid-ask</div> spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:46%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal Valuation</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt / Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Income Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Yield</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.8% – 18.2%<br/> (12.5%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Volatility</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26.0% – 26.0%<br/> (26.0%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bid-ask</div> spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments. </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the balances of assets measured at fair value on a recurring basis, as of December 31, 2023 and December 31, 2022: </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2023 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:69%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 0 0 63268000 63268000 1000 0 6000 7000 1000 0 63274000 63275000 24210000 17550000 0 0 43886000 43886000 0 0 11000 11000 0 0 43897000 43897000 14675000 13800000 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provides a summary of the changes in fair value of Level 3 assets for the years ended December 31, 2023 and 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2023 and 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">254</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">239</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities*</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,306</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,321</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,178</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,183</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">241</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2021</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">192</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities*</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,713</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,738</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,305</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,305</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,897</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">243</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">229</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes PIK capitalization and accretion of discount </div></td></tr></table> 43886000 11000 43897000 0 0 0 254000 -15000 239000 26306000 15000 26321000 -7178000 -5000 -7183000 0 0 0 0 0 0 63268000 6000 63274000 259000 -18000 241000 27286000 0 27286000 0 0 0 192000 -14000 178000 28713000 25000 28738000 -12305000 0 -12305000 0 0 0 0 0 0 43886000 11000 43897000 243000 -14000 229000 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2023 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:46%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal Valuation</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt / Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Income Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Yield</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.6% – 17.6%<br/> (13.0%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Volatility</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.9% – 18.9%<br/> (18.9%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:46%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principal Valuation</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt / Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,886</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Income Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Yield</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.8% – 18.2%<br/> (12.5%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Asset</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Market Approach</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Volatility</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26.0% – 26.0%<br/> (26.0%</td> <td style="white-space:nowrap;vertical-align:bottom"> <br/> ) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> Asset 63268000 10.6 17.6 13 Asset 6000 18.9 18.9 18.9 Asset 43886000 9.8 18.2 12.5 Asset 11000 26 26 26 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 5. Debt </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SPV Facility</div></div>—On February 18, 2022, the Company, through its wholly-owned subsidiary, SLR HC BDC SPV LLC (the “SPV”), entered into the $50,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. On May 30, 2023, the SPV Facility was amended, increasing commitments to $75,000. The stated interest rate on the SPV Facility is Term SOFR plus 3.07% with no SOFR floor requirement and the final maturity date is February 18, 2027. The fee on undrawn commitments is currently 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $24,210 of borrowings outstanding under the SPV Facility. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Facility</div></div>—On March 19, 2021, the Company established the $25,000 Subscription Facility with ING Capital LLC. The stated interest rate on the Subscription Facility is SOFR plus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.75-3.00%</div> and the current stated maturity date is March 15, 2024. On December 14, 2021, the Subscription Facility was amended, allowing for increased borrowing base availability, among other changes. On June 14, 2023, the Subscription Facility entered into a second amendment, which replaced the benchmark rate of LIBOR with SOFR. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. As of December 31, 2023, there were $17,550 of borrowings outstanding under the Subscription Facility. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The average annualized interest cost for borrowings for the years ended December 31, 2023 and 2022 was 8.11% and 4.88%, respectively. These costs are exclusive of other credit facility expenses such as unused fees. The maximum amount borrowed on the credit facilities during the years ended December 31, 2023 and 2022 was $44,010 and $32,775, respectively. </div> 50000000 75000000 Term SOFR 0.0307 no SOFR 2027-02-18 0.00875 The SPV Facility is secured by all of the assets held by the SPV 24210000 25000000 SOFR 0.0275 0.03 2024-03-15 17550000 0.0811 0.0488 44010000 32775000 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 6. Commitments and Contingencies</div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of December 31, 2023 and December 31, 2022 is $11,545 and $15,513, respectively, comprised of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:73%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AAH Topco, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,262</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">OIS Management Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,710</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Southern Orthodontic Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">670</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ardelyx, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,345</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">696</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVAUSA Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,059</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retina Midco, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Orthopedic Care Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">566</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United Digestive MSO Parent, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">391</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SCP Eye Care, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vertos Medical, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Medrina, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">239</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">UVP Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">218</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Urology Management Holdings, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SunMed Group Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exactcare Parent, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">WCI-BXC</div> Purchaser, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outset Medical, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,052</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Apeel Technology, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,852</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Glooko, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,633</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Arcutis Biotherapeutics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">786</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oral Surgery Partners Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">843</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plastics Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spectrum Pharmaceuticals, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cerapedics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">623</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pediatric Home Respiratory Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">630</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Meditrina, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">312</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ivy Fertility Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BayMark Health Services, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Commitments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,545</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 15,513</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of December 31, 2023, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of our business, we invest or trade in various financial instruments and may enter into various investment activities with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Statement of Assets and Liabilities. </div> 11545000 15513000 <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:73%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AAH Topco, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,262</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">OIS Management Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,710</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Southern Orthodontic Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">670</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ardelyx, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,345</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">696</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVAUSA Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,059</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retina Midco, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Orthopedic Care Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">566</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United Digestive MSO Parent, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">391</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SCP Eye Care, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">343</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vertos Medical, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Medrina, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">239</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">UVP Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">218</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Urology Management Holdings, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SunMed Group Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exactcare Parent, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">WCI-BXC</div> Purchaser, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outset Medical, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,052</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Apeel Technology, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,852</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Glooko, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,633</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Arcutis Biotherapeutics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">786</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oral Surgery Partners Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">843</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plastics Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spectrum Pharmaceuticals, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cerapedics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">623</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pediatric Home Respiratory Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">630</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Meditrina, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">312</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ivy Fertility Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BayMark Health Services, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Commitments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,545</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 15,513</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 2262000 0 1710000 0 1347000 670000 1345000 696000 1059000 0 966000 0 901000 566000 391000 0 343000 968000 283000 0 239000 0 218000 0 151000 0 132000 69000 102000 0 96000 0 0 3052000 0 2852000 0 1633000 0 786000 0 843000 0 794000 0 763000 0 623000 0 630000 0 312000 0 128000 0 128000 11545000 15513000 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 7. Unitholders’ Capital </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions in Unitholders’ capital were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units at beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888,565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">682,427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181,077</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">206,138</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued and outstanding at end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,069,642</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888,565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions in Unitholders’ capital were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units at beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888,565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">682,427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181,077</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">206,138</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued and outstanding at end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,069,642</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888,565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 888565 682427 181077 206138 1069642 1069642 888565 888565 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 8. Financial Highlights </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a schedule of financial highlights for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:69%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the period<br/> January 5, 2021*<br/> to December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Per Unit Data: (a)</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.77</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.41</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.07</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.97</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized and unrealized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.28</td> <td style="white-space:nowrap;vertical-align:bottom">** </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase (decrease) in Unitholders’ capital resulting from operations</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.57</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of initial units</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.62</td> <td style="white-space:nowrap;vertical-align:bottom">** </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Offering costs</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.64</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributions to Unitholders:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">From distributable earnings</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.85</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.97</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">From return of capital</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.06</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.47</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.77</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.41</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Return(b)(c)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.40</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.21</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26.93</td> <td style="white-space:nowrap;vertical-align:bottom">)% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unitholders’ capital, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,969</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,348</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,612</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units outstanding, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,069,642</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888,565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">682,427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ratios to average net assets of Unitholders’ Capital (c):</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.08</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.91</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16.59</td> <td style="white-space:nowrap;vertical-align:bottom">)% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.99</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.61</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29.12</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other credit facility expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.08</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.33</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.02</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.07</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.94</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37.14</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average debt outstanding</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,744</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,453</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,352</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Portfolio turnover ratio</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.9</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(c)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Not annualized for periods less than one year. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Commencement of operations </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">**</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a schedule of financial highlights for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:69%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the period<br/> January 5, 2021*<br/> to December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Per Unit Data: (a)</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.77</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.41</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.07</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.97</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized and unrealized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.28</td> <td style="white-space:nowrap;vertical-align:bottom">** </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase (decrease) in Unitholders’ capital resulting from operations</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.57</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of initial units</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.62</td> <td style="white-space:nowrap;vertical-align:bottom">** </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Offering costs</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.64</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributions to Unitholders:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">From distributable earnings</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.85</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.97</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">From return of capital</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.06</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.47</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.77</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.41</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Return(b)(c)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.40</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.21</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26.93</td> <td style="white-space:nowrap;vertical-align:bottom">)% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unitholders’ capital, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,969</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,348</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,612</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units outstanding, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,069,642</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">888,565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">682,427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ratios to average net assets of Unitholders’ Capital (c):</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.08</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.91</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16.59</td> <td style="white-space:nowrap;vertical-align:bottom">)% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.99</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.61</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29.12</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other credit facility expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.08</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.33</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.02</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.07</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.94</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37.14</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average debt outstanding</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,744</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,453</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,352</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Portfolio turnover ratio</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.9</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(c)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Not annualized for periods less than one year. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Commencement of operations </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">**</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end. </div></td></tr></table> 21.77 21.41 0 1.33 1.07 -2.97 0.28 0.26 0.4 1.61 1.33 -2.57 0 0 24.62 0 0 -0.64 -1.85 -0.97 0 -0.06 0 0 21.47 21.77 21.41 0.074 0.0621 -0.2693 22969000 19348000 14612000 1069642 888565 682427 0.0608 0.0491 -0.1659 0.0599 0.0661 0.2912 0.1808 0.1233 0.0802 0.2407 0.1894 0.3714 31744000 20453000 7352000 0.139 0.365 0.597 1029458 720266 276929 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 9(a). Income Tax Information and Distributions to Unitholders </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax character of distributions for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 were as follows(1): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ordinary income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,817</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92.6</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital gains</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">94</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Return of capital</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total distributions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,962</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">697</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, 2022 and 2021 the total accumulated earnings (loss) on a tax basis were as follows(1): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:78%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Undistributed ordinary income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Undistributed long-term net capital gains</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total undistributed net earnings</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Post-October capital losses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital loss carryforward</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other book/tax temporary differences</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(183</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(197</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net unrealized depreciation</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(241</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total tax accumulated loss</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(424</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(349</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes in its consolidated financial statements the tax effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. To the best of our knowledge, we did not have any uncertain tax positions that met the recognition or measurement criteria of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10-25</div></div> nor did we have any unrecognized tax benefits as of the periods presented herein. Although we file federal and state tax returns, our major tax jurisdiction is federal. Our tax returns for federal tax years since 2021 remain subject to examination by the Internal Revenue Service and the state department of revenue. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 9(b). Other Tax Information (unaudited) </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal years ended December 31, 2023 and December 31, 2022, none of the ordinary distributions paid during the year were eligible for qualified dividend income treatment or the dividends received deduction for corporate stockholders. For the fiscal years ended December 31, 2023 and December 31, 2022, 98.16% and 99.58%, respectively, of each of the ordinary distributions paid during the year represent interest-related dividends. For the fiscal years ended December 31, 2023 and December 31, 2022, 0.90% and 0%, respectively, of the distributions represent short-term capital gains dividends. There were no distributions during the period January 5, 2021 (commencement of operations) to December 31, 2021. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax character of distributions for the years ended December 31, 2023, December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 were as follows(1): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ordinary income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,817</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92.6</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital gains</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">94</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Return of capital</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total distributions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,962</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">697</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 1817000 0.926 603000 0.865 0 0 53000 0.027 94000 0.135 0 0 92000 0.047 0 0 0 0 1962000 1 697000 1 0 0 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, 2022 and 2021 the total accumulated earnings (loss) on a tax basis were as follows(1): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:78%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Undistributed ordinary income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Undistributed long-term net capital gains</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total undistributed net earnings</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Post-October capital losses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital loss carryforward</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other book/tax temporary differences</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(183</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(197</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net unrealized depreciation</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(241</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total tax accumulated loss</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(424</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(349</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year. </div></td></tr></table> 0 -155000 0 0 0 0 0 -155000 0 0 0 0 0 0 0 183000 197000 213000 -241000 -71000 -136000 -424000 -113000 -349000 0 0 98.16 99.58 0.9 0 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 10. Subsequent Events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the financial statements were issued. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 23, 2024, the Company, through the SPV, reduced the size of its $75,000 SPV Facility to $35,000. </div> 75000000 35000000 false false false false Commencement of operations Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2023, on a fair value basis, non-qualifying assets in the portfolio represented 20.8% of the total assets of the Company. Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company. Not annualized for periods less than one year. Tax information for the fiscal years ended December 31, 2023 and December 31, 2022 and the period January 5, 2021 (commencement of operations) to December 31, 2021 are/were estimates and are not final until the Company files its tax returns, typically in October each year. Floating rate debt investments typically bear interest at a rate determined by reference to either the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) has provided the current interest rate in effect as of December 31, 2023. Calculated using the average Units outstanding method. Weighted average Units outstanding for the years ended December 31, 2023, December 31, 2022 and the period March 8, 2021 (date of first sale of units) through December 31, 2021 were 1,029,458, 720,266 and 276,929, respectively. BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK. Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor. Non-income producing security. Aggregate net unrealized depreciation for U.S. federal income tax purposes is $71; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $318 and $389, respectively, based on a tax cost of $43,968. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. Calculated as the change in net asset value (“NAV”) per Unit during the period plus distributions declared per Unit, divided by the beginning NAV per unit. Total return does not include a sales load. Aggregate net unrealized depreciation for U.S. federal income tax purposes is $241; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $600 and $841, respectively, based on a tax cost of $63,516. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. Includes PIK capitalization and accretion of discount Includes the impact of the different unit amounts used in calculating per Unit data as a result of calculating certain per Unit data based upon the weighted average Units outstanding during the period and certain per Unit data based on the Units outstanding as of a period end. Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK. Denotes a Level 1 investment.